<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34785397</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2585</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of epidemiology</Title><ISOAbbreviation>Ann Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Sexual orientation-related disparities in health conditions that elevate COVID-19 severity.</ArticleTitle><Pagination><StartPage>5</StartPage><EndPage>12</EndPage><MedlinePgn>5-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.annepidem.2021.11.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1047-2797(21)00324-0</ELocationID><Abstract><AbstractText Label="PURPOSE">The Veterans Health Administration (VA) is the largest single integrated healthcare system in the US and is likely the largest healthcare provider for people with minoritized sexual orientations (e.g., gay, lesbian, bisexual). The purpose of this study was to use electronic health record (EHR) data to replicate self-reported survey findings from the general US population and assess whether sexual orientation is associated with diagnosed physical health conditions that may elevate risk of COVID-19 severity among veterans who utilize the VA.</AbstractText><AbstractText Label="METHODS">A retrospective analysis of VA EHR data from January 10, 1999-January 07, 2019 analyzed in 2021. Veterans with minoritized sexual orientations were included if they had documentation of a minoritized sexual orientation within clinical notes identified via natural language processing. Veterans without minoritized sexual orientation documentation comprised the comparison group. Adjusted prevalence and prevalence ratios (aPR) were calculated overall and by race/ethnicity while accounting for differences in distributions of sex assigned at birth, age, calendar year of first VA visit, volumes of healthcare utilization, and VA priority group.</AbstractText><AbstractText Label="RESULTS">Data from 108,401 veterans with minoritized sexual orientation and 6,511,698 controls were analyzed. After adjustment, veterans with minoritized sexual orientations had a statistically significant elevated prevalence of 10 of the 11 conditions. Amongst the highest disparities observed were COPD (aPR:1.24 [95% confidence interval:1.23-1.26]), asthma (1.22 [1.20-1.24]), and stroke (1.26 [1.24-1.28]).</AbstractText><AbstractText Label="CONCLUSIONS">Findings largely corroborated patterns among the general US population. Further research is needed to determine if these disparities translate to poorer COVID-19 outcomes for individuals with minoritized sexual orientation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT; University of Utah School of Medicine, Department of Internal Medicine, Division of Epidemiology, Salt Lake City, UT. Electronic address: Kristine.Lynch@va.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shipherd</LastName><ForeName>Jillian C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Lesbian, Gay, Bisexual, Transgender, and Queer (LGBTQ+) Health Program, Veterans Health Administration, Washington, DC; National Center for PTSD, Women's Health Sciences Division, VA Boston Healthcare System, Boston, MA; Department of Psychiatry, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gatsby</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viernes</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT; University of Utah School of Medicine, Department of Internal Medicine, Division of Epidemiology, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT; University of Utah School of Medicine, Department of Internal Medicine, Division of Epidemiology, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blosnich</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Suzanne Dworak-Peck School of Social Work, University of Southern California, Los Angeles, CA; Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Epidemiol</MedlineTA><NlmUniqueID>9100013</NlmUniqueID><ISSNLinking>1047-2797</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001727" MajorTopicYN="N">Bisexuality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018452" MajorTopicYN="Y">Homosexuality, Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014493" MajorTopicYN="N">United States Department of Veterans Affairs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="Y">Veterans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Administrative data or large data sets</Keyword><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">Sexual orientation</Keyword><Keyword MajorTopicYN="N">Veterans/department of veterans affairs/va</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>17</Day><Hour>5</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34785397</ArticleId><ArticleId IdType="pmc">PMC8601164</ArticleId><ArticleId IdType="doi">10.1016/j.annepidem.2021.11.006</ArticleId><ArticleId IdType="pii">S1047-2797(21)00324-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Medicine Institute of. National Academies Press; Washington, DC: 2011. The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding.</Citation><ArticleIdList><ArticleId IdType="pubmed">22013611</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.G., Griffin G.K., Melvin C.L. Tobacco use among sexual minorities in the USA, 1987 to May 2007: a systematic review. Tob Control. 2009;18(4):275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">19208668</ArticleId></ArticleIdList></Reference><Reference><Citation>Green K.E., Feinstein B.A. Substance use in lesbian, gay, and bisexual populations: an update on empirical research and implications for treatment. Psyhol Addict Behav. 2012;26(2):265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3288601</ArticleId><ArticleId IdType="pubmed">22061339</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman E.F., Exner D., Baughman A.L. The prevalence of sexual assault against people who identify as gay, lesbian, or bisexual in the United States: a systematic review. Trauma Violence Abuse. 2011;12(2):55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3118668</ArticleId><ArticleId IdType="pubmed">21247983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ecker J., Aubry T., Sylvestre J. A review of the literature on LGBTQ adults who experience homelessness. J Homosex. 2019;66(3):297&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">29206576</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau F., Antonio M., Davison K., Queen R., Devor A., et al. A rapid review of gender, sex, and sexual orientation documentation in electronic health records. J Am Med Inform Assoc. 2020;27(11):1774&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7671624</ArticleId><ArticleId IdType="pubmed">32935124</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslin K.C., Hall J.E. Sexual orientation disparities in risk factors for adverse COVID-19&#x2013;related outcomes, by race/ethnicity&#x2014;Behavioral Risk Factor Surveillance System, United States, 2017&#x2013;2019. MMWR Morb Mortal Wkly Rep. 2021;70(5):149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7861482</ArticleId><ArticleId IdType="pubmed">33539330</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahill S., Grasso C., Keuroghlian A., Sciortino C., Mayer K. Sexual and gender minority health in the COVID-19 pandemic: why data collection and combatting discrimination matter now more than ever. Am J Public Health. 2020;110(9):1360&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427229</ArticleId><ArticleId IdType="pubmed">32783729</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Response Team C.D.C., Chow N., Fleming-Dutra K., et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019&#x2014;United States, February 12&#x2013;March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7119513</ArticleId><ArticleId IdType="pubmed">32240123</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Yang Q., Chi J., et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis. Int J Infect Dis. 2020;99:47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381888</ArticleId><ArticleId IdType="pubmed">32721533</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory J.M., Slaughter J.C., Duffus S.H., et al. COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic's impact in type 1 and type 2 diabetes. Diabetes Care. 2021;44(2):526&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818316</ArticleId><ArticleId IdType="pubmed">33268335</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang B.Z., Chen Z., Sidell M.A., et al. Asthma disease severity, COPD, and COVID-19 severity in a large multiethnic population. J Allergy Clin Immunol Pract. 2021;9(10):3621&#x2013;3628. e3622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8353223</ArticleId><ArticleId IdType="pubmed">34389242</ArticleId></ArticleIdList></Reference><Reference><Citation>Price-Haywood E.G., Burton J., Fort D., et al. Hospitalization and mortality among black patients and white patients with Covid-19. N Engl J Med. 2020;382(26):2534&#x2013;2543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269015</ArticleId><ArticleId IdType="pubmed">32459916</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu T., Mack J.A., Salvatore M., et al. Characteristics associated with racial/ethnic disparities in COVID-19 outcomes in an academic health care system. JAMA Netw Open. 2020;3(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578774</ArticleId><ArticleId IdType="pubmed">33084902</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahill S.R. Still in the dark regarding the public health impact of COVID-19 on sexual and gender minorities. Am J Public Health. 2021;111(9):1606&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589066</ArticleId><ArticleId IdType="pubmed">34410865</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowleg L., Landers S. The needs for COVID-19 LGBTQ-specific data. Am J Public Health. 2021;111(9):1604&#x2013;1605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589062</ArticleId><ArticleId IdType="pubmed">34436923</ArticleId></ArticleIdList></Reference><Reference><Citation>Blosnich J., Jarrett T., Horn K. Disparities in smoking and acute respiratory illnesses among sexual minority young adults. Lung. 2010;188(5):401&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">20496074</ArticleId></ArticleIdList></Reference><Reference><Citation>Blosnich J.R., Lee J.G., Bossarte R., et al. Asthma disparities and within-group differences in a national, probability sample of same-sex partnered adults. Am J Public Health. 2013;103(9):e83&#x2013;e87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3780675</ArticleId><ArticleId IdType="pubmed">23865655</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldhuis C.B., George M., Everett B.G., et al. Vol. 18. Ann Am Thorac Soc; 2021. pp. 273&#x2013;280. (The association of asthma, sexual identity, and inhaled substance use among us adolescents).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869781</ArticleId><ArticleId IdType="pubmed">33027599</ArticleId></ArticleIdList></Reference><Reference><Citation>Heck J.E., Jacobson J.S. Asthma diagnosis among individuals in same-sex relationships. J Asthma. 2006;43(8):579&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">17050221</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer G.W., Bucholz K.K., Flick L.H., et al. CVD risk among men participating in the National Health and Nutrition Examination Survey (NHANES) from 2001 to 2010: differences by sexual minority status. J Epidemiol Community Health. 2013;67(9):772&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836258</ArticleId><ArticleId IdType="pubmed">23766523</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer G.W., Jabson J.M., Bucholz K.K., et al. A population-based study of cardiovascular disease risk in sexual-minority women. Am J Public Health. 2013;103(10):1845&#x2013;1850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3780727</ArticleId><ArticleId IdType="pubmed">23948018</ArticleId></ArticleIdList></Reference><Reference><Citation>Corliss H.L., VanKim N.A., Jun H.-.J., et al. Risk of type 2 diabetes among lesbian, bisexual, and heterosexual women: findings from the Nurses&#x2019; Health Study II. Diabetes Care. 2018;41(7):1448&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6014535</ArticleId><ArticleId IdType="pubmed">29720541</ArticleId></ArticleIdList></Reference><Reference><Citation>Blosnich J.R., Farmer G.W., Lee J.G., et al. Health inequalities among sexual minority adults: evidence from ten US states, 2010. Am J Prev Med. 2014;46(4):337&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102129</ArticleId><ArticleId IdType="pubmed">24650836</ArticleId></ArticleIdList></Reference><Reference><Citation>Conron K.J., Mimiaga M.J., Landers S.J. A population-based study of sexual orientation identity and gender differences in adult health. Am J Public Health. 2010;100(10):1953&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936979</ArticleId><ArticleId IdType="pubmed">20516373</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredriksen-Goldsen K.I., Kim H.-.J., Barkan S.E., et al. Health disparities among lesbian, gay, and bisexual older adults: results from a population-based study. Am J Prev Med. 2013;103(10):1802&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3770805</ArticleId><ArticleId IdType="pubmed">23763391</ArticleId></ArticleIdList></Reference><Reference><Citation>Machlin S., Cohen J., Elixhauser A., et al. Sensitivity of household reported medical conditions in the medical expenditure panel survey. Med Care. 2009:618&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">19433993</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.M., Leff M., Calonge N., et al. Validation of self-reported chronic conditions and health services in a managed care population. Am J Prev Med. 2000;18(3):215&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">10722987</ArticleId></ArticleIdList></Reference><Reference><Citation>Okura Y., Urban L.H., Mahoney D.W., et al. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol. 2004;57(10):1096&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528061</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch K.E., Deppen S.A., DuVall S.L., et al. Incrementally transforming electronic medical records into the observational medical outcomes partnership common data model: a multidimensional quality assurance approach. Appl Clin Inform. 2019;10(5):794&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6811349</ArticleId><ArticleId IdType="pubmed">31645076</ArticleId></ArticleIdList></Reference><Reference><Citation>Fihn S.D., Francis J., Clancy C., et al. Insights from advanced analytics at the Veterans Health Administration. Health Aff. 2014;33(7):1203&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">25006147</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch K.E., Alba P., Patterson O.V., et al. The utility of clinical notes for sexual minority health research. Am J Prev Med. 2020;59(5):755&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">33011005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch K.E., Alba P., Viernes B., et al. Using enriched samples for semi-automated vocabulary expansion to identify rare events in clinical text: sexual orientation as a use case. Stud Health Technol Inform. 2019;264:1532&#x2013;1533.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438217</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis K.A., Brandt C.A., Skanderson M., et al. Validating smoking data from the Veteran's Affairs Health Factors dataset, an electronic data source. Nicotine Tob Res. 2011;13(12):1233&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3223583</ArticleId><ArticleId IdType="pubmed">21911825</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch K.E., Viernes B., Schliep K.C., et al. Variation in sexual orientation documentation in a national electronic health record system. LGBT Health. 2021;8(3):201&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9545803</ArticleId><ArticleId IdType="pubmed">33625876</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B.A., Bhavsar N.A., Phelan M., et al. Controlling for informed presence bias due to the number of health encounters in an electronic health record. Am J Epidemiol. 2016;184(11):847&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5152663</ArticleId><ArticleId IdType="pubmed">27852603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson J.M., Jacobs J., Yefimova M., et al. Virtual care expansion in the Veteran Health Administration during the COVID-19 pandemic: clinical services and patient characteristics associated with utilization. J AM Med Inform Assoc. 2021;28(3):453&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665538</ArticleId><ArticleId IdType="pubmed">33125032</ArticleId></ArticleIdList></Reference><Reference><Citation>Azagba S., Shan L., Latham K. Overweight and obesity among sexual minority adults in the United States. Int J Environ Res Public Health. 2019;16(10):1828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6572698</ArticleId><ArticleId IdType="pubmed">31126042</ArticleId></ArticleIdList></Reference><Reference><Citation>Blosnich J., Foynes M.M., Shipherd J.C. Health disparities among sexual minority women veterans. J Womens Health (Larchmt) 2013;22(7):631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3761433</ArticleId><ArticleId IdType="pubmed">23746281</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehmer U., Bowen D.J., Bauer G.R. Overweight and obesity in sexual-minority women: evidence from population-based data. Am J Public Health. 2007;97(6):1134&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1874217</ArticleId><ArticleId IdType="pubmed">17463369</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf N.G., Bakken S., Hripcsak G., et al. A data quality assessment guideline for electronic health record data reuse. EGEMS (Wash. DC) 2017;5(1):14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983018</ArticleId><ArticleId IdType="pubmed">29881734</ArticleId></ArticleIdList></Reference><Reference><Citation>Agha Z., Lofgren R.P., VanRuiswyk J.V., et al. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med. 2000;160(21):3252&#x2013;3257.</Citation><ArticleIdList><ArticleId IdType="pubmed">11088086</ArticleId></ArticleIdList></Reference><Reference><Citation>Schult T.M., Schmunk S.K., Marzolf J.R., et al. The health status of veteran employees compared to civilian employees in Veterans Health Administration. Mil Med. 2019;184(7&#x2013;8):e218&#x2013;e224.</Citation><ArticleIdList><ArticleId IdType="pubmed">30793192</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilbourne A.M., Switzer G., Hyman K., et al. Advancing health disparities research within the health care system: a conceptual framework. Am J Public Health. 2006;96(12):2113&#x2013;2121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698151</ArticleId><ArticleId IdType="pubmed">17077411</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R., Ovbiagele B., Feng W. Diabetes and stroke: epidemiology, pathophysiology, pharmaceuticals and outcomes. Am J Med Sci. 2016;351(4):380&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5298897</ArticleId><ArticleId IdType="pubmed">27079344</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo C., Borrelli S., Pacilio M., et al. Hypertension and prehypertension and prediction of development of decreased estimated GFR in the general population: a meta-analysis of cohort studies. Am J Kidney Dis. 2016;67(1):89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">26475392</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattocks K.M., Sullivan J.C., Bertrand C., et al. Perceived stigma, discrimination, and disclosure of sexual orientation of sexual orientation among a sample of lesbian veterans receiving care in the Department of Veterans Affairs. LGBT. Health. 2001;2(2):147&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">26790121</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Department of Veterans Affairs: Provision of health care for Veterans who identify as lesbian, gay or bisexual. 2021 https://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=5438 Available at. Accessed October 17.</Citation></Reference><Reference><Citation>O'Malley K.J., Cook K.F., Price M.D., et al. Measuring diagnoses: ICD code accuracy. Health Serv Res. 2005;40(5):1620&#x2013;1639. Pt 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1361216</ArticleId><ArticleId IdType="pubmed">16178999</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J., Chow A. Comparing chronic condition rates using ICD-9 and ICD-10 in VA patients FY2014&#x2013;2016. BMC Health Serv Res. 2017;17(1):572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5561575</ArticleId><ArticleId IdType="pubmed">28818082</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34795073</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>287</Volume><PubDate><Year>2021</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Development of a FHIR Layer on Top of the OMOP Common Data Model for the CAPABLE Project.</ArticleTitle><Pagination><StartPage>28</StartPage><EndPage>29</EndPage><MedlinePgn>28-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210804</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gabetta</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alloni</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polce</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanzola</LastName><ForeName>Giordano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parimbelli</LastName><ForeName>Enea</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbarini</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066275" MajorTopicYN="Y">Health Information Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057208" MajorTopicYN="Y">Health Level Seven</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">API</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">HL7 FHIR</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34795073</ArticleId><ArticleId IdType="doi">10.3233/SHTI210804</ArticleId><ArticleId IdType="pii">SHTI210804</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34795074</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>287</Volume><PubDate><Year>2021</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Automatic Data Transfer from OMOP-CDM to REDCap: A Semantically-Enriched Framework.</ArticleTitle><Pagination><StartPage>30</StartPage><EndPage>31</EndPage><MedlinePgn>30-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210805</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Girani</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabetta</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alloni</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuppia</LastName><ForeName>Morena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacchi</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbarini</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>BIOMERIS (BIOMEdical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EDC</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">REDCap</Keyword><Keyword MajorTopicYN="N">Real World Data</Keyword><Keyword MajorTopicYN="N">eCRF</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34795074</ArticleId><ArticleId IdType="doi">10.3233/SHTI210805</ArticleId><ArticleId IdType="pii">SHTI210805</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34795082</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>287</Volume><PubDate><Year>2021</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Transfer of Clinical Drug Data to a Research Infrastructure on OMOP - A FAIR Concept.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>67</EndPage><MedlinePgn>63-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210815</ELocationID><Abstract><AbstractText>Generating evidence based on real-world data is gaining importance in research not least since the COVID-19 pandemic. The Common Data Model of Observational Medical Outcomes Partnership (OMOP) is a research infrastructure that implements FAIR principles. Although the transfer of German claim data to OMOP is already implemented, drug data is an open issue. This paper provides a concept to prepare electronic health record (EHR) drug data for the transfer to OMOP based on requirements analysis and descriptive statistics for profiling EHR data developed by an interdisciplinary team and also covers data quality issues. The concept not only ensures FAIR principles for research, but provides the foundation for German drug data to OMOP transfer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reinecke</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoch</LastName><ForeName>Mich&#xe9;le</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilhelm</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bathelt</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="Y">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EHR</Keyword><Keyword MajorTopicYN="N">FAIR</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">data quality</Keyword><Keyword MajorTopicYN="N">drug administration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34795082</ArticleId><ArticleId IdType="doi">10.3233/SHTI210815</ArticleId><ArticleId IdType="pii">SHTI210815</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34795096</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>287</Volume><PubDate><Year>2021</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Making EHRs Reusable: A Common Framework of Data Operations.</ArticleTitle><Pagination><StartPage>129</StartPage><EndPage>133</EndPage><MedlinePgn>129-133</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI210831</ELocationID><Abstract><AbstractText>Reuse of EHRs requires data extraction and transformation processes are based on homogeneous and formalized operations in order to make them understandable, reproducible and auditable. This work aims to define a common framework of data operations for obtaining EHR-derived datasets for secondary use. Thus, 21 operations were identified from different data-driven projects of a 1,300-beds tertiary Hospital. Then, ISO 13606 standard was used to formalize them. This work is the starting point to homogenize ETL processes for the reuse of EHRs, applicable to any condition and organization. In future studies, defined data operations will be implemented and validated in projects of different purposes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pedrera</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ETSI Telecomunicaci&#xf3;n, Universidad Polit&#xe9;cnica de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Noelia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Juan Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernal</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Data reusability</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">FAIR</Keyword><Keyword MajorTopicYN="N">ISARIC</Keyword><Keyword MajorTopicYN="N">ISO 13606</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Real World Data</Keyword><Keyword MajorTopicYN="N">Semantics</Keyword><Keyword MajorTopicYN="N">Standards</Keyword><Keyword MajorTopicYN="N">i2b2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34795096</ArticleId><ArticleId IdType="doi">10.3233/SHTI210831</ArticleId><ArticleId IdType="pii">SHTI210831</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34831777</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1660-4601</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>22</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of environmental research and public health</Title><ISOAbbreviation>Int J Environ Res Public Health</ISOAbbreviation></Journal><ArticleTitle>The Prescription of Drug Ontology 2.0 (PDRO): More Than the Sum of Its Parts.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">12025</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijerph182212025</ELocationID><Abstract><AbstractText>While drugs and related products have profoundly changed the lives of people around the world, ongoing challenges remain, including inappropriate use of a drug product. Inappropriate uses can be explained in part by ambiguous or incomplete information, for example, missing reasons for treatments, ambiguous information on how to take a medication, or lack of information on medication-related events outside the health care system. In order to fully assess the situation, data from multiple systems (electronic medical records, pharmacy and radiology information systems, laboratory management systems, etc.) from multiple organizations (outpatient clinics, hospitals, long-term care facilities, laboratories, pharmacies, registries, governments) on a large geographical scale is needed. Formal knowledge models like ontologies can help address such an information integration challenge. Existing approaches like the Observational Medical Outcomes Partnership are discussed and contrasted with the use of ontologies and systems using them for data integration. The PRescription Drug Ontology 2.0 (PDRO 2.0) is then presented and entities that are paramount in addressing this problematic are described. Finally, the benefits of using PDRO are discussed through a series of exemplar situation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ethier</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0001-9408-0109</Identifier><AffiliationInfo><Affiliation>Groupe de Recherche Interdisciplinaire en Informatique de la Sant&#xe9; (GRIIS.ca), Universit&#xe9; de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyer</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Groupe de Recherche Interdisciplinaire en Informatique de la Sant&#xe9; (GRIIS.ca), Universit&#xe9; de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabry</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Groupe de Recherche Interdisciplinaire en Informatique de la Sant&#xe9; (GRIIS.ca), Universit&#xe9; de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barton</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Groupe de Recherche Interdisciplinaire en Informatique de la Sant&#xe9; (GRIIS.ca), Universit&#xe9; de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRIT-Institut de Recherche en Informatique de Toulouse (CNRS), 31400 Toulouse, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Environ Res Public Health</MedlineTA><NlmUniqueID>101238455</NlmUniqueID><ISSNLinking>1660-4601</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055553">Prescription Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010594" MajorTopicYN="Y">Pharmacies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055553" MajorTopicYN="Y">Prescription Drugs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055656" MajorTopicYN="N">Prescriptions</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">data annotation</Keyword><Keyword MajorTopicYN="N">drug ontology</Keyword><Keyword MajorTopicYN="N">drug prescription</Keyword><Keyword MajorTopicYN="N">medication management</Keyword><Keyword MajorTopicYN="N">ontology development</Keyword><Keyword MajorTopicYN="N">optimization of prescription</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34831777</ArticleId><ArticleId IdType="pmc">PMC8619589</ArticleId><ArticleId IdType="doi">10.3390/ijerph182212025</ArticleId><ArticleId IdType="pii">ijerph182212025</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baker M., Perazella M.A. NSAIDs in CKD: Are They Safe? Am. J. Kidney Dis. 2020;76:546&#x2013;557. doi: 10.1053/j.ajkd.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2020.03.023</ArticleId><ArticleId IdType="pubmed">32479922</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara N., Ibrahim A., Satti Z., Ibrahim M., Kiernan T.J. Acute Pericarditis: A Review of Current Diagnostic and Management Guidelines. Future Cardiol. 2019;15:119&#x2013;126. doi: 10.2217/fca-2017-0102.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fca-2017-0102</ArticleId><ArticleId IdType="pubmed">30848669</ArticleId></ArticleIdList></Reference><Reference><Citation>Codes Justificatifs|RAMQ.  [(accessed on 29 September 2021)]; Available online:  https://www.ramq.gouv.qc.ca/fr/professionnels/optometristes/medicaments/nps/Pages/modalites-application-codes-justificatifs.aspx.</Citation></Reference><Reference><Citation>Wittich C.M., Burkle C.M., Lanier W.L. Medication Errors: An Overview for Clinicians. Mayo Clin. Proc. 2014;89:1116&#x2013;1125. doi: 10.1016/j.mayocp.2014.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2014.05.007</ArticleId><ArticleId IdType="pubmed">24981217</ArticleId></ArticleIdList></Reference><Reference><Citation>Laws M.B., Lee Y., Taubin T., Rogers W.H., Wilson I.B. Factors Associated with Patient Recall of Key Information in Ambulatory Specialty Care Visits: Results of an Innovative Methodology. PLoS ONE. 2018;13:e0191940. doi: 10.1371/journal.pone.0191940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0191940</ArticleId><ArticleId IdType="pmc">PMC5794108</ArticleId><ArticleId IdType="pubmed">29389994</ArticleId></ArticleIdList></Reference><Reference><Citation>Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., et al. Incidence, Predictors, and Outcome of Thrombosis after Successful Implantation of Drug-Eluting Stents. JAMA. 2005;293:2126&#x2013;2130. doi: 10.1001/jama.293.17.2126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.293.17.2126</ArticleId><ArticleId IdType="pubmed">15870416</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacio S., Hart R.G., Pearce L.A., Benavente O.R. Effect of Addition of Clopidogrel to Aspirin on Mortality Systematic Review of Randomized Trials. Stroke J. Cereb. Circ. 2012;43:2157&#x2013;2162. doi: 10.1161/STROKEAHA.112.656173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.112.656173</ArticleId><ArticleId IdType="pmc">PMC3970708</ArticleId><ArticleId IdType="pubmed">22826359</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP  CDM v5.4.  [(accessed on 30 September 2021)].  Available online:  http://ohdsi.github.io/CommonDataModel/cdm54.html#DEVICE_EXPOSURE.</Citation></Reference><Reference><Citation>Arp R., Smith B., Spear A.D. Building Ontologies with Basic Formal Ontology. MIT Press; Cambridge, CA, USA: 2015.</Citation></Reference><Reference><Citation>Klann J.G., Joss M.A.H., Embree K., Murphy S.N. Data Model Harmonization for the All of Us Research Program: Transforming I2b2 Data into the OMOP Common Data Model. PLoS ONE. 2019;14:e0212463. doi: 10.1371/journal.pone.0212463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0212463</ArticleId><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy S.N., Mendis M.E., Berkowitz D.A., Kohane I., Chueh H.C. AMIA Annual Symposium Proceedings. American Medical Informatics Association; Bethesda, MD, USA: 2006. Integration of Clinical and Genetic Data in the I2b2 Architecture; p. 1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839291</ArticleId><ArticleId IdType="pubmed">17238659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceusters W., Blaisure J. A Realism-Based View on Counts in OMOP&#x2019;s Common Data Model. Stud. Health Technol. Inform. 2017;237:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">28479543</ArticleId></ArticleIdList></Reference><Reference><Citation>HL7 HL7 Standards Product Brief&#x2014;FHIR&#xae; R4 (HL7 Fast Healthcare Interoperability Resources, Release 4)|HL7 International.  [(accessed on 7 January 2020)].  Available online:  https://www.hl7.org/implement/standards/product_brief.cfm?product_id=491.</Citation></Reference><Reference><Citation>Patient&#x2014;FHIR v1.0.2.  [(accessed on 29 September 2021)].  Available online:  http://hl7.org/fhir/dstu2/patient-definitions.html.</Citation></Reference><Reference><Citation>Lau F., Antonio M., Davison K., Queen R., Devor A. A Rapid Review of Gender, Sex, and Sexual Orientation Documentation in Electronic Health Records. J. Am. Med. Inform. Assoc. JAMIA. 2020;27:1774&#x2013;1783. doi: 10.1093/jamia/ocaa158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa158</ArticleId><ArticleId IdType="pmc">PMC7671624</ArticleId><ArticleId IdType="pubmed">32935124</ArticleId></ArticleIdList></Reference><Reference><Citation>OWL  2 Web Ontology Language Document Overview (Second Edition)  [(accessed on 29 September 2021)].  Available online:  https://www.w3.org/TR/owl-overview/</Citation></Reference><Reference><Citation>Smith B., Ashburner M., Rosse C., Bard J., Bug W., Ceusters W., Goldberg L.J., Eilbeck K., Ireland A., Mungall C.J., et al. The OBO Foundry: Coordinated Evolution of Ontologies to Support Biomedical Data Integration. Nat. Biotechnol. 2007;25:1251. doi: 10.1038/nbt1346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1346</ArticleId><ArticleId IdType="pmc">PMC2814061</ArticleId><ArticleId IdType="pubmed">17989687</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., et al. Gene Ontology: Tool for the Unification of Biology. The Gene Ontology Consortium. Nat. Genet. 2000;25:25&#x2013;29. doi: 10.1038/75556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider T., &#x160;imkus M. Ontologies and Data Management: A Brief Survey. KI-K&#xfc;nstl. Intell. 2020;34:329&#x2013;353. doi: 10.1007/s13218-020-00686-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13218-020-00686-3</ArticleId><ArticleId IdType="pmc">PMC7497697</ArticleId><ArticleId IdType="pubmed">32999532</ArticleId></ArticleIdList></Reference><Reference><Citation>Towards a New Generation of Ontology Based Data Access|Www.Semantic-Web-Journal.Net.  [(accessed on 30 September 2021)].  Available online:  http://semantic-web-journal.net/content/towards-new-generation-ontology-based-data-access.</Citation></Reference><Reference><Citation>Ethier J.-F., Dameron O., Curcin V., McGilchrist M.M., Verheij R.A., Arvanitis T.N., Taweel A., Delaney B.C., Burgun A. A Unified Structural/Terminological Interoperability Framework Based on LexEVS: Application to TRANSFoRm. J. Am. Med. Inform. Assoc. 2013;20:986&#x2013;994. doi: 10.1136/amiajnl-2012-001312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-001312</ArticleId><ArticleId IdType="pmc">PMC3756256</ArticleId><ArticleId IdType="pubmed">23571850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ethier J.-F., Curcin V., Barton A., McGilchrist M.M., Bastiaens H., Andreasson A., Rossiter J., Zhao L., Arvanitis T.N., Taweel A., et al. Clinical Data Integration Model. Core Interoperability Ontology for Research Using Primary Care Data. Methods Inf. Med. 2015;54:16&#x2013;23. doi: 10.3414/ME13-02-0024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME13-02-0024</ArticleId><ArticleId IdType="pubmed">24954896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ecarot T., Fraikin B., Lavoie L., McGilchrist M., Ethier J.-F. A Sensitive Data Access Model in Support of Learning Health Systems. Computers. 2021;10:25. doi: 10.3390/computers10030025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/computers10030025</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton A., Fabry P., Ethier J.-F. A Classification of Instructions in Drug Prescriptions and Pharmacist Documents; Proceedings of the 10th International Conference on Biomedical Ontology (ICBO 2019); Buffalo, NY, USA. 30 July&#x2013;2 August 2019; pp. 1&#x2013;7.</Citation></Reference><Reference><Citation>Ethier J.-F., Taseen R., Lavoie L., Barton A. Improving the Semantics of Drug Prescriptions with a Realist Ontology; Proceedings of the International Conference on Biomedical Ontology and BioCreative (ICBO BioCreative 2016); Corvallis, OR, USA. 1&#x2013;4 August 2016;  [(accessed on 30 September 2021)].  Available online:  CEUR-ws.org.</Citation></Reference><Reference><Citation>Barton A., Fabry P., Lavoie L., Ethier J.-F. LABO: An Ontology for Laboratory Test Prescription and Reporting; Proceedings of the Joint Ontology Workshops 2019 Episode V: The Styrian Autumn of Ontology; Graz, Austria. 23&#x2013;25 September 2019.</Citation></Reference><Reference><Citation>Smith B. Basic Formal Ontology 2.0: Specification and User&#x2019;s Guide. 2015.  [(accessed on 30 September 2021)]. p. 100. Available online:  https://github.com/BFO-ontology/BFO/raw/master/docs/bfo2-reference/BFO2-Reference.pdf.</Citation></Reference><Reference><Citation>Ceusters W., Smith B. Aboutness: Towards Foundations for the Information Artifact Ontology; Proceedings of the Sixth International Conference on Biomedical Ontology (ICBO); Lisbon, Portugal. 27&#x2013;30 July 2015; pp. 1&#x2013;5.</Citation></Reference><Reference><Citation>Bandrowski A., Brinkman R., Brochhausen M., Brush M.H., Bug B., Chibucos M.C., Clancy K., Courtot M., Derom D., Dumontier M., et al. The Ontology for Biomedical Investigations. PLoS ONE. 2016;11:e0154556. doi: 10.1371/journal.pone.0154556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0154556</ArticleId><ArticleId IdType="pmc">PMC4851331</ArticleId><ArticleId IdType="pubmed">27128319</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq R.A., Vashisht R., Sinha A., Scherbak Y. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2021. Medication Dispensing Errors And Prevention.</Citation></Reference><Reference><Citation>Fabry P., Barton A., Ethier J.-F. QUESTO&#x2014;An Ontology for Questionnaires; Proceedings of the 11th International Conference on Biomedical Ontologies, ICBO 2020; Bolzano, Italy. 17 September 2020; Bolzano, Italy: CEUR-WS.org; 2020.</Citation></Reference><Reference><Citation>Scheuermann R.H., Ceusters W., Smith B. Toward an Ontological Treatment of Disease and Diagnosis. Summit Transl. Bioinform. 2009;2009:116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041577</ArticleId><ArticleId IdType="pubmed">21347182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Combs K., Downs J., Tillman F., III Medication Adherence: The Elephant in the Room.  [(accessed on 30 September 2021)].  Available online:  https://www.uspharmacist.com/article/medication-adherence-the-elephant-in-the-room.</Citation></Reference><Reference><Citation>Prescribed and Dispensed Drugs in the DRUG_EXPOSURE Tabl&#x2014;Implementers.  [(accessed on 30 September 2021)].  Available online:  https://forums.ohdsi.org/t/prescribed-and-dispensed-drugs-in-the-drug-exposure-table/10997/2.</Citation></Reference><Reference><Citation>Cossette B., Taseen R., Roy-Petit J., Villemure M.-P., Grondin M., Ricard G., Goyer F., Blanchard C., Joly-Mischlich T., &#xc9;thier J.-F. A Pharmacist-Physician Intervention Model Using a Computerized Alert System to Reduce High-Risk Medication Use in Primary Care. Eur. J. Clin. Pharmacol. 2019;75:1017&#x2013;1023. doi: 10.1007/s00228-019-02660-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-019-02660-x</ArticleId><ArticleId IdType="pubmed">30899989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau W.C., Welch T.D., Shields T., Rubenfire M., Tantry U.S., Gurbel P.A. The Effect of St John&#x2019;s Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity. J. Cardiovasc. Pharmacol. 2011;57:86&#x2013;93. doi: 10.1097/FJC.0b013e3181ffe8d0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0b013e3181ffe8d0</ArticleId><ArticleId IdType="pubmed">20980920</ArticleId></ArticleIdList></Reference><Reference><Citation>Claire Van Hout M. &#x201c;Doctor Shopping and Pharmacy Hopping&#x201d;: Practice Innovations Relating to Codeine. Drugs Alcohol Today. 2014;14:219&#x2013;234. doi: 10.1108/DAT-03-2014-0014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1108/DAT-03-2014-0014</ArticleId></ArticleIdList></Reference><Reference><Citation>Delcher C., Harris D.R., Park C., Strickler G.K., Talbert J., Freeman P.R. &#x201c;Doctor and Pharmacy Shopping&#x201d;: A Fading Signal for Prescription Opioid Use Monitoring? Drug Alcohol Depend. 2021;221:108618. doi: 10.1016/j.drugalcdep.2021.108618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2021.108618</ArticleId><ArticleId IdType="pmc">PMC8026641</ArticleId><ArticleId IdType="pubmed">33677354</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttigieg P.L., Pafilis E., Lewis S.E., Schildhauer M.P., Walls R.L., Mungall C.J. The Environment Ontology in 2016: Bridging Domains with Increased Scope, Semantic Density, and Interoperation. J. Biomed. Semant. 2016;7:57. doi: 10.1186/s13326-016-0097-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13326-016-0097-6</ArticleId><ArticleId IdType="pmc">PMC5035502</ArticleId><ArticleId IdType="pubmed">27664130</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34841975</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0334</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Statistical methods in medical research</Title><ISOAbbreviation>Stat Methods Med Res</ISOAbbreviation></Journal><ArticleTitle>Combining cox regressions across a heterogeneous distributed research network facing small and zero counts.</ArticleTitle><Pagination><StartPage>438</StartPage><EndPage>450</EndPage><MedlinePgn>438-450</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09622802211060518</ELocationID><Abstract><AbstractText>Studies of the effects of medical interventions increasingly take place in distributed research settings using data from multiple clinical data sources including electronic health records and administrative claims. In such settings, privacy concerns typically prohibit sharing of individual patient data, and instead, cross-network analyses can only utilize summary statistics from the individual databases such as hazard ratios and standard errors. In the specific but very common context of the Cox proportional hazards model, we show that combining such per site summary statistics into a single network-wide estimate using standard meta-analysis methods leads to substantial bias when outcome counts are small. This bias derives primarily from the normal approximations of the per site likelihood that the methods utilized. Here we propose and evaluate methods that eschew normal approximations in favor of three more flexible approximations: a skew-normal, a one-dimensional grid, and a custom parametric function that mimics the behavior of the Cox likelihood function. In extensive simulation studies, we demonstrate how these approximations impact bias in the context of both fixed-effects and (Bayesian) random-effects models. We then apply these approaches to three real-world studies of the comparative safety of antidepressants, each using data from four observational health care databases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0817-5361</Identifier><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics,6572University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Khoury College of Computer Sciences, 1848Northeastern University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9818-479X</Identifier><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, 8783University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI135995</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stat Methods Med Res</MedlineTA><NlmUniqueID>9212457</NlmUniqueID><ISSNLinking>0962-2802</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016013" MajorTopicYN="N">Likelihood Functions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bayesian</Keyword><Keyword MajorTopicYN="N">distributed research networks</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">privacy preservation</Keyword><Keyword MajorTopicYN="N">proportional hazards</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>29</Day><Hour>8</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34841975</ArticleId><ArticleId IdType="doi">10.1177/09622802211060518</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34860667</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1438-8871</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Journal of medical Internet research</Title><ISOAbbreviation>J Med Internet Res</ISOAbbreviation></Journal><ArticleTitle>Open-source Software Sustainability Models: Initial White Paper From the Informatics Technology for Cancer Research Sustainability and Industry Partnership Working Group.</ArticleTitle><Pagination><StartPage>e20028</StartPage><MedlinePgn>e20028</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e20028</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/20028</ELocationID><Abstract><AbstractText Label="BACKGROUND">The National Cancer Institute Informatics Technology for Cancer Research (ITCR) program provides a series of funding mechanisms to create an ecosystem of open-source software (OSS) that serves the needs of cancer research. As the ITCR ecosystem substantially grows, it faces the challenge of the long-term sustainability of the software being developed by ITCR grantees. To address this challenge, the ITCR sustainability and industry partnership working group (SIP-WG) was convened in 2019.</AbstractText><AbstractText Label="OBJECTIVE">The charter of the SIP-WG is to investigate options to enhance the long-term sustainability of the OSS being developed by ITCR, in part by developing a collection of business model archetypes that can serve as sustainability plans for ITCR OSS development initiatives. The working group assembled models from the ITCR program, from other studies, and from the engagement of its extensive network of relationships with other organizations (eg, Chan Zuckerberg Initiative, Open Source Initiative, and Software Sustainability Institute) in support of this objective.</AbstractText><AbstractText Label="METHODS">This paper reviews the existing sustainability models and describes 10 OSS use cases disseminated by the SIP-WG and others, including 3D Slicer, Bioconductor, Cytoscape, Globus, i2b2 (Informatics for Integrating Biology and the Bedside) and tranSMART, Insight Toolkit, Linux, Observational Health Data Sciences and Informatics tools, R, and REDCap (Research Electronic Data Capture), in 10 sustainability aspects: governance, documentation, code quality, support, ecosystem collaboration, security, legal, finance, marketing, and dependency hygiene.</AbstractText><AbstractText Label="RESULTS">Information available to the public reveals that all 10 OSS have effective governance, comprehensive documentation, high code quality, reliable dependency hygiene, strong user and developer support, and active marketing. These OSS include a variety of licensing models (eg, general public license version 2, general public license version 3, Berkeley Software Distribution, and Apache 3) and financial models (eg, federal research funding, industry and membership support, and commercial support). However, detailed information on ecosystem collaboration and security is not publicly provided by most OSS.</AbstractText><AbstractText Label="CONCLUSIONS">We recommend 6 essential attributes for research software: alignment with unmet scientific needs, a dedicated development team, a vibrant user community, a feasible licensing model, a sustainable financial model, and effective product management. We also stress important actions to be considered in future ITCR activities that involve the discussion of the sustainability and licensing models for ITCR OSS, the establishment of a central library, the allocation of consulting resources to code quality control, ecosystem collaboration, security, and dependency hygiene.</AbstractText><CopyrightInformation>&#xa9;Ye Ye, Seemran Barapatre, Michael K Davis, Keith O Elliston, Christos Davatzikos, Andrey Fedorov, Jean-Christophe Fillion-Robin, Ian Foster, John R Gilbertson, Andras Lasso, James V Miller, Martin Morgan, Steve Pieper, Brigitte E Raumann, Brion D Sarachan, Guergana Savova, Jonathan C Silverstein, Donald P Taylor, Joyce B Zelnis, Guo-Qiang Zhang, Jamie Cuticchia, Michael J Becich. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 02.12.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1138-9846</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barapatre</LastName><ForeName>Seemran</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8112-6147</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Michael K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0002-7754-3957</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliston</LastName><ForeName>Keith O</ForeName><Initials>KO</Initials><Identifier Source="ORCID">0000-0002-9110-9233</Identifier><AffiliationInfo><Affiliation>Axiomedix, Inc., Bedford, MA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PHEMI Systems Corp., Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>tranSMART foundation, Wakefield, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davatzikos</LastName><ForeName>Christos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1025-8561</Identifier><AffiliationInfo><Affiliation>Department of Radiology, School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fedorov</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4806-9413</Identifier><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fillion-Robin</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-9688-8950</Identifier><AffiliationInfo><Affiliation>Kitware Inc., Clifton Park, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Ian</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2129-5269</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, University of Chicago, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbertson</LastName><ForeName>John R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0001-9679-8261</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasso</LastName><ForeName>Andras</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4220-7064</Identifier><AffiliationInfo><Affiliation>The Perk Lab for Percutaneous Surgery, School of Computing, Queen's University, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>James V</ForeName><Initials>JV</Initials><Identifier Source="ORCID">0000-0003-1877-7881</Identifier><AffiliationInfo><Affiliation>GE Global Research, Niskayuna, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5874-8148</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieper</LastName><ForeName>Steve</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4193-9578</Identifier><AffiliationInfo><Affiliation>Isomics Inc., Cambridge, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raumann</LastName><ForeName>Brigitte E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0003-3067-0366</Identifier><AffiliationInfo><Affiliation>Globus, University of Chicago, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarachan</LastName><ForeName>Brion D</ForeName><Initials>BD</Initials><Identifier Source="ORCID">0000-0002-6266-799X</Identifier><AffiliationInfo><Affiliation>GE Global Research, Niskayuna, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savova</LastName><ForeName>Guergana</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5887-200X</Identifier><AffiliationInfo><Affiliation>Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverstein</LastName><ForeName>Jonathan C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-9252-6039</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Donald P</ForeName><Initials>DP</Initials><Identifier Source="ORCID">0000-0002-2146-8804</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zelnis</LastName><ForeName>Joyce B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-5785-968X</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guo-Qiang</ForeName><Initials>GQ</Initials><Identifier Source="ORCID">0000-0002-3663-1109</Identifier><AffiliationInfo><Affiliation>The University of Texas Health Science Center at Houston, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuticchia</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2447-5161</Identifier><AffiliationInfo><Affiliation>Axiomedix, Inc., Bedford, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becich</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-5998-8074</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 CA180918</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 LM013383</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 CA180996</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 OH009077</GrantID><Acronym>OH</Acronym><Agency>NIOSH CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 CA231904</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA204826</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB015902</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 CA248010</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Internet Res</MedlineTA><NlmUniqueID>100959882</NlmUniqueID><ISSNLinking>1438-8871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017753" MajorTopicYN="Y">Ecosystem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048088" MajorTopicYN="N">Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013672" MajorTopicYN="N">Technology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer informatics</Keyword><Keyword MajorTopicYN="N">financial model</Keyword><Keyword MajorTopicYN="N">licensing model</Keyword><Keyword MajorTopicYN="N">open-source software</Keyword><Keyword MajorTopicYN="N">product management</Keyword><Keyword MajorTopicYN="N">sustainability</Keyword></KeywordList><CoiStatement>Conflicts of Interest: KOE is a shareholder or investor in Ingentium, Inc; Axiomedix, Inc; Seneca Creek Research LLC; and Trazend, Inc; KOE holds advisory roles with Open-Source Pharma Foundation nongovernmental organization and i2b2 tranSMART Foundation and currently serves as the chief executive officer of PHEMI Systems Corp. MJB is a founder and has equity (stock) in SpIntellx, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>3</Day><Hour>17</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34860667</ArticleId><ArticleId IdType="pmc">PMC8686402</ArticleId><ArticleId IdType="doi">10.2196/20028</ArticleId><ArticleId IdType="pii">v23i12e20028</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>About ITCR. National Cancer Institute Informatics Technology for Cancer Research. 2019.  [2021-11-09].  
 https://itcr.cancer.gov/about-itcr
.</Citation></Reference><Reference><Citation>Funding opportunities. National Cancer Institute Informatics Technology for Cancer Research. 2019.  [2021-11-09].  
 https://itcr.cancer.gov/funding-opportunities
.</Citation></Reference><Reference><Citation>Pratt D, Chen J, Pillich R, Rynkov V, Gary A, Demchak B, Ideker T. NDEx 2.0: a clearinghouse for research on cancer pathways. Cancer Res. 2017 Nov 01;77(21):e58&#x2013;61. doi: 10.1158/0008-5472.CAN-17-0606. 
 
77/21/e58</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-17-0606</ArticleId><ArticleId IdType="pmc">PMC5679399</ArticleId><ArticleId IdType="pubmed">29092941</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillich R. ITCR Connectivity Map.  [2020-10-22].  
 http://www.ndexbio.org/#/network/04c0a7e8-af92-11e7-94d3-0ac135e8bacf
.</Citation></Reference><Reference><Citation>Information Technology for Cancer Research (ITCR) initiative. NCI Hub. 2019.  [2021-11-09].  
 https://ncihub.org/groups/itcr/sustainability_and_industry_partnership_wg
.</Citation></Reference><Reference><Citation>Kuchinke W, Ohmann C, Stenzhorn H, Anguista A, Sfakianakis S, Graf N, Demotes J. Ensuring sustainability of software tools and services by cooperation with a research infrastructure. Per Med. 2016 Jan;13(1):43&#x2013;55. doi: 10.2217/pme.15.43. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/pme.15.43?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed</ArticleId><ArticleId IdType="doi">10.2217/pme.15.43</ArticleId><ArticleId IdType="pubmed">29749867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang V, Mills H, Newhouse S. Form open source to long term sustainability: review of business models and case studies. Proceedings of the UK e-Science All Hands Meeting 2007; Proceedings of the UK e-Science All Hands Meeting 2007; Sep 10-13, 2007; Nottingham UK. 2007.</Citation></Reference><Reference><Citation>Aartsen W, Peeters P, Wagers S, Williams-Jones B. Getting digital assets from public-private partnership research projects through "the valley of death," and making them sustainable. Front Med (Lausanne) 2018;5:65. doi: 10.3389/fmed.2018.00065. doi: 10.3389/fmed.2018.00065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00065</ArticleId><ArticleId IdType="doi">10.3389/fmed.2018.00065</ArticleId><ArticleId IdType="pmc">PMC5855043</ArticleId><ArticleId IdType="pubmed">29594123</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabella C, Durinx C, Appel R. Funding knowledgebases: towards a sustainable funding model for the UniProt use case. F1000Res. 2017;6:ELIXIR-2051. doi: 10.12688/f1000research.12989.2. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.12989.2/doi</ArticleId><ArticleId IdType="doi">10.12688/f1000research.12989.2</ArticleId><ArticleId IdType="pmc">PMC5747334</ArticleId><ArticleId IdType="pubmed">29333230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikipedia  Business Models for Open-Source Software. 2019.  [2019-02-11].  
 https://en.wikipedia.org/wiki/Business_models_for_open-source_software
.</Citation></Reference><Reference><Citation>Iaffaldano G, Steinmacher I, Calefato F, Gerosa M, Lanubile F. Why do developers take breaks from contributing to OSS projects?: a preliminary analysis. Proceedings of the 2nd International Workshop on Software Health; 2nd International Workshop on Software Health; May 28, 2019; Montreal, Quebec, Canada. 2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/SoHeal.2019.00009</ArticleId></ArticleIdList></Reference><Reference><Citation>Atiq A, Tripathi A. Impact of financial benefits on open source software sustainability. Proceedings of the Thirty Seventh International Conference on Information Systems; Thirty Seventh International Conference on Information Systems; Dec 11-14, 2016; Dublin. 2016.</Citation></Reference><Reference><Citation>Jim&#xe9;nez RC, Kuzak M, Alhamdoosh M, Barker M, Batut B, Borg M, Capella-Gutierrez S, Chue Hong N, Cook M, Corpas M, Flannery M, Garcia L, Gelp&#xed; JL, Gladman S, Goble C, Gonz&#xe1;lez Ferreiro M, Gonzalez-Beltran A, Griffin PC, Gr&#xfc;ning B, Hagberg J, Holub P, Hooft R, Ison J, Katz DS, Lesko&#x161;ek B, L&#xf3;pez G&#xf3;mez F, Oliveira LJ, Mellor D, Mosbergen R, Mulder N, Perez-Riverol Y, Pergl R, Pichler H, Pope B, Sanz F, Schneider MV, Stodden V, Suchecki R, Svobodov&#xe1; Va&#x159;ekov&#xe1; R, Talvik H, Todorov I, Treloar A, Tyagi S, van Gompel M, Vaughan D, Via A, Wang X, Watson-Haigh NS, Crouch S. Four simple recommendations to encourage best practices in research software. F1000Res. 2017;6:ELIXIR-876. doi: 10.12688/f1000research.11407.1. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.11407.1/doi</ArticleId><ArticleId IdType="doi">10.12688/f1000research.11407.1</ArticleId><ArticleId IdType="pmc">PMC5490478</ArticleId><ArticleId IdType="pubmed">28751965</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyman L, Lindman J. Code forking, governance, and sustainability in open source software. Technol Innov Manag Rev. 2013;3(1):7&#x2013;12. doi: 10.22215/timreview/644.</Citation><ArticleIdList><ArticleId IdType="doi">10.22215/timreview/644</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyman L, Mikkonen T, Lindman J, Foug&#xe8;re M. IFIP International Conference on Open Source Systems. Berlin, Heidelberg: Springer; 2012. Perspectives on code forking and sustainability in open source software; pp. 274&#x2013;9.</Citation></Reference><Reference><Citation>Prins P, de Ligt J, Tarasov A, Jansen RC, Cuppen E, Bourne PE. Toward effective software solutions for big biology. Nat Biotechnol. 2015 Jul;33(7):686&#x2013;7. doi: 10.1038/nbt.3240.nbt.3240</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3240</ArticleId><ArticleId IdType="pubmed">26154002</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin J, Pujol S, Bauer C, Jennings D, Fennessy F, Sonka M, Buatti J, Aylward S, Miller JV, Pieper S, Kikinis R. 3D Slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging. 2012 Nov;30(9):1323&#x2013;41. doi: 10.1016/j.mri.2012.05.001. 
 
S0730-725X(12)00181-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mri.2012.05.001</ArticleId><ArticleId IdType="pmc">PMC3466397</ArticleId><ArticleId IdType="pubmed">22770690</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80. doi: 10.1186/gb-2004-5-10-r80. 
 
gb-2004-5-10-r80</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2004-5-10-r80</ArticleId><ArticleId IdType="doi">10.1186/gb-2004-5-10-r80</ArticleId><ArticleId IdType="pmc">PMC545600</ArticleId><ArticleId IdType="pubmed">15461798</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003 Nov;13(11):2498&#x2013;504. doi: 10.1101/gr.1239303. 
 
13/11/2498</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Chard K, Tuecke S, Foster I. Globus: recent enhancements and future plans. Proceedings of the XSEDE16 Conference on Diversity, Big Data, and Science at Scale; XSEDE16 Conference on Diversity, Big Data, and Science at Scale; Jul 17 - 21, 2016; Miami, USA. 2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2949550.2949554</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Weber G, Mendis M, Gainer V, Chueh HC, Churchill S, Kohane I. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) J Am Med Inform Assoc. 2010 Feb 26;17(2):124&#x2013;30. doi: 10.1136/jamia.2009.000893. 
 
17/2/124</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.000893</ArticleId><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheufele E, Aronzon D, Coopersmith R, McDuffie MT, Kapoor M, Uhrich CA, Avitabile JE, Liu J, Housman D, Palchuk MB. tranSMART: an open source knowledge management and high content data analytics platform. AMIA Jt Summits Transl Sci Proc. 2014 Apr 7;2014:96&#x2013;101. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333702</ArticleId><ArticleId IdType="pubmed">25717408</ArticleId></ArticleIdList></Reference><Reference><Citation>About ITK. ITK.  [2021-10-01].  
 https://itk.org/
</Citation></Reference><Reference><Citation>About Linux. Linux.  [2021-11-09].  
 https://www.linux.org/
</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong IC, Rijnbeek PR, van der Lei J, Pratt N, Nor&#xe9;n GN, Li Y-C, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>The R Project for Statistical Computing. 2021.  [2021-10-01].  
 https://www.r-project.org/
</Citation></Reference><Reference><Citation>Obeid JS, McGraw CA, Minor BL, Conde JG, Pawluk R, Lin M, Wang J, Banks SR, Hemphill SA, Taylor R, Harris PA. Procurement of shared data instruments for Research Electronic Data Capture (REDCap) J Biomed Inform. 2013 Apr;46(2):259&#x2013;65. doi: 10.1016/j.jbi.2012.10.006. 
 
S1532-0464(12)00160-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.10.006</ArticleId><ArticleId IdType="pmc">PMC3600393</ArticleId><ArticleId IdType="pubmed">23149159</ArticleId></ArticleIdList></Reference><Reference><Citation>What Does A Sustainable Open Source Project Look Like? Libraries.io. 2017.  [2021-11-09].  
 https://medium.com/libraries-io/what-does-a-sustainable-open-source-project-look-like-bf9b8cf824f8
.</Citation></Reference><Reference><Citation>A handy guide to financial support for open source. GitHub. 2019.  [2021-10-01].  
 https://github.com/nayafia/lemonade-stand
.</Citation></Reference><Reference><Citation>i2b2 tranSMART foundation amended and restated by-laws.  [2017-04-25].  
 https://drive.google.com/file/d/0B8lizkKDeaKhTUF3QmNTTFk0ZnM/view
.</Citation></Reference><Reference><Citation>Amended and restated by-laws of i2b2 transmart foundation. i2b2 tranSMART. 2017.  [2021-11-09].  
 http://roadmap-i2b2-transmart-pmc.hms.harvard.edu
.</Citation></Reference><Reference><Citation>Documentation/Labs/Slicer5-roadmap. 3D Slicer Roadmap.  [2021-11-09].  
 https://www.slicer.org/wiki/Documentation/Labs/Slicer5-roadmap
.</Citation></Reference><Reference><Citation>Cytoscape product roadmap. Cytoscape Consortium.  [2021-11-09].  
 https://cytoscape.org/roadmap.htm
.</Citation></Reference><Reference><Citation>Product roadmap. Globus Online.  [2021-11-09].  
 https://www.globusworld.org/files/2010/02/120412-GW2012_Tuecke_Roadmap.pdf
.</Citation></Reference><Reference><Citation>ITK  ITK Roadmap 2005-2006.  [2020-09-01].  
 https://itk.org/Wiki/ITK/Roadmap_2005_2006
.</Citation></Reference><Reference><Citation>ITK Roadmap 2008-2009. ITK.  [2021-11-09].  
 https://itk.org/Wiki/ITK_Roadmap_2008_2009
.</Citation></Reference><Reference><Citation>ITK/Release 4/DICOM/Meeting Roadmap. ITK.  [2021-11-09].  
 https://itk.org/Wiki/ITK/Release_4/DICOM/Meeting_2011.09.01_Roadmap
.</Citation></Reference><Reference><Citation>OHDSI architecture roadmap. Observational Health Data Sciences and Informatics.  [2021-11-09].  
 https://www.ohdsi.org/web/wiki/doku.php?id=development:roadmap
.</Citation></Reference><Reference><Citation>CDM v6.0 Roadmap. Observational Health Data Sciences and Informatics.  [2021-11-09].  
 https://forums.ohdsi.org/t/cdm-v6-0-roadmap/4809
.</Citation></Reference><Reference><Citation>OHDSI WebAPI Roadmap. Observational Health Data Sciences and Informatics.  [2021-11-09].  
 https://github.com/OHDSI/WebAPI/wiki/Roadmap
.</Citation></Reference><Reference><Citation>The Linux roadmap. Corbet.  [2021-11-09].  
 https://lwn.net/Articles/114804/
</Citation></Reference><Reference><Citation>The ITK Software Guide. ITK. 2021.  [2021-11-09].  
 https://itk.org/ItkSoftwareGuide.pdf
.</Citation></Reference><Reference><Citation>Linux guide. Wikibooks.  [2021-11-09].  
 https://en.wikibooks.org/wiki/Linux_Guide
.</Citation></Reference><Reference><Citation>An Introduction to R. R-project. 2009.  [2021-10-26].  
 https://cran.r-project.org/doc/manuals/r-release/R-intro.pdf
.</Citation></Reference><Reference><Citation>Welcome to 3D Slicer&#x2019;s Documentation. 3D Slicer.  [2021-10-01].  
 https://slicer.readthedocs.io
.</Citation></Reference><Reference><Citation>3D Slicer Wiki. GitHub.  [2021-11-09].  
 https://github.com/Slicer/Slicer/wiki
.</Citation></Reference><Reference><Citation>Welcome to the i2b2 Community Wiki. i2b2 Community Wiki.  [2021-11-09].  
 https://community.i2b2.org/wiki/pages/viewpage.action?pageId=342684
.</Citation></Reference><Reference><Citation>Bioconductor Tutorial Part I. Bioconductor. 2003.  [2021-11-09].  
 https://bioconductor.org/help/course-materials/2003/MGED6/MGED6I.pdf
.</Citation></Reference><Reference><Citation>Harness the power of the Globus research data management cloud. Globus Docs.  [2021-11-09].  
 https://docs.globus.org/
</Citation></Reference><Reference><Citation>Cytoscape tutorials. GitHub.  [2021-11-09].  
 https://github.com/cytoscape/cytoscape-tutorials/wiki
.</Citation></Reference><Reference><Citation>tranSMART Platform Tutorials. i2b2 tranSMART Foundation.  [2021-11-09].  
 https://transmartfoundation.org/transmart-platform-tutorials/
</Citation></Reference><Reference><Citation>3D Slicer Nightly Tutorials.  [2020-03-12].  
 https://www.slicer.org/wiki/Documentation/Nightly/Training
.</Citation></Reference><Reference><Citation>OHDSI  2019 Tutorials &#x2013; OMOP Common Data Model and Standardized Vocabularies. Observational Health Data Sciences and Informatics. 2019.  [2021-11-09].  
 https://www.ohdsi.org/2019-tutorials-omop-common-data-model-and-standardized-vocabularies/
</Citation></Reference><Reference><Citation>REDCap Tutorial. YouTube.  [2021-11-09].  
 https://www.youtube.com/playlist?list=PLrnf34ZtZ9FohXnuD6KmwVb1xgbGDu3rY
.</Citation></Reference><Reference><Citation>3D Slicer YouTube Tutorials. YouTube.  [2021-11-09].  
 https://www.youtube.com/channel/UC8vxI0-dEWrw0_tBF-v8xGA
.</Citation></Reference><Reference><Citation>Cytoscape YouTube Channel. YouTube.  [2021-11-09].  
 https://www.youtube.com/channel/UCv6auk9FK4NgXiXiqrDLccw
.</Citation></Reference><Reference><Citation>Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, Gatto L, Girke T, Gottardo R, Hahne F, Hansen KD, Irizarry RA, Lawrence M, Love MI, MacDonald J, Obenchain V, Ole&#x15b; AK, Pag&#xe8;s H, Reyes A, Shannon P, Smyth GK, Tenenbaum D, Waldron L, Morgan M. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015 Feb;12(2):115&#x2013;21. doi: 10.1038/nmeth.3252. 
 
nmeth.3252</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3252</ArticleId><ArticleId IdType="pmc">PMC4509590</ArticleId><ArticleId IdType="pubmed">25633503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytoscape app ladder. GitHub. 2019.  [2021-11-09].  
 https://github.com/cytoscape/cytoscape/wiki/Cytoscape-App-Ladder
.</Citation></Reference><Reference><Citation>The R Manuals. CRAN.  [2021-11-09].  
 https://cran.r-project.org/manuals.html
.</Citation></Reference><Reference><Citation>3D Slicer Preview. CDash.  [2021-11-09].  
 http://slicer.cdash.org/index.php?project=SlicerPreview
.</Citation></Reference><Reference><Citation>Releasing a package. R Packages.  [2021-11-09].  
 http://r-pkgs.had.co.nz/release.html
.</Citation></Reference><Reference><Citation>Documentation/Nightly/Developers/Style Guide. 3D Slicer.  [2021-11-09].  
 https://www.slicer.org/wiki/Documentation/Nightly/Developers/Style_Guide
.</Citation></Reference><Reference><Citation>R Internals for R Version 3.6.3. 2020.  [2020-03-12].  
 https://cran.r-project.org/doc/manuals/R-ints.html
.</Citation></Reference><Reference><Citation>OHDSI  OHDSI Forums. Observational Health Data Sciences and Informatics.  [2021-11-09].  
 https://forums.ohdsi.org/
</Citation></Reference><Reference><Citation>OHDSI Github Repository. Observational Health Data Sciences and Informatics.  [2021-11-09].  
 https://github.com/ohdsi/
</Citation></Reference><Reference><Citation>Linux Help Center. Linux Foundation.  [2021-11-09].  
 https://support.linuxfoundation.org/
</Citation></Reference><Reference><Citation>Cytoscape Helpdesk homepage. Cytoscape Helpdesk.  [2021-11-09].  
 https://groups.google.com/forum/#!forum/cytoscape-helpdesk
.</Citation></Reference><Reference><Citation>ITK discussion forum. ITK.  [2021-11-09].  
 https://discourse.itk.org
.</Citation></Reference><Reference><Citation>Connect with Globus on social media. Globus.  [2021-11-09].  
 https://www.globus.org/contact-us
.</Citation></Reference><Reference><Citation>Mookhey K, Burghate N. Linux: Security, Audit and Control Features. East Golf Road, Schaumburg, Illinois: ISACA; 2005.</Citation></Reference><Reference><Citation>UNIX/LINUX Security Features. Winsock.  [2021-11-09].  
 https://www.tenouk.com/linuxunixsecurityfeatures.html
.</Citation></Reference><Reference><Citation>How R Packages on bioconductor are licensed. CRAN.  [2021-11-09].  
 http://seankross.com/2016/08/02/How-R-Packages-are-Licensed.html
.</Citation></Reference><Reference><Citation>The i2b2 MPL 2.0 License with Healthcare Disclaimer Addendum. i2b2 Web Client.  [2021-11-09].  
 https://community.i2b2.org/wiki/display/webclient/The+i2b2+MPL+2.0+License+with+Healthcare+Disclaimer+Addendum
.</Citation></Reference><Reference><Citation>Documentation/4.x/Acknowledgments. 3D Slicer.  [2021-11-09].  
 https://www.slicer.org/wiki/Documentation/4.x/Acknowledgments
.</Citation></Reference><Reference><Citation>Linux Foundation Membership. The Linux Foundation.  [2021-11-09].  
 https://www.linuxfoundation.org/membership/
</Citation></Reference><Reference><Citation>i2b2 tranSMART Foundation Sponsorship Programs.  [2021-11-09].  
 https://transmartfoundation.org/contributing-sponsors-program/
</Citation></Reference><Reference><Citation>Wagholikar KB, Dessai P, Sanz J, Mendis ME, Bell DS, Murphy SN. Implementation of informatics for integrating biology and the bedside (i2b2) platform as Docker containers. BMC Med Inform Decis Mak. 2018 Jul 16;18(1):66. doi: 10.1186/s12911-018-0646-2. 
 
10.1186/s12911-018-0646-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-018-0646-2</ArticleId><ArticleId IdType="doi">10.1186/s12911-018-0646-2</ArticleId><ArticleId IdType="pmc">PMC6048900</ArticleId><ArticleId IdType="pubmed">30012140</ArticleId></ArticleIdList></Reference><Reference><Citation>Open source sustainability. Tech Crunch. 2018.  [2021-11-09].  
 https://techcrunch.com/2018/06/23/open-source-sustainability/
</Citation></Reference><Reference><Citation>Masys DR, Harris PA, Fearn PA, Kohane IS. Designing a public square for research computing. Sci Transl Med. 2012 Aug 29;4(149):149fs32. doi: 10.1126/scitranslmed.3004032. 
 
4/149/149fs32</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004032</ArticleId><ArticleId IdType="pmc">PMC3725749</ArticleId><ArticleId IdType="pubmed">22932220</ArticleId></ArticleIdList></Reference><Reference><Citation>Software for science: some personal reflections. arXiv. 2013.  [2021-11-09].  
 https://arxiv.org/abs/1309.2357
.</Citation></Reference><Reference><Citation>Open source licenses: trends and predictions. White Source. 2021.  [2021-11-09].  
 https://resources.whitesourcesoftware.com/blog-whitesource/open-source-licenses-trends-and-predictions
.</Citation></Reference><Reference><Citation>Guest Blog: Globus and the Path to Sustainability. Science Gateways. 2019.  [2021-11-09].  
 https://sciencegateways.org/-/guest-blog-globus-and-the-path-to-sustainability?inheritRedirect=true&amp;redirect=/community/blog
.</Citation></Reference><Reference><Citation>Fogel K. Producing Open Source Software: How to Run a Successful Free Software Project. Second edition. Under the CreativeCommons Attribution-ShareAlike (4.0) license: Copyright &#xa9; 2005-2021 Karl Fogel; 2020. Chapter 2: getting started.</Citation></Reference><Reference><Citation>Teixeira J Release early, release often and release on time. An empirical case study of release management. Proceedings of the IFIP International Conference on Open Source Systems; IFIP International Conference on Open Source Systems; May 22-23, 2017; Buenos Aires, Argentina. 2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-57735-7_16</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogel K. Producing Open Source Software: How to Run a Successful Free Software Project. Second edition. Under the CreativeCommons Attribution-ShareAlike (4.0) license: Copyright &#xa9; 2005-2021 Karl Fogel; 2020. Chapter 5: participating as a business, non-profit, or government agency.</Citation></Reference><Reference><Citation>Fogel K. Producing Open Source Software: How to Run a Successful Free Software Project. Second edition. Under the CreativeCommons Attribution-ShareAlike (4.0) license: Copyright &#xa9; 2005-2021 Karl Fogel; 2020. Chapter 3: techinical infrastructure.</Citation></Reference><Reference><Citation>Eghbal N. Roads and Bridges: The Unseen Labor Behind Our Digital Infrastructure. New York, NY: Ford Foundation; 2016.</Citation></Reference><Reference><Citation>Rougier N, Hinsen K, Alexandre F, Arildsen T, Barba LA, Benureau FC, Brown CT, de Buyl P, Caglayan O, Davison AP, Delsuc M-A, Detorakis G, Diem AK, Drix D, Enel P, Girard B, Guest O, Hall MG, Henriques RN, Hinaut X, Jaron KS, Khamassi M, Klein A, Manninen T, Marchesi P, McGlinn D, Metzner C, Petchey O, Plesser HE, Poisot T, Ram K, Ram Y, Roesch E, Rossant C, Rostami V, Shifman A, Stachelek J, Stimberg M, Stollmeier F, Vaggi F, Viejo G, Vitay J, Vostinar AE, Yurchak R, Zito T. Sustainable computational science: the ReScience initiative. PeerJ Comput Sci. 2017;3:e142. doi: 10.7717/peerj-cs.142. 
 
cs-142</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj-cs.142</ArticleId><ArticleId IdType="pmc">PMC8530091</ArticleId><ArticleId IdType="pubmed">34722870</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck S. Solving reproducibility. Science. 2015 Jun 25;348(6242):1403. doi: 10.1126/science.aac8041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aac8041</ArticleId><ArticleId IdType="pubmed">26113692</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoettle H. Open source license compliance-why and how? Computer. 2019 Aug;52(8):63&#x2013;7. doi: 10.1109/mc.2019.2915690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/mc.2019.2915690</ArticleId></ArticleIdList></Reference><Reference><Citation>Big Data to Knowledge. National Institutes of Health Office of Strategic Coordination The Common Fund.  [2021-11-09].  
 https://commonfund.nih.gov/bd2k
.</Citation></Reference><Reference><Citation>Bourne PE, Bonazzi V, Dunn M, Green ED, Guyer M, Komatsoulis G, Larkin J, Russell B. The NIH Big Data to Knowledge (BD2K) initiative. J Am Med Inform Assoc. 2015 Nov;22(6):1114. doi: 10.1093/jamia/ocv136. 
 
ocv136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv136</ArticleId><ArticleId IdType="pmc">PMC5009910</ArticleId><ArticleId IdType="pubmed">26555016</ArticleId></ArticleIdList></Reference><Reference><Citation>Data science at NIH. National Institutes of Health Office of Data Science Strategy.  [2021-11-09].  
 https://datascience.nih.gov/
</Citation></Reference><Reference><Citation>The precision medicine initiative cohort program &#x2013; building a research foundation for 21st century medicine. NIH. 2015.  [2021-11-09].  
 https://www.nih.gov/sites/default/files/research-training/initiatives/pmi/pmi-working-group-report-20150917-2.pdf
.</Citation></Reference><Reference><Citation>UK research and development roadmap. Gov.UK. 2020.  [2021-11-09].  
 https://www.gov.uk/government/publications/uk-research-and-development-roadmap
.</Citation></Reference><Reference><Citation>Reynolds CJ, Wyatt JC. Open source, open standards, and health care information systems. J Med Internet Res. 2011 Feb 17;13(1):e24. doi: 10.2196/jmir.1521. 
 
v13i1e24</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.1521</ArticleId><ArticleId IdType="pmc">PMC3221346</ArticleId><ArticleId IdType="pubmed">21447469</ArticleId></ArticleIdList></Reference><Reference><Citation>Recommendations on the Development, Use and Provision of Research Software. Zenodo. 2018.  [2021-11-09].  
 https://zenodo.org/record/1172988#.X9Q1UdhKiF
.</Citation></Reference><Reference><Citation>Katz D, Choi S, Lapp H, Maheshwari K, L&#xf6;ffler F, Turk M. Summary of the first Workshop on Sustainable Software for Science: Practice and Experiences (WSSSPE1) J Open Res Softw. 2014;2(1):e6. doi: 10.5334/jors.an.</Citation><ArticleIdList><ArticleId IdType="doi">10.5334/jors.an</ArticleId></ArticleIdList></Reference><Reference><Citation>Science Gateways Community Institute.  [2021-11-09].  
 https://sciencegateways.org/gateway-support/consulting-services
.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34870731</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-7347</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA</Title><ISOAbbreviation>Knee Surg Sports Traumatol Arthrosc</ISOAbbreviation></Journal><ArticleTitle>90-Day all-cause mortality can be predicted following a total knee replacement: an international, network study to develop and validate a prediction model.</ArticleTitle><Pagination><StartPage>3068</StartPage><EndPage>3075</EndPage><MedlinePgn>3068-3075</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00167-021-06799-y</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The purpose of this study was to develop and validate a prediction model for 90-day mortality following a total knee replacement (TKR). TKR is a safe and cost-effective surgical procedure for treating severe knee osteoarthritis (OA). Although complications following surgery are rare, prediction tools could help identify high-risk patients who could be targeted with preventative interventions. The aim was to develop and validate a simple model to help inform treatment choices.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A mortality prediction model for knee OA patients following TKR was developed and externally validated using a US claims database and a UK general practice database. The target population consisted of patients undergoing a primary TKR for knee OA, aged&#x2009;&#x2265;&#x2009;40&#xa0;years and registered for&#x2009;&#x2265;&#x2009;1&#xa0;year before surgery. LASSO logistic regression models were developed for post-operative (90-day) mortality. A second mortality model was developed with a reduced feature set to increase interpretability and usability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 193,615 patients were included, with 40,950 in The Health Improvement Network (THIN) database and 152,665 in Optum. The full model predicting 90-day mortality yielded AUROC of 0.78 when trained in OPTUM and 0.70 when externally validated on THIN. The 12 variable model achieved internal AUROC of 0.77 and external AUROC of 0.71 in THIN.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A simple prediction model based on sex, age, and 10 comorbidities that can identify patients at high risk of short-term mortality following TKR was developed that demonstrated good, robust performance. The 12-feature mortality model is easily implemented and the performance suggests it could be used to inform evidence based shared decision-making prior to surgery and targeting prophylaxis for those at high risk.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">III.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>OHDSI/EHDEN Knee Arthroplasty Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>NDORMS, University of Oxford, Oxford, UK. daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>806968</GrantID><Agency>the innovative medicines initiative 2 joint</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Knee Surg Sports Traumatol Arthrosc</MedlineTA><NlmUniqueID>9314730</NlmUniqueID><ISSNLinking>0942-2056</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="Y">Arthroplasty, Replacement, Knee</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020370" MajorTopicYN="Y">Osteoarthritis, Knee</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical decision aid</Keyword><Keyword MajorTopicYN="N">Knee arthroplasty</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Prediction</Keyword><Keyword MajorTopicYN="N">Risk model</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword></KeywordList><CoiStatement>All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: AS, JW, JR, MvS and PBR are full-time employees of Janssen Research &amp; Development, a pharmaceutical company of Johnson &amp; Johnson, and shareholders in Johnson &amp; Johnson. the Johnson &amp; Johnson family of companies also includes DePuy Synthes, which is the maker of medical devices for joint reconstruction. DPA reports grants from Amgen, Grants from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work. CO is a part-time employee of IQVIA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>6</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34870731</ArticleId><ArticleId IdType="pmc">PMC9418076</ArticleId><ArticleId IdType="doi">10.1007/s00167-021-06799-y</ArticleId><ArticleId IdType="pii">10.1007/s00167-021-06799-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arden N, Altman D, Beard D, Carr A, Clarke N, Collins G et al (2017) Lower limb arthroplasty: Can we produce a tool to predict outcome and failure, and is it cost-effective? An epidemiological study. Programme Grants Appl Res 5(12)</Citation><ArticleIdList><ArticleId IdType="pubmed">28678462</ArticleId></ArticleIdList></Reference><Reference><Citation>Berstock JR, Beswick AD, Lopez-Lopez JA, Whitehouse MR, Blom AW. Mortality after total knee arthroplasty: a systematic review of incidence, temporal trends, and risk factors. J Bone Jt Surg Am. 2018;100:1064&#x2013;1070. doi: 10.2106/JBJS.17.00249.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.17.00249</ArticleId><ArticleId IdType="pubmed">29916935</ArticleId></ArticleIdList></Reference><Reference><Citation>Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19:251&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">22828580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford MK, Beattie WS, Wijeysundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. Ann Intern Med. 2010;152:26&#x2013;35. doi: 10.7326/0003-4819-152-1-201001050-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-152-1-201001050-00007</ArticleId><ArticleId IdType="pubmed">20048269</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt LP, Ben-Shlomo Y, Clark EM, Dieppe P, Judge A, MacGregor AJ, et al. 45-day mortality after 467,779 knee replacements for osteoarthritis from the National Joint Registry for England and Wales: an observational study. Lancet. 2014;384:1429&#x2013;1436. doi: 10.1016/S0140-6736(14)60540-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60540-7</ArticleId><ArticleId IdType="pubmed">25012118</ArticleId></ArticleIdList></Reference><Reference><Citation>Inacio MCS, Pratt NL, Roughead EE, Graves SE. Evaluation of three co-morbidity measures to predict mortality in patients undergoing total joint arthroplasty. Osteoarthr Cartil. 2016;24:1718&#x2013;1726. doi: 10.1016/j.joca.2016.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2016.05.006</ArticleId><ArticleId IdType="pubmed">27188683</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal J, Vergouwe Y, Bourantas CV, van Klaveren D, Zhang YJ, Campos CM, et al. Predicting 3-year mortality after percutaneous coronary intervention: updated logistic clinical SYNTAX score based on patient-level data from 7 contemporary stent trials. JACC Cardiovasc Interv. 2014;7:464&#x2013;470. doi: 10.1016/j.jcin.2014.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2014.02.007</ArticleId><ArticleId IdType="pubmed">24852801</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka JF, Hansen VJ, Rubash HE, Freiberg AA. Risk assessment tools used to predict outcomes of total hip and total knee arthroplasty. Orthop Clin N Am. 2015;46(351&#x2013;362):ix&#x2013;x.</Citation><ArticleIdList><ArticleId IdType="pubmed">26043049</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunutsor SK, Whitehouse MR, Blom AW, Beswick AD. Systematic review of risk prediction scores for surgical site infection or periprosthetic joint infection following joint arthroplasty. Epidemiol Infect. 2017;145:1738&#x2013;1749. doi: 10.1017/S0950268817000486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268817000486</ArticleId><ArticleId IdType="pmc">PMC9203287</ArticleId><ArticleId IdType="pubmed">28264756</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W1&#x2013;73. doi: 10.7326/M14-0698.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-0698</ArticleId><ArticleId IdType="pubmed">25560730</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C, et al. Mortality after surgery in Europe: a 7 day cohort study. Lancet. 2012;380:1059&#x2013;1065. doi: 10.1016/S0140-6736(12)61148-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61148-9</ArticleId><ArticleId IdType="pmc">PMC3493988</ArticleId><ArticleId IdType="pubmed">22998715</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018 doi: 10.1093/jamia/ocy032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Williams RD, You SC, Falconer T, Minty E, Callahan A, et al. Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation. BMC Med Res Methodol. 2020;20:102. doi: 10.1186/s12874-020-00991-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-020-00991-3</ArticleId><ArticleId IdType="pmc">PMC7201646</ArticleId><ArticleId IdType="pubmed">32375693</ArticleId></ArticleIdList></Reference><Reference><Citation>Springer BD, Cahue S, Etkin CD, Lewallen DG, McGrory BJ. Infection burden in total hip and knee arthroplasties: an international registry-based perspective. Arthroplasty Today. 2017;3:137&#x2013;140. doi: 10.1016/j.artd.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.artd.2017.05.003</ArticleId><ArticleId IdType="pmc">PMC5485227</ArticleId><ArticleId IdType="pubmed">28695187</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23:10. doi: 10.1145/2414416.2414791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Series B Stat Methodol. 1996;58:267&#x2013;288.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34899334</PMID><DateRevised><Year>2021</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Bias, Precision and Timeliness of Historical (Background) Rate Comparison Methods for Vaccine Safety Monitoring: An Empirical Multi-Database Analysis.</ArticleTitle><Pagination><StartPage>773875</StartPage><MedlinePgn>773875</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">773875</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2021.773875</ELocationID><Abstract><AbstractText>Using real-world data and past vaccination data, we conducted a large-scale experiment to quantify bias, precision and timeliness of different study designs to estimate historical background (expected) compared to post-vaccination (observed) rates of safety events for several vaccines. We used negative (not causally related) and positive control outcomes. The latter were synthetically generated true safety signals with incident rate ratios ranging from 1.5 to 4. Observed vs. expected analysis using within-database historical background rates is a sensitive but unspecific method for the identification of potential vaccine safety signals. Despite good discrimination, most analyses showed a tendency to overestimate risks, with 20%-100% type 1 error, but low (0% to 20%) type 2 error in the large databases included in our study. Efforts to improve the comparability of background and post-vaccine rates, including age-sex adjustment and anchoring background rates around a visit, reduced type 1 error and improved precision but residual systematic error persisted. Additionally, empirical calibration dramatically reduced type 1 to nominal but came at the cost of increasing type 2 error.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Li, Lai, Ostropolets, Arshad, Tan, Casajust, Alshammari, Duarte-Salles, Minty, Areia, Pratt, Ryan, Hripcsak, Suchard, Schuemie and Prieto-Alhambra.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xintong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana Yh</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arshad</LastName><ForeName>Faaizah</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Eng Hooi</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casajust</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Real-World Evidence, Trial Form Support, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institut Universitari D'Investigaci&#xf3; en Atenci&#xf3; Prim&#xe0;ria Jordi Gol (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>O'Brien Institute for Public Health, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen R&amp;D, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, NewYork-Presbyterian Hospital, NewYork, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, California, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, California, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen R&amp;D, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Sciences, Medical Informatics, Erasmus Medical Center University, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">background rate</Keyword><Keyword MajorTopicYN="N">empirical - comparison</Keyword><Keyword MajorTopicYN="N">incidence rate</Keyword><Keyword MajorTopicYN="N">real world data</Keyword><Keyword MajorTopicYN="N">vaccine safety</Keyword></KeywordList><CoiStatement>DP's research group has received grants for unrelated work from Amgen, Chiesi-Taylor, and UCB Biopharma SRL; and his department has received speaker/consultancy fees from Amgen, Astra-Zeneca, Astellas, Janssen, and UCB Bioparhma SRL. Authors PR and MJS were employed by Janssen R&amp;D. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>13</Day><Hour>17</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34899334</ArticleId><ArticleId IdType="pmc">PMC8652333</ArticleId><ArticleId IdType="doi">10.3389/fphar.2021.773875</ArticleId><ArticleId IdType="pii">773875</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barker C. I., Snape M. D. (2014). Pandemic Influenza A H1N1 Vaccines and Narcolepsy: Vaccine Safety Surveillance in Action. Lancet Infect. Dis. 14 (3), 227&#x2013;238. 10.1016/S1473-3099(13)70238-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70238-X</ArticleId><ArticleId IdType="pubmed">24360892</ArticleId></ArticleIdList></Reference><Reference><Citation>Belongia E. A., Irving S. A., Shui I. M., Kulldorff M., Lewis E., Yin R., et al. (2010). Real-time Surveillance to Assess Risk of Intussusception and Other Adverse Events after Pentavalent, Bovine-Derived Rotavirus Vaccine. Pediatr. Infect. Dis. J. 29 (1), 1&#x2013;5. 10.1097/INF.0b013e3181af8605</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3181af8605</ArticleId><ArticleId IdType="pubmed">19907356</ArticleId></ArticleIdList></Reference><Reference><Citation>Benecke O., DeYoung S. E. (2019). Anti-Vaccine Decision-Making and Measles Resurgence in the United States. Glob. Pediatr. Health 6, 2333794X19862949&#x2013;2333794X. 10.1177/2333794X19862949</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2333794X19862949</ArticleId><ArticleId IdType="pmc">PMC6657116</ArticleId><ArticleId IdType="pubmed">31384629</ArticleId></ArticleIdList></Reference><Reference><Citation>Black S., Eskola J., Siegrist C. A., Halsey N., MacDonald N., Law B., et al. (2009). Importance of Background Rates of Disease in Assessment of Vaccine Safety during Mass Immunisation with Pandemic H1N1 Influenza Vaccines. Lancet 374 (9707), 2115&#x2013;2122. 10.1016/S0140-6736(09)61877-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId><ArticleId IdType="pmc">PMC2861912</ArticleId><ArticleId IdType="pubmed">19880172</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttery J. P., Danchin M. H., Lee K. J., Carlin J. B., McIntyre P. B., Elliott E. J., et al. (2011). Intussusception Following Rotavirus Vaccine Administration: post-marketing Surveillance in the National Immunization Program in Australia. Vaccine 29 (16), 3061&#x2013;3066. 10.1016/j.vaccine.2011.01.088</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.01.088</ArticleId><ArticleId IdType="pubmed">21316503</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Network of Centres of Pharmacoepidemiology and Pharmacovigilance (2021). EUMAEUS: Evaluating Use of Methods for Adverse Event under Surveillance (For Vaccines). 2021 [updated 15 April 2021. Available at: http://www.encepp.eu/encepp/viewResource.htm?id=40341
. </Citation></Reference><Reference><Citation>Gee J., Naleway A., Shui I., Baggs J., Yin R., Li R., et al. (2011). Monitoring the Safety of Quadrivalent Human Papillomavirus Vaccine: Findings from the Vaccine Safety Datalink. Vaccine 29 (46), 8279&#x2013;8284. 10.1016/j.vaccine.2011.08.106</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.08.106</ArticleId><ArticleId IdType="pubmed">21907257</ArticleId></ArticleIdList></Reference><Reference><Citation>Godlee F., Smith J., Marcovitch H. (2011). Wakefield's Article Linking MMR Vaccine and Autism Was Fraudulent. BMJ 342, c7452. 10.1136/bmj.c7452</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c7452</ArticleId><ArticleId IdType="pubmed">21209060</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolley D., Douglas K. M. (2014). The Effects of Anti-vaccine Conspiracy Theories on Vaccination Intentions. PLOS ONE 9 (2), e89177. 10.1371/journal.pone.0089177</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089177</ArticleId><ArticleId IdType="pmc">PMC3930676</ArticleId><ArticleId IdType="pubmed">24586574</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Ostropolets A., Makadia R., Shaoibi A., Rao G., Sena A. G., et al. (2021). Characterizing the Incidence of Adverse Events of Special Interest for COVID-19 Vaccines across Eight Countries: a Multinational Network Cohort Study. medRxiv, 2021. 10.1101/2021.03.25.21254315</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.25.21254315</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieu T. A., Kulldorff M., Davis R. L., Lewis E. M., Weintraub E., Yih K., et al. (2007). Real-time Vaccine Safety Surveillance for the Early Detection of Adverse Events. Med. Care 45 (10 Suppl. 2), S89&#x2013;S95. 10.1097/MLR.0b013e3180616c0a</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e3180616c0a</ArticleId><ArticleId IdType="pubmed">17909389</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahaux O., Bauchau V., Van Holle L. (2016). Pharmacoepidemiological Considerations in Observed-To-Expected Analyses for Vaccines. Pharmacoepidemiol. Drug Saf. 25 (2), 215&#x2013;222. 10.1002/pds.3918</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3918</ArticleId><ArticleId IdType="pmc">PMC5063172</ArticleId><ArticleId IdType="pubmed">26602179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesfin Y. M., Cheng A., Lawrie J., Buttery J. (2019). Use of Routinely Collected Electronic Healthcare Data for Postlicensure Vaccine Safety Signal Detection: a Systematic Review. BMJ Glob. Health 4 (4), e001065. 10.1136/bmjgh-2018-001065</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2018-001065</ArticleId><ArticleId IdType="pmc">PMC6615875</ArticleId><ArticleId IdType="pubmed">31354969</ArticleId></ArticleIdList></Reference><Reference><Citation>
OHDSI (2019). The Book of OHDSI: Observational Health Data Sciences and Informatics. OHDSI. Available at: https://ohdsi.github.io/TheBookOfOhdsi/TheBookOfOhdsi.pdf

</Citation></Reference><Reference><Citation>Remschmidt C., Wichmann O., Harder T. (2015). Frequency and Impact of Confounding by Indication and Healthy Vaccinee Bias in Observational Studies Assessing Influenza Vaccine Effectiveness: a Systematic Review. BMC Infect. Dis. 15, 429. 10.1186/s12879-015-1154-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1154-y</ArticleId><ArticleId IdType="pmc">PMC4609091</ArticleId><ArticleId IdType="pubmed">26474974</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Cepeda M. S., Suchard M. A., Yang J., Tian Y., Schuler A., et al. (2020). How Confident Are We about Observational Findings in Healthcare: A Benchmark Study. Harv. Data Sci. Rev. 2 (1). 10.1162/99608f92.147cc28e</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/99608f92.147cc28e</ArticleId><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Hripcsak G., Ryan P. B., Madigan D., Suchard M. A. (2018). Empirical Confidence Interval Calibration for Population-Level Effect Estimation Studies in Observational Healthcare Data. Proc. Natl. Acad. Sci. U S A. 115 (11), 2571&#x2013;2577. 10.1073/pnas.1708282114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Hripcsak G., Ryan P. B., Madigan D., Suchard M. A. (2016). Robust Empirical Calibration of P-Values Using Observational Data. Stat. Med. 35 (22), 3883&#x2013;3888. 10.1002/sim.6977</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6977</ArticleId><ArticleId IdType="pmc">PMC5108459</ArticleId><ArticleId IdType="pubmed">27592566</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijnans L., Lecomte C., de Vries C., Weibel D., Sammon C., Hviid A., et al. (2013). The Incidence of Narcolepsy in Europe: before, during, and after the Influenza A(H1N1)pdm09 Pandemic and Vaccination Campaigns. Vaccine 31 (8), 1246&#x2013;1254. 10.1016/j.vaccine.2012.12.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.12.015</ArticleId><ArticleId IdType="pubmed">23246544</ArticleId></ArticleIdList></Reference><Reference><Citation>
Winton Centre for Risk and Evidence Communication (2021). Communicating the Potential Benefits and Harms of the Astra-Zeneca COVID-19 Vaccine. 2021 [updated 7 April 2021. Available at: https://wintoncentre.maths.cam.ac.uk/news/communicating-potential-benefits-and-harms-astra-zeneca-covid-19-vaccine/
. </Citation></Reference><Reference><Citation>Yih W. K., Kulldorff M., Fireman B. H., Shui I. M., Lewis E. M., Klein N. P., et al. (2011). Active Surveillance for Adverse Events: the Experience of the Vaccine Safety Datalink Project. Pediatrics 127 (Suppl. 1), S54&#x2013;S64. 10.1542/peds.2010-1722I</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-1722I</ArticleId><ArticleId IdType="pubmed">21502252</ArticleId></ArticleIdList></Reference><Reference><Citation>Yih W. K., Nordin J. D., Kulldorff M., Lewis E., Lieu T. A., Shi P., et al. (2009). An Assessment of the Safety of Adolescent and Adult Tetanus-Diphtheria-Acellular Pertussis (Tdap) Vaccine, Using Active Surveillance for Adverse Events in the Vaccine Safety Datalink. Vaccine 27 (32), 4257&#x2013;4262. 10.1016/j.vaccine.2009.05.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.05.036</ArticleId><ArticleId IdType="pubmed">19486957</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34904958</PMID><DateRevised><Year>2022</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Transformation and Evaluation of the MIMIC Database in the OMOP Common Data Model: Development and Usability Study.</ArticleTitle><Pagination><StartPage>e30970</StartPage><MedlinePgn>e30970</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e30970</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/30970</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the era of big data, the intensive care unit (ICU) is likely to benefit from real-time computer analysis and modeling based on close patient monitoring and electronic health record data. The Medical Information Mart for Intensive Care (MIMIC) is the first open access database in the ICU domain. Many studies have shown that common data models (CDMs) improve database searching by allowing code, tools, and experience to be shared. The Observational Medical Outcomes Partnership (OMOP) CDM is spreading all over the world.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective was to transform MIMIC into an OMOP database and to evaluate the benefits of this transformation for analysts.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We transformed MIMIC (version 1.4.21) into OMOP format (version 5.3.3.1) through semantic and structural mapping. The structural mapping aimed at moving the MIMIC data into the right place in OMOP, with some data transformations. The mapping was divided into 3 phases: conception, implementation, and evaluation. The conceptual mapping aimed at aligning the MIMIC local terminologies to OMOP's standard ones. It consisted of 3 phases: integration, alignment, and evaluation. A documented, tested, versioned, exemplified, and open repository was set up to support the transformation and improvement of the MIMIC community's source code. The resulting data set was evaluated over a 48-hour datathon.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">With an investment of 2 people for 500 hours, 64% of the data items of the 26 MIMIC tables were standardized into the OMOP CDM and 78% of the source concepts mapped to reference terminologies. The model proved its ability to support community contributions and was well received during the datathon, with 160 participants and 15,000 requests executed with a maximum duration of 1 minute.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The resulting MIMIC-OMOP data set is the first MIMIC-OMOP data set available free of charge with real disidentified data ready for replicable intensive care research. This approach can be generalized to any medical field.</AbstractText><CopyrightInformation>&#xa9;Nicolas Paris, Antoine Lamer, Adrien Parrot. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 14.12.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Paris</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1533-5087</Identifier><AffiliationInfo><Affiliation>InterHop, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamer</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9546-1808</Identifier><AffiliationInfo><Affiliation>InterHop, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de sant&#xe9; et des Pratiques m&#xe9;dicales, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Parrot</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9862-1408</Identifier><AffiliationInfo><Affiliation>InterHop, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">big data</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">data reuse</Keyword><Keyword MajorTopicYN="N">digital health</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">health care</Keyword><Keyword MajorTopicYN="N">health data</Keyword><Keyword MajorTopicYN="N">health database</Keyword><Keyword MajorTopicYN="N">health informatics</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">open access database</Keyword><Keyword MajorTopicYN="N">open data</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>14</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34904958</ArticleId><ArticleId IdType="pmc">PMC8715361</ArticleId><ArticleId IdType="doi">10.2196/30970</ArticleId><ArticleId IdType="pii">v9i12e30970</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angus DC, Kelley MA, Schmitz RJ, White A, Popovich J, Committee on Manpower for Pulmonary and Critical Care Societies (COMPACCS) Caring for the critically ill patient. Current and projected workforce requirements for care of the critically ill and patients with pulmonary disease: can we meet the requirements of an aging population? JAMA. 2000 Dec 06;284(21):2762&#x2013;70. doi: 10.1001/jama.284.21.2762.jce00009</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.284.21.2762</ArticleId><ArticleId IdType="pubmed">11105183</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoulay E, Alberti C, Legendre I, Buisson CB, Le Gall JR, European Sepsis Group Post-ICU mortality in critically ill infected patients: an international study. Intensive Care Med. 2005 Jan;31(1):56&#x2013;63. doi: 10.1007/s00134-004-2484-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-004-2484-1</ArticleId><ArticleId IdType="pubmed">15526186</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J. Is the current management of severe sepsis and septic shock really evidence based? PLoS Med. 2006 Sep;3(9):e346. doi: 10.1371/journal.pmed.0030346. 
 
06-PLME-PF-0080R2</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0030346</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.0030346</ArticleId><ArticleId IdType="pmc">PMC1550732</ArticleId><ArticleId IdType="pubmed">16933970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross MK, Wei W, Ohno-Machado L. "Big data" and the electronic health record. Yearb Med Inform. 2014 Aug 15;9:97&#x2013;104. doi: 10.15265/IY-2014-0003. 
 
me2014-0003</Citation><ArticleIdList><ArticleId IdType="doi">10.15265/IY-2014-0003</ArticleId><ArticleId IdType="pmc">PMC4287068</ArticleId><ArticleId IdType="pubmed">25123728</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Guo S, Han L, Li T. Application and exploration of big data mining in clinical medicine. Chin Med J (Engl) 2016 Mar 20;129(6):731&#x2013;8. doi: 10.4103/0366-6999.178019. 
 
ChinMedJ_2016_129_6_731_178019</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.178019</ArticleId><ArticleId IdType="pmc">PMC4804421</ArticleId><ArticleId IdType="pubmed">26960378</ArticleId></ArticleIdList></Reference><Reference><Citation>Safran C. Reuse of clinical data. Yearb Med Inform. 2014 Aug 15;9:52&#x2013;4. doi: 10.15265/IY-2014-0013. 
 
me2014-0013</Citation><ArticleIdList><ArticleId IdType="doi">10.15265/IY-2014-0013</ArticleId><ArticleId IdType="pmc">PMC4287069</ArticleId><ArticleId IdType="pubmed">25123722</ArticleId></ArticleIdList></Reference><Reference><Citation>Meystre SM, Lovis C, B&#xfc;rkle T, Tognola G, Budrionis A, Lehmann CU. Clinical data reuse or secondary use: current status and potential future progress. Yearb Med Inform. 2017 Aug;26(1):38&#x2013;52. doi: 10.15265/IY-2017-007. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.15265/IY-2017-007</ArticleId><ArticleId IdType="pmc">PMC6239225</ArticleId><ArticleId IdType="pubmed">28480475</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AEW, Pollard TJ, Shen L, Lehman LH, Feng M, Ghassemi M, Moody B, Szolovits P, Celi LA, Mark RG. MIMIC-III, a freely accessible critical care database. Sci Data. 2016 May 24;3:160035. doi: 10.1038/sdata.2016.35. doi: 10.1038/sdata.2016.35.sdata201635</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.35</ArticleId><ArticleId IdType="doi">10.1038/sdata.2016.35</ArticleId><ArticleId IdType="pmc">PMC4878278</ArticleId><ArticleId IdType="pubmed">27219127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Batson D, Schilling LM. Data model considerations for clinical effectiveness researchers. Med Care. 2012 Jul;50 Suppl:S60&#x2013;7. doi: 10.1097/MLR.0b013e318259bff4. 
 
00005650-201207001-00013</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e318259bff4</ArticleId><ArticleId IdType="pmc">PMC3824370</ArticleId><ArticleId IdType="pubmed">22692260</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne JJ. Common models, different approaches. Drug Saf. 2015 Aug;38(8):683&#x2013;6. doi: 10.1007/s40264-015-0313-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0313-9</ArticleId><ArticleId IdType="pubmed">26088718</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R, Lieu T. Data enclaves for sharing information derived from clinical and administrative data. JAMA. 2018 Aug 28;320(8):753&#x2013;754. doi: 10.1001/jama.2018.9342. 
 
2696616</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.9342</ArticleId><ArticleId IdType="pubmed">30083726</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Zhou X, Suehs BT, Hartzema AG, Kahn MG, Moride Y, Sauer BC, Liu Q, Moll K, Pasquale MK, Nair VP, Bate A. A comparative assessment of observational medical outcomes partnership and mini-sentinel common data models and analytics: implications for active drug safety surveillance. Drug Saf. 2015 Aug;38(8):749&#x2013;65. doi: 10.1007/s40264-015-0297-5.10.1007/s40264-015-0297-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0297-5</ArticleId><ArticleId IdType="pubmed">26055920</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, Suchard MA, DuMouchel W, Berlin JA. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013 Aug 15;178(4):645&#x2013;51. doi: 10.1093/aje/kwt010. 
 
kwt010</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwt010</ArticleId><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgenstern H, Rafaely B. Spatial reverberation and dereverberation using an acoustic multiple-input multiple-output system. J Audio Eng Soc. 2017 Feb 17;65(1/2):42&#x2013;55. doi: 10.17743/jaes.2016.0063.</Citation><ArticleIdList><ArticleId IdType="doi">10.17743/jaes.2016.0063</ArticleId></ArticleIdList></Reference><Reference><Citation>Klungel O, Kurz X, de Groot MCH, Schlienger R, Tcherny-Lessenot S, Grimaldi L, Ib&#xe1;&#xf1;ez L, Groenwold R, Reynolds R. Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:156&#x2013;65. doi: 10.1002/pds.3968. doi: 10.1002/pds.3968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3968</ArticleId><ArticleId IdType="doi">10.1002/pds.3968</ArticleId><ArticleId IdType="pubmed">27038361</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H, Vormstein P, Bieber R, Bernarding J, Herrmann T, Haverkamp C, Horki P, Laufer J, Berger F, H&#xf6;ning G, Fritsch HW, Sch&#xfc;ttler J, Ganslandt T, Prokosch HU, Sedlmayr M. Towards implementation of OMOP in a German university hospital consortium. Appl Clin Inform. 2018 Jan;9(1):54&#x2013;61. doi: 10.1055/s-0037-1617452. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1617452</ArticleId><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, Resnic FS, Robbins SL, Denton J, Nookala L, Meeker D, Ohno-Machado L, Matheny ME. Creating a common data model for comparative effectiveness with the observational medical outcomes partnership. Appl Clin Inform. 2015;6(3):536&#x2013;47. doi: 10.4338/ACI-2014-12-CR-0121. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/ACI-2014-12-CR-0121</ArticleId><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Depas N, Doutreligne M, Parrot A, Verloop D, Defebvre M, Ficheur G, Chazard E, Beuscart J. Transforming French electronic health records into the Observational Medical Outcome Partnership's common data model: a feasibility study. Appl Clin Inform. 2020 Jan;11(1):13&#x2013;22. doi: 10.1055/s-0039-3402754. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-3402754</ArticleId><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, van der Lei J, Pratt N, Nor&#xe9;n GN, Li Y, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  OHDSI: Observational Health Data Sciences and Informatics. 2021. Dec 01,  [2019-05-03].  
 https://www.ohdsi.org/
</Citation></Reference><Reference><Citation>Karwin B. Keeping It Simple: Rendering Trees with Closure Tables.  [2021-11-01].  
 https://karwin.blogspot.com/2010/03/rendering-trees-with-closure-tables.html
.</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376. 
 
amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012 Aug;45(4):689&#x2013;96. doi: 10.1016/j.jbi.2012.05.002. 
 
S1532-0464(12)00069-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.05.002</ArticleId><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamsuzzoha B, Vojtech H, Joydeep G. Conversion of MIMIC to OHDSI CDM.  [2021-12-01].  
 https://www.ohdsi.org/web/wiki/lib/exe/fetch.php?media=resources:2016_ohdsi_paper_mimic_bayzid.pdf
.</Citation></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016 Dec;64:333&#x2013;341. doi: 10.1016/j.jbi.2016.10.016. 
 
S1532-0464(16)30153-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.10.016</ArticleId><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronaki C, Shahin A, Mark R. Designing reliable cohorts of cardiac patients across MIMIC and eICU. Comput Cardiol (2010) 2015;42:189&#x2013;192. doi: 10.1109/CIC.2015.7408618. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/CIC.2015.7408618</ArticleId><ArticleId IdType="pmc">PMC5072526</ArticleId><ArticleId IdType="pubmed">27774488</ArticleId></ArticleIdList></Reference><Reference><Citation>HL7  Welcome to FHIR&#xae;.  [2021-12-01].  
 https://www.hl7.org/fhir/
</Citation></Reference><Reference><Citation>Athena.  [2019-01-03].  
 http://athena.ohdsi.org/search-terms/terms
.</Citation></Reference><Reference><Citation>MIT Laboratory for Computational Physiology  MIT-LCP/mimic-code.  [2021-12-01].  
 https://github.com/MIT-LCP/mimic-code
.</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  OHDSI Forums.  [2021-12-01].  
 https://forums.ohdsi.org/
</Citation></Reference><Reference><Citation>MIT Laboratory for Computational Physiology  MIT-LCP/mimic-omop.  [2021-12-01].  
 https://github.com/MIT-LCP/mimic-omop
.</Citation></Reference><Reference><Citation>Moody DL, Shanks GG. Improving the quality of data models: empirical validation of a quality management framework. Inf Syst. 2003 Sep;28(6):619&#x2013;650. doi: 10.1016/s0306-4379(02)00043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0306-4379(02)00043-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  OHDSI/Achilles.  [2019-10-17].  
 https://github.com/OHDSI/Achilles
.</Citation></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, Shin D, Park H, Park RW. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016 Jan;22(1):54&#x2013;8. doi: 10.4258/hir.2016.22.1.54. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2016.22.1.54</ArticleId><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. National Library of Medicine  ICD-9-CM Diagnostic Codes to SNOMED CT Map Internet.  [2021-12-01].  
 https://www.nlm.nih.gov/research/umls/mapping_projects/icd9cm_to_snomedct.html
.</Citation></Reference><Reference><Citation>Logical Observation Identifiers Names and Codes  LOINC Version 2.63 and RELMA Version 6.22 Are Now Available.  [2021-12-01].  
 https://loinc.org/news/loinc-version-2-63-and-relma-version-6-22-are-now-available/
</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  OHDSI/Usagi.  [2021-12-01].  
 https://github.com/OHDSI/Usagi
.</Citation></Reference><Reference><Citation>Denny JC, Spickard A, Johnson KB, Peterson NB, Peterson JF, Miller RA. Evaluation of a method to identify and categorize section headers in clinical documents. J Am Med Inform Assoc. 2009;16(6):806&#x2013;15. doi: 10.1197/jamia.M3037. 
 
M3037</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M3037</ArticleId><ArticleId IdType="pmc">PMC3002123</ArticleId><ArticleId IdType="pubmed">19717800</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOPonFHIR  The FHIR Project at Georgia Tech Internet.  [2021-12-01].  
 http://omoponfhir.org/
</Citation></Reference><Reference><Citation>Aboab J, Celi LA, Charlton P, Feng M, Ghassemi M, Marshall DC, Mayaud L, Naumann T, McCague N, Paik KE, Pollard TJ, Resche-Rigon M, Salciccioli JD, Stone DJ. A "datathon" model to support cross-disciplinary collaboration. Sci Transl Med. 2016 Apr 06;8(333):333ps8. doi: 10.1126/scitranslmed.aad9072. 
 
8/333/333ps8</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad9072</ArticleId><ArticleId IdType="pmc">PMC5679209</ArticleId><ArticleId IdType="pubmed">27053770</ArticleId></ArticleIdList></Reference><Reference><Citation>Celi LA, Lokhandwala S, Montgomery R, Moses C, Naumann T, Pollard T, Spitz D, Stretch R. Datathons and software to promote reproducible research. J Med Internet Res. 2016 Aug 24;18(8):e230. doi: 10.2196/jmir.6365. 
 
v18i8e230</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.6365</ArticleId><ArticleId IdType="pmc">PMC5014984</ArticleId><ArticleId IdType="pubmed">27558834</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo EM, Newman S, Amat M, Charpignon M, Duralde ER, Jain S, Kaufman AR, Korolev I, Lai Y, Lam BD, Lipcsey M, Martinez A, Mechanic OJ, Mlabasati J, McCoy LG, Nguyen FT, Samuel M, Yang E, Celi LA. MIT COVID-19 datathon: data without boundaries. BMJ Innov. 2021 Jan 31;7(1):231&#x2013;234. doi: 10.1136/bmjinnov-2020-000492. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjinnov-2020-000492</ArticleId><ArticleId IdType="pmc">PMC7799368</ArticleId><ArticleId IdType="pubmed">33437494</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Xie C, Pollard T, Johnson AEW, Cao D, Kang H, Liang H, Zhang Y, Liu X, Fan Y, Zhang Y, Xue W, Xie L, Celi LA, Zhang Z. Promoting secondary analysis of electronic medical records in China: summary of the PLAGH-MIT Critical Data Conference and Health Datathon. JMIR Med Inform. 2017 Nov 14;5(4):e43. doi: 10.2196/medinform.7380. 
 
v5i4e43</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/medinform.7380</ArticleId><ArticleId IdType="pmc">PMC5705855</ArticleId><ArticleId IdType="pubmed">29138126</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34911976</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Preliminary feasibility assessment of CDM-based active surveillance using current status of medical device data in medical records and OMOP-CDM.</ArticleTitle><Pagination><StartPage>24070</StartPage><MedlinePgn>24070</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24070</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-03332-6</ELocationID><Abstract><AbstractText>In recent years, there has been an emerging interest in the use of claims and electronic health record (EHR) data for evaluation of medical device safety and effectiveness. In Korea, national insurance electronic data interchange (EDI) code has been used as a medical device data source for common data model (CDM). This study performed a preliminary feasibility assessment of CDM-based vigilance. A cross-sectional study of target medical device data in EHR and CDM was conducted. A total of 155 medical devices were finally enrolled, with 58.7% of them having EDI codes. Femoral head prosthesis was selected as a focus group. It was registered in our institute with 11 EDI codes. However, only three EDI codes were converted to systematized nomenclature of medicine clinical terms concept. EDI code was matched in one-to-many (up to 104) with unique device identifier (UDI), including devices classified as different global medical device nomenclature. The use of UDI rather than EDI code as a medical device data source is recommended. We hope that this study will share the current state of medical device data recorded in the EHR and contribute to the introduction of CDM-based medical device vigilance by selecting appropriate medical device data sources.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sooin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Genetics, Center for Medical Device Safety Monitoring, Soonchunhyang University College of Medicine, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Soo Jeong</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Center for Medical Device Safety Monitoring, Soonchunhyang University College of Medicine, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin Kuk</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Center for Medical Device Safety Monitoring, Soonchunhyang University College of Medicine, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Ki Chang</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Medical Engineering, Dongguk University College of Medicine, Gyeongju, 38066, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suehyun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, College of Medicine, Konyang University, Daejeon, 35365, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ju Han</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Seoul National University Biomedical Informatics (SNUBI), Seoul National University College of Medicine, Seoul, 08826, Republic of Korea. juhan@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>You Kyoung</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Genetics, Center for Medical Device Safety Monitoring, Soonchunhyang University College of Medicine, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea. cecilia@schmc.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34911976</ArticleId><ArticleId IdType="pmc">PMC8674329</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-03332-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-03332-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hauser RG, Kallinen LM, Almquist AK, Gornick CC, Katsiyiannis WT. Early failure of a small-diameter high-voltage implantable cardioverter&#x2013;defibrillator lead. Heart Rhythm. 2007;4:892&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">17599673</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisel WH. Semper fidelis&#x2014;Consumer protection for patients with implanted medical devices. N. Engl. J. Med. 2008;358:985&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322280</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon C, et al. Differences in perspectives of medical device adverse events: Observational results in training program using virtual cases. J. Korean Med. Sci. 2019;34:e255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786964</ArticleId><ArticleId IdType="pubmed">31602825</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Shea JC, Kramer JM, Califf RM, Peterson ED. Part I: Identifying holes in the safety net. Am. Heart J. 2004;147:977&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pubmed">15199343</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnic FS. Postmarketing surveillance of medical devices&#x2014;Filling in the gaps. N. Engl. J. Med. 2012;366:875.</Citation><ArticleIdList><ArticleId IdType="pubmed">22332950</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidi VD, Matheny ME, Resnic FS. Post-marketing device safety surveillance. Contemp. Clin. Trials. 2011;32:307&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">21371573</ArticleId></ArticleIdList></Reference><Reference><Citation>Normand S-LT, Hatfield L, Drozda J, Resnic FS. Postmarket surveillance for medical devices: America&#x2019;s new strategy. Br. Med. J. 2012;345:e8648.</Citation><ArticleIdList><ArticleId IdType="pubmed">23060660</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, et al. ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model. J. Biomed. Inform. 2019;91:103&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6432939</ArticleId><ArticleId IdType="pubmed">30738946</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, et al. An evaluation of the THIN database in the OMOP common data model for active drug safety surveillance. Drug Saf. 2013;36:119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320:867&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">30105359</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M-F, et al. Web-based experience sharing platform on medical device incidents for clinical engineers in hospitals. J. Med. Biol. Eng. 2018;38:835&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132694</ArticleId><ArticleId IdType="pubmed">30220902</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidi VD, Matheny ME, Donnelly S, Resnic FS. An evaluation of a distributed medical device safety surveillance system: The DELTA network study. Contemp. Clin. Trials. 2011;32:309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070041</ArticleId><ArticleId IdType="pubmed">21356331</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat. Commun. 2020;11:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Park RW. The distributied research network, observational health data sciences and informatics, and the South Korea research network. Korean J. Med. 2019;94:309&#x2013;114.</Citation></Reference><Reference><Citation>Evidnet, FeederNet, https://feedernet.com/resource (2021).</Citation></Reference><Reference><Citation>White J, Carolan-Rees G. Current state of medical device nomenclature and taxonomy systems in the UK: Spotlight on GMDN and SNOMED CT. JRSM Short Rep. 2013;4:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704061</ArticleId><ArticleId IdType="pubmed">23885299</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig A, O&#x2019;Meley P, Carter P. The need for greater reporting of medical device incidents. Innovations. 2019;3:56&#x2013;63.</Citation></Reference><Reference><Citation>Krupka DC, et al. Transmitting device identifiers of implants from the point of care to insurers: A demonstration project. J. Patient Saf. 2021;17:223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7984755</ArticleId><ArticleId IdType="pubmed">33734207</ArticleId></ArticleIdList></Reference><Reference><Citation>Seong Y, et al. Incorporation of Korean Electronic data interchange vocabulary into observational medical outcomes partnership vocabulary. Healthc. Inform. Res. 2021;27:29&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7921574</ArticleId><ArticleId IdType="pubmed">33611874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang, E. J. et al. Mapping Korean EDI medical procedure code to SNOMED CT. In MEDINFO 2019: Health and Wellbeing e-Networks for All 178&#x2013;182 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31437909</ArticleId></ArticleIdList></Reference><Reference><Citation>You, S. C. et al. Conversion of national health insurance service-national sample cohort (NHIS-NSC) database into observational medical outcomes partnership-common data model (OMOP-CDM). In MEDINFO 2017:Precision Healthcare Through Informatics 467&#x2013;470 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>Korea Health Information Service. Healthcare information standard, https://hins.or.kr (2021).</Citation></Reference><Reference><Citation>Paxton EW, Inacio MCS, Khatod M, Yue EJ, Namba RS. Kaiser Permanente national total joint replacement registry: Aligning operations with information technology. Clin. Orthop. Relat. Res. 2010;468:2646&#x2013;2663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049637</ArticleId><ArticleId IdType="pubmed">20652461</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbloom ST, et al. Data from clinical notes: A perspective on the tension between structure and flexible documentation. J. Am. Med. Inform. Assoc. 2011;18:181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3116264</ArticleId><ArticleId IdType="pubmed">21233086</ArticleId></ArticleIdList></Reference><Reference><Citation>Nancy AM, Maheswari R. A review on unstructured data in medical data. J. Crit. Rev. 2020;7:2202&#x2013;2208.</Citation></Reference><Reference><Citation>Campion TR, Jr, Johnson SB, Paxton EW, Mushlin AI, Sedrakyan A. Implementing unique device identification in electronic health record systems: Organizational, workflow, and technological challenges. Med. Care. 2014;52:26&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">24322986</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedrakyan A, et al. The international consortium of orthopaedic registries: Overview and summary. JBJS. 2011;93:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262417</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertsson O, Mendenhall S, Paxton EW, Inacio MCS, Graves S. Challenges in prosthesis classification. JBJS. 2011;93:72&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262428</ArticleId></ArticleIdList></Reference><Reference><Citation>IMDRF UDI Working Group. Unique Device Identification (UDI) of Medical Devices, http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-131209-udi-guidance (2013).</Citation></Reference><Reference><Citation>Barlas S. New FDA medical device rule imposes minimal burden on hospitals: Facilities able to scan unique device identifiers will benefit. Pharm. Ther. 2013;38:720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875269</ArticleId><ArticleId IdType="pubmed">24391393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross TP, Crowley J. Unique device identification in the service of public health. N. Engl. J. Med. 2012;367:1583.</Citation><ArticleIdList><ArticleId IdType="pubmed">23013051</ArticleId></ArticleIdList></Reference><Reference><Citation>Aston JW, Howarth AL, Wilson NA, Mahabir RC. The value of unique device identifiers in plastic surgery. Aesthet. Surg. J. 2018;38:1264&#x2013;1266.</Citation><ArticleIdList><ArticleId IdType="pubmed">30202871</ArticleId></ArticleIdList></Reference><Reference><Citation>Camus D, et al. New European medical device regulation: How the French ecosystem should seize the opportunity of the EUDAMED and the UDI system, while overcoming the constraints thereof. Therapies. 2019;74:73&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">30598315</ArticleId></ArticleIdList></Reference><Reference><Citation>Melvin T, Torre M. New medical device regulations: The regulator&#x2019;s view. EFORT Open Rev. 2019;4:351&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6598613</ArticleId><ArticleId IdType="pubmed">31312522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Food and Drug Safety. Medical devices act, https://elaw.klri.re.kr/kor_service/lawView.do?hseq=50798&amp;lang=ENG (2019).</Citation></Reference><Reference><Citation>Wilson NA, Drozda J. Value of unique device identification in the digital health infrastructure. JAMA. 2013;309:2107&#x2013;2108.</Citation><ArticleIdList><ArticleId IdType="pubmed">23695480</ArticleId></ArticleIdList></Reference><Reference><Citation>Drozda JP, Jr, Dudley C, Helmering P, Roach J, Hutchison L. The Mercy unique device identifier demonstration project: Implementing point of use product identification in the cardiac catheterization laboratories of a regional health system. Healthcare. 2016;4:116&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">27343161</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhruva SS, Ross JS, Schulz WL, Krumholz HM. Fulfilling the promise of unique device identifiers. Ann. Intern. Med. 2018;7:183&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">29868760</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon EG, et al. Effect of bar-code technology on the safety of medication administration. N. Engl. J. Med. 2010;362:1698&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">20445181</ArticleId></ArticleIdList></Reference><Reference><Citation>Senders JW. On the complexity of medical devices and systems. BMJ Qual. Saf. 2006;15:i41&#x2013;i43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2464875</ArticleId><ArticleId IdType="pubmed">17142608</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnic FS, et al. Quantifying the learning curve in the use of a novel vascular closure device: an analysis of the NCDR (National Cardiovascular Data Registry) CathPCI registry. JACC Cardiovasc. Interv. 2012;5:82&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">22230153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, et al. The data extraction and longitudinal trend analysis network study of distributed automated postmarket cardiovascular device safety surveillance. Circ. Cardiovasc. Qual. Outcomes. 2015;8:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5130285</ArticleId><ArticleId IdType="pubmed">25491915</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah JS, Maisel WH. Recalls and safety alerts affecting automated external defibrillators. JAMA. 2006;296:655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">16896108</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen CJJ. The rosiglitazone story&#x2014;Lessons from an FDA Advisory Committee meeting. N. Engl. J. Med. 2007;357:844&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">17687124</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Yu Y, Kingsbury PR, Shah N. Augmenting medical device evaluation using a reusable unique device identifier interoperability solution based on the OHDSI common data model. Stud. Health Technol. Inform. 2019;264:1502&#x2013;1503.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438202</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K, Veermaram C, Saini SK, Singh BK. Global medical device nomenclature: The concept for reducing device-related medical errors. J. Young Pharm. 2010;2:403&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3019382</ArticleId><ArticleId IdType="pubmed">21264103</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;yrinen K, Saranto K, Nyk&#xe4;nen P. Definition, structure, content, use and impacts of electronic health records: A review of the research literature. Int. J. Med. Inform. 2008;77:291&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">17951106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health and Welfare, Ministry of Health and Welfare notice 2021-174, Medical device price list, https://www.hira.or.kr/rd/insuadtcrtr/bbsView.do?pgmid=HIRAA030069000400&amp;brdScnBltNo=4&amp;brdBltNo=51884&amp;isPopupYn=Y (2021).</Citation></Reference><Reference><Citation>Ministry of Food and Drug Safety. Medical device information portal https://udiportal.mfds.go.kr (2021).</Citation></Reference><Reference><Citation>U.S. National library of medicine, Access GUDID, https://accessgudid.nlm.nih.gov (2021).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34930903</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Predictors of diagnostic transition from major depressive disorder to bipolar disorder: a retrospective observational network study.</ArticleTitle><Pagination><StartPage>642</StartPage><MedlinePgn>642</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">642</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-021-01760-6</ELocationID><Abstract><AbstractText>Many patients with bipolar disorder (BD) are initially misdiagnosed with major depressive disorder (MDD) and are treated with antidepressants, whose potential iatrogenic effects are widely discussed. It is unknown whether MDD is a comorbidity of BD or its earlier stage, and no consensus exists on individual conversion predictors, delaying BD's timely recognition and treatment. We aimed to build a predictive model of MDD to BD conversion and to validate it across a multi-national network of patient databases using the standardization afforded by the Observational Medical Outcomes Partnership (OMOP) common data model. Five "training" US databases were retrospectively analyzed: IBM MarketScan CCAE, MDCR, MDCD, Optum EHR, and Optum Claims. Cyclops regularized logistic regression models were developed on one-year MDD-BD conversion with all standard covariates from the HADES PatientLevelPrediction package. Time-to-conversion Kaplan-Meier analysis was performed up to a decade after MDD, stratified by model-estimated risk. External validation of the final prediction model was performed across 9 patient record databases within the Observational Health Data Sciences and Informatics (OHDSI) network internationally. The model's area under the curve (AUC) varied 0.633-0.745 (&#xb5; = 0.689) across the five US training databases. Nine variables predicted one-year MDD-BD transition. Factors that increased risk were: younger age, severe depression, psychosis, anxiety, substance misuse, self-harm thoughts/actions, and prior mental disorder. AUCs of the validation datasets ranged 0.570-0.785 (&#xb5; = 0.664). An assessment algorithm was built for MDD to BD conversion that allows distinguishing as much as 100-fold risk differences among patients and validates well across multiple international data sources.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nestsiarovich</LastName><ForeName>Anastasiya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of New Mexico Health Sciences Center, Department of Internal Medicine, Center for Global Health, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-3217-4147</Identifier><AffiliationInfo><Affiliation>Vanderbilt University, Department of Biomedical Informatics, Department of Medicine, Department of Biostatistics, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System VA, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Veterans Affairs Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Utah, Department of Internal Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Veterans Affairs Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Utah, Department of Internal Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beaton</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, Department of Biomedical Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xinzhuo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, Department of Biomedical Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2869-0237</Identifier><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, Department of Biomedical Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfohl</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Stanford University, Stanford Center for Biomedical Informatics Research, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0001-9385-7158</Identifier><AffiliationInfo><Affiliation>Stanford University, Stanford Center for Biomedical Informatics Research, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre</LastName><ForeName>Carmen Olga</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>IQVIA, Real World Solutions, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>IQVIA, Real World Solutions, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Yun</ForeName><Initials>DY</Initials><Identifier Source="ORCID">0000-0002-3678-9862</Identifier><AffiliationInfo><Affiliation>Ajou University School of Medicine, Department of Psychiatry, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Sang Joon</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0001-7434-7996</Identifier><AffiliationInfo><Affiliation>Ajou University School of Medicine, Department of Psychiatry, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5052-6399</Identifier><AffiliationInfo><Affiliation>Ajou University School of Medicine, Department of Biomedical Informatics, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Ajou University School of Medicine, Department of Biomedical Informatics, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, Department of Biomedical Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Christophe G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0003-1994-2893</Identifier><AffiliationInfo><Affiliation>University of New Mexico Health Sciences Center, Department of Internal Medicine, Center for Global Health, Albuquerque, NM, USA. cglambert@unm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of New Mexico Health Sciences Center, Department of Internal Medicine, Center for Global Health, Division of Translational Informatics, Albuquerque, NM, USA. cglambert@unm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 MH120826</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="Y">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>J.M.R. and P.B.R. are employees of Janssen Research &amp; Development and shareholders of Johnson &amp; Johnson. C.G.R. and C.O.T. are employees of IQVIA. All other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34930903</ArticleId><ArticleId IdType="pmc">PMC8688463</ArticleId><ArticleId IdType="doi">10.1038/s41398-021-01760-6</ArticleId><ArticleId IdType="pii">10.1038/s41398-021-01760-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD. Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789&#x2013;858. 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6227754</ArticleId><ArticleId IdType="pubmed">30496104</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Mental Health. NIMH &#xbb; Major Depression. https://www.nimh.nih.gov/health/statistics/major-depression.shtml (accessed 11 Feb 2020).</Citation></Reference><Reference><Citation>National Alliance on Mental Illness. Mental Health By the Numbers. https://www.nami.org/learn-more/mental-health-by-the-numbers (accessed 11 Feb 2020).</Citation></Reference><Reference><Citation>WHO, World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. World Health Organization; 1993.</Citation></Reference><Reference><Citation>Fagiolini A, Cuomo A. On the centrality of mixed features in mood disorders: listening to Kraepelin and Weygandt and moving forward. Bipolar Disord. 2017;19:704&#x2013;5. doi: 10.1111/bdi.12537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.12537</ArticleId><ArticleId IdType="pubmed">28833966</ArticleId></ArticleIdList></Reference><Reference><Citation>Angst J, Merikangas KR, Cui L, Van Meter A, Ajdacic-Gross V, R&#xf6;ssler W. Bipolar spectrum in major depressive disorders. Eur Arch Psychiatry Clin Neurosci. 2018;268:741&#x2013;8. doi: 10.1007/s00406-018-0927-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-018-0927-x</ArticleId><ArticleId IdType="pubmed">30032467</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhi GS, Bell E. Mixed states: an early warning sign of profound problems in our taxonomy? Acta Psychiatr Scand. 2019;139:489&#x2013;92. doi: 10.1111/acps.13037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acps.13037</ArticleId><ArticleId IdType="pubmed">31093974</ArticleId></ArticleIdList></Reference><Reference><Citation>Musliner KL, &#xd8;stergaard SD. Patterns and predictors of conversion to bipolar disorder in 91 587 individuals diagnosed with unipolar depression. Acta Psychiatr Scand. 2018;137:422&#x2013;32. doi: 10.1111/acps.12869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acps.12869</ArticleId><ArticleId IdType="pubmed">29498031</ArticleId></ArticleIdList></Reference><Reference><Citation>Angst J, Sellaro R, Stassen HH, Gamma A. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J Affect Disord. 2005;84:149&#x2013;57. doi: 10.1016/S0165-0327(03)00195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0327(03)00195-2</ArticleId><ArticleId IdType="pubmed">15708412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessing LV, Willer I, Andersen PK, Bukh JD. Rate and predictors of conversion from unipolar to bipolar disorder: A systematic review and meta-analysis. Bipolar Disord. 2017;19:324&#x2013;35. doi: 10.1111/bdi.12513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.12513</ArticleId><ArticleId IdType="pubmed">28714575</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C-T, Bai Y-M, Huang Y-L, Chen Y-S, Chen T-J, Cheng J-Y, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry. 2012;200:45&#x2013;51. doi: 10.1192/bjp.bp.110.086983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.110.086983</ArticleId><ArticleId IdType="pubmed">22016435</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno C, Hasin DS, Arango C, Oquendo MA, Vieta E, Liu S, et al. Depression in bipolar disorder versus major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Bipolar Disord. 2012;14:271&#x2013;82. doi: 10.1111/j.1399-5618.2012.01009.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-5618.2012.01009.x</ArticleId><ArticleId IdType="pmc">PMC3349442</ArticleId><ArticleId IdType="pubmed">22548900</ArticleId></ArticleIdList></Reference><Reference><Citation>Truman CJ, Goldberg JF, Ghaemi SN, Baldassano CF, Wisniewski SR, Dennehy EB, et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) J Clin Psychiatry. 2007;68:1472&#x2013;9. doi: 10.4088/JCP.v68n1002.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v68n1002</ArticleId><ArticleId IdType="pubmed">17960960</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y-H, Chen K, Chang I-C, Shen C-C. Critical predictors for the early detection of conversion from unipolar major depressive disorder to bipolar disorder: nationwide population-based retrospective cohort study. JMIR Med Inf. 2020;8:e14278. doi: 10.2196/14278.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/14278</ArticleId><ArticleId IdType="pmc">PMC7165312</ArticleId><ArticleId IdType="pubmed">32242821</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankland A, Roberts G, Holmes-Preston E, Perich T, Levy F, Lenroot R, et al. Clinical predictors of conversion to bipolar disorder in a prospective longitudinal familial high-risk sample: focus on depressive features. Psychol Med. 2018;48:1713&#x2013;21. doi: 10.1017/S0033291717003233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291717003233</ArticleId><ArticleId IdType="pubmed">29108524</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Kim Y, Baek JH, Fava M, Mischoulon D, Nierenberg AA, et al. Predictive factors of diagnostic conversion from major depressive disorder to bipolar disorder in young adults ages 19-34: A nationwide population study in South Korea. J Affect Disord. 2020;265:52&#x2013;58. doi: 10.1016/j.jad.2020.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.01.009</ArticleId><ArticleId IdType="pubmed">31957692</ArticleId></ArticleIdList></Reference><Reference><Citation>James A, Wotton CJ, Duffy A, Hoang U, Goldacre M. Conversion from depression to bipolar disorder in a cohort of young people in England, 1999-2011: a national record linkage study. J Affect Disord. 2015;185:123&#x2013;8. doi: 10.1016/j.jad.2015.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2015.06.018</ArticleId><ArticleId IdType="pubmed">26172983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EY, Kim NW, Kim MJ, Yang BR, Rhee SJ, Park CHK, et al. Rate of diagnostic conversion to bipolar disorder in adults with unipolar depression and psychopharmacological treatment in the republic of Korea: A nationwide register-based study. J Affect Disord. 2020;273:240&#x2013;6. doi: 10.1016/j.jad.2020.03.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.03.159</ArticleId><ArticleId IdType="pubmed">32421610</ArticleId></ArticleIdList></Reference><Reference><Citation>McPadden J, Durant TJ, Bunch DR, Coppi A, Price N, Rodgerson K, et al. Health care and precision medicine research: analysis of a scalable data science platform. J Med Internet Res. 2019;21:e13043. doi: 10.2196/13043.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13043</ArticleId><ArticleId IdType="pmc">PMC6477571</ArticleId><ArticleId IdType="pubmed">30964441</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration hierarchy for risk models was defined: from utopia to empirical data. J Clin Epidemiol. 2016;74:167&#x2013;76. doi: 10.1016/j.jclinepi.2015.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.12.005</ArticleId><ArticleId IdType="pubmed">26772608</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S, Posada J, Olson G, Li W, O&#x2019;Reilly C, Balraj D, et al. A new paradigm for accelerating clinical data science at Stanford Medicine. Preprint at http://arxiv.org/abs/2003.10534 (2020).</Citation></Reference><Reference><Citation>Bowden CL. A different depression: clinical distinctions between bipolar and unipolar depression. J Affect Disord. 2005;84:117&#x2013;25. doi: 10.1016/S0165-0327(03)00194-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0327(03)00194-0</ArticleId><ArticleId IdType="pubmed">15708408</ArticleId></ArticleIdList></Reference><Reference><Citation>Othmer E, Desouza CM, Penick EC, Nickel EJ, Hunter EE, Othmer SC, et al. Indicators of mania in depressed outpatients: a retrospective analysis of data from the Kansas 1500 study. J Clin Psychiatry. 2007;68:47&#x2013;51. doi: 10.4088/JCP.v68n0106.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v68n0106</ArticleId><ArticleId IdType="pubmed">17284129</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am J Psychiatry. 2001;158:1265&#x2013;70. doi: 10.1176/appi.ajp.158.8.1265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.158.8.1265</ArticleId><ArticleId IdType="pubmed">11481161</ArticleId></ArticleIdList></Reference><Reference><Citation>Holma KM, Melartin TK, Holma IAK, Isomets&#xe4; ET. Predictors for switch from unipolar major depressive disorder to bipolar disorder type I or II: a 5-year prospective study. J Clin Psychiatry. 2008;69:1267&#x2013;75. doi: 10.4088/JCP.v69n0809.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v69n0809</ArticleId><ArticleId IdType="pubmed">18681753</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue T, Kimura T, Inagaki Y, Shirakawa O. Prevalence of comorbid anxiety disorders and their associated factors in patients with bipolar disorder or major depressive disorder. Neuropsychiatr Dis Treat. 2020;16:1695&#x2013;704. doi: 10.2147/NDT.S246294.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S246294</ArticleId><ArticleId IdType="pmc">PMC7369363</ArticleId><ArticleId IdType="pubmed">32764945</ArticleId></ArticleIdList></Reference><Reference><Citation>Goes FS, McCusker MG, Bienvenu OJ, Mackinnon DF, Mondimore FM, Schweizer B, et al. Co-morbid anxiety disorders in bipolar disorder and major depression: familial aggregation and clinical characteristics of co-morbid panic disorder, social phobia, specific phobia and obsessive-compulsive disorder. Psychol Med. 2012;42:1449&#x2013;59. doi: 10.1017/S0033291711002637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291711002637</ArticleId><ArticleId IdType="pmc">PMC3643205</ArticleId><ArticleId IdType="pubmed">22099954</ArticleId></ArticleIdList></Reference><Reference><Citation>Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, et al. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J Affect Disord. 2001;67:45&#x2013;59. doi: 10.1016/S0165-0327(01)00432-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0327(01)00432-3</ArticleId><ArticleId IdType="pubmed">11869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64:161&#x2013;74. doi: 10.4088/JCP.v64n0209.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v64n0209</ArticleId><ArticleId IdType="pubmed">12633125</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63:985&#x2013;91. doi: 10.4088/JCP.v63n1105.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v63n1105</ArticleId><ArticleId IdType="pubmed">12444811</ArticleId></ArticleIdList></Reference><Reference><Citation>Keck PE Jr, Kessler RC, Ross R. Clinical and economic effects of unrecognized or inadequately treated bipolar disorder. J Psychiatr Pr. 2008;14:31&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18677197</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk M, Malhi GS, Hallam K, Gama CS, Dodd S, Andreazza AC, et al. Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives. J Affect Disord. 2009;114:1&#x2013;13. doi: 10.1016/j.jad.2008.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2008.08.011</ArticleId><ArticleId IdType="pubmed">18819715</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe PJ, Christopher PP, Pinals DA, Fisher WH. Predictors of criminal justice involvement in severe mania. J Affect Disord. 2013;149:367&#x2013;74. doi: 10.1016/j.jad.2013.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2013.02.015</ArticleId><ArticleId IdType="pubmed">23477847</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue T, Abekawa T, Nakagawa S, Suzuki K, Tanaka T, Kitaichi Y, et al. Long-term naturalistic follow-up of lithium augmentation: relevance to bipolarity. J Affect Disord. 2011;129:64&#x2013;67. doi: 10.1016/j.jad.2010.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2010.08.022</ArticleId><ArticleId IdType="pubmed">20837361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34937726</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Characteristics and outcomes of patients with COVID-19 with and without prevalent hypertension: a multinational cohort study.</ArticleTitle><Pagination><StartPage>e057632</StartPage><MedlinePgn>e057632</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e057632</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2021-057632</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To characterise patients with and without prevalent hypertension and COVID-19 and to assess adverse outcomes in both inpatients and outpatients.</AbstractText><AbstractText Label="DESIGN AND SETTING">This is a retrospective cohort study using 15 healthcare databases (primary and secondary electronic healthcare records, insurance and national claims data) from the USA, Europe and South Korea, standardised to the Observational Medical Outcomes Partnership common data model. Data were gathered from 1 March to 31 October 2020.</AbstractText><AbstractText Label="PARTICIPANTS">Two non-mutually exclusive cohorts were defined: (1) individuals diagnosed with COVID-19 (diagnosed cohort) and (2) individuals hospitalised with COVID-19 (hospitalised cohort), and stratified by hypertension status. Follow-up was from COVID-19 diagnosis/hospitalisation to death, end of the study period or 30 days.</AbstractText><AbstractText Label="OUTCOMES">Demographics, comorbidities and 30-day outcomes (hospitalisation and death for the 'diagnosed' cohort and adverse events and death for the 'hospitalised' cohort) were reported.</AbstractText><AbstractText Label="RESULTS">We identified 2&#x2009;851&#x2009;035 diagnosed and 563&#x2009;708 hospitalised patients with COVID-19. Hypertension was more prevalent in the latter (ranging across databases from 17.4% (95% CI 17.2 to 17.6) to 61.4% (95% CI 61.0 to 61.8) and from 25.6% (95% CI 24.6 to 26.6) to 85.9% (95% CI 85.2 to 86.6)). Patients in both cohorts with hypertension were predominantly &gt;50 years old and female. Patients with hypertension were frequently diagnosed with obesity, heart disease, dyslipidaemia and diabetes. Compared with patients without hypertension, patients with hypertension in the COVID-19 diagnosed cohort had more hospitalisations (ranging from 1.3% (95% CI 0.4 to 2.2) to 41.1% (95% CI 39.5 to 42.7) vs from 1.4% (95% CI 0.9 to 1.9) to 15.9% (95% CI 14.9 to 16.9)) and increased mortality (ranging from 0.3% (95% CI 0.1 to 0.5) to 18.5% (95% CI 15.7 to 21.3) vs from 0.2% (95% CI 0.2 to 0.2) to 11.8% (95% CI 10.8 to 12.8)). Patients in the COVID-19 hospitalised cohort with hypertension were more likely to have acute respiratory distress syndrome (ranging from 0.1% (95% CI 0.0 to 0.2) to 65.6% (95% CI 62.5 to 68.7) vs from 0.1% (95% CI 0.0 to 0.2) to 54.7% (95% CI 50.5 to 58.9)), arrhythmia (ranging from 0.5% (95% CI 0.3 to 0.7) to 45.8% (95% CI 42.6 to 49.0) vs from 0.4% (95% CI 0.3 to 0.5) to 36.8% (95% CI 32.7 to 40.9)) and increased mortality (ranging from 1.8% (95% CI 0.4 to 3.2) to 25.1% (95% CI 23.0 to 27.2) vs from 0.7% (95% CI 0.5 to 0.9) to 10.9% (95% CI 10.4 to 11.4)) than patients without hypertension.</AbstractText><AbstractText Label="CONCLUSIONS">COVID-19 patients with hypertension were more likely to suffer severe outcomes, hospitalisations and deaths compared with those without hypertension.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Carlen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8486-3265</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistillo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bertol&#xed;n</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recalde</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puente</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Janssen Research and Development Titusville, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research and Development Titusville, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Waheed-Ui-Rahman</ForeName><Initials>WU</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Health, University of Exeter, St Luke's Campus, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6743-803X</Identifier><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Heba</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8234-5843</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Islamic University of Gaza, Gaza, Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4668-7069</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawoud</LastName><ForeName>Dalia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Institute for Health and Care Excellence (NICE), London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Pharmacy, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Center for Statistics in Medicine, NDORMS, University of Oxford, Botnar Research Center, Nuffield Orthopaedic Center, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valveny</LastName><ForeName>Neus</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Real-World Evidence, TFS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Maeztu</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>IOMED, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorl&#xed; Red&#xf3;</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d'Investigaci&#xf3; M&#xe8;dica (IMIM), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez Roldan</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Director of Innovation and Digital Transformation, Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez Montesinos</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d'Investigaci&#xf3; M&#xe8;dica (IMIM), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>University of Colorado - Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Tarrytown, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jose D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, The University of Utah School of Medicine, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, The University of Utah School of Medicine, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, The University of Utah School of Medicine, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterial Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0003-0621-1979</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Publich Health, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research and Development Titusville, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2595-8736</Identifier><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The OHDSI Center at the Roux Institute, Northeastern University, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8274-0357</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain tduarte@idiapjgol.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RES 13-457</GrantID><Acronym>RD</Acronym><Agency>ORD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword></KeywordList><CoiStatement>Competing interests: SLD reports grants from Anolinx. MAS reports grants from US National Institutes of Health, grants from Department of Veterans Affairs, during the conduct of the study; grants from IQVIA, personal fees from Janssen Research and Development, grants from US Food and Drug Administration, personal fees from Private Health Management, outside the submitted work. GH reports grants from NIH, during the conduct of the study; and grants from Janssen Research, outside the submitted work. FN reports being an employee of AstraZeneca until 2019 and holds some AstraZeneca shares, outside the submitted work. KK reports personal fees from the National Institutes of Health, outside the submitted work, and at the time of data analysis and initial drafting of the manuscript. KK was an employee of IQVIA. CRei reports he is an employee of IQVIA. GdM is an employee of IOMED. NV is an employee of TFS. AGS reports personal fees from Janssen R&amp;D, outside the submitted work, and is a full-time employee of Janssen R&amp;D and a Johnson and Johnson shareholder. CB reports personal fees from Janssen R&amp;D, outside the submitted work, and is a full-time employee of Janssen R&amp;D and a Johnson and Johnson shareholder. JDP reports grants from the National Library of Medicine, during the conduct of the study. AG is an employee of Regeneron Pharmaceuticals and reports stocks from Regeneron Pharmaceuticals. PRR reports having received research group grants from Innovative Medicine Initiative and Janssen Research and Development. PR reports being an employee of Janssen Research and Development and a shareholder of Johnson &amp; Johnson. ER, SF-B, NS, LMS, DP, SCY, MR, AP-U, HA, KEL, MEM, AO, CA, CRey, TD-S, TMA, OA, W-U-RA, ILM, JMR, LSR, DD, LL and AP have nothing to declare. No other relationships or activities could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>23</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34937726</ArticleId><ArticleId IdType="pmc">PMC8704062</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2021-057632</ArticleId><ArticleId IdType="pii">bmjopen-2021-057632</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weekly Operational Update on COVID-19-6 Sep 2021 [internet] . WHO. Available: https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---6-september-2021</Citation></Reference><Reference><Citation>Unger T, Borghi C, Charchar F. 2020 International Society of hypertension global hypertension practice guidelines. J Hypertens 2020;75:982&#x2013;1004. 10.1161/HYPERTENSIONAHA.120.1502</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.1502</ArticleId><ArticleId IdType="pubmed">32371787</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook TM. The importance of hypertension as a risk factor for severe illness and mortality in COVID-19. Anaesthesia 2020;75:976&#x2013;7. 10.1111/anae.15103</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.15103</ArticleId><ArticleId IdType="pmc">PMC7267452</ArticleId><ArticleId IdType="pubmed">32339251</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Hayek SS, Wang W, et al. . Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 2020;180:1436&#x2013;12. 10.1001/jamainternmed.2020.3596</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3596</ArticleId><ArticleId IdType="pmc">PMC7364338</ArticleId><ArticleId IdType="pubmed">32667668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez E, Font&#xe1;n-Vela M, Valencia J, et al. . Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study. BMJ Open 2020;10:e042398. 10.1136/bmjopen-2020-042398</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-042398</ArticleId><ArticleId IdType="pmc">PMC7656887</ArticleId><ArticleId IdType="pubmed">33172949</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Wang J, Liu F, et al. . COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res 2020;43:824&#x2013;31. 10.1038/s41440-020-0485-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-020-0485-2</ArticleId><ArticleId IdType="pmc">PMC7261650</ArticleId><ArticleId IdType="pubmed">32483311</ArticleId></ArticleIdList></Reference><Reference><Citation>Park BE, Lee JH, Park HK, et al. . Impact of cardiovascular risk factors and cardiovascular diseases on outcomes in patients hospitalized with COVID-19 in Daegu metropolitan City. J Korean Med Sci 2021;36:e15. 10.3346/jkms.2021.36.e15</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2021.36.e15</ArticleId><ArticleId IdType="pmc">PMC7801150</ArticleId><ArticleId IdType="pubmed">33429474</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Q, Ni J, Hu T-T, et al. . Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) patients with and without hypertension: a retrospective study. Rev Cardiovasc Med 2020;21:615&#x2013;25. 10.31083/j.rcm.2020.04.113</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm.2020.04.113</ArticleId><ArticleId IdType="pubmed">33388007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054&#x2013;62. 10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Lu X, Li Y, et al. . Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 2020;201:1430&#x2013;4. 10.1164/rccm.202003-0736LE</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202003-0736LE</ArticleId><ArticleId IdType="pmc">PMC7258632</ArticleId><ArticleId IdType="pubmed">32267160</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, et al. . Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574&#x2013;81. 10.1001/jama.2020.5394</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.5394</ArticleId><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C, Cai Y, Zhang K, et al. . Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J 2020;41:2058&#x2013;66. 10.1093/eurheartj/ehaa433</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa433</ArticleId><ArticleId IdType="pmc">PMC7314067</ArticleId><ArticleId IdType="pubmed">32498076</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W-J, Liang W-H, Zhao Y, et al. . Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547. 10.1183/13993003.00547-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00547-2020</ArticleId><ArticleId IdType="pmc">PMC7098485</ArticleId><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji W, Huh K, Kang M, et al. . Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study. J Korean Med Sci 2020;35:e237. 10.3346/jkms.2020.35.e237</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e237</ArticleId><ArticleId IdType="pmc">PMC7324262</ArticleId><ArticleId IdType="pubmed">32597048</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilimuri S, Sun H, Alemam A, et al. . Predictors of mortality in adults admitted with COVID-19: retrospective cohort study from New York City. West J Emerg Med 2020;21:779&#x2013;84. 10.5811/westjem.2020.6.47919</Citation><ArticleIdList><ArticleId IdType="doi">10.5811/westjem.2020.6.47919</ArticleId><ArticleId IdType="pmc">PMC7390589</ArticleId><ArticleId IdType="pubmed">32726241</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, et al. . Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area. JAMA 2020;323:2052&#x2013;9. 10.1001/jama.2020.6775</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6775</ArticleId><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorjee K, Kim H, Bonomo E, et al. . Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: a comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. PLoS One 2020;15:e0243191. 10.1371/journal.pone.0243191</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243191</ArticleId><ArticleId IdType="pmc">PMC7721151</ArticleId><ArticleId IdType="pubmed">33284825</ArticleId></ArticleIdList></Reference><Reference><Citation>Javanmardi F, Keshavarzi A, Akbari A, et al. . Prevalence of underlying diseases in died cases of COVID-19: a systematic review and meta-analysis. PLoS One 2020;15:e0241265. 10.1371/journal.pone.0241265</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0241265</ArticleId><ArticleId IdType="pmc">PMC7584167</ArticleId><ArticleId IdType="pubmed">33095835</ArticleId></ArticleIdList></Reference><Reference><Citation>Pranata R, Lim MA, Huang I, et al. . Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst 2020;21:147032032092689. 10.1177/1470320320926899</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1470320320926899</ArticleId><ArticleId IdType="pmc">PMC7231906</ArticleId><ArticleId IdType="pubmed">32408793</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverio A, Di Maio M, Citro R, et al. . Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients. BMC Cardiovasc Disord 2021;21:23. 10.1186/s12872-020-01816-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-020-01816-3</ArticleId><ArticleId IdType="pmc">PMC7789083</ArticleId><ArticleId IdType="pubmed">33413093</ArticleId></ArticleIdList></Reference><Reference><Citation>Moazzami B, Chaichian S, Kasaeian A, et al. . Metabolic risk factors and risk of Covid-19: a systematic review and meta-analysis. PLoS One 2020;15:e0243600. 10.1371/journal.pone.0243600</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243600</ArticleId><ArticleId IdType="pmc">PMC7737901</ArticleId><ArticleId IdType="pubmed">33320875</ArticleId></ArticleIdList></Reference><Reference><Citation>Baj J, Karaku&#x142;a-Juchnowicz H, Teresi&#x144;ski G, et al. . COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med 2020;9:1753. 10.3390/jcm9061753</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9061753</ArticleId><ArticleId IdType="pmc">PMC7356953</ArticleId><ArticleId IdType="pubmed">32516940</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-Alhambra D, Kostka K, Duarte-Salles T. Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using Charybdis. Res Sq [Preprint] 2021:rs.3.rs-279400.</Citation></Reference><Reference><Citation>Garc&#xed;a-Gil MDM, Hermosilla E, Prieto-Alhambra D, et al. . Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care 2011;19:135&#x2013;45. 10.14236/jhi.v19i3.806</Citation><ArticleIdList><ArticleId IdType="doi">10.14236/jhi.v19i3.806</ArticleId><ArticleId IdType="pubmed">22688222</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S, Posada J, Olson G. A new paradigm for accelerating clinical data science at Stanford medicine. arXiv 2003;10534.</Citation></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. . Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015;22:553&#x2013;64. 10.1093/jamia/ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, et al. . Hypertension and diabetes mellitus: Coprediction and time trajectories. Hypertension 2018;71:422&#x2013;8. 10.1161/HYPERTENSIONAHA.117.10546</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.117.10546</ArticleId><ArticleId IdType="pmc">PMC5877818</ArticleId><ArticleId IdType="pubmed">29335249</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34952111</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>299</Volume><PubDate><Year>2022</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Network modeling of anxiety and psychological characteristics on suicidal behavior: Cross-sectional study.</ArticleTitle><Pagination><StartPage>545</StartPage><EndPage>552</EndPage><MedlinePgn>545-552</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2021.12.050</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(21)01369-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Suicide is influenced by complex interactions among various psychopathological features. We aimed to examine the relationship between suicide risk and psychological risk factors such as defense mechanisms, personality, and anxiety.</AbstractText><AbstractText Label="METHODS">We established a psychiatric database by utilizing the Observational Medical Outcomes Partnership Common Data Model. We conducted a 1:1 propensity score matching with age, sex, and depression severity, and identified a sample (n&#xa0;=&#xa0;258) with two groups: those with suicidal behavior and those with non-suicidal behavior. Using principal component analysis, we extracted nine psychological scales and applied network analysis to compare relationships among psychological factors between the two groups.</AbstractText><AbstractText Label="RESULTS">Patients with non-suicidal behaviors showed associations between trait anxiety and defense mechanisms, while those with suicidal behaviors did not. For patients with suicidal ideation there was an association between somatization and trait anxiety. Patients with suicide attempts showed associations between paranoia and dissociation connected to trait anxiety.</AbstractText><AbstractText Label="LIMITATIONS">Longitudinal research is required to fully observe transitions from suicidal ideation to attempts and recurrent suicidal events. In addition, these networks may not generalize suicidal behaviors because the group participants are not homogeneous. Lastly, data from self-report questionnaires limits the reliability of responses.</AbstractText><AbstractText Label="CONCLUSIONS">We presented important new insights on suicidal behavior by estimating psychological networks. Patients with non-suicidal behavior may exhibit discrete relationships between defense mechanisms and anxiety, compared to those with suicidal behavior. Patients with suicidal ideation and suicide attempts may show distinct associations between anxiety and psychopathological features.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eunyoung</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, 164 World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea; Office of Biostatistics, Medical Research Collaborating Center, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center, Suwon, Republic of Korea; Department of Medical Sciences, Graduate school of Ajou University, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karim</LastName><ForeName>Helmet</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States; Department of Bioengineering, University of Pittsburgh School of Medicine, Pittsburgh, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreescu</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuno</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aizenstein</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States; Department of Bioengineering, University of Pittsburgh School of Medicine, Pittsburgh, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Heirim</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, 164 World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea; Office of Biostatistics, Medical Research Collaborating Center, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dongyun</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, 164 World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea; Department of Medical Sciences, Graduate school of Ajou University, Suwon, Republic of Korea; Department of Psychiatry, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyungmin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Sun-Mi</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Doyeop</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, 164 World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, 164 World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Sang Joon</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States; Department of Psychiatry, Ajou University School of Medicine, Suwon, Republic of Korea. Electronic address: sjsonpsy@ajou.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Bumhee</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, 164 World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea; Office of Biostatistics, Medical Research Collaborating Center, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center, Suwon, Republic of Korea. Electronic address: bhpark@ajou.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059020" MajorTopicYN="Y">Suicidal Ideation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="Y">Suicide, Attempted</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anxiety</Keyword><Keyword MajorTopicYN="N">Defense mechanism</Keyword><Keyword MajorTopicYN="N">Network analysis</Keyword><Keyword MajorTopicYN="N">Personality</Keyword><Keyword MajorTopicYN="N">Suicide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34952111</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2021.12.050</ArticleId><ArticleId IdType="pii">S0165-0327(21)01369-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34952871</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>24</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Investigating the impact of development and internal validation design when training prognostic models using a retrospective cohort in big US observational healthcare data.</ArticleTitle><Pagination><StartPage>e050146</StartPage><MedlinePgn>e050146</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e050146</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2021-050146</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The internal validation of prediction models aims to quantify the generalisability of a model. We aim to determine the impact, if any, that the choice of development and internal validation design has on the internal performance bias and model generalisability in big data (n~500&#x2009;000).</AbstractText><AbstractText Label="DESIGN">Retrospective cohort.</AbstractText><AbstractText Label="SETTING">Primary and secondary care; three US claims databases.</AbstractText><AbstractText Label="PARTICIPANTS">1 200 769 patients pharmaceutically treated for their first occurrence of depression.</AbstractText><AbstractText Label="METHODS">We investigated the impact of the development/validation design across 21 real-world prediction questions. Model discrimination and calibration were assessed. We trained LASSO logistic regression models using US claims data and internally validated the models using eight different designs: 'no test/validation set', 'test/validation set' and cross validation with 3-fold, 5-fold or 10-fold with and without a test set. We then externally validated each model in two new US claims databases. We estimated the internal validation bias per design by empirically comparing the differences between the estimated internal performance and external performance.</AbstractText><AbstractText Label="RESULTS">The differences between the models' internal estimated performances and external performances were largest for the 'no test/validation set' design. This indicates even with large data the 'no test/validation set' design causes models to overfit. The seven alternative designs included some validation process to select the hyperparameters and a fair testing process to estimate internal performance. These designs had similar internal performance estimates and performed similarly when externally validated in the two external databases.</AbstractText><AbstractText Label="CONCLUSIONS">Even with big data, it is important to use some validation process to select the optimal hyperparameters and fairly assess internal validation using a test set or cross-validation.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2970-0778</Identifier><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics Community, New York, New York, USA jreps@its.jnj.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology, Janssen Research and Development LLC, Raritan, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics Community, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology, Janssen Research and Development LLC, Raritan, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>P R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0003-0621-1979</Identifier><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics Community, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="Y">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">health informatics</Keyword><Keyword MajorTopicYN="N">preventive medicine</Keyword><Keyword MajorTopicYN="N">statistics &amp; research methods</Keyword></KeywordList><CoiStatement>Competing interests: JMR and PR report and are employees of Janssen Research and Development and are shareholders of Johnson &amp; Johnson. PRR reports grants from Innovative Medicines Initiative, grants from Janssen Research and development, during the conduct of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34952871</ArticleId><ArticleId IdType="pmc">PMC8710861</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2021-050146</ArticleId><ArticleId IdType="pii">bmjopen-2021-050146</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Steyerberg EW, Moons KGM, van der Windt DA, et al. . Prognosis research strategy (progress) 3: prognostic model research. PLoS Med 2013;10:e1001381. 10.1371/journal.pmed.1001381</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001381</ArticleId><ArticleId IdType="pmc">PMC3564751</ArticleId><ArticleId IdType="pubmed">23393430</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein BA, Navar AM, Pencina MJ, et al. . Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. J Am Med Inform Assoc 2017;24:198&#x2013;208. 10.1093/jamia/ocw042</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocw042</ArticleId><ArticleId IdType="pmc">PMC5201180</ArticleId><ArticleId IdType="pubmed">27189013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying X. An overview of overfitting and its solutions. Journal of Physics: Conference Series 2019;1168:022022. 10.1088/1742-6596/1168/2/022022</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1742-6596/1168/2/022022</ArticleId></ArticleIdList></Reference><Reference><Citation>Efron B, Tibshirani RJ. An introduction to the bootstrap. CRC Press, 1994.</Citation></Reference><Reference><Citation>Steyerberg EW, Harrell FE, Borsboom GJ, et al. . Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001;54:774&#x2013;81. 10.1016/s0895-4356(01)00341-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0895-4356(01)00341-9</ArticleId><ArticleId IdType="pubmed">11470385</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Harrell FE. Prediction models need appropriate internal, internal-external, and external validation. J Clin Epidemiol 2016;69:245&#x2013;7. 10.1016/j.jclinepi.2015.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.04.005</ArticleId><ArticleId IdType="pmc">PMC5578404</ArticleId><ArticleId IdType="pubmed">25981519</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, et al. . Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc 2018;25:969&#x2013;75. 10.1093/jamia/ocy032</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, et al. . Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul 2013;23:1&#x2013;17. 10.1145/2414416.2414791</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York, NY: Springer-Verlag, 2001.</Citation></Reference><Reference><Citation>John LH, Kors JA, Reps JM. How little data do we need for patient-level prediction? arXiv preprint 2020:2008.07361.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34970858</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2045-7634</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Cancer medicine</Title><ISOAbbreviation>Cancer Med</ISOAbbreviation></Journal><ArticleTitle>Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1217</StartPage><EndPage>1231</EndPage><MedlinePgn>1217-1231</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.4514</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIMS">Although several chemopreventive drugs against gastric cancer have been proposed, their effects have not been fully evaluated. We examined the impacts of aspirin, metformin, and statin use on gastric cancer development in a population-based cohort in Korea.</AbstractText><AbstractText Label="METHODS">We analyzed the association between potential chemopreventive drugs-aspirin, metformin, and statin-and gastric cancer through the Observational Medical Outcomes Partnership Common Data Model-based Korean nationwide cohort. Use of aspirin, metformin, and statin was defined by &#x2265;365&#xa0;days of prescriptions for each drug in the general population. To summarize the current evidence, we further performed a systematic review and meta-analysis of the impact of aspirin, metformin, and statin on gastric cancer development.</AbstractText><AbstractText Label="RESULTS">After propensity score matching, 31,839, 6764, and 10,251&#xa0;subjects were observed for medians of 4.7, 4.2, and 4.2&#xa0;years for aspirin, metformin, and statin analysis, respectively. Use of aspirin or statin was associated with lower risks of gastric cancer compared to their non-use, respectively (hazard ratio [HR] [95% confidence interval [CI]]: aspirin, 0.72 [0.60-0.85], p&#xa0;&lt;&#xa0;0.01; statin, 0.67 [0.49-0.92], p&#xa0;=&#xa0;0.01). However, no association was observed between metformin use and gastric cancer development (HR [95% CI]: 0.85 [0.59-1.23], p&#xa0;=&#xa0;0.40). A subgroup of subjects with diabetes mellitus showed a lower risk of gastric cancer development with statin use. The meta-analysis showed the highest effect size of gastric cancer development for statin, followed by aspirin and metformin.</AbstractText><AbstractText Label="CONCLUSIONS">Statin and aspirin use were associated with significantly reduced risks of gastric cancer development, while the use of metformin was not associated with the gastric cancer risk. The protective effect of statin against gastric cancer was also significant in patients with diabetes mellitus.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Seung In</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Chan Hyuk</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae Jun</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bang</LastName><ForeName>Chang Seok</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>University Industry Foundation, Hallym University, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyung Joo</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>University Industry Foundation, Hallym University, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinseob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Seoul National University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyon Hee</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Statistics and Information Science, Dongduk Women's University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Woon Geon</ForeName><Initials>WG</Initials><Identifier Source="ORCID">0000-0002-9851-5576</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Med</MedlineTA><NlmUniqueID>101595310</NlmUniqueID><ISSNLinking>2045-7634</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013274" MajorTopicYN="Y">Stomach Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aspirin</Keyword><Keyword MajorTopicYN="N">chemoprevention</Keyword><Keyword MajorTopicYN="N">gastric cancer</Keyword><Keyword MajorTopicYN="N">metformin</Keyword><Keyword MajorTopicYN="N">statin</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34970858</ArticleId><ArticleId IdType="pmc">PMC8855895</ArticleId><ArticleId IdType="doi">10.1002/cam4.4514</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability&#x2010;adjusted life&#x2010;years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553&#x2010;1568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6248091</ArticleId><ArticleId IdType="pubmed">29860482</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet&#x2010;Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87&#x2010;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YC, Chiang TH, Chou CK, et al. Association between helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta&#x2010;analysis. Gastroenterology. 2016;150(5):1113&#x2010;1124.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">26836587</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KS, Chan EW, Wong AYS, et al. Aspirin and risk of gastric cancer after helicobacter pylori eradication: a territory&#x2010;wide study. J Natl Cancer Inst. 2018;110(7):743&#x2010;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">29361002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MH, Chang J, Kim WJ, Banerjee S, Park SM. Cumulative dose threshold for the chemopreventive effect of aspirin against gastric cancer. Am J Gastroenterol. 2018;113(6):845&#x2010;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">29855546</ArticleId></ArticleIdList></Reference><Reference><Citation>Murff HJ, Roumie CL, Greevy RA, et al. Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer. Cancer Causes Control. 2018;29(9):823&#x2010;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6108939</ArticleId><ArticleId IdType="pubmed">30022336</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Xie SH, Santoni G, Lagergren J. Metformin use and risk of gastric adenocarcinoma in a Swedish population&#x2010;based cohort study. Br J Cancer. 2019;121(10):877&#x2010;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6889304</ArticleId><ArticleId IdType="pubmed">31591459</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CJ, Liao WC, Lin HJ, et al. Statins attenuate Helicobacter pylori CagA translocation and reduce incidence of gastric cancer. In vitro and population&#x2010;based case&#x2010;control studies. PLoS One. 2016;11(1):e0146432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4701455</ArticleId><ArticleId IdType="pubmed">26730715</ArticleId></ArticleIdList></Reference><Reference><Citation>You HS, You N, Lee JW, Lim HJ, Kim J, Kang HT. Inverse association between statin use and stomach cancer incidence in individuals with hypercholesterolemia, from the 2002&#x2013;2015 NHIS&#x2010;HEALS Data. Int J Environ Res Public Health. 2020;17(3):1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7037780</ArticleId><ArticleId IdType="pubmed">32046107</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KS, Chan EW, Wong AYS, et al. Statins were associated with a reduced gastric cancer risk in patients with eradicated Helicobacter Pylori infection: a territory&#x2010;wide propensity score matched study. Cancer Epidemiol Biomarkers Prev. 2020;29(2):493&#x2010;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">31792089</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2010;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National Health Insurance Service&#x2010;National Sample Cohort (NHIS&#x2010;NSC), South Korea. Int J Epidemiol. 2017;46(2):e15.</Citation><ArticleIdList><ArticleId IdType="pubmed">26822938</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, Lee S, Cho SY, et al. Conversion of National Health Insurance Service&#x2010;National Sample Cohort (NHIS&#x2010;NSC) Database into Observational Medical Outcomes Partnership&#x2010;Common Data Model (OMOP&#x2010;CDM). Stud Health Technol Inform. 2017;245:467&#x2010;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, et al. Association of Hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the observational health data sciences and informatics initiative. JAMA Netw Open. 2018;1(4):e181755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first&#x2010;line antihypertensive drug classes: a systematic, multinational, large&#x2010;scale analysis. The Lancet. 2019;394(10211):1816&#x2010;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, Jung S, Swerdel JN, et al. Comparison of first&#x2010;line dual combination treatments in hypertension: real&#x2010;world evidence from multinational heterogeneous cohorts. Korean Circ J. 2020;50(1):52&#x2010;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6923236</ArticleId><ArticleId IdType="pubmed">31642211</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo SI, Park CH, You SC, et al. Association between proton pump inhibitor use and gastric cancer: a population&#x2010;based cohort study using two different types of nationwide databases in Korea. Gut. 2021;70(11):2066&#x2010;2075.</Citation><ArticleIdList><ArticleId IdType="pubmed">33975868</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large&#x2010;scale propensity score performance through real&#x2010;world and synthetic data experiments. Int J Epidemiol. 2018;47(6):2005&#x2010;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383&#x2010;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta&#x2010;analyses. BMJ. 2003;327(7414):557&#x2010;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta&#x2010;analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19631507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Aspirin protects against gastric cancer: results of a case&#x2010;control study from Moscow, Russia. Int J Cancer. 1999;82(4):473&#x2010;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">10404057</ArticleId></ArticleIdList></Reference><Reference><Citation>Coogan PF, Rosenberg L, Palmer JR, et al. Nonsteroidal anti&#x2010;inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev. 2000;9(1):119&#x2010;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">10667472</ArticleId></ArticleIdList></Reference><Reference><Citation>Akre K, Ekstr&#xf6;m AM, Signorello LB, Hansson LE, Nyr&#xe9;n O. Aspirin and risk for gastric cancer: a population&#x2010;based case&#x2010;control study in Sweden. Br J Cancer. 2001;84(7):965&#x2010;968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2363844</ArticleId><ArticleId IdType="pubmed">11286478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindblad M, Lagergren J, Garc&#xed;a Rodr&#xed;guez LA. Nonsteroidal anti&#x2010;inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(2):444&#x2010;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734971</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortuny J, Johnson CC, Bohlke K, et al. Use of anti&#x2010;inflammatory drugs and lower esophageal sphincter&#x2010;relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol. 2007;5(10):1154&#x2010;1159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2140196</ArticleId><ArticleId IdType="pubmed">17644046</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan L, Wu AH, Sullivan&#x2010;Halley J, Bernstein L. Nonsteroidal anti&#x2010;inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev. 2008;17(1):126&#x2010;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">18187391</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa JD, Terry MB, Gammon MD, et al. Cigarette smoking, body mass index, gastro&#x2010;esophageal reflux disease, and non&#x2010;steroidal anti&#x2010;inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control. 2009;20(3):361&#x2010;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726999</ArticleId><ArticleId IdType="pubmed">18989634</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertuccio P, Bravi F, Bosetti C, Negri E, La Vecchia C. Aspirin and gastric cancer risk. Eur J Cancer Prev. 2010;19(6):426&#x2010;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">20881520</ArticleId></ArticleIdList></Reference><Reference><Citation>Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non&#x2010;steroidal anti&#x2010;inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta&#x2010;analysis. Br J Cancer. 2009;100(3):551&#x2010;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2658549</ArticleId><ArticleId IdType="pubmed">19156150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Lee SH, Hur KY, Woo SY, Kim SW, Kang WK. Statins and the risk of gastric cancer in diabetes patients. BMC Cancer. 2012;12:596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541242</ArticleId><ArticleId IdType="pubmed">23234464</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong EJ, Ahn JY, Jung HY, et al. Risk factors and clinical outcomes of gastric cancer identified by screening endoscopy: a case&#x2010;control study. J Gastroenterol Hepatol. 2014;29(2):301&#x2010;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">24117845</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Shen C, Ge J, Duan H. Regular aspirin use and stomach cancer risk in China. Eur J Surg Oncol. 2015;41(6):801&#x2010;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">25796983</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal U, Yang HC, Jian WS, Yen Y, Li YJ. Does aspirin use reduce the risk for cancer? J Investig Med. 2017;65(2):391&#x2010;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">27789660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh YH, Chan HL, Lin CF, et al. Antipsychotic use is inversely associated with gastric cancer risk: a nationwide population&#x2010;based nested case&#x2010;control study. Cancer Med. 2019;8(9):4484&#x2010;4496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675741</ArticleId><ArticleId IdType="pubmed">31183993</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate&#x2010;day, low&#x2010;dose aspirin and cancer risk: long&#x2010;term observational follow&#x2010;up of a randomized trial. Ann Intern Med. 2013;159(2):77&#x2010;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3713531</ArticleId><ArticleId IdType="pubmed">23856681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiter R, Visser LE, van Herk&#x2010;Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population&#x2010;based follow&#x2010;up study. Diabetes Care. 2012;35(1):119&#x2010;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241334</ArticleId><ArticleId IdType="pubmed">22100960</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YI, Kim SY, Cho SJ, et al. Long&#x2010;term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Ther. 2014;39(8):854&#x2010;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">24612291</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention&#x2010;to&#x2010;treat trial. Diabetes Care. 2014;37(9):2522&#x2010;2532.</Citation><ArticleIdList><ArticleId IdType="pubmed">24898303</ArticleId></ArticleIdList></Reference><Reference><Citation>Valent F. Diabetes mellitus and cancer of the digestive organs: an Italian population&#x2010;based cohort study. J Diabetes Complications. 2015;29(8):1056&#x2010;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">26275864</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng CH. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging. 2016;8(8):1636&#x2010;1649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5032687</ArticleId><ArticleId IdType="pubmed">27587088</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong RG, Burden AM, de Kort S, et al. No decreased risk of gastrointestinal cancers in users of metformin in The Netherlands; A time&#x2010;varying analysis of metformin exposure. Cancer Prev Res (Phila). 2017;10(5):290&#x2010;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">28274936</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KS, Chan EW, Wong AYS, et al. Metformin use and gastric cancer risk in diabetic patients after helicobacter pylori eradication. J Natl Cancer Inst. 2019;111(5):484&#x2010;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">30329127</ArticleId></ArticleIdList></Reference><Reference><Citation>Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar H&#x2010;J. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388&#x2010;2394.</Citation><ArticleIdList><ArticleId IdType="pubmed">15197200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004;90(3):635&#x2010;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409598</ArticleId><ArticleId IdType="pubmed">14760377</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow&#x2010;up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008;17(1):27&#x2010;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">17944002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley&#x2010;Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874131</ArticleId><ArticleId IdType="pubmed">20488911</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita Y, Sugihara M, Kaburagi J, et al. Pravastatin use and cancer risk: a meta&#x2010;analysis of individual patient data from long&#x2010;term prospective controlled trials in Japan. Pharmacoepidemiol Drug Saf. 2010;19(2):196&#x2010;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">19856484</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinogradova Y, Coupland C, Hippisley&#x2010;Cox J. Exposure to statins and risk of common cancers: a series of nested case&#x2010;control studies. BMC Cancer. 2011;11:409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197575</ArticleId><ArticleId IdType="pubmed">21943022</ArticleId></ArticleIdList></Reference><Reference><Citation>Busby J, Karasneh R, Murchie P, et al. The role of 5alpha&#x2010;reductase inhibitors in gastro&#x2010;oesophageal cancer risk: a nested case&#x2010;control study. Pharmacoepidemiol Drug Saf. 2020;29(1):48&#x2010;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8520491</ArticleId><ArticleId IdType="pubmed">31713940</ArticleId></ArticleIdList></Reference><Reference><Citation>Suissa S. Immortal time bias in pharmaco&#x2010;epidemiology. Am J Epidemiol. 2008;167(4):492&#x2010;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056625</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida K, Solomon DH, Kim SC. Active&#x2010;comparator design and new&#x2010;user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437&#x2010;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486631</ArticleId><ArticleId IdType="pubmed">25800216</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim ME, Gustafson P, Petkau J, Tremlett H. Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies. Am J Epidemiol. 2016;184(4):325&#x2010;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4983651</ArticleId><ArticleId IdType="pubmed">27455963</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xfc;rmer T, Wang T, Golightly YM, Keil A, Lund JL, Jonsson FM. Methodological considerations when analysing and interpreting real&#x2010;world data. Rheumatology. 2020;59(1):14&#x2010;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909905</ArticleId><ArticleId IdType="pubmed">31834408</ArticleId></ArticleIdList></Reference><Reference><Citation>Niikura R, Hayakawa Y, Hirata Y, et al. Distinct chemopreventive effects of aspirin in diffuse and intestinal&#x2010;type gastric cancer. Cancer Prev Res (Phila). 2018;11(5):279&#x2010;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">29453233</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35012410</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-4303</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of asthma : official journal of the Association for the Care of Asthma</Title><ISOAbbreviation>J Asthma</ISOAbbreviation></Journal><ArticleTitle>Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe.</ArticleTitle><Pagination><StartPage>76</StartPage><EndPage>86</EndPage><MedlinePgn>76-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/02770903.2021.2025392</ELocationID><Abstract><AbstractText><b>Objective:</b> Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma.<b>Methods:</b> We included nine databases contributing data from January to June 2020 from the US, South Korea (KR), Spain, UK and the Netherlands. We defined two cohorts of COVID-19 patients ('diagnosed' and 'hospitalized') based on COVID-19 disease codes. We followed patients from COVID-19 index date to 30&#x2009;days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes in people with asthma defined by codes and prescriptions.<b>Results:</b> The diagnosed and hospitalized cohorts contained 666,933 and 159,552 COVID-19 patients respectively. Exacerbation in people with asthma was recorded in 1.6-8.6% of patients at presentation. Asthma prevalence ranged from 6.2% (95% CI 5.7-6.8) to 18.5% (95% CI 18.2-18.8) in the diagnosed cohort and 5.2% (95% CI 4.0-6.8) to 20.5% (95% CI 18.6-22.6) in the hospitalized cohort. Asthma patients with COVID-19 had high prevalence of comorbidity including hypertension, heart disease, diabetes and obesity. Mortality ranged from 2.1% (95% CI 1.8-2.4) to 16.9% (95% CI 13.8-20.5) and similar or lower compared to COVID-19 patients without asthma. Acute respiratory distress syndrome occurred in 15-30% of hospitalized COVID-19 asthma patients.<b>Conclusion:</b> The prevalence of asthma among COVID-19 patients varies internationally. Asthma patients with COVID-19 have high comorbidity. The prevalence of asthma exacerbation at presentation was low. Whilst mortality was similar among COVID-19 patients with and without asthma, this could be confounded by differences in clinical characteristics. Further research could help identify high-risk asthma patients.[Box: see text]Supplemental data for this article is available online at https://doi.org/10.1080/02770903.2021.2025392 .</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-0063-8069</Identifier><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The University of Manchester, University of Manchester, Manchester, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duvall</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Utah Health, Epidemiology, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9818-479X</Identifier><AffiliationInfo><Affiliation>UCLA, Biomathematics, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhamme</LastName><ForeName>Katia</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8162-4904</Identifier><AffiliationInfo><Affiliation>Erasmus MC, Medical Informatics, Erasmus MC, Dr Molewaterplein, Rotterdam, CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rjinbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Erasmus MC, Medical Informatics, Erasmus MC, Dr Molewaterplein, Rotterdam, CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Stanford University, Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Waheed</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammary</LastName><ForeName>Thamer</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5630-2468</Identifier><AffiliationInfo><Affiliation>King Saud University, Medicine, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Heba</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Islamic University of Gaza, Medicine, Gaza, State of Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Erasmus MC, Medical Informatics, Erasmus MC, Dr Molewaterplein, Rotterdam, CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casajust</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Trial Form Support, Real World Evidence, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Ajou University, Medicine, Suwon, The Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawoud</LastName><ForeName>Dalia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Stanford University, Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Johns Hopkins University, Epidemiology, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Menchung</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>DC Technologies, DC Technologies, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonnagaddala</LastName><ForeName>Jitendra</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UNSW, Public Health, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Utah Health, Epidemiology, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Utah Health, Epidemiology, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Calgary, Public Health, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Gothenburg, Public health, Goteborg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recalde</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IDIAP Jordi Gol, IDIAP, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IQVIA, Real World Solutions, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheumie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Karishma</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Stanford University, Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Colorado, School of Medicine, Denver, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizcaya</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bayer Pharmaceuticals, Bayer, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Chinese Academy of Medical Sciences and Peking Union Medical College, Public health, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durate-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>IDIAP Jordi Gol, IDIAP, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>IDIAP Jordi Gol, IDIAP, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>214588/Z/18/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Asthma</MedlineTA><NlmUniqueID>8106454</NlmUniqueID><ISSNLinking>0277-0903</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asthma</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">comorbidity</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35012410</ArticleId><ArticleId IdType="doi">10.1080/02770903.2021.2025392</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35040608</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1976-2437</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>Suppl</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Yonsei medical journal</Title><ISOAbbreviation>Yonsei Med J</ISOAbbreviation></Journal><ArticleTitle>Development and Validation of the Radiology Common Data Model (R-CDM) for the International Standardization of Medical Imaging Data.</ArticleTitle><Pagination><StartPage>S74</StartPage><EndPage>S83</EndPage><MedlinePgn>S74-S83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3349/ymj.2022.63.S74</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Digital Imaging and Communications in Medicine (DICOM), a standard file format for medical imaging data, contains metadata describing each file. However, metadata are often incomplete, and there is no standardized format for recording metadata, leading to inefficiency during the metadata-based data retrieval process. Here, we propose a novel standardization method for DICOM metadata termed the Radiology Common Data Model (R-CDM).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">R-CDM was designed to be compatible with Health Level Seven International (HL7)/Fast Healthcare Interoperability Resources (FHIR) and linked with the Observational Medical Outcomes Partnership (OMOP)-CDM to achieve a seamless link between clinical data and medical imaging data. The terminology system was standardized using the RadLex playbook, a comprehensive lexicon of radiology. As a proof of concept, the R-CDM conversion process was conducted with 41.7 TB of data from the Ajou University Hospital. The R-CDM database visualizer was developed to visualize the main characteristics of the R-CDM database.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Information from 2801360 cases and 87203226 DICOM files was organized into two tables constituting the R-CDM. Information on imaging device and image resolution was recorded with more than 99.9% accuracy. Furthermore, OMOP-CDM and R-CDM were linked to efficiently extract specific types of images from specific patient cohorts.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">R-CDM standardizes the structure and terminology for recording medical imaging data to eliminate incomplete and unstandardized information. Successful standardization was achieved by the extract, transform, and load process and image classifier. We hope that the R-CDM will contribute to deep learning research in the medical imaging field by enabling the securement of large-scale medical imaging data from multinational institutions.</AbstractText><CopyrightInformation>&#xa9; Copyright: Yonsei University College of Medicine 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Park</LastName><ForeName>ChulHyoung</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0531-9144</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5052-6399</Identifier><AffiliationInfo><Affiliation>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Hokyun</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-6220-4207</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Chang Won</ForeName><Initials>CW</Initials><Identifier Source="ORCID">0000-0002-9305-4686</Identifier><AffiliationInfo><Affiliation>Medical Convergence Research Center, Wonkwang University, Iksan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jin Wook</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0002-2396-4705</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Ajou University Medical Center, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea. veritas@ajou.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20003883</GrantID><Agency>Ministry of Trade, Industry &amp; Energy</Agency><Country>Korea</Country></Grant><Grant><GrantID>20005021</GrantID><Agency>Ministry of Trade, Industry &amp; Energy</Agency><Country>Korea</Country></Grant><Grant><GrantID>20001234</GrantID><Agency>Ministry of Trade, Industry &amp; Energy</Agency><Country>Korea</Country></Grant><Grant><GrantID>HR16C0001</GrantID><Agency>Korea Health Industry Development Institute</Agency><Country>Republic of Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Yonsei Med J</MedlineTA><NlmUniqueID>0414003</NlmUniqueID><ISSNLinking>0513-5796</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="Y">Diagnostic Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011871" MajorTopicYN="Y">Radiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012015" MajorTopicYN="N">Reference Standards</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Metadata</Keyword><Keyword MajorTopicYN="N">radiology information system</Keyword><Keyword MajorTopicYN="N">standardization</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>8</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35040608</ArticleId><ArticleId IdType="pmc">PMC8790584</ArticleId><ArticleId IdType="doi">10.3349/ymj.2022.63.S74</ArticleId><ArticleId IdType="pii">63.S74</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soffer S, Ben-Cohen A, Shimon O, Amitai MM, Greenspan H, Klang E. Convolutional neural networks for radiologic images: a radiologist&#x2019;s guide. Radiology. 2019;290:590&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">30694159</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildenberger P, Eichelberg M, Martin E. Introduction to the DICOM standard. Eur Radiol. 2002;12:920&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">11960249</ArticleId></ArticleIdList></Reference><Reference><Citation>Willemink MJ, Koszek WA, Hardell C, Wu J, Fleischmann D, Harvey H, et al. Preparing medical imaging data for machine learning. Radiology. 2020;295:4&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7104701</ArticleId><ArticleId IdType="pubmed">32068507</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu A, Warzel D, Eftekhari A, Kirby JS, Freymann J, Knable J, et al. Call for data standardization: lessons learned and recommendations in an imaging study. JCO Clin Cancer Inform. 2019;3:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939740</ArticleId><ArticleId IdType="pubmed">31834820</ArticleId></ArticleIdList></Reference><Reference><Citation>Gueld MO, Kohnen M, Keysers D, Schubert H, Wein BB, Bredno J, et al. Quality of DICOM header information for image categorization. Medical Imaging. 2002;4685:280&#x2013;287.</Citation></Reference><Reference><Citation>Gauriau R, Bridge C, Chen L, Kitamura F, Tenenholtz NA, Kirsch JE, et al. Using DICOM metadata for radiological image series categorization: a feasibility study on large clinical brain MRI datasets. J Digit Imaging. 2020;33:747&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256138</ArticleId><ArticleId IdType="pubmed">31950302</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackledge J, Al-Rawi A, Tobin P. Stegacryption of DICOM metadata; Proceedings of the 25th IET Irish Signals &amp; Systems Conference 2014 and 2014 China-Ireland International Conference on Information and Communications Technologies (ISSC 2014/CIICT 2014); 2014 Jun 26-27; Limerick, Ireland. ISSC; 2014. pp. 304&#x2013;309.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Vreeman DJ, Abhyankar S, Wang KC, Carr C, Collins B, Rubin DL, et al. The LOINC RSNA radiology playbook-a unified terminology for radiology procedures. J Am Med Inform Assoc. 2018;25:885&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6016707</ArticleId><ArticleId IdType="pubmed">29850823</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Shang N, Peissig PL, Rasmussen LV, Liu C, Benoit B, et al. Facilitating phenotype transfer using a common data model. J Biomed Inform. 2019;96:103253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Y, Zhang J, Heilbrun ME, Kahn CE., Jr Analysis of RadLex coverage and term co-occurrence in radiology reporting templates. J Digit Imaging. 2012;25:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264705</ArticleId><ArticleId IdType="pubmed">22011936</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng P, Beitia AO, Vreeman DJ, Loo GT, Delman BN, Thum F, et al. Mapping of HIE CT terms to LOINC&#xae;: analysis of content-dependent coverage and coverage improvement through new term creation. J Am Med Inform Assoc. 2019;26:19&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7587153</ArticleId><ArticleId IdType="pubmed">30445562</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf. 2014;37:945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012;45:689&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima DM, Rodrigues-Jr JF, Traina AJM, Pires FA, Gutierrez MA. Transforming two decades of ePR data to OMOP CDM for clinical research. Stud Health Technol Inform. 2019;264:233&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437920</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller H, Michoux N, Bandon D, Geissbuhler A. A review of content-based image retrieval systems in medical applications-clinical benefits and future directions. Int J Med Inform. 2004;73:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15036075</ArticleId></ArticleIdList></Reference><Reference><Citation>Akg&#xfc;l CB, Rubin DL, Napel S, Beaulieu CF, Greenspan H, Acar B. Content-based image retrieval in radiology: current status and future directions. J Digit Imaging. 2011;24:208&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056970</ArticleId><ArticleId IdType="pubmed">20376525</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Zhang X, M&#xfc;ller H, Zhang S. Large-scale retrieval for medical image analytics: a comprehensive review. Med Image Anal. 2018;43:66&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">29031831</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizarro R, Assemlal HE, De Nigris D, Elliott C, Antel S, Arnold D, et al. Using deep learning algorithms to automatically identify the brain MRI contrast: implications for managing large databases. Neuroinformatics. 2019;17:115&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">29956131</ArticleId></ArticleIdList></Reference><Reference><Citation>Beam AL, Manrai AK, Ghassemi M. Challenges to the reproducibility of machine learning models in health care. JAMA. 2020;323:305&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7335677</ArticleId><ArticleId IdType="pubmed">31904799</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B, Jr, Seltzer SE, Langlotz CP, Dreyer KP, Summers RM, Petrick N, et al. A road map for translational research on artificial intelligence in medical imaging: from the 2018 National Institutes of Health/RSNA/ACR/The Academy Workshop. J Am Coll Radiol. 2019;16:1179&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pubmed">31151893</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25:969&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrah&#xe3;o MTF, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun. 2020;11:5009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J, Kim C, Williams R, Markus A, Yang C, Salles TD, et al. Can we trust the prediction model? Demonstrating the importance of external validation by investigating the COVID-19 vulnerability (C-19) index across an international network of observational healthcare datasets. [accessed on 2021 November 1];medRxiv [Preprint] 2020 doi: 10.1101/2020.06.15.20130328. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.15.20130328</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams RD, Markus AF, Yang C, Salles TD, Falconer T, Jonnagaddala J, et al. Seek COVER: development and validation of a personalized risk calculator for COVID-19 outcomes in an international network. [accessed on 2021 November 1];MedRxiv [Preprint] 2020 doi: 10.1101/2020.05.26.20112649. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.26.20112649</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer SG, Shih G, Nagy P, Landman BA. Collaborative and reproducible research: goals, challenges, and strategies. J Digit Imaging. 2018;31:275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959829</ArticleId><ArticleId IdType="pubmed">29476392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli MD, Summers RM, Geis JR. Medical image data and datasets in the era of machine learning&#x2014;whitepaper from the 2016 C-MIMI meeting dataset session. J Digit Imaging. 2017;30:392&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5537092</ArticleId><ArticleId IdType="pubmed">28516233</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin SJ, You SC, Park YR, Roh J, Kim JH, Haam S, et al. Genomic common data model for seamless interoperation of biomedical data in clinical practice: retrospective study. J Med Internet Res. 2019;21:e13249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454347</ArticleId><ArticleId IdType="pubmed">30912749</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenkaya R, Gurley MJ, Golozar A, Dymshyts D, Miller RT, Williams AE, et al. Extending the OMOP common data model and standardized vocabularies to support observational cancer research. JCO Clin Cancer Inform. 2021;5:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8140810</ArticleId><ArticleId IdType="pubmed">33411620</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DL, Kahn CE., Jr Common data elements in radiology. Radiology. 2017;283:837&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">27831831</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma H, Mao C, Zhang Y, Vatani H, Yao L, Zhong Y, et al. Developing a portable natural language processing based phenotyping system. BMC Med Inform Decis Mak. 2019;19:78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448187</ArticleId><ArticleId IdType="pubmed">30943974</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, You SC, Jeong E, Weng C, Park D, Roh J, et al. A framework (SOCRATex) for hierarchical annotation of unstructured electronic health records and integration into a standardized medical database: development and usability study. JMIR Med Inform. 2021;9:e23983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8044740</ArticleId><ArticleId IdType="pubmed">33783361</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongkolwat P, Kleper V, Talbot S, Rubin D. The national cancer informatics program (NCIP) annotation and image markup (AIM) foundation model. J Digit Imaging. 2014;27:692&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4391072</ArticleId><ArticleId IdType="pubmed">24934452</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35046809</PMID><DateRevised><Year>2022</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Combining a Pharmacological Network Model with a Bayesian Signal Detection Algorithm to Improve the Detection of Adverse Drug Events.</ArticleTitle><Pagination><StartPage>773135</StartPage><MedlinePgn>773135</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">773135</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2021.773135</ELocationID><Abstract><AbstractText><b>Introduction:</b> Improving adverse drug event (ADE) detection is important for post-marketing drug safety surveillance. Existing statistical approaches can be further optimized owing to their high efficiency and low cost. <b>Objective:</b> The objective of this study was to evaluate the proposed approach for use in pharmacovigilance, the early detection of potential ADEs, and the improvement of drug safety. <b>Methods:</b> We developed a novel integrated approach, the Bayesian signal detection algorithm, based on the pharmacological network model (IC<sub>PNM</sub>) using the FDA Adverse Event Reporting System (FAERS) data published from 2004 to 2009 and from 2014 to 2019Q2, PubChem, and DrugBank database. First, we used a pharmacological network model to generate the probabilities for drug-ADE associations, which comprised the proper prior information component (IC). We then defined the probability of the propensity score adjustment based on a logistic regression model to control for the confounding bias. Finally, we chose the Side Effect Resource (SIDER) and the Observational Medical Outcomes Partnership (OMOP) data to evaluate the detection performance and robustness of the IC<sub>PNM</sub> compared with the statistical approaches [disproportionality analysis (DPA)] by using the area under the receiver operator characteristics curve (AUC) and Youden's index. <b>Results:</b> Of the statistical approaches implemented, the IC<sub>PNM</sub> showed the best performance (AUC, 0.8291; Youden's index, 0.5836). Meanwhile, the AUCs of the IC, EBGM, ROR, and PRR were 0.7343, 0.7231, 0.6828, and 0.6721, respectively. <b>Conclusion:</b> The proposed IC<sub>PNM</sub> combined the strengths of the pharmacological network model and the Bayesian signal detection algorithm and performed better in detecting true drug-ADE associations. It also detected newer ADE signals than a DPA and may be complementary to the existing statistical approaches.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Ji, Cui, Xu, Hou, Zhang and Ren.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Xiangmin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Information Engineering, Inner Mongolia University of Science and Technology, Baotou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Guimei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Information Engineering, Inner Mongolia University of Science and Technology, Baotou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Chengzhen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Computer Science and Technology, Huaibei Normal University, Huaibei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yunfei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Mathematics and Computer Engineering, Ordos Institute of Technology, Ordos, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Information Engineering, Inner Mongolia University of Science and Technology, Baotou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FDA adverse event reporting system</Keyword><Keyword MajorTopicYN="N">adverse drug events</Keyword><Keyword MajorTopicYN="N">pharmacological network model</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">signal detection algorithm</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35046809</ArticleId><ArticleId IdType="pmc">PMC8762263</ArticleId><ArticleId IdType="doi">10.3389/fphar.2021.773135</ArticleId><ArticleId IdType="pii">773135</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banda J. M., Evans L., Vanguri R. S., Tatonetti N. P., Ryan P. B., Shah N. H. (2016). A Curated and Standardized Adverse Drug Event Resource to Accelerate Drug Safety Research. Sci. Data 3, 160026. 10.1038/sdata.2016.26</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.26</ArticleId><ArticleId IdType="pmc">PMC4872271</ArticleId><ArticleId IdType="pubmed">27193236</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate A., Lindquist M., Edwards I. R., Olsson S., Orre R., Lansner A., et al. (1998). A Bayesian Neural Network Method for Adverse Drug Reaction Signal Generation. Eur. J. Clin. Pharmacol. 54, 315&#x2013;321. 10.1007/s002280050466</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002280050466</ArticleId><ArticleId IdType="pubmed">9696956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cami A., Arnold A., Manzi S., Reis B. (2011). Predicting Adverse Drug Events Using Pharmacological Network Models. Sci. Transl Med. 3, 114ra127&#x2013;127. 10.1126/scitranslmed.3002774</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002774</ArticleId><ArticleId IdType="pubmed">22190238</ArticleId></ArticleIdList></Reference><Reference><Citation>Candore G., Juhlin K., Manlik K., Thakrar B., Quarcoo N., Seabroke S., et al. (2015). Comparison of Statistical Signal Detection Methods within and across Spontaneous Reporting Databases. Drug Saf. 38, 577&#x2013;587. 10.1007/s40264-015-0289-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0289-5</ArticleId><ArticleId IdType="pubmed">25899605</ArticleId></ArticleIdList></Reference><Reference><Citation>Caster O., Nor&#xe9;n G. N., Madigan D., Bate A. (2010). Large-scale Regression-Based Pattern Discovery: The Example of Screening the WHO Global Drug Safety Database. Stat. Analy Data Mining 3, 197&#x2013;208. 10.1002/sam.10078</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sam.10078</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F., Li W., Wang X., Zhou Y., Wu Z., Shen J., et al. (2013). Adverse Drug Events: Database Construction and In Silico Prediction. J. Chem. Inf. Model. 53, 744&#x2013;752. 10.1021/ci4000079</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci4000079</ArticleId><ArticleId IdType="pubmed">23521697</ArticleId></ArticleIdList></Reference><Reference><Citation>Davazdahemami B., Delen D. (2018). A Chronological Pharmacovigilance Network Analytics Approach for Predicting Adverse Drug Events. J. Am. Med. Inform. Assoc. 25, 1311&#x2013;1321. 10.1093/jamia/ocy097</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy097</ArticleId><ArticleId IdType="pmc">PMC7646912</ArticleId><ArticleId IdType="pubmed">30085102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y., Markatou M., Ball R. (2020). An Evaluation of Statistical Approaches to Postmarketing Surveillance. Stat. Med. 39, 845&#x2013;874. 10.1002/sim.8447</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8447</ArticleId><ArticleId IdType="pubmed">31912927</ArticleId></ArticleIdList></Reference><Reference><Citation>
DrugBank (2020). Available From: https://go.drugbank.com
.</Citation></Reference><Reference><Citation>DuMouchel W., Ryan P. B., Schuemie M. J., Madigan D. (2013). Evaluation of Disproportionality Safety Signaling Applied to Healthcare Databases. Drug Saf. 36, S123&#x2013;S132. 10.1007/s40264-013-0106-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0106-y</ArticleId><ArticleId IdType="pubmed">24166229</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMouchel W. (1999). Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System. The Am. Statistician 53, 177&#x2013;190. 10.1080/00031305.1999.10474456</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00031305.1999.10474456</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans S. J., Waller P. C., Davis S. (2001). Use of Proportional Reporting Ratios (PRRs) for Signal Generation from Spontaneous Adverse Drug Reaction Reports. Pharmacoepidemiol. Drug Saf. 10, 483&#x2013;486. 10.1002/pds.677</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.677</ArticleId><ArticleId IdType="pubmed">11828828</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomini K. M., Krauss R. M., Roden D. M., Eichelbaum M., Hayden M. R., Nakamura Y. (2007). When Good Drugs Go Bad. Nature 446, 975&#x2013;977. 10.1038/446975a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/446975a</ArticleId><ArticleId IdType="pubmed">17460642</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B. A., Navar A. M., Pencina M. J., Ioannidis J. P. (2017). Opportunities and Challenges in Developing Risk Prediction Models with Electronic Health Records Data: a Systematic Review. J. Am. Med. Inform. Assoc. 24, 198&#x2013;208. 10.1093/jamia/ocw042</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocw042</ArticleId><ArticleId IdType="pmc">PMC5201180</ArticleId><ArticleId IdType="pubmed">27189013</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., Dumouchel W., Lependu P., Bauer-Mehren A., Ryan P., Shah N. H. (2013a). Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System. Clin. Pharmacol. Ther. 93, 539&#x2013;546. 10.1038/clpt.2013.24</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2013.24</ArticleId><ArticleId IdType="pmc">PMC3857139</ArticleId><ArticleId IdType="pubmed">23571771</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., Dumouchel W., Schuemie M., Bodenreider O., Friedman C., Horvitz E., et al. (2017). Toward Multimodal Signal Detection of Adverse Drug Reactions. J. Biomed. Inform. 76, 41&#x2013;49. 10.1016/j.jbi.2017.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2017.10.013</ArticleId><ArticleId IdType="pmc">PMC8502488</ArticleId><ArticleId IdType="pubmed">29081385</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., Dumouchel W., Shah N. H., Madigan D., Ryan P., Friedman C. (2012). Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis. Clin. Pharmacol. Ther. 91, 1010&#x2013;1021. 10.1038/clpt.2012.50</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.50</ArticleId><ArticleId IdType="pmc">PMC3675775</ArticleId><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., Vilar S., DuMouchel W., Salmasian H., Haerian K., Shah N. H., et al. (2013b). Combing Signals from Spontaneous Reports and Electronic Health Records for Detection of Adverse Drug Reactions. J. Am. Med. Inform. Assoc. 20, 413&#x2013;419. 10.1136/amiajnl-2012-000930</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000930</ArticleId><ArticleId IdType="pmc">PMC3628045</ArticleId><ArticleId IdType="pubmed">23118093</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Zalkikar J., Tiwari R. C. (2011). A Likelihood Ratio Test Based Method for Signal Detection with Application to FDA's Drug Safety Data. J. Am. Stat. Assoc. 106, 1230&#x2013;1241. 10.1198/jasa.2011.ap10243</Citation><ArticleIdList><ArticleId IdType="doi">10.1198/jasa.2011.ap10243</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamal S., Ali W., Nagpal P., Grover S., Grover A. (2019). Computational Models for the Prediction of Adverse Cardiovascular Drug Reactions. J. Transl Med. 17, 171. 10.1186/s12967-019-1918-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-1918-z</ArticleId><ArticleId IdType="pmc">PMC6530172</ArticleId><ArticleId IdType="pubmed">31118067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji X., Wang L., Hua L., Wang X., Zhang P., Shendre A., et al. (2021). Improved Adverse Drug Event Prediction through Information Component Guided Pharmacological Network Model (IC-PNM). Ieee/acm Trans. Comput. Biol. Bioinf. 18, 1113&#x2013;1121. 10.1109/TCBB.2019.2928305</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TCBB.2019.2928305</ArticleId><ArticleId IdType="pubmed">31443040</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarou J., Pomeranz B. H., Corey P. N. (1998). Incidence of Adverse Drug Reactions in Hospitalized Patients: a Meta-Analysis of Prospective Studies. JAMA 279, 1200&#x2013;1205. 10.1001/jama.279.15.1200</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.279.15.1200</ArticleId><ArticleId IdType="pubmed">9555760</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Jimeno Yepes A., Xiao C. (2020). Combining Social media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions. Drug Saf. 43, 893&#x2013;903. 10.1007/s40264-020-00943-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-00943-2</ArticleId><ArticleId IdType="pmc">PMC7434724</ArticleId><ArticleId IdType="pubmed">32385840</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Ryan P. B., Wei Y., Friedman C. (2015). A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions. Drug Saf. 38, 895&#x2013;908. 10.1007/s40264-015-0314-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0314-8</ArticleId><ArticleId IdType="pmc">PMC4579260</ArticleId><ArticleId IdType="pubmed">26153397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J., Kuang Q., Li Y., Zhang Y., Sun J., Ding Z., et al. (2013). Prediction of Adverse Drug Reactions by a Network Based External Link Prediction Method. Anal. Methods 5, 6120&#x2013;6127. 10.1039/c3ay41290c</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c3ay41290c</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Wu Y., Chen Y., Sun J., Zhao Z., Chen X. W., et al. (2012). Large-scale Prediction of Adverse Drug Reactions Using Chemical, Biological, and Phenotypic Properties of Drugs. J. Am. Med. Inform. Assoc. 19, e28&#x2013;35. 10.1136/amiajnl-2011-000699</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000699</ArticleId><ArticleId IdType="pmc">PMC3392844</ArticleId><ArticleId IdType="pubmed">22718037</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., Zhang P. (2019). Towards Early Detection of Adverse Drug Reactions: Combining Pre-clinical Drug Structures and post-market Safety Reports. BMC Med. Inform. Decis. Mak 19, 279. 10.1186/s12911-019-0999-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-019-0999-1</ArticleId><ArticleId IdType="pmc">PMC6918608</ArticleId><ArticleId IdType="pubmed">31849321</ArticleId></ArticleIdList></Reference><Reference><Citation>
MedDRA (2020). Available From: http://www.meddramsso.com/index.asp
.</Citation></Reference><Reference><Citation>Pham M., Cheng F., Ramachandran K. (2019). A Comparison Study of Algorithms to Detect Drug-Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches. Drug Saf. 42, 743&#x2013;750. 10.1007/s40264-018-00792-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-018-00792-0</ArticleId><ArticleId IdType="pubmed">30762164</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P. B., Schuemie M. J., Welebob E., Duke J., Valentine S., Hartzema A. G. (2013). Defining a Reference Set to Support Methodological Research in Drug Safety. Drug Saf. 36, S33&#x2013;S47. 10.1007/s40264-013-0097-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0097-8</ArticleId><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>
Side Effect Resource (2020). Available From: http://sideeffects.embl.de/

</Citation></Reference><Reference><Citation>Tatonetti N. P., Denny J. C., Murphy S. N., Fernald G. H., Krishnan G., Castro V., et al. (2011). Detecting Drug Interactions from Adverse-Event Reports: Interaction between Paroxetine and Pravastatin Increases Blood Glucose Levels. Clin. Pharmacol. Ther. 90, 133&#x2013;142. 10.1038/clpt.2011.83</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2011.83</ArticleId><ArticleId IdType="pmc">PMC3216673</ArticleId><ArticleId IdType="pubmed">21613990</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti N. P., Ye P. P., Daneshjou R., Altman R. B. (2012). Data-driven Prediction of Drug Effects and Interactions. Sci. Transl. Med. 4, 125ra31&#x2013;131. 10.1126/scitranslmed.3003377</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003377</ArticleId><ArticleId IdType="pmc">PMC3382018</ArticleId><ArticleId IdType="pubmed">22422992</ArticleId></ArticleIdList></Reference><Reference><Citation>
Us Food and Drug Administration (2020). Adverse Event Reporting System (FAERS). Available From: https://www.fda.gov/Drugs/InformationOnDrugs/ucm135151.htm
. </Citation></Reference><Reference><Citation>Van Puijenbroek E. P., Bate A., Leufkens H. G., Lindquist M., Orre R., Egberts A. C. (2002). A Comparison of Measures of Disproportionality for Signal Detection in Spontaneous Reporting Systems for Adverse Drug Reactions. Pharmacoepidemiol. Drug Saf. 11, 3&#x2013;10. 10.1002/pds.668</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.668</ArticleId><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R., Wang Q. (2014). Large-scale Combining Signals from Both Biomedical Literature and the FDA Adverse Event Reporting System (FAERS) to Improve post-marketing Drug Safety Signal Detection. BMC Bioinformatics 15, 17. 10.1186/1471-2105-15-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-15-17</ArticleId><ArticleId IdType="pmc">PMC3906761</ArticleId><ArticleId IdType="pubmed">24428898</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Li M., Chiang C. W., Wang L., Xiang Y., Cheng L., et al. (2018). Three-Component Mixture Model-Based Adverse Drug Event Signal Detection for the Adverse Event Reporting System. CPT Pharmacometrics Syst. Pharmacol. 7, 499&#x2013;506. 10.1002/psp4.12294</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.12294</ArticleId><ArticleId IdType="pmc">PMC6118321</ArticleId><ArticleId IdType="pubmed">30091855</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35077901</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>127</Volume><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Developing an ETL tool for converting the PCORnet CDM into the OMOP CDM to facilitate the COVID-19 data integration.</ArticleTitle><Pagination><StartPage>104002</StartPage><MedlinePgn>104002</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2022.104002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(22)00018-1</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The large-scale collection of observational data and digital technologies could help curb the COVID-19 pandemic. However, the coexistence of multiple Common Data Models (CDMs) and the lack of data extract, transform, and load (ETL) tool between different CDMs causes potential interoperability issue between different data systems. The objective of this study is to design, develop, and evaluate an ETL tool that transforms the PCORnet CDM format data into the OMOP CDM.</AbstractText><AbstractText Label="METHODS">We developed an open-source ETL tool to facilitate the data conversion from the PCORnet CDM and the OMOP CDM. The ETL tool was evaluated using a dataset with 1000 patients randomly selected from the PCORnet CDM at Mayo Clinic. Information loss, data mapping accuracy, and gap analysis approaches were conducted to assess the performance of the ETL tool. We designed an experiment to conduct a real-world COVID-19 surveillance task to assess the feasibility of the ETL tool. We also assessed the capacity of the ETL tool for the COVID-19 data surveillance using data collection criteria of the MN EHR Consortium COVID-19 project.</AbstractText><AbstractText Label="RESULTS">After the ETL process, all the records of 1000 patients from 18 PCORnet CDM tables were successfully transformed into 12 OMOP CDM tables. The information loss for all the concept mapping was less than 0.61%. The string mapping process for the unit concepts lost 2.84% records. Almost all the fields in the manual mapping process achieved 0% information loss, except the specialty concept mapping. Moreover, the mapping accuracy for all the fields were 100%. The COVID-19 surveillance task collected almost the same set of cases (99.3% overlaps) from the original PCORnet CDM and target OMOP CDM separately. Finally, all the data elements for MN EHR Consortium COVID-19 project could be captured from both the PCORnet CDM and the OMOP CDM.</AbstractText><AbstractText Label="CONCLUSION">We demonstrated that our ETL tool could satisfy the data conversion requirements between the PCORnet CDM and the OMOP CDM. The outcome of the work would facilitate the data retrieval, communication, sharing, and analysis between different institutions for not only COVID-19 related project, but also other real-world evidence-based observational studies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zong</LastName><ForeName>Nansu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Sijia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knaack</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chamberlain</LastName><ForeName>Alanna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Davera</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nilay</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Guoqian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA. Electronic address: Jiang.Guoqian@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EB030529</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 EB028101</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="N">Information Storage and Retrieval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>20</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35077901</ArticleId><ArticleId IdType="pmc">PMC8791245</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2022.104002</ArticleId><ArticleId IdType="pii">S1532-0464(22)00018-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gill J., Prasad V. Improving observational studies in the era of big data. Lancet. 2018;392(10149):716&#x2013;717. doi: 10.1016/S0140-6736(18)31619-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31619-2</ArticleId><ArticleId IdType="pubmed">30191816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ienca M., Vayena E. On the responsible use of digital data to tackle the COVID-19 pandemic. Nat Med. 2020;26(4):463&#x2013;464. doi: 10.1038/s41591-020-0832-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0832-5</ArticleId><ArticleId IdType="pmc">PMC7100462</ArticleId><ArticleId IdType="pubmed">32284619</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd J., Miller B.S., Manning E.M., Lampos V., Zhuang M., Edelstein M., Rees G., Emery V.C., Stevens M.M., Keegan N., Short M.J., Pillay D., Manley E.d., Cox I.J., Heymann D., Johnson A.M., McKendry R.A. Digital technologies in the public-health response to COVID-19. Nat Med. 2020;26(8):1183&#x2013;1192. doi: 10.1038/s41591-020-1011-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1011-4</ArticleId><ArticleId IdType="pubmed">32770165</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage J.M., Ryan P.B., Reich C.G., Hartzema A.G., Stang P.E. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson K., Hartz A.J. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878&#x2013;1886. doi: 10.1056/NEJM200006223422506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200006223422506</ArticleId><ArticleId IdType="pubmed">10861324</ArticleId></ArticleIdList></Reference><Reference><Citation>Concato J., Shah N., Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887&#x2013;1892. doi: 10.1056/NEJM200006223422507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200006223422507</ArticleId><ArticleId IdType="pmc">PMC1557642</ArticleId><ArticleId IdType="pubmed">10861325</ArticleId></ArticleIdList></Reference><Reference><Citation>P. Velentgas, N.A. Dreyer, P. Nourjah, et al., editors. Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide. Rockville (MD): Agency for Healthcare Research and Quality (US); (2013) Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK126190/.</Citation><ArticleIdList><ArticleId IdType="pubmed">23469377</ArticleId></ArticleIdList></Reference><Reference><Citation>R.E. Gliklich, M.B. Leavy, N.A. Dreyer, (Eds.), Tools and Technologies for Registry Interoperability, Registries for Evaluating Patient Outcomes: A User&#x2019;s Guide, 3rd Edition, Addendum 2 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); (2019) Oct. Report No.: 19(20)-EHC017-EF. PMID: 31891455.</Citation><ArticleIdList><ArticleId IdType="pubmed">31891455</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M., Del Fiol G., Tenenbaum J., Walden A., Zozus M.N. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64:333&#x2013;341. doi: 10.1016/j.jbi.2016.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.10.016</ArticleId><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>PCORnet Common Data Model (CDM), https://pcornet.org/data/. Accessed Jan. 25, 2022.</Citation></Reference><Reference><Citation>Observational Health DataSciences and Informatics (OHDSI), https://www.ohdsi.org/. Accessed Jan. 25, 2022.</Citation></Reference><Reference><Citation>Sentinel Common Data Model, https://www.sentinelinitiative.org/methods-data-tools/sentinel-common-data-model. Accessed Jan. 25, 2022.</Citation></Reference><Reference><Citation>i2b2Research Data Warehouse, https://community.i2b2.org/wiki/display/BUN/i2b2+Common+Data+Model+Documentation. Accessed Jan. 25, 2022.</Citation></Reference><Reference><Citation>Klann J.G., Joss M.A.H., Embree K., Murphy S.N., Lovis C. Data model harmonization for the All Of Us Research Program: Transforming i2b2 data into the OMOP common data model. PLoS ONE. 2019;14(2):e0212463. doi: 10.1371/journal.pone.0212463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0212463</ArticleId><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration (FDA), National Institutes of Health's National Library of Medicine (NLM), National Cancer Institute (NCI) and National Center for Advancing Translational Sciences (NCATS), Office of the National Coordinator for Health Information Technology (ONC). Common Data Model Harmonization (CDMH) and Open Standards for Evidence Generation: Final Report. (2020). Available from: https://aspe.hhs.gov/sites/default/files/private/pdf/259016/CDMH-Final-Report-14August2020.pdf.</Citation></Reference><Reference><Citation>Klann J.G., et al. Web services for data warehouses: OMOP and PCORnet on i2b2. J Am Med Inform Assoc. 2018;25:1331&#x2013;1338. doi: 10.1093/jamia/ocy093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy093</ArticleId><ArticleId IdType="pmc">PMC6188504</ArticleId><ArticleId IdType="pubmed">30085008</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann J.G., Abend A., Raghavan V.A., Mandl K.D., Murphy S.N. Data interchange using i2b2. J Am Med Inform Assn. 2016;23:909&#x2013;915. doi: 10.1093/jamia/ocv188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv188</ArticleId><ArticleId IdType="pmc">PMC4997035</ArticleId><ArticleId IdType="pubmed">26911824</ArticleId></ArticleIdList></Reference><Reference><Citation>Common Data Models Harmonization, https://build.fhir.org/ig/HL7/cdmh/index.html. Accessed Aug. 13, 2020.</Citation></Reference><Reference><Citation>M. Choi, R. Starr, M. Braunstein, J. Duke, OHDSI on FHIR platform development with OMOP CDM mapping to FHIR Resources. In OHDSI Symposium, Observational Health Data Sciences and Informatics, Washington, DC (2016).</Citation></Reference><Reference><Citation>The OMOPonFHIR Project at Georgia Tech, http://omoponfhir.org/ . Accessed Aug. 13, 2020.</Citation></Reference><Reference><Citation>Belenkaya R., Mirhaji P., Khayter M., Torok D., Khare R., Ong T., Schilling L. In OHDSI workshop. 2015. Establishing Interoperability Standards between OMOP CDM v4, v5, and PCORnet CDM v1.</Citation></Reference><Reference><Citation>National COVID Cohort Collaborative (N3C), https://ncats.nih.gov/n3c. Accessed Aug. 13, 2020.</Citation></Reference><Reference><Citation>MN EHR Consortium, https://www.hennepinhealthcare.org/ehrconsortium/. Accessed Aug. 13, 2020.</Citation></Reference><Reference><Citation>Haendel M.A., et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. J Am Med Inform Assoc. 2021;28:427&#x2013;443. doi: 10.1093/jamia/ocaa196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa196</ArticleId><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelman T., et al. Minnesota Electronic Health Record Consortium COVID-19 Project: Informing Pandemic Response Through Statewide Collaboration Using Observational Data. Public Health Rep. 2022 doi: 10.1177/00333549211061317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00333549211061317</ArticleId><ArticleId IdType="pmc">PMC8900228</ArticleId><ArticleId IdType="pubmed">35060411</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence R.L., Curtis L.H., Califf R.M., Platt R., Selby J.V., Brown J.S. Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc. 2014;21(4):578&#x2013;582. doi: 10.1136/amiajnl-2014-002747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002747</ArticleId><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Common Data Model (CDM) Specification, Version 5.1, https://cprn.org/data-submission/PCORnet-Common-Data-Model-v51-2019_09_12.pdf. Accessed Aug. 13, 2020.</Citation></Reference><Reference><Citation>Forrest C.B., et al. PCORnet(R) 2020: current state, accomplishments, and future directions. J Clin Epidemiol. 2021;129:60&#x2013;67. doi: 10.1016/j.jclinepi.2020.09.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2020.09.036</ArticleId><ArticleId IdType="pmc">PMC7521354</ArticleId><ArticleId IdType="pubmed">33002635</ArticleId></ArticleIdList></Reference><Reference><Citation>The Book of OHDSI, https://ohdsi.github.io/TheBookOfOhdsi/CommonDataModel.html . Accessed Aug. 13, 2020.</Citation></Reference><Reference><Citation>Hripcsak G., et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>N3C Data Ingestion and Harmonization, https://github.com/National-COVID-Cohort-Collaborative/Data-Ingestion-and-Harmonization/tree/master/CDMDataMaps/PCORNet2OMOP . Accessed Aug. 13, 2020.</Citation></Reference><Reference><Citation>N3C Phenotype Data Acquisition, https://github.com/National-COVID-Cohort-Collaborative/Phenotype_Data_Acquisition/wiki/Latest-Phenotype. Accessed Aug. 13, 2020.</Citation></Reference><Reference><Citation>ATLAS, https://atlas.ohdsi.org/. Accessed Aug. 13, 2020.</Citation></Reference><Reference><Citation>W.L. Schulz, H.P. Young, K.J. Ruddy, N.D. Shah, J.S. Ross, S. Gordon, M. Rocca, G. Jiang, A Multi-Institutional Review and Validation of Federated Query Results in Multiple Common Data Models. In AMIA (2018).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">35094685</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>BMC medical research methodology</Title><ISOAbbreviation>BMC Med Res Methodol</ISOAbbreviation></Journal><ArticleTitle>Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network.</ArticleTitle><Pagination><StartPage>35</StartPage><MedlinePgn>35</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">35</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12874-022-01505-z</ELocationID><Abstract><AbstractText Label="BACKGROUND">We investigated whether we could use influenza data to develop prediction models for COVID-19 to increase the speed at which prediction models can reliably be developed and validated early in a pandemic. We developed COVID-19 Estimated Risk (COVER) scores that quantify a patient's risk of hospital admission with pneumonia (COVER-H), hospitalization with pneumonia requiring intensive services or death (COVER-I), or fatality (COVER-F) in the 30-days following COVID-19 diagnosis using historical data from patients with influenza or flu-like symptoms and tested this in COVID-19 patients.</AbstractText><AbstractText Label="METHODS">We analyzed a federated network of electronic medical records and administrative claims data from 14 data sources and 6 countries containing data collected on or before 4/27/2020. We used a 2-step process to develop 3 scores using historical data from patients with influenza or flu-like symptoms any time prior to 2020. The first step was to create a data-driven model using LASSO regularized logistic regression, the covariates of which were used to develop aggregate covariates for the second step where the COVER scores were developed using a smaller set of features. These 3 COVER scores were then externally validated on patients with 1) influenza or flu-like symptoms and 2) confirmed or suspected COVID-19 diagnosis across 5 databases from South Korea, Spain, and the United States. Outcomes included i) hospitalization with pneumonia, ii) hospitalization with pneumonia requiring intensive services or death, and iii) death in the 30&#x2009;days after index date.</AbstractText><AbstractText Label="RESULTS">Overall, 44,507 COVID-19 patients were included for model validation. We identified 7 predictors (history of cancer, chronic obstructive pulmonary disease, diabetes, heart disease, hypertension, hyperlipidemia, kidney disease) which combined with age and sex discriminated which patients would experience any of our three outcomes. The models achieved good performance in influenza and COVID-19 cohorts. For COVID-19 the AUC ranges were, COVER-H: 0.69-0.81, COVER-I: 0.73-0.91, and COVER-F: 0.72-0.90. Calibration varied across the validations with some of the COVID-19 validations being less well calibrated than the influenza validations.</AbstractText><AbstractText Label="CONCLUSIONS">This research demonstrated the utility of using a proxy disease to develop a prediction model. The 3 COVER models with 9-predictors that were developed using influenza data perform well for COVID-19 patients for predicting hospitalization, intensive services, and fatality. The scores showed good discriminatory performance which transferred well to the COVID-19 population. There was some miscalibration in the COVID-19 validations, which is potentially due to the difference in symptom severity between the two diseases. A possible solution for this is to recalibrate the models in each location before use.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Doctor Molewaterplein, 403015, GD, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Markus</LastName><ForeName>Aniek F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Doctor Molewaterplein, 403015, GD, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Doctor Molewaterplein, 403015, GD, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonnagaddala</LastName><ForeName>Jitendra</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rho</LastName><ForeName>Yeunsook</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Big Data Strategy, National Health Insurance Service, Wonju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Tufts University School of Medicine, Institute for Clinical Research and Health Policy Studies, Boston, MA, 02111, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Amanda Alberga</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Independent Epidemiologist, OHDSI, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Min Ho</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>So Ahn Public Health Center, Wando County Health Center and Hospital, Wando, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arag&#xf3;n</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Young Hwa</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drakos</LastName><ForeName>Iannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Koege, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrah&#xe3;o</LastName><ForeName>Maria Tereza Fernandes</ForeName><Initials>MTF</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bertol&#xed;n</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaas-Hansen</LastName><ForeName>Benjamin Skov</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NNF Centre for Protein Research, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandukuri</LastName><ForeName>Prasanna L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Abbvie, Chicago, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kors</LastName><ForeName>Jan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Doctor Molewaterplein, 403015, GD, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liaw</LastName><ForeName>Siaw-Teng</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machnicki</LastName><ForeName>Gerardo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Latin America, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, Washington D. C, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt University, Nashville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Marcela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bayer Pharmaceuticals, Bayer Hispania, S.L., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seinen</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Doctor Molewaterplein, 403015, GD, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steyerberg</LastName><ForeName>Ewout W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Public Health, Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne School of Public Health, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Abbvie, Chicago, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Doctor Molewaterplein, 403015, GD, Rotterdam, The Netherlands. p.rijnbeek@erasmusmc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Res Methodol</MedlineTA><NlmUniqueID>100968545</NlmUniqueID><ISSNLinking>1471-2288</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Patient-level prediction modelling</Keyword><Keyword MajorTopicYN="N">Risk score</Keyword></KeywordList><CoiStatement>RDW, AM, CY, TDS, TF, JJ, CK, YR, AW, AA, MHO, MA, CA, EB, YHC, ID, MTFA, SFB, JAK, STL, FN, RWP, NP, TS, MS, EWS, SCY, LZ(Zhang), LZ(Zhou), report no conflicts of interest. MM reports grants from Department of Veteran Affairs, grants from National Institutes of Health, outside the submitted work; SLD reports grants from Anolinx, LLC, grants from Astellas Pharma, Inc., grants from AstraZeneca Pharmaceuticals LP, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc., grants from Genomic Health, Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation, outside the submitted work; BK-H reports grants from Innovation Fund Denmark, grants from Novo Nordisk Foundation, during the conduct of the study; DPA reports grants and other from UCB Biopharma SRL, grants and other from Amgen, grants from Servier Laboratoires, outside the submitted work; DM reports grants from Wellcome Trust (Clinical Research Development Fellowship), grants from Chief Scientist Office (CSO), grants from Health Data Research UK (HDR-UK), grants from National Institute of Health Research (NIHR), outside the submitted work; AP-U reports grants from Fundacion Alfonso Martin Escudero, grants from Medical Research Council, outside the submitted work; GH reports grants from NIH National Library of Medicine, during the conduct of the study; grants from Janssen Research, outside the submitted work; JMR, PBR, AS, GR are employees of Janssen Research and Development and are shareholders of Johnson &amp; Johnson. KK and CR report as employees of IQVIA. MR reports personal fees from Bayer Hispania, S.L., outside the submitted work; PLK and LZ are AbbVie employees. MAS reports grants from US National Institutes of Health, grants from IQVIA, personal fees from Janssen Research and Development, personal fees from Private Health Management, during the conduct of the study; PRR reports grants from Innovative Medicines Initiative, grants from Janssen Research and Development, during the conduct of the study; GM is a full-time employee of Janssen Latin America, outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>31</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35094685</ArticleId><ArticleId IdType="pmc">PMC8801189</ArticleId><ArticleId IdType="doi">10.1186/s12874-022-01505-z</ArticleId><ArticleId IdType="pii">10.1186/s12874-022-01505-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 march 2020. Geneva: World Health Organization; 2020.</Citation></Reference><Reference><Citation>Prieto-Alhambra D, Ballo E, Coma-Redon E, et al. Hospitalization and 30-day fatality in 121,263 COVID-19 outpatient cases. medRxiv. 2020:2020.2005.2004.20090050.</Citation></Reference><Reference><Citation>World Health Organization. Coronavirus disease 2019 (COVID-19) situation report - 51 2020, 11 march 2020. Geneva: World Health Organization; 2020.</Citation></Reference><Reference><Citation>Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ. 2020;369:m1328. doi: 10.1136/bmj.m1328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1328</ArticleId><ArticleId IdType="pmc">PMC7222643</ArticleId><ArticleId IdType="pubmed">32265220</ArticleId></ArticleIdList></Reference><Reference><Citation>Piroth L, Cottenet J, Mariet AS, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9(3):251&#x2013;259. doi: 10.1016/S2213-2600(20)30527-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30527-0</ArticleId><ArticleId IdType="pmc">PMC7832247</ArticleId><ArticleId IdType="pubmed">33341155</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen E. COVID-19 is not influenza. Lancet Respir Med. 2021;9(3):219&#x2013;220. doi: 10.1016/S2213-2600(20)30577-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30577-4</ArticleId><ArticleId IdType="pmc">PMC7834708</ArticleId><ArticleId IdType="pubmed">33341154</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons KG, Altman DG, Reitsma JB, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1&#x2013;73. doi: 10.7326/M14-0698.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-0698</ArticleId><ArticleId IdType="pubmed">25560730</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25(8):969&#x2013;975. doi: 10.1093/jamia/ocy032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Williams RD, You SC, et al. Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation. BMC Med Res Methodol. 2020;20(1):102. doi: 10.1186/s12874-020-00991-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-020-00991-3</ArticleId><ArticleId IdType="pmc">PMC7201646</ArticleId><ArticleId IdType="pubmed">32375693</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>John LH, Kors JA, Reps JM, Ryan PB, Rijnbeek PR. How little data do we need for patient-level prediction? arXiv preprint arXiv:200807361. 2020.</Citation></Reference><Reference><Citation>Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441. doi: 10.1136/bmj.m441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m441</ArticleId><ArticleId IdType="pubmed">32188600</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul (TOMACS) 2013;23(1):1&#x2013;17. doi: 10.1145/2414416.2414791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925&#x2013;1931. doi: 10.1093/eurheartj/ehu207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu207</ArticleId><ArticleId IdType="pmc">PMC4155437</ArticleId><ArticleId IdType="pubmed">24898551</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational health data sciences and informatics. The Book of OHDSI. OHDSI; 2019.</Citation></Reference><Reference><Citation>Steyerberg EW, Borsboom GJ, van Houwelingen HC, Eijkemans MJ, Habbema JD. Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med. 2004;23(16):2567&#x2013;2586. doi: 10.1002/sim.1844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1844</ArticleId><ArticleId IdType="pubmed">15287085</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen KJ, Moons KG, Kalkman CJ, Grobbee DE, Vergouwe Y. Updating methods improved the performance of a clinical prediction model in new patients. J Clin Epidemiol. 2008;61(1):76&#x2013;86. doi: 10.1016/j.jclinepi.2007.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2007.04.018</ArticleId><ArticleId IdType="pubmed">18083464</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JDF. Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol. 2005;58(5):475&#x2013;483. doi: 10.1016/j.jclinepi.2004.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2004.06.017</ArticleId><ArticleId IdType="pubmed">15845334</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med. 2016;35(2):214&#x2013;226. doi: 10.1002/sim.6787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6787</ArticleId><ArticleId IdType="pmc">PMC4738418</ArticleId><ArticleId IdType="pubmed">26553135</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35115001</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6947</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>BMC medical informatics and decision making</Title><ISOAbbreviation>BMC Med Inform Decis Mak</ISOAbbreviation></Journal><ArticleTitle>Evaluating the performance of temporal pattern discovery: new application using statins and rhabdomyolysis in OMOP databases.</ArticleTitle><Pagination><StartPage>31</StartPage><MedlinePgn>31</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">31</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12911-022-01765-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Temporal pattern discovery (TPD) is a method of signal detection using electronic healthcare databases, serving as an alternative to spontaneous reporting of adverse drug events. Here, we aimed to replicate and optimise a TPD approach previously used to assess temporal signals of statins with rhabdomyolysis (in The Health Improvement Network (THIN) database) by using the OHDSI tools designed for OMOP data sources.</AbstractText><AbstractText Label="METHODS">We used data from the Truven MarketScan US Commercial Claims and the Commercial Claims and Encounters (CCAE). Using an extension of the OHDSI ICTemporalPatternDiscovery package, we ran positive and negative controls through four analytical settings and calculated sensitivity, specificity, bias and AUC to assess performance.</AbstractText><AbstractText Label="RESULTS">Similar to previous findings, we noted an increase in the Information Component (IC) for simvastatin and rhabdomyolysis following initial exposure and throughout the surveillance window. For example, the change in IC was 0.266 for the surveillance period of 1-30&#xa0;days as compared to the control period of&#x2009;-&#x2009;180 to&#x2009;-&#x2009;1&#xa0;days. Our modification of the existing OHDSI software allowed for faster queries and more efficient generation of chronographs.</AbstractText><AbstractText Label="CONCLUSION">Our OMOP replication matched the we can account forwe can account for of the original THIN study, only simvastatin had a signal. The TPD method is a useful signal detection tool that provides a single statistic on temporal association and a graphical depiction of the temporal pattern of the drug outcome combination. It remains unclear if the method works well for rare adverse events, but it has been shown to be a useful risk identification tool for longitudinal observational databases. Future work should compare the performance of TPD with other pharmacoepidemiology methods and mining techniques of signal detection. In addition, it would be worth investigating the relative TPD performance characteristics using a variety of observational data sources.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lavallee</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Former Bayer Healthcare Pharmaceutical Inc, Whippany, NJ, USA. lavalleema@vcu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Virginia Commonwealth University, Richmond, VA, USA. lavalleema@vcu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LTS Computing LLC, West Chester, PA, USA. lavalleema@vcu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>LTS Computing LLC, West Chester, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>LTS Computing LLC, West Chester, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Hemelrijck</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7317-0858</Identifier><AffiliationInfo><Affiliation>Translational Oncology &amp; Urology Research (TOUR), King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosco</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Translational Oncology &amp; Urology Research (TOUR), King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Former Bayer Healthcare Pharmaceutical Inc, Whippany, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asiimwe</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bayer AG, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Inform Decis Mak</MedlineTA><NlmUniqueID>101088682</NlmUniqueID><ISSNLinking>1472-6947</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012206" MajorTopicYN="Y">Rhabdomyolysis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse events</Keyword><Keyword MajorTopicYN="N">Rhabdomyolysis</Keyword><Keyword MajorTopicYN="N">Statins</Keyword><Keyword MajorTopicYN="N">Temporal pattern discover</Keyword></KeywordList><CoiStatement>Martin Lavallee worked on this project as a contractor for Bayer from January to July 2018. Martin is now a PhD student in Biostatistics at Virginia Commonwealth University and an intern for LTS Computing LLC. Lee Evans and Theresa Yu are employees of LTS Computing LLC. LTS manages the real-world evidence platform (OHDSI/OMOP common data model) for Bayer.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35115001</ArticleId><ArticleId IdType="pmc">PMC8812213</ArticleId><ArticleId IdType="doi">10.1186/s12911-022-01765-1</ArticleId><ArticleId IdType="pii">10.1186/s12911-022-01765-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnaud M, Begaud B, Thurin N, Moore N, Pariente A, Salvo F. Methods for safety signal detection in healthcare databases: a literature review. Expert Opin Drug Saf. 2017;16(6):721&#x2013;732. doi: 10.1080/14740338.2017.1325463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2017.1325463</ArticleId><ArticleId IdType="pubmed">28490262</ArticleId></ArticleIdList></Reference><Reference><Citation>Noren GN, Bergvall T, Ryan PB, Juhlin K, Schuemie MJ, Madigan D. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S107&#x2013;S121. doi: 10.1007/s40264-013-0095-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0095-x</ArticleId><ArticleId IdType="pubmed">24166228</ArticleId></ArticleIdList></Reference><Reference><Citation>Star K, Watson S, Sandberg L, Johansson J, Edwards IR. Longitudinal medical records as a complement to routine drug safety signal analysis. Pharmacoepidemiol Drug Saf. 2015;24(5):486&#x2013;494. doi: 10.1002/pds.3739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3739</ArticleId><ArticleId IdType="pmc">PMC5024044</ArticleId><ArticleId IdType="pubmed">25623045</ArticleId></ArticleIdList></Reference><Reference><Citation>Noren G, Hopstadius J, Bate A, Star K, Edwards I. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Disc. 2010;20:361&#x2013;387. doi: 10.1007/s10618-009-0152-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10618-009-0152-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben N, Liu K, Hung E, Blackwell W, Fram D, Bate A. Signal detection using temporal pattern discovery in electronich health records&#x2014;lessons from statins and rhabdomyolysis. In: 32nd ICPE; 25&#x2013;28 Aug; Dublin, Ireland; 2016.</Citation></Reference><Reference><Citation>Commonwealth Informatics. Detect &amp; refine safety signals faster with CVW Longitudinal 2019; Available from https://www.commoninf.com/products/commonwealth-vigilance-workbench-cvw/cvw-longitudinal/.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong IC, Rijnbeek PR, van der Lei J, Pratt N, Noren GN, Li YC, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, Suchard MA, DuMouchel W, Berlin JA. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178(4):645&#x2013;651. doi: 10.1093/aje/kwt010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwt010</ArticleId><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M. Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies. Ther Adv Drug Saf. 2013;4(2):53&#x2013;62. doi: 10.1177/2042098613477445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2042098613477445</ArticleId><ArticleId IdType="pmc">PMC4110833</ArticleId><ArticleId IdType="pubmed">25083251</ArticleId></ArticleIdList></Reference><Reference><Citation>IBM. BM MarketScan&#xae; Explorys&#xae; Claims-EMR Data Set 2019; Available from https://marketscan.truvenhealth.com/marketscanportal/.</Citation></Reference><Reference><Citation>Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, Reich CG, Schuemie MJ, Madigan D. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36(Suppl 1):S143&#x2013;S158. doi: 10.1007/s40264-013-0108-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0108-9</ArticleId><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>The ODHSI Community. The book of OHDSI 2019 [cited 2019 15 Dec]. Available from https://ohdsi.github.io/TheBookOfOhdsi/.</Citation></Reference><Reference><Citation>Azemawah V, Movahed MR, Centuori P, Penaflor R, Riel PL, Situ S, Shadmehr M, Hashemzadeh M. State of the art comprehensive review of individual statins their differences pharmacology and clinical implications. Cardiovasc Drugs Ther. 2019;33(5):625-639. 10.1007/s10557-019-06904-x.</Citation><ArticleIdList><ArticleId IdType="pubmed">31773344</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care. 2013;36(Supplement_2):S325-S330. 10.2337/dcS13-2038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3920796</ArticleId><ArticleId IdType="pubmed">23882066</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerman LJ, Shen MC. Rhabdomyolysis. Chest. 2013;144(3):1058&#x2013;1065. 10.1378/chest.12-2016.</Citation><ArticleIdList><ArticleId IdType="pubmed">24008958</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Garibaldi JM, Aickelin U, Soria D, Gibson JE, Hubbard RB. A novel semisupervised algorithm for rare prescription side effect discovery. IEEE J Biomed Health Inform. 2014;18(2):537&#x2013;547. doi: 10.1109/JBHI.2013.2281505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/JBHI.2013.2281505</ArticleId><ArticleId IdType="pubmed">24043412</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35191114</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries.</ArticleTitle><Pagination><StartPage>495</StartPage><EndPage>510</EndPage><MedlinePgn>495-510</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.5419</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9286-1128</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xintong</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-6872-5804</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2595-8736</Identifier><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The OHDSI Center at The Roux Institute, Northeastern University, Portland, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Henry Morgan</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3641-055X</Identifier><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seager</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8274-0357</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Bertolin</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0029-6564</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arag&#xf3;n</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Carlen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Hernandez</LastName><ForeName>Eugenia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8317-7068</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hospital Clinic and University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marti</LastName><ForeName>Edelmira</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-5678-2916</Identifier><AffiliationInfo><Affiliation>Hemostasis and Thrombosis Unit, Hematology Department, Hospital Cl&#xed;nico Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0388-3403</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhamme</LastName><ForeName>Katia</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8162-4904</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0621-1979</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horban</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-0063-8069</Identifier><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013921" MajorTopicYN="Y">Thrombocytopenia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="afr"><AbstractText Label="BACKGROUND">Thrombosis with thrombocytopenia syndrome (TTS) has been reported among individuals vaccinated with adenovirus-vectored COVID-19 vaccines. In this study, we describe the background incidence of non-vaccine induced TTS in six European countries.</AbstractText><AbstractText Label="METHODS">Electronic medical records from France, the Netherlands, Italy, Germany, Spain, and the United Kingdom informed the study. Incidence rates of cerebral venous sinus thrombosis (CVST), splanchnic vein thrombosis (SVT), deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction or ischemic stroke, all with concurrent thrombocytopenia, were estimated among the general population of persons in a database between 2017 and 2019. A range of additional potential adverse events of special interest for COVID-19 vaccinations were also studied in a similar manner.</AbstractText><AbstractText Label="FINDINGS">A total of 38&#x2009;611&#x2009;617 individuals were included. Background rates ranged from 1.0 (95% CI: 0.7-1.4) to 8.5 (7.4-9.9) per 100&#x2009;000 person-years for DVT with thrombocytopenia, from 0.5 (0.3-0.6) to 20.8 (18.9-22.8) for PE with thrombocytopenia, from 0.1 (0.0-0.1) to 2.5 (2.2-2.7) for SVT with thrombocytopenia, and from 1.0 (0.8-1.2) to 43.4 (40.7-46.3) for myocardial infarction or ischemic stroke with thrombocytopenia. CVST with thrombocytopenia was only identified in one database, with incidence rate of 0.1 (0.1-0.2) per 100&#x2009;000 person-years. The incidence of non-vaccine induced TTS increased with age, and was typically greater among those with more comorbidities and greater medication use than the general population. It was also more often seen in men than women. A large proportion of those affected were seen to have been taking antithrombotic and anticoagulant therapies prior to their event.</AbstractText><AbstractText Label="INTERPRETATION">Although rates vary across databases, non-vaccine induced TTS has consistently been seen to be a very rare event among the general population. While still remaining very rare, rates were typically higher among older individuals, and those affected were also seen to generally be male and have more comorbidities and greater medication use than the general population.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">post vaccine</Keyword><Keyword MajorTopicYN="N">thrombosis-thrombocytopenia syndromes (TTS)</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>DPA's research group has received research grants from the European Medicines Agency, from the Innovative Medicines Initiative, from Amgen, Chiesi, and from UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen and UCB Biopharma. At the time of analysis, Kristin Kostka, Henry Morgan Stewart, Carlen Reyes and Sarah Seager were employees of IQVIA. Kristin Kostka reported receiving funding from the National Institutes of Health National COVID Cohort Collaborative (N3C). IQVIA received funding from the University of Oxford on behalf of the Bill &amp; Melinda Gates Foundation for the conversion of LPD Italy and utilisation of DA Germany data for COVID&#x2010;19 related research. Katia Verhamme and Peter Rijnbeek work for a research group that received unconditional research grants from Yamanouchi, Pfizer/Boehringer Ingelheim, Novartis, GSK, Amgen, Astra&#x2010;Zeneca, UCB, J&amp;J, the European Medicines Agency and the Innovative Medicines Initiative.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35191114</ArticleId><ArticleId IdType="pmc">PMC9088543</ArticleId><ArticleId IdType="doi">10.1002/pds.5419</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Krammer F. SARS&#x2010;CoV&#x2010;2 vaccines in development. Nature. 2020;586(7830):516&#x2010;527. doi:10.1038/s41586-020-2798-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2798-3</ArticleId><ArticleId IdType="pubmed">32967006</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA&#x2010;1273 SARS&#x2010;CoV&#x2010;2 vaccine. N Engl J Med. 2020;384(5):403&#x2010;416. doi:10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid&#x2010;19 vaccine. N Engl J Med. 2020;383(27):2603&#x2010;2615. doi:10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV&#x2010;19 vaccine (AZD1222) against SARS&#x2010;CoV&#x2010;2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99&#x2010;111. doi:10.1016/S0140-6736(20)32661-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature . &#x2018;Unprecedented achievement&#x2019;: who received the first billion COVID vaccinations? 2021.</Citation></Reference><Reference><Citation>Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid&#x2010;19 vaccine in a Nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412&#x2010;1423. doi:10.1056/NEJMoa2101765</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101765</ArticleId><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first&#x2010;dose mass COVID&#x2010;19 vaccination roll&#x2010;out and COVID&#x2010;19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646&#x2010;1657. doi:10.1016/S0140-6736(21)00677-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00677-2</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>MHRA . Coronavirus vaccine&#x2014;weekly summary of Yellow Card reporting. 2021.</Citation></Reference><Reference><Citation>CDC . J&amp;J/Janssen Update. 2021.</Citation></Reference><Reference><Citation>Long B, Bridwell R, Gottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID&#x2010;19 vaccines. Am J Emerg Med. 2021;49:58&#x2010;61. doi:10.1016/j.ajem.2021.05.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2021.05.054</ArticleId><ArticleId IdType="pmc">PMC8143907</ArticleId><ArticleId IdType="pubmed">34062319</ArticleId></ArticleIdList></Reference><Reference><Citation>Cines DB, Bussel JB. SARS&#x2010;CoV&#x2010;2 vaccine&#x2013;induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;384:2254&#x2010;2256. doi:10.1056/NEJMe2106315</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2106315</ArticleId><ArticleId IdType="pmc">PMC8063912</ArticleId><ArticleId IdType="pubmed">33861524</ArticleId></ArticleIdList></Reference><Reference><Citation>Warkentin TE, Greinacher A. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine&#x2010;induced immune thrombotic thrombocytopenia. Thromb Res. 2021;204:40&#x2010;51. doi:10.1016/j.thromres.2021.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2021.05.018</ArticleId><ArticleId IdType="pubmed">34144250</ArticleId></ArticleIdList></Reference><Reference><Citation>Black S, Eskola J, Siegrist C&#x2010;A, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009;374(9707):2115&#x2010;2122. doi:10.1016/S0140-6736(09)61877-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inf Assoc. 2015;22:553&#x2010;564. doi:10.1093/jamia/ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2010;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Informatics Assoc. 2011;19(1):54&#x2010;60. doi:10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827&#x2010;836. doi:10.1093/ije/dyv098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv098</ArticleId><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A, Dedman D, Campbell J, et al. Data resource profile: clinical practice research Datalink (CPRD) aurum. Int J Epidemiol. 2019;48(6):1740. doi:10.1093/ije/dyz034</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz034</ArticleId><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>Jouaville SL, Miotti H, Coffin G, Sarfati B, Meihoc A. Validity and limitations of the longitudinal patient database France for use in Pharmacoepidemiological and Pharmacoeconomics studies. Value Heal. 2015;18(3):A18. doi:10.1016/j.jval.2015.03.115</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2015.03.115</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a&#x2010;Gil MDM, Hermosilla E, Prieto&#x2010;Alhambra D, et al. Construction and validation of a scoring system for the selection of high&#x2010;quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care. 2011;19(3):135&#x2010;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M, Ryan P, Weaver J. Cohort diagnostics: diagnostics for OHDSI studies. 2020.</Citation></Reference><Reference><Citation>White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:I&#x2010;4&#x2010;I&#x2010;8. doi:10.1161/01.CIR.0000078468.11849.66</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000078468.11849.66</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007;44(2):62&#x2010;69. doi:10.1053/j.seminhematol.2007.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminhematol.2007.02.004</ArticleId><ArticleId IdType="pmc">PMC2020806</ArticleId><ArticleId IdType="pubmed">17433897</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362(23):2155&#x2010;2165. doi:10.1056/NEJMoa0908610</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0908610</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Feigin VL, Lawes CMM, Bennett DA, Barker&#x2010;Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population&#x2010;based studies: a systematic review. Lancet Neurol. 2009;8(4):355&#x2010;369. doi:10.1016/S1474-4422(09)70025-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70025-0</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first&#x2010;ever ischaemic and haemorrhagic stroke during 1990&#x2013;2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Heal. 2013;1(5):e259&#x2010;e281. doi:10.1016/S2214-109X(13)70089-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(13)70089-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Otite FO, Patel S, Sharma R, et al. Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States. Neurology. 2020;95(16):e2200. doi:10.1212/WNL.0000000000010598</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010598</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791&#x2010;1798. doi:10.1056/NEJMra042354</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra042354</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Coutinho JM, Zuurbier SM, Majid A, Jan S. The incidence of cerebral venous thrombosis. Stroke. 2012;43(12):3375&#x2010;3377. doi:10.1161/STROKEAHA.112.671453</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.112.671453</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon D, Ben W, James L, Timothy K. Cerebral venous sinus thrombosis incidence is higher than previously thought. Stroke. 2016;47(9):2180&#x2010;2182. doi:10.1161/STROKEAHA.116.013617</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.116.013617</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageno W, Dentali F, Pomero F, et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd&#x2010;Chiari syndrome. Thromb Haemost. 2017;117(04):794&#x2010;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Potteg&#xe5;rd A, Lund LC, Karlstad &#xd8;, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford&#x2010;AstraZeneca ChAdOx1&#x2010;S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114. doi:10.1136/bmj.n1114</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1114</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Egbers T, Belbachir L, Dur&#xe1;n C, et al. Access&#x2010;background rate of adverse events&#x2010; definition&#x2014;coagulation disorders. 2021. doi:10.5281/zenodo.5228687</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.5228687</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz NH, S&#xf8;rvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV&#x2010;19 vaccination. N Engl J Med. 2021;384:2124&#x2010;2130. doi:10.1056/NEJMoa2104882</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104882</ArticleId><ArticleId IdType="pmc">PMC8112568</ArticleId><ArticleId IdType="pubmed">33835768</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV&#x2010;19 vaccination. N Engl J Med. 2021;384:2202&#x2010;2211. doi:10.1056/NEJMoa2105385</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105385</ArticleId><ArticleId IdType="pmc">PMC8112532</ArticleId><ArticleId IdType="pubmed">33861525</ArticleId></ArticleIdList></Reference><Reference><Citation>See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination. JAMA. 2021;325(24). doi:10.1001/jama.2021.7517</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.7517</ArticleId><ArticleId IdType="pmc">PMC8087975</ArticleId><ArticleId IdType="pubmed">33929487</ArticleId></ArticleIdList></Reference><Reference><Citation>Panozzo CA, Woodworth TS, Welch EC, et al. Early impact of the ICD&#x2010;10&#x2010;CM transition on selected health outcomes in 13 electronic health care databases in the United States. Pharmacoepidemiol Drug Saf. 2018;27(8):839&#x2010;847. doi:10.1002/pds.4563</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4563</ArticleId><ArticleId IdType="pubmed">29947033</ArticleId></ArticleIdList></Reference><Reference><Citation>Karron RA, Key NS, Sharfstein JM. Assessing a rare and serious adverse event following administration of the Ad26.COV2.S vaccine. JAMA. 2021;325(24). doi:10.1001/jama.2021.7637</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.7637</ArticleId><ArticleId IdType="pubmed">33929484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35204354</PMID><DateRevised><Year>2022</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>21</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Cancer: A Population-Based Cohort Study Using a Common Data Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">263</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics12020263</ELocationID><Abstract><AbstractText>Studies have reported conflicting results on the association between the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and cancer development. We compared the incidence of cancer between patients using RAAS inhibitors and other antihypertensive drugs. This retrospective observational cohort study used data from seven hospitals in Korea that were converted for use in the Observational Medical Outcomes Partnership Common Data Model. A total of 166,071 patients on antihypertensive therapy across the databases of the seven hospitals were divided into two groups according to the use of RAAS inhibitors. The primary outcome was the occurrence of cancer. A total of 166,071 patients across the databases of the seven hospitals was included in the final analysis; 26,650 (16%) were in the RAAS inhibitors group and 139,421 (84%) in the other antihypertensive drugs group. The meta-analysis of the whole cohort showed a lower incidence of cancer occurrence in the RAAS inhibitor group (9.90 vs. 13.28 per 1000 person years; HR, 0.81; 95% confidence interval [CI], 0.75-0.88). After propensity-score matching, the RAAS inhibitor group consistently showed a lower incidence of cancer (9.90 vs. 13.28 per 1000 person years; HR, 0.86; 95% CI, 0.81-0.91). The patients using RAAS inhibitors showed a lower incidence of cancer compared with those using other antihypertensive drugs. These findings support the association between the use of RAAS inhibitors and cancer occurrence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung-Hwa</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0001-5508-7519</Identifier><AffiliationInfo><Affiliation>Rehabilitation and Prevention Center, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jungchan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon 16499, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon 16499, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Seo Jeong</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-0861-3576</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon 16499, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinseob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Seoul National University, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Ji Dong</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-1006-5727</Identifier><AffiliationInfo><Affiliation>Rehabilitation and Prevention Center, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dae Jung</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0003-1025-2044</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon 16499, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Kwangmo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon 16499, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Health Promotion, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HI19C0811</GrantID><Agency>Ministry of Health and Welfare</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer occurrence</Keyword><Keyword MajorTopicYN="N">renin-angiotensin-aldosterone system inhibitors</Keyword></KeywordList><CoiStatement>The authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35204354</ArticleId><ArticleId IdType="pmc">PMC8871518</ArticleId><ArticleId IdType="doi">10.3390/diagnostics12020263</ArticleId><ArticleId IdType="pii">diagnostics12020263</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sipahi I., Debanne S.M., Rowland D.Y., Simon D.I., Fang J.C. Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627&#x2013;636. doi: 10.1016/S1470-2045(10)70106-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(10)70106-6</ArticleId><ArticleId IdType="pmc">PMC4070221</ArticleId><ArticleId IdType="pubmed">20542468</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanif K., Bid H.K., Konwar R. Reinventing the ACE inhibitors: Some old and new implications of ACE inhibition. Hypertens. Res. 2010;33:11&#x2013;21. doi: 10.1038/hr.2009.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/hr.2009.184</ArticleId><ArticleId IdType="pubmed">19911001</ArticleId></ArticleIdList></Reference><Reference><Citation>Song T., Choi C.H., Kim M.K., Kim M.L., Yun B.S., Seong S.J. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis. Eur. J. Cancer Prev. 2017;26:78&#x2013;85. doi: 10.1097/CEJ.0000000000000269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CEJ.0000000000000269</ArticleId><ArticleId IdType="pubmed">27158979</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadic M., Cuspidi C., Belyavskiy E., Grassi G. Intriguing relationship between antihypertensive therapy and cancer. Pharmacol. Res. 2019;141:501&#x2013;511. doi: 10.1016/j.phrs.2019.01.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2019.01.037</ArticleId><ArticleId IdType="pubmed">30682424</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipahi I., Chou J., Mishra P., Debanne S.M., Simon D.I., Fang J.C. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am. J. Cardiol. 2011;108:294&#x2013;301. doi: 10.1016/j.amjcard.2011.03.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2011.03.038</ArticleId><ArticleId IdType="pubmed">21600543</ArticleId></ArticleIdList></Reference><Reference><Citation>Afsar B., Afsar R.E., Ertuglu L.A., Kuwabara M., Ortiz A., Covic A., Kanbay M. Renin-angiotensin system and cancer: Epidemiology, cell signaling, genetics and epigenetics. Clin. Transl. Oncol. 2021;23:682&#x2013;696. doi: 10.1007/s12094-020-02488-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12094-020-02488-3</ArticleId><ArticleId IdType="pubmed">32930920</ArticleId></ArticleIdList></Reference><Reference><Citation>You S.C., Lee S., Cho S.Y., Park H., Jung S., Cho J., Yoon D., Park R.W. Conversion of National Health Insurance Service-National Sample Cohort (NHIS-NSC) Database into Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM) Stud. Health Technol. Inform. 2017;245:467&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials. 1986;7:177&#x2013;188. doi: 10.1016/0197-2456(86)90046-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiers B.H. Association of ACE Inhibitors and Angiotensin Receptor Blockers with Keratinocyte Cancer Prevention in the Randomized VATTC Trial. Year Book Dermatol. Dermatol. Surg. 2009;2009:318&#x2013;319. doi: 10.1016/S0093-3619(08)79209-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0093-3619(08)79209-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni H., Rui Q., Zhu X., Yu Z., Gao R., Liu H. Antihypertensive drug use and breast cancer risk: A meta-analysis of observational studies. Oncotarget. 2017;8:62545&#x2013;62560. doi: 10.18632/oncotarget.19117.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.19117</ArticleId><ArticleId IdType="pmc">PMC5617528</ArticleId><ArticleId IdType="pubmed">28977968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L., Zhang S., Jia C.M., He W., Wu L.T., Li Y.Q., Wang W., Li Z., Ma J. Antihypertensive drugs use and the risk of prostate cancer: A meta-analysis of 21 observational studies. BMC Urol. 2018;18:17. doi: 10.1186/s12894-018-0318-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12894-018-0318-7</ArticleId><ArticleId IdType="pmc">PMC5842557</ArticleId><ArticleId IdType="pubmed">29514670</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Acebo I., Dierssen-Sotos T., Palazuelos C., Perez-Gomez B., Lope V., Tusquets I., Alonso M.H., Moreno V., Amiano P., Molina de la Torre A.J., et al. The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study. PLoS ONE. 2016;11:e0159672. doi: 10.1371/journal.pone.0159672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0159672</ArticleId><ArticleId IdType="pmc">PMC4979888</ArticleId><ArticleId IdType="pubmed">27508297</ArticleId></ArticleIdList></Reference><Reference><Citation>Friis S., Sorensen H.T., Mellemkjaer L., McLaughlin J.K., Nielsen G.L., Blot W.J., Olsen J.H. Angiotensin-converting enzyme inhibitors and the risk of cancer: A population-based cohort study in Denmark. Cancer. 2001;92:2462&#x2013;2470. doi: 10.1002/1097-0142(20011101)92:9&lt;2462::AID-CNCR1596&gt;3.0.CO;2-L.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(20011101)92:9&lt;2462::AID-CNCR1596&gt;3.0.CO;2-L</ArticleId><ArticleId IdType="pubmed">11745304</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt S.A.J., Schmidt M., Mehnert F., Lemeshow S., S&#xf8;rensen H.T. Use of antihypertensive drugs and risk of skin cancer. J. Eur. Acad. Dermatol. Venereol. 2015;29:1545&#x2013;1554. doi: 10.1111/jdv.12921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.12921</ArticleId><ArticleId IdType="pubmed">25640031</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsushige S., Yoshio Y., Naohito S., Takahisa F. Role of renin-angiotensin system in gastric oncogenesis. J. Gastroenterol. Hepatol. 2012;27:442&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739298</ArticleId><ArticleId IdType="pubmed">22114933</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Q., Davis M., Chipitsyna G., Yeo C.J., Arafat H.A. Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas. 2010;39:581&#x2013;594. doi: 10.1097/MPA.0b013e3181c314cd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPA.0b013e3181c314cd</ArticleId><ArticleId IdType="pubmed">20118823</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes D.R., Ateeq B., Cao Q., Tomlins S.A., Mehra R., Laxman B., Kalyana-Sundaram S., Lonigro R.J., Helgeson B.E., Bhojani M.S., et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc. Natl. Acad. Sci. USA. 2009;106:10284&#x2013;10289. doi: 10.1073/pnas.0900351106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900351106</ArticleId><ArticleId IdType="pmc">PMC2689309</ArticleId><ArticleId IdType="pubmed">19487683</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto Y., Sasaki T., Tsuchida A., Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001;495:197&#x2013;200. doi: 10.1016/S0014-5793(01)02377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(01)02377-8</ArticleId><ArticleId IdType="pubmed">11334891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilop S., von Hobe S., Crysandt M., Esser A., Osieka R., Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J. Cancer Res. Clin. Oncol. 2009;135:1429&#x2013;1435. doi: 10.1007/s00432-009-0587-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00432-009-0587-3</ArticleId><ArticleId IdType="pubmed">19399518</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Schuemie M.J., Suchard M.A. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int. J. Epidemiol. 2018;47:2005&#x2013;2014. doi: 10.1093/ije/dyy120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee C., Dantes R., Epstein L., Murphy D.J., Seymour C.W., Iwashyna T.J., Kadri S.S., Angus D.C., Danner R.L., Fiore A.E., et al. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs. Claims Data, 2009&#x2013;2014. JAMA. 2017;318:1241&#x2013;1249. doi: 10.1001/jama.2017.13836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.13836</ArticleId><ArticleId IdType="pmc">PMC5710396</ArticleId><ArticleId IdType="pubmed">28903154</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35211336</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2059-8661</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of clinical and translational science</Title><ISOAbbreviation>J Clin Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Ensuring a safe(r) harbor: Excising personally identifiable information from structured electronic health record data.</ArticleTitle><Pagination><StartPage>e10</StartPage><MedlinePgn>e10</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e10</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/cts.2021.880</ELocationID><Abstract><AbstractText>Recent findings have shown that the continued expansion of the scope and scale of data collected in electronic health records are making the protection of personally identifiable information (PII) more challenging and may inadvertently put our institutions and patients at risk if not addressed. As clinical terminologies expand to include new terms that may capture PII (e.g., Patient First Name, Patient Phone Number), institutions may start using them in clinical data capture (and in some cases, they already have). Once in use, PII-containing values associated with these terms may find their way into laboratory or observation data tables via extract-transform-load jobs intended to process structured data, putting institutions at risk of unintended disclosure. Here we aim to inform the informatics community of these findings, as well as put out a call to action for remediation by the community.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Emily R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0002-6840-9756</Identifier><AffiliationInfo><Affiliation>Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haendel</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The OHDSI Center at the Roux Institute, Northeastern University, Portland, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>TraCS Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niehaus</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palchuk</LastName><ForeName>Matvey B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>TriNetX LLC, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walters</LastName><ForeName>Kellie</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7473-1709</Identifier><AffiliationInfo><Affiliation>TraCS Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Schools of Medicine, Public Health, and Nursing, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Clin Transl Sci</MedlineTA><NlmUniqueID>101689953</NlmUniqueID><ISSNLinking>2059-8661</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Electronic health records</Keyword><Keyword MajorTopicYN="N">data privacy</Keyword><Keyword MajorTopicYN="N">medical terminologies</Keyword></KeywordList><CoiStatement>Melissa Haendel is a co-founder of Pryzm Health. Kristin Kostka reports consulting fees from the National Institutes of Health. Matvey Palchuk is a full-time employee of TriNetX, LLC. Emily Niehaus is a full-time employee of Palantir Technologies. All other authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35211336</ArticleId><ArticleId IdType="pmc">PMC8826001</ArticleId><ArticleId IdType="doi">10.1017/cts.2021.880</ArticleId><ArticleId IdType="pii">S2059866121008803</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Office of the Secretary. Department of Health and Human Services. Federal Register 2013; 78(17): 5566&#x2013;5702.</Citation><ArticleIdList><ArticleId IdType="pubmed">23476971</ArticleId></ArticleIdList></Reference><Reference><Citation>
Methods for De-identification of PHI. HHS.gov [Internet], 2021. (https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html)</Citation></Reference><Reference><Citation>Heider PM, Obeid JS, Meystre SM. A comparative analysis of speed and accuracy for three off-the-shelf de-identification tools. AMIA Joint Summits on Translational Science Proceedings 2020; 2020: 241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233098</ArticleId><ArticleId IdType="pubmed">32477643</ArticleId></ArticleIdList></Reference><Reference><Citation>Pintus R, Yang Y, Rushmeier H. Athena. Journal on Computing and Cultural Heritage 2015; 8(1): 1&#x2013;25. DOI 10.1145/2659020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2659020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Heider P, Meystre S. Ensemble-based methods to improve de-identification of electronic health record narratives. AMIA Annual Symposium Proceedings 2018; 2018: 663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6371277</ArticleId><ArticleId IdType="pubmed">30815108</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubbs A, Kotfila C, Uzuner O. Automated systems for the de-identification of longitudinal clinical narratives: overview of 2014 i2b2/UTHealth shared task track 1. Journal of Biomedical Informatics 2015; 58(Suppl): S11&#x2013;S19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4989908</ArticleId><ArticleId IdType="pubmed">26225918</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35212277</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>25</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.</ArticleTitle><Pagination><StartPage>e28823</StartPage><MedlinePgn>e28823</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e28823</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000028823</ELocationID><Abstract><AbstractText>The comparative effectiveness of oral hypoglycemic agents on glycemic control and chronic complications in clinical practice is unknown in Korea. This study aimed to compare glycemic control and the incidence of hypoglycemia and chronic complications among adult patients with type 2 diabetes prescribed metformin, dipeptidyl peptidase-4 inhibitors (DPP4I), and sulfonylurea (SU) as monotherapy or dual combination therapy.We retrospectively analyzed propensity-matched cohort data from 3 national university hospitals in Korea. All electronic health records were transformed into a unified Observational Medical Outcomes Partnership Common Data Model and analyzed using ATLAS, an open-source analytical tool, and R software. Glycemic control was assessed as the first observation of a reduction in glycosylated hemoglobin (HbA1c) level below 7% after prescription of the drug. Differences in the incidence of chronic complications were compared based on the first observation of each complication. Glycemic control and chronic complications were evaluated in patients who maintained the same prescription for at least 3 and 12&#x200a;months, respectively.Patients who received metformin had lower hazard of reaching HbA1c levels below 7% as compared with those who received SU, and had higher hazard compared with those who received DPP4I (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.75-0.98; and HR, 1.68; 95% CI, 1.42-1.99, respectively). The incidence of hypoglycemia was significantly higher in the SU group than in the metformin and DPP4I groups (metformin vs SU; HR, 0.30; 95% CI, 0.21-0.43; SU vs DPP4I; HR, 4.42; 95% CI, 2.35-8.31). Metformin&#x200a;+&#x200a;DPP4I had similar hazard of reaching HbA1c levels below 7% compared with metformin&#x200a;+&#x200a;SU (HR, 1.19; 95% CI, 0.99-1.43) and the incidence of hypoglycemia was significantly lower in the metformin&#x200a;+&#x200a;DPP4I group (HR 0.13; 95% CI 0.05-0.30). There was no significant difference in the analysis of the occurrence of chronic complications.SU followed by metformin was effective, and both drugs showed an increased hazard of reaching HbA1c levels below 7% compared with DPP4I. Metformin&#x200a;+&#x200a;DPP4I is comparatively effective for HbA1c level reduction below 7% compared with metformin&#x200a;+&#x200a;SU. Hypoglycemia was high in the SU-containing therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyung Ae</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0003-3700-8279</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Heung Yong</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yu Ji</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sang Soo</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Eun-Hee</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, Kangwon National University, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Tae Sun</ForeName><Initials>TS</Initials><Identifier Source="ORCID">0000-0001-7216-8468</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HI19C0543</GrantID><Agency>Korea Health Industry Development Institute</Agency><Country>Republic of Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013453">Sulfonylurea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007003" MajorTopicYN="Y">Hypoglycemia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013453" MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>8</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35212277</ArticleId><ArticleId IdType="pmc">PMC8878728</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000028823</ArticleId><ArticleId IdType="pii">00005792-202202250-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saeedi P, Petersohn I, Salpea P, et al. . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. 9th ed. Diabetes Res Clin Pract 2019;57:107843.</Citation><ArticleIdList><ArticleId IdType="pubmed">31518657</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care 2021;44: (Suppl 1): S111&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">33298420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MK, Ko SH, Kim BY, et al. . 2019 clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J 2019;43:398&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6712226</ArticleId><ArticleId IdType="pubmed">31441247</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661582</ArticleId><ArticleId IdType="pubmed">19336687</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean Diabetes Association. Diabetes fact sheet in Korea 2018. Available at: https://www.diabetes.or.kr/pro/news/admin.php?category=A&amp;code=admin&amp;number=1972&amp;mode=view. Accessed September 6, 2021.</Citation></Reference><Reference><Citation>Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2013;12:153&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3977601</ArticleId><ArticleId IdType="pubmed">23241069</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhury A, Duvoor C, Reddy Dendi VSR, et al. . Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne) 2017;8:06.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5256065</ArticleId><ArticleId IdType="pubmed">28167928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. . Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon Y, Choi Y, Kim EH, Oh SY, Lee H. Common data model-based real-world data for practical clinical practice guidelines: clinical pharmacology perspectives. Transl Clin Pharmacol 2020;28:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7327188</ArticleId><ArticleId IdType="pubmed">32656157</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, et al. . Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the observational health data sciences and informatics initiative. JAMA Netw Open 2018;1:e181755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational health data science and informatics (OHDSI). Available at: https://www.ohdsi.org/software-tools/last. Accessed September 6, 2021.</Citation></Reference><Reference><Citation>Reinecke I, Gulden C, K&#xfc;mmel M, Nassirian A, Blasini R, Sedlmayr M. Design for a modular clinical trial recruitment support system based on FHIR and OMOP. Stud Health Technol Inform 2020;270:158&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">32570366</ArticleId></ArticleIdList></Reference><Reference><Citation>Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. . Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 2020;21:6275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503727</ArticleId><ArticleId IdType="pubmed">32872570</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">18784090</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruthur NM, Tseng E, Hutfless S, et al. . Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016;164:740&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">27088241</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu A, Mehta A, Guerrero P, et al. . Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia. Endocr Pract 2009;15:696&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">19625243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmingsen B, Schroll JB, Wetterslev J, et al. . Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2014;2:E162&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185978</ArticleId><ArticleId IdType="pubmed">25295236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab 2014;16:30&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23803146</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon KH, Shin JA, Kwon HS, et al. . Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in Korean drug-naive type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. Diabetes Metab J 2011;35:26&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3080564</ArticleId><ArticleId IdType="pubmed">21537410</ArticleId></ArticleIdList></Reference><Reference><Citation>De Broe ME, Kajbaf F, Lalau JD. Renoprotective effects of metformin. Nephron 2018;138:261&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">29241197</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson SV, Tomlinson LA, Iwagami M, Stirnadel-Farrant HA, Smeeth L, Douglas I. A systematic review comparing the evidence for kidney function outcomes between oral antidiabetic drugs for type 2 diabetes. Wellcome Open Res 2018;3:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107985</ArticleId><ArticleId IdType="pubmed">30175243</ArticleId></ArticleIdList></Reference><Reference><Citation>Esaki H, Tachi T, Goto C, et al. . Renoprotective effect of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus. Front Pharmacol 2017;8:835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5694778</ArticleId><ArticleId IdType="pubmed">29187821</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodera R, Shikata K. Renoprotective effects of incretin-based drugs: a novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor. J Diabetes Investig 2016;7:29&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718108</ArticleId><ArticleId IdType="pubmed">26816598</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega C, Teixeira-de-Lemos E, Fernandes R, Reis F. Renoprotective effects of the dipeptidyl peptidase-4 inhibitor sitagliptin: a review in type 2 diabetes. J Diabetes Res 2017;2017:5164292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5643039</ArticleId><ArticleId IdType="pubmed">29098166</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolen S, Feldman L, Vassy J, et al. . Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">17638715</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceriello A. Glucose variability and diabetic complications: is it time to treat? Diabetes Care 2020;43:1169&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">32434893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Sun B, Huang S, Zhu C, Bian M. Glycemic variability: adverse clinical outcomes and how to improve it? Cardiovasc Diabetol 2020;19:102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7335439</ArticleId><ArticleId IdType="pubmed">32622354</ArticleId></ArticleIdList></Reference><Reference><Citation>Scirica BM, Bhatt DL, Braunwald E, et al. . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">23992601</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56:696&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">23344728</ArticleId></ArticleIdList></Reference><Reference><Citation>Foroutan N, Muratov S, Levine M. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review and meta-analysis. Clin Invest Med 2016;39:E48&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">27040861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35249830</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4733</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</Title><ISOAbbreviation>Value Health</ISOAbbreviation></Journal><ArticleTitle>The Value of Federated Data Networks in Oncology: What Research Questions Do They Answer? Outcomes From a Systematic Literature Review.</ArticleTitle><Pagination><StartPage>855</StartPage><EndPage>868</EndPage><MedlinePgn>855-868</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jval.2021.11.1357</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1098-3015(21)03188-0</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Real-world evidence (RWE) plays an important role in addressing key research questions of interest to healthcare decision makers. Federated data networks (FDNs) apply novel technology to enable the conduct of RWE studies with multiple partners, without the need to share the individual partner's data set. A systematic review of the published literature was performed to determine which types of research questions can best be addressed through FDNs, specifically in the field of oncology.</AbstractText><AbstractText Label="METHODS">Systematic searches of MEDLINE and Embase were undertaken to identify the types of research questions that had been addressed in studies using FDNs. Additional information was retrieved about study characteristics, statistical methods, and the FDN itself.</AbstractText><AbstractText Label="RESULTS">In total, 40 publications were included where research questions on the following had been addressed (multiple categories possible): disease natural history (58%), safety surveillance (18%), treatment pathways (15%), comparative effectiveness (10%), and cost/resource use studies (3%)-13% of studies had to be left uncategorized. A total of 50% of the studies were run with data partners in networks of &#x2264;5. The size of the networks ranged from 227 patients to &gt;5 million patients. Statistical methods used included distributed learning and distributed regression methods.</AbstractText><AbstractText Label="CONCLUSIONS">Further work is needed to raise awareness of the important role that FDNs can play in leveraging readily available RWE to address key research questions of interest in cancer and the benefits to the research community in engaging in federated data initiatives with a long-term perspective.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hunger</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ICON plc, Global Health Economics, Outcomes Research and Epidemiology, Dublin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bardenheuer</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica N.V., Belgium. Electronic address: kbardenh@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passey</LastName><ForeName>Alun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica N.V., Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schade</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ICON plc, Global Health Economics, Outcomes Research and Epidemiology, Dublin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Ruchika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ICON plc, Global Health Economics, Outcomes Research and Epidemiology, Dublin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hague</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica N.V., Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Value Health</MedlineTA><NlmUniqueID>100883818</NlmUniqueID><ISSNLinking>1098-3015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008495" MajorTopicYN="Y">Medical Oncology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">data analysis</Keyword><Keyword MajorTopicYN="N">evidence generation</Keyword><Keyword MajorTopicYN="N">federated data network</Keyword><Keyword MajorTopicYN="N">oncology</Keyword><Keyword MajorTopicYN="N">real-world evidence</Keyword><Keyword MajorTopicYN="N">systematic literature review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>7</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35249830</ArticleId><ArticleId IdType="doi">10.1016/j.jval.2021.11.1357</ArticleId><ArticleId IdType="pii">S1098-3015(21)03188-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35253022</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><JournalIssue CitedMedium="Print"><Volume>2020</Volume><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Proceedings : ... IEEE International Conference on Big Data. IEEE International Conference on Big Data</Title><ISOAbbreviation>Proc IEEE Int Conf Big Data</ISOAbbreviation></Journal><ArticleTitle>Leveraging Differential Privacy in Geospatial Analyses of Standardized Healthcare Data.</ArticleTitle><Pagination><StartPage>3119</StartPage><EndPage>3122</EndPage><MedlinePgn>3119-3122</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1109/bigdata50022.2020.9378390</ELocationID><Abstract><AbstractText>We present a collection of geodatabase functions which expedite utilizing differential privacy for privacy-aware geospatial analysis of healthcare data. The healthcare domain has a long history of standardization and research communities have developed open-source common data models to support the larger goals of interoperability, reproducibility, and data sharing; these models also standardize geospatial patient data. However, patient privacy laws and institutional regulations complicate geospatial analyses and dissemination of research findings due to protective restrictions in how data and results are shared. This results in infrastructures with great abilities to organize and store healthcare data, yet which lack the innate ability to produce shareable results that preserve privacy and conform to regulatory requirements. Differential privacy is a model for performing privacy-preserving analytics. We detail our process and findings in inserting an open-source library for differential privacy into a workflow for leveraging a geodatabase for geocoding and analyzing geospatial data stored as part of the Observational Medical Outcomes Partnership (OMOP) common data model. We pilot this process using an open big data repository of addresses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Center for Clinical and Translational Sciences, Institute for Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Kentucky, Lexington, KY USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001998</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc IEEE Int Conf Big Data</MedlineTA><NlmUniqueID>101649640</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">big data applications</Keyword><Keyword MajorTopicYN="N">data privacy</Keyword><Keyword MajorTopicYN="N">geographic information systems</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35253022</ArticleId><ArticleId IdType="mid">NIHMS1782925</ArticleId><ArticleId IdType="pmc">PMC8896738</ArticleId><ArticleId IdType="doi">10.1109/bigdata50022.2020.9378390</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scholten HJ and De Lepper M, &#x201c;The benefits of the application of geographical information systems in public and environmental health.&#x201d; World Health Statistics quarterly. Rapport Trimestriel de Statistiques Sanitaires Mondiales, vol. 44, no. 3, pp. 160&#x2013;170, 1991.</Citation><ArticleIdList><ArticleId IdType="pubmed">1949884</ArticleId></ArticleIdList></Reference><Reference><Citation>Kistemann T, Dangendorf F, and Schweikart J, &#x201c;New perspectives on the use of geographical information systems (gis) in environmental health sciences,&#x201d; International journal of hygiene and environmental health, vol. 205, no. 3, pp. 169&#x2013;181, 2002.</Citation><ArticleIdList><ArticleId IdType="pubmed">12040915</ArticleId></ArticleIdList></Reference><Reference><Citation>Nykiforuk CI and Flaman LM, &#x201c;Geographic information systems (gis) for health promotion and public health: a review,&#x201d; Health promotion practice, vol. 12, no. 1, pp. 63&#x2013;73, 2011.</Citation><ArticleIdList><ArticleId IdType="pubmed">19546198</ArticleId></ArticleIdList></Reference><Reference><Citation>Olaronke I and Oluwaseun O, &#x201c;Big data in healthcare: Prospects, challenges and resolutions,&#x201d; in 2016 Future Technologies Conference (FTC). IEEE, 2016, pp. 1152&#x2013;1157.</Citation></Reference><Reference><Citation>Rosenbloom S, Carroll R, Warner J, Matheny M, and Denny J, &#x201c;Representing knowledge consistently across health systems,&#x201d; Yearbook of medical informatics, vol. 26, no. 1, p. 139, 2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6239235</ArticleId><ArticleId IdType="pubmed">29063555</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, and Stang PE, &#x201c;Validation of a common data model for active safety surveillance research,&#x201d; Journal of the American Medical Informatics Association, vol. 19, no. 1, pp. 54&#x2013;60, 2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Qualls LG, Phillips TA, Hammill BG, Topping J, Louzao DM, Brown JS, Curtis LH, and Marsolo K, &#x201c;Evaluating foundational data quality in the national patient-centered clinical research network (pcornet&#xae;),&#x201d; eGEMs, vol. 6, no. 1, 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983028</ArticleId><ArticleId IdType="pubmed">29881761</ArticleId></ArticleIdList></Reference><Reference><Citation>Blatt AJ, &#x201c;Geospatial data mining and knowledge discovery,&#x201d; in Health, Science, and Place. Springer, 2015, pp. 77&#x2013;87.</Citation></Reference><Reference><Citation>Benitez K and Malin B, &#x201c;Evaluating re-identification risks with respect to the hipaa privacy rule,&#x201d; Journal of the American Medical Informatics Association, vol. 17, no. 2, pp. 169&#x2013;177, 2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000773</ArticleId><ArticleId IdType="pubmed">20190059</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandbergen PA, &#x201c;Ensuring confidentiality of geocoded health data: assessing geographic masking strategies for individual-level data,&#x201d; Advances in medicine, vol. 2014, 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4590956</ArticleId><ArticleId IdType="pubmed">26556417</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis A, Mills JW, Agustin L, and Cockburn M, &#x201c;Confidentiality risks in fine scale aggregations of health data,&#x201d; Computers, Environment and Urban Systems, vol. 35, no. 1, pp. 57&#x2013;64, 2011.</Citation></Reference><Reference><Citation>Kounadi O and Leitner M, &#x201c;Why does geoprivacy matter? the scientific publication of confidential data presented on maps,&#x201d; Journal of Empirical Research on Human Research Ethics, vol. 9, no. 4, pp. 34&#x2013;45, 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">25747295</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwork C, &#x201c;Differential privacy: A survey of results,&#x201d; in International conference on theory and applications of models of computation. Springer, 2008, pp. 1&#x2013;19.</Citation></Reference><Reference><Citation>Dwork C, McSherry F, Nissim K, and Smith A, &#x201c;Calibrating noise to sensitivity in private data analysis,&#x201d; in Theory of cryptography conference. Springer, 2006, pp. 265&#x2013;284.</Citation></Reference><Reference><Citation>Dankar FK and El Emam K, &#x201c;Practicing differential privacy in health care: A review.&#x201d; Trans. Data Priv, vol. 6, no. 1, pp. 35&#x2013;67, 2013.</Citation></Reference><Reference><Citation>Alnemari A, Romanowski CJ, and Raj RK, &#x201c;An adaptive differential privacy algorithm for range queries over healthcare data,&#x201d; in 2017 IEEE International Conference on Healthcare Informatics (ICHI). IEEE, 2017, pp. 397&#x2013;402.</Citation></Reference><Reference><Citation>Harris/dp-omop: using differential privacy with omop. Accessed
Oct. 1, 2020. [Online]. Available: https://bitbucket.org/_harris/dp-OMOP</Citation></Reference><Reference><Citation>Postgis: Spatial and geographic objects for postgresql. Accessed
Oct. 1, 2020. [Online]. Available: https://postgis.net</Citation></Reference><Reference><Citation>Postgresql: the world&#x2019;s most advanced open-source database. Accessed
Oct. 1, 2020. [Online]. Available: https://www.postgresql.org/</Citation></Reference><Reference><Citation>Sunderland N, Bristed H, Gudes O, Boddy J, and Da Silva M, &#x201c;What does it feel like to live here? exploring sensory ethnography as a collaborative methodology for investigating social determinants of health in place,&#x201d; Health &amp; Place, vol. 18, no. 5, pp. 1056&#x2013;1067, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22722015</ArticleId></ArticleIdList></Reference><Reference><Citation>google/differential-privacy: Google&#x2019;s differential privacy library. Accessed
Oct. 1, 2020. [Online]. Available: https://github.com/google/differential-privacy</Citation></Reference><Reference><Citation>Openaddresses: the free and open global address collection. Accessed
Oct. 1, 2020. [Online]. Available: http://openaddresses.io</Citation></Reference><Reference><Citation>Harris DR and Delcher C, &#x201c;bench4gis: Benchmarking privacy-aware geocoding with open big data,&#x201d; in 2019 IEEE International Conference on Big Data (Big Data). IEEE, 2019, pp. 4067&#x2013;4070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7076902</ArticleId><ArticleId IdType="pubmed">32185372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J and Clifton C, &#x201c;How much is enough? choosing &#x3b5; for differential privacy,&#x201d; in International Conference on Information Security. Springer, 2011, pp. 325&#x2013;340.</Citation></Reference><Reference><Citation>Garfinkel SL, Abowd JM, and Powazek S, &#x201c;Issues encountered deploying differential privacy,&#x201d; in Proceedings of the 2018 Workshop on Privacy in the Electronic Society, 2018, pp. 133&#x2013;137.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35275076</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Patient-Level Fall Risk Prediction Using the Observational Medical Outcomes Partnership's Common Data Model: Pilot Feasibility Study.</ArticleTitle><Pagination><StartPage>e35104</StartPage><MedlinePgn>e35104</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e35104</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/35104</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Falls in acute care settings threaten patients' safety. Researchers have been developing fall risk prediction models and exploring risk factors to provide evidence-based fall prevention practices; however, such efforts are hindered by insufficient samples, limited covariates, and a lack of standardized methodologies that aid study replication.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objectives of this study were to (1) convert fall-related electronic health record data into the standardized Observational Medical Outcome Partnership's (OMOP) common data model format and (2) develop models that predict fall risk during 2 time periods.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">As a pilot feasibility test, we converted fall-related electronic health record data (nursing notes, fall risk assessment sheet, patient acuity assessment sheet, and clinical observation sheet) into standardized OMOP common data model format using an extraction, transformation, and load process. We developed fall risk prediction models for 2 time periods (within 7 days of admission and during the entire hospital stay) using 2 algorithms (least absolute shrinkage and selection operator logistic regression and random forest).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 6277 nursing statements, 747,049,486 clinical observation sheet records, 1,554,775 fall risk scores, and 5,685,011 patient acuity scores were converted into OMOP common data model format. All our models (area under the receiver operating characteristic curve 0.692-0.726) performed better than the Hendrich II Fall Risk Model. Patient acuity score, fall history, age &#x2265;60 years, movement disorder, and central nervous system agents were the most important predictors in the logistic regression models.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">To enhance model performance further, we are currently converting all nursing records into the OMOP common data model data format, which will then be included in the models. Thus, in the near future, the performance of fall risk prediction models could be improved through the application of abundant nursing records and external validation.</AbstractText><CopyrightInformation>&#xa9;Hyesil Jung, Sooyoung Yoo, Seok Kim, Eunjeong Heo, Borham Kim, Ho-Young Lee, Hee Hwang. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 11.03.2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Hyesil</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-8346-9343</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8620-4925</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4996-8613</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Eunjeong</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9632-0188</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Borham</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-6914-5721</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ho-Young</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0001-6518-0602</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Hee</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7964-1630</Identifier><AffiliationInfo><Affiliation>Kakao Healthcare Company-In-Company, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">accidental falls</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">data model</Keyword><Keyword MajorTopicYN="N">electronic health record</Keyword><Keyword MajorTopicYN="N">fall risk</Keyword><Keyword MajorTopicYN="N">health data</Keyword><Keyword MajorTopicYN="N">medical informatics</Keyword><Keyword MajorTopicYN="N">nursing records</Keyword><Keyword MajorTopicYN="N">prediction model</Keyword><Keyword MajorTopicYN="N">risk prediction</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>12</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35275076</ArticleId><ArticleId IdType="pmc">PMC8957002</ArticleId><ArticleId IdType="doi">10.2196/35104</ArticleId><ArticleId IdType="pii">v10i3e35104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dykes PC, Burns Z, Adelman J, Benneyan J, Bogaisky M, Carter E, Ergai A, Lindros ME, Lipsitz SR, Scanlan M, Shaykevich S, Bates DW. Evaluation of a patient-centered fall-prevention tool kit to reduce falls and injuries: a nonrandomized controlled trial. JAMA Netw Open. 2020 Nov 02;3(11):e2025889. doi: 10.1001/jamanetworkopen.2020.25889. 
 
2773051</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.25889</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.25889</ArticleId><ArticleId IdType="pmc">PMC7672520</ArticleId><ArticleId IdType="pubmed">33201236</ArticleId></ArticleIdList></Reference><Reference><Citation>Florence CS, Bergen G, Atherly A, Burns E, Stevens J, Drake C. Medical costs of fatal and nonfatal falls in older adults. J Am Geriatr Soc. 2018 Apr;66(4):693&#x2013;698. doi: 10.1111/jgs.15304. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.15304</ArticleId><ArticleId IdType="pmc">PMC6089380</ArticleId><ArticleId IdType="pubmed">29512120</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrich AL, Bender PS, Nyhuis A. Validation of the Hendrich II Fall Risk Model: a large concurrent case/control study of hospitalized patients. Appl Nurs Res. 2003 Feb;16(1):9&#x2013;21. doi: 10.1053/apnr.2003.YAPNR2.S0897189702109025</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/apnr.2003.YAPNR2</ArticleId><ArticleId IdType="pubmed">12624858</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse JM, Morse RM, Tylko SJ. Development of a scale to identify the fall-prone patient. Can J Aging. 2010 Nov 29;8(4):366&#x2013;377. doi: 10.1017/s0714980800008576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s0714980800008576</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H, Park H, Hwang H. Improving prediction of fall risk using electronic health record data with various types and sources at multiple times. Comput Inform Nurs. 2020 Mar;38(3):157&#x2013;164. doi: 10.1097/CIN.0000000000000561.00024665-202003000-00007</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CIN.0000000000000561</ArticleId><ArticleId IdType="pubmed">31498252</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho I, Boo E, Chung E, Bates DW, Dykes P. Novel approach to inpatient fall risk prediction and its cross-site validation using time-variant data. J Med Internet Res. 2019 Feb 19;21(2):e11505. doi: 10.2196/11505. doi: 10.2196/11505.v21i2e11505</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/11505</ArticleId><ArticleId IdType="doi">10.2196/11505</ArticleId><ArticleId IdType="pmc">PMC6399571</ArticleId><ArticleId IdType="pubmed">30777849</ArticleId></ArticleIdList></Reference><Reference><Citation>Marier A, Olsho LEW, Rhodes W, Spector WD. Improving prediction of fall risk among nursing home residents using electronic medical records. J Am Med Inform Assoc. 2016 Mar;23(2):276&#x2013;82. doi: 10.1093/jamia/ocv061.ocv061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv061</ArticleId><ArticleId IdType="pmc">PMC7784312</ArticleId><ArticleId IdType="pubmed">26104743</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018 Aug 01;25(8):969&#x2013;975. doi: 10.1093/jamia/ocy032. 
 
4989437</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce RD, Handler SM, Karp JF, Perera S, Reynolds CF. Preparing nursing home data from multiple sites for clinical research - a case study using observational health data sciences and informatics. EGEMS (Wash DC) 2016;4(1):1252. doi: 10.13063/2327-9214.1252. 
 
egems1252</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1252</ArticleId><ArticleId IdType="pmc">PMC5108634</ArticleId><ArticleId IdType="pubmed">27891528</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Kostka K, Posada JD, Kim Y, Seo SI, Lee DY, Shah NH, Roh S, Lim Y, Chae SG, Jin U, Son SJ, Reich C, Rijnbeek PR, Park RW, You SC. Prediction of major depressive disorder following beta-blocker therapy in patients with cardiovascular diseases. J Pers Med. 2020 Dec 18;10(4):288. doi: 10.3390/jpm10040288. 
 
jpm10040288</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm10040288</ArticleId><ArticleId IdType="pmc">PMC7766565</ArticleId><ArticleId IdType="pubmed">33352870</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Reps JM, Kostka KF, Ryan PB, Zou Y, Voss EA, Rijnbeek PR, Chen R, Rao GA, Morgan Stewart H, Williams AE, Williams RD, Van Zandt M, Falconer T, Fernandez-Chas M, Vashisht R, Pfohl SR, Shah NH, Kasthurirathne SN, You SC, Jiang Q, Reich C, Zhou Y. Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network. PLoS One. 2020;15(1):e0226718. doi: 10.1371/journal.pone.0226718. 
 
PONE-D-19-25005</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0226718</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0226718</ArticleId><ArticleId IdType="pmc">PMC6946584</ArticleId><ArticleId IdType="pubmed">31910437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Kim S, Ryu B, Song W, Lee H, Yoo S. Transforming electronic health record polysomnographic data into the Observational Medical Outcome Partnership's common data model: a pilot feasibility study. Sci Rep. 2021 Mar 29;11(1):7013. doi: 10.1038/s41598-021-86564-w. doi: 10.1038/s41598-021-86564-w.10.1038/s41598-021-86564-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-86564-w</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-86564-w</ArticleId><ArticleId IdType="pmc">PMC8007756</ArticleId><ArticleId IdType="pubmed">33782494</ArticleId></ArticleIdList></Reference><Reference><Citation>The common data model. The Book of OHDSI. 2021. Jan 11,  [2022-03-02].  
 https://ohdsi.github.io/TheBookOfOhdsi/
</Citation></Reference><Reference><Citation>Jung H, Park H. Testing the predictive validity of the Hendrich II fall risk model. West J Nurs Res. 2018 Dec;40(12):1785&#x2013;1799. doi: 10.1177/0193945918766554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0193945918766554</ArticleId><ArticleId IdType="pubmed">29577823</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Jeong I, Jeon S. A comparative study on the predictive validity among pressure ulcer risk assessment scales. Taehan Kanho Hakhoe Chi. 2003 Apr;33(2):162&#x2013;9. doi: 10.4040/jkan.2003.33.2.162.200306162</Citation><ArticleIdList><ArticleId IdType="doi">10.4040/jkan.2003.33.2.162</ArticleId><ArticleId IdType="pubmed">15314444</ArticleId></ArticleIdList></Reference><Reference><Citation>John L, Kors J, Reps J, Ryan P, Rijnbeek P. How little data do we need for patient-level prediction? Arxiv.  doi: 10.48550/arXiv.2008.07361. Preprint posted online Aug 14, 2020.
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.2008.07361</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid S, Yang C, Blacketer C, Duarte-Salles T, Fern&#xe1;ndez-Bertol&#xed;n S, Kim C, Park RW, Park J, Schuemie MJ, Sena AG, Suchard MA, You SC, Rijnbeek PR, Reps JM. A standardized analytics pipeline for reliable and rapid development and validation of prediction models using observational health data. Comput Methods Programs Biomed. 2021 Nov;211:106394. doi: 10.1016/j.cmpb.2021.106394. 
 
S0169-2607(21)00468-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2021.106394</ArticleId><ArticleId IdType="pmc">PMC8420135</ArticleId><ArticleId IdType="pubmed">34560604</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota S, Ohe K. Construction and evaluation of FiND, a fall risk prediction model of inpatients from nursing data. Jpn J Nurs Sci. 2016 Apr;13(2):247&#x2013;55. doi: 10.1111/jjns.12103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jjns.12103</ArticleId><ArticleId IdType="pubmed">27040735</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H, Park H. Use of EHR Data to Identify Factors Affecting the Time to Fall. Stud Health Technol Inform. 2017;245:1043&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295260</ArticleId></ArticleIdList></Reference><Reference><Citation>Couronn&#xe9; R, Probst P, Boulesteix A. Random forest versus logistic regression: a large-scale benchmark experiment. BMC Bioinformatics. 2018 Jul 17;19(1):270. doi: 10.1186/s12859-018-2264-5. 
 
10.1186/s12859-018-2264-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-018-2264-5</ArticleId><ArticleId IdType="doi">10.1186/s12859-018-2264-5</ArticleId><ArticleId IdType="pmc">PMC6050737</ArticleId><ArticleId IdType="pubmed">30016950</ArticleId></ArticleIdList></Reference><Reference><Citation>Christodoulou E, Ma J, Collins GS, Steyerberg EW, Verbakel JY, Van Calster B. A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. J Clin Epidemiol. 2019 Jun;110:12&#x2013;22. doi: 10.1016/j.jclinepi.2019.02.004.S0895-4356(18)31081-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2019.02.004</ArticleId><ArticleId IdType="pubmed">30763612</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong H, Kim N, Jin Y, Piao J, Lee S. Trigger factors and outcomes of falls among korean hospitalized patients: analysis of electronic medical records. Clin Nurs Res. 2015 Feb;24(1):51&#x2013;72. doi: 10.1177/1054773814524225.1054773814524225</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1054773814524225</ArticleId><ArticleId IdType="pubmed">24615824</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver D, Daly F, Martin FC, McMurdo MET. Risk factors and risk assessment tools for falls in hospital in-patients: a systematic review. Age Ageing. 2004 Mar;33(2):122&#x2013;30. doi: 10.1093/ageing/afh017.33/2/122</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afh017</ArticleId><ArticleId IdType="pubmed">14960426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrose AF, Paul G, Hausdorff JM. Risk factors for falls among older adults: a review of the literature. Maturitas. 2013 May;75(1):51&#x2013;61. doi: 10.1016/j.maturitas.2013.02.009.S0378-5122(13)00054-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2013.02.009</ArticleId><ArticleId IdType="pubmed">23523272</ArticleId></ArticleIdList></Reference><Reference><Citation>Panel on Prevention of Falls in Older Persons&#x201a; American Geriatrics Society/British Geriatrics Society Summary of the updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. J Am Geriatr Soc. 2011 Jan;59(1):148&#x2013;57. doi: 10.1111/j.1532-5415.2010.03234.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2010.03234.x</ArticleId><ArticleId IdType="pubmed">21226685</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Commission on Safety and Quality in Healthcare  Preventing falls and harm from falls in older people: best practice guidelines for Australian hospitals. Australian Clinical Practice Guidelines.  [2022-03-02].  
 https://www.safetyandquality.gov.au/sites/default/files/migrated/Guidelines-HOSP.pdf
.</Citation></Reference><Reference><Citation>J&#xf8;rstad EC, Hauer K, Becker C, Lamb SE, ProFaNE Group Measuring the psychological outcomes of falling: a systematic review. J Am Geriatr Soc. 2005 Mar;53(3):501&#x2013;10. doi: 10.1111/j.1532-5415.2005.53172.x.JGS53172</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53172.x</ArticleId><ArticleId IdType="pubmed">15743297</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazibara T, Kurtagic I, Kisic-Tepavcevic D, Nurkovic S, Kovacevic N, Gazibara T, Pekmezovic T. Falls, risk factors and fear of falling among persons older than 65 years of age. Psychogeriatrics. 2017 Jul;17(4):215&#x2013;223. doi: 10.1111/psyg.12217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/psyg.12217</ArticleId><ArticleId IdType="pubmed">28130862</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreland JD, Richardson JA, Goldsmith CH, Clase CM. Muscle weakness and falls in older adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2004 Jul;52(7):1121&#x2013;9. doi: 10.1111/j.1532-5415.2004.52310.x.JGS52310</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2004.52310.x</ArticleId><ArticleId IdType="pubmed">15209650</ArticleId></ArticleIdList></Reference><Reference><Citation>Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc. 1999 Jan;47(1):30&#x2013;9. doi: 10.1111/j.1532-5415.1999.tb01898.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.1999.tb01898.x</ArticleId><ArticleId IdType="pubmed">9920227</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Pinto LN, Venable LR, Fahrenbach J, Churpek MM. Comparison of variable selection methods for clinical predictive modeling. Int J Med Inform. 2018 Aug;116:10&#x2013;17. doi: 10.1016/j.ijmedinf.2018.05.006. 
 
S1386-5056(18)30581-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2018.05.006</ArticleId><ArticleId IdType="pmc">PMC6003624</ArticleId><ArticleId IdType="pubmed">29887230</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012 Aug;45(4):689&#x2013;96. doi: 10.1016/j.jbi.2012.05.002. 
 
S1532-0464(12)00069-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.05.002</ArticleId><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35276502</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-5069</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Epilepsy &amp; behavior : E&amp;B</Title><ISOAbbreviation>Epilepsy Behav</ISOAbbreviation></Journal><ArticleTitle>Patient characteristics and antiseizure medication pathways in newly diagnosed epilepsy: Feasibility and pilot results using the common data model in a single-center electronic medical record database.</ArticleTitle><Pagination><StartPage>108630</StartPage><MedlinePgn>108630</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yebeh.2022.108630</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1525-5050(22)00079-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Efforts to characterize variability in epilepsy treatment pathways are limited by the large number of possible antiseizure medication (ASM) regimens and sequences, heterogeneity of patients, and challenges of measuring confounding variables and outcomes across institutions. The Observational Health Data Science and Informatics (OHDSI) collaborative is an international data network representing over 1 billion patient records using common data standards. However, few studies have applied OHDSI's Common Data Model (CDM) to the population with epilepsy and none have validated relevant concepts. The goals of this study were to demonstrate the feasibility of characterizing adult patients with epilepsy and ASM treatment pathways using the CDM in an electronic health record (EHR)-derived database.</AbstractText><AbstractText Label="METHODS">We validated a phenotype algorithm for epilepsy in adults using the CDM in an EHR-derived database (2001-2020) against source records and a prospectively maintained database of patients with confirmed epilepsy. We obtained the frequency of all antecedent conditions and procedures for patients meeting the epilepsy phenotype criteria and characterized ASM exposure sequences over time and by age and sex.</AbstractText><AbstractText Label="RESULTS">The phenotype algorithm identified epilepsy with 73.0-85.0% positive predictive value and 86.3% sensitivity. Many patients had neurologic conditions and diagnoses antecedent to meeting epilepsy criteria. Levetiracetam incrementally replaced phenytoin as the most common first-line agent, but significant heterogeneity remained, particularly in second-line and subsequent agents. Drug sequences included up to 8 unique ingredients and a total of 1,235 unique pathways were observed.</AbstractText><AbstractText Label="CONCLUSIONS">Despite the availability of additional ASMs in the last 2 decades and accumulated guidelines and evidence, ASM use varies significantly in practice, particularly for second-line and subsequent agents. Multi-center OHDSI studies have the potential to better characterize the full extent of variability and support observational comparative effectiveness research, but additional work is needed to validate covariates and outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castano</LastName><ForeName>Victor G</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Columbia University Irving Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldman</LastName><ForeName>Genna J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Irving Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argenziano</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Columbia University Irving Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ottman</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Irving Medical Center, United States; The Gertrude H. Sergievsky Center, Columbia University Vagelos College of Physicians and Surgeons, United States; Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, United States; Division of Translational Epidemiology, New York State Psychiatric Institute, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Hyunmi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Irving Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youngerman</LastName><ForeName>Brett E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Columbia University Irving Medical Center, United States. Electronic address: bey2103@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 TR001874</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epilepsy Behav</MedlineTA><NlmUniqueID>100892858</NlmUniqueID><ISSNLinking>1525-5050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>44YRR34555</RegistryNumber><NameOfSubstance UI="D000077287">Levetiracetam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="Y">Epilepsy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077287" MajorTopicYN="N">Levetiracetam</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiseizure medication</Keyword><Keyword MajorTopicYN="N">Epilepsy</Keyword><Keyword MajorTopicYN="N">Observational Health Data Science and Informatics (OHDSI)</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership (OMOP)</Keyword><Keyword MajorTopicYN="N">Practice patterns</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>20</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35276502</ArticleId><ArticleId IdType="doi">10.1016/j.yebeh.2022.108630</ArticleId><ArticleId IdType="pii">S1525-5050(22)00079-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35292697</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM.</ArticleTitle><Pagination><StartPage>4451</StartPage><MedlinePgn>4451</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4451</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-08595-1</ELocationID><Abstract><AbstractText>Anti-dementia medications are widely prescribed to patients with Alzheimer's dementia (AD) in South Korea. This study investigated the pattern of medical management in newly diagnosed patients with AD using a standardized data format-the Observational Medical Outcome Partnership Common Data Model from five hospitals. We examined the anti-dementia treatment patterns from datasets that comprise&#x2009;&gt;&#x2009;5 million patients during 2009-2019. The medication utility information was analyzed with respect to treatment trends and persistence across 11&#xa0;years. Among the 8653 patients with newly diagnosed AD, donepezil was the most commonly prescribed anti-dementia medication (4218; 48.75%), followed by memantine (1565; 18.09%), rivastigmine (1777; 8.98%), and galantamine (494; 5.71%). The rising prescription trend during observation period was found only with donepezil. The treatment pathways for the three cholinesterase inhibitors combined with N-methyl-D-aspartate receptor antagonist were different according to the drugs (19.6%; donepezil; 28.1%; rivastigmine, and 17.2%; galantamine). A 12-month persistence analysis showed values of approximately 50% for donepezil and memantine and approximately 40% for rivastigmine and galantamine. There were differences in the prescribing pattern and persistence among anti-dementia medications from database using the Observational Medical Outcome Partnership Common Data Model on the Federated E-health Big Data for Evidence Renovation Network platform in Korea.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Byun</LastName><ForeName>JungHyun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Healthcare Bigdata Section, Health research office, Radiation health institution, Korea Hydro &amp; Nuclear Power Co, Ltd, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Yun</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Chang-Won</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Medical Convergence Research Center, Wonkwang University, Iksan, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Smart Business Team in Information Management Office, Wonkwang University Hospital, Iksan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yerim</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Hak Young</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyung Hee University Hospital at Gangdong, College of Medicine Kyung Hee University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Ki Won</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Jeongwon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Yoonki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Woo Jin</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Seung-Joo</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Hoon Sung</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Ji In</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>In Kook</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bak</LastName><ForeName>So Hyeon</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyoungyul</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byeon</LastName><ForeName>Gi Hwan</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kyoung Lae</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Opthalmology, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jeong-Ah</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Opthalmology, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Young Joo</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Opthalmology, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jeong Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun Ju</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Environmental Health Center, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang-Ah</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Sung Ok</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Department of Medical Bigdata Convergence, Kangwon National University, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sang-Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Medical Bigdata Convergence, Kangwon National University, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasani</LastName><ForeName>Payam Hosseinzadeh</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Medical Bigdata Convergence, Kangwon National University, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jung-Kyeom</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Medical Bigdata Convergence, Kangwon National University, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yeshin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seongheon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kangwon National University Hospital, Chuncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Jae-Won</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Kangwon National University School of Medicine, Chuncheon, Korea. light26@kangwon.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Bigdata Convergence, Kangwon National University, Chuncheon, Korea. light26@kangwon.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kangwon National University Hospital, Chuncheon, Korea. light26@kangwon.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="Y">Galantamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>16</Day><Hour>5</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35292697</ArticleId><ArticleId IdType="pmc">PMC8924152</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-08595-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-08595-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matthews KA, et al. Racial and ethnic estimates of Alzheimer&#x2019;s disease and related dementias in the United States (2015&#x2013;2060) in adults aged &#x2265;65 years. Alzheimers Dement. 2019;15:17&#x2013;24. doi: 10.1016/j.jalz.2018.06.3063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.06.3063</ArticleId><ArticleId IdType="pmc">PMC6333531</ArticleId><ArticleId IdType="pubmed">30243772</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince, M., Guerchet, M. &amp; Prina, M. World Alzheimer Report 2015, The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. World Health Organ.87, 6&#x2013;8 (2015).</Citation></Reference><Reference><Citation>Prince M, et al. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement. 2013;9:63&#x2013;75.e2. doi: 10.1016/j.jalz.2012.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.11.007</ArticleId><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri CP, et al. Global prevalence of dementia: A Delphi consensus study. Lancet. 2005;366:2112&#x2013;2117. doi: 10.1016/S0140-6736(05)67889-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)67889-0</ArticleId><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for observational researchers. Stud. Health Technol. Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, et al. Evaluation of electronic healthcare databases for post-marketing drug safety surveillance and pharmacoepidemiology in China. Drug Saf. 2018;41:125&#x2013;137. doi: 10.1007/s40264-017-0589-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-017-0589-z</ArticleId><ArticleId IdType="pubmed">28815480</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J. Am. Med. Inform. Assoc. JAMIA. 2012;19:54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, et al. Conversion and data quality assessment of electronic health record data at a Korean Tertiary Teaching Hospital to a common data model for distributed network research. Healthc. Inform. Res. 2016;22:54&#x2013;58. doi: 10.4258/hir.2016.22.1.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2016.22.1.54</ArticleId><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the premier perspective hospital database into the observational medical outcomes partnership (OMOP) common data model. EGEMS Wash. DC. 2014;2:1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J. Am. Med. Inform. Assoc. JAMIA. 2015;22:553&#x2013;564. doi: 10.1093/jamia/ocu023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, et al. Conversion of National Health Insurance Service-National Sample Cohort (NHIS-NSC) Database into observational medical outcomes partnership-common data model (OMOP-CDM) Stud. Health Technol. Inform. 2017;245:467&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornet R, de Keizer N. Forty years of SNOMED: A literature review. BMC Med. Inform. Decis. Mak. 2008;8(Suppl 1):S2. doi: 10.1186/1472-6947-8-S1-S2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-8-S1-S2</ArticleId><ArticleId IdType="pmc">PMC2582789</ArticleId><ArticleId IdType="pubmed">19007439</ArticleId></ArticleIdList></Reference><Reference><Citation>ICD - ICD-9-CM&#x2014;International Classification of Diseases, Ninth Revision, Clinical Modification. https://www.cdc.gov/nchs/icd/icd9cm.htm (2019). (Accessed on 26 June 2021).
</Citation></Reference><Reference><Citation>Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J. Am. Med. Inform. Assoc. JAMIA. 2011;18:441&#x2013;448. doi: 10.1136/amiajnl-2011-000116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000116</ArticleId><ArticleId IdType="pmc">PMC3128404</ArticleId><ArticleId IdType="pubmed">21515544</ArticleId></ArticleIdList></Reference><Reference><Citation>WHOCC&#x2014;Structure and principles. https://www.whocc.no/atc/structure_and_principles/. (Accessed on 26 June 2021).</Citation></Reference><Reference><Citation>Drug Database &amp; Clinical Decision Support Software | Multilex. FDB (First Databank)https://www.fdbhealth.co.uk/solutions/multilex-clinical-decision-support. (Accessed on 26 June 2021).</Citation></Reference><Reference><Citation>Caetano PA, Lam JMC, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization. Clin. Ther. 2006;28:1411&#x2013;1424. doi: 10.1016/j.clinthera.2006.09.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2006.09.021</ArticleId><ArticleId IdType="pubmed">17062314</ArticleId></ArticleIdList></Reference><Reference><Citation>Umegaki H, Itoh A, Suzuki Y, Nabeshima T. Discontinuation of donepezil for the treatment of Alzheimer&#x2019;s disease in geriatric practice. Int. Psychogeriatr. 2008;20:800&#x2013;806. doi: 10.1017/S1041610208007011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610208007011</ArticleId><ArticleId IdType="pubmed">18341753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn S-H, et al. Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea. Arch. Pharm. Res. 2015;38:1255&#x2013;1262. doi: 10.1007/s12272-014-0500-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-014-0500-8</ArticleId><ArticleId IdType="pubmed">25336105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H-J, Roughead EE, Han E, Lee J, Kalisch Ellett L. Post-market utilization patterns of Alzheimer&#x2019;s disease treatments in South Korea: Comparison with countries with universal health coverage. Eur. J. Clin. Pharmacol. 2021;77:921&#x2013;929. doi: 10.1007/s00228-020-03065-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-020-03065-x</ArticleId><ArticleId IdType="pubmed">33409682</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang J-W, et al. Prevalence and incidence of dementia in South Korea: A nationwide analysis of the national health insurance service senior cohort. J. Clin. Neurol. 2021;17:249. doi: 10.3988/jcn.2021.17.2.249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2021.17.2.249</ArticleId><ArticleId IdType="pmc">PMC8053535</ArticleId><ArticleId IdType="pubmed">33835746</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DW, Seong SJ. Korean national dementia plans: From 1st to 3rd. J. Korean Med. Assoc. 2018;61:298&#x2013;303. doi: 10.5124/jkma.2018.61.5.298.</Citation><ArticleIdList><ArticleId IdType="doi">10.5124/jkma.2018.61.5.298</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M-S. Preparation and measures for elderly with dementia in Korea: Focus on national strategies and action plan against dementia. J. Agric. Med. Community Health. 2019;44:11&#x2013;27.</Citation></Reference><Reference><Citation>HIRA. Health Insurance Review and Assessment Service (HIRA) (2021) Pharmaceutical Reimbursement and Price List. https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014050000. (Accessed on 26 June 2021).</Citation></Reference><Reference><Citation>Ngo J, Holroyd-Leduc JM. Systematic review of recent dementia practice guidelines. Age Ageing. 2015;44:25&#x2013;33. doi: 10.1093/ageing/afu143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afu143</ArticleId><ArticleId IdType="pubmed">25341676</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomasang-Layno E, Bronsther R. Diagnosis and treatment of Alzheimer&#x2019;s disease: An update. Del. J. Public Health. 2021;7:74&#x2013;85. doi: 10.32481/djph.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.32481/djph.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8482985</ArticleId><ArticleId IdType="pubmed">34604768</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks, J. &amp; Harvey, R. J. Donepezil for dementia due to Alzheimer&#x2019;s disease. In Cochrane Database of Systematic Reviews (ed. The Cochrane Collaboration) (Wiley, 2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16437430</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen RA, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer&#x2019;s disease: A systematic review and meta-analysis. Clin. Interv. Aging. 2008;3:211&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546466</ArticleId><ArticleId IdType="pubmed">18686744</ArticleId></ArticleIdList></Reference><Reference><Citation>Hort J, et al. EFNS guidelines for the diagnosis and management of Alzheimer&#x2019;s disease: EFNS guidelines for Alzheimer&#x2019;s disease. Eur. J. Neurol. 2010;17:1236&#x2013;1248. doi: 10.1111/j.1468-1331.2010.03040.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2010.03040.x</ArticleId><ArticleId IdType="pubmed">20831773</ArticleId></ArticleIdList></Reference><Reference><Citation>Oken BS, Smith Doody R. Practice parameter: Management of dementia (an evidence-based review) Neurology. 2001;57:2323&#x2013;2323. doi: 10.1212/WNL.57.12.2323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.12.2323</ArticleId><ArticleId IdType="pubmed">11756625</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, et al. Memantine in moderate-to-severe Alzheimer&#x2019;s disease. N. Engl. J. Med. 2003;348:1333&#x2013;1341. doi: 10.1056/NEJMoa013128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa013128</ArticleId><ArticleId IdType="pubmed">12672860</ArticleId></ArticleIdList></Reference><Reference><Citation>McShane R, et al. Memantine for dementia. Cochrane Database Syst. Rev. 2019;3:CD003154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425228</ArticleId><ArticleId IdType="pubmed">30891742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishi T, Matsunaga S, Iwata N. The effects of memantine on behavioral disturbances in patients with Alzheimer&#x2019;s disease: A meta-analysis. Neuropsychiatr. Dis. Treat. 2017;13:1909&#x2013;1928. doi: 10.2147/NDT.S142839.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S142839</ArticleId><ArticleId IdType="pmc">PMC5530072</ArticleId><ArticleId IdType="pubmed">28790827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc. Natl. Acad. Sci. 2016;113:7329&#x2013;7336. doi: 10.1073/pnas.1510502113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. Analysis of treatment pathways for three chronic diseases using OMOP CDM. J. Med. Syst. 2018;42:260. doi: 10.1007/s10916-018-1076-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10916-018-1076-5</ArticleId><ArticleId IdType="pmc">PMC6244882</ArticleId><ArticleId IdType="pubmed">30421323</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A, Carney G, Bassett K, Chappell NL. Cholinesterase inhibitor utilization: The impact of provincial drug policy on discontinuation. Value Health. 2016;19:688&#x2013;696. doi: 10.1016/j.jval.2016.03.1832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2016.03.1832</ArticleId><ArticleId IdType="pubmed">27565287</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A, Carney G, Bassett K, Dormuth CR. Tolerability of cholinesterase inhibitors: A population-based study of persistence, adherence, and switching. Drugs Aging. 2017;34:221&#x2013;231. doi: 10.1007/s40266-017-0438-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40266-017-0438-x</ArticleId><ArticleId IdType="pubmed">28138912</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Silvente L, et al. Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer&#x2019;s disease: A meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients. Int. J. Neuropsychopharmacol. 2017;20:519&#x2013;528. doi: 10.1093/ijnp/pyx012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyx012</ArticleId><ArticleId IdType="pmc">PMC5492783</ArticleId><ArticleId IdType="pubmed">28201726</ArticleId></ArticleIdList></Reference><Reference><Citation>Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract. Suppl. 2002;127:45&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139367</ArticleId></ArticleIdList></Reference><Reference><Citation>Park KH, et al. Discontinuation rate of newly prescribed donepezil in Alzheimer&#x2019;s disease patients in Asia. J. Clin. Neurol. 2021;17:376&#x2013;384. doi: 10.3988/jcn.2021.17.3.376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2021.17.3.376</ArticleId><ArticleId IdType="pmc">PMC8242303</ArticleId><ArticleId IdType="pubmed">34184445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemssen T, Hillert J, Butzkueven H. The importance of collecting structured clinical information on multiple sclerosis. BMC Med. 2016;14:81. doi: 10.1186/s12916-016-0627-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-016-0627-1</ArticleId><ArticleId IdType="pmc">PMC4888646</ArticleId><ArticleId IdType="pubmed">27246898</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer L, Bennett K, McGreevy C, Williams D. A population-based study of dosing and persistence with anti-dementia medications. Eur. J. Clin. Pharmacol. 2013;69:1467&#x2013;1475. doi: 10.1007/s00228-013-1483-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-013-1483-y</ArticleId><ArticleId IdType="pubmed">23443628</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadzhanova S, Roughead L, Mackson J. Anticholinesterase duration in the Australian veteran population. Aust. N. Z. J. Psychiatry. 2010;44:469&#x2013;474. doi: 10.3109/00048670903555104.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00048670903555104</ArticleId><ArticleId IdType="pubmed">20397790</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardette V, et al. A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer&#x2019;s disease in Europe. CNS Drugs. 2014 doi: 10.1007/s40263-013-0133-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-013-0133-3</ArticleId><ArticleId IdType="pubmed">24408842</ArticleId></ArticleIdList></Reference><Reference><Citation>Taipale H, et al. Antidementia drug use among community-dwelling individuals with Alzheimer&#x2019;s disease in Finland: A nationwide register-based study. Int. Clin. Psychopharmacol. 2014;29:216&#x2013;223. doi: 10.1097/YIC.0000000000000032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YIC.0000000000000032</ArticleId><ArticleId IdType="pmc">PMC4047310</ArticleId><ArticleId IdType="pubmed">24608822</ArticleId></ArticleIdList></Reference><Reference><Citation>Abughosh SM, Kogut SJ. Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program. Patient Prefer. Adherence. 2008;2:79&#x2013;85. doi: 10.2147/PPA.S2652.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PPA.S2652</ArticleId><ArticleId IdType="pmc">PMC2770391</ArticleId><ArticleId IdType="pubmed">19920947</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheol Seong S, et al. Data resource profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int. J. Epidemiol. 2017;46:799&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837262</ArticleId><ArticleId IdType="pubmed">27794523</ArticleId></ArticleIdList></Reference><Reference><Citation>NHISS. National Health Insurance Bigdata. https://nhiss.nhis.or.kr/bd/ab/bdaba021eng.do. (Accessed on 26 June 2021).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35297548</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-1004</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Human mutation</Title><ISOAbbreviation>Hum Mutat</ISOAbbreviation></Journal><ArticleTitle>Beacon v2 and Beacon networks: A "lingua franca" for federated data discovery in biomedical genomics, and beyond.</ArticleTitle><Pagination><StartPage>791</StartPage><EndPage>799</EndPage><MedlinePgn>791-799</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/humu.24369</ELocationID><Abstract><AbstractText>Beacon is a basic data discovery protocol issued by the Global Alliance for Genomics and Health (GA4GH). The main goal addressed by version 1 of the Beacon protocol was to test the feasibility of broadly sharing human genomic data, through providing simple "yes" or "no" responses to queries about the presence of a given variant in datasets hosted by Beacon providers. The popularity of this concept has fostered the design of a version 2, that better serves real-world requirements and addresses the needs of clinical genomics research and healthcare, as assessed by several contributing projects and organizations. Particularly, rare disease genetics and cancer research will benefit from new case level and genomic variant level requests and the enabling of richer phenotype and clinical queries as well as support for fuzzy searches. Beacon is designed as a "lingua franca" to bridge data collections hosted in software solutions with different and rich interfaces. Beacon version 2 works alongside popular standards like Phenopackets, OMOP, or FHIR, allowing implementing consortia to return matches in beacon responses and provide a handover to their preferred data exchange format. The protocol is being explored by other research domains and is being tested in several international projects.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Human Mutation published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rambla</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9091-257X</Identifier><AffiliationInfo><Affiliation>Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), PRBB, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baudis</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9903-4248</Identifier><AffiliationInfo><Affiliation>Department of Molecular Life Sciences, University of Zurich and Swiss Institute of Bioinformatics, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ariosa</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8348-2524</Identifier><AffiliationInfo><Affiliation>Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetics &amp; Genome Biology, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fromont</LastName><ForeName>Lauren A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Arcadi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2162-8246</Identifier><AffiliationInfo><Affiliation>Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental and Health Sciences, IBE, Institute of Evolutionary Biology (UPF-CSIC), Universitat Pompeu Fabra. PRBB, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituci&#xf3; Catalana de Recerca i Estudis Avan&#xe7;ats (ICREA), Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona Beta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paloots</LastName><ForeName>Rahel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1239-1689</Identifier><AffiliationInfo><Affiliation>Department of Molecular Life Sciences, University of Zurich and Swiss Institute of Bioinformatics, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rueda</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9280-058X</Identifier><AffiliationInfo><Affiliation>Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>Gary</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-7468-0008</Identifier><AffiliationInfo><Affiliation>European Infrastructure for Translational Medicine, EATRIS, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Babita</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-7989-9084</Identifier><AffiliationInfo><Affiliation>Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spalding</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>ELIXIR Finland; CSC - IT Center for Science Ltd, Espoo, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xf6;rnroos</LastName><ForeName>Juha</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9216-0455</Identifier><AffiliationInfo><Affiliation>ELIXIR Finland; CSC - IT Center for Science Ltd, Espoo, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasallo</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0043-0882</Identifier><AffiliationInfo><Affiliation>Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veal</LastName><ForeName>Colin D</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0002-9840-2512</Identifier><AffiliationInfo><Affiliation>Department of Genetics &amp; Genome Biology, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brookes</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0001-8686-0017</Identifier><AffiliationInfo><Affiliation>Department of Genetics &amp; Genome Biology, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_18031</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_19024</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S003703/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Mutat</MedlineTA><NlmUniqueID>9215429</NlmUniqueID><ISSNLinking>1059-7794</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="Y">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="Y">Information Dissemination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035583" MajorTopicYN="N">Rare Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Beacon</Keyword><Keyword MajorTopicYN="N">GA4GH</Keyword><Keyword MajorTopicYN="N">REST API</Keyword><Keyword MajorTopicYN="N">clinical genomics</Keyword><Keyword MajorTopicYN="N">data discovery</Keyword><Keyword MajorTopicYN="N">data sharing</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>17</Day><Hour>8</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35297548</ArticleId><ArticleId IdType="pmc">PMC9322265</ArticleId><ArticleId IdType="doi">10.1002/humu.24369</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ayaz, M. , Pasha, M. F. , Alzahrani, M. Y. , Budiarto, R. , &amp; Stiawan, D. (2021). The fast health interoperability resources (FHIR) standard: Systematic literature review of implementations, applications, challenges and opportunities. JMIR Medical Informatics, 9(7), e21929. 10.2196/21929</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/21929</ArticleId><ArticleId IdType="pmc">PMC8367140</ArticleId><ArticleId IdType="pubmed">34328424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernier, A. , Liu, H. , &amp; Knoppers, B. M. (2022). Computational tools for genomic data de&#x2010;identification: Facilitating data protection law compliance. Nature Communications, 13, 391. 10.1038/s41467-021-27890-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27890-5</ArticleId><ArticleId IdType="pmc">PMC8758730</ArticleId><ArticleId IdType="pubmed">35027557</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosca, D. , Moner, D. , Maldonado, J. A. , &amp; Robles, M. (2015). Combining archetypes with fast health interoperability resources in future&#x2010;proof health information systems. Studies in Health Technology and Informatics, 210, 180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">25991126</ArticleId></ArticleIdList></Reference><Reference><Citation>Cezard, T. , Cunningham, F. , Hunt, S. E. , Koylass, B. , Kumar, N. , Saunders, G. , Shen, A. , Silva, A. F. , Tsukanov, K. , Venkataraman, S. , Flicek, P. , Parkinson, H. , &amp; Keane, T. M. (2022). The European Variation Archive: A FAIR resource of genomic variation for all species. Nucleic Acids Research, 50, gkab960. 10.1093/nar/gkab960</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab960</ArticleId><ArticleId IdType="pmc">PMC8728205</ArticleId><ArticleId IdType="pubmed">34718739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cline, M. S. , Liao, R. G. , Parsons, M. T. , Paten, B. , Alquaddoomi, F. , Antoniou, A. , Baxter, S. , Brody, L. , Cook&#x2010;Deegan, R. , Coffin, A. , Couch, F. J. , Craft, B. , Currie, R. , Dlott, C. C. , Dolman, L. , den Dunnen, J. T. , Dyke, S. , Domchek, S. M. , Easton, D. , &#x2026; Spurdle, A. B. (2018). BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 14, e1007752. 10.1371/journal.pgen.1007752</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007752</ArticleId><ArticleId IdType="pmc">PMC6324924</ArticleId><ArticleId IdType="pubmed">30586411</ArticleId></ArticleIdList></Reference><Reference><Citation>
ELIXIR
. (2021). ELIXIR Beacon 2019&#x2013;21 Deliverable
D3.3. https://docs.google.com/document/d/1q7XuUB-Z4A_DogWT1AVrvkp_qHWWtbbICxokHup_tts/edit
</Citation></Reference><Reference><Citation>
European Commission
. (2021). 1+ Million genomes. Shaping Europe's digital future. https://digital-strategy.ec.europa.eu/en/policies/1-million-genomes
</Citation></Reference><Reference><Citation>
European Parliament and Council
. (2016). General Data Protection Regulations (GDPR): Regulation (EU) 2016/679; Article 5. https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32016R0679%26from=EN#d1e1807-1-1
</Citation></Reference><Reference><Citation>Fiume, M. , Cupak, M. , Keenan, S. , Rambla, J. , de la Torre, S. , Dyke, S. , Brookes, A. J. , Carey, K. , Lloyd, D. , Goodhand, P. , Haeussler, M. , Baudis, M. , Stockinger, H. , Dolman, L. , Lappalainen, I. , T&#xf6;rnroos, J. , Linden, M. , Spalding, J. D. , Ur&#x2010;Rehman, S. , &#x2026; Scollen, S. (2019). Federated discovery and sharing of genomic data using Beacons. Nature Biotechnology, 37(3), 220&#x2013;224. 10.1038/s41587-019-0046-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0046-x</ArticleId><ArticleId IdType="pmc">PMC6728157</ArticleId><ArticleId IdType="pubmed">30833764</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeberg, M. A. , Fromont, L. A. , D'altri, T. , Romero, A. F. , Ciges, J. I. , Jene, A. , Kerry, G. , Moldes, M. , Ariosa, R. , Bahena, S. , Barrowdale, D. , Barbero, M. C. , Fernandez&#x2010;Orth, D. , Garcia&#x2010;Linares, C. , Garcia&#x2010;Rios, E. , Haziza, F. , Juhasz, B. , Llobet, O. M. , Milla, G. , &#x2026; Rambla, J. (2022). The European Genome&#x2010;phenome Archive in 2021. Nucleic Acids Research, 50, gkab1059. 10.1093/nar/gkab1059</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab1059</ArticleId><ArticleId IdType="pmc">PMC8728218</ArticleId><ArticleId IdType="pubmed">34791407</ArticleId></ArticleIdList></Reference><Reference><Citation>

Fromont, L. A.
 (2021). Beacon cohorts: A model for cohort discovery in CINECA and beyond&#x2014;CINECA&#x2014;Common Infrastructure for National Cohorts in Europe, Canada, and Africa. CINECA. https://www.cineca-project.eu/blog-all/beacon-cohorts-a-model-for-cohort-discovery-in-cineca-and-beyond
</Citation></Reference><Reference><Citation>Harrison, P. W. , Ahamed, A. , Aslam, R. , Alako, B. T. F. , Burgin, J. , Buso, N. , Courtot, M. , Fan, J. , Gupta, D. , Haseeb, M. , Holt, S. , Ibrahim, T. , Ivanov, E. , Jayathilaka, S. , Balavenkataraman Kadhirvelu, V. , Kumar, M. , Lopez, R. , Kay, S. , Leinonen, R. , &#x2026; Cochrane, G. (2021). The European Nucleotide Archive in 2020. Nucleic Acids Research, 49(D1), D82&#x2013;D85. 10.1093/nar/gkaa1028</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa1028</ArticleId><ArticleId IdType="pmc">PMC7778925</ArticleId><ArticleId IdType="pubmed">33175160</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak, G. , Duke, J. D. , Shah, N. H. , Reich, C. G. , Huser, V. , Schuemie, M. J. , &amp; Ryan, P. B. (2015). Observational health data sciences and informatics (OHDSI): Opportunities for observational researchers. Studies in Health Technology and Informatics, 216, 574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, Q. , Carrio&#x2010;Cordo, P. , Gao, B. , Paloots, R. , &amp; Baudis, M. (2021). The Progenetix oncogenomic resource in 2021. Database: The Journal of Biological Databases and Curation, 2021, baab043. 10.1093/database/baab043</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/database/baab043</ArticleId><ArticleId IdType="pmc">PMC8285936</ArticleId><ArticleId IdType="pubmed">34272855</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen, J. O. B. , Baudis, M. , Baynam, G. S. , Beckmann, J. S. , Beltran, S. , Callahan, T. J. , Chute, C. G. , Courtot, M. , Danis, D. , Elemento, O. , Freimuth, R. R. , Gargano, M. A. , Groza, T. , Hamosh, A. , Harris, N. L. , Kaliyaperumal, R. , Khalifa, A. , Krawitz, P. M. , K&#xf6;hler, S. , &#x2026; Robinson, P. N. (2021). The GA4GH Phenopacket schema: A computable representation of clinical data for precision medicine. medRxiv, 11(27), 21266944. 10.1101/2021.11.27.21266944</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.27.21266944</ArticleId><ArticleId IdType="pubmed">35705716</ArticleId></ArticleIdList></Reference><Reference><Citation>Koepfli, K. P. , Paten, B. , Genome 10K Community of Scientists O'Brien, S. J . (2015). The Genome 10K Project: A way forward. Annual Review of Animal Biosciences, 3, 57&#x2013;111. 10.1146/annurev-animal-090414-014900</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-animal-090414-014900</ArticleId><ArticleId IdType="pmc">PMC5837290</ArticleId><ArticleId IdType="pubmed">25689317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster, O. , Beck, T. , Atlan, D. , Swertz, M. , Thangavelu, D. , Veal, C. , Dalgleish, R. , &amp; Brookes, A. J. (2015). Cafe Variome: General&#x2010;purpose software for making genotype&#x2010;phenotype data discoverable in restricted or open access contexts. Human Mutation, 36(10), 957&#x2013;964. 10.1002/humu.22841</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22841</ArticleId><ArticleId IdType="pubmed">26224250</ArticleId></ArticleIdList></Reference><Reference><Citation>Matalonga, L. , Hern&#xe1;ndez&#x2010;Ferrer, C. , Piscia, D. , Solve&#x2010;RD SNV&#x2010;indel working, g , Sch&#xfc;le, R. , Synofzik, M. , T&#xf6;pf, A. , Vissers, L. , de Voer, R. , Solve&#x2010;Rd, D. , Solve&#x2010;Rd, D. , Solve&#x2010;Rd, D. , Solve&#x2010;Rd, D. , Tonda, R. , Laurie, S. , Fernandez&#x2010;Callejo, M. , Pic&#xf3;, D. , Garcia&#x2010;Linares, C. , Papakonstantinou, A. , &#x2026; Solve&#x2010;RD, C. (2021). Solving patients with rare diseases through programmatic reanalysis of genome&#x2010;phenome data. European Journal of Human Genetics, 29(9), 1337&#x2013;1347. 10.1038/s41431-021-00852-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-021-00852-7</ArticleId><ArticleId IdType="pmc">PMC8440686</ArticleId><ArticleId IdType="pubmed">34075210</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder, N. , Abimiku, A. , Adebamowo, S. N. , de Vries, J. , Matimba, A. , Olowoyo, P. , Ramsay, M. , Skelton, M. , &amp; Stein, D. J. (2018). H3Africa: Current perspectives. Pharmacogenomics and Personalized Medicine, 11, 59&#x2013;66. 10.2147/PGPM.S141546</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PGPM.S141546</ArticleId><ArticleId IdType="pmc">PMC5903476</ArticleId><ArticleId IdType="pubmed">29692621</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippakis, A. A. , Azzariti, D. R. , Beltran, S. , Brookes, A. J. , Brownstein, C. A. , Brudno, M. , Brunner, H. G. , Buske, O. J. , Carey, K. , Doll, C. , Dumitriu, S. , Dyke, S. O. , den Dunnen, J. T. , Firth, H. V. , Gibbs, R. A. , Girdea, M. , Gonzalez, M. , Haendel, M. A. , Hamosh, A. , &#x2026; Rehm, H. L. (2015). The Matchmaker Exchange: A platform for rare disease gene discovery. Human Mutation, 36(10), 915&#x2013;921. 10.1002/humu.22858</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22858</ArticleId><ArticleId IdType="pmc">PMC4610002</ArticleId><ArticleId IdType="pubmed">26295439</ArticleId></ArticleIdList></Reference><Reference><Citation>Pi&#xf1;ero, J. , Ram&#xed;rez&#x2010;Anguita, J. M. , Sa&#xfc;ch&#x2010;Pitarch, J. , Ronzano, F. , Centeno, E. , Sanz, F. , &amp; Furlong, L. I. (2020). The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Research, 48(D1), D845&#x2013;D855. 10.1093/nar/gkz1021</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1021</ArticleId><ArticleId IdType="pmc">PMC7145631</ArticleId><ArticleId IdType="pubmed">31680165</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehm, H. L. , Page, A. J. H. , Smith, L. , Adams, J. B. , Alterovitz, G. , Babb, L. J. , Barkley, M. P. , Baudis, M. , Beauvais, M. , Beck, T. , Beckmann, J. S. , Beltran, S. , Bernick, D. , Bernier, A. , Bonfield, J. K. , Boughtwood, T. F. , Bourque, G. , Bowers, S. R. , Brookes, A. J. , &#x2026; Rodarmer, K. W. (2021a). CanDIG: Federated network across Canada for multi&#x2010;omic and health data discovery and analysis. Cell Genomics, 1(2),&#xa0;100033.&#xa0;10.1016/j.xgen.2021.100033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xgen.2021.100033</ArticleId><ArticleId IdType="pmc">PMC8774288</ArticleId><ArticleId IdType="pubmed">35072136</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehm, H. L. , Page, A. J. H. , Smith, L. , Adams, J. B. , Alterovitz, G. , Babb, L. J. , Barkley, M. P. , Baudis, M. , Beauvais, M. J. S. , Beck, T. , Beckmann, J. S. , Beltran, S. , Bernick, D. , Bernier, A. , Bonfield, J. K. , Boughtwood, T. F. , Bourque, G. , Bowers, S. R. , Brookes, A. J. , &#x2026; Rodarmer, K. W. (2021b). GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell Genomics, 1(2), 100029. 10.1016/j.xgen.2021.100029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xgen.2021.100029</ArticleId><ArticleId IdType="pmc">PMC8774288</ArticleId><ArticleId IdType="pubmed">35072136</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinstein, Y. R. , Robinson, P. N. , Gahl, W. A. , Avillach, P. , Baynam, G. , Cederroth, H. , Goodwin, R. M. , Groft, S. C. , Hansson, M. G. , Harris, N. L. , Huser, V. , Mascalzoni, D. , McMurry, J. A. , Might, M. , Nellaker, C. , Mons, B. , Paltoo, D. N. , Pevsner, J. , Posada, M. , &#x2026; Haendel, M. A. (2020). The case for open science: Rare diseases. JAMIA Open, 3(3), 472&#x2013;486. 10.1093/jamiaopen/ooaa030</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooaa030</ArticleId><ArticleId IdType="pmc">PMC7660964</ArticleId><ArticleId IdType="pubmed">33426479</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson, R. , Johnston, L. , Taruscio, D. , Monaco, L. , B&#xe9;roud, C. , Gut, I. G. , Hansson, M. G. , t Hoen, P.&#x2010;B. A. , Patrinos, G. P. , Dawkins, H. , Ensini, M. , Zatloukal, K. , Koubi, D. , Heslop, E. , Paschall, J. E. , Posada, M. , Robinson, P. N. , Bushby, K. , &amp; Lochm&#xfc;ller, H. (2014). RD&#x2010;Connect: An integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. Journal of General Internal Medicine, 29, 780&#x2013;787. 10.1007/s11606-014-2908-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-014-2908-8</ArticleId><ArticleId IdType="pmc">PMC4124112</ArticleId><ArticleId IdType="pubmed">25029978</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner, A. H. , Babb, L. , Alterovitz, G. , Baudis, M. , Brush, M. , Cameron, D. L. , Cline, M. , Griffith, M. , Griffith, O. L. , Hunt, S. E. , Kreda, D. , Lee, J. M. , Li, S. , Lopez, J. , Moyer, E. , Nelson, T. , Patel, R. Y. , Riehle, K. , Robinson, P. N. , &#x2026; Hart, R. K. (2021). The GA4GH Variation Representation Specification: A computational framework for variation representation and federated identification. Cell Genomics, 1(2), 100027. 10.1016/j.xgen.2021.100027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xgen.2021.100027</ArticleId><ArticleId IdType="pmc">PMC8929418</ArticleId><ArticleId IdType="pubmed">35311178</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoch, M. , Gierschner, C. , Peng, Y. , Gruhl, M. , Leutner, L. A. , Sedlmayr, M. , &amp; Bathelt, F. (2021). Adaption of the OMOP CDM for rare diseases. Studies in Health Technology and Informatics, 281, 138&#x2013;142. 10.3233/SHTI210136</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210136</ArticleId><ArticleId IdType="pubmed">34042721</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurek, B. , Ellwanger, K. , Vissers, L. E. L. M. , Sch&#xfc;le, R. , Synofzik, M. , T&#xf6;pf, A. , de Voer, R. M. , Laurie, S. , Matalonga, L. , Gilissen, C. , Ossowski, S. , 't Hoen, P. , Vitobello, A. , Schulze&#x2010;Hentrich, J. M. , Riess, O. , Brunner, H. G. , Brookes, A. J. , Rath, A. , Bonne, G. , &#x2026; Solve&#x2010;RD, c (2021). Solve&#x2010;RD: Systematic pan&#x2010;European data sharing and collaborative analysis to solve rare diseases. European Journal of Human Genetics, 29, 1325&#x2013;1331. 10.1038/s41431-021-00859-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-021-00859-0</ArticleId><ArticleId IdType="pmc">PMC8440542</ArticleId><ArticleId IdType="pubmed">34075208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35308947</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-597X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2021</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>AMIA ... Annual Symposium proceedings. AMIA Symposium</Title><ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation></Journal><ArticleTitle>Extracting Patient-level Social Determinants of Health into the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>989</StartPage><EndPage>998</EndPage><MedlinePgn>989-998</MedlinePgn></Pagination><Abstract><AbstractText>Deficiencies in data sharing capabilities limit Social Determinants of Health (SDoH) analysis as part of COVID-19 research. The National COVID Cohort Collaborative (N3C) is an example of an Electronic Health Record (EHR) database of patients tested for COVID-19 that could benefit from a SDoH elements framework that captures various screening instruments in EHR data warehouse systems. This paper uses the University of Washington Enterprise Data Warehouse (a data contributor to N3C) to demonstrate how SDoH can be represented and managed to be made available within an OMOP common data model. We found that these data varied by type of social determinants data and where it was collected, in the time period that it was collected, and in how it was represented.</AbstractText><CopyrightInformation>&#xa9;2021 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phuong</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Biomedical and Health Informatics, UW Medicine, Seattle, Washington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Washington Medicine Research IT, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zampino</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Biomedical and Health Informatics, UW Medicine, Seattle, Washington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Washington Medicine Research IT, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobbins</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Biomedical and Health Informatics, UW Medicine, Seattle, Washington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Washington Medicine Research IT, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinoza</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeker</LastName><ForeName>Daniella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spratt</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Preventative Medicine and Population Health, University of Texas Medical Branch, Galveston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madlock-Brown</LastName><ForeName>Charisse</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dept of Health Informatics and Information Management, University of Tennessee Health Science Center, Memphis, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiskopf</LastName><ForeName>Nicole G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics and Clinical Epidemiology, OHSU, Portland, Oregon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilcox</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Biomedical and Health Informatics, UW Medicine, Seattle, Washington.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Annu Symp Proc</MedlineTA><NlmUniqueID>101209213</NlmUniqueID><ISSNLinking>1559-4076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064890" MajorTopicYN="Y">Social Determinants of Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>21</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35308947</ArticleId><ArticleId IdType="pmc">PMC8861735</ArticleId><ArticleId IdType="pii">3577690</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rollston R, Galea S. COVID-19 and the Social Determinants of Health. Am J Health Promot [Internet] 2020 [cited 2021 Jun 6];34:687&#x2013;9. Available at:  http://journals.sagepub.com/doi/10.1177/0890117120930536b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0890117120930536b</ArticleId><ArticleId IdType="pubmed">32551932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez IJ, Lee J. COVID-19 Emergence and Social and Health Determinants in Colorado: A Rapid Spatial Analysis. International Journal of Environmental Research and Public Health [Internet] 2020[cited 2020 Nov 9];17:3856. doi: 10.3390/ijerph17113856. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17113856</ArticleId><ArticleId IdType="pmc">PMC7312929</ArticleId><ArticleId IdType="pubmed">32485854</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Gersing K. The National COVID Cohort Collaborative (N3C): Rationale, Design, Infrastructure, and Deployment. Journal of the American Medical Informatics Association [Internet] 2020. [cited 2020 Nov 9]; Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa196</ArticleId><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al.  The National COVID Cohort Collaborative: Clinical Characterization and Early Severity Prediction [Internet] Health Informatics. 2021.  Jan [cited 2021 Jul 6]. Available at:  http://medrxiv.org/lookup/doi/10.1101/2021.01.12.21249511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.12.21249511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatef E, Rouhizadeh M, Tia I, Lasser E, Hill-Briggs F, Marsteller J, et al.  Assessing the Availability of Data on Social and Behavioral Determinants in Structured and Unstructured Electronic Health Records: A Retrospective Analysis of a Multilevel Health Care System. JMIR Med Inform [Internet] 2019[cited 2021 Feb 18];7:e13802. Available at:  http://medinform.jmir.org/2019/3/e13802/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6696855</ArticleId><ArticleId IdType="pubmed">31376277</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong HP, Luke AA, Hammond G, Wadhera RK, Reidhead M, Joynt Maddox KE. Utilization of Social Determinants of Health ICD-10 Z-Codes Among Hospitalized Patients in the United States, 2016-2017. Medical Care [Internet] 2020 [cited 2021 Feb 18];58:1037&#x2013;43. Available at:  https://journals.lww.com/10.1097/MLR.0000000000001418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000001418</ArticleId><ArticleId IdType="pmc">PMC7666017</ArticleId><ArticleId IdType="pubmed">32925453</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscrop A, Ziebland S, Bloch G, Iraola JR. If social determinants of health are so important, shouldn&#x2019;t we ask patients about them? BMJ [Internet] 2020.  [cited 2021 Feb 18];m4150. Available at:  https://www.bmj.com/lookup/doi/10.1136/bmj.m4150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4150</ArticleId><ArticleId IdType="pubmed">33234506</ArticleId></ArticleIdList></Reference><Reference><Citation>Giroir BP. Healthy People 2030: A Call to Action to Lead America to Healthier Lives. Journal of Public Health Management and Practice [Internet] 2020.  [cited 2021 Jun 6];Publish Ahead of Print. Available at:  https://journals.lww.com/10.1097/PHH.0000000000001266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHH.0000000000001266</ArticleId><ArticleId IdType="pmc">PMC8478292</ArticleId><ArticleId IdType="pubmed">33278185</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuels&#x2010;Kalow ME, Ciccolo GE, Lin MP, Schoenfeld EM, Camargo CA. The terminology of social emergency medicine: Measuring social determinants of health, social risk, and social need. Journal of the American College of Emergency Physicians Open [Internet] 2020 [cited 2021 Feb 18];1:852&#x2013;6. Available at:  https://onlinelibrary.wiley.com/doi/10.1002/emp2.12191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emp2.12191</ArticleId><ArticleId IdType="pmc">PMC7593464</ArticleId><ArticleId IdType="pubmed">33145531</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorr D, Bejan CA, Pizzimenti C, Singh S, Storer M, Quinones A. Identifying Patients with Significant Problems Related to Social Determinants of Health with Natural Language Processing. 264:1456&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438179</ArticleId></ArticleIdList></Reference><Reference><Citation>Lybarger K, Ostendorf M, Yetisgen M. Annotating Social Determinants of Health Using Active Learning, and Characterizing Determinants Using Neural Event Extraction.  Available at:  https://arxiv.org/abs/2004.05438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7856628</ArticleId><ArticleId IdType="pubmed">33290878</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng A, Wilcox A. A Simplified Framework to Extract Social Determinants: A Data Science Approach. Submitted for publication.</Citation></Reference><Reference><Citation>Winden TJ, Chen ES, Monsen KA, Melton GB. Evaluation of Flowsheet Documentation in the Electronic Health Record for Residence, Living Situation, and Living Conditions. 2018:236&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961798</ArticleId><ArticleId IdType="pubmed">29888079</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold R, Bunce A, Cowburn S, Dambrun K, Dearing M, Middendorf M, et al.  Adoption of Social Determinants of Health EHR Tools by Community Health Centers. Ann Fam Med [Internet] 2018 [cited 2021 Feb 18];16:399&#x2013;407. Available at:  http://www.annfammed.org/lookup/doi/10.1370/afm.2275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1370/afm.2275</ArticleId><ArticleId IdType="pmc">PMC6131002</ArticleId><ArticleId IdType="pubmed">30201636</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottrell EK, Dambrun K, Cowburn S, Mossman N, Bunce AE, Marino M, et al.  Variation in Electronic Health Record Documentation of Social Determinants of Health Across a National Network of Community Health Centers. American Journal of Preventive Medicine [Internet] 2019.  [cited 2020 Dec 17];57:S65-73. Available at:  https://linkinghub.elsevier.com/retrieve/pii/S0749379719303228.</Citation><ArticleIdList><ArticleId IdType="pubmed">31753281</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Boynton-Jarrett R, Dworkin PH. Avoiding the Unintended Consequences of Screening for Social Determinants of Health. JAMA [Internet] 2016.  [cited 2021 Jul 6];316:813. Available at:  http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.9282.</Citation><ArticleIdList><ArticleId IdType="pubmed">27367226</ArticleId></ArticleIdList></Reference><Reference><Citation>Page-Reeves J, Kaufman W, Bleecker M, Norris J, McCalmont K, Ianakieva V, et al.  Addressing Social Determinants of Health in a Clinic Setting: The WellRx Pilot in Albuquerque, New Mexico. The Journal of the American Board of Family Medicine [Internet] 2016 [cited 2021 Jul 6];29:414&#x2013;8. Available at:  http://www.jabfm.org/cgi/doi/10.3122/jabfm.2016.03.150272.</Citation><ArticleIdList><ArticleId IdType="doi">10.3122/jabfm.2016.03.150272</ArticleId><ArticleId IdType="pubmed">27170801</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb L. Uses and Misuses of Patient-and Neighborhood-level Social Determinants of Health Data. The Permanente Journal [Internet] 2018 [cited 2020 Dec 17]. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.7812/TPP/18-078</ArticleId><ArticleId IdType="pmc">PMC6141653</ArticleId><ArticleId IdType="pubmed">30227912</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrikson NB, Blasi PR, Dorsey CN, Mettert KD, Nguyen MB, Walsh-Bailey C, et al. Psychometric and Pragmatic Properties of Social Risk Screening Tools: A Systematic Review. American Journal of Preventive Medicine [Internet] 2019 [cited 2020 Dec 17];57:S13&#x2013;24. doi: 10.1016/j.amepre.2019.07.012. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amepre.2019.07.012</ArticleId><ArticleId IdType="pubmed">31753276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold R, Bunce A, Cottrell E, Marino M, Middendorf M, Cowburn S, et al. Study protocol: a pragmatic, stepped-wedge trial of tailored support for implementing social determinants of health documentation/action in community health centers, with realist evaluation. Implementation Science. 2019. [cited 2020 Dec 17];14. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13012-019-0855-9</ArticleId><ArticleId IdType="pmc">PMC6348649</ArticleId><ArticleId IdType="pubmed">30691480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kindig DA. A Population Health Framework for Setting National and State Health Goals. JAMA [Internet] 2008 [cited 2019 Dec 20];299:2081.</Citation><ArticleIdList><ArticleId IdType="pubmed">18460667</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharrazi H, Gamache R, Weiner J.  Cham: Springer International Publishing; 2020 [cited 2020 Nov 9]. Role of Informatics in Bridging Public and Population Health. In: Magnuson JA, Dixon BE, editors. Public Health Informatics and Information Systems [Internet] pp. 59&#x2013;79. (Health Informatics). Available at:  http://link.springer.com/10.1007/978-3-030-41215-9_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-41215-9_5</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HN, Lan KF, Nkyekyer E, Neme S, Pierre-Louis M, Chew L, et al. Assessment of Disparities in COVID-19 Testing and Infection Across Language Groups in Seattle, Washington. JAMA Network Open [Internet] 2020 [cited 2020 Oct 2];3:1&#x2013;4. doi: 10.1001/jamanetworkopen.2020.21213. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.21213</ArticleId><ArticleId IdType="pmc">PMC7516622</ArticleId><ArticleId IdType="pubmed">32970156</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt-Groh&#xe9; S, Teoh K, Uribe M.  Cambridge, MA: National Bureau of Economic Research; 2020. Covid-19: Testing Inequality in New York City [Internet] Apr [cited 2020 Nov 9]. Report No.: w27019. Available at:  http://www.nber.org/papers/w27019.</Citation></Reference><Reference><Citation>Seto E, Min E, Ingram C, Cummings B, Farquhar SA. Community-Level Factors Associated with COVID-19 Cases and Testing Equity in King County, Washington. International Journal of Environmental Research and Public Health [Internet] 2020.  [cited 2021 Jan 6];17:9516. Available at:  https://www.mdpi.com/1660-4601/17/24/9516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767300</ArticleId><ArticleId IdType="pubmed">33353095</ArticleId></ArticleIdList></Reference><Reference><Citation>McClung N, Chamberland M, Kinlaw K, Matthew DB, Wallace M, Bell B, et al.  The Advisory Committee on Immunization Practices&#x2019; Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine &#x2014; United States, 2020 [Internet] U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. 2012 Oct [cited 2021 Jan 21].  (Morbidity and Mortality Weekly Report). Available at:  https://www.cdc.gov/niosh/docs/2012-161/</Citation></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association [Internet] 2015 [cited 2020 May 28];22:553&#x2013;64. doi: 10.1093/jamia/ocu023. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Recalde M, Roel E, Pistillo A, Sena AG, Prats-Uribe A, Ahmed W-U-R, et al.  Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom [Internet] Epidemiology. 2020 Sep [cited 2021 Jul 6].  Available at:  http://medrxiv.org/lookup/doi/10.1101/2020.09.02.20185173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.02.20185173</ArticleId><ArticleId IdType="pmc">PMC8281807</ArticleId><ArticleId IdType="pubmed">34267326</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-Alhambra D, Kostka K, Duarte-Salles T, Prats-Uribe A, Sena A, Pistillo A, et al.  Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS [Internet]. In Review; 2021 Mar [cited 2021 Jul 6]  Available at:  https://www.researchsquare.com/article/rs-279400/v1.</Citation></Reference><Reference><Citation>Burn E, You SC, Sena A, Kostka K, Abedtash H, Abrahao MTF, et al.  Deep phenotyping of 34,128 patients hospitalised with COVID-19 and a comparison with 81,596 influenza patients in America, Europe and Asia: an international network study. 2020.  [cited 2020 Nov 9]; Available at:  http://medrxiv.org/lookup/doi/10.1101/2020.04.22.20074336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.22.20074336</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>UCSF Social Interventions Research &amp; Evaluation Network (SIREN) [Internet] Social Needs Screening Tool Comparison Table [Internet] 2020.  [cited 2021 Mar 10]. Available at:  https://sirenetwork.ucsf.edu/SocialNeedsScreeningToolComparisonTable.</Citation></Reference><Reference><Citation>OHDSI ATHENA standardized vocabularies [Internet]. [cited 2021 Jul 2]  Available at:  https://athena.ohdsi.org/</Citation></Reference><Reference><Citation>2018 Census Occupation Code List with Crosswalk. US Census Bureau. 2019.  [cited 2020 Aug 3]. Available at:  https://www2.census.gov/programs-surveys/demo/guidance/industry-occupation/2018-occupation-code-list-and-crosswalk.xlsx.</Citation></Reference><Reference><Citation>Espinoza J, Meeker D, Bahroos N. Social and Environmental Determinants of Health (SEDoH) in Clinical Informatics. Presented at: CD2H Informatics Maturity And Best Practices Community Meeting; 2020 May 21.</Citation></Reference><Reference><Citation>Thornton RLJ, Glover CM, Cen&#xe9; CW, Glik DC, Henderson JA, Williams DR. Evaluating Strategies For Reducing Health Disparities By Addressing The Social Determinants Of Health. Health Affairs [Internet] 2016 [cited 2021 Jul 6];35:1416&#x2013;23. Available at:  http://www.healthaffairs.org/doi/10.1377/hlthaff.2015.1357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2015.1357</ArticleId><ArticleId IdType="pmc">PMC5524193</ArticleId><ArticleId IdType="pubmed">27503966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lofters AK, Schuler A, Slater M, Baxter NN, Persaud N, Pinto AD, et al.  Using self-reported data on the social determinants of health in primary care to identify cancer screening disparities: opportunities and challenges. BMC Fam Pract [Internet] 2017.  [cited 2021 Jul 6];18:31. Available at:  http://bmcfampract.biomedcentral.com/articles/10.1186/s12875-017-0599-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12875-017-0599-z</ArticleId><ArticleId IdType="pmc">PMC5330155</ArticleId><ArticleId IdType="pubmed">28241787</ArticleId></ArticleIdList></Reference><Reference><Citation>Higginbotham K, Crutcher TD, Karp SM. Screening for Social Determinants of Health at Well-Child Appointments: A Quality Improvement Project. Nursing Clinics of North America [Internet] 2019;54:141&#x2013;8. doi: 10.1016/j.cnur.2018.10.009. Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cnur.2018.10.009</ArticleId><ArticleId IdType="pubmed">30712540</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Toy S, Tripodis Y, Silverstein M, Freeman E. Addressing Social Determinants of Health at Well Child Care Visits: A Cluster RCT. PEDIATRICS [Internet] 2015.  [cited 2021 Jul 6];135:e296-304. Available at:  http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2014-2888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2014-2888</ArticleId><ArticleId IdType="pmc">PMC4306802</ArticleId><ArticleId IdType="pubmed">25560448</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35313835</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>21</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Gender differences in outpatients with dementia from a large psychiatric hospital in China.</ArticleTitle><Pagination><StartPage>208</StartPage><MedlinePgn>208</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">208</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12888-022-03852-z</ELocationID><Abstract><AbstractText Label="BACKGROUND">The sociodemographic characteristics and clinical features of dementia patients in psychiatric hospitals have not been thoroughly studied in China. This study aimed to explore the psychiatric outpatient attendance of dementia patients at a psychiatric hospital in China, with particular emphasis on gender differences.</AbstractText><AbstractText Label="METHODS">This retrospective study examined outpatients with dementia from January 2013 to August 2019 using data in the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) in Beijing Anding Hospital. Age, sex, number of visits, use of drugs and comorbid conditions were extracted from medical records.</AbstractText><AbstractText Label="RESULTS">Nine thousand four patients were recruited from a specific outpatient clinic of a hospital in Beijing, and the mean number of visits was 6.92. There were 3,433 (38.13%) male patients and 5,571 (61.87%) female patients. The most common comorbidities were generalized anxiety disorder, nonorganic insomnia, delusional disorder and depressive disorder. The proportion of patients using antidementia was the highest, with the rate of 68.3%, followed by benzodiazepines (48.83%), antipsychotics (45.43%), antidepressants (22.24%) and nonbenzodiazepines (19.96%). Patients with dementia showed a significant gender difference in average age (t&#x2009;=&#x2009;6.36, P&#x2009;&lt;&#x2009;0.0001). Compared to male patients, female patients had a higher number of visits (7.40&#x2009;&#xb1;&#x2009;12.90 vs 6.15&#x2009;&#xb1;&#x2009;10.50, t&#x2009;=&#x2009;4.81, P&#x2009;&lt;&#x2009;0.0001). There were significant differences in comorbidity composition between male and female patients (t&#x2009;=&#x2009;23.09, P&#x2009;&lt;&#x2009;0.0001).</AbstractText><AbstractText Label="CONCLUSIONS">Our present findings suggested significant gender differences in the proportion of age, number of visits and comorbidity composition in outpatients with dementia.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Jiaojiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital &amp; the Advanced Innovation Center for Human Brain Protection, Capital Medical University, No. 5 Ankang Hutong, Xicheng District, Beijing, 100035, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Guo</LastName><ForeName>Chengwei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital &amp; the Advanced Innovation Center for Human Brain Protection, Capital Medical University, No. 5 Ankang Hutong, Xicheng District, Beijing, 100035, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital &amp; the Advanced Innovation Center for Human Brain Protection, Capital Medical University, No. 5 Ankang Hutong, Xicheng District, Beijing, 100035, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Dandi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital &amp; the Advanced Innovation Center for Human Brain Protection, Capital Medical University, No. 5 Ankang Hutong, Xicheng District, Beijing, 100035, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhen</LastName><ForeName>Wenfeng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital &amp; the Advanced Innovation Center for Human Brain Protection, Capital Medical University, No. 5 Ankang Hutong, Xicheng District, Beijing, 100035, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Saina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital &amp; the Advanced Innovation Center for Human Brain Protection, Capital Medical University, No. 5 Ankang Hutong, Xicheng District, Beijing, 100035, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qing'e</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The National Clinical Research Center for Mental Disorders &amp; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital &amp; the Advanced Innovation Center for Human Brain Protection, Capital Medical University, No. 5 Ankang Hutong, Xicheng District, Beijing, 100035, China. zqe81@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="N">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="Y">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age</Keyword><Keyword MajorTopicYN="N">Comorbidity</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Gender</Keyword><Keyword MajorTopicYN="N">Number of visits</Keyword><Keyword MajorTopicYN="N">Outpatient</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35313835</ArticleId><ArticleId IdType="pmc">PMC8935692</ArticleId><ArticleId IdType="doi">10.1186/s12888-022-03852-z</ArticleId><ArticleId IdType="pii">10.1186/s12888-022-03852-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Silva MVF, Loures CDMG, Alves LCV, Souza LCD, Carvalho MDG. Alzheimer's disease: Risk factors and potentially protective measures. J Biomed Sci. 2019;26:33. doi: 10.1186/s12929-019-0524-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0524-y</ArticleId><ArticleId IdType="pmc">PMC6507104</ArticleId><ArticleId IdType="pubmed">31072403</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth H, LaFerla F. Alzheimer's disease. N Engl J Med. 2010;362:329&#x2013;344. doi: 10.1056/NEJMra0909142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0909142</ArticleId><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord. 2003;17:63&#x2013;67. doi: 10.1097/00002093-200304000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-200304000-00002</ArticleId><ArticleId IdType="pubmed">12794381</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6:211&#x2013;224. doi: 10.1016/S2215-0366(18)30511-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(18)30511-X</ArticleId><ArticleId IdType="pubmed">30792114</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018;14:483&#x2013;491. doi: 10.1016/j.jalz.2017.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.12.006</ArticleId><ArticleId IdType="pubmed">29433981</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Wu F, Guo Y, Gutierrez Robledo L, O'Donnell M, Sullivan R, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385:549&#x2013;562. doi: 10.1016/S0140-6736(14)61347-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61347-7</ArticleId><ArticleId IdType="pubmed">25468153</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Wang J, Wimo A, Fratiglioni L, Qiu C. The economic burden of dementia in China, 1990&#x2013;2030: implications for health policy. Bull World Health Organ. 2017;95:18&#x2013;26. doi: 10.2471/BLT.15.167726.</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.15.167726</ArticleId><ArticleId IdType="pmc">PMC5180346</ArticleId><ArticleId IdType="pubmed">28053361</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse R, DuBeau C. Update in geriatric medicine: evidence published in 2014. Ann Intern Med. 2015;162:W102&#x2013;105. doi: 10.7326/M15-0298.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M15-0298</ArticleId><ArticleId IdType="pubmed">25927564</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadstock M, Ballard C, Corbett A. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Expert Opin Pharmacother. 2014;15:1797&#x2013;1810. doi: 10.1517/14656566.2014.936848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2014.936848</ArticleId><ArticleId IdType="pubmed">24992196</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzkopf L, Menn P, Leidl R, Wunder S, Mehlig H, Marx P, et al. Excess costs of dementia disorders and the role of age and gender-an analysis of German health and long-term care insurance claims data. BMC Health Serv Res. 2012;12:165. doi: 10.1186/1472-6963-12-165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6963-12-165</ArticleId><ArticleId IdType="pmc">PMC3425320</ArticleId><ArticleId IdType="pubmed">22713212</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2016 Dementia Collaborators Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88&#x2013;106. doi: 10.1016/S1474-4422(18)30403-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30403-4</ArticleId><ArticleId IdType="pmc">PMC6291454</ArticleId><ArticleId IdType="pubmed">30497964</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia L, Quan M, Fu Y, Zhao T, Li Y, Wei C, et al. Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol. 2020;19:81&#x2013;92. doi: 10.1016/S1474-4422(19)30290-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30290-X</ArticleId><ArticleId IdType="pubmed">31494009</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson F, Baxter A, Cheng H, Shidhaye R, Whiteford H. The burden of mental, neurological, and substance use disorders in China and India: a systematic analysis of community representative epidemiological studies. Lancet. 2016;388:376&#x2013;389. doi: 10.1016/S0140-6736(16)30590-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)30590-6</ArticleId><ArticleId IdType="pubmed">27209143</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30:421&#x2013;442. doi: 10.1016/j.cger.2014.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cger.2014.04.001</ArticleId><ArticleId IdType="pmc">PMC4104432</ArticleId><ArticleId IdType="pubmed">25037289</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K, Wang W, Wu J, Liu L, Theodoratou E, Car J, et al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990&#x2013;2010: a systematic review and analysis. Lancet. 2013;381:2016&#x2013;2023. doi: 10.1016/S0140-6736(13)60221-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)60221-4</ArticleId><ArticleId IdType="pubmed">23746902</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;vheim H, Sandman P, Karlsson S, Gustafson Y. Sex differences in the prevalence of behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2009;21:469&#x2013;475. doi: 10.1017/S1041610209008497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610209008497</ArticleId><ArticleId IdType="pubmed">19243654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson P, Izmeth Z. Continuation and maintenance treatments for depression in older people. Cochrane Database Syst Rev. 2012;11:CD006727. doi: 10.1002/14651858.CD006727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD006727</ArticleId><ArticleId IdType="pubmed">23152240</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Kelly L, Lewisholmes E, Baio G, Morris S, Patel N, et al. A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technol Assess. 2014;18:1&#x2013;226. doi: 10.3310/hta18390.</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/hta18390</ArticleId><ArticleId IdType="pmc">PMC4781145</ArticleId><ArticleId IdType="pubmed">24947468</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson M, Sandman P, Karlsson S, Gustafson Y, L&#xf6;vheim H. Association between behavioral and psychological symptoms and psychotropic drug use among old people with cognitive impairment living in geriatric care settings. Int Psychogeriatr. 2013;25:1415&#x2013;1423. doi: 10.1017/S1041610213000859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610213000859</ArticleId><ArticleId IdType="pubmed">23782794</ArticleId></ArticleIdList></Reference><Reference><Citation>Taipale H, Koponen M, Tanskanen A, Tolppanen A, Tiihonen J, Hartikainen S. High prevalence of psychotropic drug use among persons with and without Alzheimer's disease in Finnish nationwide cohort. Eur Neuropsychopharmacol. 2014;24:1729&#x2013;1737. doi: 10.1016/j.euroneuro.2014.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2014.10.004</ArticleId><ArticleId IdType="pubmed">25453487</ArticleId></ArticleIdList></Reference><Reference><Citation>Beam C, Kaneshiro C, Jang J, Reynolds C, Pedersen N, Gatz M. Differences Between Women and Men in Incidence Rates of Dementia and Alzheimer's Disease. J Alzheimers Dis. 2018;64:1077&#x2013;1083. doi: 10.3233/JAD-180141.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180141</ArticleId><ArticleId IdType="pmc">PMC6226313</ArticleId><ArticleId IdType="pubmed">30010124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Lee H, Yang S, Chen T, Lin K, Lin C, et al. A nationwide survey of mild cognitive impairment and dementia, including very mild dementia, in Taiwan. PLoS ONE. 2014;9:e100303. doi: 10.1371/journal.pone.0100303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100303</ArticleId><ArticleId IdType="pmc">PMC4062510</ArticleId><ArticleId IdType="pubmed">24940604</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke M, Vemuri P, Rocca W. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37&#x2013;48. doi: 10.2147/CLEP.S37929.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37929</ArticleId><ArticleId IdType="pmc">PMC3891487</ArticleId><ArticleId IdType="pubmed">24470773</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, Verhey FRJ, Boziki M, Bullock R, Robert PH. Neuropsychiatric Syndromes in Dementia. Dement Geriatr Cogn Disord. 2007;24(6):457&#x2013;463. doi: 10.1159/000110738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000110738</ArticleId><ArticleId IdType="pubmed">17986816</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Mussele S, Mari&#xeb;n P, Saerens J, Somers N, Goeman J, De Deyn P, et al. Behavioral syndromes in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2014;38:319&#x2013;329. doi: 10.3233/JAD-130596.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-130596</ArticleId><ArticleId IdType="pubmed">23963290</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura T, Kitamura M, Hino S, Tanaka N, Kurata K. Gender differences in clinical manifestations and outcomes among hospitalized patients with behavioral and psychological symptoms of dementia. J Clin Psychiatry. 2012;73:1548&#x2013;1554. doi: 10.4088/JCP.11m07614.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.11m07614</ArticleId><ArticleId IdType="pubmed">23290328</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xe4;nnstr&#xf6;m J, Bostr&#xf6;m G, Rosendahl E, Nordstr&#xf6;m P, Littbrand H, L&#xf6;vheim H, et al. Psychotropic drug use and mortality in old people with dementia: investigating sex differences. BMC Pharmacol Toxicol. 2017;18:36. doi: 10.1186/s40360-017-0142-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40360-017-0142-9</ArticleId><ArticleId IdType="pmc">PMC5445267</ArticleId><ArticleId IdType="pubmed">28545507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kales H, Gitlin L, Lyketsos C. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369. doi: 10.1136/bmj.h369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.h369</ArticleId><ArticleId IdType="pmc">PMC4707529</ArticleId><ArticleId IdType="pubmed">25731881</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35323951</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort.</ArticleTitle><Pagination><StartPage>e223877</StartPage><MedlinePgn>e223877</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e223877</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.3877</ELocationID><Abstract><AbstractText Label="IMPORTANCE">More than 1 billion adults have hypertension globally, of whom 70% cannot achieve their hypertension control goal with monotherapy alone. Data are lacking on clinical use patterns of dual combination therapies prescribed to patients who escalate from monotherapy.</AbstractText><AbstractText Label="OBJECTIVE">To investigate the most common dual combinations prescribed for treatment escalation in different countries and how treatment use varies by age, sex, and history of cardiovascular disease.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cohort study used data from 11 electronic health record databases that cover 118 million patients across 8 countries and regions between January 2000 and December 2019. Included participants were adult patients (ages &#x2265;18 years) who newly initiated antihypertensive dual combination therapy after escalating from monotherapy. There were 2 databases included for 3 countries: the Iqvia Longitudinal Patient Database (LPD) Australia and Electronic Practice-based Research Network 2019 linked data set from South Western Sydney Local Health District (ePBRN SWSLHD) from Australia, Ajou University School of Medicine (AUSOM) and Kyung Hee University Hospital (KHMC) databases from South Korea, and Khoo Teck Puat Hospital (KTPH) and National University Hospital (NUH) databases from Singapore. Data were analyzed from June 2020 through August 2021.</AbstractText><AbstractText Label="EXPOSURES">Treatment with dual combinations of the 4 most commonly used antihypertensive drug classes (angiotensin-converting enzyme inhibitor [ACEI] or angiotensin receptor blocker [ARB]; calcium channel blocker [CCB]; &#x3b2;-blocker; and thiazide or thiazide-like diuretic).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The proportion of patients receiving each dual combination regimen, overall and by country and demographic subgroup.</AbstractText><AbstractText Label="RESULTS">Among 970&#x202f;335 patients with hypertension who newly initiated dual combination therapy included in the final analysis, there were 11&#x202f;494 patients from Australia (including 9291 patients in Australia LPD and 2203 patients in ePBRN SWSLHD), 6980 patients from South Korea (including 6029 patients in Ajou University and 951 patients in KHMC), 2096 patients from Singapore (including 842 patients in KTPH and 1254 patients in NUH), 7008 patients from China, 8544 patients from Taiwan, 103&#x202f;994 patients from France, 76&#x202f;082 patients from Italy, and 754&#x202f;137 patients from the US. The mean (SD) age ranged from 57.6 (14.8) years in China to 67.7 (15.9) years in the Singapore KTPH database, and the proportion of patients by sex ranged from 24&#x202f;358 (36.9%) women in Italy to 408&#x202f;964 (54.3%) women in the US. Among 12 dual combinations of antihypertensive drug classes commonly used, there were significant variations in use across country and patient subgroup. For example starting an ACEI or ARB monotherapy followed by a CCB (ie, ACEI or ARB&#x2009;+&#x2009;CCB) was the most commonly prescribed combination in Australia (698 patients in ePBRN SWSLHD [31.7%] and 3842 patients in Australia LPD [41.4%]) and Singapore (216 patients in KTPH [25.7%] and 439 patients in NUH [35.0%]), while in South Korea, CCB&#x2009;+&#x2009;ACEI or ARB (191 patients in KHMC [20.1%] and 1487 patients in Ajou University [24.7%]), CCB&#x2009;+&#x2009;&#x3b2;-blocker (814 patients in Ajou University [13.5%] and 217 patients in KHMC [22.8%]), and ACEI or ARB&#x2009;+&#x2009;CCB (147 patients in KHMC [15.5%] and 1216 patients in Ajou University [20.2%]) were the 3 most commonly prescribed combinations. The distribution of 12 dual combination therapies were significantly different by age and sex in almost all databases. For example, use of ACEI or ARB&#x2009;+&#x2009;CCB varied from 873 of 3737 patients ages 18 to 64 years (23.4%) to 343 of 2292 patients ages 65 years or older (15.0%) in South Korea's Ajou University database (P for database distribution by age&#x2009;&lt;&#x2009;.001), while use of ACEI or ARB&#x2009;+&#x2009;CCB varied from 2121 of 4718 (44.8%) men to 1721 of 4549 (37.7%) women in Australian LPD (P for drug combination distributions by sex&#x2009;&lt;&#x2009;.001).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this study, large variation in the transition between monotherapy and dual combination therapy for hypertension was observed across countries and by demographic group. These findings suggest that future research may be needed to investigate what dual combinations are associated with best outcomes for which patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Zandt</LastName><ForeName>Mui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Real World Solutions, Iqvia, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering and Informatics, Department of Medical Informatics, Nanjing Medical University, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Real World Solutions, Iqvia, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xialin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Real World Solutions, Iqvia, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhengfeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National University Heart Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Jaehyeong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorajoo</LastName><ForeName>Sreemanee Raaj</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Health Sciences Authority, Singapore and Khoo Teck Puat Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Mengling</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Saw Swee Hock School of Public Health, National University of Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Data Science, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Min-Huei</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Jason C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>International PhD Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Usman</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>International Center for Health Information Technology, Taipei Medical University, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonnagaddala</LastName><ForeName>Jitendra</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>World Health Organization Collaborating Center on eHealth, School of Population Health, University of New South Wales Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yu-Chuan</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liaw</LastName><ForeName>Siaw-Teng</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>World Health Organization Collaborating Center on eHealth, School of Population Health, University of New South Wales Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Hong-Seok</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngiam</LastName><ForeName>Kee Yuan</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Group Chief Technology Office, National University Health System, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Phung-Anh</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>International Center for Health Information Technology, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Health Technology, Taiwan Department of Healthcare Information and Management, Ming Chuan University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Center, Clinical and Health Sciences, University of South Australia, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Real World Solutions, Iqvia, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Sang Youl</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Kyung Hee University Medical Center, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sathappan</LastName><ForeName>Selva Muthu Kumaran</ForeName><Initials>SMK</Initials><AffiliationInfo><Affiliation>Saw Swee Hock School of Public Health, National University of Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Seo Jeong</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Hui Xing</ForeName><Initials>HX</Initials><AffiliationInfo><Affiliation>Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering and Informatics, Department of Medical Informatics, Nanjing Medical University, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University of Texas Health Science Center at Houston, Houston.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D049971">Thiazides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="Y">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049971" MajorTopicYN="N">Thiazides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Lu reported receiving grants from the US National Heart, Lung, and Blood Institute during the conduct of the study. Dr Krumholz reported receiving expenses or personal fees in the last 3 years from UnitedHealth, Element Science, Aetna, Reality Labs, Tesseract/4Catalyst, F-Prime, Siegfried and Jensen, Arnold and Porter, and Martin-Baughman; being a co-founder of Refactor Health and HugoHealth; and being associated through Yale New Haven Hospital with contracts from the Centers for Medicare &amp; Medicaid Services and Johnson &amp; Johnson. Dr Suchard reported receiving grants from the US Department of Veterans Affairs during the conduct of the study and grants from the US National Institutes of Health, US FDA, and Iqvia outside the submitted work. Dr Xu reported receiving grants from the US National Institutes of Health and owning stocks at Melax Technologies. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>24</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35323951</ArticleId><ArticleId IdType="pmc">PMC8948532</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.3877</ArticleId><ArticleId IdType="pii">2790440</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Forouzanfar MH, Liu P, Roth GA, et al. . Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165-182. doi:10.1001/jama.2016.19043</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.19043</ArticleId><ArticleId IdType="pubmed">28097354</ArticleId></ArticleIdList></Reference><Reference><Citation>NCD Risk Factor Collaboration (NCD-RisC) . Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19&#xb7;1 million participants. Lancet. 2017;389(10064):37-55. doi:10.1016/S0140-6736(16)31919-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31919-5</ArticleId><ArticleId IdType="pmc">PMC5220163</ArticleId><ArticleId IdType="pubmed">27863813</ArticleId></ArticleIdList></Reference><Reference><Citation>Martiniuk AL, Lee CM, Lawes CM, et al. ; Asia-Pacific Cohort Studies Collaboration . Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens. 2007;25(1):73-79. doi:10.1097/HJH.0b013e328010775f</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0b013e328010775f</ArticleId><ArticleId IdType="pubmed">17143176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290-300. doi:10.1016/j.amjmed.2008.09.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2008.09.038</ArticleId><ArticleId IdType="pubmed">19272490</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogihara T, Matsuzaki M, Umemoto S, et al. ; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group . Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial. Hypertens Res. 2012;35(4):441-448. doi:10.1038/hr.2011.216</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/hr.2011.216</ArticleId><ArticleId IdType="pubmed">22278623</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamerson K, Weber MA, Bakris GL, et al. ; ACCOMPLISH Trial Investigators . Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428. doi:10.1056/NEJMoa0806182</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0806182</ArticleId><ArticleId IdType="pubmed">19052124</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W, et al. ; Authors/Task Force Members . 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041. doi:10.1097/HJH.0000000000001940</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000001940</ArticleId><ArticleId IdType="pubmed">30234752</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelton PK, Carey RM, Aronow WS, et al. . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e426-e483. doi:10.1161/CIR.0000000000000597</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000597</ArticleId><ArticleId IdType="pubmed">30354655</ArticleId></ArticleIdList></Reference><Reference><Citation>Su M, Zhang Q, Bai X, et al. . Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. Lancet. 2017;390(10112):2559-2568. doi:10.1016/S0140-6736(17)32476-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32476-5</ArticleId><ArticleId IdType="pubmed">29102087</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SC Jr, Benjamin EJ, Bonow RO, et al. ; World Heart Federation and the Preventive Cardiovascular Nurses Association . AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458-2473. doi:10.1161/CIR.0b013e318235eb4d</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0b013e318235eb4d</ArticleId><ArticleId IdType="pubmed">22052934</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. . Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816-1826. doi:10.1016/S0140-6736(19)32317-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, et al. . Principles of Large-scale Evidence Generation and Evaluation Across a Network of Databases (LEGEND). J Am Med Inform Assoc. 2020;27(8):1331-1337. doi:10.1093/jamia/ocaa103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa103</ArticleId><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, et al. . Large-scale Evidence Generation and Evaluation Across a Network of Databases (LEGEND): assessing validity using hypertension as a case study. J Am Med Inform Assoc. 2020;27(8):1268-1277. doi:10.1093/jamia/ocaa124</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa124</ArticleId><ArticleId IdType="pmc">PMC7481033</ArticleId><ArticleId IdType="pubmed">32827027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. . Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574-578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, Jung S, Swerdel JN, et al. . Comparison of first-line dual combination treatments in hypertension: real-world evidence from multinational heterogeneous cohorts. Korean Circ J. 2020;50(1):52-68. doi:10.4070/kcj.2019.0173</Citation><ArticleIdList><ArticleId IdType="doi">10.4070/kcj.2019.0173</ArticleId><ArticleId IdType="pmc">PMC6923236</ArticleId><ArticleId IdType="pubmed">31642211</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Suchard MA, Krumholz HM, et al. . Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78(3):591-603. doi:10.1161/HYPERTENSIONAHA.120.16667</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.16667</ArticleId><ArticleId IdType="pmc">PMC8363588</ArticleId><ArticleId IdType="pubmed">34304580</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson S, Cho MC, Tsioufis K, Yang E. 2018 Korean Society of Hypertension guideline for the management of hypertension: a comparison of American, European, and Korean blood pressure guidelines. Eur Heart J. 2020;41(14):1384-1386. doi:10.1093/eurheartj/ehaa114</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa114</ArticleId><ArticleId IdType="pubmed">32259269</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint Committee for Guideline Revision . 2018 Chinese guidelines for prevention and treatment of hypertension&#x2014;a report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2019;16(3):182-241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6500570</ArticleId><ArticleId IdType="pubmed">31080465</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19(8):858-868. doi:10.1002/pds.1926</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1926</ArticleId><ArticleId IdType="pmc">PMC2917262</ArticleId><ArticleId IdType="pubmed">20681003</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics . Atlas. Accessed August 19, 2020. https://www.ohdsi.org/web/atlas</Citation></Reference><Reference><Citation>Rao G, Schuemie M, Ryan P, Weaver J. CohortDiagnostics. Accessed February 15, 2022. https://ohdsi.github.io/CohortDiagnostics/</Citation></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Chobanian AV, Bakris GL, Black HR, et al. ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee . The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572. doi:10.1001/jama.289.19.2560</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.19.2560</ArticleId><ArticleId IdType="pubmed">12748199</ArticleId></ArticleIdList></Reference><Reference><Citation>James PA, Oparil S, Carter BL, et al. . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.284427</ArticleId><ArticleId IdType="pubmed">24352797</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W, et al. ; List of authors/Task Force members . 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2018;36(12):2284-2309. doi:10.1097/HJH.0000000000001961</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000001961</ArticleId><ArticleId IdType="pubmed">30379783</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003. doi:10.1002/14651858.CD002003.pub5</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002003.pub5</ArticleId><ArticleId IdType="pmc">PMC5369873</ArticleId><ArticleId IdType="pubmed">28107561</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan You S, Krumholz HM, Suchard MA, et al. . Comprehensive comparative effectiveness and safety of first-line &#x3b2;-blocker monotherapy in hypertensive patients: a large-scale multicenter observational study. Hypertension. 2021;77(5):1528-1538. doi:10.1161/HYPERTENSIONAHA.120.16402</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.16402</ArticleId><ArticleId IdType="pmc">PMC8035236</ArticleId><ArticleId IdType="pubmed">33775125</ArticleId></ArticleIdList></Reference><Reference><Citation>Derington CG, King JB, Herrick JS, et al. . Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005-2016. Hypertension. 2020;75(4):973-981. doi:10.1161/HYPERTENSIONAHA.119.14360</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.119.14360</ArticleId><ArticleId IdType="pmc">PMC7398637</ArticleId><ArticleId IdType="pubmed">32148129</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine GN, Bates ER, Bittl JA, et al. . 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123-e155. doi:10.1161/CIR.0000000000000404</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000404</ArticleId><ArticleId IdType="pubmed">27026020</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez B, James S, Agewall S, et al. ; ESC Scientific Document Group . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx393</ArticleId><ArticleId IdType="pubmed">28886621</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, et al. . Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329-7336. doi:10.1073/pnas.1510502113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35345821</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-1349</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Clinical epidemiology</Title><ISOAbbreviation>Clin Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS.</ArticleTitle><Pagination><StartPage>369</StartPage><EndPage>384</EndPage><MedlinePgn>369-384</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/CLEP.S323292</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Routinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) Characterizing Health Associated Risks and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) framework for standardisation and analysis of COVID-19 RWD.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="UNASSIGNED">We conducted a descriptive retrospective database study using a federated network of data partners in the United States, Europe (the Netherlands, Spain, the UK, Germany, France and Italy) and Asia (South Korea and China). The study protocol and analytical package were released on 11th June 2020 and are iteratively updated via GitHub. We identified three non-mutually exclusive cohorts of 4,537,153 individuals with a clinical <i>COVID-19 diagnosis or positive test</i>, 886,193 <i>hospitalized with COVID-19</i>, and 113,627 <i>hospitalized with COVID-19 requiring intensive services</i>.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We aggregated over 22,000 unique characteristics describing patients with COVID-19. All comorbidities, symptoms, medications, and outcomes are described by cohort in aggregate counts and are readily available online. Globally, we observed similarities in the USA and Europe: more women diagnosed than men but more men hospitalized than women, most diagnosed cases between 25 and 60 years of age versus most hospitalized cases between 60 and 80 years of age. South Korea differed with more women than men hospitalized. Common comorbidities included type 2 diabetes, hypertension, chronic kidney disease and heart disease. Common presenting symptoms were dyspnea, cough and fever. Symptom data availability was more common in hospitalized cohorts than diagnosed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">We constructed a global, multi-centre view to describe trends in COVID-19 progression, management and evolution over time. By characterising baseline variability in patients and geography, our work provides critical context that may otherwise be misconstrued as data quality issues. This is important as we perform studies on adverse events of special interest in COVID-19 vaccine surveillance.</AbstractText><CopyrightInformation>&#xa9; 2022 Kostka et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2595-8736</Identifier><AffiliationInfo><Affiliation>IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Center at The Roux Institute, Northeastern University, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8274-0357</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistillo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4467-0220</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalid</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana Y H</ForeName><Initials>LYH</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Tarrytown, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-5630-2468</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawoud</LastName><ForeName>Dalia M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>National Institute for Health and Care Excellence, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0892-5668</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilcox</LastName><ForeName>Adam B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unviersity of Washington Medicine, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andryc</LastName><ForeName>Alan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2663-2298</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tufts Institute for Clinical Research and Health Policy Studies, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Chi Young</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harle</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0002-3641-055X</Identifier><AffiliationInfo><Affiliation>IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Center at The Roux Institute, Northeastern University, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorr</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics &amp; Clinical Epidemiology, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9286-1128</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Eng Hooi</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>O'Brien Institute for Public Health, Faculty of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Maeztu</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>IOMED, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipori</LastName><ForeName>Gigi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Hiba</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8234-5843</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Islamic University of Gaza, Gaza, Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Jason A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jimyung</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6998-2546</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez Rold&#xe1;n</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Director of Innovation and Digital Transformation, Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jose D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Stanford University, Redwood City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banda</LastName><ForeName>Juan M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-8499-824X</Identifier><AffiliationInfo><Affiliation>Georgia State University, Department of Computer Science, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horcajada</LastName><ForeName>Juan P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0001-9873-5459</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d'Investigaci&#xf3; M&#xe8;dica (IMIM), Universitat Aut&#xf2;noma de Barcelona, Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohler</LastName><ForeName>Julianna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>United States Agency for International Development, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Karishma</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Botnar Research Centre, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9066-9431</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5265-4159</Identifier><AffiliationInfo><Affiliation>Biomedical Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Data Science to Patient Value Program, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recalde</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unviersity of Washington Medicine, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Mengchun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Health Management, Southern Medical University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valveny</LastName><ForeName>Neus</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1105-5018</Identifier><AffiliationInfo><Affiliation>Real-World Evidence, TFS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiskopf</LastName><ForeName>Nicole G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics &amp; Clinical Epidemiology, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Stanford University, Redwood City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casajust</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2733-5436</Identifier><AffiliationInfo><Affiliation>Real-World Evidence, TFS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuff</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics &amp; Clinical Epidemiology, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seager</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-4898-3865</Identifier><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Seokyoung</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5653-7005</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Catholic University of Daegu, School of Medicine, Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bertol&#xed;n</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magoc</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8213-2266</Identifier><AffiliationInfo><Affiliation>University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6904-1394</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbian</LastName><ForeName>Vignesh</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>College of Engineering, The University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Waheed-Ul-Rahman</ForeName><Initials>WU</Initials><Identifier Source="ORCID">0000-0003-0880-0355</Identifier><AffiliationInfo><Affiliation>Botnar Research Centre, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Health, University of Exeter, St Luke's Campus, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>William</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-5346-3453</Identifier><AffiliationInfo><Affiliation>Data Science to Patient Value Program, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Yin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>DHC Technologies Co. Ltd., Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galvan</LastName><ForeName>Yankuic</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>University of Florida Health, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9818-479X</Identifier><AffiliationInfo><Affiliation>Departments of Biostatistics, Computational Medicine, and Human Genetics, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>INV-016201</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-016910</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-016284</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-019257</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Epidemiol</MedlineTA><NlmUniqueID>101531700</NlmUniqueID><ISSNLinking>1179-1349</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Res Sq. 2021 Mar 01;:</RefSource><PMID Version="1">33688639</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">descriptive epidemiology</Keyword><Keyword MajorTopicYN="N">open science</Keyword><Keyword MajorTopicYN="N">real world data</Keyword><Keyword MajorTopicYN="N">real world evidence</Keyword></KeywordList><CoiStatement>Ms. Kostka was an employee of IQVIA during the conduct of this study and received grant funding from the NIH NCATS National COVID Cohort Collaborative and the Bill and Melinda Gates Foundation. Mr. Sena is an employee and holds stock at Janssen Research &amp; Development, a Johnson and Johnson family of companies. Dr. Golozar reports personal fees from Regeneron Pharmaceuticals, outside the submitted work. She is a full-time employee at Regeneron Pharmaceuticals. This work was not conducted at Regeneron Pharmaceuticals. Dr. Nyberg was an employee of AstraZeneca until 2019 and hold some shares. Dr. Wilcox reports grants from Bill and Melinda Gates Foundation, grants from National Institute of Health, during the conduct of the study. Mr. Andryc is an employee of Janssen Research &amp; Development, a subsidiary of Johnson &amp; Johnson. Dr. Reich is an employee of IQVIA. Dr. Blacketer reports she is an employee and holds stock at Janssen Research &amp; Development, a Johnson and Johnson family of companies. Dr. Morales is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z) and reports grants from Chief Scientist Office (CSO), grants from Health Data Research UK (HDR-UK), grants from National Institute of Health Research (NIHR), outside the submitted work. Mr. DeFalco reports he is an employee and holds stock at Janssen Research &amp; Development, a Johnson and Johnson family of companies. Mr. Thomas reports grants from Bill and Melinda Gates Foundation (INV-016910), grants from National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR002369 to his institution, during the conduct of the study. Dr Jiang Bian reports grants from NIH/NIEHS (R21ES032762), during the conduct of the study. Dr. Posada reports grants from National Library of Medicine, during the conduct of the study. Dr. Natarajan reports grants from US NIH, during the conduct of the study. Dr. Matheny reports grants from US NIH, grants from US VA HSR&amp;D, during the conduct of the study. Dr. Weiskopf reports personal fees from Merck, during the conduct of the study and outside the submitted work. Dr. Shah reports grants from National Library of Medicine, during the conduct of the study. Dr. Park reports grants from Ministry of Trade, Industry &amp; Energy, Republic of Korea, grants from Ministry of Health &amp; Welfare, Republic of Korea, grants from Bill &amp; Melinda Gates Foundation, during the conduct of the study. Mr Robert Schuff reports grants from Gates Foundation, grants from NIH-NCATS, during the conduct of the study. Ms. Seager is an employee of IQVIA. Dr. DuVall reports grants from Anolinx, LLC, Astellas Pharma, Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Genentech Inc., Genomic Health, Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Innocrin Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Kantar Health, Myriad Genetic Laboratories, Inc., Novartis International AG, and Parexel International Corporation through the University of Utah or Western Institute for Veteran Research outside the submitted work. Dr. Fortin is an employee of Janssen R&amp;D, a subsidiary of Johnson and Johnson. Dr. Subbian reports grants from State of Arizona; Arizona Board of Regents, during the conduct of the study; grants from National Science Foundation (grant# 1838745), grants from Agency for Healthcare Research and Quality, grants from National Institutes of Health, outside the submitted work. Dr. Rijnbeek reports grants from Innovative Medicines Initiative, Janssen Research and Development, during the conduct of the study. He also works for a research institute which receives/received unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, GSK, Amgen, UCB, Novartis, Astra-Zeneca, Chiesi, Janssen Research and Development, none of which relate to the content of this work. Dr. Hripcsak reports grants from US NIH and Janssen Research. Dr. Ryan is an employee of Janssen Research and Development and shareholder of Johnson &amp; Johnson. Dr. Suchard reports grants from US National Institutes of Health, Department of Veterans Affairs, during the conduct of the study; grants and/or personal fees from IQVIA, Janssen Research and Development, US Food and Drug Administration, and Private Health Management, outside the submitted work. Dr. Prieto-Alhambra reports grants, non-financial support, speaker/consultancy services and/or advisory board membership from AMGEN, UCB Biopharma, and Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA&#x2019;s Department and open for external participants. The views expressed are those of the authors and do not necessarily represent the views or policy of the Department of Veterans Affairs or the United States Government. No other relationships or activities that could appear to have influenced the submitted work. The authors report no other conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>29</Day><Hour>5</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35345821</ArticleId><ArticleId IdType="pmc">PMC8957305</ArticleId><ArticleId IdType="doi">10.2147/CLEP.S323292</ArticleId><ArticleId IdType="pii">323292</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kent S, Burn E, Dawoud D, et al. Common problems, common data model solutions: evidence generation for health technology assessment. Pharmacoeconomics. 2020;39:275&#x2013;285. doi:10.1007/s40273-020-00981-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-020-00981-9</ArticleId><ArticleId IdType="pmc">PMC7746423</ArticleId><ArticleId IdType="pubmed">33336320</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest CB, McTigue KM, Hernandez AF, et al. PCORnet&#xae; 2020: current state, accomplishments, and future directions. J Clin Epidemiol. 2021;129:60&#x2013;67. doi:10.1016/j.jclinepi.2020.09.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2020.09.036</ArticleId><ArticleId IdType="pmc">PMC7521354</ArticleId><ArticleId IdType="pubmed">33002635</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sena A, Kostka K, Schuemie M, Posada JD, Schuemie M. ohdsi-studies/Covid19CharacterizationCharybdis: Charybdis v1.1.1 - Publication Package. 2020. doi:10.5281/zenodo.4033034.</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.4033034</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Director-General&#x2019;s opening remarks at the media briefing on COVID-19-11 March 2020; 2021. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-The-media-briefing-on-covid-19&#x2014;11-march-2020.</Citation></Reference><Reference><Citation>Johns Hopkins Coronavirus Resource Center. COVID-19 map; 2021. Available from: https://coronavirus.jhu.edu/map.html. Accessed March
4, 2022.</Citation></Reference><Reference><Citation>COVID-19-related medical research: a meta-research and critical appraisal; 2021. Available from: https://www.docwirenews.com/abstracts/covid-19-related-Medical-research-A-meta-research-and-critical-appraisal/.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7780085</ArticleId><ArticleId IdType="pubmed">33397292</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira da Silva JA, Tsigaris P, Erfanmanesh M. Publishing volumes in major databases related to Covid-19. Scientometrics. 2020;1&#x2013;12. doi:10.1007/s11192-020-03675-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11192-020-03675-3</ArticleId><ArticleId IdType="pmc">PMC7454548</ArticleId><ArticleId IdType="pubmed">32904414</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You SC, Sena AG, et al. Deep phenotyping of 34,128 adult patients hospitalized with COVID-19 in an international network study. Nat Commun. 2020;11:5009. doi:10.1038/s41467-020-18849-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbian V, Solomonides A, Clarkson M, et al. Ethics and Informatics in the age of COVID-19: challenges and recommendations for public health organization and public policy. J Am Med Inform Assoc. 2020;27. doi:10.1093/jamia/ocaa188</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa188</ArticleId><ArticleId IdType="pmc">PMC7454584</ArticleId><ArticleId IdType="pubmed">32722749</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhavan S, Bastarache L, Brown JS, et al. Use of electronic health records to support a public health response to the COVID-19 pandemic in the United States: a perspective from 15 academic medical centers. J Am Med Inform Assoc. 2020. doi:10.1093/jamia/ocaa287</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa287</ArticleId><ArticleId IdType="pmc">PMC7665546</ArticleId><ArticleId IdType="pubmed">33260207</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430&#x2013;436. doi:10.1038/s41586-020-2521-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60. doi:10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31:4401&#x2013;4415. doi:10.1002/sim.5620</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5620</ArticleId><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisinger SJ, Ryan PB, O&#x2019;Hara DJ, et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J Am Med Inform Assoc. 2010;17:652&#x2013;662. doi:10.1136/jamia.2009.002477</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.002477</ArticleId><ArticleId IdType="pmc">PMC3000752</ArticleId><ArticleId IdType="pubmed">20962127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Callahan TJ, Barnard J, et al. A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS (Wash DC). 2016;4:1244. doi:10.13063/2327-9214.1244</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1244</ArticleId><ArticleId IdType="pmc">PMC5051581</ArticleId><ArticleId IdType="pubmed">27713905</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational health data sciences, informatics. Chapter 15 data quality; 2021. Available from: https://ohdsi.github.io/TheBookOfOhdsi/DataQuality.html#data-quality-in-general. Accessed March
4, 2022.</Citation></Reference><Reference><Citation>Schuemie MJ, Cepeda MS, Suchard MA, et al. How confident are we about observational findings in healthcare: a benchmark study. Harv Data Sci Rev. 2020;2. doi:10.1162/99608f92.147cc28e</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/99608f92.147cc28e</ArticleId><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadri SS, Gundrum J, Warner S, et al. Uptake and accuracy of the diagnosis code for COVID-19 among US hospitalizations. JAMA. 2020;324:2553&#x2013;2554. doi:10.1001/jama.2020.20323</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.20323</ArticleId><ArticleId IdType="pmc">PMC7756233</ArticleId><ArticleId IdType="pubmed">33351033</ArticleId></ArticleIdList></Reference><Reference><Citation>HADES. Observational health data sciences and informatics; 2021. Available from: https://ohdsi.github.io/Hades/index.html. Accessed March
4, 2022.</Citation></Reference><Reference><Citation>Prats-Uribe A, Sena AG, Lai LYH, et al. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. BMJ. 2021;373:n1038. doi:10.1136/bmj.n1038</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1038</ArticleId><ArticleId IdType="pmc">PMC8111167</ArticleId><ArticleId IdType="pubmed">33975825</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021; 373 :n1435. doi:10.1136/bmj.n1435</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel M, Chute C, Gersing K. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J Am Med Inform Assoc. 2020. doi:10.1093/jamia/ocaa196</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa196</ArticleId><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber GM, Hong C, Palmer NP, et al.; 4CE Collaborative. International comparisons of harmonized laboratory value trajectories to predict severe COVID-19: leveraging the 4CE collaborative across 342 hospitals and 6 countries: a retrospective cohort study. bioRxiv medRxiv. 2020. doi:10.1101/2020.12.16.20247684</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.16.20247684</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte-Salles T, Vizcaya D, Pistillo A, et al. Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience. Pediatrics September. 2021; 148 (3): e2020042929. doi:10.1542/peds.2020-042929</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2020-042929</ArticleId><ArticleId IdType="pubmed">34049958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai LYH, Golozar A, Sena A, et al. Clinical characteristics, symptoms, management and health outcomes in 8598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis. medRxiv. 2020. doi:10.1101/2020.10.29.20222083</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.29.20222083</ArticleId></ArticleIdList></Reference><Reference><Citation>Roel E, Pistillo A, Recalde M, et al. Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain. Cancer Epidemiol Biomarkers Prev. 1 October 2021; 30 (10): 1884&#x2013;1894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8974356</ArticleId><ArticleId IdType="pubmed">34272262</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EH, Sena AG, Prats-Uribe A, et al. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology. 2021;60:SI37&#x2013;SI50. doi:10.1093/rheumatology/keab250</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab250</ArticleId><ArticleId IdType="pmc">PMC7989171</ArticleId><ArticleId IdType="pubmed">33725121</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35354802</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>DLMM as a lossless one-shot algorithm for collaborative multi-site distributed linear mixed models.</ArticleTitle><Pagination><StartPage>1678</StartPage><MedlinePgn>1678</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1678</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-29160-4</ELocationID><Abstract><AbstractText>Linear mixed models are commonly used in healthcare-based association analyses for analyzing multi-site data with heterogeneous site-specific random effects. Due to regulations for protecting patients' privacy, sensitive individual patient data (IPD) typically cannot be shared across sites. We propose an algorithm for fitting distributed linear mixed models (DLMMs) without sharing IPD across sites. This algorithm achieves results identical to those achieved using pooled IPD from multiple sites (i.e., the same effect size and standard error estimates), hence demonstrating the lossless property. The algorithm requires each site to contribute minimal&#xa0;aggregated data in only one round of communication. We demonstrate the lossless property of the proposed DLMM algorithm by investigating the associations between demographic and clinical characteristics and length of hospital stay in COVID-19 patients using administrative claims from the UnitedHealth Group Clinical Discovery Database. We extend this association study by incorporating 120,609 COVID-19 patients from 11 collaborative data sources worldwide.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Chongliang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Public Health Sciences, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Islam</LastName><ForeName>Md Nazmul</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Optum Labs, Minnetonka, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheils</LastName><ForeName>Natalie E</ForeName><Initials>NE</Initials><Identifier Source="ORCID">0000-0002-0631-5834</Identifier><AffiliationInfo><Affiliation>Optum Labs, Minnetonka, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buresh</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Optum Labs, Minnetonka, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2970-0778</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edmondson</LastName><ForeName>Mackenzie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3690-1444</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Rui</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9261-4864</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1213-6699</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marks-Anglin</LastName><ForeName>Arielle</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2238-5429</Identifier><AffiliationInfo><Affiliation>Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhaoyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bertol&#xed;n</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1802-1777</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfohl</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0001-9385-7158</Identifier><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0002-0692-412X</Identifier><AffiliationInfo><Affiliation>Institute for Clinical Research and Health Policy Studies, Tufts University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yujia</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0889-2261</Identifier><AffiliationInfo><Affiliation>School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lautenbach</LastName><ForeName>Ebbing</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doshi</LastName><ForeName>Jalpa A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Rachel M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cpl Michael J Crescenz VA Medical Center, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asch</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0002-7970-286X</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0835-0788</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG069880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013519</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA091842</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012607</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI130460</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003219" MajorTopicYN="N">Confidentiality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>N.E.S., M.N.I. and J.B. are/were full-time employees in Optum Labs and own stock in its parent company, UnitedHealth Group, Inc. J.R. and M.J.S. are full-time employees of Janssen Research and Development. Other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>31</Day><Hour>5</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35354802</ArticleId><ArticleId IdType="pmc">PMC8967932</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-29160-4</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-29160-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dash S, Shakyawar SK, Sharma M, Kaushik S. Big data in healthcare: management, analysis and future prospects. J. Big Data. 2019;6:1&#x2013;25. doi: 10.1186/s40537-019-0217-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40537-019-0217-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, et al. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med. Care. 2010;48:S45&#x2013;S51. doi: 10.1097/MLR.0b013e3181d9919f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e3181d9919f</ArticleId><ArticleId IdType="pubmed">20473204</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins FS, Hudson KL, Briggs JP, Lauer MS. PCORnet: turning a dream into reality. J. Am. Med. Inform. Assoc. 2014;21:576&#x2013;577. doi: 10.1136/amiajnl-2014-002864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002864</ArticleId><ArticleId IdType="pmc">PMC4078299</ArticleId><ArticleId IdType="pubmed">24821744</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest CB, et al. PCORnet&#xae; 2020: current state, accomplishments, and future directions. J. Clin. Epidemiol. 2021;129:60&#x2013;67. doi: 10.1016/j.jclinepi.2020.09.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2020.09.036</ArticleId><ArticleId IdType="pmc">PMC7521354</ArticleId><ArticleId IdType="pubmed">33002635</ArticleId></ArticleIdList></Reference><Reference><Citation>Carton, T. W., Marsolo, K. &amp; Block, J. P. PCORnet COVID-19 common data model design and results. Zenodo10.5281/ZENODO.3897398 (2020).</Citation></Reference><Reference><Citation>Hripcsak G, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud. Heal. Technol. Inf. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Visweswaran S, et al. Accrual to Clinical Trials (ACT): a clinical and translational science award consortium network. JAMIA Open. 2018;1:147&#x2013;152. doi: 10.1093/jamiaopen/ooy033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooy033</ArticleId><ArticleId IdType="pmc">PMC6241502</ArticleId><ArticleId IdType="pubmed">30474072</ArticleId></ArticleIdList></Reference><Reference><Citation>Findlay, S. The FDA&#x2019;s sentinel initiative. Health Policy Brief. Health Affairs. https://www.healthaffairs.org/do/10.1377/hpb20150604.936915/full/healthpolicybrief_139.pdf (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hpb20150604.936915/full/healthpolicybrief_139.pdf</ArticleId></ArticleIdList></Reference><Reference><Citation>Topaloglu U, Palchuk MB. Using a federated network of real-world data to optimize clinical trials operations. JCO Clin. Cancer Inform. 2018;2:1&#x2013;10. doi: 10.1200/CCI.17.00067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.17.00067</ArticleId><ArticleId IdType="pmc">PMC6816049</ArticleId><ArticleId IdType="pubmed">30652541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimmel, S. E., Califf, R. M., Dean, N. E., Goodman, S. N. &amp; Ogburn, E. L. COVID-19 clinical trials: a teachable moment for improving our research infrastructure and relevance. Ann Intern Med.173, 652&#x2013;653 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7322771</ArticleId><ArticleId IdType="pubmed">32543881</ArticleId></ArticleIdList></Reference><Reference><Citation>Brat GA, et al. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. Npj Digit. Med. 2020;3:1&#x2013;9. doi: 10.1038/s41746-020-00308-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00308-0</ArticleId><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat. Commun. 2020;11:1&#x2013;11. doi: 10.1038/s41467-020-18849-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-L, et al. WebDISCO: a web service for distributed cox model learning without patient-level data sharing. J. Am. Med. Inform. Assoc. 2015;22:1212&#x2013;1219. doi: 10.1093/jamia/ocv083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv083</ArticleId><ArticleId IdType="pmc">PMC5009917</ArticleId><ArticleId IdType="pubmed">26159465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Jiang X, Kim J, Ohno-Machado L. Grid Binary LOgistic REgression (GLORE): building shared models without sharing data. J. Am. Med. Inform. Assoc. 2012;19:758&#x2013;764. doi: 10.1136/amiajnl-2012-000862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000862</ArticleId><ArticleId IdType="pmc">PMC3422844</ArticleId><ArticleId IdType="pubmed">22511014</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno-Machado L, et al. pSCANNER: patient-centered Scalable National Network for Effectiveness Research. J. Am. Med. Inform. Assoc. 2014;21:621&#x2013;626. doi: 10.1136/amiajnl-2014-002751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002751</ArticleId><ArticleId IdType="pmc">PMC4078293</ArticleId><ArticleId IdType="pubmed">24780722</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SA, van der Vaart AW. On profile likelihood. J. Am. Stat. Assoc. 2000;95:449&#x2013;465. doi: 10.1080/01621459.2000.10474219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.2000.10474219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruppert, D., Wand, M. P. &amp; Carroll, R. J. Semiparametric regression. (Cambridge university press, 2003).</Citation></Reference><Reference><Citation>Chen Y, et al. Regression cubes with lossless compression and aggregation. IEEE Trans. Knowl. Data Eng. 2006;18:1585&#x2013;1599. doi: 10.1109/TKDE.2006.196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TKDE.2006.196</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibner J, et al. Revolutionizing medical data sharing using advanced privacy-enhancing technologies: technical, legal, and ethical synthesis. J. Med. Internet Res. 2021;23:e25120&#x2013;e25120. doi: 10.2196/25120.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/25120</ArticleId><ArticleId IdType="pmc">PMC7952236</ArticleId><ArticleId IdType="pubmed">33629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Harhay MO, et al. Measuring and analyzing length of stay in critical care trials. Med. Care. 2019;57:e53&#x2013;e53. doi: 10.1097/MLR.0000000000001059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000001059</ArticleId><ArticleId IdType="pmc">PMC6635104</ArticleId><ArticleId IdType="pubmed">30664613</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees EM, et al. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med. 2020;18:1&#x2013;22. doi: 10.1186/s12916-020-01726-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01726-3</ArticleId><ArticleId IdType="pmc">PMC7467845</ArticleId><ArticleId IdType="pubmed">32878619</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, et al. Understanding factors influencing the length of hospital stay among non-severe COVID-19 patients: a retrospective cohort study in a Fangcang shelter hospital. PLoS One. 2020;15:e0240959&#x2013;e0240959. doi: 10.1371/journal.pone.0240959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240959</ArticleId><ArticleId IdType="pmc">PMC7577449</ArticleId><ArticleId IdType="pubmed">33085709</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu, A. et al. Comorbidity and its impact on patients with COVID-19. SN Compr. Clin. Med. 2, 1069&#x2013;1076 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314621</ArticleId><ArticleId IdType="pubmed">32838147</ArticleId></ArticleIdList></Reference><Reference><Citation>Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. N. Engl. J. Med. 2020;382:2534&#x2013;2543. doi: 10.1056/NEJMsa2011686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsa2011686</ArticleId><ArticleId IdType="pmc">PMC7269015</ArticleId><ArticleId IdType="pubmed">32459916</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J. Infect. 2020;80:639&#x2013;645. doi: 10.1016/j.jinf.2020.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.019</ArticleId><ArticleId IdType="pmc">PMC7118526</ArticleId><ArticleId IdType="pubmed">32240670</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R, et al. Learning from local to global-an efficient distributed algorithm for modeling time-to-event data. J. Am. Med. Inform. Assoc. 2020;27:1028&#x2013;1036. doi: 10.1093/jamia/ocaa044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa044</ArticleId><ArticleId IdType="pmc">PMC7647322</ArticleId><ArticleId IdType="pubmed">32626900</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R, et al. Learning from electronic health records across multiple sites: A communication-efficient and privacy-preserving distributed algorithm. J. Am. Med. Inform. Assoc. 2020;27:376&#x2013;385. doi: 10.1093/jamia/ocz199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocz199</ArticleId><ArticleId IdType="pmc">PMC7025371</ArticleId><ArticleId IdType="pubmed">31816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Debray TPA, Koffijberg H, Vergouwe Y, Moons KGM, Steyerberg EW. Aggregating published prediction models with individual participant data: a comparison of different approaches. Stat. Med. 2012;31:2697&#x2013;2712. doi: 10.1002/sim.5412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5412</ArticleId><ArticleId IdType="pubmed">22733546</ArticleId></ArticleIdList></Reference><Reference><Citation>Debray TPA, et al. Meta&#x2010;analysis and aggregation of multiple published prediction models. Stat. Med. 2014;33:2341&#x2013;2362. doi: 10.1002/sim.6080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6080</ArticleId><ArticleId IdType="pubmed">24752993</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng E, Zhou XH, Chen H, Hu G, Duncan A. A new synthesis analysis method for building logistic regression prediction models. Stat. Med. 2014;33:2567&#x2013;2576. doi: 10.1002/sim.6125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6125</ArticleId><ArticleId IdType="pubmed">24634227</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher, D. J., Carpenter, J. R., Morris, T. P., Freeman, S. C. &amp; Tierney, J. F. Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach? BMJ356, j573 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5421441</ArticleId><ArticleId IdType="pubmed">28258124</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley RD, et al. Individual participant data meta&#x2010;analysis to examine interactions between treatment effect and participant&#x2010;level covariates: statistical recommendations for conduct and planning. Stat. Med. 2020;39:2115&#x2013;2137. doi: 10.1002/sim.8516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8516</ArticleId><ArticleId IdType="pmc">PMC7401032</ArticleId><ArticleId IdType="pubmed">32350891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney L. k-anonymity: a model for protecting privacy. Int. J. Uncertain. Fuzziness Knowl. Based Syst. 2002;10:557&#x2013;570. doi: 10.1142/S0218488502001648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1142/S0218488502001648</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwork C, McSherry F, Nissim K, Smith A. Calibrating noise to sensitivity in private data analysis. J. Priv. Confid. 2017;7:17&#x2013;51.</Citation></Reference><Reference><Citation>Wasserman L, Zhou S. A statistical framework for differential privacy. J. Am. Stat. Assoc. 2010;105:375&#x2013;389. doi: 10.1198/jasa.2009.tm08651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1198/jasa.2009.tm08651</ArticleId></ArticleIdList></Reference><Reference><Citation>Froelicher, D. et al. Truly privacy-preserving federated analytics for precision medicine with multiparty homomorphic encryption. Nat Commun.12, 5910 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8505638</ArticleId><ArticleId IdType="pubmed">34635645</ArticleId></ArticleIdList></Reference><Reference><Citation>Asch DA, et al. Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic. JAMA Intern. Med. 2021;181:471&#x2013;478. doi: 10.1001/jamainternmed.2020.8193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.8193</ArticleId><ArticleId IdType="pmc">PMC7756246</ArticleId><ArticleId IdType="pubmed">33351068</ArticleId></ArticleIdList></Reference><Reference><Citation>Breslow NE, Clayton DG. Approximate inference in generalized linear mixed models. J. Am. Stat. Assoc. 2012;88:9&#x2013;25.</Citation></Reference><Reference><Citation>Luo, C. et al. dPQL: a lossless distributed algorithm for generalized linear mixed model with application to privacy-preserving hospital profiling. medRxiv10.1101/2021.05.03.21256561 (2021).</Citation></Reference><Reference><Citation>Rieke N, et al. The future of digital health with federated learning. NPJ Digit. Med. 2020;3:1&#x2013;7. doi: 10.1038/s41746-020-00323-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00323-1</ArticleId><ArticleId IdType="pmc">PMC7490367</ArticleId><ArticleId IdType="pubmed">33015372</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest CB, et al. PEDSnet: a National Pediatric Learning Health System. J. Am. Med. Inform. Assoc. 2014;21:602&#x2013;606. doi: 10.1136/amiajnl-2014-002743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002743</ArticleId><ArticleId IdType="pmc">PMC4078288</ArticleId><ArticleId IdType="pubmed">24821737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman J, Morrison WJ. Adjustment of an inverse matrix corresponding to a change in one element of a given matrix. Ann. Math. Stat. 1950;21:124&#x2013;127. doi: 10.1214/aoms/1177729893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/aoms/1177729893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, Zhou A. Eigenvalues of rank-one updated matrices with some applications. Appl. Math. Lett. 2007;20:1223&#x2013;1226. doi: 10.1016/j.aml.2006.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aml.2006.11.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Self SG, Liang K-Y. Asymptotic properties of maximum likelihood estimators and likelihood ratio tests under nonstandard conditions. J. Am. Stat. Assoc. 1987;82:605&#x2013;610. doi: 10.1080/01621459.1987.10478472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1987.10478472</ArticleId></ArticleIdList></Reference><Reference><Citation>Stram, D. O. &amp; Lee, J. W. Variance components testing in the longitudinal mixed effects model. Biometrics50, 1171&#x2013;1177 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7786999</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Liang K.-Y. On the asymptotic behaviour of the pseudolikelihood ratio test statistic with boundary problems. Biometrika. 2010;97:603&#x2013;620. doi: 10.1093/biomet/asq031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/asq031</ArticleId><ArticleId IdType="pmc">PMC3372243</ArticleId><ArticleId IdType="pubmed">22822249</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35362796</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1619-7089</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur J Nucl Med Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics.</ArticleTitle><Pagination><StartPage>3547</StartPage><EndPage>3556</EndPage><MedlinePgn>3547-3556</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00259-022-05779-9</ELocationID><Abstract><AbstractText Label="PURPOSE">Risk of second primary malignancy (SPM) after radioiodine (RAI) therapy has been continuously debated. The aim of this study is to identify the risk of SPM in thyroid cancer (TC) patients with RAI compared with TC patients without RAI from matched cohort.</AbstractText><AbstractText Label="METHODS">Retrospective propensity-matched cohorts were constructed across 4 hospitals in South Korea via the Observational Health Data Science and Informatics (OHDSI), and electrical health records were converted to data of common data model. TC patients who received RAI therapy constituted the target group, whereas TC patients without RAI therapy constituted the comparative group with 1:1 propensity score matching. Hazard ratio (HR) by Cox proportional hazard model was used to estimate the risk of SPM, and meta-analysis was performed to pool the HRs.</AbstractText><AbstractText Label="RESULTS">Among a total of 24,318 patients, 5,374 patients from each group were analyzed (mean age 48.9 and 49.2, women 79.4% and 79.5% for target and comparative group, respectively). All hazard ratios of SPM in TC patients with RAI therapy were&#x2009;&#x2264;&#x2009;1 based on 95% confidence interval(CI) from full or subgroup analyses according to thyroid cancer stage, time-at-risk period, SPM subtype (hematologic or non-hematologic), and initial age (&lt;&#x2009;30&#xa0;years or&#x2009;&#x2265;&#x2009;30&#xa0;years). The HR within the target group was not significantly higher (&lt;&#x2009;1) in patients who received over 3.7&#xa0;GBq of I-131 compared with patients who received less than 3.7&#xa0;GBq of I-131 based on 95% CI.</AbstractText><AbstractText Label="CONCLUSION">There was no significant difference of the SPM risk between TC patients treated with I-131 and propensity-matched TC patients without I-131 therapy.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bang</LastName><ForeName>Ji-In</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boo</LastName><ForeName>Dachung</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Borham</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>In Young</ForeName><Initials>IY</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>SooJeong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedicine &amp; Health Sciences, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Ie Ryung</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kwangsoo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Transdisciplinary Department of Medicine &amp; Advanced Technology, Seoul National University Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Big Data Research Center, Seoul National University Medical Research Center, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Junmo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joo</LastName><ForeName>YoungHwan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryoo</LastName><ForeName>Hyun Gee</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paeng</LastName><ForeName>Jin Chul</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jung Mi</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Soonchunhyang University Bucheon Hospital, Gyeonggido, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Woncheol</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Statistics, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Byungwon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Statistics, Kyungpook National University, Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Yangha</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Statistics, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dongyoon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea. yoosoo0@snubh.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ho-Young</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0001-6518-0602</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Office of eHealth Research and Business, Seoul National University Bundang Hospital, 166, Gumi-ro, Seongnam-si 436-707, Republic of Korea. debobkr@snubh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000614965">Iodine-131</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="N">Data Science</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048088" MajorTopicYN="N">Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016609" MajorTopicYN="Y">Neoplasms, Second Primary</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Iodine-131</Keyword><Keyword MajorTopicYN="N">Neoplasm, Second primary</Keyword><Keyword MajorTopicYN="N">Observational study</Keyword><Keyword MajorTopicYN="N">Risk</Keyword><Keyword MajorTopicYN="N">Thyroid cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>12</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35362796</ArticleId><ArticleId IdType="doi">10.1007/s00259-022-05779-9</ArticleId><ArticleId IdType="pii">10.1007/s00259-022-05779-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Becker DV, Sawin CT. Radioiodine and thyroid disease: the beginning. Semin Nucl Med. 1996;26:155&#x2013;64. https://doi.org/10.1016/s0001-2998(96)80020-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0001-2998(96)80020-1</ArticleId><ArticleId IdType="pubmed">8829276</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229&#x2013;42. https://doi.org/10.1089/thy.2006.16.1229 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2006.16.1229</ArticleId><ArticleId IdType="pubmed">17199433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol. 2012;19:1874&#x2013;80. https://doi.org/10.1245/s10434-011-2129-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-011-2129-x</ArticleId><ArticleId IdType="pubmed">22065195</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazaure HS, Roman SA, Sosa JA. Insular thyroid cancer: a population-level analysis of patient characteristics and predictors of survival. Cancer. 2012;118:3260&#x2013;7. https://doi.org/10.1002/cncr.26638 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.26638</ArticleId><ArticleId IdType="pubmed">22252610</ArticleId></ArticleIdList></Reference><Reference><Citation>Podnos YD, Smith DD, Wagman LD, Ellenhorn JD. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol. 2007;96:3&#x2013;7. https://doi.org/10.1002/jso.20656 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.20656</ArticleId><ArticleId IdType="pubmed">17567872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015;100:1529&#x2013;36. https://doi.org/10.1210/jc.2014-4332 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2014-4332</ArticleId><ArticleId IdType="pubmed">25642591</ArticleId><ArticleId IdType="pmc">4399282</ArticleId></ArticleIdList></Reference><Reference><Citation>Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up&#x2020;. Ann Oncol. 2019;30:1856&#x2013;83. https://doi.org/10.1093/annonc/mdz400 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdz400</ArticleId><ArticleId IdType="pubmed">31549998</ArticleId></ArticleIdList></Reference><Reference><Citation>Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1&#x2013;133. https://doi.org/10.1089/thy.2015.0020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2015.0020</ArticleId><ArticleId IdType="pubmed">26462967</ArticleId><ArticleId IdType="pmc">4739132</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CY, Saeed O, Goldberg AS, Farooq S, Fazelzad R, Goldstein DP, et al. A systematic review and meta-analysis of subsequent malignant neoplasm risk after radioactive iodine treatment of thyroid cancer. Thyroid. 2018;28:1662&#x2013;73. https://doi.org/10.1089/thy.2018.0244 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2018.0244</ArticleId><ArticleId IdType="pubmed">30370820</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallahi B, Adabi K, Majidi M, Fard-Esfahani A, Heshmat R, Larijani B, et al. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clin Nucl Med. 2011;36:277&#x2013;82. https://doi.org/10.1097/RLU.0b013e31820a9fe3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RLU.0b013e31820a9fe3</ArticleId><ArticleId IdType="pubmed">21368600</ArticleId></ArticleIdList></Reference><Reference><Citation>Khang AR, Cho SW, Choi HS, Ahn HY, Yoo WS, Kim KW, et al. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq. Clin Endocrinol (Oxf). 2015;83:117&#x2013;23. https://doi.org/10.1111/cen.12581 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen.12581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang BH, Wong IO, Wong KP, Cowling BJ, Wan KY. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery. 2012;151:844&#x2013;50. https://doi.org/10.1016/j.surg.2011.12.019 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2011.12.019</ArticleId><ArticleId IdType="pubmed">22341041</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza MC, Momesso DP, Vaisman F, Vieira Neto L, Martins RA, Corbo R, et al. Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer? Arch Endocrinol Metab. 2016;60:9&#x2013;15. https://doi.org/10.1590/2359-3997000000078 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/2359-3997000000078</ArticleId><ArticleId IdType="pubmed">26222230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Bi X, Pan D, Chen Y, Carling T, Ma S, et al. The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid. 2013;23:575&#x2013;82. https://doi.org/10.1089/thy.2011.0406 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2011.0406</ArticleId><ArticleId IdType="pubmed">23237308</ArticleId><ArticleId IdType="pmc">3643257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CY, Lin CL, Huang WS, Kao CH. Risk of breast cancer in patients with thyroid cancer receiving or not receiving 131I treatment: a nationwide population-based cohort study. J Nucl Med. 2016;57:685&#x2013;90. https://doi.org/10.2967/jnumed.115.164830 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.164830</ArticleId><ArticleId IdType="pubmed">26719377</ArticleId></ArticleIdList></Reference><Reference><Citation>Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, et al. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia. 2018;32:952&#x2013;9. https://doi.org/10.1038/leu.2017.323 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2017.323</ArticleId><ArticleId IdType="pubmed">29104287</ArticleId></ArticleIdList></Reference><Reference><Citation>Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, et al. Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. J Clin Oncol. 2018;36:1831&#x2013;9. https://doi.org/10.1200/jco.2017.75.0232 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2017.75.0232</ArticleId><ArticleId IdType="pubmed">29252123</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo GH, Cho YY, Chung JH, Kim SW. Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: a nationwide population-based study in Korea. Thyroid. 2015;25:927&#x2013;34. https://doi.org/10.1089/thy.2014.0557 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2014.0557</ArticleId><ArticleId IdType="pubmed">26133388</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko KY, Kao CH, Lin CL, Huang WS, Yen RF. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study. Eur J Nucl Med Mol Imaging. 2015;42:1172&#x2013;8. https://doi.org/10.1007/s00259-015-3055-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-015-3055-0</ArticleId><ArticleId IdType="pubmed">25900274</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60. https://doi.org/10.1136/amiajnl-2011-000376 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26262116</ArticleId><ArticleId IdType="pmc">4815923</ArticleId></ArticleIdList></Reference><Reference><Citation>AJCC cancer staging manual, 7th edition.: Springer; 2010.</Citation></Reference><Reference><Citation>Hong CM, Shin JY, Kim BI, Song HC, Yoon JK, Won KS, et al. Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05608-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05608-5</ArticleId><ArticleId IdType="pubmed">34773164</ArticleId></ArticleIdList></Reference><Reference><Citation>Laha D, Nilubol N, Boufraqech M. New therapies for advanced thyroid cancer. Front Endocrinol. 2020;11. https://doi.org/10.3389/fendo.2020.00082 .</Citation></Reference><Reference><Citation>Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30:3734&#x2013;45. https://doi.org/10.1200/jco.2012.41.8681 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2012.41.8681</ArticleId><ArticleId IdType="pubmed">23008293</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">35390589</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8243</ISSN><JournalIssue CitedMedium="Internet"><Volume>162</Volume><PubDate><Year>2022</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of medical informatics</Title><ISOAbbreviation>Int J Med Inform</ISOAbbreviation></Journal><ArticleTitle>Development and validation of a management system and dataset quality assessment tool for the Radiology Common Data Model (R_CDM): A case study in liver disease.</ArticleTitle><Pagination><StartPage>104759</StartPage><MedlinePgn>104759</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijmedinf.2022.104759</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1386-5056(22)00073-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM), a distributed research network, has low clinical data coverage. Radiological data are valuable, but imaging metadata are often incomplete, and a standardized recording format in the OMOP-CDM is lacking. We developed a web-based management system and data quality assessment (RQA) tool for a radiology_CDM (R_CDM) and evaluated the feasibility of clinically applying this dataset.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We designed an R_CDM with Radiology_Occurrence and Radiology_Image tables. This was seamlessly linked to the OMOP-CDM clinical data. We adopted the standardized terminology using the RadLex playbook and mapped 5,753 radiology protocol terms to the OMOP vocabulary. An extract, transform, and load (ETL) process was developed to extract detailed information that was difficult to extract from metadata and to compensate for missing values. Image-based quantification was performed to measure liver surface nodularity (LSN), using customized Wonkwang abdomen and liver total solution (WALTS) software.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">On a PACS, 368,333,676 DICOM files (1,001,797 cases) were converted to R_CDM chronic liver disease (CLD) data (316,596 MR images, 228 cases; 926,753 CT images, 782 cases) and uploaded to a web-based management system. Acquisition date and resolution were extracted accurately, but other information, such as "contrast administration status" and "photography direction", could not be extracted from the metadata. Using WALTS, 9,609 pre-contrast axial-plane abdominal MR images (197 CLD cases) were assigned LSN scores by METAVIR fibrosis grades, which differed significantly by ANOVA (p&#xa0;&lt;&#xa0;0.001). The mean RQA score (83.5) indicated good quality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study developed a web-based system for management of the R_CDM dataset, RQA tool, and constructed a CLD R_CDM dataset, with good quality for clinical application. Our management system and R_CDM CLD dataset would be useful for multicentric and image-based quantification researches.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae-Hoon</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Medical Convergence Research Center, Wonkwang University, Iksan 54538, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noh</LastName><ForeName>SiHyeong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Convergence Research Center, Wonkwang University, Iksan 54538, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Youe Ree</ForeName><Initials>YR</Initials><AffiliationInfo><Affiliation>Department of Radiology, Wonkwang University School of Medicine and Wonkwang University Hospital, Iksan 54538, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>ChungSub</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Convergence Research Center, Wonkwang University, Iksan 54538, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji Eon</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Medical Convergence Research Center, Wonkwang University, Iksan 54538, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Chang-Won</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Medical Convergence Research Center, Wonkwang University, Iksan 54538, Republic of Korea. Electronic address: mediblue@wku.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Kwon-Ha</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Medical Convergence Research Center, Wonkwang University, Iksan 54538, Republic of Korea; Department of Radiology, Wonkwang University School of Medicine and Wonkwang University Hospital, Iksan 54538, Republic of Korea. Electronic address: khy1646@wku.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Int J Med Inform</MedlineTA><NlmUniqueID>9711057</NlmUniqueID><ISSNLinking>1386-5056</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic liver disease (CLD)</Keyword><Keyword MajorTopicYN="N">Metadata</Keyword><Keyword MajorTopicYN="N">Radiology_common data model (R_CDM)</Keyword><Keyword MajorTopicYN="N">Standardization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>20</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35390589</ArticleId><ArticleId IdType="doi">10.1016/j.ijmedinf.2022.104759</ArticleId><ArticleId IdType="pii">S1386-5056(22)00073-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35396302</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Impact of the COVID-19 pandemic on diagnoses of common mental health disorders in adults in Catalonia, Spain: a population-based cohort study.</ArticleTitle><Pagination><StartPage>e057866</StartPage><MedlinePgn>e057866</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e057866</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2021-057866</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To investigate how trends in incidence of anxiety and depressive disorders have been affected by the COVID-19 pandemic.</AbstractText><AbstractText Label="DESIGN">Population-based cohort study.</AbstractText><AbstractText Label="SETTING">Retrospective cohort study from 2018 to 2021 using the Information System for Research in Primary Care (SIDIAP) database in Catalonia, Spain.</AbstractText><AbstractText Label="PARTICIPANTS">3&#x2009;640&#x2009;204 individuals aged 18 or older in SIDIAP on 1 March 2018 with no history of anxiety and depressive disorders.</AbstractText><AbstractText Label="PRIMARY AND SECONDARY OUTCOMES MEASURES">The incidence of anxiety and depressive disorders during the prelockdown period (March 2018-February 2020), lockdown period (March-June 2020) and postlockdown period (July 2020-March 2021) was calculated. Forecasted rates over the COVID-19 periods were estimated using negative binomial regression models based on prelockdown data. The percentage of reduction was estimated by comparing forecasted versus observed events, overall and by sex, age and socioeconomic status.</AbstractText><AbstractText Label="RESULTS">The incidence rates per 100&#x2009;000 person-months of anxiety and depressive disorders were 151.1 (95% CI 150.3 to 152.0) and 32.3 (31.9 to 32.6), respectively, during the prelockdown period. We observed an increase of 37.1% (95% prediction interval 25.5 to 50.2) in incident anxiety diagnoses compared with the expected in March 2020, followed by a reduction of 15.8% (7.3 to 23.5) during the postlockdown period. A reduction in incident depressive disorders occurred during the lockdown and postlockdown periods (45.6% (39.2 to 51.0) and 22.0% (12.6 to 30.1), respectively). Reductions were higher among women during the lockdown period, adults aged 18-34 years and individuals living in the most deprived areas.</AbstractText><AbstractText Label="CONCLUSIONS">The COVID-19 pandemic in Catalonia was associated with an initial increase in anxiety disorders diagnosed in primary care but a reduction in cases as the pandemic continued. Diagnoses of depressive disorders were lower than expected throughout the pandemic.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ravent&#xf3;s</LastName><ForeName>Berta</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-4668-2970</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistillo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Carlen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8486-3265</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bertol&#xed;n</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arag&#xf3;n</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berenguera</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0889-2002</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacques-Avi&#xf1;&#xf3;</LastName><ForeName>Constanza</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medina-Perucha</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2981-2614</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9286-1128</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8274-0357</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain tduarte@idiapjgol.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anxiety disorders</Keyword><Keyword MajorTopicYN="N">depression &amp; mood disorders</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">primary care</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>5</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35396302</ArticleId><ArticleId IdType="pmc">PMC8995576</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2021-057866</ArticleId><ArticleId IdType="pii">bmjopen-2021-057866</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bolet&#xed;n oficial del estado (BOE). Real Decreto 463/2020, de 14 marzo, por el que se declara el estado de alarma para la gesti&#xf3;n de la situaci&#xf3;n de crisis sanitaria ocasionada por el COVID-19. Available: https://boe.es/buscar/act.php?id=BOE-A-2020-3692 [Accessed 27 May 2021].</Citation></Reference><Reference><Citation>Bolet&#xed;n oficial del estado (BOE). Real Decreto 555/2020, de 5 de junio, POR El que se prorroga el estado de alarma declarado por el real Decreto 463/2020, de 14 de marzo, por el que se declara el estado de alarma para la gesti&#xf3;n de la situaci&#xf3;n de crisis sanitaria ocasionada por el COVID-19. Available: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2020-5767 [Accessed 27 May 2021].</Citation></Reference><Reference><Citation>Bolet&#xed;n oficial del estado (BOE). Real Decreto 926/2020, de 25 de octubre, por el que Se declara el estado de alarma para contener la propagaci&#xf3;n de infecciones causadas por el SARS-CoV-2. Available: https://www.boe.es/buscar/doc.php?id=BOE-A-2020-12898 [Accessed 27 May 2021].</Citation></Reference><Reference><Citation>O'Connor RC, Wetherall K, Cleare S, et al. . Mental health and well-being during the COVID-19 pandemic: longitudinal analyses of adults in the UK COVID-19 Mental Health &amp; Wellbeing study. Br J Psychiatry 2021;218:326&#x2013;33. 10.1192/bjp.2020.212</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.2020.212</ArticleId><ArticleId IdType="pmc">PMC7684009</ArticleId><ArticleId IdType="pubmed">33081860</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Sanguino C, Aus&#xed;n B, Castellanos Miguel &#xc1;ngel, et al. . Mental health consequences during the initial stage of the 2020 coronavirus pandemic (COVID-19) in Spain. Brain Behav Immun 2020;87:172&#x2013;6. 10.1016/j.bbi.2020.05.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.05.040</ArticleId><ArticleId IdType="pmc">PMC7219372</ArticleId><ArticleId IdType="pubmed">32405150</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Pan R, Wan X. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health 2020;17:1729. 10.3390/ijerph17051729</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17051729</ArticleId><ArticleId IdType="pmc">PMC7084952</ArticleId><ArticleId IdType="pubmed">32155789</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo M, Guo L, Yu M, et al. . The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public &#x2013; a systematic review and meta-analysis. Psychiatry Res 2020;291:113190. 10.1016/j.psychres.2020.113190</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2020.113190</ArticleId><ArticleId IdType="pmc">PMC7276119</ArticleId><ArticleId IdType="pubmed">32563745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacques-Avi&#xf1;&#xf3; C, L&#xf3;pez-Jim&#xe9;nez T, Medina-Perucha L, et al. . Gender-Based approach on the social impact and mental health in Spain during COVID-19 lockdown: a cross-sectional study. BMJ Open 2020;10:e044617. 10.1136/bmjopen-2020-044617</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-044617</ArticleId><ArticleId IdType="pmc">PMC7688440</ArticleId><ArticleId IdType="pubmed">33234664</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan&#xe9;-Llopis E, Anderson P, Segura L, et al. . Mental ill-health during COVID-19 confinement. BMC Psychiatry 2021;21:194. 10.1186/s12888-021-03191-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-021-03191-5</ArticleId><ArticleId IdType="pmc">PMC8045571</ArticleId><ArticleId IdType="pubmed">33853562</ArticleId></ArticleIdList></Reference><Reference><Citation>Departament de Salut. Generalitat de Catalunya . Informe breu n&#xfa;m 42: Efectes del confinament en La salut mental. Available: https://catsalut.gencat.cat/ca/detalls/noticies/2021-02-08-informe-breu-num-42-efectes-confiament-salut-mental [Accessed 27 May 2021].</Citation></Reference><Reference><Citation>Ghio L, Gotelli S, Marcenaro M, et al. . Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis. J Affect Disord 2014;152-154:45&#x2013;51. 10.1016/j.jad.2013.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2013.10.002</ArticleId><ArticleId IdType="pubmed">24183486</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung R, O'Donnell S, Madi N, et al. . Factors associated with delayed diagnosis of mood and/or anxiety disorders. Health Promot Chronic Dis Prev Can 2017;37:137&#x2013;48. 10.24095/hpcdp.37.5.02</Citation><ArticleIdList><ArticleId IdType="doi">10.24095/hpcdp.37.5.02</ArticleId><ArticleId IdType="pmc">PMC5650019</ArticleId><ArticleId IdType="pubmed">28493658</ArticleId></ArticleIdList></Reference><Reference><Citation>United Nations . United nations policy brief: COVID-19 and the need for action on mental health. Available: https://unsdg.un.org/sites/default/files/2020-05/UN-Policy-Brief-COVID-19-and-mental-health.pdf [Accessed 14 Feb 2021].</Citation></Reference><Reference><Citation>COVID-19 Mental Disorders Collaborators . Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021;398:1700&#x2013;12. 10.1016/S0140-6736(21)02143-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02143-7</ArticleId><ArticleId IdType="pmc">PMC8500697</ArticleId><ArticleId IdType="pubmed">34634250</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Gil MDM, Hermosilla E, Prieto-Alhambra D, et al. . Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care 2011;19:135&#x2013;45. 10.14236/jhi.v19i3.806</Citation><ArticleIdList><ArticleId IdType="doi">10.14236/jhi.v19i3.806</ArticleId><ArticleId IdType="pubmed">22688222</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. . Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015;22:553&#x2013;64. 10.1093/jamia/ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Fel&#xed;citas Dom&#xed;nguez-Berj&#xf3;n M, Borrell C, Cano-Serral G, et al. . Construcci&#xf3;n de un &#xed;ndice de privaci&#xf3;n a partir de datos censales en grandes ciudades espa&#xf1;olas (Proyecto Medea). Gaceta Sanitaria 2008;22:179&#x2013;87. 10.1157/13123961</Citation><ArticleIdList><ArticleId IdType="doi">10.1157/13123961</ArticleId><ArticleId IdType="pubmed">18579042</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;mmel A, Bonate PL, Dingemanse J, et al. . Confidence and prediction intervals for pharmacometric models. CPT Pharmacometrics Syst Pharmacol 2018;7:360&#x2013;73. 10.1002/psp4.12286</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.12286</ArticleId><ArticleId IdType="pmc">PMC6027739</ArticleId><ArticleId IdType="pubmed">29388347</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams R, Jenkins DA, Ashcroft DM, et al. . Diagnosis of physical and mental health conditions in primary care during the COVID-19 pandemic: a retrospective cohort study. Lancet Public Health 2020;5:e543&#x2013;50. 10.1016/S2468-2667(20)30201-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30201-2</ArticleId><ArticleId IdType="pmc">PMC7511209</ArticleId><ArticleId IdType="pubmed">32979305</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr MJ, Steeg S, Webb RT, et al. . Effects of the COVID-19 pandemic on primary care-recorded mental illness and self-harm episodes in the UK: a population-based cohort study. Lancet Public Health 2021;6:e124&#x2013;35. 10.1016/S2468-2667(20)30288-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30288-7</ArticleId><ArticleId IdType="pmc">PMC7843955</ArticleId><ArticleId IdType="pubmed">33444560</ArticleId></ArticleIdList></Reference><Reference><Citation>Pifarr&#xe9; I Arolas H, Vidal-Alaball J, Gil J, et al. . Missing diagnoses during the COVID-19 pandemic: a year in review. Int J Environ Res Public Health 2021;18:5335. 10.3390/ijerph18105335</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18105335</ArticleId><ArticleId IdType="pmc">PMC8156815</ArticleId><ArticleId IdType="pubmed">34067807</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Segui F, Hernandez Guillamet G, Pifarr&#xe9; Arolas H, et al. . Characterization and identification of variations in types of primary care visits before and during the COVID-19 pandemic in Catalonia: big data analysis study. J Med Internet Res 2021;23:e29622. 10.2196/29622</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/29622</ArticleId><ArticleId IdType="pmc">PMC8767991</ArticleId><ArticleId IdType="pubmed">34313600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayuso-Mateos JL, Mediavilla R, McGreevy KR, et al. . Informing the response to COVID-19 in Spain: priorities for mental health research. Revista de Psiquiatr&#xed;a y Salud Mental 2021;14:79&#x2013;82. 10.1016/j.rpsm.2021.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpsm.2021.04.001</ArticleId><ArticleId IdType="pmc">PMC8114090</ArticleId><ArticleId IdType="pubmed">33992223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzerini M, Barbi E, Apicella A, et al. . Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health 2020;4:e10&#x2013;11. 10.1016/S2352-4642(20)30108-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(20)30108-5</ArticleId><ArticleId IdType="pmc">PMC7146704</ArticleId><ArticleId IdType="pubmed">32278365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell&#xf3;n JA, Conejo-Cer&#xf3;n S, Rodr&#xed;guez-Bay&#xf3;n A, et al. . Enfermedades mentales comunes en atenci&#xf3;n primaria: dificultades diagn&#xf3;sticas Y terap&#xe9;uticas, Y nuevos retos en predicci&#xf3;n Y prevenci&#xf3;n. Informe SESPAS 2020. Gaceta Sanitaria 2020;34:20&#x2013;6. 10.1016/j.gaceta.2020.05.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gaceta.2020.05.013</ArticleId><ArticleId IdType="pubmed">32843196</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepoiu M, McCusker J, Cole MG, et al. . Recognition of depression by non-psychiatric physicians--a systematic literature review and meta-analysis. J Gen Intern Med 2008;23:25&#x2013;36. 10.1007/s11606-007-0428-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-007-0428-5</ArticleId><ArticleId IdType="pmc">PMC2173927</ArticleId><ArticleId IdType="pubmed">17968628</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton C, Gunn J. Do longer consultations improve the management of psychological problems in general practice? A systematic literature review. BMC Health Serv Res 2007;7:71. 10.1186/1472-6963-7-71</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6963-7-71</ArticleId><ArticleId IdType="pmc">PMC1890290</ArticleId><ArticleId IdType="pubmed">17506904</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 2009;374:609&#x2013;19. 10.1016/S0140-6736(09)60879-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)60879-5</ArticleId><ArticleId IdType="pubmed">19640579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. Mental health effects of school closures during COVID-19. Lancet Child Adolesc Health 2020;4:421. 10.1016/S2352-4642(20)30109-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(20)30109-7</ArticleId><ArticleId IdType="pmc">PMC7156240</ArticleId><ArticleId IdType="pubmed">32302537</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno C, Wykes T, Galderisi S, et al. . How mental health care should change as a consequence of the COVID-19 pandemic. Lancet Psychiatry 2020;7:813&#x2013;24. 10.1016/S2215-0366(20)30307-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30307-2</ArticleId><ArticleId IdType="pmc">PMC7365642</ArticleId><ArticleId IdType="pubmed">32682460</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-Alhambra D, Ball&#xf3; E, Coma E, et al. . Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118&#x2009;150 cases diagnosed in outpatient settings in Spain. Int J Epidemiol 2021;49:1930&#x2013;9. 10.1093/ije/dyaa190</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa190</ArticleId><ArticleId IdType="pmc">PMC7665572</ArticleId><ArticleId IdType="pubmed">33118037</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, Teb&#xe9; C, Fernandez-Bertolin S, et al. . The natural history of symptomatic COVID-19 during the first wave in Catalonia. Nat Commun 2021;12:777. 10.1038/s41467-021-21100-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21100-y</ArticleId><ArticleId IdType="pmc">PMC7858639</ArticleId><ArticleId IdType="pubmed">33536436</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35404974</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Extract, transform, load framework for the conversion of health databases to OMOP.</ArticleTitle><Pagination><StartPage>e0266911</StartPage><MedlinePgn>e0266911</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0266911</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0266911</ELocationID><Abstract><AbstractText>Common data models standardize the structures and semantics of health datasets, enabling reproducibility and large-scale studies that leverage the data from multiple locations and settings. The Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) is one of the leading common data models. While there is a strong incentive to convert datasets to OMOP, the conversion is time and resource-intensive, leaving the research community in need of tools for mapping data to OMOP. We propose an extract, transform, load (ETL) framework that is metadata-driven and generic across source datasets. The ETL framework uses a new data manipulation language (DML) that organizes SQL snippets in YAML. Our framework includes a compiler that converts YAML files with mapping logic into an ETL script. Access to the ETL framework is available via a web application, allowing users to upload and edit YAML files via web editor and obtain an ETL SQL script for use in development environments. The structure of the DML maximizes readability, refactoring, and maintainability, while minimizing technical debt and standardizing the writing of ETL operations for mapping to OMOP. Our framework also supports transparency of the mapping process and reuse by different institutions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-0241-5376</Identifier><AffiliationInfo><Affiliation>Centre for Big Data Research in Health, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chard</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centre for Big Data Research in Health, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sa</LastName><ForeName>Zhisheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Centre for Big Data Research in Health, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Angus</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8164-8786</Identifier><AffiliationInfo><Affiliation>Concord Clinical School, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Informatics Unit, Sydney Local Health District, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jorm</LastName><ForeName>Louisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Big Data Research in Health, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallego</LastName><ForeName>Blanca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Big Data Research in Health, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="Y">Plant Extracts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>11</Day><Hour>17</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35404974</ArticleId><ArticleId IdType="pmc">PMC9000122</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0266911</ArticleId><ArticleId IdType="pii">PONE-D-21-34040</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harron K, Dibben C, Boyd J, Hjern A, Azimaee M, Barreto ML, et al.. Challenges in administrative data linkage for research. Big Data Soc. 2017;4: 2053951717745678. doi: 10.1177/2053951717745678</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2053951717745678</ArticleId><ArticleId IdType="pmc">PMC6187070</ArticleId><ArticleId IdType="pubmed">30381794</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey JA, Schwartz BS, Stewart WF, Adler NE. Using Electronic Health Records for Population Health Research: A Review of Methods and Applications. Annu Rev Public Health. 2016;37: 61&#x2013;81. doi: 10.1146/annurev-publhealth-032315-021353</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-publhealth-032315-021353</ArticleId><ArticleId IdType="pmc">PMC6724703</ArticleId><ArticleId IdType="pubmed">26667605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016;183: 758&#x2013;764. doi: 10.1093/aje/kwv254</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwv254</ArticleId><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Abul-Husn NS, Kenny EE. Personalized Medicine and the Power of Electronic Health Records. Cell. 2019;177: 58&#x2013;69. doi: 10.1016/j.cell.2019.02.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.02.039</ArticleId><ArticleId IdType="pmc">PMC6921466</ArticleId><ArticleId IdType="pubmed">30901549</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, Resnic FS, Robbins SL, Denton J, Nookala L, Meeker D, et al.. Creating a Common Data Model for Comparative Effectiveness with the Observational Medical Outcomes Partnership. Appl Clin Inform. 2015;06: 536&#x2013;547. doi: 10.4338/ACI-2014-12-CR-0121</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/ACI-2014-12-CR-0121</ArticleId><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, et al.. An Evaluation of the THIN Database in the OMOP Common Data Model for Active Drug Safety Surveillance. Drug Saf. 2013;36: 119&#x2013;134. doi: 10.1007/s40264-012-0009-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-012-0009-3</ArticleId><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Depas N, Doutreligne M, Parrot A, Verloop D, Defebvre M-M, et al.. Transforming French Electronic Health Records into the Observational Medical Outcome Partnership&#x2019;s Common Data Model: A Feasibility Study. Appl Clin Inform. 2020;11: 13&#x2013;22. doi: 10.1055/s-0039-3402754</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-3402754</ArticleId><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C. Fidelity Assessment of a Clinical Practice Research Datalink Conversion to the OMOP Common Data Model. Drug Saf. 2014;37: 945&#x2013;959. doi: 10.1007/s40264-014-0214-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0214-3</ArticleId><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai EC-C, Ryan P, Zhang Y, Schuemie M, Hardy NC, Kamijima Y, et al.. Applying a common data model to Asian databases for multinational pharmacoepidemiologic studies: opportunities and challenges. Clin Epidemiol. 2018;10: 875&#x2013;885. doi: 10.2147/CLEP.S149961</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S149961</ArticleId><ArticleId IdType="pmc">PMC6067778</ArticleId><ArticleId IdType="pubmed">30100761</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke L, Sa D, Sl D, B V, A C, D P, et al.. Incrementally Transforming Electronic Medical Records into the Observational Medical Outcomes Partnership Common Data Model: A Multidimensional Quality Assurance Approach. Appl Clin Inform. 2019;10: 794&#x2013;803. doi: 10.1055/s-0039-1697598</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-1697598</ArticleId><ArticleId IdType="pmc">PMC6811349</ArticleId><ArticleId IdType="pubmed">31645076</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberson A, Rinner C, Sch&#xf6;berl A, Gall W. Feasibility of Mapping Austrian Health Claims Data to the OMOP Common Data Model. J Med Syst. 2019;43: 314. doi: 10.1007/s10916-019-1436-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10916-019-1436-9</ArticleId><ArticleId IdType="pmc">PMC6732152</ArticleId><ArticleId IdType="pubmed">31494719</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19: 54&#x2013;60. doi: 10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael CL, Sholle ET, Wulff RT, Roboz GJ, Campion TR. Mapping Local Biospecimen Records to the OMOP Common Data Model. AMIA Summits Transl Sci Proc. 2020;2020: 422&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233045</ArticleId><ArticleId IdType="pubmed">32477663</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64: 333&#x2013;341. doi: 10.1016/j.jbi.2016.10.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.10.016</ArticleId><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijnbeek PR. Converting to a Common Data Model: What is Lost in Translation? Drug Saf. 2014;37: 893&#x2013;896. doi: 10.1007/s40264-014-0221-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0221-4</ArticleId><ArticleId IdType="pubmed">25187018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasserman RC. Electronic Medical Records (EMRs), Epidemiology, and Epistemology: Reflections on EMRs and Future Pediatric Clinical Research. Acad Pediatr. 2011;11: 280&#x2013;287. doi: 10.1016/j.acap.2011.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acap.2011.02.007</ArticleId><ArticleId IdType="pmc">PMC3138824</ArticleId><ArticleId IdType="pubmed">21622040</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al.. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. The Lancet. 2019;394: 1816&#x2013;1826. doi: 10.1016/S0140-6736(19)32317-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Reps JM, Kostka KF, Ryan PB, Zou Y, Voss EA, et al.. Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network. PLOS ONE. 2020;15: e0226718. doi: 10.1371/journal.pone.0226718</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0226718</ArticleId><ArticleId IdType="pmc">PMC6946584</ArticleId><ArticleId IdType="pubmed">31910437</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI/WhiteRabbit. 3 Feb 2021 [cited 18 Feb 2021]. Available: https://github.com/OHDSI/WhiteRabbit</Citation></Reference><Reference><Citation>Johnson AEW, Pollard TJ, Shen L, Lehman LH, Feng M, Ghassemi M, et al.. MIMIC-III, a freely accessible critical care database. Sci Data. 2016;3: 160035. doi: 10.1038/sdata.2016.35</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.35</ArticleId><ArticleId IdType="pmc">PMC4878278</ArticleId><ArticleId IdType="pubmed">27219127</ArticleId></ArticleIdList></Reference><Reference><Citation>MIMIC-OMOP. MIT Laboratory for Computational Physiology; 2022. Available: https://github.com/MIT-LCP/mimic-omop</Citation></Reference><Reference><Citation>Karwin B. SQL Antipatterns: Avoiding the Pitfalls of Database Programming. 1st edition. Pragmatic Bookshelf; 2010.</Citation></Reference><Reference><Citation>Weber JH, Cleve A, Meurice L, Ruiz FJB. Managing Technical Debt in Database Schemas of Critical Software. 2014 Sixth International Workshop on Managing Technical Debt. 2014. pp. 43&#x2013;46. doi: 10.1109/MTD.2014.17</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/MTD.2014.17</ArticleId></ArticleIdList></Reference><Reference><Citation>Filho FG de A, Martins ADF, Vinuto T da S, Monteiro JM, Sousa &#xcd;P de, Machado J de C, et al.. Prevalence of Bad Smells in PL/SQL Projects. 2019 IEEE/ACM 27th International Conference on Program Comprehension (ICPC). 2019. pp. 116&#x2013;121. doi: 10.1109/ICPC.2019.00025</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/ICPC.2019.00025</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson L, Boland MR. Comparative Analysis and Evaluation of State-of-the-Art Medication Mapping Tools to Transform a Local Medication Terminology to RxNorm. AMIA Summits Transl Sci Proc. 2020;2020: 126&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233099</ArticleId><ArticleId IdType="pubmed">32477631</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI/Usagi. 2 Feb 2021 [cited 18 Feb 2021]. Available: https://github.com/OHDSI/Usagi</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35426943</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Combining human and machine intelligence for clinical trial eligibility querying.</ArticleTitle><Pagination><StartPage>1161</StartPage><EndPage>1171</EndPage><MedlinePgn>1161-1171</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocac051</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To combine machine efficiency and human intelligence for converting complex clinical trial eligibility criteria text into cohort queries.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Criteria2Query (C2Q) 2.0 was developed to enable real-time user intervention for criteria selection and simplification, parsing error correction, and concept mapping. The accuracy, precision, recall, and F1 score of enhanced modules for negation scope detection, temporal and value normalization were evaluated using a previously curated gold standard, the annotated eligibility criteria of 1010 COVID-19 clinical trials. The usability and usefulness were evaluated by 10 research coordinators in a task-oriented usability evaluation using 5 Alzheimer's disease trials. Data were collected by user interaction logging, a demographic questionnaire, the Health Information Technology Usability Evaluation Scale (Health-ITUES), and a feature-specific questionnaire.</AbstractText><AbstractText Label="RESULTS">The accuracies of negation scope detection, temporal and value normalization were 0.924, 0.916, and 0.966, respectively. C2Q 2.0 achieved a moderate usability score (3.84 out of 5) and a high learnability score (4.54 out of 5). On average, 9.9 modifications were made for a clinical study. Experienced researchers made more modifications than novice researchers. The most frequent modification was deletion (5.35 per study). Furthermore, the evaluators favored cohort queries resulting from modifications (score 4.1 out of 5) and the user engagement features (score 4.3 out of 5).</AbstractText><AbstractText Label="DISCUSSION AND CONCLUSION">Features to engage domain experts and to overcome the limitations in automated machine output are shown to be useful and user-friendly. We concluded that human-computer collaboration is key to improving the adoption and user-friendliness of natural language processing.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yilu</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2681-1931</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idnay</LastName><ForeName>Betina</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-4318-5987</Identifier><AffiliationInfo><Affiliation>School of Nursing, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yingcheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1975-1272</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhehuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marder</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5274-4672</Identifier><AffiliationInfo><Affiliation>School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnall</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2184-4045</Identifier><AffiliationInfo><Affiliation>School of Nursing, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heilbrunn Department of Population and Family Health, Mailman School of Public Health, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9624-0214</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT2 TR003434</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 NR018621</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R36 HS028752</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NR007969</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="N">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004608" MajorTopicYN="N">Eligibility Determination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="N">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cohort identification</Keyword><Keyword MajorTopicYN="N">eligibility prescreening</Keyword><Keyword MajorTopicYN="N">human&#x2013;computer collaboration</Keyword><Keyword MajorTopicYN="N">informatics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>12</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35426943</ArticleId><ArticleId IdType="pmc">PMC9196697</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocac051</ArticleId><ArticleId IdType="pii">6569054</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams M, Caffrey L, McKevitt C. &#xa0;Barriers and opportunities for enhancing patient recruitment and retention in clinical research: findings from an interview study in an NHS academic health science centre. Health Res Policy Syst &#xa0;2015; 13: 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4429658</ArticleId><ArticleId IdType="pubmed">25971302</ArticleId></ArticleIdList></Reference><Reference><Citation>Nipp RD, Hong K, Paskett ED. &#xa0;Overcoming barriers to clinical trial enrollment. Am Soc Clin Oncol Educ Book &#xa0;2019; 39: 105&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31099636</ArticleId></ArticleIdList></Reference><Reference><Citation>Embi PJ, Payne PR. &#xa0;Clinical research informatics: challenges, opportunities and definition for an emerging domain. J Am Med Inform Assoc &#xa0;2009; 16 (3): 316&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732242</ArticleId><ArticleId IdType="pubmed">19261934</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivade C, Hebert C, Lopetegui M. et al. Textual inference for eligibility criteria resolution in clinical trials. J Biomed Inform &#xa0;2015; 58 (Suppl): S211&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978353</ArticleId><ArticleId IdType="pubmed">26376462</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuggia M, Campillo-Gimenez B, Bouzille G, et al. &#xa0;Automatic selection of clinical trials based on a semantic web approach. Stud Health Technol Inform &#xa0;2015; 216: 564&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26262114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansart M, Epelbaum S, Gagliardi G, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative and the INSIGHT-preAD study. Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis. Stat Methods Med Res &#xa0;2020; 29 (1): 151&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30698081</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C. &#xa0;Optimizing clinical research participant selection with informatics. Trends Pharmacol Sci &#xa0;2015; 36 (11): 706&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4686428</ArticleId><ArticleId IdType="pubmed">26549161</ArticleId></ArticleIdList></Reference><Reference><Citation>Vydiswaran VGV, Strayhorn A, Zhao X, et al. &#xa0;Hybrid bag of approaches to characterize selection criteria for cohort identification. J Am Med Inform Assoc &#xa0;2019; 26 (11): 1172&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647216</ArticleId><ArticleId IdType="pubmed">31197354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Y, Kennebeck S, Dexheimer JW, et al. &#xa0;Automated clinical trial eligibility prescreening: increasing the efficiency of patient identification for clinical trials in the emergency department. J Am Med Inform Assoc &#xa0;2015; 22 (1): 166&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433376</ArticleId><ArticleId IdType="pubmed">25030032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Y, Wright J, Perentesis J, et al. &#xa0;Increasing the efficiency of trial-patient matching: automated clinical trial eligibility pre-screening for pediatric oncology patients. BMC Med Inform Decis Mak &#xa0;2015; 15: 28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407835</ArticleId><ArticleId IdType="pubmed">25881112</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao T, Liu H, Weng C. &#xa0;Valx: a system for extracting and structuring numeric lab test comparison statements from text. Methods Inf Med &#xa0;2016; 55 (3): 266&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573874</ArticleId><ArticleId IdType="pubmed">26940748</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang T, Zhang S, Tang Y, et al. &#xa0;EliIE: an open-source information extraction system for clinical trial eligibility criteria. J Am Med Inform Assoc &#xa0;2017; 24 (6): 1062&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6259668</ArticleId><ArticleId IdType="pubmed">28379377</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan C, Ryan PB, Ta C, et al. &#xa0;Criteria2Query: a natural language interface to clinical databases for cohort definition. J Am Med Inform Assoc &#xa0;2019; 26 (4): 294&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402359</ArticleId><ArticleId IdType="pubmed">30753493</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseo Y, Salkola M, Mohamed A. et&#xa0;al. Information extraction of clinical trial eligibility criteria. arXiv preprint arXiv:200607296. &#xa0;2020.</Citation></Reference><Reference><Citation>Liu X, Finelli LA, Hersch GL. et&#xa0;al. Attention-based LSTM network for COVID-19 clinical trial parsing. In: 2020 IEEE International Conference on Big Data (Big Data); Dec 10&#x2013;13, 2020: 3761&#x2013;6; Atlanta, GA, USA.</Citation></Reference><Reference><Citation>Tian S, Erdengasileng A, Yang X, et al. Transformer-based named entity recognition for parsing clinical trial eligibility criteria. In: Proceedings of the 12th ACM Conference on Bioinformatics, Computational Biology, and Health Informatics; Aug 1&#x2013;4, 2021; Gainesville, FL, USA.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373041</ArticleId><ArticleId IdType="pubmed">34414397</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Hersch GL, Khalil I. et&#xa0;al. Clinical trial information extraction with BERT. In: 2021 IEEE 9th International Conference on Healthcare Informatics (ICHI); Aug 9&#x2013;12, 2021: 505&#x2013;6; Victoria, BC, Canada.</Citation></Reference><Reference><Citation>Chen M, Du F, Lan G. et&#xa0;al. Using pre-trained transformer deep learning models to identify named entities and syntactic relations for clinical protocol analysis. In: AAAI Spring Symposium: Combining Machine Learning with Knowledge Engineering (1); Mar 23&#x2013;25, 2020; Palo Alto, CA, USA.</Citation></Reference><Reference><Citation>Ji Z, Wei Q, Xu H. &#xa0;BERT-based ranking for biomedical entity normalization. AMIA Summits Transl Sci Proc &#xa0;2020; 2020: 269&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233044</ArticleId><ArticleId IdType="pubmed">32477646</ArticleId></ArticleIdList></Reference><Reference><Citation>Miftahutdinov Z, Kadurin A, Kudrin R. et&#xa0;al. Medical concept normalization in clinical trials with drug and disease representation learning. Bioinformatics &#xa0;2021; 37 (21): 3856&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8570806</ArticleId><ArticleId IdType="pubmed">34213526</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross J, Tu S, Carini S. et&#xa0;al. Analysis of eligibility criteria complexity in clinical trials. Summit Transl Bioinform &#xa0;2010; 2010: 46&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041539</ArticleId><ArticleId IdType="pubmed">21347148</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Liu H, Kury F, et al. A comparison between human and NLP-based annotation of clinical trial eligibility criteria text using the OMOP Common Data Model. AMIA Jt Summits Transl Sci Proc 2021; 2021: 394&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8378608</ArticleId><ArticleId IdType="pubmed">34457154</ArticleId></ArticleIdList></Reference><Reference><Citation>Idnay B, Dreisbach C, Weng C. et&#xa0;al. A systematic review on natural language processing systems for eligibility prescreening in clinical research. J Am Med Inform Assoc &#xa0;2021; 29 (1): 197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8714283</ArticleId><ArticleId IdType="pubmed">34725689</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y, Kim JH, Idnay BR, et al. &#xa0;Participatory design of a clinical trial eligibility criteria simplification method. Stud Health Technol Inform &#xa0;2021; 281: 984&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">34042820</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandelwal A, Sawant S. NegBERT: a transfer learning approach for negation detection and scope resolution. In: Proceedings of the 12th Language Resources and Evaluation Conference; May 2020:. 5739&#x2013;48; Marseille, France.</Citation></Reference><Reference><Citation>Gu Y, Tinn R, Cheng H, et al. &#xa0;Domain-specific language model pretraining for biomedical natural language processing. ACM Trans Comput Healthc &#xa0;2021; 3 (1): 1&#x2013;23.</Citation></Reference><Reference><Citation>Britto BK, Khandelwal A. Resolving the scope of speculation and negation using transformer-based architectures. arXiv preprint arXiv:200102885. &#xa0;2020.</Citation></Reference><Reference><Citation>Vincze V, Szarvas G, Farkas R. et&#xa0;al. The BioScope corpus: biomedical texts annotated for uncertainty, negation and their scopes. BMC Bioinform &#xa0;2008; 9 (S11): 1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586758</ArticleId><ArticleId IdType="pubmed">19025695</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang AX, Manning CD. Sutime: a library for recognizing and normalizing time expressions. In: Proceedings of the Eighth International Conference on Language Resources and Evaluation (LREC'12); May 2012: 3735&#x2013;40; Istanbul, Turkey.</Citation></Reference><Reference><Citation>Manning CD, Surdeanu M, Bauer J. et&#xa0;al. The Stanford CoreNLP natural language processing toolkit. In:&#xa0;Proceedings of 52nd Annual Meeting of the Association for Computational Linguistics: System Demonstrations; June 2014: 55&#x2013;60; Baltimore, MD, USA.</Citation></Reference><Reference><Citation>Sun Y, Butler A, Stewart LA, et al. &#xa0;Building an OMOP common data model-compliant annotated corpus for COVID-19 clinical trials. J Biomed Inform &#xa0;2021; 118: 103790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8079156</ArticleId><ArticleId IdType="pubmed">33887457</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasneem A, Aberle L, Ananth H, et al. &#xa0;The database for aggregate analysis of ClinicalTrials. gov (AACT) and subsequent regrouping by clinical specialty. PLoS One &#xa0;2012; 7 (3): e33677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306288</ArticleId><ArticleId IdType="pubmed">22438982</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernacki P, Waldorf D. &#xa0;Snowball sampling: problems and techniques of chain referral sampling. Sociol Methods Res &#xa0;1981; 10 (2): 141&#x2013;63.</Citation></Reference><Reference><Citation>Hwang W, Salvendy G. &#xa0;Number of people required for usability evaluation. Commun ACM &#xa0;2010; 53 (5): 130&#x2013;3.</Citation></Reference><Reference><Citation>Yen PY, Wantland D, Bakken S. &#xa0;Development of a customizable Health IT Usability Evaluation Scale. AMIA Annu Symp Proc &#xa0;2010; 2010: 917&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041285</ArticleId><ArticleId IdType="pubmed">21347112</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen PY, Sousa KH, Bakken S. &#xa0;Examining construct and predictive validity of the Health-IT Usability Evaluation Scale: confirmatory factor analysis and structural equation modeling results. J Am Med Inform Assoc &#xa0;2014; 21 (e2): e241&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4173162</ArticleId><ArticleId IdType="pubmed">24567081</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnall R, Cho H, Liu J. &#xa0;Health Information Technology Usability Evaluation Scale (Health-ITUES) for usability assessment of mobile health technology: validation study. JMIR Mhealth Uhealth &#xa0;2018; 6 (1): e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5775483</ArticleId><ArticleId IdType="pubmed">29305343</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh KP, Liu J, Ganzhorn S. et&#xa0;al. Establishing a usability cut-point for the Health Information Technology Usability Evaluation Scale (Health-ITUES). Int J Med Inform &#xa0;2022; 160: 104713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903058</ArticleId><ArticleId IdType="pubmed">35144102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund AM. &#xa0;Measuring usability with the use questionnaire. Usability Interface &#xa0;2001; 8 (2): 3&#x2013;6.</Citation></Reference><Reference><Citation>Zhang Y, Zhang G, Shang Q. &#xa0;Computer-aided clinical trial recruitment based on domain-specific language translation: a case study of retinopathy of prematurity. J Healthc Eng &#xa0;2017; 2017: 7862672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5396472</ArticleId><ArticleId IdType="pubmed">29065644</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubbs A, Filannino M, Soysal E. et&#xa0;al. Cohort selection for clinical trials: n2c2 2018 shared task track 1. J Am Med Inform Assoc &#xa0;2019; 26 (11): 1163&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6798568</ArticleId><ArticleId IdType="pubmed">31562516</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng K, Vydiswaran VG, Liu Y, et al. &#xa0;Ease of adoption of clinical natural language processing software: an evaluation of five systems. J Biomed Inform &#xa0;2015; 58 (Suppl): S189&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974203</ArticleId><ArticleId IdType="pubmed">26210361</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones K, Galliers J. &#xa0;Evaluating Natural Language Processing Systems: An Analysis and Review. Berlin, Heidelberg: Springer-Verlag; 1995.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35429722</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8243</ISSN><JournalIssue CitedMedium="Internet"><Volume>163</Volume><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>International journal of medical informatics</Title><ISOAbbreviation>Int J Med Inform</ISOAbbreviation></Journal><ArticleTitle>Logistic regression models for patient-level prediction based on massive observational data: Do we need all data?</ArticleTitle><Pagination><StartPage>104762</StartPage><MedlinePgn>104762</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijmedinf.2022.104762</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1386-5056(22)00076-4</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Provide guidance on sample size considerations for developing predictive models by empirically establishing the adequate sample size, which balances the competing objectives of improving model performance and reducing model complexity as well as computational requirements.</AbstractText><AbstractText Label="MATERIALS AND METHODS">We empirically assess the effect of sample size on prediction performance and model complexity by generating learning curves for 81 prediction problems (23 outcomes predicted in a depression cohort, 58 outcomes predicted in a hypertension cohort) in three large observational health databases, requiring training of 17,248 prediction models. The adequate sample size was defined as the sample size for which the performance of a model equalled the maximum model performance minus a small threshold value.</AbstractText><AbstractText Label="RESULTS">The adequate sample size achieves a median reduction of the number of observations of 9.5%, 37.3%, 58.5%, and 78.5% for the thresholds of 0.001, 0.005, 0.01, and 0.02, respectively. The median reduction of the number of predictors in the models was 8.6%, 32.2%, 48.2%, and 68.3% for the thresholds of 0.001, 0.005, 0.01, and 0.02, respectively.</AbstractText><AbstractText Label="DISCUSSION">Based on our results a conservative, yet significant, reduction in sample size and model complexity can be estimated for future prediction work. Though, if a researcher is willing to generate a learning curve a much larger reduction of the model complexity may be possible as suggested by a large outcome-dependent variability.</AbstractText><AbstractText Label="CONCLUSION">Our results suggest that in most cases only a fraction of the available data was sufficient to produce a model close to the performance of one developed on the full data set, but with a substantially reduced model complexity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>John</LastName><ForeName>Luis H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic address: l.john@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kors</LastName><ForeName>Jan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Int J Med Inform</MedlineTA><NlmUniqueID>9711057</NlmUniqueID><ISSNLinking>1386-5056</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="Y">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Learning curve</Keyword><Keyword MajorTopicYN="N">Logistic regression</Keyword><Keyword MajorTopicYN="N">Model complexity</Keyword><Keyword MajorTopicYN="N">Observational data</Keyword><Keyword MajorTopicYN="N">Prediction model</Keyword><Keyword MajorTopicYN="N">Sample size</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35429722</ArticleId><ArticleId IdType="doi">10.1016/j.ijmedinf.2022.104762</ArticleId><ArticleId IdType="pii">S1386-5056(22)00076-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35435957</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Harmonizing units and values of quantitative data elements in a very large nationally pooled electronic health record (EHR) dataset.</ArticleTitle><Pagination><StartPage>1172</StartPage><EndPage>1182</EndPage><MedlinePgn>1172-1182</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocac054</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The goals of this study were to harmonize data from electronic health records (EHRs) into common units, and impute units that were missing.</AbstractText><AbstractText Label="MATERIALS AND METHODS">The National COVID Cohort Collaborative (N3C) table of laboratory measurement data-over 3.1 billion patient records and over 19&#xa0;000 unique measurement concepts in the Observational Medical Outcomes Partnership (OMOP) common-data-model format from 55 data partners. We grouped ontologically similar OMOP concepts together for 52 variables relevant to COVID-19 research, and developed a unit-harmonization pipeline comprised of (1) selecting a canonical unit for each measurement variable, (2) arriving at a formula for conversion, (3) obtaining clinical review of each formula, (4) applying the formula to convert data values in each unit into the target canonical unit, and (5) removing any harmonized value that fell outside of accepted value ranges for the variable. For data with missing units for all the results within a lab test for a data partner, we compared values with pooled values of all data partners, using the Kolmogorov-Smirnov test.</AbstractText><AbstractText Label="RESULTS">Of the concepts without missing values, we harmonized 88.1% of the values, and imputed units for 78.2% of records where units were absent (41% of contributors' records lacked units).</AbstractText><AbstractText Label="DISCUSSION">The harmonization and inference methods developed herein can serve as a resource for initiatives aiming to extract insight from heterogeneous EHR collections. Unique properties of centralized data are harnessed to enable unit inference.</AbstractText><AbstractText Label="CONCLUSION">The pipeline we developed for the pooled N3C data enables use of measurements that would otherwise be unavailable for analysis.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bradwell</LastName><ForeName>Katie R</ForeName><Initials>KR</Initials><Identifier Source="ORCID">0000-0002-9730-1808</Identifier><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wooldridge</LastName><ForeName>Jacob T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amor</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials><Identifier Source="ORCID">0000-0003-1483-4236</Identifier><AffiliationInfo><Affiliation>Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Adit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bremer</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Yun Jae</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Zhenglong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Institute for Health Informatics, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Emily R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0002-6840-9756</Identifier><AffiliationInfo><Affiliation>Department of Medicine, North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girvin</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manna</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niehaus</LastName><ForeName>Emily A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Stephanie S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>School of Medicine, Section of Biomedical Informatics and Data Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaohan Tanner</ForeName><Initials>XT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0002-4289-7632</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bissell</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Nabeel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saltz</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haendel</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9114-8737</Identifier><AffiliationInfo><Affiliation>Center for Health AI, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0001-5437-2545</Identifier><AffiliationInfo><Affiliation>Schools of Medicine, Public Health, and Nursing, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Harold P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moffitt</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-2723-5902</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>N3C Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM104938</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002649</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003167</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001433</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001860</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104942</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002243</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003096</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002537</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001412</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001878</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002529</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002736</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5U54GM104942-04</GrantID><Agency>NIGMS National Institute of General Medical Sciences</Agency><Country/></Grant><Grant><GrantID>U54 GM115516</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002001</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115458</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001442</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002535</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001866</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001449</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001453</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104940</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003107</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003015</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002733</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002003</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001876</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001436</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002384</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002553</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002389</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104941</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002014</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002550</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002319</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003017</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>N3C Attribution &amp;amp; Publication Policy v1.2-2020-08-25b</Agency><Country/></Grant><Grant><GrantID>UL1 TR001439</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001998</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001881</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002645</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24TR002306</GrantID><Agency>National Center for Advancing Translational Sciences Institute</Agency><Country/></Grant><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115428</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002377</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115677</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003098</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001430</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">data accuracy</Keyword><Keyword MajorTopicYN="N">data collection</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">reference standards</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>18</Day><Hour>12</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35435957</ArticleId><ArticleId IdType="pmc">PMC9196692</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocac054</ArticleId><ArticleId IdType="pii">6569865</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haendel MA, Chute CG, Bennett TD, et al.; N3C Consortium. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J Am Med Inform Assoc &#xa0;2021; 28 (3): 427&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI). Definition and DDLs for the OMOP Common Data Model (CDM) l Version 5.3. Github; 2018. https://github.com/OHDSI/CommonDataModel Accessed April 13, 2020.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. &#xa0;Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform &#xa0;2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff SM, Rocha RA, McDonald CJ, et al. &#xa0;Development of the Logical Observation Identifier Names and Codes (LOINC) vocabulary. J Am Med Inform Assoc &#xa0;1998; 5 (3): 276&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61302</ArticleId><ArticleId IdType="pubmed">9609498</ArticleId></ArticleIdList></Reference><Reference><Citation>Schadow G, McDonald CJ. The Unified Code for Units of Measure [Internet]. Indianapolis, IN: Regenstrief Institute, Inc.; c1999&#x2013;2013 [cited 2021 Sept 01]. http://unitsofmeasure.org/trac/. Jointly published with the UCUM Organization.</Citation></Reference><Reference><Citation>Ficheur G, Chazard E, Schaffar A, Genty M, Beuscart R. &#xa0;Interoperability of medical databases: construction of mapping between hospitals laboratory results assisted by automated comparison of their distributions. AMIA Annu Symp Proc &#xa0;2011; 2011: 392&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243167</ArticleId><ArticleId IdType="pubmed">22195092</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajput AM, Ballout S, Drenkhahn C. &#xa0;Standardizing the unit of measurements in LOINC-coded laboratory tests can significantly improve semantic interoperability. Stud Health Technol Inform &#xa0;2020; 275: 234&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">33227779</ArticleId></ArticleIdList></Reference><Reference><Citation>Drenkhahn C, Ingenerf J. &#xa0;The LOINC content model and its limitations of usage in the laboratory domain. Stud Health Technol Inform &#xa0;2020; 270: 437&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">32570422</ArticleId></ArticleIdList></Reference><Reference><Citation>Drenkhahn C, Duhm-Harbeck P, Ingenerf J. &#xa0;Aggregation and visualization of laboratory data by using ontological tools based on LOINC and SNOMED CT. Stud Health Technol Inform &#xa0;2019; 264: 108&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437895</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser RG, Quine DB, Ryder A, Campbell S. &#xa0;Unit conversions between LOINC codes. J Am Med Inform Assoc &#xa0;2018; 25 (2): 192&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251580</ArticleId><ArticleId IdType="pubmed">28637208</ArticleId></ArticleIdList></Reference><Reference><Citation>Vreeman DJ, Abhyankar S, McDonald CJ. &#xa0;Response to unit conversions between LOINC codes. J Am Med Inform Assoc &#xa0;2018; 25 (5): 614&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251552</ArticleId><ArticleId IdType="pubmed">29025119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett TD, Moffitt RA, Hajagos JG, et al., National COVID Cohort Collaborative (N3C) Consortium. Clinical characterization and prediction of clinical severity of SARS-CoV-2 infection among US adults using data from the US National COVID Cohort Collaborative. JAMA Netw Open &#xa0;2021; 4 (7): e2116901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8278272</ArticleId><ArticleId IdType="pubmed">34255046</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarti IM, Laha RG, Roy J. &#xa0;Handbook of Methods of Applied Statistics. Vol. 1. New York, NY: Wiley; 1967.</Citation></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA. &#xa0;Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci 2018; 376 (2128): 20170356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>LOINC release notes. LOINC by Regenstrief; 2021. https://loinc.org/kb/loinc-release-notes/.&#xa0;Accessed February 15, 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35460296</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0609</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of haematology</Title><ISOAbbreviation>Eur J Haematol</ISOAbbreviation></Journal><ArticleTitle>Haematology Outcomes Network in Europe (HONEUR)-A collaborative, interdisciplinary platform to harness the potential of real-world data in hematology.</ArticleTitle><Pagination><StartPage>138</StartPage><EndPage>145</EndPage><MedlinePgn>138-145</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ejh.13780</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">There remains a need to optimize treatments and improve outcomes among patients with hematologic malignancies. The timely synthesis and analysis of real-world data could play a key role.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The Haematology Outcomes Network in Europe (HONEUR) is a federated data network (FDN) that aims to overcome the challenges of heterogenous data collected from different registries, hospitals, and other databases in different countries. It has the functionality required to analyze data from various sources in a time efficient manner, while preserving local data security and governance. With this, research studies can be performed that can increase knowledge and understanding of the management of patients with hematologic malignancies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">HONEUR uses the Observational Medical Outcomes Partnership (OMOP) common data model, which allows analysis scripts to be run by multiple sites using their own data, ultimately generating aggregated results. Furthermore, distributed analytics can be used to run statistical analyses across multiple sites, as if data were pooled. The external governance model ensures high-quality standards, while data ownership is retained locally. Twenty partners from nine countries are now participating, with data from more than 26&#x2009;000 patients available for analysis. Research questions that can be addressed through HONEUR include assessments of natural disease history, treatment patterns, and clinical effectiveness.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The HONEUR FDN marks an important step forward in increasing the value of information routinely captured by individual hospitals, registries and other database holders, thus enabling larger-scale studies to be undertaken rapidly and efficiently.</AbstractText><CopyrightInformation>&#xa9; 2022 Janssen Pharmaceutica NV. European Journal of Haematology published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bardenheuer</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica N.V, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Speybroeck</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica N.V, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hague</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica N.V, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikai</LastName><ForeName>Enkeleida</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica N.V, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica N.V, Beerse, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Janssen Pharmaceutica N.V.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Haematol</MedlineTA><NlmUniqueID>8703985</NlmUniqueID><ISSNLinking>0902-4441</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="Y">Hematologic Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006405" MajorTopicYN="Y">Hematology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Haematology Outcomes Network in Europe</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">data analysis</Keyword><Keyword MajorTopicYN="N">evidence generation</Keyword><Keyword MajorTopicYN="N">federated data network</Keyword><Keyword MajorTopicYN="N">real-world evidence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>8</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35460296</ArticleId><ArticleId IdType="doi">10.1111/ejh.13780</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295-304.</Citation></Reference><Reference><Citation>Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10:326-335.</Citation></Reference><Reference><Citation>Goettsch W, Makady A. Glossary of Definitions of common terms. 2016. https://www.getreal-institute.org/about-us/focus-areas/ (accessed May 2nd, 2022)</Citation></Reference><Reference><Citation>Wang Y, Kung L, Byrd TA. Big data analytics: understanding its capabilities and potential benefits for healthcare organizations. Technol Forecast Soc Change. 2018;126:3-13.</Citation></Reference><Reference><Citation>Kahn MG, Callahan TJ, Barnard J, et al. A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS (Wash DC). 2016;4:1244.</Citation></Reference><Reference><Citation>Makady A, van Veelen A, Jonsson P, et al. Using real-world data in Health Technology Assessment (HTA) practice: a comparative study of five HTA agencies. Pharmacoeconomics. 2018;36:359-368.</Citation></Reference><Reference><Citation>Makady A, Ham RT, de Boer A, et al. Policies for use of real-world data in Health Technology Assessment (HTA): a comparative study of six HTA agencies. Value Health. 2017;20:520-532.</Citation></Reference><Reference><Citation>Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106:36-39.</Citation></Reference><Reference><Citation>Geldof T, Huys I, Van Dyck W. Real-world evidence gathering in oncology: the need for a biomedical big data insight-providing federated network. Front Med (Lausanne). 2019;6:43.</Citation></Reference><Reference><Citation>European Health Data &amp; Evidence Network (EHDEN). The role of a common data model (CDM) for harmonised real world data, (RWD) analytics and real world evidence (RWE) generation; unpublished internal document, 2021.</Citation></Reference><Reference><Citation>Hunger M, Bardenheuer K, Passey A, et al. The value of federated data networks in oncology: what research questions do they answer? Outcomes from a systematic literature review, Value in Health.</Citation></Reference><Reference><Citation>HONEUR. 6 more data partners have joined the Haematology outcomes network in Europe (HONEUR). Improving results for patients by realising the transformational potential of real world data: Janssen Pharmaceutical Companies of Johnson &amp; Johnson. 2019.</Citation></Reference><Reference><Citation>Agency EM. EMA/614680/2018 - A Common Data Model for Europe? - Why? Which? How? European Medicines Agency; 2018.</Citation></Reference><Reference><Citation>Chen R, Ryan P, Natarajan K, et al. Treatment patterns for chronic comorbid conditions in patients with cancer using a large-scale observational data network. JCO Clin Cancer Inform. 2020;4:171-183.</Citation></Reference><Reference><Citation>HONEUR. Brochure: accelerated real-world data analysis and evidence sharing. Janssen Pharmaceutical Companies of Johnson &amp; Johnson; 2020. https://portal.honeur.org/honeur-materials (accessed May 2nd, 2022)</Citation></Reference><Reference><Citation>OHDSI. OMOP Common Data Model. v5.3.1 ed. https://ohdsi.github.io/CommonDataModel/cdm531.html (accessed May 2nd, 2022)</Citation></Reference><Reference><Citation>Mohty M, Terpos E, Mateos MV, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018;18:e401-e419.</Citation></Reference><Reference><Citation>Toh S, Shetterly S, Powers JD, Arterburn D. Privacy-preserving analytic methods for multisite comparative effectiveness and patient-centered outcomes research. Med Care. 2014;52:664-668.</Citation></Reference><Reference><Citation>Narasimhan B, Rubin D, Gross S, et al. Software for distributed computation on medical databases: a demonstration project. J Stat Softw. 2017;77:1-22.</Citation></Reference><Reference><Citation>Passey A, Perualilia NJ, Bardenheuer K, et al. HONEUR (Haematology Outcomes Network in Europe) - Distributed Statistics in a Federated Model to Support Real World Data Research in Haematology. Presented at the Annual Meeting 2019 of the European Hematology Association Amsterdamm 13-16 June 2019. 2019.</Citation></Reference><Reference><Citation>OHDSI. Data Quality Dashboard. v1.3.1 ed. 2020. https://github.com/OHDSI/DataQualityDashboard (accessed May 2nd, 2022)</Citation></Reference><Reference><Citation>ICMJE. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. 2019. http://www.icmje.org/ (accessed May 2nd, 2022)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35482996</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2369-2960</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>17</Day></PubDate></JournalIssue><Title>JMIR public health and surveillance</Title><ISOAbbreviation>JMIR Public Health Surveill</ISOAbbreviation></Journal><ArticleTitle>Characterizing Anchoring Bias in Vaccine Comparator Selection Due to Health Care Utilization With COVID-19 and Influenza: Observational Cohort Study.</ArticleTitle><Pagination><StartPage>e33099</StartPage><MedlinePgn>e33099</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e33099</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/33099</ELocationID><Abstract><AbstractText Label="BACKGROUND">Observational data enables large-scale vaccine safety surveillance but requires careful evaluation of the potential sources of bias. One potential source of bias is the index date selection procedure for the unvaccinated cohort or unvaccinated comparison time ("anchoring").</AbstractText><AbstractText Label="OBJECTIVE">Here, we evaluated the different index date selection procedures for 2 vaccinations: COVID-19 and influenza.</AbstractText><AbstractText Label="METHODS">For each vaccine, we extracted patient baseline characteristics on the index date and up to 450 days prior and then compared them to the characteristics of the unvaccinated patients indexed on (1) an arbitrary date or (2) a date of a visit. Additionally, we compared vaccinated patients indexed on the date of vaccination and the same patients indexed on a prior date or visit.</AbstractText><AbstractText Label="RESULTS">COVID-19 vaccination and influenza vaccination differ drastically from each other in terms of the populations vaccinated and their status on the day of vaccination. When compared to indexing on a visit in the unvaccinated population, influenza vaccination had markedly higher covariate proportions, and COVID-19 vaccination had lower proportions of most covariates on the index date. In contrast, COVID-19 vaccination had similar covariate proportions when compared to an arbitrary date. These effects attenuated, but were still present, with a longer lookback period. The effect of day 0 was present even when the patients served as their own controls.</AbstractText><AbstractText Label="CONCLUSIONS">Patient baseline characteristics are sensitive to the choice of the index date. In vaccine safety studies, unexposed index event should represent vaccination settings. Study designs previously used to assess influenza vaccination must be reassessed for COVID-19 to account for a potentially healthier population and lack of medical activity on the day of vaccination.</AbstractText><CopyrightInformation>&#xa9;Anna Ostropolets, Patrick B Ryan, Martijn J Schuemie, George Hripcsak. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 17.06.2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0847-6682</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><Identifier Source="ORCID">0000-0002-9727-2138</Identifier><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0817-5361</Identifier><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2664-7614</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterian Hospital, New York, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Public Health Surveill</MedlineTA><NlmUniqueID>101669345</NlmUniqueID><ISSNLinking>2369-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anchoring</Keyword><Keyword MajorTopicYN="N">bias</Keyword><Keyword MajorTopicYN="N">cohort</Keyword><Keyword MajorTopicYN="N">comparator selection</Keyword><Keyword MajorTopicYN="N">flu</Keyword><Keyword MajorTopicYN="N">index</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">observational</Keyword><Keyword MajorTopicYN="N">time-at-risk</Keyword><Keyword MajorTopicYN="N">utilization</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>Conflicts of Interest: GH and AO receive funding from the US National Institutes of Health and the US Food and Drug Administration. PBR and MJS are employees of Janssen Research and Development and shareholders in Johnson and Johnson. Funders had no role in the conceptualization, design, data&#xa0;collection, analysis, decision to&#xa0;publish,&#xa0;nor preparation of the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>28</Day><Hour>15</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35482996</ArticleId><ArticleId IdType="pmc">PMC9250064</ArticleId><ArticleId IdType="doi">10.2196/33099</ArticleId><ArticleId IdType="pii">v8i6e33099</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Forni G, Mantovani A, COVID-19 Commission of Accademia Nazionale dei Lincei&#x201a; Rome  COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021 Feb;28(2):626&#x2013;639. doi: 10.1038/s41418-020-00720-9. 
 
10.1038/s41418-020-00720-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-00720-9</ArticleId><ArticleId IdType="pmc">PMC7818063</ArticleId><ArticleId IdType="pubmed">33479399</ArticleId></ArticleIdList></Reference><Reference><Citation>Zayet S, Kadiane-Oussou NJ, Lepiller Q, Zahra H, Royer P, Toko L, Gendrin V, Klopfenstein T. Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. Microbes Infect. 2020 Oct;22(9):481&#x2013;488. doi: 10.1016/j.micinf.2020.05.016. 
 
S1286-4579(20)30094-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2020.05.016</ArticleId><ArticleId IdType="pmc">PMC7297177</ArticleId><ArticleId IdType="pubmed">32561409</ArticleId></ArticleIdList></Reference><Reference><Citation>Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin M, Bhatia S, Boonyasiri A, Cori A, Cucunub&#xe1; Zulma, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun;20(6):669&#x2013;677. doi: 10.1016/S1473-3099(20)30243-7. 
 
S1473-3099(20)30243-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30243-7</ArticleId><ArticleId IdType="pmc">PMC7158570</ArticleId><ArticleId IdType="pubmed">32240634</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrah&#xe3;o Maria Tereza F, Alberga A, Alghoul H, Alser O, Alshammari TM, Aragon M, Areia C, Banda JM, Cho J, Culhane AC, Davydov A, DeFalco FJ, Duarte-Salles T, DuVall S, Falconer T, Fernandez-Bertolin S, Gao W, Golozar A, Hardin J, Hripcsak G, Huser V, Jeon H, Jing Y, Jung CY, Kaas-Hansen BS, Kaduk D, Kent S, Kim Y, Kolovos S, Lane JCE, Lee H, Lynch KE, Makadia R, Matheny ME, Mehta PP, Morales DR, Natarajan K, Nyberg F, Ostropolets A, Park RW, Park J, Posada JD, Prats-Uribe A, Rao G, Reich C, Rho Y, Rijnbeek P, Schilling LM, Schuemie M, Shah NH, Shoaibi A, Song S, Spotnitz M, Suchard MA, Swerdel JN, Vizcaya D, Volpe S, Wen H, Williams AE, Yimer BB, Zhang L, Zhuk O, Prieto-Alhambra D, Ryan P. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun. 2020 Oct 06;11(1):5009. doi: 10.1038/s41467-020-18849-z. doi: 10.1038/s41467-020-18849-z.10.1038/s41467-020-18849-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooling K, Marin M, Wallace M, McClung N, Chamberland M, Lee GM, Talbot HK, Romero JR, Bell BP, Oliver SE. The Advisory Committee on Immunization Practices' updated interim recommendation for allocation of COVID-19 vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1657&#x2013;1660. doi: 10.15585/mmwr.mm695152e2. doi: 10.15585/mmwr.mm695152e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm695152e2</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm695152e2</ArticleId><ArticleId IdType="pmc">PMC9191902</ArticleId><ArticleId IdType="pubmed">33382671</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19) vaccinations. Our World in Data.  [2021-05-31].  
 https://ourworldindata.org/covid-vaccinations
.</Citation></Reference><Reference><Citation>Lee BY, Brown ST, Korch GW, Cooley PC, Zimmerman RK, Wheaton WD, Zimmer SM, Grefenstette JJ, Bailey RR, Assi T, Burke DS. A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine. 2010 Jul 12;28(31):4875&#x2013;9. doi: 10.1016/j.vaccine.2010.05.002. 
 
S0264-410X(10)00664-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.05.002</ArticleId><ArticleId IdType="pmc">PMC2906666</ArticleId><ArticleId IdType="pubmed">20483192</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrie JG, Ohmit SE, Cheng CK, Martin ET, Malosh RE, Lauring AS, Lamerato LE, Reyes KC, Flannery B, Ferdinands JM, Monto AS. Influenza vaccine effectiveness against antigenically drifted influenza higher than expected in hospitalized adults: 2014-2015. Clin Infect Dis. 2016 Oct 15;63(8):1017&#x2013;25. doi: 10.1093/cid/ciw432.ciw432</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciw432</ArticleId><ArticleId IdType="pubmed">27369320</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilishvili T, Fleming-Dutra KE, Farrar JL, Gierke R, Mohr NM, Talan DA, Krishnadasan A, Harland KK, Smithline HA, Hou PC, Lee LC, Lim SC, Moran GJ, Krebs E, Steele M, Beiser DG, Faine B, Haran JP, Nandi U, Schrading WA, Chinnock B, Henning DJ, LoVecchio F, Nadle J, Barter D, Brackney M, Britton A, Marceaux-Galli K, Lim S, Phipps EC, Dumyati G, Pierce R, Markus TM, Anderson DJ, Debes AK, Lin M, Mayer J, Babcock HM, Safdar N, Fischer M, Singleton R, Chea N, Magill SS, Verani J, Schrag S, Vaccine Effectiveness Among Healthcare Personnel Study Team Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel - 33 U.S. Sites, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):753&#x2013;758. doi: 10.15585/mmwr.mm7020e2. doi: 10.15585/mmwr.mm7020e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7020e2</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7020e2</ArticleId><ArticleId IdType="pmc">PMC8136422</ArticleId><ArticleId IdType="pubmed">34014909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets A, Li X, Makadia R, Rao G, Rijnbeek P, Duarte-Salles T, Sena A, Shaoibi A, Suchard M, Ryan P, Prieto-Alhambra D, Hripcsak G. Factors influencing background incidence rate calculation: systematic empirical evaluation across an international network of observational databases. Front Pharmacol. 2022 Apr 26;13:814198. doi: 10.3389/fphar.2022.814198. doi: 10.3389/fphar.2022.814198.814198</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.814198</ArticleId><ArticleId IdType="doi">10.3389/fphar.2022.814198</ArticleId><ArticleId IdType="pmc">PMC9087898</ArticleId><ArticleId IdType="pubmed">35559254</ArticleId></ArticleIdList></Reference><Reference><Citation>Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991 Jan 15;133(2):144&#x2013;53. doi: 10.1093/oxfordjournals.aje.a115853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a115853</ArticleId><ArticleId IdType="pubmed">1985444</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics - Simulation and Computation. 2009 Apr 09;38(6):1228&#x2013;1234. doi: 10.1080/03610910902859574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03610910902859574</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A, Patrick. Lauer. Hornbrook. Marin. Platt. Roger. Stang. Schneeweiss  A tool for assessing the feasibility of comparative effectiveness research. CER. 2013 Jan;:11. doi: 10.2147/cer.s40357. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/cer.s40357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, van der Lei Johan, Pratt N, Nor&#xe9;n G Niklas, Li Y, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne JJ, Fireman B, Ryan PB, Maclure M, Gerhard T, Toh S, Rassen JA, Nelson JC, Schneeweiss S. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012 Jan 19;21 Suppl 1:32&#x2013;40. doi: 10.1002/pds.2316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2316</ArticleId><ArticleId IdType="pubmed">22262591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellfritzsch M, Thomsen RW, Baggesen LM, Larsen FB, S&#xf8;rensen Henrik Toft, Christiansen CF. Lifestyle, socioeconomic characteristics, and medical history of elderly persons who receive seasonal influenza vaccination in a tax-supported healthcare system. Vaccine. 2017 Apr 25;35(18):2396&#x2013;2403. doi: 10.1016/j.vaccine.2017.03.040.S0264-410X(17)30356-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.03.040</ArticleId><ArticleId IdType="pubmed">28343782</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan AJ, Niesen MJM, O'Horo JC, Virk A, Swift MD, Badley AD, Halamka J, Soundararajan V. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med (N Y) 2021 Aug 13;2(8):979&#x2013;992.e8. doi: 10.1016/j.medj.2021.06.007. 
 
S2666-6340(21)00238-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.06.007</ArticleId><ArticleId IdType="pmc">PMC8238652</ArticleId><ArticleId IdType="pubmed">34223401</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldeselassie Y G, Whitaker H J, Farrington C P. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiol Infect. 2011 Dec;139(12):1805&#x2013;17. doi: 10.1017/S0950268811001531.S0950268811001531</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268811001531</ArticleId><ArticleId IdType="pubmed">21849099</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35511233</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Inclusion of social determinants of health improves sepsis readmission prediction models.</ArticleTitle><Pagination><StartPage>1263</StartPage><EndPage>1270</EndPage><MedlinePgn>1263-1270</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocac060</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Sepsis has a high rate of 30-day unplanned readmissions. Predictive modeling has been suggested as a tool to identify high-risk patients. However, existing sepsis readmission models have low predictive value and most predictive factors in such models are not actionable.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Data from patients enrolled in the AllofUs Research Program cohort from 35 hospitals were used to develop a multicenter validated sepsis-related unplanned readmission model that incorporates clinical and social determinants of health (SDH) to predict 30-day unplanned readmissions. Sepsis cases were identified using concepts represented in the Observational Medical Outcomes Partnership. The dataset included over 60 clinical/laboratory features and over 100 SDH features.</AbstractText><AbstractText Label="RESULTS">Incorporation of SDH factors into our model of clinical and demographic features improves model area under the receiver operating characteristic curve (AUC) significantly (from 0.75 to 0.80; P&#x2009;&lt;&#x2009;.001). Model-agnostic interpretability techniques revealed demographics, economic stability, and delay in getting medical care as important SDH predictive features of unplanned hospital readmissions.</AbstractText><AbstractText Label="DISCUSSION">This work represents one of the largest studies of sepsis readmissions using objective clinical data to date (8935 septic index encounters). SDH are important to determine which sepsis patients are more likely to have an unplanned 30-day readmission. The AllofUS dataset provides granular data from a diverse set of individuals, making this model potentially more generalizable than prior models.</AbstractText><AbstractText Label="CONCLUSION">Use of SDH improves predictive performance of a model to identify which sepsis patients are at high risk of an unplanned 30-day readmission.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amrollahi</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Biomedical Informatics, University of California San Diego, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shashikumar</LastName><ForeName>Supreeth P</ForeName><Initials>SP</Initials><Identifier Source="ORCID">0000-0002-0348-4261</Identifier><AffiliationInfo><Affiliation>Division of Biomedical Informatics, University of California San Diego, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meier</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohno-Machado</LastName><ForeName>Lucila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Biomedical Informatics, University of California San Diego, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nemati</LastName><ForeName>Shamim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Biomedical Informatics, University of California San Diego, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wardi</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego, San Diego, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of California San Diego, San Diego, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>NIH NHLBI</Agency><Country/></Grant><Grant><GrantID>R35 GM143121</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 LM013517</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>National Foundation of Emergency Medicine</Agency><Country/></Grant><Grant><GrantID>1KL2TR001444</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GBMF9052</GrantID><Agency>Gordon and Betty Moore Foundation</Agency><Country/></Grant><Grant><GrantID>K23 GM146092</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2OD026552</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>#GBMF9052</GrantID><Agency>Gordon and Betty Moore Foundation</Agency><Country/></Grant><Grant><GrantID>KL2 TR001444</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56LM013517</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>#R56LM013517</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RM1 HG011558</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG010971</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35GM143121</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013998</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="Y">Patient Readmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064890" MajorTopicYN="N">Social Determinants of Health</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">interpretable</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">readmission</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>5</Day><Hour>11</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35511233</ArticleId><ArticleId IdType="pmc">PMC9196687</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocac060</ArticleId><ArticleId IdType="pii">6576837</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rhee C, Dantes R, Epstein L, et al.; CDC Prevention Epicenter Program. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009&#x2013;2014. JAMA &#xa0;2017; 318 (13): 1241&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710396</ArticleId><ArticleId IdType="pubmed">28903154</ArticleId></ArticleIdList></Reference><Reference><Citation>
Torio CM, Moore BJ. National inpatient hospital costs: the most expensive conditions by payer, 2013: statistical brief #204. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Healthcare Research and Quality (US); 2006. http://www.ncbi.nlm.nih.gov/books/NBK368492/ Accessed January 21, 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">27359025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayr FB, Talisa VB, Balakumar V, et al. &#xa0;Proportion and cost of unplanned 30-day readmissions after sepsis compared with other medical conditions. JAMA &#xa0;2017; 317 (5): 530&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">28114505</ArticleId></ArticleIdList></Reference><Reference><Citation>Prescott HC, Angus DC. &#xa0;Enhancing recovery from sepsis: a review. JAMA &#xa0;2018; 319 (1): 62&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839473</ArticleId><ArticleId IdType="pubmed">29297082</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwashyna TJ, Ely EW, Smith DM, et al. &#xa0;Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA &#xa0;2010; 304 (16): 1787&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345288</ArticleId><ArticleId IdType="pubmed">20978258</ArticleId></ArticleIdList></Reference><Reference><Citation>Readmission diagnoses after hospitalization for severe sepsis and other acute medical conditions. JAMA | JAMA Network. https://jamanetwork.com/journals/jama/fullarticle/2190975 Accessed January 21, 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4760618</ArticleId><ArticleId IdType="pubmed">25756444</ArticleId></ArticleIdList></Reference><Reference><Citation>Social Determinants of Health &#x2013; Healthy People 2030. health.gov. https://health.gov/healthypeople/objectives-and-data/social-determinants-health Accessed January 21, 2022.</Citation></Reference><Reference><Citation>Meddings J, Reichert H, Smith SN, et al. &#xa0;The impact of disability and social determinants of health on condition-specific readmissions beyond Medicare risk adjustments: a cohort study. J Gen Intern Med &#xa0;2017; 32 (1): 71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215164</ArticleId><ArticleId IdType="pubmed">27848189</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin MH, Goldman L. &#xa0;Correlates of early hospital readmission or death in patients with congestive heart failure. Am J Cardiol &#xa0;1997; 79 (12): 1640&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202355</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans WN, Kroeger S, Munnich EL, et al. &#xa0;Reducing readmissions by addressing the social determinants of health. Am J Health Econ &#xa0;2021; 7 (1): 1&#x2013;40.</Citation></Reference><Reference><Citation>Wardi G, Shashikumar S, Allen T, et al. &#xa0;1233: development and validation of a novel machine learning algorithm to predict sepsis readmissions. Crit Care Med &#xa0;2021; 49 (1): 620.</Citation></Reference><Reference><Citation>Taylor SP, Murphy S, Rios A, et al. &#xa0;Effect of a multicomponent sepsis transition and recovery program on mortality and readmissions after sepsis: the improving morbidity during post-acute care transitions for sepsis randomized clinical trial. Crit Care Med 2022; 50 (3): 469&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">34534130</ArticleId></ArticleIdList></Reference><Reference><Citation>The &#x201c;All of Us&#x201d; Research Program. N Engl J Med. https://www.nejm.org/doi/full/10.1056/NEJMsr1809937 Accessed January 21, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsr1809937</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, et al. &#xa0;Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Med &#xa0;2015; 13: 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284921</ArticleId><ArticleId IdType="pubmed">25563062</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al. &#xa0;The Third International Consensus definitions for sepsis and septic shock (Sepsis-3). JAMA &#xa0;2016; 315 (8): 801&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardi G, Carlile M, Holder A, et al. &#xa0;Predicting progression to septic shock in the emergency department using an externally generalizable machine-learning algorithm. Ann Emerg Med &#xa0;2021; 77 (4): 395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554871</ArticleId><ArticleId IdType="pubmed">33455840</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz L, Partovian C, Lin Z, et al. Measure updates and specification report: hospital-wide all-cause risk-standardized readmission measure&#x2013;version 4.0. Prepared for the Centers for Medicare and Medicaid Services. Prepared by Centers for Medicare Medicaid Services New Haven CT Yale New Haven Health Services Corporation Outcomes Research and Evaluation; 2015: 26.</Citation></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. &#xa0;Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics &#xa0;1988; 44 (3): 837&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemati S, Holder A, Razmi F, et al. &#xa0;An interpretable machine learning model for accurate prediction of sepsis in the ICU. Crit Care Med &#xa0;2018; 46 (4): 547&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5851825</ArticleId><ArticleId IdType="pubmed">29286945</ArticleId></ArticleIdList></Reference><Reference><Citation>About Social Determinants of Health (SDOH); 2021. https://www.cdc.gov/socialdeterminants/about.html Accessed January 24, 2022.</Citation></Reference><Reference><Citation>Baehrens D, Schroeter T, Harmeling S, Kawanabe M, Hansen K, M&#xfc;ller K-R. How to explain individual classification decisions. J Mach Learn Res 2010; 11: 1803&#x2013;31.</Citation></Reference><Reference><Citation>Harris CR, Millman KJ, van der Walt SJ, et al. &#xa0;Array programming with NumPy. Nature &#xa0;2020; 585 (7825): 357&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7759461</ArticleId><ArticleId IdType="pubmed">32939066</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwashyna TJ, Odden A, Rohde J, et al. &#xa0;Identifying patients with severe sepsis using administrative claims: patient-level validation of the angus implementation of the international consensus conference definition of severe sepsis. Med Care &#xa0;2014; 52 (6): e39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568444</ArticleId><ArticleId IdType="pubmed">23001437</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee C, Li Z, Wang R, et al. &#xa0;Impact of risk adjustment using clinical vs administrative data on hospital sepsis mortality comparisons. Open Forum Infect Dis &#xa0;2020; 7 (6): ofaa213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320830</ArticleId><ArticleId IdType="pubmed">32617377</ArticleId></ArticleIdList></Reference><Reference><Citation>Popejoy AB, Fullerton SM. &#xa0;Genomics is failing on diversity. Nature &#xa0;2016; 538 (7624): 161&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5089703</ArticleId><ArticleId IdType="pubmed">27734877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. &#xa0;The FAIR Guiding Principles for scientific data management and stewardship. Sci Data &#xa0;2016; 3: 160018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4792175</ArticleId><ArticleId IdType="pubmed">26978244</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Butler A, Stewart LA, et al. &#xa0;Building an OMOP common data model-compliant annotated corpus for COVID-19 clinical trials. J Biomed Inform &#xa0;2021; 118: 103790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8079156</ArticleId><ArticleId IdType="pubmed">33887457</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenkaya R, Gurley MJ, Golozar A, et al. &#xa0;Extending the OMOP common data model and standardized vocabularies to support observational cancer research. JCO Clin Cancer Inform &#xa0;2021; 5: 12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8140810</ArticleId><ArticleId IdType="pubmed">33411620</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Sin M, Tsapepas D, et al. &#xa0;Content coverage evaluation of the OMOP vocabulary on the transplant domain focusing on concepts relevant for kidney transplant outcomes analysis. Appl Clin Inform &#xa0;2020; 11 (4): 650&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7557323</ArticleId><ArticleId IdType="pubmed">33027834</ArticleId></ArticleIdList></Reference><Reference><Citation>Papez V, Moinat M, Payralbe S, et al. &#xa0;Transforming and evaluating electronic health record disease phenotyping algorithms using the OMOP common data model: a case study in heart failure. JAMIA Open &#xa0;2021; 4 (3): ooab001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423424</ArticleId><ArticleId IdType="pubmed">34514354</ArticleId></ArticleIdList></Reference><Reference><Citation>Prats-Uribe A, Sena AG, Lai LYH, et al. &#xa0;Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. BMJ &#xa0;2021; 373 : n1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8111167</ArticleId><ArticleId IdType="pubmed">33975825</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadre SK, Shah M, Mireles-Cabodevila E, et al. &#xa0;Epidemiology and predictors of 30-day readmission in patients with sepsis. Chest &#xa0;2019; 155 (3): 483&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">30846065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Monneret G, Payen D. &#xa0;Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol &#xa0;2013; 13 (12): 862&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4077177</ArticleId><ArticleId IdType="pubmed">24232462</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson WF, Cavassani KA, Dou Y, et al. &#xa0;Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics &#xa0;2011; 6 (3): 273&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3092675</ArticleId><ArticleId IdType="pubmed">21048427</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Xie M, Yang M, et al. &#xa0;PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun &#xa0;2014; 5: 4436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104986</ArticleId><ArticleId IdType="pubmed">25019241</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah FA, Pike F, Alvarez K, et al. &#xa0;Bidirectional relationship between cognitive function and pneumonia. Am J Respir Crit Care Med &#xa0;2013; 188 (5): 586&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3827700</ArticleId><ArticleId IdType="pubmed">23848267</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor SP, Chou S-H, Sierra MF, et al. &#xa0;Association between adherence to recommended care and outcomes for adult survivors of sepsis. Ann Am Thorac Soc &#xa0;2020; 17 (1): 89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6944350</ArticleId><ArticleId IdType="pubmed">31644304</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly JP, Hohmann SF, Wang HE. &#xa0;Unplanned readmissions after hospitalization for severe sepsis at academic medical center-affiliated hospitals. Crit Care Med &#xa0;2015; 43 (9): 1916&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4537666</ArticleId><ArticleId IdType="pubmed">26082977</ArticleId></ArticleIdList></Reference><Reference><Citation>Galiatsatos P, Follin A, Alghanim F, et al. &#xa0;The association between neighborhood socioeconomic disadvantage and readmissions for patients hospitalized with sepsis. Crit Care Med &#xa0;2020; 48 (6): 808&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391606</ArticleId><ArticleId IdType="pubmed">32271185</ArticleId></ArticleIdList></Reference><Reference><Citation>Cafagna G, Seghieri C. &#xa0;Educational level and 30-day outcomes after hospitalization for acute myocardial infarction in Italy. BMC Health Serv Res &#xa0;2017; 17 (1): 18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5220616</ArticleId><ArticleId IdType="pubmed">28069004</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey A, Keshvani N, Khera R, et al. &#xa0;Temporal trends in racial differences in 30-day readmission and mortality rates after acute myocardial infarction among Medicare beneficiaries. JAMA Cardiol &#xa0;2020; 5 (2): 136&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990949</ArticleId><ArticleId IdType="pubmed">31913411</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatana SAM, Wadhera RK, Choi E, et al. &#xa0;Association of homelessness with hospital readmissions &#x2013; an analysis of three large states. J Gen Intern Med &#xa0;2020; 35 (9): 2576&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7458973</ArticleId><ArticleId IdType="pubmed">32556872</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieck CJ, Sheon A, Ancker JS, et al. &#xa0;Digital inclusion as a social determinant of health. NPJ Digit Med &#xa0;2021; 4: 1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7969595</ArticleId><ArticleId IdType="pubmed">33731887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardi G, Tainter CR, Ramnath VR, et al. &#xa0;Age-related incidence and outcomes of sepsis in California, 2008&#x2013;2015. J Crit Care &#xa0;2021; 62: 212&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8898199</ArticleId><ArticleId IdType="pubmed">33429114</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35559254</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Factors Influencing Background Incidence Rate Calculation: Systematic Empirical Evaluation Across an International Network of Observational Databases.</ArticleTitle><Pagination><StartPage>814198</StartPage><MedlinePgn>814198</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">814198</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2022.814198</ELocationID><Abstract><AbstractText><b>Objective:</b> Background incidence rates are routinely used in safety studies to evaluate an association of an exposure and outcome. Systematic research on sensitivity of rates to the choice of the study parameters is lacking. <b>Materials and Methods:</b> We used 12 data sources to systematically examine the influence of age, race, sex, database, time-at-risk, season and year, prior observation and clean window on incidence rates using 15 adverse events of special interest for COVID-19 vaccines as an example. For binary comparisons we calculated incidence rate ratios and performed random-effect meta-analysis. <b>Results:</b> We observed a wide variation of background rates that goes well beyond age and database effects previously observed. While rates vary up to a factor of 1,000 across age groups, even after adjusting for age and sex, the study showed residual bias due to the other parameters. Rates were highly influenced by the choice of anchoring (e.g., health visit, vaccination, or arbitrary date) for the time-at-risk start<i>.</i> Anchoring on a healthcare encounter yielded higher incidence comparing to a random date, especially for short time-at-risk. Incidence rates were highly influenced by the choice of the database (varying by up to a factor of 100), clean window choice and time-at-risk duration, and less so by secular or seasonal trends. <b>Conclusion:</b> Comparing background to observed rates requires appropriate adjustment and careful time-at-risk start and duration choice. Results should be interpreted in the context of study parameter choices.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Ostropolets, Li, Makadia, Rao, Rijnbeek, Duarte-Salles, Sena, Shaoibi, Suchard, Ryan, Prieto-Alhambra and Hripcsak.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xintong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makadia</LastName><ForeName>Rupa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la Recerca a L'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaoibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">background rates</Keyword><Keyword MajorTopicYN="N">incidence rates</Keyword><Keyword MajorTopicYN="N">sensitivity analysis</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>13</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35559254</ArticleId><ArticleId IdType="pmc">PMC9087898</ArticleId><ArticleId IdType="doi">10.3389/fphar.2022.814198</ArticleId><ArticleId IdType="pii">814198</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barker-Collo S., Bennett D. A., Krishnamurthi R. V., Parmar P., Feigin V. L., Naghavi M., et al. (2015). Sex Differences in Stroke Incidence, Prevalence, Mortality and Disability-Adjusted Life Years: Results from the Global Burden of Disease Study 2013. Neuroepidemiology 45, 203&#x2013;214. 10.1159/000441103</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000441103</ArticleId><ArticleId IdType="pmc">PMC4632242</ArticleId><ArticleId IdType="pubmed">26505984</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E., Chi&#xf2; A., Couratier P., Esteban J., Hardiman O., Logroscino G., et al. (2011). The Epidemiology and Treatment of ALS: Focus on the Heterogeneity of the Disease and Critical Appraisal of Therapeutic Trials. Amyotroph. Lateral Scler. 12, 1&#x2013;10. 10.3109/17482968.2010.502940</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.502940</ArticleId><ArticleId IdType="pmc">PMC3513399</ArticleId><ArticleId IdType="pubmed">20698807</ArticleId></ArticleIdList></Reference><Reference><Citation>Black S., Eskola J., Siegrist C. A., Halsey N., MacDonald N., Law B., et al. (2009). Importance of Background Rates of Disease in Assessment of Vaccine Safety during Mass Immunisation with Pandemic H1N1 Influenza Vaccines. Lancet 374, 2115&#x2013;2122. 10.1016/S0140-6736(09)61877-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Black S. B., Law B., Chen R. T., Dekker C. L., Sturkenboom M., Huang W. T., et al. (2021). The Critical Role of Background Rates of Possible Adverse Events in the Assessment of COVID-19 Vaccine Safety. Vaccine 39, 2712&#x2013;2718. 10.1016/j.vaccine.2021.03.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.03.016</ArticleId><ArticleId IdType="pmc">PMC7936550</ArticleId><ArticleId IdType="pubmed">33846042</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E., Li X., Kostka K., Stewart H. M., Reich C., Seager S., et al. (2021). Background Rates of Five Thrombosis with Thrombocytopenia Syndromes of Special Interest for COVID-19 Vaccine Safety Surveillance: Incidence between 2017 and 2019 and Patient Profiles from 25.4 Million People in Six European Countries. medRxiv. 10.1101/2021.05.12.21257083</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.12.21257083</ArticleId><ArticleId IdType="pmc">PMC9088543</ArticleId><ArticleId IdType="pubmed">35191114</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaaban M. R., Warren Z., Baillargeon J. G., Baillargeon G., Resto V., Kuo Y. F. (2019). Epidemiology and Trends of Anaphylaxis in the United States, 2004-2016. Int. Forum Allergy Rhinol 9, 607&#x2013;614. 10.1002/alr.22293</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alr.22293</ArticleId><ArticleId IdType="pubmed">30715793</ArticleId></ArticleIdList></Reference><Reference><Citation>
CohortDiagnostics (2022). Observational Health Data Sciences and Informatics. Available at: https://github.com/OHDSI/CohortDiagnostics
 [Accessed February 6, 2022]. </Citation></Reference><Reference><Citation>Cologne J., Kim J., Sugiyama H., French B., Cullings H. M., Preston D. L., et al. (2019). Effect of Heterogeneity in Background Incidence on Inference about the Solid-Cancer Radiation Dose Response in Atomic Bomb Survivors. Radiat. Res. 192, 388&#x2013;398. 10.1667/RR15127.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1667/RR15127.1</ArticleId><ArticleId IdType="pmc">PMC6827345</ArticleId><ArticleId IdType="pubmed">31355713</ArticleId></ArticleIdList></Reference><Reference><Citation>
Covid-19 Vaccine AESI Incidence Characterization protocol. 2021. 
Covid-19 Vaccine AESI Incidence Characterization Protocol GitHub. Available at: https://github.com/ohdsi-studies/Covid19VaccineAesiIncidenceCharacterization
 [Accessed May 4, 2021]. </Citation></Reference><Reference><Citation>Dasgupta P., Henshaw C., Youlden D. R., Clark P. J., Aitken J. F., Baade P. D. (2020). Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Front. Oncol. 10, 171. 10.3389/fonc.2020.00171</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.00171</ArticleId><ArticleId IdType="pmc">PMC7058661</ArticleId><ArticleId IdType="pubmed">32185125</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd C. N., de Ridder M., Huang W. T., Weibel D., Giner-Soriano M., Perez-Vilar S., et al. (2018). Incidence Rates of Narcolepsy Diagnoses in Taiwan, Canada, and Europe: The Use of Statistical Simulation to Evaluate Methods for the Rapid Assessment of Potential Safety Issues on a Population Level in the SOMNIA Study. PLoS ONE 13, e0204799. 10.1371/journal.pone.0204799</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0204799</ArticleId><ArticleId IdType="pmc">PMC6192586</ArticleId><ArticleId IdType="pubmed">30332477</ArticleId></ArticleIdList></Reference><Reference><Citation>Drozd E. M., Miller L., Johnsrud M. (2017). Impact of Pharmacist Immunization Authority on Seasonal Influenza Immunization Rates across States. Clin. Ther. 39, 1563&#x2013;e17. e17. 10.1016/j.clinthera.2017.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2017.07.004</ArticleId><ArticleId IdType="pubmed">28781217</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Network of Centres for Pharmacoepidemiology and Phamacovigilance (2020). Background Rates of Adverse Events of Special Interest for Monitoring COVID-19 Vaccines, 54. Available at: https://www.bestinitiative.org/wp-content/uploads/2021/01/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-2020.pdf
. </Citation></Reference><Reference><Citation>Fairweather D., Cooper L. T., Blauwet L. A. (2013). Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy. Curr. Probl. Cardiol. 38, 7&#x2013;46. 10.1016/j.cpcardiol.2012.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2012.07.003</ArticleId><ArticleId IdType="pmc">PMC4136454</ArticleId><ArticleId IdType="pubmed">23158412</ArticleId></ArticleIdList></Reference><Reference><Citation>
Food and Drug Administration and Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative (2020). Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring, 32. Available at: https://www.bestinitiative.org/wp-content/uploads/2021/01/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-2020.pdf
. </Citation></Reference><Reference><Citation>Gracia Guti&#xe9;rrez A., Poblador-Plou B., Prados-Torres A., Ruiz Laiglesia F. J., Gimeno-Miguel A. (2020). Sex Differences in Comorbidity, Therapy, and Health Services' Use of Heart Failure in Spain: Evidence from Real-World Data. Int. J. Environ. Res. Public Health 17, 2136. 10.3390/ijerph17062136</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17062136</ArticleId><ArticleId IdType="pmc">PMC7143043</ArticleId><ArticleId IdType="pubmed">32210137</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamedani A. G., Blank L., Thibault D. P., Willis A. W. (2021). Impact of ICD-9 to ICD-10 Coding Transition on Prevalence Trends in Neurology. Neurol. Clin. Pract. 11, e612&#x2013;e619. 10.1212/CPJ.0000000000001046</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000001046</ArticleId><ArticleId IdType="pmc">PMC8610531</ArticleId><ArticleId IdType="pubmed">34840874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanratty B., Lawlor D. A., Robinson M. B., Sapsford R. J., Greenwood D., Hall A. (2000). Sex Differences in Risk Factors, Treatment and Mortality after Acute Myocardial Infarction: an Observational Study. J. Epidemiol. Community Health 54, 912&#x2013;916. 10.1136/jech.54.12.912</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech.54.12.912</ArticleId><ArticleId IdType="pmc">PMC1731594</ArticleId><ArticleId IdType="pubmed">11076987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hense S., Schink T., Kreisel S. H., Marcelon L., Simondon F., Tahden M., et al. (2014). Estimation of Background Incidence Rates of Guillain-Barr&#xe9; Syndrome in Germany - a Retrospective Cohort Study with Electronic Healthcare Data. Neuroepidemiology 43, 244&#x2013;252. 10.1159/000369344</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000369344</ArticleId><ArticleId IdType="pubmed">25531827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch L., Jette N., Frolkis A., Steeves T., Pringsheim T. (2016). The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology 46, 292&#x2013;300. 10.1159/000445751</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000445751</ArticleId><ArticleId IdType="pubmed">27105081</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R. J., Sharp N., Talamoa R. O., Ji H. P., Hwang J. H., Palaniappan L. P. (2020). One Size Does Not Fit All: Marked Heterogeneity in Incidence of and Survival from Gastric Cancer Among Asian American Subgroups. Cancer Epidemiol. Biomarkers Prev. 29, 903&#x2013;909. 10.1158/1055-9965.EPI-19-1482</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-19-1482</ArticleId><ArticleId IdType="pubmed">32152216</ArticleId></ArticleIdList></Reference><Reference><Citation>Huedo-Medina T. B., S&#xe1;nchez-Meca J., Mar&#xed;n-Mart&#xed;nez F., Botella J. (2006). Assessing Heterogeneity in Meta-Analysis: Q Statistic or I2 index? Psychol. Methods 11, 193&#x2013;206. 10.1037/1082-989X.11.2.193</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/1082-989X.11.2.193</ArticleId><ArticleId IdType="pubmed">16784338</ArticleId></ArticleIdList></Reference><Reference><Citation>Idrees R., Fatima S., Abdul-Ghafar J., Raheem A., Ahmad Z. (2018). Cancer Prevalence in Pakistan: Meta-Analysis of Various Published Studies to Determine Variation in Cancer Figures Resulting from Marked Population Heterogeneity in Different Parts of the Country. World J. Surg. Oncol. 16, 129. 10.1186/s12957-018-1429-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12957-018-1429-z</ArticleId><ArticleId IdType="pmc">PMC6034324</ArticleId><ArticleId IdType="pubmed">29976196</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadambari S., Okike I., Ribeiro S., Ramsay M. E., Heath P. T., Sharland M., et al. (2014). Seven-fold Increase in Viral Meningo-Encephalitis Reports in England and Wales during 2004-2013. J. Infect. 69, 326&#x2013;332. 10.1016/j.jinf.2014.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2014.05.012</ArticleId><ArticleId IdType="pubmed">24887614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaya A. M., Adler N., Moffet H. H., Liu J., Schillinger D., Adams A., et al. (2011). Heterogeneity of Diabetes Outcomes Among Asians and pacific Islanders in the US: the Diabetes Study of Northern california (DISTANCE). Diabetes Care 34, 930&#x2013;937. 10.2337/dc10-1964</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc10-1964</ArticleId><ArticleId IdType="pmc">PMC3064053</ArticleId><ArticleId IdType="pubmed">21350114</ArticleId></ArticleIdList></Reference><Reference><Citation>Katan M., Luft A. (2018). Global Burden of Stroke. Semin. Neurol. 38 (2), 208&#x2013;211. 10.1055/s-0038-1649503</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1649503</ArticleId><ArticleId IdType="pubmed">29791947</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopman C., Bots M. L., van Oeffelen A. A., van Dis I., Verschuren W. M., Engelfriet P. M., et al. (2013). Population Trends and Inequalities in Incidence and Short-Term Outcome of Acute Myocardial Infarction between 1998 and 2007. Int. J. Cardiol. 168, 993&#x2013;998. 10.1016/j.ijcard.2012.10.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2012.10.036</ArticleId><ArticleId IdType="pubmed">23168007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. S., Kim Y. H. (2021). Epidemiological Trends of Bell's Palsy Treated with Steroids in Korea between 2008 and 2018. Muscle &amp; Nerve 63, 845&#x2013;851. 10.1002/mus.27213</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27213</ArticleId><ArticleId IdType="pubmed">33651414</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Ostropolets A., Makadia R., Shoaibi A., Rao G., Sena A. G., et al. (2021). Characterising the Background Incidence Rates of Adverse Events of Special Interest for Covid-19 Vaccines in Eight Countries: Multinational Network Cohort Study. BMJ n1435, n1435. 10.1136/bmj.n1435</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K. J., Garc&#xed;a Rodr&#xed;guez L. A., Hern&#xe1;ndez-D&#xed;az S. (2011). Systematic Review of Peptic Ulcer Disease Incidence Rates: Do Studies without Validation Provide Reliable Estimates? Pharmacoepidemiol. Drug Saf. 20, 718&#x2013;728. 10.1002/pds.2153</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2153</ArticleId><ArticleId IdType="pubmed">21626606</ArticleId></ArticleIdList></Reference><Reference><Citation>Linn F. H., Rinkel G. J., Algra A., van Gijn J. (1996). Incidence of Subarachnoid Hemorrhage: Role of Region, Year, and Rate of Computed Tomography: A Meta-Analysis. Stroke 27, 625&#x2013;629. 10.1161/01.STR.27.4.625</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.27.4.625</ArticleId><ArticleId IdType="pubmed">8614919</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrero O., Hung E. Y., Hauben M. (2016). Seasonal and Geographic Variation in Adverse Event Reporting. Drugs Real World Outcomes 3, 297&#x2013;306. 10.1007/s40801-016-0081-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40801-016-0081-6</ArticleId><ArticleId IdType="pmc">PMC5042937</ArticleId><ArticleId IdType="pubmed">27747826</ArticleId></ArticleIdList></Reference><Reference><Citation>Marty L., Cazein F., Panjo H., Pillonel J., Costagliola D., Supervie V., et al. (2018). Revealing Geographical and Population Heterogeneity in HIV Incidence, Undiagnosed HIV Prevalence and Time to Diagnosis to Improve Prevention and Care: Estimates for France. J. Int. AIDS Soc. 21, e25100. 10.1002/jia2.25100</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jia2.25100</ArticleId><ArticleId IdType="pmc">PMC5878416</ArticleId><ArticleId IdType="pubmed">29603879</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A., Ryan P., Fife D., Gifkins D., Knoll C., Friedman A. (2018). Inferring Pregnancy Episodes and Outcomes within a Network of Observational Databases. PLoS ONE 13, e0192033. 10.1371/journal.pone.0192033</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0192033</ArticleId><ArticleId IdType="pmc">PMC5794136</ArticleId><ArticleId IdType="pubmed">29389968</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan V., Fonarow G. C., Ju C., Pencina M., Laskey W. K., Maddox T. M., et al. (2017). Seasonal and Circadian Variations of Acute Myocardial Infarction: Findings from the Get with the Guidelines-Coronary Artery Disease (GWTG-CAD) Program. Am. Heart J. 189, 85&#x2013;93. 10.1016/j.ahj.2017.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2017.04.002</ArticleId><ArticleId IdType="pubmed">28625385</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreen S., Calzavara A., Sundaram M., MacDonald S. E., Righolt C., Pai M., et al. (2021). Background Rates of Hospitalizations and Emergency Department Visits for Selected Thromboembolic and Coagulation Disorders in Ontario, Canada, 2015 to 2020, to Inform COVID-19 Vaccine Safety Surveillance. medRxiv. 10.1101/2021.04.02.21254856</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.02.21254856</ArticleId><ArticleId IdType="pmc">PMC8685534</ArticleId><ArticleId IdType="pubmed">34921078</ArticleId></ArticleIdList></Reference><Reference><Citation>
PHOEBE. 2022. Available at: https://data.ohdsi.org/PHOEBE/
[Accessed February 6, 2022].</Citation></Reference><Reference><Citation>Sejvar J. J., Baughman A. L., Wise M., Morgan O. W. (2011). Population Incidence of Guillain-Barr&#xe9; Syndrome: a Systematic Review and Meta-Analysis. Neuroepidemiology 36, 123&#x2013;133. 10.1159/000324710</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000324710</ArticleId><ArticleId IdType="pmc">PMC5703046</ArticleId><ArticleId IdType="pubmed">21422765</ArticleId></ArticleIdList></Reference><Reference><Citation>Spronk I., Korevaar J. C., Poos R., Davids R., Hilderink H., Schellevis F. G., et al. (2019). Calculating Incidence Rates and Prevalence Proportions: Not as Simple as it Seems. BMC Public Health 19, 512. 10.1186/s12889-019-6820-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-019-6820-3</ArticleId><ArticleId IdType="pmc">PMC6501456</ArticleId><ArticleId IdType="pubmed">31060532</ArticleId></ArticleIdList></Reference><Reference><Citation>Susantitaphong P., Cruz D. N., Cerda J., Abulfaraj M., Alqahtani F., Koulouridis I., et al. (2013). World Incidence of AKI: A Meta-Analysis. Clin. J. Am. Soc. Nephrol. 8, 1482&#x2013;1493. 10.2215/CJN.00710113</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.00710113</ArticleId><ArticleId IdType="pmc">PMC3805065</ArticleId><ArticleId IdType="pubmed">23744003</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsch&#xf6;pe C., Ammirati E., Bozkurt B., Caforio A. L. P., Cooper L. T., Felix S. B., et al. (2021). Myocarditis and Inflammatory Cardiomyopathy: Current Evidence and Future Directions. Nat. Rev. Cardiol. 18, 169&#x2013;193. 10.1038/s41569-020-00435-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-00435-x</ArticleId><ArticleId IdType="pmc">PMC7548534</ArticleId><ArticleId IdType="pubmed">33046850</ArticleId></ArticleIdList></Reference><Reference><Citation>Umasunthar T., Leonardi-Bee J., Hodes M., Turner P. J., Gore C., Habibi P., et al. (2013). Incidence of Fatal Food Anaphylaxis in People with Food Allergy: a Systematic Review and Meta-Analysis. Clin. Exp. Allergy 43, 1333&#x2013;1341. 10.1111/cea.12211</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.12211</ArticleId><ArticleId IdType="pmc">PMC4165304</ArticleId><ArticleId IdType="pubmed">24118190</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. (2010). Conducting Meta-Analyses inRwith themetaforPackage. J. Stat. Soft. 36. 10.18637/jss.v036.i03</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v036.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Allen K. J., Suaini N. H. A., McWilliam V., Peters R. L., Koplin J. J. (2019). The Global Incidence and Prevalence of Anaphylaxis in Children in the General Population: A Systematic Review. Allergy 74, 1063&#x2013;1080. 10.1111/all.13732</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.13732</ArticleId><ArticleId IdType="pubmed">30688375</ArticleId></ArticleIdList></Reference><Reference><Citation>Willame C., Dodd C., van der Aa L., Picelli G., Emborg H. D., Kahlert J., et al. (2021). Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project. Drug Saf. 44, 383&#x2013;395. 10.1007/s40264-020-01031-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-01031-1</ArticleId><ArticleId IdType="pmc">PMC7892524</ArticleId><ArticleId IdType="pubmed">33462778</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">35570298</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study.</ArticleTitle><Pagination><StartPage>84</StartPage><MedlinePgn>84</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">84</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-022-01813-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce pain, fever, and inflammation but have been associated with complications in community-acquired pneumonia. Observations shortly after the start of the COVID-19 pandemic in 2020 suggested that ibuprofen was associated with an increased risk of adverse events in COVID-19 patients, but subsequent observational studies failed to demonstrate increased risk and in one case showed reduced risk associated with NSAID use.</AbstractText><AbstractText Label="METHODS">A 38-center retrospective cohort study was performed that leveraged the harmonized, high-granularity electronic health record data of the National COVID Cohort Collaborative. A propensity-matched cohort of 19,746 COVID-19 inpatients was constructed by matching cases (treated with NSAIDs at the time of admission) and 19,746 controls (not treated) from 857,061 patients with COVID-19 available for analysis. The primary outcome of interest was COVID-19 severity in hospitalized patients, which was classified as: moderate, severe, or mortality/hospice. Secondary outcomes were acute kidney injury (AKI), extracorporeal membrane oxygenation (ECMO), invasive ventilation, and all-cause mortality at any time following COVID-19 diagnosis.</AbstractText><AbstractText Label="RESULTS">Logistic regression showed that NSAID use was not associated with increased COVID-19 severity (OR: 0.57 95% CI: 0.53-0.61). Analysis of secondary outcomes using logistic regression showed that NSAID use was not associated with increased risk of all-cause mortality (OR 0.51 95% CI: 0.47-0.56), invasive ventilation (OR: 0.59 95% CI: 0.55-0.64), AKI (OR: 0.67 95% CI: 0.63-0.72), or ECMO (OR: 0.51 95% CI: 0.36-0.7). In contrast, the odds ratios indicate reduced risk of these outcomes, but our quantitative bias analysis showed E-values of between 1.9 and 3.3 for these associations, indicating that comparatively weak or moderate confounder associations could explain away the observed associations.</AbstractText><AbstractText Label="CONCLUSIONS">Study interpretation is limited by the observational design. Recording of NSAID use may have been incomplete. Our study demonstrates that NSAID use is not associated with increased COVID-19 severity, all-cause mortality, invasive ventilation, AKI, or ECMO in COVID-19 inpatients. A conservative interpretation in light of the quantitative bias analysis is that there is no evidence that NSAID use is associated with risk of increased severity or the other measured outcomes. Our results confirm and extend analogous findings in previous observational studies using a large cohort of patients drawn from 38 centers in a nationally representative multicenter database.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reese</LastName><ForeName>Justin T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA. justin.reese@lbl.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Systems Genomics, University of Connecticut, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Translational and Integrative Sciences Center, Oregon State University, Corvallis, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blau</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Tiffany J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Computational Bioscience, University of Colorado Anschutz Medical Campus, Boulder, CO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cappelletti</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>AnacletoLab, Dipartimento Di Informatica, Universit&#xe0; Degli Studi Di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontana</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>AnacletoLab, Dipartimento Di Informatica, Universit&#xe0; Degli Studi Di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradwell</LastName><ForeName>Katie R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Nomi L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casiraghi</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>AnacletoLab, Dipartimento Di Informatica, Universit&#xe0; Degli Studi Di Milano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CINI, National Laboratory in Artificial Intelligence and Intelligent Systems-AIIS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valentini</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>AnacletoLab, Dipartimento Di Informatica, Universit&#xe0; Degli Studi Di Milano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CINI, National Laboratory in Artificial Intelligence and Intelligent Systems-AIIS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlebach</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deer</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMurry</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haendel</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Schools of Medicine, Public Health, and Nursing, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>North Carolina Translational and Clinical Sciences Institute (NC TraCS), University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moffitt</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spratt</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Jasvinder A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Service, VA Medical Center, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mungall</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Tufts Medical Center Clinical and Translational Science Institute, Tufts Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical Research and Health Policy Studies, Tufts University School of Medicine, Boston, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Center at the Roux Institute, Northeastern University, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Peter N</ForeName><Initials>PN</Initials><Identifier Source="ORCID">0000-0002-0736-9199</Identifier><AffiliationInfo><Affiliation>The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. Peter.Robinson@jax.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Systems Genomics, University of Connecticut, Farmington, CT, USA. Peter.Robinson@jax.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 TR002306</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104940</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NIH UL1TR001439</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NCATS U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2021 Dec 22;:</RefSource><PMID Version="1">33907758</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cyclooxygenase inhibitors</Keyword><Keyword MajorTopicYN="N">NSAIDs</Keyword><Keyword MajorTopicYN="N">Observational study</Keyword></KeywordList><CoiStatement>Katie Rebecca Bradwell: employee of Palantir Technologies; Melissa A. Haendel: co-founder Pryzm Health; Julie A. McMurry: Cofounder, Pryzm Health; Jasvinder Singh: JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc, Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in TPT Global Tech, Vaxart pharmaceuticals and Charlotte&#x2019;s Web Holdings, Inc. JAS previously owned stock options in Amarin, Viking and Moderna pharmaceuticals. JAS is on the speaker&#x2019;s bureau of Simply Speaking. JAS is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organization that develops outcome measures in rheumatology and receives arms-length funding from 12 companies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>15</Day><Hour>23</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35570298</ArticleId><ArticleId IdType="pmc">PMC9107579</ArticleId><ArticleId IdType="doi">10.1186/s12985-022-01813-2</ArticleId><ArticleId IdType="pii">10.1186/s12985-022-01813-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19 Map - Johns Hopkins Coronavirus Resource Center. Available from: https://coronavirus.jhu.edu/map.html</Citation></Reference><Reference><Citation>Ortiz-Prado E, Simba&#xf1;a-Rivera K, G&#xf3;mez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020;98:115094. doi: 10.1016/j.diagmicrobio.2020.115094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2020.115094</ArticleId><ArticleId IdType="pmc">PMC7260568</ArticleId><ArticleId IdType="pubmed">32623267</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer RR, Rock MA, Vasilevsky N, Carmody L, Rando H, Anzalone AJ, et al. Characterizing Long COVID: Deep Phenotype of a Complex Condition. EBioMedicine. 2021;74:103722. doi: 10.1016/j.ebiom.2021.103722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103722</ArticleId><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15&#x2013;19. doi: 10.1136/bmj.329.7456.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.329.7456.15</ArticleId><ArticleId IdType="pmc">PMC443443</ArticleId><ArticleId IdType="pubmed">15231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham NM, Burrell CJ, Douglas RM, Debelle P, Davies L. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis. 1990;162:1277&#x2013;1282. doi: 10.1093/infdis/162.6.1277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/162.6.1277</ArticleId><ArticleId IdType="pubmed">2172402</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancos S, Bernard MP, Topham DJ, Phipps RP. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol. 2009;258:18&#x2013;28. doi: 10.1016/j.cellimm.2009.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2009.03.007</ArticleId><ArticleId IdType="pmc">PMC2693360</ArticleId><ArticleId IdType="pubmed">19345936</ArticleId></ArticleIdList></Reference><Reference><Citation>Torjesen I. Ibuprofen can mask symptoms of infection and might worsen outcomes, says European drugs agency. BMJ. 2020;369:m1614. doi: 10.1136/bmj.m1614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1614</ArticleId><ArticleId IdType="pubmed">32321708</ArticleId></ArticleIdList></Reference><Reference><Citation>Micallef J, Soeiro T, Jonville-B&#xe9;ra A-P. French Society of Pharmacology, Therapeutics (SFPT). Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. Therapie. 2020;75:355&#x2013;362. doi: 10.1016/j.therap.2020.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2020.05.003</ArticleId><ArticleId IdType="pmc">PMC7204680</ArticleId><ArticleId IdType="pubmed">32418728</ArticleId></ArticleIdList></Reference><Reference><Citation>Voiriot G, Dury S, Parrot A, Mayaud C, Fartoukh M. Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. Chest. 2011;139:387&#x2013;394. doi: 10.1378/chest.09-3102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.09-3102</ArticleId><ArticleId IdType="pubmed">20724739</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaja R, Chan JSK, Ferreira P, Harky A, Rogers LJ, Gashaw HH, et al. The COVID-19 ibuprofen controversy: a systematic review of NSAIDs in adult acute lower respiratory tract infections. Br J Clin Pharmacol. 2021;87:776&#x2013;784. doi: 10.1111/bcp.14514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14514</ArticleId><ArticleId IdType="pubmed">32805057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund LC, Reilev M, Hallas J, Kristensen KB, Thomsen RW, Christiansen CF, et al. Association of nonsteroidal anti-inflammatory drug use and adverse outcomes among patients hospitalized with influenza. JAMA Netw Open. 2020;3:e2013880. doi: 10.1001/jamanetworkopen.2020.13880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.13880</ArticleId><ArticleId IdType="pmc">PMC7330719</ArticleId><ArticleId IdType="pubmed">32609352</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JS, Alfajaro MM, Chow RD, Wei J, Filler RB, Eisenbarth SC, et al. Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection. J Virol. 2021;95:e00014&#x2013;e00021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092681</ArticleId><ArticleId IdType="pubmed">33441348</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383:2255&#x2013;2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368:m1086. doi: 10.1136/bmj.m1086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1086</ArticleId><ArticleId IdType="pubmed">32184201</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi MH, Ahn H, Ryu HS, Kim B-J, Jang J, Jung M, et al. Clinical characteristics and disease progression in early-stage COVID-19 patients in South Korea. J Clin Med Res. 2020 doi: 10.3390/jcm9061959.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9061959</ArticleId><ArticleId IdType="pmc">PMC7355553</ArticleId><ArticleId IdType="pubmed">32585855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859&#x2013;866. doi: 10.1136/annrheumdis-2020-217871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020;26:1259.e5&#x2013;1259.e7. doi: 10.1016/j.cmi.2020.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.06.003</ArticleId><ArticleId IdType="pmc">PMC7289730</ArticleId><ArticleId IdType="pubmed">32535147</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce E, Barlow-Pay F, Short R, Vilches-Moraga A, Price A, McGovern A, et al. Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19. J Clin Med Res. 2020 doi: 10.3390/jcm9082586.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9082586</ArticleId><ArticleId IdType="pmc">PMC7465199</ArticleId><ArticleId IdType="pubmed">32785086</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a Danish nationwide cohort study. PLoS Med. 2020;17:e1003308. doi: 10.1371/journal.pmed.1003308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003308</ArticleId><ArticleId IdType="pmc">PMC7478808</ArticleId><ArticleId IdType="pubmed">32898149</ArticleId></ArticleIdList></Reference><Reference><Citation>Kragholm K, Gerds TA, Fosb&#xf8;l E, Andersen MP, Phelps M, Butt JH, et al. Association between prescribed ibuprofen and severe COVID-19 Infection: a nationwide register-based cohort study. Clin Transl Sci. 2020;13:1103&#x2013;1107. doi: 10.1111/cts.12904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12904</ArticleId><ArticleId IdType="pmc">PMC7537121</ArticleId><ArticleId IdType="pubmed">32970921</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu Esba LC, Alqahtani RA, Thomas A, Shamas N, Alswaidan L, Mardawi G. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study. Infect Dis Ther. 2021;10:253&#x2013;268. doi: 10.1007/s40121-020-00363-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-020-00363-w</ArticleId><ArticleId IdType="pmc">PMC7604230</ArticleId><ArticleId IdType="pubmed">33135113</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, Zali A, et al. Mortality risk factors among hospitalized COVID-19 patients in a Major Referral Center in Iran. Tohoku J Exp Med. 2020;252:73&#x2013;84. doi: 10.1620/tjem.252.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1620/tjem.252.73</ArticleId><ArticleId IdType="pubmed">32908083</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandan JS, Zemedikun DT, Thayakaran R, Byne N, Dhalla S, Acosta-Mena D, et al. Nonsteroidal antiinflammatory drugs and susceptibility to COVID-19. Arthritis Rheumatol. 2021;73:731&#x2013;739. doi: 10.1002/art.41593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41593</ArticleId><ArticleId IdType="pmc">PMC8252419</ArticleId><ArticleId IdType="pubmed">33185016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang J-M, Kim J-H, Park J-S, Chang MC, Park D. Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study. Neurol Sci. 2020;41:2317&#x2013;2324. doi: 10.1007/s10072-020-04541-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04541-z</ArticleId><ArticleId IdType="pmc">PMC7342552</ArticleId><ArticleId IdType="pubmed">32643133</ArticleId></ArticleIdList></Reference><Reference><Citation>Imam Z, Odish F, Gill I, O&#x2019;Connor D, Armstrong J, Vanood A, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020;288:469&#x2013;476. doi: 10.1111/joim.13119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13119</ArticleId><ArticleId IdType="pmc">PMC7300881</ArticleId><ArticleId IdType="pubmed">32498135</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahai A, Bhandari R, Godwin M, McIntyre T, Chung MK, Iskandar J-P, et al. Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. Vasc Med. 2021;26:626&#x2013;632. doi: 10.1177/1358863X211012754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1358863X211012754</ArticleId><ArticleId IdType="pmc">PMC8137864</ArticleId><ArticleId IdType="pubmed">34010070</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatol. 2021;3:e498&#x2013;506. doi: 10.1016/S2665-9913(21)00104-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00104-1</ArticleId><ArticleId IdType="pmc">PMC8104907</ArticleId><ArticleId IdType="pubmed">33997800</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021 doi: 10.1136/annrheumdis-2020-219517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-219517</ArticleId><ArticleId IdType="pmc">PMC7823433</ArticleId><ArticleId IdType="pubmed">33478953</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Bennett TD, Eichmann DA, Guinney J, Kibbe WA, et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. J Am Med Inform Assoc. 2021;28:427&#x2013;443. doi: 10.1093/jamia/ocaa196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa196</ArticleId><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22:553&#x2013;564. doi: 10.1093/jamia/ocu023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al. The National COVID Cohort Collaborative: Clinical Characterization and Early Severity Prediction. medRxiv. 2021. 10.1101/2021.01.12.21249511</Citation></Reference><Reference><Citation>Maier C, Kapsner LA, Mate S, Prokosch H-U, Kraus S. Patient cohort identification on time series data using the OMOP common data model. Appl Clin Inform. 2021;12:57&#x2013;64. doi: 10.1055/s-0040-1721481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1721481</ArticleId><ArticleId IdType="pmc">PMC7840432</ArticleId><ArticleId IdType="pubmed">33506478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373&#x2013;383. doi: 10.1016/0021-9681(87)90171-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al. Clinical characterization and prediction of clinical severity of SARS-CoV-2 infection among US adults using data from the US National COVID Cohort Collaborative. JAMA Netw Open. 2021;4:e2116901. doi: 10.1001/jamanetworkopen.2021.16901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.16901</ArticleId><ArticleId IdType="pmc">PMC8278272</ArticleId><ArticleId IdType="pubmed">34255046</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value. Ann Intern Med. 2017;167:268&#x2013;274. doi: 10.7326/M16-2607.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M16-2607</ArticleId><ArticleId IdType="pubmed">28693043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z. Propensity score method: a non-parametric technique to reduce model dependence. Ann Transl Med. 2017;5:7. doi: 10.21037/atm.2016.08.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2016.08.57</ArticleId><ArticleId IdType="pmc">PMC5253298</ArticleId><ArticleId IdType="pubmed">28164092</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore N, Bosco-Levy P, Thurin N, Blin P, Droz-Perroteau C. NSAIDs and COVID-19: a systematic review and meta-analysis. Drug Saf. 2021;44:929&#x2013;938. doi: 10.1007/s40264-021-01089-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-021-01089-5</ArticleId><ArticleId IdType="pmc">PMC8327046</ArticleId><ArticleId IdType="pubmed">34339037</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35570696</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-9077</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Thyroid : official journal of the American Thyroid Association</Title><ISOAbbreviation>Thyroid</ISOAbbreviation></Journal><ArticleTitle>Heart Failure and Stroke Risks in Users of Liothyronine With or Without Levothyroxine Compared with Levothyroxine Alone: A Propensity Score-Matched Analysis.</ArticleTitle><Pagination><StartPage>764</StartPage><EndPage>771</EndPage><MedlinePgn>764-771</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/thy.2021.0634</ELocationID><Abstract><AbstractText><b><i>Background:</i></b> Combination therapy with liothyronine (LT3) and levothyroxine (LT4) is used in patients with persistent symptoms, despite being administered an adequate dose of LT4. LT3 may also be used in some thyroid cancer patients preparing for radioactive iodine therapy. However, there is a controversy regarding the safety of LT3 use, and there has been no definite evidence of long-term safety of LT3 therapy in Asian populations. The aim of this study was to examine the long-term safety of LT3 therapy using the Common Data Model (CDM). <b><i>Methods:</i></b> We conducted a retrospective multicenter study across four hospital databases encoded in the Observational Medical Outcomes Partnership (OMOP) CDM. LT3 users were defined as those who received an LT3 prescription for at least 90 days (with or without LT4), and their safety outcomes were compared with those in LT4-only users after 1:4 propensity score matching. Safety outcomes included the incidences of osteoporosis, cardiovascular disease, cancer, anxiety disorder, and mood disorder. <b><i>Results:</i></b> We identified 1434 LT3 users and 3908 LT4-only users. There was a statistically significant difference in the incidence rate of safety outcomes between LT3 users and LT4-only users. The risks of heart failure (incidence rate ratio [IRR]&#x2009;=&#x2009;1.664, 95% confidence interval [95% CI] 1.002-2.764, <i>p</i>&#x2009;=&#x2009;0.049) and stroke (IRR&#x2009;=&#x2009;1.757, CI 1.073-2.877, <i>p</i>&#x2009;=&#x2009;0.025) were higher in LT3 users than in LT4-only users. When subgroup analysis was performed according to the presence/absence of thyroid cancer history and duration of thyroid hormone replacement, the risk of heart failure was higher in LT3 users with a history of thyroid cancer and those who underwent &#x2265;52 weeks of LT3 therapy. In addition, the risk of stroke was higher in LT3 users without thyroid cancer history and those who underwent &#x2265;52 weeks of LT3 therapy. <b><i>Conclusions:</i></b> The use of LT3 was associated with increased incidence of heart failure and stroke in patients with a longer duration of LT3 use and history of thyroid cancer. Therefore, clinicians should consider the risk of heart failure and stroke in thyroid cancer patients with long-term use of LT3. These findings require confirmation in other populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Wook</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Bo Hyun</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Mijin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinmi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Im</LastName><ForeName>Myungsoo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryang</LastName><ForeName>Soree</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eun Heui</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Yun Kyung</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sang Soo</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>In Joo</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Thyroid</MedlineTA><NlmUniqueID>9104317</NlmUniqueID><ISSNLinking>1050-7256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>06LU7C9H1V</RegistryNumber><NameOfSubstance UI="D014284">Triiodothyronine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-71-5</RegistryNumber><NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q51BO43MG4</RegistryNumber><NameOfSubstance UI="D013974">Thyroxine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="Y">Hypothyroidism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013974" MajorTopicYN="N">Thyroxine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014284" MajorTopicYN="N">Triiodothyronine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">hypothyroidism</Keyword><Keyword MajorTopicYN="N">levothyroxine</Keyword><Keyword MajorTopicYN="N">liothyronine</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>16</Day><Hour>3</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35570696</ArticleId><ArticleId IdType="doi">10.1089/thy.2021.0634</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35571357</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2574-2531</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>JAMIA open</Title><ISOAbbreviation>JAMIA Open</ISOAbbreviation></Journal><ArticleTitle>Trajectories: a framework for detecting temporal clinical event sequences from health data standardized to the Observational Medical Outcomes Partnership (OMOP) Common Data Model.</ArticleTitle><Pagination><StartPage>ooac021</StartPage><MedlinePgn>ooac021</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ooac021</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamiaopen/ooac021</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To develop a framework for identifying temporal clinical event trajectories from Observational Medical Outcomes Partnership-formatted observational healthcare data.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">A 4-step framework based on significant temporal event pair detection is described and implemented as an open-source R package. It is used on a population-based Estonian dataset to first replicate a large Danish population-based study and second, to conduct a disease trajectory detection study for type 2 diabetes patients in the Estonian and Dutch databases as an example.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">As a proof of concept, we apply the methods in the Estonian database and provide a detailed breakdown of our findings. All Estonian population-based event pairs are shown. We compare the event pairs identified from Estonia to Danish and Dutch data and discuss the causes of the differences. The overlap in the results was only 2.4%, which highlights the need for running similar studies in different populations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">For the first time, there is a complete software package for detecting disease trajectories in health data.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>K&#xfc;nnapuu</LastName><ForeName>Kadri</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>STACC, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ioannou</LastName><ForeName>Solomon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ligi</LastName><ForeName>Kadri</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>STACC, Tartu, Estonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolde</LastName><ForeName>Raivo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laur</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>STACC, Tartu, Estonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilo</LastName><ForeName>Jaak</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5604-4107</Identifier><AffiliationInfo><Affiliation>STACC, Tartu, Estonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quretec, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Sulev</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6835-9632</Identifier><AffiliationInfo><Affiliation>STACC, Tartu, Estonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quretec, Tartu, Estonia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMIA Open</MedlineTA><NlmUniqueID>101730643</NlmUniqueID><ISSNLinking>2574-2531</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">R package</Keyword><Keyword MajorTopicYN="N">observational data</Keyword><Keyword MajorTopicYN="N">trajectory</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>16</Day><Hour>3</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35571357</ArticleId><ArticleId IdType="pmc">PMC9097714</ArticleId><ArticleId IdType="doi">10.1093/jamiaopen/ooac021</ArticleId><ArticleId IdType="pii">ooac021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jensen AB, Moseley PL, Oprea TI, et al.Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. Nat Commun 2014; 5 (1): 4022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090719</ArticleId><ArticleId IdType="pubmed">24959948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu JX, Helleberg M, Jensen AB, et al.A large-cohort, longitudinal study determines precancer disease routes across different cancer types. Cancer Res 2019; 79 (4): 864&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">30591553</ArticleId></ArticleIdList></Reference><Reference><Citation>Siggaard T, Reguant R, J&#xf8;rgensen IF, et al.Disease trajectory browser for exploring temporal, population-wide disease progression patterns in 7.2 million Danish patients. Nat Commun 2020; 11 (1): 4952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7532164</ArticleId><ArticleId IdType="pubmed">33009368</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoula A, Centeno E, Mayer MA, et al.A system-level analysis of patient disease trajectories based on clinical, phenotypic and molecular similarities. Bioinformatics 2021; 37 (10): 1435&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">33185649</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Hou C, Yang H, et al.Disease trajectories and mortality among individuals diagnosed with depression: a community-based cohort study in UK Biobank. Mol Psychiatry 2021; 26 (11): 6736&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8145187</ArticleId><ArticleId IdType="pubmed">34035478</ArticleId></ArticleIdList></Reference><Reference><Citation>Paik H, Kim J.. Condensed trajectory of the temporal correlation of diseases and mortality extracted from over 300,000 patients in hospitals. PLoS One 2021; 16 (10): e0257894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491897</ArticleId><ArticleId IdType="pubmed">34610032</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoula A, Gutierrez-Sacrist&#xe1;n A, Bravo &#xc1;, et al.Identifying temporal patterns in patient disease trajectories using dynamic time warping: a population-based study. Sci Rep 2018; 8 (1): 1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5844976</ArticleId><ArticleId IdType="pubmed">29523868</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroux H, Metke-Jimenez A, Lawley MJ.. Towards achieving semantic interoperability of clinical study data with FHIR. J Biomed Semant 2017; 8 (1): 1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5606031</ArticleId><ArticleId IdType="pubmed">28927443</ArticleId></ArticleIdList></Reference><Reference><Citation>Iroju O, Soriyan A, Gambo I, et al.Interoperability in healthcare: benefits, challenges and resolutions. Int J Innov Appl Stud 2013; 3 (1): 262&#x2013;70.</Citation></Reference><Reference><Citation>
Observational Health Data Sciences and Informatics. The Book of OHDSI.
https://ohdsi.github.io/TheBookOfOhdsi/. Accessed March 13,
2022.</Citation></Reference><Reference><Citation>
Sachson C, Ryan P, Kostka K,
et al. Our Journey. Where the OHDSI Community has been and Where We are
Going. https://www.ohdsi.org/wp-content/uploads/2021/09/OHDSI-Book2021-Final.pdf.
Accessed March 13, 2022.</Citation></Reference><Reference><Citation>Chandran U, Reps J, Stang PE, et al.Inferring disease severity in rheumatoid arthritis using predictive modeling in administrative claims databases. PLoS One 2019; 14 (12): e0226255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919633</ArticleId><ArticleId IdType="pubmed">31851711</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf8;rgensen IF, Brunak S.. Time-ordered comorbidity correlations identify patients at risk of mis- and overdiagnosis. NPJ Digit Med 2021; 4 (1): 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846731</ArticleId><ArticleId IdType="pubmed">33514862</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergaard D, Moseley P, S&#xf8;rup FK, et al.Population-wide analysis of differences in disease progression patterns in men and women. Nat Commun 2019; 10 (1): 1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368599</ArticleId><ArticleId IdType="pubmed">30737381</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, et al.Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc 2018; 25 (8): 969&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Ostropolets A, Makadia R, et al.Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study. BMJ 2021; 373: n1435.</Citation></Reference><Reference><Citation>Trajectories R-package. https://github.com/EHDEN/Trajectories/. Accessed March 13,
2022.</Citation></Reference><Reference><Citation>Stuart EA, King G, Imai K, et al.MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011; 42 (8): 1&#x2013;28.</Citation></Reference><Reference><Citation>Hansen BB, Klopfer SO.. Optimal full matching and related designs via network flows. J Comput Graph Stat 2006; 15 (3): 609&#x2013;27.</Citation></Reference><Reference><Citation>Gress TW, Nieto FJ, Shahar E, et al.Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342 (13): 905&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10738048</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo R, De Simone G, Chinali M, et al.Insufficient control of blood pressure and incident diabetes. Diabetes Care 2009; 32 (5): 845&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671117</ArticleId><ArticleId IdType="pubmed">19223610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Lim NK, Choi SJ, et al.Hypertension is an independent risk factor for type 2 diabetes: the Korean genome and epidemiology study. Hypertens Res 2015; 38 (11): 783&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4644940</ArticleId><ArticleId IdType="pubmed">26178151</ArticleId></ArticleIdList></Reference><Reference><Citation>Horr S, Nissen S.. Managing hypertension in type 2 diabetes mellitus. Best Pract Res Clin Endocrinol Metabol 2016; 30 (3): 445&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">27432077</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D, Zhou T, Heianza Y, et al.Type 2 diabetes and hypertension: a study on bidirectional causality. Circ Res 2019; 124 (6): 930&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417940</ArticleId><ArticleId IdType="pubmed">30646822</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Mamza J, Morris T, et al.Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473399 individuals. Eur Heart J 2020; 41 (Suppl 2): ehaa946&#x2013;3313.</Citation></Reference><Reference><Citation>Shah BR, Hux JE.. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26 (2): 510&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12547890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets A, Reich C, Ryan P, et al.Characterizing database granularity using SNOMED-CT hierarchy. AMIA Annu Symp Proc 2021; 2020: 983&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075504</ArticleId><ArticleId IdType="pubmed">33936474</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35576963</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study.</ArticleTitle><Pagination><StartPage>1142</StartPage><EndPage>1152</EndPage><MedlinePgn>1142-1152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(22)00223-7</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(22)00223-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">There are few data on the incidence of thrombosis among COVID-19 cases, with most research concentrated on hospitalised patients. We aimed to estimate the incidence of venous thromboembolism, arterial thromboembolism, and death among COVID-19 cases and to assess the impact of these events on the risks of hospitalisation and death.</AbstractText><AbstractText Label="METHODS">We conducted a distributed network cohort study using primary care records from the Netherlands, Italy, Spain, and the UK, and outpatient specialist records from Germany. The Spanish database was linked to hospital admissions. Participants were followed up from the date of a diagnosis of COVID-19 or positive RT-PCR test for SARS-CoV-2 (index date) for 90 days. The primary study outcomes were venous thromboembolic events, arterial thromboembolic events, and death, all over the 90 days from the index date. We estimated cumulative incidences for the study outcomes. Multistate models were used to calculate adjusted hazard ratios (HRs) for the association between venous thromboembolism or arterial thromboembolism occurrence and risks of hospitalisation or COVID-19 fatality.</AbstractText><AbstractText Label="FINDINGS">Overall, 909&#x2008;473 COVID-19 cases and 32&#x2008;329 patients hospitalised with COVID-19 on or after Sept 1, 2020, were studied. The latest index dates across the databases ranged from Jan 30, 2021, to July 31, 2021. Cumulative 90-day incidence of venous thromboembolism ranged from 0&#xb7;2% to 0&#xb7;8% among COVID-19 cases, and up to 4&#xb7;5% for those hospitalised. For arterial thromboembolism, estimates ranged from 0&#xb7;1% to 0&#xb7;8% among COVID-19 cases, increasing to 3&#xb7;1% among those hospitalised. Case fatality ranged from 1&#xb7;1% to 2&#xb7;0% among patients with COVID-19, rising to 14&#xb7;6% for hospitalised patients. The occurrence of venous thromboembolism in patients with COVID-19 was associated with an increased risk of death (adjusted HRs 4&#xb7;42 [3&#xb7;07-6&#xb7;36] for those not hospitalised and 1&#xb7;63 [1&#xb7;39-1&#xb7;90] for those hospitalised), as was the occurrence of arterial thromboembolism (3&#xb7;16 [2&#xb7;65-3&#xb7;75] and 1&#xb7;93 [1&#xb7;57-2&#xb7;37]).</AbstractText><AbstractText Label="INTERPRETATION">Risks of venous thromboembolism and arterial thromboembolism were up to 1% among COVID-19 cases, and increased with age, among males, and in those who were hospitalised. Their occurrence was associated with excess mortality, underlying the importance of developing effective treatment strategies that reduce their frequency.</AbstractText><AbstractText Label="FUNDING">European Medicines Agency.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Bertolin</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Carlen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA; The Observational Health Data Sciences and Informatics Center at The Roux Institute, Northeastern University, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhamme</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands. Electronic address: daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Infect Dis. 2022 Aug;22(8):1093-1094</RefSource><PMID Version="1">35576962</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests DP-A's research group has received research grants from the European Medicines Agency, the Innovative Medicines Initiative, Amgen, Chiesi, and UCB Biopharma; consultancy fees from Amgen, UCB Biopharma, and AstraZeneca; and speaker fees from Astellas, Amgen, and UCB Biopharma. From the time of study design to analysis, KK was an employee of IQVIA. KK reported receiving funding from the National Institutes of Health National COVID Cohort Collaborative. IQVIA received funding from the University of Oxford on behalf of the Bill &amp; Melinda Gates Foundation for the standardisation of data from IQVIA LPD Italy to a common data model for analysis, and the use of IQVIA DA Germany data for COVID-19-related research. TDS acknowledges receiving financial support from the Instituto de Salud Carlos III (ISCIII; Miguel Servet 2021: CP21/00023). All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>16</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35576963</ArticleId><ArticleId IdType="pmc">PMC9106320</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(22)00223-7</ArticleId><ArticleId IdType="pii">S1473-3099(22)00223-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2950&#x2013;2973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021;76:970&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">33622981</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2020;4:1178&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537137</ArticleId><ArticleId IdType="pubmed">33043231</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, Teb&#xe9; C, Fernandez-Bertolin S, et al. The natural history of symptomatic COVID-19 during the first wave in Catalonia. Nat Commun. 2021;12:777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7858639</ArticleId><ArticleId IdType="pubmed">33536436</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilev M, Kristensen KB, Potteg&#xe5;rd A, et al. Characteristics and predictors of hospitalization and death in the first 11&#x2008;122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49:1468&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499657</ArticleId><ArticleId IdType="pubmed">32887982</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty AB, Harrison EM, Green CA, et al. Features of 20&#x2008;133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Hayek SS, Wang W, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180:1436&#x2013;1447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364338</ArticleId><ArticleId IdType="pubmed">32667668</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19 death in 17 million patients. Nature. 2020;584:430&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe GDO. Common risk factors for both arterial and venous thrombosis. Br J Haematol. 2008;140:488&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">18275426</ArticleId></ArticleIdList></Reference><Reference><Citation>Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus. 2011;9:120&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096855</ArticleId><ArticleId IdType="pubmed">21084000</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22:553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>de Ridder MAJ, de Wilde M, de Ben C, et al. Data resource profile: the Integrated Primary Care Information (IPCI) database, the Netherlands. Int J Epidemiol. 2022 doi: 10.1093/ije/dyac026. published online Feb 19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyac026</ArticleId><ArticleId IdType="pmc">PMC9749682</ArticleId><ArticleId IdType="pubmed">35182144</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD) Int J Epidemiol. 2015;44:827&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Recalde M, Rodr&#xed;guez C, Burn E, et al. Data resource profile: the Information System for Research in Primary Care (SIDIAP) Int J Epidemiol. 2022 doi: 10.1093/ije/dyac068. published online April 13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyac068</ArticleId><ArticleId IdType="pmc">PMC9749711</ArticleId><ArticleId IdType="pubmed">35415748</ArticleId></ArticleIdList></Reference><Reference><Citation>Jouaville SL, Miotti H, Coffin G, Sarfati B, Meihoc A. Validity and limitations of the Longitudinal Patient Database France for use in pharmacoepidemiological and pharmacoeconomics studies. Value Health. 2015;18:A18.</Citation></Reference><Reference><Citation>Burn E, Li X, Kostka K, et al. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiol Drug Saf. 2022;31:495&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088543</ArticleId><ArticleId IdType="pubmed">35191114</ArticleId></ArticleIdList></Reference><Reference><Citation>Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389&#x2013;2430.</Citation><ArticleIdList><ArticleId IdType="pubmed">17031868</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J. 2008;29:96&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063596</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton TC, Gaskin M, Meade TW. Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database. Int J Epidemiol. 2011;40:819&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3147071</ArticleId><ArticleId IdType="pubmed">21324940</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe GDO. Common risk factors for both arterial and venous thrombosis. Br J Haematol. 2008;140:488&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">18275426</ArticleId></ArticleIdList></Reference><Reference><Citation>Roach REJ, Lijfering WM, Rosendaal FR, Cannegieter SC, le Cessie S. Sex difference in risk of second but not of first venous thrombosis: paradox explained. Circulation. 2014;129:51&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">24146250</ArticleId></ArticleIdList></Reference><Reference><Citation>Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. BMJ. 2018;363</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6364292</ArticleId><ArticleId IdType="pubmed">30404896</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelros P, Stegmayr B, Ter&#xe9;nt A. Sex differences in stroke epidemiology: a systematic review. Stroke. 2009;40:1082&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">19211488</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith GJ, Morris TT, Tudball MJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665028</ArticleId><ArticleId IdType="pubmed">33184277</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19 death in 17 million patients. Nature. 2020;584:430&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Westreich D, Edwards JK, van Smeden M. Comment on Williamson et al. The table 2 fallacy in a study of COVID-19 mortality risk factors. Epidemiology. 2021;32:e1&#x2013;e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">33065610</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35576979</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2093-3681</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Healthcare informatics research</Title><ISOAbbreviation>Healthc Inform Res</ISOAbbreviation></Journal><ArticleTitle>Applying the OMOP Common Data Model to Facilitate Benefit-Risk Assessments of Medicinal Products Using Real-World Data from Singapore and South Korea.</ArticleTitle><Pagination><StartPage>112</StartPage><EndPage>122</EndPage><MedlinePgn>112-122</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4258/hir.2022.28.2.112</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to characterize the benefits of converting Electronic Medical Records (EMRs) to a common data model (CDM) and to assess the potential of CDM-converted data to rapidly generate insights for benefit-risk assessments in post-market regulatory evaluation and decisions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">EMRs from January 2013 to December 2016 were mapped onto the Observational Medical Outcomes Partnership-CDM (OMOP-CDM) schema. Vocabulary mappings were applied to convert source data values into OMOP-CDM-endorsed terminologies. Existing analytic codes used in a prior OMOP-CDM drug utilization study were modified to conduct an illustrative analysis of oral anticoagulants used for atrial fibrillation in Singapore and South Korea, resembling a typical benefit-risk assessment. A novel visualization is proposed to represent the comparative effectiveness, safety and utilization of the drugs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over 90% of records were mapped onto the OMOP-CDM. The CDM data structures and analytic code templates simplified the querying of data for the analysis. In total, 2,419 patients from Singapore and South Korea fulfilled the study criteria, the majority of whom were warfarin users. After 3 months of follow-up, differences in cumulative incidence of bleeding and thromboembolic events were observable via the proposed visualization, surfacing insights as to the agent of preference in a given clinical setting, which may meaningfully inform regulatory decision-making.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">While the structure of the OMOP-CDM and its accessory tools facilitate real-world data analysis, extending them to fulfil regulatory analytic purposes in the post-market setting, such as benefit-risk assessments, may require layering on additional analytic tools and visualization techniques.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Hui Xing</ForeName><Initials>HX</Initials><AffiliationInfo><Affiliation>Vigilance &amp; Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teo</LastName><ForeName>Desmond Chun Hwee</ForeName><Initials>DCH</Initials><AffiliationInfo><Affiliation>Vigilance &amp; Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dongyun</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Graduate School of Medicine, Ajou University, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neo</LastName><ForeName>Jing Wei</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Vigilance &amp; Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Vigilance &amp; Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Services and Systems Research, Duke-NUS Medical School, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chahed</LastName><ForeName>Haroun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Vigilance &amp; Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ang</LastName><ForeName>Pei San</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Vigilance &amp; Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Doreen Su Yin</ForeName><Initials>DSY</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Khoo Teck Puat Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Graduate School of Medicine, Ajou University, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorajoo</LastName><ForeName>Sreemanee Raaj</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Vigilance &amp; Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Healthc Inform Res</MedlineTA><NlmUniqueID>101534553</NlmUniqueID><ISSNLinking>2093-3681</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anticoagulants</Keyword><Keyword MajorTopicYN="N">Data Visualization</Keyword><Keyword MajorTopicYN="N">Health Policy</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance</Keyword><Keyword MajorTopicYN="N">Risk Assessment</Keyword></KeywordList><CoiStatement>
<b>Conflict of interest</b>
. Rae Woong Park is an editorial member of Healthcare Informatics Research; however, he did not involve in the peer reviewer selection, evaluation, and decision process of this article. Otherwise, no potential conflict of interest relevant to this article was reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>16</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35576979</ArticleId><ArticleId IdType="pmc">PMC9117808</ArticleId><ArticleId IdType="doi">10.4258/hir.2022.28.2.112</ArticleId><ArticleId IdType="pii">hir.2022.28.2.112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Franklin JM, Glynn RJ, Martin D, Schneeweiss S. Evaluating the use of nonrandomized real-world data analyses for regulatory decision making. Clin Pharmacol Ther. 2019;105(4):867&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30636285</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisinger SJ, Ryan PB, O&#x2019;Hara DJ, Powell GE, Painter JL, Pattishall EN, et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J Am Med Inform Assoc. 2010;17(6):652&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Glynn RJ. Real-world data analytics fit for regulatory decision-making. Am J Law Med. 2018;44(2&#x2013;3):197&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet. 2002;359(9302):248&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Bakken S, Hripcsak G, Weng C. A data quality assessment guideline for electronic health record data reuse. EGEMS (Wash DC) 2017;5(1):14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983018</ArticleId><ArticleId IdType="pubmed">29881734</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  . The book of OHDSI [Internet]. [place unknown] Observational Health Data Sciences and Informatics; 2021.  [cited at 2022 Apr 15]. Available from:  https://ohdsi.github.io/TheBookOfOhdsi/
</Citation></Reference><Reference><Citation>Maier C, Lang L, Storf H, Vormstein P, Bieber R, Bernarding J, et al. Towards implementation of OMOP in a German university hospital consortium. Appl Clin Inform. 2018;9(1):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, et al. Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA. 2020;324(16):1640&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592033</ArticleId><ArticleId IdType="pubmed">33107944</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Van Zandt M, Liu Y, Li J, Wang X, Chen Y, et al. Analysis of dual combination therapies used in treatment of hypertension in a multinational cohort. JAMA Netw Open. 2022;5(3):e223877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8948532</ArticleId><ArticleId IdType="pubmed">35323951</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathappan S, Jeon YS, Dang TK, Lim SC, Shao YM, Tai ES, et al. Transformation of electronic health records and questionnaire data to OMOP CDM: a feasibility study using SG_T2DM Dataset. Appl Clin Inform. 2021;12(4):757&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357458</ArticleId><ArticleId IdType="pubmed">34380168</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  . OMOP common data model [Internet]. [place unknown] Observational Health Data Sciences and Informatics; c2022.  [cited at 2022 Apr 15]. Available from:  https://www.ohdsi.org/data-standardization/the-common-data-model/
</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  . Rabbit-in-a-Hat [Internet]. [place unknown] Observational Health Data Sciences and Informatics; c2022.  [cited at 2022 Apr 15]. Available from:  http://ohdsi.github.io/WhiteRabbit/RabbitInAHat.html
.</Citation></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, et al. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016;22(1):54&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Park RW. Sharing clinical big data while protecting confidentiality and security: Observational Health Data Sciences and Informatics. Healthc Inform Res. 2017;23(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sentinel Initiative Level 1 analyses [Internet] Silver Spring (MD): US Food and Drug Administration; c2022.  [cited at 2022 Apr 15]. Available from:  https://www.sentinelinitiative.org/methods-data-tools/routine-querying-tools/level-1-analyses
.</Citation></Reference><Reference><Citation>Sentinel Initiative Level 2 analyses [Internet] Silver Spring (MD): US Food and Drug Administration; c2022.  [cited at 2022 Apr 15]. Available from:  https://www.sentinelinitiative.org/methods-data-tools/routine-querying-tools/level-2-analyses
.</Citation></Reference><Reference><Citation>Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng RD, Dominici F, Zeger SL. Reproducible epidemiologic research. Am J Epidemiol. 2006;163(9):783&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35579818</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Using Iterative Pairwise External Validation to Contextualize Prediction Model Performance: A Use Case Predicting 1-Year Heart Failure Risk in Patients with Diabetes Across Five Data Sources.</ArticleTitle><Pagination><StartPage>563</StartPage><EndPage>570</EndPage><MedlinePgn>563-570</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-022-01161-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION">External validation of prediction models is increasingly being seen as a minimum requirement for acceptance in clinical practice. However, the lack of interoperability of healthcare databases has been the biggest barrier to this occurring on a large scale. Recent improvements in database interoperability enable a standardized analytical framework for model development and external validation. External validation of a model in a new database lacks context, whereby the external validation can be compared with a benchmark in this database. Iterative pairwise external validation (IPEV) is a framework that uses a rotating model development and validation approach to contextualize the assessment of performance across a network of databases. As a use case, we predicted 1-year risk of heart failure in patients with type 2 diabetes mellitus.</AbstractText><AbstractText Label="METHODS">The method follows a two-step process involving (1) development of baseline and data-driven models in each database according to best practices and (2) validation of these models across the remaining databases. We introduce a heatmap visualization that supports the assessment of the internal and external model performance in all available databases. As a use case, we developed and validated models to predict 1-year risk of heart failure in patients initializing a second pharmacological intervention for type 2 diabetes mellitus. We leveraged the power of the Observational Medical Outcomes Partnership common data model to create an open-source software package to increase the consistency, speed, and transparency of this process.</AbstractText><AbstractText Label="RESULTS">A total of 403,187 patients from five databases were included in the study. We developed five models that, when assessed internally, had a discriminative performance ranging from 0.73 to 0.81 area under the receiver operating characteristic curve with acceptable calibration. When we externally validated these models in a new database, three models achieved consistent performance and in context often performed similarly to models developed in the database itself. The visualization of IPEV provided valuable insights. From this, we identified the model developed in the Commercial Claims and Encounters (CCAE) database as the best performing model overall.</AbstractText><AbstractText Label="CONCLUSION">Using IPEV lends weight to the model development process. The rotation of development through multiple databases provides context to model assessment, leading to improved understanding of transportability and generalizability. The inclusion of a baseline model in all modelling steps provides further context to the performance gains of increasing model complexity. The CCAE model was identified as a candidate for clinical use. The use case demonstrates that IPEV provides a huge opportunity in a new era of standardised data and analytics to improve insight into and trust in prediction models at an unprecedented scale.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0001-7723-417X</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC, University Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. r.williams@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kors</LastName><ForeName>Jan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC, University Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steyerberg</LastName><ForeName>Ewout</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhamme</LastName><ForeName>Katia M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC, University Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC, University Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Ross D. Williams, Jan A. Kors, and Ewout Steyerberg have no conflicts of interest that are directly relevant to the content of this article. Katia M. Verhamme and Peter R. Rijnbeek work for a research group that has received unconditional research grants from Boehringer-Ingelheim, GSK, Janssen Research &amp; Development, Novartis, Pfizer, Yamanouchi, and Servier. Jenna M. Reps and Patrick B. Ryan are employees and shareholders of Janssen Research &amp; Development and shareholders of Johnson &amp; Johnson.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35579818</ArticleId><ArticleId IdType="pmc">PMC9114056</ArticleId><ArticleId IdType="doi">10.1007/s40264-022-01161-8</ArticleId><ArticleId IdType="pii">10.1007/s40264-022-01161-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Steyerberg EW, Harrell FE., Jr Prediction models need appropriate internal, internal-external, and external validation. J Clin Epidemiol. 2016;69:245&#x2013;247. doi: 10.1016/j.jclinepi.2015.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.04.005</ArticleId><ArticleId IdType="pmc">PMC5578404</ArticleId><ArticleId IdType="pubmed">25981519</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, de Groot JA, Dutton S, Omar O, Shanyinde M, Tajar A, et al. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol. 2014;19(14):40. doi: 10.1186/1471-2288-14-40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-40</ArticleId><ArticleId IdType="pmc">PMC3999945</ArticleId><ArticleId IdType="pubmed">24645774</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehne M, Sass J, Essenwanger A, Schepers J, Thun S. Why digital medicine depends on interoperability. NPJ Digit Med. 2019;2:79. doi: 10.1038/s41746-019-0158-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-019-0158-1</ArticleId><ArticleId IdType="pmc">PMC6702215</ArticleId><ArticleId IdType="pubmed">31453374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent S, Burn E, Dawoud D, Jonsson P, Ostby JT, Hughes N, et al. Common problems, common data model solutions: evidence generation for health technology assessment. Pharmacoeconomics. 2021;39(3):275&#x2013;285. doi: 10.1007/s40273-020-00981-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-020-00981-9</ArticleId><ArticleId IdType="pmc">PMC7746423</ArticleId><ArticleId IdType="pubmed">33336320</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25:969&#x2013;975. doi: 10.1093/jamia/ocy032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Williams RD, You SC, Falconer T, Minty E, Callahan A, et al. Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation. BMC Med Res Methodol. 2020;20(1):102. doi: 10.1186/s12874-020-00991-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-020-00991-3</ArticleId><ArticleId IdType="pmc">PMC7201646</ArticleId><ArticleId IdType="pubmed">32375693</ArticleId></ArticleIdList></Reference><Reference><Citation>Woelfle M, Olliaro P, Todd MH. Open science is a research accelerator. Nat Chem. 2011;3(10):745&#x2013;748. doi: 10.1038/nchem.1149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchem.1149</ArticleId><ArticleId IdType="pubmed">21941234</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooney SJ, Pejaver V. Big data in public health: terminology, machine learning, and privacy. Annu Rev Public Health. 2018;1(39):95&#x2013;112. doi: 10.1146/annurev-publhealth-040617-014208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-publhealth-040617-014208</ArticleId><ArticleId IdType="pmc">PMC6394411</ArticleId><ArticleId IdType="pubmed">29261408</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandl KD, Kohane IS. Federalist principles for healthcare data networks. Nat Biotechnol. 2015;33(4):360&#x2013;363. doi: 10.1038/nbt.3180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3180</ArticleId><ArticleId IdType="pmc">PMC4392383</ArticleId><ArticleId IdType="pubmed">25850061</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012;98(9):683&#x2013;690. doi: 10.1136/heartjnl-2011-301246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2011-301246</ArticleId><ArticleId IdType="pubmed">22397945</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement. Br J Surg. 2015;102(3):148&#x2013;158. doi: 10.1002/bjs.9736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9736</ArticleId><ArticleId IdType="pubmed">25627261</ArticleId></ArticleIdList></Reference><Reference><Citation>Damen JA, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ. 2016;16(353):i2416. doi: 10.1136/bmj.i2416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i2416</ArticleId><ArticleId IdType="pmc">PMC4868251</ArticleId><ArticleId IdType="pubmed">27184143</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons KG, Kengne AP, Grobbee DE, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart. 2012;98(9):691&#x2013;698. doi: 10.1136/heartjnl-2011-301247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2011-301247</ArticleId><ArticleId IdType="pubmed">22397946</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley RD, Ensor J, Snell KI, Debray TP, Altman DG, Moons KG, et al. External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges. BMJ. 2016;353:i3140. doi: 10.1136/bmj.i3140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i3140</ArticleId><ArticleId IdType="pmc">PMC4916924</ArticleId><ArticleId IdType="pubmed">27334381</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramspek CL, Jager KJ, Dekker FW, Zoccali C, van Diepen M. External validation of prognostic models: what, why, how, when and where? Clin Kidney J. 2020;14(1):49&#x2013;58. doi: 10.1093/ckj/sfaa188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfaa188</ArticleId><ArticleId IdType="pmc">PMC7857818</ArticleId><ArticleId IdType="pubmed">33564405</ArticleId></ArticleIdList></Reference><Reference><Citation>Helgeson C, Srikrishnan V, Keller K, Tuana N. Why simpler computer simulation models can be epistemically better for informing decisions. Philos Sci. 2021;88(2):213&#x2013;233. doi: 10.1086/711501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/711501</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Wang Y, Molino P, Li L, Ebert DS. Manifold: a model-agnostic framework for interpretation and diagnosis of machine learning models. IEEE Trans Vis Comput Graph. 2019;25(1):364&#x2013;373. doi: 10.1109/TVCG.2018.2864499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TVCG.2018.2864499</ArticleId><ArticleId IdType="pubmed">30130197</ArticleId></ArticleIdList></Reference><Reference><Citation>Tousoulis D, Oikonomou E, Siasos G, Stefanadis C. Diabetes mellitus and heart failure. Eur Cardiol Rev. 2014;9(1):37&#x2013;42. doi: 10.15420/ecr.2014.9.1.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/ecr.2014.9.1.37</ArticleId><ArticleId IdType="pmc">PMC6159396</ArticleId><ArticleId IdType="pubmed">30310483</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24(9):1614&#x2013;1619. doi: 10.2337/diacare.24.9.1614.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.24.9.1614</ArticleId><ArticleId IdType="pubmed">11522708</ArticleId></ArticleIdList></Reference><Reference><Citation>Care F. Standards of medical care in diabetes 2019. Diabetes Care. 2019;42(Suppl 1):S124&#x2013;S138.</Citation><ArticleIdList><ArticleId IdType="pubmed">30559237</ArticleId></ArticleIdList></Reference><Reference><Citation>Association AD. Updates to the standards of medical care in diabetes-2018. Diabetes Care. 2018;41(9):2045&#x2013;2047. doi: 10.2337/dc18-su09.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc18-su09</ArticleId><ArticleId IdType="pubmed">30135199</ArticleId></ArticleIdList></Reference><Reference><Citation>Marathe PH, Gao HX, Close KL. American diabetes association standards of medical care in diabetes 2017. J Diabetes. 2017;9(4):320&#x2013;324. doi: 10.1111/1753-0407.12524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1753-0407.12524</ArticleId><ArticleId IdType="pubmed">28070960</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc B Metorol. 1996;58(1):267&#x2013;288.</Citation></Reference><Reference><Citation>Debray TP, Vergouwe Y, Koffijberg H, Nieboer D, Steyerberg EW, Moons KG. A new framework to enhance the interpretation of external validation studies of clinical prediction models. J Clin Epidemiol. 2015;68(3):279&#x2013;289. doi: 10.1016/j.jclinepi.2014.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2014.06.018</ArticleId><ArticleId IdType="pubmed">25179855</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35589253</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1600-0641</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of hepatology</Title><ISOAbbreviation>J Hepatol</ISOAbbreviation></Journal><ArticleTitle>"Beyond MELD" - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation.</ArticleTitle><Pagination><StartPage>1318</StartPage><EndPage>1329</EndPage><MedlinePgn>1318-1329</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhep.2022.03.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-8278(22)00141-6</ELocationID><Abstract><AbstractText>In this review article, we discuss the model for end-stage liver disease (MELD) score and its dual purpose in general and transplant hepatology. As the landscape of liver disease and transplantation has evolved considerably since the advent of the MELD score, we summarise emerging concepts, methodologies, and technologies that may improve mortality prognostication in the future. Finally, we explore how these novel concepts and technologies may be incorporated into clinical practice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of California - San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>W Ray</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: wrkim@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of California - San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Allison J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AA029197</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK026743</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG059183</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK127224</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Hepatol</MedlineTA><NlmUniqueID>8503886</NlmUniqueID><ISSNLinking>0168-8278</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Hepatol. 2023 Mar;78(3):e98-e99</RefSource><PMID Version="1">35870703</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Hepatol. 2023 Mar;78(3):e100-e101</RefSource><PMID Version="1">36402449</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D058625" MajorTopicYN="Y">End Stage Liver Disease</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009927" MajorTopicYN="Y">Tissue and Organ Procurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014850" MajorTopicYN="N">Waiting Lists</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Allocation</Keyword><Keyword MajorTopicYN="N">Clinical Decision Support</Keyword><Keyword MajorTopicYN="N">EHR</Keyword><Keyword MajorTopicYN="N">Frailty</Keyword><Keyword MajorTopicYN="N">MELD</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Prognostication</Keyword><Keyword MajorTopicYN="N">Sarcopenia</Keyword></KeywordList><CoiStatement>Conflict of interest The authors of this manuscript have no conflicts of interest to disclose as described by the Journal of Hepatology. Please refer to the accompanying ICMJE disclosure forms for further details.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>19</Day><Hour>21</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35589253</ArticleId><ArticleId IdType="mid">NIHMS1904959</ArticleId><ArticleId IdType="pmc">PMC10286631</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2022.03.003</ArticleId><ArticleId IdType="pii">S0168-8278(22)00141-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Organ Procurement and Transplantation Network (OPTN). Final Rule as revised by amendments. 1999.</Citation></Reference><Reference><Citation>Jochmans I, van Rosmalen M, Pirenne J, Samuel U. Adult liver allocation in eurotransplant. Transplantation 2017;101:1542&#x2013;1550. 10.1097/TP.0000000000001631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000001631</ArticleId><ArticleId IdType="pubmed">28060242</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudsmit BFJ, Putter H, Tushuizen ME, Vogelaar S, Pirenne J, Alwayn IPJ, et al. Refitting the model for end-stage liver disease for the eurotransplant region. Hepatology 2021;74:351&#x2013;363. 10.1002/hep.31677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31677</ArticleId><ArticleId IdType="pmc">PMC8359978</ArticleId><ArticleId IdType="pubmed">33301607</ArticleId></ArticleIdList></Reference><Reference><Citation>Trotter JF. Liver transplantation around the world. Curr Opin Organ Transpl 2017;22:123&#x2013;127. 10.1097/MOT.0000000000000392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOT.0000000000000392</ArticleId><ArticleId IdType="pubmed">28151809</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91&#x2013;96. 10.1053/gast.2003.50016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2003.50016</ArticleId><ArticleId IdType="pubmed">12512033</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman RB, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002;8:851&#x2013;858. 10.1053/jlts.2002.35927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jlts.2002.35927</ArticleId><ArticleId IdType="pubmed">12200791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464&#x2013;470. 10.1053/jhep.2001.22172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jhep.2001.22172</ArticleId><ArticleId IdType="pubmed">11172350</ArticleId></ArticleIdList></Reference><Reference><Citation>Quante M, Benckert C, Thelen A, Jonas S. Experience since MELD implementation: how does the new system deliver? Int J Hepatol 2012;2012:264015. 10.1155/2012/264015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/264015</ArticleId><ArticleId IdType="pmc">PMC3467768</ArticleId><ArticleId IdType="pubmed">23091734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018&#x2013;1026. 10.1056/NEJMoa0801209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0801209</ArticleId><ArticleId IdType="pmc">PMC4374557</ArticleId><ArticleId IdType="pubmed">18768945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology 2021. 10.1053/j.gastro.2021.08.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.08.050</ArticleId><ArticleId IdType="pmc">PMC8608337</ArticleId><ArticleId IdType="pubmed">34481845</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong AJ, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, et al. OPTN/SRTR 2019 annual data report: liver. Am J Transpl 2021;21(Suppl 2):208&#x2013;315. 10.1111/ajt.16494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16494</ArticleId><ArticleId IdType="pubmed">33595192</ArticleId></ArticleIdList></Reference><Reference><Citation>Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020;69:564&#x2013;568. 10.1136/gutjnl-2019-318813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-318813</ArticleId><ArticleId IdType="pubmed">31366455</ArticleId></ArticleIdList></Reference><Reference><Citation>Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011;140:1952&#x2013;1960. 10.1053/j.gastro.2011.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.02.017</ArticleId><ArticleId IdType="pmc">PMC4546828</ArticleId><ArticleId IdType="pubmed">21334338</ArticleId></ArticleIdList></Reference><Reference><Citation>Godfrey EL, Malik TH, Lai JC, Mindikoglu AL, Galv&#xe1;n NTN, Cotton RT, et al. The decreasing predictive power of MELD in an era of changing etiology of liver disease. Am J Transpl 2019;19:3299&#x2013;3307. 10.1111/ajt.15559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15559</ArticleId><ArticleId IdType="pubmed">31394020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong A, Mannalithara A, Kim WR. Reply to: &#x201c;The decreasing predictive power of MELD in an era of changing etiology of liver disease&#x201d;. Am J Transpl 2020;20:901&#x2013;902. 10.1111/ajt.15733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15733</ArticleId><ArticleId IdType="pubmed">31814299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernaez R, Liu Y, Kramer JR, Rana A, El-Serag HB, Kanwal F. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol 2020;73:1425&#x2013;1433. 10.1016/j.jhep.2020.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.06.005</ArticleId><ArticleId IdType="pubmed">32531416</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen AM, Heimbach JK, Larson JJ, Mara KC, Kim WR, Kamath PS, et al. Reduced access to liver transplantation in women: role of height, MELD exception scores, and renal function underestimation. Transplantation 2018;102:1710&#x2013;1716. 10.1097/TP.0000000000002196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000002196</ArticleId><ArticleId IdType="pmc">PMC6153066</ArticleId><ArticleId IdType="pubmed">29620614</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers RP, Shaheen AAM, Aspinall AI, Quinn RR, Burak KW. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. J Hepatol 2011;54:462&#x2013;470. 10.1016/j.jhep.2010.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2010.07.015</ArticleId><ArticleId IdType="pubmed">21109324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur AK, Schaubel DE, Gong Q, Guidinger MK, Merion RM. Sexbased disparities in liver transplant rates in the United States. Am J Transpl 2011;11:1435&#x2013;1443. 10.1111/j.1600-6143.2011.03498.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2011.03498.x</ArticleId><ArticleId IdType="pmc">PMC3132137</ArticleId><ArticleId IdType="pubmed">21718440</ArticleId></ArticleIdList></Reference><Reference><Citation>Verna EC, Lai JC. Time for action to address the persistent sex-based disparity in liver transplant access. JAMA Surg 2020;155:545&#x2013;547. 10.1001/jamasurg.2020.1126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2020.1126</ArticleId><ArticleId IdType="pubmed">32432664</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholongitas E, Marelli L, Kerry A, Goodier DW, Nair D, Thomas M, et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores&#x2013;a systematic bias. Am J Transpl 2007;7:685&#x2013;692. 10.1111/j.1600-6143.2007.01666.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2007.01666.x</ArticleId><ArticleId IdType="pubmed">17217437</ArticleId></ArticleIdList></Reference><Reference><Citation>Leithead JA, MacKenzie SM, Ferguson JW, Hayes PC. Is estimated glomerular filtration rate superior to serum creatinine in predicting mortality on the waiting list for liver transplantation? Transpl Int 2011;24:482&#x2013;488. 10.1111/j.1432-2277.2011.01231.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-2277.2011.01231.x</ArticleId><ArticleId IdType="pubmed">21362061</ArticleId></ArticleIdList></Reference><Reference><Citation>Asrani SK, Jennings LW, Kim WR, Kamath PS, Levitsky J, Nadim MK, et al. MELD-GRAIL-Na: glomerular filtration rate and mortality on liver-transplant waiting list. Hepatology 2020;71:1766&#x2013;1774. 10.1002/hep.30932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.30932</ArticleId><ArticleId IdType="pubmed">31523825</ArticleId></ArticleIdList></Reference><Reference><Citation>Asrani SK, Jennings LW, Trotter JF, Levitsky J, Nadim MK, Kim WR, et al. A model for glomerular filtration rate assessment in liver disease (GRAIL) in the presence of renal dysfunction. Hepatology 2019;69:1219&#x2013;1230. 10.1002/hep.30321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.30321</ArticleId><ArticleId IdType="pubmed">30338870</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkenstedt A, Dorn L, Edlinger M, Prokop W, Risch L, Griesmacher A, et al. Cystatin C is a strong predictor of survival in patients with cirrhosis: is a cystatin C-based MELD better? Liver Int 2012;32:1211&#x2013;1216. 10.1111/j.1478-3231.2012.02766.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2012.02766.x</ArticleId><ArticleId IdType="pubmed">22380485</ArticleId></ArticleIdList></Reference><Reference><Citation>De Souza V, Hadj-Aissa A, Dolomanova O, Rabilloud M, Rognant N, Lemoine S, et al. Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology 2014;59:1522&#x2013;1531. 10.1002/hep.26886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.26886</ArticleId><ArticleId IdType="pubmed">24123197</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephew LD, Goldberg DS, Lewis JD, Abt P, Bryan M, Forde KA. Exception points and body size contribute to gender disparity in liver transplantation. Clin Gastroenterol Hepatol 2017;15:1286&#x2013;1293.e2. 10.1016/j.cgh.2017.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2017.02.033</ArticleId><ArticleId IdType="pubmed">28288834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood NL, VanDerwerken D, Segev DL, Gentry SE. Correcting the sex disparity in MELD-Na. Am J Transpl 2021;21:3296&#x2013;3304. 10.1111/ajt.16731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16731</ArticleId><ArticleId IdType="pmc">PMC8500920</ArticleId><ArticleId IdType="pubmed">34174151</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight - reconsidering the use of race correction in clinical algorithms. N Engl J Med 2020;383:874&#x2013;882. 10.1056/NEJMms2004740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMms2004740</ArticleId><ArticleId IdType="pubmed">32853499</ArticleId></ArticleIdList></Reference><Reference><Citation>Linecker M, Krones T, Berg T, Niemann CU, Steadman RH, Dutkowski P, et al. Potentially inappropriate liver transplantation in the era of the &#x201c;sickest first&#x201d; policy - a search for the upper limits. J Hepatol 2018;68:798&#x2013;813. 10.1016/j.jhep.2017.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2017.11.008</ArticleId><ArticleId IdType="pubmed">29133246</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana A, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transpl 2008;8:2537&#x2013;2546. 10.1111/j.1600-6143.2008.02400.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2008.02400.x</ArticleId><ArticleId IdType="pubmed">18945283</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutkowski P, Oberkofler CE, Slankamenac K, Puhan MA, Schadde E, M&#xfc;llhaupt B, et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg 2011;254:745&#x2013;753. 10.1097/SLA.0b013e3182365081. discussion 753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3182365081</ArticleId><ArticleId IdType="pubmed">22042468</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg D, Mantero A, Newcomb C, Delgado C, Forde K, Kaplan D, et al. Development and validation of a model to predict long-term survival after liver transplantation. Liver Transpl 2021;27:797&#x2013;807. 10.1002/lt.26002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.26002</ArticleId><ArticleId IdType="pmc">PMC8742146</ArticleId><ArticleId IdType="pubmed">33540489</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X, Leanza J, Massie AB, Garonzik-Wang JM, Haugen CE, Gentry SE, et al. MELD as a metric for survival benefit of liver transplantation. Am J Transpl 2018;18:1231&#x2013;1237. 10.1111/ajt.14660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.14660</ArticleId><ArticleId IdType="pmc">PMC6116532</ArticleId><ArticleId IdType="pubmed">29316310</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong AJ, Kim WR. Predicting survival after liver transplantation: a noble pursuit or a fool&#x2019;s errand? Liver Transpl 2021;27:789&#x2013;790. 10.1002/lt.26057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.26057</ArticleId><ArticleId IdType="pubmed">33773023</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman RB, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L, et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006;12:S128&#x2013;S136. 10.1002/lt.20979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.20979</ArticleId><ArticleId IdType="pubmed">17123284</ArticleId></ArticleIdList></Reference><Reference><Citation>Cillo U, Burra P, Mazzaferro V, Belli L, Pinna AD, Spada M, et al. A multistep, consensus-based approach to organ allocation in liver transplantation: toward a &#x201c;blended principle model&#x201d;. Am J Transpl 2015;15:2552&#x2013;2561. 10.1111/ajt.13408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.13408</ArticleId><ArticleId IdType="pubmed">26274338</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasiske BL, Pyke J, Snyder JJ. Continuous distribution as an organ allocation framework. Curr Opin Organ Transpl 2020;25:115&#x2013;121. 10.1097/MOT.0000000000000733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOT.0000000000000733</ArticleId><ArticleId IdType="pubmed">32073498</ArticleId></ArticleIdList></Reference><Reference><Citation>Continuous Distribution - OPTN n.d. https://optn.transplant.hrsa.gov/governance/key-initiatives/continuous-distribution/
(accessed October 3,
2021).</Citation></Reference><Reference><Citation>Snyder JJ, Salkowski N, Wey A, Pyke J, Israni AK, Kasiske BL. Organ distribution without geographic boundaries: a possible framework for organ allocation. Am J Transpl 2018;18:2635&#x2013;2640. 10.1111/ajt.15115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15115</ArticleId><ArticleId IdType="pubmed">30203912</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the american association for the study of liver diseases. Hepatology 2021;74:1611&#x2013;1644. 10.1002/hep.32049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.32049</ArticleId><ArticleId IdType="pmc">PMC9134787</ArticleId><ArticleId IdType="pubmed">34233031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lochs H, Allison SP, Meier R, Pirlich M, Kondrup J, Schneider S, et al. Introductory to the ESPEN guidelines on enteral nutrition: terminology, definitions and general topics. Clin Nutr 2006;25:180&#x2013;186. 10.1016/j.clnu.2006.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2006.02.007</ArticleId><ArticleId IdType="pubmed">16697086</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, et al. Frailty consensus: a call to action. J Am Med Dir Assoc 2013;14:392&#x2013;397. 10.1016/j.jamda.2013.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2013.03.022</ArticleId><ArticleId IdType="pmc">PMC4084863</ArticleId><ArticleId IdType="pubmed">23764209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai JC, Covinsky KE, Dodge JL, Boscardin WJ, Segev DL, Roberts JP, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017;66:564&#x2013;574. 10.1002/hep.29219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.29219</ArticleId><ArticleId IdType="pmc">PMC5519430</ArticleId><ArticleId IdType="pubmed">28422306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai JC, Rahimi RS, Verna EC, Kappus MR, Dunn MA, McAdams-DeMarco M, et al. Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study. Gastroenterology 2019;156:1675&#x2013;1682. 10.1053/j.gastro.2019.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.01.028</ArticleId><ArticleId IdType="pmc">PMC6475483</ArticleId><ArticleId IdType="pubmed">30668935</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transpl 2014;14:1870&#x2013;1879. 10.1111/ajt.12762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.12762</ArticleId><ArticleId IdType="pmc">PMC4107151</ArticleId><ArticleId IdType="pubmed">24935609</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon P, Tangri N, Thomas L, Zenith L, Shaikh T, Carbonneau M, et al. A rapid bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: a prospective evaluation of the clinical frailty scale. Am J Gastroenterol 2016;111:1759&#x2013;1767. 10.1038/ajg.2016.303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.303</ArticleId><ArticleId IdType="pubmed">27481305</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapper EB, Konerman M, Murphy S, Sonnenday CJ. Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index. Am J Transpl 2018;18:2566&#x2013;2570. 10.1111/ajt.15020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15020</ArticleId><ArticleId IdType="pmc">PMC6166663</ArticleId><ArticleId IdType="pubmed">30019835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai JC, Sonnenday CJ, Tapper EB, Duarte-Rojo A, Dunn MA, Bernal W, et al. Frailty in liver transplantation: an expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am J Transpl 2019;19:1896&#x2013;1906. 10.1111/ajt.15392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15392</ArticleId><ArticleId IdType="pmc">PMC6814290</ArticleId><ArticleId IdType="pubmed">30980701</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai JC, Segev DL, McCulloch CE, Covinsky KE, Dodge JL, Feng S. Physical frailty after liver transplantation. Am J Transpl 2018;18:1986&#x2013;1994. 10.1111/ajt.14675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.14675</ArticleId><ArticleId IdType="pmc">PMC6066446</ArticleId><ArticleId IdType="pubmed">29380529</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy&#xe8;re O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16&#x2013;31. 10.1093/ageing/afy169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afy169</ArticleId><ArticleId IdType="pmc">PMC6322506</ArticleId><ArticleId IdType="pubmed">30312372</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey EJ, Lai JC, Wang CW, Dasarathy S, Lobach I, Montano-Loza AJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl 2017;23:625&#x2013;633. 10.1002/lt.24750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.24750</ArticleId><ArticleId IdType="pmc">PMC5762612</ArticleId><ArticleId IdType="pubmed">28240805</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazurak VC, Tandon P, Montano-Loza AJ. Nutrition and the transplant candidate. Liver Transpl 2017;23:1451&#x2013;1464. 10.1002/lt.24848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.24848</ArticleId><ArticleId IdType="pubmed">29072825</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris MT, Tandon P, Heyland DK, Furberg H, Premji T, Low G, et al. Automated body composition analysis of clinically acquired computed tomography scans using neural networks. Clin Nutr 2020;39:3049&#x2013;3055. 10.1016/j.clnu.2020.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2020.01.008</ArticleId><ArticleId IdType="pmc">PMC7374050</ArticleId><ArticleId IdType="pubmed">32007318</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey EJ, Lai JC, Sonnenday C, Tapper EB, Tandon P, Duarte-Rojo A, et al. A north american expert opinion statement on sarcopenia in liver transplantation. Hepatology 2019;70:1816&#x2013;1829. 10.1002/hep.30828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.30828</ArticleId><ArticleId IdType="pmc">PMC6819202</ArticleId><ArticleId IdType="pubmed">31220351</ArticleId></ArticleIdList></Reference><Reference><Citation>Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010;211:271&#x2013;278. 10.1016/j.jamcollsurg.2010.03.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2010.03.039</ArticleId><ArticleId IdType="pmc">PMC2914324</ArticleId><ArticleId IdType="pubmed">20670867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaido T, Ogawa K, Fujimoto Y, Ogura Y, Hata K, Ito T, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transpl 2013;13:1549&#x2013;1556. 10.1111/ajt.12221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.12221</ArticleId><ArticleId IdType="pubmed">23601159</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch N, Dasarathy J, Runkana A, Penumatsa R, Bellar A, Reen J, et al. Continued muscle loss increases mortality in cirrhosis: impact of aetiology of liver disease. Liver Int 2020;40:1178&#x2013;1188. 10.1111/liv.14358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14358</ArticleId><ArticleId IdType="pmc">PMC7195232</ArticleId><ArticleId IdType="pubmed">31889396</ArticleId></ArticleIdList></Reference><Reference><Citation>Leppke S, Leighton T, Zaun D, Chen S-C, Skeans M, Israni AK, et al. Scientific Registry of Transplant Recipients: collecting, analyzing, and reporting data on transplantation in the United States. Transpl Rev 2013;27:50&#x2013;56. 10.1016/j.trre.2013.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trre.2013.01.002</ArticleId><ArticleId IdType="pubmed">23481320</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer RM, Cohen B, Rahmel A. History of eurotransplant. Transpl Proc 2012;44:2130&#x2013;2131. 10.1016/j.transproceed.2012.07.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2012.07.125</ArticleId><ArticleId IdType="pubmed">22974933</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmud N, Goldberg DS, Bittermann T. Best practices in large database clinical epidemiology research in hepatology: barriers and opportunities. Liver Transpl 2021. 10.1002/lt.26231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.26231</ArticleId><ArticleId IdType="pmc">PMC8688188</ArticleId><ArticleId IdType="pubmed">34265178</ArticleId></ArticleIdList></Reference><Reference><Citation>Okafor PN, Chiejina M, de Pretis N, Talwalkar JA. Secondary analysis of large databases for hepatology research. J Hepatol 2016;64:946&#x2013;956. 10.1016/j.jhep.2015.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2015.12.019</ArticleId><ArticleId IdType="pubmed">26739689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US adults. JAMA Netw Open 2020;3:e201997. 10.1001/jamanetworkopen.2020.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.1997</ArticleId><ArticleId IdType="pmc">PMC7118516</ArticleId><ArticleId IdType="pubmed">32239220</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI &#x2013; Observational Health Data Sciences and Informatics n.d. https://ohdsi.org/ (accessed
February 21, 2021).</Citation></Reference><Reference><Citation>Haendel MA, Chute CG, Bennett TD, Eichmann DA, Guinney J, Kibbe WA, et al. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J Am Med Inform Assoc 2021;28:427&#x2013;443. 10.1093/jamia/ocaa196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa196</ArticleId><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson TA, Fontil V, Koliwad SK, Patel A, Butte AJ. Quantifying variation in treatment utilization for type 2 diabetes across five major university of California health systems. Diabetes Care 2021. 10.2337/dc20-0344.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-0344</ArticleId><ArticleId IdType="pmc">PMC7985428</ArticleId><ArticleId IdType="pubmed">33531419</ArticleId></ArticleIdList></Reference><Reference><Citation>Adoption of Electronic Health Record Systems among U.S. Non-Federal Acute Care Hospitals: 2008&#x2013;2015 | HealthIT.gov
n.d. https://www.healthit.gov/data/data-briefs/adoption-electronic-health-record-systems-among-us-non-federal-acute-care-1
(accessed October 3,
2021).</Citation></Reference><Reference><Citation>Villanueva FL, Folkvord F, Fauli C. Benchmarking deployment of eHealth among general practitioners. RAND org; 2018.</Citation></Reference><Reference><Citation>Obermeyer Z, Emanuel EJ. Predicting the future - big data, machine learning, and clinical medicine. N Engl J Med 2016;375:1216&#x2013;1219. 10.1056/NEJMp1606181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1606181</ArticleId><ArticleId IdType="pmc">PMC5070532</ArticleId><ArticleId IdType="pubmed">27682033</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua H-R, Zheng K, Vathsala A, Ngiam K-Y, Yap H-K, Lu L, et al. Health care analytics with time-invariant and time-variant feature importance to predict hospital-acquired acute kidney injury: observational longitudinal study. J Med Internet Res 2021;23:e30805. 10.2196/30805.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/30805</ArticleId><ArticleId IdType="pmc">PMC8742216</ArticleId><ArticleId IdType="pubmed">34951595</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisenthal SJ, Quill C, Farooq S, Kautz H, Zand MS. Predicting acute kidney injury at hospital re-entry using high-dimensional electronic health record data. PLoS One 2018;13:e0204920. 10.1371/journal.pone.0204920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0204920</ArticleId><ArticleId IdType="pmc">PMC6245516</ArticleId><ArticleId IdType="pubmed">30458044</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkomar A, Oren E, Chen K, Dai AM, Hajaj N, Hardt M, et al. Scalable and accurate deep learning with electronic health records. Npj Digital Med 2018;1:18. 10.1038/s41746-018-0029-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-018-0029-1</ArticleId><ArticleId IdType="pmc">PMC6550175</ArticleId><ArticleId IdType="pubmed">31304302</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge J, Najafi N, Zhao W, Somsouk M, Fang M, Lai JC. A methodology to generate longitudinally updated acute-on-chronic liver failure prognostication scores from electronic health record data. Hepatol Commun 2021;5:1069&#x2013;1080. 10.1002/hep4.1690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep4.1690</ArticleId><ArticleId IdType="pmc">PMC8183167</ArticleId><ArticleId IdType="pubmed">34141990</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Robinson PN. Classification, ontology, and precision medicine. N Engl J Med 2018;379:1452&#x2013;1462. 10.1056/NEJMra1615014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1615014</ArticleId><ArticleId IdType="pmc">PMC6503847</ArticleId><ArticleId IdType="pubmed">30304648</ArticleId></ArticleIdList></Reference><Reference><Citation>Atiemo K, Skaro A, Maddur H, Zhao L, Montag S, VanWagner L, et al. Mortality risk factors among patients with cirrhosis and a low model for End-Stage Liver Disease Sodium score (&lt;&#x2212;15): an analysis of liver transplant allocation policy using aggregated electronic health record data. Am J Transpl 2017;17:2410&#x2013;2419. 10.1111/ajt.14239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.14239</ArticleId><ArticleId IdType="pmc">PMC5769449</ArticleId><ArticleId IdType="pubmed">28226199</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Level Seven International - Homepage | HL7 International n.d. https://www.hl7.org/
(accessed October 3,
2021).</Citation></Reference><Reference><Citation>European Health Data Evidence Network &#x2013; ehden.eu n.d. https://www.ehden.eu/ (accessed
November 20, 2021).</Citation></Reference><Reference><Citation>Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al. The national COVID cohort collaborative: clinical characterization and early severity prediction. medRxiv 2021. 10.1101/2021.01.12.21249511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.12.21249511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge J, Pletcher MJ, Lai JC, N3C Consortium. Outcomes of SARS-CoV-2 infection in patients with chronic liver disease and cirrhosis: a national COVID cohort collaborative study. Gastroenterology 2021. 10.1053/j.gastro.2021.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.07.010</ArticleId><ArticleId IdType="pmc">PMC8286237</ArticleId><ArticleId IdType="pubmed">34284037</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumsfeld JS, Joynt KE, Maddox TM. Big data analytics to improve cardiovascular care: promise and challenges. Nat Rev Cardiol 2016;13:350&#x2013;359. 10.1038/nrcardio.2016.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2016.42</ArticleId><ArticleId IdType="pubmed">27009423</ArticleId></ArticleIdList></Reference><Reference><Citation>Genta RM, Sonnenberg A. Big data in gastroenterology research. Nat Rev Gastroenterol Hepatol 2014;11:386&#x2013;390. 10.1038/nrgastro.2014.18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.18</ArticleId><ArticleId IdType="pubmed">24594912</ArticleId></ArticleIdList></Reference><Reference><Citation>Favaretto M, De Clercq E, Schneble CO, Elger BS. What is your definition of Big Data? Researchers&#x2019; understanding of the phenomenon of the decade. PLoS One 2020;15:e0228987. 10.1371/journal.pone.0228987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0228987</ArticleId><ArticleId IdType="pmc">PMC7041862</ArticleId><ArticleId IdType="pubmed">32097430</ArticleId></ArticleIdList></Reference><Reference><Citation>Asri H, Mousannif H, Al Moatassime H, Noel T. Big data in healthcare: Challenges and opportunities. In: 2015 International Conference on Cloud Technologies and Applications (CloudTech). IEEE; 2015. p. 1&#x2013;7. 10.1109/CloudTech.2015.7337020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/CloudTech.2015.7337020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiens J, Shenoy ES. Machine learning for healthcare: on the verge of a major shift in healthcare epidemiology. Clin Infect Dis 2018;66:149&#x2013;153. 10.1093/cid/cix731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix731</ArticleId><ArticleId IdType="pmc">PMC5850539</ArticleId><ArticleId IdType="pubmed">29020316</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeyer Z, Weinstein JN. Adoption of artificial intelligence and machine learning is increasing, but irrational exuberance remains. NEJM Catal 2020;1. 10.1056/CAT.19.1090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/CAT.19.1090</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med 2019;380:1347&#x2013;1358. 10.1056/NEJMra1814259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1814259</ArticleId><ArticleId IdType="pubmed">30943338</ArticleId></ArticleIdList></Reference><Reference><Citation>Spann A, Yasodhara A, Kang J, Watt K, Wang B, Goldenberg A, et al. Applying machine learning in liver disease and transplantation: a comprehensive review. Hepatology 2020;71:1093&#x2013;1105. 10.1002/hep.31103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31103</ArticleId><ArticleId IdType="pubmed">31907954</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanwal F, Taylor TJ, Kramer JR, Cao Y, Smith D, Gifford AL, et al. Development, validation, and evaluation of a simple machine learning model to predict cirrhosis mortality. JAMA Netw Open 2020;3:e2023780. 10.1001/jamanetworkopen.2020.23780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.23780</ArticleId><ArticleId IdType="pmc">PMC7610191</ArticleId><ArticleId IdType="pubmed">33141161</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain AK, Mao Jianchang, Mohiuddin KM. Artificial neural networks: a tutorial. Computer (Long Beach Calif) 1996;29:31&#x2013;44. 10.1109/2.485891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/2.485891</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster M, Paliwal KK. Bidirectional recurrent neural networks. IEEE Trans Signal Process 1997;45:2673&#x2013;2681. 10.1109/78.650093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/78.650093</ArticleId></ArticleIdList></Reference><Reference><Citation>LeCun Y, Bengio Y, Hinton G. Deep learning. Nature 2015;521:436&#x2013;444. 10.1038/nature14539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14539</ArticleId><ArticleId IdType="pubmed">26017442</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo A, Mazumder NR, Ladner DP, Foraker RE. Predicting mortality among patients with liver cirrhosis in electronic health records with machine learning. PLoS One 2021;16:e0256428. 10.1371/journal.pone.0256428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0256428</ArticleId><ArticleId IdType="pmc">PMC8407576</ArticleId><ArticleId IdType="pubmed">34464403</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee R, Das A, Ghoshal UC, Sinha M. Predicting mortality in patients with cirrhosis of liver with application of neural network technology. J Gastroenterol Hepatol 2003;18:1054&#x2013;1060. 10.1046/j.1440-1746.2003.03123.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1746.2003.03123.x</ArticleId><ArticleId IdType="pubmed">12911662</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucchetti A, Vivarelli M, Heaton ND, Phillips S, Piscaglia F, Bolondi L, et al. Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. Gut 2007;56:253&#x2013;258. 10.1136/gut.2005.084434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2005.084434</ArticleId><ArticleId IdType="pmc">PMC1856758</ArticleId><ArticleId IdType="pubmed">16809421</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou GN, Tang W, Beste LA, Tincopa MA, Su GL, Van T, et al. Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis. JAMA Netw Open 2020;3:e2015626. 10.1001/jamanetworkopen.2020.15626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.15626</ArticleId><ArticleId IdType="pmc">PMC7489819</ArticleId><ArticleId IdType="pubmed">32870314</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrarese A, Sartori G, Orr&#xf9; G, Frigo AC, Pelizzaro F, Burra P, et al. Machine learning in liver transplantation: a tool for some unsolved questions? Transpl Int 2021;34:398&#x2013;411. 10.1111/tri.13818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tri.13818</ArticleId><ArticleId IdType="pubmed">33428298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsimas D, Kung J, Trichakis N, Wang Y, Hirose R, Vagefi PA. Development and validation of an optimized prediction of mortality for candidates awaiting liver transplantation. Am J Transpl 2019;19:1109&#x2013;1118. 10.1111/ajt.15172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15172</ArticleId><ArticleId IdType="pubmed">30411495</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong AJ, Asrani SK. Artificial neural networks and liver transplantation: are we ready for self-driving cars? Liver Transpl 2018;24:161&#x2013;163. 10.1002/lt.24993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.24993</ArticleId><ArticleId IdType="pubmed">29211925</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller PE, Pawar S, Vaccaro B, McCullough M, Rao P, Ghosh R, et al. Predictive abilities of machine learning techniques may be limited by dataset characteristics: insights from the UNOS database. J Card Fail 2019;25:479&#x2013;483. 10.1016/j.cardfail.2019.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2019.01.018</ArticleId><ArticleId IdType="pubmed">30738152</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C,Anjur V, Saboo K, Reddy KR, O&#x2bc;Leary J, Tandon P, et al. Low predictability of readmissions and death using machine learning in cirrhosis. Am J Gastroenterol 2020. 10.14309/ajg.0000000000000971.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000971</ArticleId><ArticleId IdType="pubmed">33038139</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghupathi W, Raghupathi V. Big data analytics in healthcare: promise and potential. Health Inf Sci Syst 2014;2:3. 10.1186/2047-s2501-2-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2047-s2501-2-3</ArticleId><ArticleId IdType="pmc">PMC4341817</ArticleId><ArticleId IdType="pubmed">25825667</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates DW, Auerbach A, Schulam P, Wright A, Saria S. Reporting and implementing interventions involving machine learning and artificial intelligence. Ann Intern Med 2020;172:S137&#x2013;S144. 10.7326/M19-0872.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M19-0872</ArticleId><ArticleId IdType="pubmed">32479180</ArticleId></ArticleIdList></Reference><Reference><Citation>Finlayson SG, Subbaswamy A, Singh K, Bowers J, Kupke A, Zittrain J, et al. The clinician and dataset shift in artificial intelligence. N Engl J Med 2021;385:283&#x2013;286. 10.1056/NEJMc2104626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2104626</ArticleId><ArticleId IdType="pmc">PMC8665481</ArticleId><ArticleId IdType="pubmed">34260843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A, Otles E, Donnelly JP, Krumm A, McCullough J, DeTroyer-Cooley O, et al. External validation of a widely implemented proprietary sepsis prediction model in hospitalized patients. JAMA Intern Med 2021;181:1065&#x2013;1070. 10.1001/jamainternmed.2021.2626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.2626</ArticleId><ArticleId IdType="pmc">PMC8218233</ArticleId><ArticleId IdType="pubmed">34152373</ArticleId></ArticleIdList></Reference><Reference><Citation>What Do We Do About the Biases in AI? n.d. https://hbr.org/2019/10/what-do-we-do-about-the-biases-in-ai
(accessed October 3,
2021).</Citation></Reference><Reference><Citation>Gianfrancesco MA, Tamang S, Yazdany J, Schmajuk G. Potential biases in machine learning algorithms using electronic health record data. JAMA Intern Med 2018;178:1544&#x2013;1547. 10.1001/jamainternmed.2018.3763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2018.3763</ArticleId><ArticleId IdType="pmc">PMC6347576</ArticleId><ArticleId IdType="pubmed">30128552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuppachi S, Norman SP, Lentine KL, Axelrod DA. Using race to estimate glomerular filtration and its impact in kidney transplantation. Clin Transpl 2021;35:e14136. 10.1111/ctr.14136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.14136</ArticleId><ArticleId IdType="pubmed">33232529</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MH, Nguyen A, Lo M, Kumar SR, Bucuvalas J, Glynn EF, et al. Big data in transplantation practice-the devil is in the detail-Fontan-associated liver disease. Transplantation 2021;105:18&#x2013;22. 10.1097/TP.0000000000003308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000003308</ArticleId><ArticleId IdType="pubmed">32639398</ArticleId></ArticleIdList></Reference><Reference><Citation>Adnan K, Akbar R, Khor SW, Ali ABA. Role and challenges of unstructured big data in healthcare. In: Sharma N, Chakrabarti A, Balas VE, editors. Data management, analytics and innovation: proceedings of ICDMAI 2019, volume 1, vol. 1042. Singapore: Springer Singapore; 2020. p. 301&#x2013;323. 10.1007/978-981-32-9949-8_22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-32-9949-8_22</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo RYL, Harrison CJ, Jones BE, Geoghegan L, Furniss D. Perspectives: a surgeon&#x2019;s guide to machine learning. Int J Surg 2021;94:106133. 10.1016/j.ijsu.2021.106133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2021.106133</ArticleId><ArticleId IdType="pubmed">34597822</ArticleId></ArticleIdList></Reference><Reference><Citation>Cauley RP, Vakili K, Fullington N, Potanos K, Graham DA, Finkelstein JA, et al. Deceased-donor split-liver transplantation in adult recipients: is the learning curve over? J Am Coll Surg 2013;217:672&#x2013;684.e1. 10.1016/j.jamcollsurg.2013.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2013.06.005</ArticleId><ArticleId IdType="pmc">PMC4876853</ArticleId><ArticleId IdType="pubmed">23978530</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transpl 2006;6:783&#x2013;790. 10.1111/j.1600-6143.2006.01242.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2006.01242.x</ArticleId><ArticleId IdType="pubmed">16539636</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapero-Marug&#xe1;n M, Little EC, Berenguer M. Stretching the boundaries for liver transplant in the 21st century. Lancet Gastroenterol Hepatol 2018;3:803&#x2013;811. 10.1016/S2468-1253(18)30213-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(18)30213-9</ArticleId><ArticleId IdType="pubmed">30353857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartoletti I AI in healthcare: ethical and privacy challenges. In: Ria&#xf1;o D, Wilk S, ten Teije A, editors. Artificial intelligence in medicine, vol. 11526. Cham: Springer International Publishing; 2019. p. 7&#x2013;10. 10.1007/978-3-030-21642-9_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-21642-9_2</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCamp M, Lindvall C. Latent bias and the implementation of artificial intelligence in medicine. J Am Med Inform Assoc 2020;27:2020&#x2013;2023. 10.1093/jamia/ocaa094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa094</ArticleId><ArticleId IdType="pmc">PMC7727353</ArticleId><ArticleId IdType="pubmed">32574353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Kaushal R, Khullar D. Should health care demand interpretable artificial intelligence or accept &#x201c;black box&#x201d; medicine? Ann Intern Med 2020;172:59&#x2013;60. 10.7326/M19-2548.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M19-2548</ArticleId><ArticleId IdType="pubmed">31842204</ArticleId></ArticleIdList></Reference><Reference><Citation>Blease C, Bernstein MH, Gaab J, Kaptchuk TJ, Kossowsky J, Mandl KD, et al. Computerization and the future of primary care: a survey of general practitioners in the UK. PLoS One 2018;13:e0207418. 10.1371/journal.pone.0207418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0207418</ArticleId><ArticleId IdType="pmc">PMC6291067</ArticleId><ArticleId IdType="pubmed">30540791</ArticleId></ArticleIdList></Reference><Reference><Citation>Pazzani MJ, Mani S, Shankle WR. Acceptance of rules generated by machine learning among medical experts. Methods Inf Med 2001;40:380&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">11776735</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakar D, Ongena YP, Kwee TC, Haan M. Do people favor artificial intelligence over physicians? A survey among the general population and their view on artificial intelligence in medicine. Value Health 2021. 10.1016/j.jval.2021.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2021.09.004</ArticleId><ArticleId IdType="pubmed">35227448</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzinger A, Langs G, Denk H, Zatloukal K, M&#xfc;ller H. Causability and explainability of artificial intelligence in medicine. Wiley Interdiscip Rev Data Min Knowl Discov 2019;9:e1312. 10.1002/widm.1312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/widm.1312</ArticleId><ArticleId IdType="pmc">PMC7017860</ArticleId><ArticleId IdType="pubmed">32089788</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennatas ED, Friedman JH, Ungar LH, Pirracchio R, Eaton E, Reichmann LG, et al. Expert-augmented machine learning. Proc Natl Acad Sci USA 2020;117:4571&#x2013;4577. 10.1073/pnas.1906831117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1906831117</ArticleId><ArticleId IdType="pmc">PMC7060733</ArticleId><ArticleId IdType="pubmed">32071251</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Dhiman P, Andaur Navarro CL, Ma J, Hooft L, Reitsma JB, et al. Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence. BMJ Open 2021;11:e048008. 10.1136/bmjopen-2020-048008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048008</ArticleId><ArticleId IdType="pmc">PMC8273461</ArticleId><ArticleId IdType="pubmed">34244270</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadkarni PM, Ohno-Machado L, Chapman WW. Natural language processing: an introduction. J Am Med Inform Assoc 2011;18:544&#x2013;551. 10.1136/amiajnl-2011-000464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000464</ArticleId><ArticleId IdType="pmc">PMC3168328</ArticleId><ArticleId IdType="pubmed">21846786</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury GG. Natural language processing. Ann Rev Info Sci Tech 2005;37:51&#x2013;89. 10.1002/aris.1440370103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/aris.1440370103</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vleck TT, Chan L, Coca SG, Craven CK, Do R, Ellis SB, et al. Augmented intelligence with natural language processing applied to electronic health records for identifying patients with non-alcoholic fatty liver disease at risk for disease progression. Int J Med Inform 2019;129:334&#x2013;341. 10.1016/j.ijmedinf.2019.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2019.06.028</ArticleId><ArticleId IdType="pmc">PMC6717556</ArticleId><ArticleId IdType="pubmed">31445275</ArticleId></ArticleIdList></Reference><Reference><Citation>Redman JS, Natarajan Y, Hou JK, Wang J, Hanif M, Feng H, et al. Accurate identification of fatty liver disease in data warehouse utilizing natural language processing. Dig Dis Sci 2017;62:2713&#x2013;2718. 10.1007/s10620-017-4721-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-017-4721-9</ArticleId><ArticleId IdType="pubmed">28861720</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapper EB, Sengupta N, Lai M, Horowitz G. Understanding and reducing ceruloplasmin overuse with a decision support intervention for liver disease evaluation. Am J Med 2016;129. 10.1016/j.amjmed.2015.07.019. 115.e17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2015.07.019</ArticleId><ArticleId IdType="pubmed">26254122</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidlow R, Msaouel P. Improving hepatitis C virus screening rates in primary care: a targeted intervention using the electronic health record. J Healthc Qual 2015;37:319&#x2013;323. 10.1097/JHQ.0000000000000010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JHQ.0000000000000010</ArticleId><ArticleId IdType="pubmed">26186704</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudireddy PR, Mull NK, Williams K, Bushen JL, Kasbekar N, Krok K, et al. Impact of a clinical decision support intervention on albumin utilization and appropriateness of use in an academic healthcare system. medRxiv 2021. 10.1101/2021.04.05.21254943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.05.21254943</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel JC, Kreda DA, Mandl KD, Kohane IS, Ramoni RB. SMART on FHIR: a standards-based, interoperable apps platform for electronic health records. J Am Med Inform Assoc 2016;23:899&#x2013;908. 10.1093/jamia/ocv189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv189</ArticleId><ArticleId IdType="pmc">PMC4997036</ArticleId><ArticleId IdType="pubmed">26911829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloomfield RA, Polo-Wood F, Mandel JC, Mandl KD. Opening the Duke electronic health record to apps: implementing SMART on FHIR. Int J Med Inform 2017;99:1&#x2013;10. 10.1016/j.ijmedinf.2016.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2016.12.005</ArticleId><ArticleId IdType="pubmed">28118917</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamoto K, Kukhareva P, Shakib JH, Kramer H, Rodriguez S, Warner PB, et al. Association of an electronic health record add-on app for neonatal bilirubin management with physician efficiency and care quality. JAMA Netw Open 2019;2:e1915343. 10.1001/jamanetworkopen.2019.15343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.15343</ArticleId><ArticleId IdType="pmc">PMC6902796</ArticleId><ArticleId IdType="pubmed">31730181</ArticleId></ArticleIdList></Reference><Reference><Citation>Debnath S, Barnaby DP, Coppa K, Makhnevich A, Kim EJ, Chatterjee S, et al. Machine learning to assist clinical decision-making during the COVID-19 pandemic. Bioelectron Med 2020;6:14. 10.1186/s42234-020-00050-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42234-020-00050-8</ArticleId><ArticleId IdType="pmc">PMC7347420</ArticleId><ArticleId IdType="pubmed">32665967</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipnis P, Turk BJ, Wulf DA, LaGuardia JC, Liu V, Churpek MM, et al. Development and validation of an electronic medical record-based alert score for detection of inpatient deterioration outside the ICU. J Biomed Inform 2016;64:10&#x2013;19. 10.1016/j.jbi.2016.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.09.013</ArticleId><ArticleId IdType="pmc">PMC5510648</ArticleId><ArticleId IdType="pubmed">27658885</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs J, Weir C, Evans RS, Staes C. Assessment of readiness for clinical decision support to aid laboratory monitoring of immunosuppressive care at U.S. liver transplant centers. Appl Clin Inform 2014;5:988&#x2013;1004. 10.4338/ACI-2014-08-RA-0060.</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/ACI-2014-08-RA-0060</ArticleId><ArticleId IdType="pmc">PMC4287676</ArticleId><ArticleId IdType="pubmed">25589912</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao D, Larson C, Fletcher D, Stegner K. Clinical decision support may link multiple domains to improve patient care: viewpoint. JMIR Med Inform 2020;8:e20265. 10.2196/20265.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/20265</ArticleId><ArticleId IdType="pmc">PMC7600021</ArticleId><ArticleId IdType="pubmed">33064106</ArticleId></ArticleIdList></Reference><Reference><Citation>Pletcher MJ, Flaherman V, Najafi N, Patel S, Rushakoff RJ, Hoffman A, et al. Randomized controlled trials of electronic health record interventions: design, conduct, and reporting considerations. Ann Intern Med 2020;172:S85&#x2013;S91. 10.7326/M19-0877.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M19-0877</ArticleId><ArticleId IdType="pubmed">32479183</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz LI, Kuznetsova M, Jones SA. Creating a learning health system through rapid-cycle, randomized testing. N Engl J Med 2019;381:1175&#x2013;1179. 10.1056/NEJMsb1900856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb1900856</ArticleId><ArticleId IdType="pubmed">31532967</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646&#x2013;649. 10.1002/bjs.1800600817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.1800600817</ArticleId><ArticleId IdType="pubmed">4541913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartoun U, Corey KE, Simon TG, Zheng H, Aggarwal R, Ng K, et al. The MELD-Plus: a generalizable prediction risk score in cirrhosis. PLoS One 2017;12:e0186301. 10.1371/journal.pone.0186301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0186301</ArticleId><ArticleId IdType="pmc">PMC5656314</ArticleId><ArticleId IdType="pubmed">29069090</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmud N, Asrani SK, Kaplan DE, Ogola GO, Taddei TH, Kamath PS, et al. The predictive role of model for end-stage liver disease-lactate and lactate clearance for in-hospital mortality among a national cirrhosis cohort. Liver Transpl 2021;27:177&#x2013;189. 10.1002/lt.25913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.25913</ArticleId><ArticleId IdType="pmc">PMC7880877</ArticleId><ArticleId IdType="pubmed">33025731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009;137:865&#x2013;872. 10.1053/j.gastro.2009.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.06.005</ArticleId><ArticleId IdType="pubmed">19524579</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin W, Yi W, Liu H, Haixia L, Dongdong L, Ma Y, et al. Early prediction of acute kidney injury after liver transplantation by scoring system and decision tree. Ren Fail 2021;43:1137&#x2013;1145. 10.1080/0886022X.2021.1945462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2021.1945462</ArticleId><ArticleId IdType="pmc">PMC8281092</ArticleId><ArticleId IdType="pubmed">34261422</ArticleId></ArticleIdList></Reference><Reference><Citation>Audureau E, Carrat F, Layese R, Cagnot C, Asselah T, Guyader D, et al. Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status. J Hepatol 2020;73:1434&#x2013;1445. 10.1016/j.jhep.2020.05.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.05.052</ArticleId><ArticleId IdType="pubmed">32615276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J, et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004;39:518&#x2013;527. 10.1002/hep.20053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.20053</ArticleId><ArticleId IdType="pubmed">14768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, He K, Cheng M, Si H-Y, Zhang H-L, Song W, et al. Two classifiers based on serum peptide pattern for prediction of HBV-induced liver cirrhosis using MALDI-TOF MS. Biomed Res Int 2013;2013:814876. 10.1155/2013/814876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/814876</ArticleId><ArticleId IdType="pmc">PMC3590609</ArticleId><ArticleId IdType="pubmed">23509784</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GN, Fujita H. K-means clustering for classifying unlabelled MRI data. In: 9th Biennial Conference of the Australian Pattern Recognition Society on Digital Image Computing Techniques and Applications (DICTA 2007). IEEE; 2007. p. 92&#x2013;98. 10.1109/DICTA.2007.4426781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/DICTA.2007.4426781</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;ller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011;60:1254&#x2013;1259. 10.1136/gut.2010.235473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2010.235473</ArticleId><ArticleId IdType="pubmed">21504996</ArticleId></ArticleIdList></Reference><Reference><Citation>Das A, Rajendra Acharya U, Panda SS, Sabut S. Deep learning based liver cancer detection using watershed transform and Gaussian mixture model techniques. Cogn Syst Res 2018;54:165&#x2013;175. 10.1016/j.cogsys.2018.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cogsys.2018.12.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolomeo N, Trerotoli P, Serio G. Progression of liver cirrhosis to HCC: an application of hidden Markov model. BMC Med Res Methodol 2011;11:38. 10.1186/1471-2288-11-38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-11-38</ArticleId><ArticleId IdType="pmc">PMC3087702</ArticleId><ArticleId IdType="pubmed">21457586</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35589549</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2589-7500</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Lancet. Digital health</Title><ISOAbbreviation>Lancet Digit Health</ISOAbbreviation></Journal><ArticleTitle>Identifying who has long COVID in the USA: a machine learning approach using N3C data.</ArticleTitle><Pagination><StartPage>e532</StartPage><EndPage>e541</EndPage><MedlinePgn>e532-e541</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2589-7500(22)00048-6</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2589-7500(22)00048-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Post-acute sequelae of SARS-CoV-2 infection, known as long COVID, have severely affected recovery from the COVID-19 pandemic for patients and society alike. Long COVID is characterised by evolving, heterogeneous symptoms, making it challenging to derive an unambiguous definition. Studies of electronic health records are a crucial element of the US National Institutes of Health's RECOVER Initiative, which is addressing the urgent need to understand long COVID, identify treatments, and accurately identify who has it-the latter is the aim of this study.</AbstractText><AbstractText Label="METHODS">Using the National COVID Cohort Collaborative's (N3C) electronic health record repository, we developed XGBoost machine learning models to identify potential patients with long COVID. We defined our base population (n=1&#x2009;793&#x2009;604) as any non-deceased adult patient (age &#x2265;18 years) with either an International Classification of Diseases-10-Clinical Modification COVID-19 diagnosis code (U07.1) from an inpatient or emergency visit, or a positive SARS-CoV-2 PCR or antigen test, and for whom at least 90 days have passed since COVID-19 index date. We examined demographics, health-care utilisation, diagnoses, and medications for 97&#x2009;995 adults with COVID-19. We used data on these features and 597 patients from a long COVID clinic to train three machine learning models to identify potential long COVID among all patients with COVID-19, patients hospitalised with COVID-19, and patients who had COVID-19 but were not hospitalised. Feature importance was determined via Shapley values. We further validated the models on data from a fourth site.</AbstractText><AbstractText Label="FINDINGS">Our models identified, with high accuracy, patients who potentially have long COVID, achieving areas under the receiver operator characteristic curve of 0&#xb7;92 (all patients), 0&#xb7;90 (hospitalised), and 0&#xb7;85 (non-hospitalised). Important features, as defined by Shapley values, include rate of health-care utilisation, patient age, dyspnoea, and other diagnosis and medication information available within the electronic health record.</AbstractText><AbstractText Label="INTERPRETATION">Patients identified by our models as potentially having long COVID can be interpreted as patients warranting care at a specialty clinic for long COVID, which is an essential proxy for long COVID diagnosis as its definition continues to evolve. We also achieve the urgent goal of identifying potential long COVID in patients for clinical trials. As more data sources are identified, our models can be retrained and tuned based on the needs of individual studies.</AbstractText><AbstractText Label="FUNDING">US National Institutes of Health and National Center for Advancing Translational Sciences through the RECOVER Initiative.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Emily R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USA. Electronic address: epfaff@email.unc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girvin</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Section of Informatics and Data Science, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Section of Critical Care Medicine, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Carolina Health Informatics Program, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Ian M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Colorado Center for Personalised Medicine, Division of Biomedical Informatics &amp; Personalized Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deer</LastName><ForeName>Rachel R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Metabolism, and Rehabilitation Sciences, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dekermanjian</LastName><ForeName>Jonathan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jolley</LastName><ForeName>Sarah Elizabeth</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Section of Informatics and Data Science, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The OHDSI Center at the Roux Institute, Northeastern University, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMurry</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moffitt</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walden</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Section of Biomedical Informatics and Data Science, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haendel</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>N3C Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Digit Health</MedlineTA><NlmUniqueID>101751302</NlmUniqueID><ISSNLinking>2589-7500</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests ATG is an employee of Palantir Technologies. ERP, JPD, SEJ, RRD, CGC, TDB, JAM, RM, AW, and MAH report research funding from the NIH. ERP and MGK report research funding from PCORI. MAH and JAM are co-founders of Pryzm Health. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Bramante</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorr</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parker</LastName><ForeName>Ann M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sidky</LastName><ForeName>Hythem</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gersing</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hong</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niehaus</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>19</Day><Hour>22</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35589549</ArticleId><ArticleId IdType="pmc">PMC9110014</ArticleId><ArticleId IdType="doi">10.1016/S2589-7500(22)00048-6</ArticleId><ArticleId IdType="pii">S2589-7500(22)00048-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Puelles VG, L&#xfc;tgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383:590&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriatopoulou M, Korompoki E, Fotiou D, et al. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020;20:493&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383117</ArticleId><ArticleId IdType="pubmed">32720223</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Pinto MD, Borelli JL, et al. COVID symptoms, symptom clusters, and predictors for becoming a long-hauler: looking for clarity in the haze of the pandemic. medRxiv. 2021 doi: 10.1101/2021.03.03.21252086. published online March 5. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.03.21252086</ArticleId><ArticleId IdType="pmc">PMC7941647</ArticleId><ArticleId IdType="pubmed">33688670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rando HM, Bennett TD, Byrd JB, et al. Challenges in defining long COVID: striking differences across literature, electronic health records, and patient-reported information. medRxiv. 2021 doi: 10.1101/2021.03.20.21253896. published online March 26. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.20.21253896</ArticleId></ArticleIdList></Reference><Reference><Citation>McCorkell L, Assaf GS, Davis HE, Wei H, Akrami A. Patient-led research collaborative: embedding patients in the long COVID narrative. Pain Rep. 2021;6:e913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112577</ArticleId><ArticleId IdType="pubmed">33987484</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. bioRxiv. 2020 doi: 10.1101/2020.12.24.20248802. published online Dec 26. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.24.20248802</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer RR, Rock MA, Vasilevsky N, et al. Characterizing long COVID: deep phenotype of a complex condition. bioRxiv. 2021 doi: 10.1101/2021.06.23.21259416. published online June 29. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.23.21259416</ArticleId><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Oct 6, 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation></Reference><Reference><Citation>RECOVER  Researching COVID to enhance recovery. https://recovercovid.org/research</Citation></Reference><Reference><Citation>Richesson R, Smerek M. Electronic health records-based phenotyping. https://sites.duke.edu/rethinkingclinicaltrials/ehr-phenotyping/</Citation></Reference><Reference><Citation>Mo H, Thompson WK, Rasmussen LV, et al. Desiderata for computable representations of electronic health records-driven phenotype algorithms. J Am Med Inform Assoc. 2015;22:1220&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639716</ArticleId><ArticleId IdType="pubmed">26342218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ. Next-generation phenotyping of electronic health records. J Am Med Inform Assoc. 2013;20:117&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555337</ArticleId><ArticleId IdType="pubmed">22955496</ArticleId></ArticleIdList></Reference><Reference><Citation>Richesson RL, Rusincovitch SA, Wixted D, et al. A comparison of phenotype definitions for diabetes mellitus. J Am Med Inform Assoc. 2013;20:e319&#x2013;e326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861928</ArticleId><ArticleId IdType="pubmed">24026307</ArticleId></ArticleIdList></Reference><Reference><Citation>Beesley LJ, Mukherjee B. Statistical inference for association studies using electronic health records: handling both selection bias and outcome misclassification. Biometrics. 2022;78:214&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">33179768</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, the N3C Consortium. Chute CG, et al. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J Am Med Inform Assoc. 2021;28:427&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett TD, Moffitt RA, Hajagos JG, et al. Clinical characterization and prediction of clinical severity of SARS-CoV-2 infection among US adults using data from the US National COVID Cohort Collaborative. JAMA Netw Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8278272</ArticleId><ArticleId IdType="pubmed">34255046</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Advancing Translational Sciences  NIH COVID-19 data warehouse data transfer agreement. Aug 5, 2020. https://ncats.nih.gov/files/NCATS_Data_Transfer_Agreement_05-11-2020_Updated%20508.pdf</Citation></Reference><Reference><Citation>Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. arXiv. 2017 doi: 10.48550/arXiv.1705.07874. published online May 22. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.1705.07874</ArticleId></ArticleIdList></Reference><Reference><Citation>Chute C, Walden A. N3C results download policy. 2021. https://zenodo.org/record/4743236#.YnQ8MOjMJ3g</Citation></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngai JC, Ko FW, Ng SS, To K-W, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010;15:543&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192220</ArticleId><ArticleId IdType="pubmed">20337995</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauroux B, Sim&#xf5;es EAF, Checchia PA, et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther. 2017;6:173&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446364</ArticleId><ArticleId IdType="pubmed">28357706</ArticleId></ArticleIdList></Reference><Reference><Citation>US Centers for Disease Control and Prevention  Science Brief: evidence used to update the list of underlying medical conditions associated with higher risk for severe COVID-19. Feb 15, 2022. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-evidence-table.html</Citation><ArticleIdList><ArticleId IdType="pubmed">34009770</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35593971</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1128-045X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Techniques in coloproctology</Title><ISOAbbreviation>Tech Coloproctol</ISOAbbreviation></Journal><ArticleTitle>Training prediction models for individual risk assessment of postoperative complications after surgery for colorectal cancer.</ArticleTitle><Pagination><StartPage>665</StartPage><EndPage>675</EndPage><MedlinePgn>665-675</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10151-022-02624-x</ELocationID><Abstract><AbstractText Label="BACKGROUND">The occurrence of postoperative complications and anastomotic leakage are major drivers of mortality in the immediate phase after colorectal cancer surgery. We trained prediction models for calculating patients' individual risk of complications based only on preoperatively available data in a multidisciplinary team setting. Knowing prior to surgery the probability of developing a complication could aid in improving informed decision-making by surgeon and patient and individualize surgical treatment trajectories.</AbstractText><AbstractText Label="METHODS">All patients over 18&#xa0;years of age undergoing any resection for colorectal cancer between January 1, 2014 and December 31, 2019 from the nationwide Danish Colorectal Cancer Group database were included. Data from the database were converted into Observational Medical Outcomes Partnership Common Data Model maintained by the Observation Health Data Science and Informatics initiative. Multiple machine learning models were trained to predict postoperative complications of Clavien-Dindo grade&#x2009;&#x2265;&#x2009;3B and anastomotic leakage within 30&#xa0;days after surgery.</AbstractText><AbstractText Label="RESULTS">Between 2014 and 2019, 23,907 patients underwent resection for colorectal cancer in Denmark. A Clavien-Dindo complication grade&#x2009;&#x2265;&#x2009;3B occurred in 2,958 patients (12.4%). Of 17,190 patients that received an anastomosis, 929 experienced anastomotic leakage (5.4%). Among the compared machine learning models, Lasso Logistic Regression performed best. The predictive model for complications had an area under the receiver operating characteristic curve (AUROC) of 0.704 (95%CI 0.683-0.724) and an AUROC of 0.690 (95%CI 0.655-0.724) for anastomotic leakage.</AbstractText><AbstractText Label="CONCLUSIONS">The prediction of postoperative complications based only on preoperative variables using a national quality assurance colorectal cancer database shows promise for calculating patient's individual risk. Future work will focus on assessing the value of adding laboratory parameters and drug exposure as candidate predictors. Furthermore, we plan to assess the external validity of our proposed model.</AbstractText><CopyrightInformation>&#xa9; 2022. Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>V</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-9895-7219</Identifier><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital K&#xf8;ge, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark. vial@regionsjaelland.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsouchnika</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital K&#xf8;ge, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allakhverdiiev</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital K&#xf8;ge, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>A W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital K&#xf8;ge, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;genur</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital K&#xf8;ge, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clausen</LastName><ForeName>J S R</ForeName><Initials>JSR</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital K&#xf8;ge, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xe4;uner</LastName><ForeName>K B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital K&#xf8;ge, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walbech</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital K&#xf8;ge, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drakos</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital K&#xf8;ge, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;genur</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Department of Surgery, Zealand University Hospital K&#xf8;ge, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Tech Coloproctol</MedlineTA><NlmUniqueID>9613614</NlmUniqueID><ISSNLinking>1123-6337</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057868" MajorTopicYN="Y">Anastomotic Leak</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colorectal cancer</Keyword><Keyword MajorTopicYN="N">Complications</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Prediction model</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35593971</ArticleId><ArticleId IdType="doi">10.1007/s10151-022-02624-x</ArticleId><ArticleId IdType="pii">10.1007/s10151-022-02624-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dekker JWT, van den Broek CBM, Bastiaannet E, van de Geest LGM, Tollenaar RAEM, Liefers GJ (2011) Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients. Ann Surg Oncol 18:1533&#x2013;1539. https://doi.org/10.1245/s10434-011-1671-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-011-1671-x</ArticleId><ArticleId IdType="pubmed">21445672</ArticleId><ArticleId IdType="pmc">3087879</ArticleId></ArticleIdList></Reference><Reference><Citation>Duraes LC, Stocchi L, Steele SR et al (2018) The relationship between clavien-dindo morbidity classification and oncologic outcomes after colorectal cancer resection. Ann Surg Oncol 25:188&#x2013;196. https://doi.org/10.1245/s10434-017-6142-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-017-6142-6</ArticleId><ArticleId IdType="pubmed">29116488</ArticleId></ArticleIdList></Reference><Reference><Citation>Krarup P-M, Nordholm-Carstensen A, Jorgensen LN, Harling H (2014) Anastomotic leak increases distant recurrence and long-term mortality after curative resection for colonic cancer: a nationwide cohort study. Ann Surg 259:930&#x2013;938. https://doi.org/10.1097/SLA.0b013e3182a6f2fc</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3182a6f2fc</ArticleId><ArticleId IdType="pubmed">24045445</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CHA, Kong JCH, Heriot AG, Warrier S, Zalcberg J, Sitzler P (2019) Short-term outcome of emergency colorectal cancer surgery: results from Bi-National Colorectal Cancer Audit. Int J Colorectal Dis 34:63&#x2013;69. https://doi.org/10.1007/s00384-018-3169-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-018-3169-5</ArticleId><ArticleId IdType="pubmed">30269226</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasson M, Granero-Castro P, Ramos Rodr&#xed;guez JL et al (2016) Risk factors for anastomotic leak and postoperative morbidity and mortality after elective right colectomy for cancer: results from a prospective, multicentric study of 1102 patients. Int J Colorectal Dis 31:105&#x2013;114. https://doi.org/10.1007/s00384-015-2376-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-015-2376-6</ArticleId><ArticleId IdType="pubmed">26315015</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn DE, Mao D, Yerkovich ST et al (2020) The impact of comorbidities on post-operative complications following colorectal cancer surgery. PLoS ONE 15:e0243995. https://doi.org/10.1371/journal.pone.0243995</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243995</ArticleId><ArticleId IdType="pubmed">33362234</ArticleId><ArticleId IdType="pmc">7757883</ArticleId></ArticleIdList></Reference><Reference><Citation>Merath K, Hyer JM, Mehta R et al (2020) Use of machine learning for prediction of patient risk of postoperative complications after liver, pancreatic, and colorectal surgery. J Gastrointest Surg 24:1843&#x2013;1851. https://doi.org/10.1007/s11605-019-04338-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-019-04338-2</ArticleId><ArticleId IdType="pubmed">31385172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingeholm P, G&#xf6;genur I, Iversen LH (2016) Danish colorectal cancer group database. Clin Epidemiol 8:465&#x2013;468. https://doi.org/10.2147/CLEP.S99481</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S99481</ArticleId><ArticleId IdType="pubmed">27822086</ArticleId><ArticleId IdType="pmc">5094575</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein MF, G&#xf6;genur I, Ingeholm P et al (2020) Validation of the Danish colorectal cancer group (DCCG.dk) database&#x2014;on behalf of the Danish colorectal cancer group. Colorectal Dis 22:2057&#x2013;2067. https://doi.org/10.1111/codi.15352</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/codi.15352</ArticleId><ArticleId IdType="pubmed">32894818</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187&#x2013;196. https://doi.org/10.1097/SLA.0b013e3181b13ca2</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181b13ca2</ArticleId><ArticleId IdType="pubmed">19638912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH et al (2015) Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 216:574&#x2013;578</Citation><ArticleIdList><ArticleId IdType="pubmed">26262116</ArticleId><ArticleId IdType="pmc">4815923</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE (2012) Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 19:54&#x2013;60. https://doi.org/10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KGM (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350:g7594. https://doi.org/10.1136/bmj.g7594</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g7594</ArticleId><ArticleId IdType="pubmed">25569120</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahbari NN, Weitz J, Hohenberger W et al (2010) Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery 147:339&#x2013;351. https://doi.org/10.1016/j.surg.2009.10.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2009.10.012</ArticleId><ArticleId IdType="pubmed">20004450</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR (2018) Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc 25:969&#x2013;975. https://doi.org/10.1093/jamia/ocy032</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId><ArticleId IdType="pmc">6077830</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid S, Yang C, Blacketer C et al (2021) A standardized analytics pipeline for reliable and rapid development and validation of prediction models using observational health data. Comput Methods Programs Biomed 211:106394. https://doi.org/10.1016/j.cmpb.2021.106394</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2021.106394</ArticleId><ArticleId IdType="pubmed">34560604</ArticleId><ArticleId IdType="pmc">8420135</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasson M, Flor-Lorente B, Rodr&#xed;guez JLR et al (2015) Risk factors for anastomotic leak after colon resection for cancer: multivariate analysis and nomogram from a multicentric, prospective, national study with 3193 patients. Ann Surg 262:321&#x2013;330. https://doi.org/10.1097/SLA.0000000000000973</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000000973</ArticleId><ArticleId IdType="pubmed">25361221</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilimoria KY, Liu Y, Paruch JL et al (2013) Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. J Am Coll Surg 217:833-842.e3. https://doi.org/10.1016/j.jamcollsurg.2013.07.385</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2013.07.385</ArticleId><ArticleId IdType="pubmed">24055383</ArticleId><ArticleId IdType="pmc">3805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller DS, Ho JW, Mercadel AJ, Ogola GO, Steele SR (2018) Are we taking a risk with risk assessment tools? Evaluating the relationship between NSQIP and the ACS risk calculator in colorectal surgery. Am J Surg 216:645&#x2013;651. https://doi.org/10.1016/j.amjsurg.2018.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2018.07.015</ArticleId><ArticleId IdType="pubmed">30049434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler MA, Bauman JC, Welsh RJ, Wasvary HJ (2020) Can the American college of surgeons national surgical quality improvement program risk calculator predict outcomes for urgent colectomies? Am Surg. https://doi.org/10.1177/0003134820973392</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0003134820973392</ArticleId><ArticleId IdType="pubmed">33345578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma M, Liu Y, Gotoh M et al (2021) Validation study of the ACS NSQIP surgical risk calculator for two procedures in Japan. Am J Surg. https://doi.org/10.1016/j.amjsurg.2021.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2021.06.008</ArticleId><ArticleId IdType="pubmed">34785031</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman SK, Hrabe JE, Huang E, Cromwell JW, Byrn JC (2018) Prospective validation of the iowa rectal surgery risk calculator. J Gastrointest 22:1258&#x2013;1267. https://doi.org/10.1007/s11605-018-3770-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-018-3770-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T, Miyata H, Konno H et al (2017) Prediction model for complications after low anterior resection based on data from 33,411 Japanese patients included in the national clinical database. Surgery 161:1597&#x2013;1608. https://doi.org/10.1016/j.surg.2016.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2016.12.011</ArticleId><ArticleId IdType="pubmed">28153378</ArticleId></ArticleIdList></Reference><Reference><Citation>Arezzo A, Migliore M, Chiaro P et al (2019) The REAL (Rectal anastomotic leak) score for prediction of anastomotic leak after rectal cancer surgery. Tech Coloproctol 23:649&#x2013;663. https://doi.org/10.1007/s10151-019-02028-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10151-019-02028-4</ArticleId><ArticleId IdType="pubmed">31240416</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker JWT, Liefers GJ, de van Mol Otterloo JCA, Putter H, Tollenaar RAEM (2011) Predicting the risk of anastomotic leakage in left-sided colorectal surgery using a colon leakage score. J Surg Res 166:27&#x2013;34. https://doi.org/10.1016/j.jss.2010.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2010.11.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Sammour T, Cohen L, Karunatillake AI et al (2017) Validation of an online risk calculator for the prediction of anastomotic leak after colon cancer surgery and preliminary exploration of artificial intelligence-based analytics. Tech Coloproctol 21:869&#x2013;877. https://doi.org/10.1007/s10151-017-1701-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10151-017-1701-1</ArticleId><ArticleId IdType="pubmed">29080956</ArticleId></ArticleIdList></Reference><Reference><Citation>Klose J, Tarantino I, von Fournier A et al (2018) A nomogram to predict anastomotic leakage in open rectal surgery-hope or hype? J Gastrointest 22:1619&#x2013;1630. https://doi.org/10.1007/s11605-018-3782-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-018-3782-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SU, Park EJ, Baik SH, Lee KY, Kang J (2019) Modified colon leakage score to predict anastomotic leakage in patients who underwent left-sided colorectal surgery. J Clin Med. https://doi.org/10.3390/jcm8091450</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8091450</ArticleId><ArticleId IdType="pubmed">31905621</ArticleId><ArticleId IdType="pmc">7020017</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X-Q, Zhao B, Zhou W-P et al (2016) Utility of colon leakage score in left-sided colorectal surgery. J Surg Res 202:398&#x2013;402. https://doi.org/10.1016/j.jss.2015.12.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2015.12.046</ArticleId><ArticleId IdType="pubmed">27229115</ArticleId></ArticleIdList></Reference><Reference><Citation>Marres CCM, van de Ven AWH, Verbeek PCM, van Dieren S, Bemelman WA, Buskens CJ (2016) The effect of a postoperative quality improvement program on outcomes in colorectal surgery in a community hospital. Int J Colorectal Dis 31:1603&#x2013;1609. https://doi.org/10.1007/s00384-016-2619-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-016-2619-1</ArticleId><ArticleId IdType="pubmed">27385205</ArticleId><ArticleId IdType="pmc">4989010</ArticleId></ArticleIdList></Reference><Reference><Citation>Carli F, Charlebois P, Baldini G, Cachero O, Stein B (2009) An integrated multidisciplinary approach to implementation of a fast-track program for laparoscopic colorectal surgery. Can J Anaesth 56:837&#x2013;842. https://doi.org/10.1007/s12630-009-9159-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-009-9159-x</ArticleId><ArticleId IdType="pubmed">19639371</ArticleId></ArticleIdList></Reference><Reference><Citation>Tr&#xe9;panier M, Minnella EM, Paradis T et al (2019) Improved disease-free survival after prehabilitation for colorectal cancer surgery. Ann Surg 270:493&#x2013;501. https://doi.org/10.1097/SLA.0000000000003465</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000003465</ArticleId><ArticleId IdType="pubmed">31318793</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen AB, Thorsen-Meyer H-C, Belling K et al (2019) Survival prediction in intensive-care units based on aggregation of long-term disease history and acute physiology: a retrospective study of the Danish national patient registry and electronic patient records. Lancet Digit Health 1:e78&#x2013;e89. https://doi.org/10.1016/S2589-7500(19)30024-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(19)30024-X</ArticleId><ArticleId IdType="pubmed">33323232</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35606846</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1475-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>23</Day></PubDate></JournalIssue><Title>Cardiovascular diabetology</Title><ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation></Journal><ArticleTitle>Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases.</ArticleTitle><Pagination><StartPage>82</StartPage><MedlinePgn>82</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">82</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-022-01524-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Statin treatment increases the risk of new-onset diabetes mellitus (NODM); however, data directly comparing the risk of NODM among individual statins is limited. We compared the risk of NODM between patients using pitavastatin and atorvastatin or rosuvastatin using reliable, large-scale data.</AbstractText><AbstractText Label="METHODS">Data of electronic health records from ten hospitals converted to the Observational Medical Outcomes Partnership Common Data Model (n&#x2009;=&#x2009;14,605,368 patients) were used to identify new users of pitavastatin, atorvastatin, or rosuvastatin (atorvastatin&#x2009;+&#x2009;rosuvastatin) for &#x2265;&#x2009;180 days without a previous history of diabetes or HbA1c level&#x2009;&#x2265;&#x2009;5.7%. We conducted a cohort study using Cox regression analysis to examine the hazard ratio (HR) of NODM after propensity score matching (PSM) and then performed an aggregate meta-analysis of the HR.</AbstractText><AbstractText Label="RESULTS">After 1:2 PSM, 10,238 new pitavastatin users (15,998 person-years of follow-up) and 18,605 atorvastatin&#x2009;+&#x2009;rosuvastatin users (33,477 person-years of follow-up) were pooled from 10 databases. The meta-analysis of the HRs demonstrated that pitavastatin resulted in a significantly reduced risk of NODM than atorvastatin&#x2009;+&#x2009;rosuvastatin (HR 0.72; 95% CI 0.59-0.87). In sub-analysis, pitavastatin was associated with a lower risk of NODM than atorvastatin or rosuvastatin after 1:1 PSM (HR 0.69; CI 0.54-0.88 and HR 0.74; CI 0.55-0.99, respectively). A consistently low risk of NODM in pitavastatin users was observed when compared with low-to-moderate-intensity atorvastatin&#x2009;+&#x2009;rosuvastatin users (HR 0.78; CI&#xa0;0.62-0.98).</AbstractText><AbstractText Label="CONCLUSIONS">In this retrospective, multicenter active-comparator, new-user, cohort study, pitavastatin reduced the risk of NODM compared with atorvastatin or rosuvastatin.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Won-Woo</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Departments of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 150, Seongan-ro, Gangdong-gu, Seoul, 05355, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Seung In</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Departments of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 150, Seongan-ro, Gangdong-gu, Seoul, 05355, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yerim</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Departments of Neurology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Jong Jin</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Departments of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 150, Seongan-ro, Gangdong-gu, Seoul, 05355, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Woon Geon</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Departments of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 150, Seongan-ro, Gangdong-gu, Seoul, 05355, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinseob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Young Min</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kyung-Jin</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Ewha Womans University Medical Center, Ewha Womans University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Sang Youl</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Meeyoung</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Eun-Sun</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Cardiovascular Center, Kyung Hee University Hospital at Gangdong, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sung Eun</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Departments of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 150, Seongan-ro, Gangdong-gu, Seoul, 05355, South Korea. drhyangii@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Diabetol</MedlineTA><NlmUniqueID>101147637</NlmUniqueID><ISSNLinking>1475-2840</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011804">Quinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>83MVU38M7Q</RegistryNumber><NameOfSubstance UI="D000068718">Rosuvastatin Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>A0JWA85V8F</RegistryNumber><NameOfSubstance UI="D000069059">Atorvastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>M5681Q5F9P</RegistryNumber><NameOfSubstance UI="C108475">pitavastatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000069059" MajorTopicYN="N">Atorvastatin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068718" MajorTopicYN="N">Rosuvastatin Calcium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Pitavastatin</Keyword><Keyword MajorTopicYN="N">Statin</Keyword></KeywordList><CoiStatement>The authors declare that there are no relationships or activities that might bias or be perceived to bias their work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>23</Day><Hour>23</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35606846</ArticleId><ArticleId IdType="pmc">PMC9128291</ArticleId><ArticleId IdType="doi">10.1186/s12933-022-01524-6</ArticleId><ArticleId IdType="pii">10.1186/s12933-022-01524-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111&#x2013;88. doi: 10.1093/eurheartj/ehz455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz455</ArticleId><ArticleId IdType="pubmed">31504418</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74(10):e177-e232. doi: 10.1016/j.jacc.2019.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.03.009</ArticleId><ArticleId IdType="pmc">PMC7685565</ArticleId><ArticleId IdType="pubmed">30894318</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735&#x2013;742. doi: 10.1016/S0140-6736(09)61965-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61965-6</ArticleId><ArticleId IdType="pubmed">20167359</ArticleId></ArticleIdList></Reference><Reference><Citation>Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556&#x2013;64. doi: 10.1001/jama.2011.860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2011.860</ArticleId><ArticleId IdType="pubmed">21693744</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR. Mamdani MM Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610. doi: 10.1136/bmj.f2610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.f2610</ArticleId><ArticleId IdType="pmc">PMC3662830</ArticleId><ArticleId IdType="pubmed">23704171</ArticleId></ArticleIdList></Reference><Reference><Citation>Betteridge DJ, Carmena R. The diabetogenic action of statins&#x2014;mechanisms and clinical implications. Nat Rev Endocrinol. 2016;12(2):99&#x2013;110. doi: 10.1038/nrendo.2015.194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2015.194</ArticleId><ArticleId IdType="pubmed">26668119</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Sheen SS, Lee S, Choi YJ, Park RW, Lim HS. Statins and risk for new-onset diabetes mellitus. A real-world cohort study using a clinical research database. Medicine. 2016;95(46):e5429. doi: 10.1097/MD.0000000000005429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000005429</ArticleId><ArticleId IdType="pmc">PMC5120943</ArticleId><ArticleId IdType="pubmed">27861386</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123&#x2013;30. doi: 10.1016/j.amjcard.2012.12.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2012.12.037</ArticleId><ArticleId IdType="pubmed">23352266</ArticleId></ArticleIdList></Reference><Reference><Citation>Alagona P., Jr Pitavastatin: evidence for its place in treatment of hypercholesterolemia. Core Evid. 2010;5:91&#x2013;105. doi: 10.2147/CE.S8008.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CE.S8008</ArticleId><ArticleId IdType="pmc">PMC3065553</ArticleId><ArticleId IdType="pubmed">21468365</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe M, Ozaki Y, Takahashi H, Ishii M, Masunaga N, Ismail TF, et al. Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy. Am Heart J. 2021;240:89&#x2013;100. doi: 10.1016/j.ahj.2021.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2021.06.009</ArticleId><ArticleId IdType="pubmed">34174217</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M, Nakamura K, Miyoshi T, Yoshida M, Kondo M, Akazawa K, et al. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet. Cardiovasc Diabetol. 2020;19(1):1&#x2013;10. doi: 10.1186/s12933-019-0977-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-019-0977-z</ArticleId><ArticleId IdType="pmc">PMC7520032</ArticleId><ArticleId IdType="pubmed">32979918</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihm S-H, Chung W-B, Lee J-M, Hwang B-H, Yoo K-D, Her S-H, et al. Efficacy and tolerability of pitavastatin versus pitavastatin/fenofibrate in high-risk Korean patients with mixed dyslipidemia: a multicenter, randomized, double-blinded, parallel, therapeutic confirmatory clinical trial. Clin Ther. 2020;42(10):2021&#x2013;35. doi: 10.1016/j.clinthera.2020.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2020.08.002</ArticleId><ArticleId IdType="pubmed">32891418</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther. 2011;9(5):555&#x2013;62. doi: 10.1586/erc.11.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erc.11.47</ArticleId><ArticleId IdType="pubmed">21615316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4&#xa0;mg and atorvastatin 20&#x2013;40&#xa0;mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011;13(11):1047&#x2013;55. doi: 10.1111/j.1463-1326.2011.01477.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1463-1326.2011.01477.x</ArticleId><ArticleId IdType="pubmed">21812889</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallejo-Vaz AJ, Seshasai SRK, Kurogi K, Michishita I, Nozue T, Sugiyama S, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241(2):409&#x2013;18. doi: 10.1016/j.atherosclerosis.2015.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2015.06.001</ArticleId><ArticleId IdType="pubmed">26074315</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakker D, Nair S, Pagada A, Jamdade V. Malik A Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25(10):1131&#x2013;49. doi: 10.1002/pds.4020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4020</ArticleId><ArticleId IdType="pubmed">27277934</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho Y, Choe E, Lee YH, Seo JW, Choi Y, Yun Y, et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism. 2015;64(4):482&#x2013;8. doi: 10.1016/j.metabol.2014.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2014.09.008</ArticleId><ArticleId IdType="pubmed">25312577</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, You SC, Cho J, Park CH, Shin WG, Park RW, et al. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study. BMC Pharmacol Toxicol. 2022;23(1):1&#x2013;10. doi: 10.1186/s40360-022-00549-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40360-022-00549-7</ArticleId><ArticleId IdType="pmc">PMC8762632</ArticleId><ArticleId IdType="pubmed">35039078</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo SI, Park CH, You SC, Kim JY, Lee KJ, Kim J, et al. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut. 2021;70(11):2066&#x2013;75. doi: 10.1136/gutjnl-2020-323845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323845</ArticleId><ArticleId IdType="pubmed">33975868</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo SI, You SC, Park CH, Kim TJ, Ko YS, Kim Y, et al. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: a 15&#x2010;year hospital cohort study using a common data model. J Gastroenterol Hepatol. 2020;35(8):1325&#x2013;30. doi: 10.1111/jgh.14983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.14983</ArticleId><ArticleId IdType="pubmed">31970824</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, et al. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016;22(1):54&#x2013;8. doi: 10.4258/hir.2016.22.1.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2016.22.1.54</ArticleId><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the Premier Perspective&#xae; hospital database into the Observational Medical Outcomes Partnership (OMOP) common data model. EGEMS. 2014;2(1):15. doi: 10.13063/2327-9214.1110.</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1110</ArticleId><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285&#x2013;350. doi: 10.1016/j.jacc.2018.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.11.003</ArticleId><ArticleId IdType="pubmed">30423393</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Suchard M, Ryan P. CohortMethod: new-user cohort method with large scale propensity and outcome models. 2018. https://ohdsi.github.io/CohortMethod/.</Citation></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23(1):1&#x2013;17. doi: 10.1145/2414416.2414791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano PS, Roos LL, Jollis JG. Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075&#x2013;9. doi: 10.1016/0895-4356(93)90103-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(93)90103-8</ArticleId><ArticleId IdType="pubmed">8410092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012;60(14):1231&#x2013;8. doi: 10.1016/j.jacc.2012.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2012.05.019</ArticleId><ArticleId IdType="pubmed">22884288</ArticleId></ArticleIdList></Reference><Reference><Citation>Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism. 2014;63(6):735&#x2013;45. doi: 10.1016/j.metabol.2014.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2014.02.014</ArticleId><ArticleId IdType="pubmed">24641882</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh KK, Lim S, Sakuma I, Quon MJ. Caveats to aggressive lowering of lipids by specific statins. Int J Cardiol. 2012;154(2):97&#x2013;101. doi: 10.1016/j.ijcard.2011.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2011.09.002</ArticleId><ArticleId IdType="pubmed">21993228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Zhao SP. Different effects of statins on induction of diabetes mellitus: an experimental study. Drug Des Devel Ther. 2015;9:6211&#x2013;23. doi: 10.2147/DDDT.S87979.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S87979</ArticleId><ArticleId IdType="pmc">PMC4664500</ArticleId><ArticleId IdType="pubmed">26648697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashiri MA, Nohara A, Tada H, Mori M, Tsuchida M, Katsuda S, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther. 2008;83(5):731&#x2013;9. doi: 10.1038/sj.clpt.6100396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.clpt.6100396</ArticleId><ArticleId IdType="pubmed">17957184</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302(2):179&#x2013;88. doi: 10.1001/jama.2009.976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.976</ArticleId><ArticleId IdType="pubmed">19584347</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomura S, Shouzu A, Omoto S, Inami N, Tanaka A, Nanba M, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008;122(1):39&#x2013;45. doi: 10.1016/j.thromres.2007.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2007.08.013</ArticleId><ArticleId IdType="pubmed">17920663</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrusciel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, et al. Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194&#x2013;208. doi: 10.1016/j.atherosclerosis.2016.07.897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2016.07.897</ArticleId><ArticleId IdType="pubmed">27498397</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WT, Lin C, Tsai MC, Cheng CC, Chen SJ, Liou JT, et al. Effects of pitavastatin, atorvastatin, and rosuvastatin on the risk of new-onset diabetes mellitus: a single-center cohort study. Biomedicines. 2020;8(11):499. doi: 10.3390/biomedicines8110499.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8110499</ArticleId><ArticleId IdType="pmc">PMC7696728</ArticleId><ArticleId IdType="pubmed">33202854</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437&#x2013;41. doi: 10.1038/nrrheum.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.30</ArticleId><ArticleId IdType="pmc">PMC4486631</ArticleId><ArticleId IdType="pubmed">25800216</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JY, Choi CU, Hwang SY, Choi BG, Jang WY, Kim DY, et al. Effect of pitavastatin compared with atorvastatin and rosuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction. Am J Cardiol. 2018;122(6):922&#x2013;8. doi: 10.1016/j.amjcard.2018.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2018.06.017</ArticleId><ArticleId IdType="pubmed">30217375</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CH, Huang YY, Hsu BR. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. J Diabetes Investig. 2016;7(5):769&#x2013;76. doi: 10.1111/jdi.12483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.12483</ArticleId><ArticleId IdType="pmc">PMC5009141</ArticleId><ArticleId IdType="pubmed">27181110</ArticleId></ArticleIdList></Reference><Reference><Citation>Na E, Cho S, Kim DJ, Choi J, Han E. Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study. Cardiovasc Diabetol. 2020;19(1):1&#x2013;11. doi: 10.1186/s12933-020-01037-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-01037-0</ArticleId><ArticleId IdType="pmc">PMC7231413</ArticleId><ArticleId IdType="pubmed">32416728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Noh Y, Shin S, Lim HS, Park RW, Bae SK, et al. Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. Ther Clin Risk Manag. 2016;12:1533&#x2013;43. doi: 10.2147/TCRM.S117150.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S117150</ArticleId><ArticleId IdType="pmc">PMC5066992</ArticleId><ArticleId IdType="pubmed">27785041</ArticleId></ArticleIdList></Reference><Reference><Citation>Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Supplement_1):S17-S38.</Citation><ArticleIdList><ArticleId IdType="pubmed">34964875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D-Y, Zeng D. On the relative efficiency of using summary statistics versus individual-level data in meta-analysis. Biometrika. 2010;97(2):321&#x2013;32. doi: 10.1093/biomet/asq006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/asq006</ArticleId><ArticleId IdType="pmc">PMC3412575</ArticleId><ArticleId IdType="pubmed">23049122</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35612079</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>294</Volume><PubDate><Year>2022</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Usability of OMOP Common Data Model for Detailed Lab Microbiology Results.</ArticleTitle><Pagination><StartPage>292</StartPage><EndPage>296</EndPage><MedlinePgn>292-296</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI220461</ELocationID><Abstract><AbstractText>Anti-microbial resistance surveillance systems in Europe are limited by the inability to link laboratory data and patient data. The OMOP Common Data Model (OMOP CDM) is an option to store and use patient data in an international context supporting observational research. Detailed medical microbiology laboratory data are usually not stored in OMOP CDM. We propose here a solution to deal with the inherent complexity of microbiology data and store those in the OMOP CDM v5.4. We demonstrate the feasibility of our approach by capturing data from a microbiology in vitro diagnostic middleware, modeling in OMOP CDM 5.4 and querying for visualization.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Theron</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>bioM&#xe9;rieux, Data Science, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorse</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>bioM&#xe9;rieux, Data Science, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gansel</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>bioM&#xe9;rieux, Data Science, Grenoble, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="Y">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Interoperability</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">data model</Keyword><Keyword MajorTopicYN="N">microbiology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35612079</ArticleId><ArticleId IdType="doi">10.3233/SHTI220461</ArticleId><ArticleId IdType="pii">SHTI220461</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35612098</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>294</Volume><PubDate><Year>2022</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>FAIRifying a Quality Registry Using OMOP CDM: Challenges and Solutions.</ArticleTitle><Pagination><StartPage>367</StartPage><EndPage>371</EndPage><MedlinePgn>367-371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI220476</ELocationID><Abstract><AbstractText>The need for health data to be internationally Findable, Accessible, Interoperable and Reusable (FAIR) and thereby support integrative analysis with other datasets has become crystal clear in the ongoing pandemic. The Dutch National Intensive Care Evaluation (NICE) quality registry adopted the Observational Medical Outcomes Partnership Common Database Model (OMOP CDM) to achieve a FAIR database. In the process of adopting the OMOP CDM, many modeling, technical, and communication challenges needed to be solved. Through communication with the OMOP CDM implementation community, previously done research and trial-and-error we found solutions that we believe can help other healthcare institutions, especially ICU quality registries, FAIRify their databases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puttmann</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The National Intensive Care Evaluation (NICE) registry, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Keizer</LastName><ForeName>Nicolette</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The National Intensive Care Evaluation (NICE) registry, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornet</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Der Zwan</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>The National Intensive Care Evaluation (NICE) registry, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakhshi-Raiez</LastName><ForeName>Ferishta</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The National Intensive Care Evaluation (NICE) registry, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ETL Process</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Quality Registry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>8</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35612098</ArticleId><ArticleId IdType="doi">10.3233/SHTI220476</ArticleId><ArticleId IdType="pii">SHTI220476</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35612106</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>294</Volume><PubDate><Year>2022</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Evaluation and Challenges of Medical Procedure Data Harmonization to SNOMED-CT for Observational Research.</ArticleTitle><Pagination><StartPage>405</StartPage><EndPage>406</EndPage><MedlinePgn>405-406</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI220484</ELocationID><Abstract><AbstractText>The relevance of health data research on real world data (RWD) is increasing. To prepare national RWD for international research, harmonization with standard terminologies is required. In this paper, we evaluate to what extent the German OPS vocabulary in OHDSI covers codes present in RWD and mappings to SNOMED-CT. The evaluation identified a mapping gap of 21.1% in the RWD set.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reinecke</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kallfelz</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Odysseus Data Services GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siebel</LastName><ForeName>Joscha</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bathelt</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039061" MajorTopicYN="Y">Systematized Nomenclature of Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014825" MajorTopicYN="Y">Vocabulary</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">OPS</Keyword><Keyword MajorTopicYN="N">SNOMED-CT</Keyword><Keyword MajorTopicYN="N">interoperability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>8</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35612106</ArticleId><ArticleId IdType="doi">10.3233/SHTI220484</ArticleId><ArticleId IdType="pii">SHTI220484</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35612110</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>294</Volume><PubDate><Year>2022</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Beyond the Brain: MIDS Extends BIDS to Multiple Modalities and Anatomical Regions.</ArticleTitle><Pagination><StartPage>413</StartPage><EndPage>414</EndPage><MedlinePgn>413-414</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI220488</ELocationID><Abstract><AbstractText>Brain Imaging Data Structure (BIDS) provides a valuable tool to organise brain imaging data into a clear and easy standard directory structure. Moreover, BIDS is widely supported by the scientific community and has been established as a powerful standard for medical imaging management. Nonetheless, the original BIDS is restricted to magnetic resonance imaging (MRI) of the brain, limiting its implantation to other techniques and anatomical regions. We developed Medical Imaging Data Structure (MIDS), conceived to extend BIDS methodology to other anatomical regions and multiple imaging systems in these areas. The MIDS standard was developed to store and manage medical images as an extension of BIDS. It allows the user to handily save studies of multiple anatomical regions and imaging techniques. Besides, MIDS improves the classification of multiple images within the structure, allowing the possibility to unify them in a single study to apply on them preprocessing or artificial intelligence algorithms. Finally, the results generated are saved in the derivatives folder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saborit-Torres</LastName><ForeName>Jose Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadal-Almela</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montell-Serrano</LastName><ForeName>Joaquim Angel</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliver-Garcia</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carceller</LastName><ForeName>Hector</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERSAM, ISC III. Av. Blasco Ib&#xe1;&#xf1;ez 15, 46010 - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Biotechnology and Biomedicine (BIOTECMED), Universitat de Valencia, Burjassot, 46100, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-&#xc1;drian</LastName><ForeName>Jon Ander</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Computer Systems and Computation, Universitat Polit&#xe8;cnica de Val&#xe8;ncia - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caparr&#xf3;s-Redondo</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Garc&#xed;a</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioinformatics &amp; Biostatistics Unit, Principe Felipe Research Center - Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domenech-Fern&#xe1;ndez</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Arnau de Vilanova - Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De La Iglesia-Vay&#xe1;</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERSAM, ISC III. Av. Blasco Ib&#xe1;&#xf1;ez 15, 46010 - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Directorate of Research, Innovation, Technology and Quality. Subdirectorate General of Information Systems for Health - Valencia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="Y">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BIDS</Keyword><Keyword MajorTopicYN="N">Database</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Standardization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>8</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35612110</ArticleId><ArticleId IdType="doi">10.3233/SHTI220488</ArticleId><ArticleId IdType="pii">SHTI220488</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35612126</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>294</Volume><PubDate><Year>2022</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Towards the Improvement of Clinical Guidelines Based on Real World Data.</ArticleTitle><Pagination><StartPage>480</StartPage><EndPage>484</EndPage><MedlinePgn>480-484</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI220505</ELocationID><Abstract><AbstractText>Computerized clinical guidelines (CCG) are effective instruments for standardizing, monitoring and optimizing medical treatment processes. Nevertheless, due to barriers in flexibility, transferability and acceptance, the widespread use of CCG in clinical practice is not yet common. To overcome those issues, we present a concept on how to use real world data to evaluate CCG and to recommend improvements. As a first result, we defined an algorithm to extract treatment processes based on the standardized Observational Medical Outcomes Partnership (OMOP) Common Data Model as well as their visualization using the graphical modeling language Business Process Model and Notation (BPMN).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinecke</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoch</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bathelt</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Business Process Model and Notation</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">computerized clinical guidelines</Keyword><Keyword MajorTopicYN="N">interoperability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>8</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35612126</ArticleId><ArticleId IdType="doi">10.3233/SHTI220505</ArticleId><ArticleId IdType="pii">SHTI220505</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35614485</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6947</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>BMC medical informatics and decision making</Title><ISOAbbreviation>BMC Med Inform Decis Mak</ISOAbbreviation></Journal><ArticleTitle>Learning patient-level prediction models across multiple healthcare databases: evaluation of ensembles for increasing model transportability.</ArticleTitle><Pagination><StartPage>142</StartPage><MedlinePgn>142</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">142</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12911-022-01879-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Prognostic models that are accurate could help aid medical decision making. Large observational databases often contain temporal medical data for large and diverse populations of patients. It may be possible to learn prognostic models using the large observational data. Often the performance of a prognostic model undesirably worsens when transported to a different database (or into a clinical setting). In this study we investigate different ensemble approaches that combine prognostic models independently developed using different databases (a simple federated learning approach) to determine whether ensembles that combine models developed across databases can improve model transportability (perform better in new data than single database models)?</AbstractText><AbstractText Label="METHODS">For a given prediction question we independently trained five single database models each using a different observational healthcare database. We then developed and investigated numerous ensemble models (fusion, stacking and mixture of experts) that combined the different database models. Performance of each model was investigated via discrimination and calibration using a leave one dataset out technique, i.e., hold out one database to use for validation and use the remaining four datasets for model development. The internal validation of a model developed using the hold out database was calculated and presented as the 'internal benchmark' for comparison.</AbstractText><AbstractText Label="RESULTS">In this study the fusion ensembles generally outperformed the single database models when transported to a previously unseen database and the performances were more consistent across unseen databases. Stacking ensembles performed poorly in terms of discrimination when the labels in the unseen database were limited. Calibration was consistently poor when both ensembles and single database models were applied to previously unseen databases.</AbstractText><AbstractText Label="CONCLUSION">A simple federated learning approach that implements ensemble techniques to combine models independently developed across different databases for the same prediction question may improve the discriminative performance in new data (new database or clinical setting) but will need to be recalibrated using the new data. This could help medical decision making by improving prognostic model performance.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Reps</LastName><ForeName>Jenna Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA. jreps@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Inform Decis Mak</MedlineTA><NlmUniqueID>101088682</NlmUniqueID><ISSNLinking>1472-6947</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002138" MajorTopicYN="N">Calibration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="Y">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ensemble learning</Keyword><Keyword MajorTopicYN="N">Model transportability</Keyword><Keyword MajorTopicYN="N">Observational data</Keyword><Keyword MajorTopicYN="N">Patient-level prediction</Keyword><Keyword MajorTopicYN="N">Prognostic model</Keyword></KeywordList><CoiStatement>JMR, MJS, PBR are employees of Janssen Research and Development and shareholders of Johnson and Johnson. PRR and RDW work for a research group who received unconditional research grants from Boehringer-Ingelheim, GSK, Janssen Research &amp; Development, Novartis, Pfizer, Yamanouchi, Servier. None of these grants result in a conflict of interest to the content of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35614485</ArticleId><ArticleId IdType="pmc">PMC9134686</ArticleId><ArticleId IdType="doi">10.1186/s12911-022-01879-6</ArticleId><ArticleId IdType="pii">10.1186/s12911-022-01879-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farzadfar F. Cardiovascular disease risk prediction models: challenges and perspectives. Lancet Glob Health. 2019;7(10):e1288&#x2013;e1289. doi: 10.1016/S2214-109X(19)30365-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(19)30365-1</ArticleId><ArticleId IdType="pubmed">31488388</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, et al. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25(8):969&#x2013;975. doi: 10.1093/jamia/ocy032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Debray TP, Vergouwe Y, Koffijberg H, et al. A new framework to enhance the interpretation of external validation studies of clinical prediction models. J Clin Epidemiol. 2015;68(3):279&#x2013;289. doi: 10.1016/j.jclinepi.2014.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2014.06.018</ArticleId><ArticleId IdType="pubmed">25179855</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergouwe Y, Moons KG, Steyerberg EW. External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol. 2010;172(8):971&#x2013;980. doi: 10.1093/aje/kwq223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwq223</ArticleId><ArticleId IdType="pmc">PMC2984249</ArticleId><ArticleId IdType="pubmed">20807737</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochems A, Deist TM, Van Soest J, Eble M, Bulens P, Coucke P, Dries W, Lambin P, Dekker A. Distributed learning: developing a predictive model based on data from multiple hospitals without data leaving the hospital&#x2013;a real life proof of concept. Radiother Oncol. 2016;121(3):459&#x2013;467. doi: 10.1016/j.radonc.2016.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radonc.2016.10.002</ArticleId><ArticleId IdType="pubmed">28029405</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogowicz M, Jochems A, Deist TM, Tanadini-Lang S, Huang SH, Chan B, Waldron JN, Bratman S, O&#x2019;Sullivan B, Riesterer O, Studer G. Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. Sci Rep. 2020;10(1):1&#x2013;10. doi: 10.1038/s41598-020-61297-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-61297-4</ArticleId><ArticleId IdType="pmc">PMC7066122</ArticleId><ArticleId IdType="pubmed">32161279</ArticleId></ArticleIdList></Reference><Reference><Citation>Deist TM, Dankers FJ, Ojha P, Marshall MS, Janssen T, Faivre-Finn C, Masciocchi C, Valentini V, Wang J, Chen J, Zhang Z. Distributed learning on 20,000+ lung cancer patients&#x2013;The Personal Health Train. Radiother Oncol. 2020;144:189&#x2013;200. doi: 10.1016/j.radonc.2019.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radonc.2019.11.019</ArticleId><ArticleId IdType="pubmed">31911366</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo C, Islam MN, Sheils NE, Reps JM, Buresh J, Duan R, Tong JM, Edmondson M, Schuemie MJ, Chen Y. Lossless distributed linear mixed model with application to integration of heterogeneous healthcare data.&#xa0;medRxiv. 2020.</Citation></Reference><Reference><Citation>Sheller MJ, Edwards B, Reina GA, Martin J, Pati S, Kotrotsou A, Milchenko M, Xu W, Marcus D, Colen RR, Bakas S. Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data. Sci Rep. 2020;10(1):1&#x2013;2. doi: 10.1038/s41598-020-69250-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-69250-1</ArticleId><ArticleId IdType="pmc">PMC7387485</ArticleId><ArticleId IdType="pubmed">32724046</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieke N, Hancox J, Li W, Milletari F, Roth HR, Albarqouni S, Bakas S, Galtier MN, Landman BA, Maier-Hein K, Ourselin S. The future of digital health with federated learning. NPJ Digit Med. 2020;3(1):1&#x2013;7. doi: 10.1038/s41746-020-00323-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00323-1</ArticleId><ArticleId IdType="pmc">PMC7490367</ArticleId><ArticleId IdType="pubmed">33015372</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Sahu AK, Talwalkar A, Smith V. Federated learning: Challenges, methods, and future directions. IEEE Signal Process Mag. 2020;37(3):50&#x2013;60. doi: 10.1109/MSP.2020.2975749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/MSP.2020.2975749</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan B, Moore E, Ramage D, Hampson S, y Arcas BA. Communication-efficient learning of deep networks from decentralized data. In Artificial intelligence and statistics 2017;1273&#x2013;1282.</Citation></Reference><Reference><Citation>Tsoumakas G, Partalas I, Vlahavas I. A taxonomy and short review of ensemble selection. In&#xa0;Workshop on Supervised and Unsupervised Ensemble Methods and Their Applications&#xa0;2008;1&#x2013;6.</Citation></Reference><Reference><Citation>Rokach L. Ensemble-based classifiers. Artif Intell Rev. 2010;33(1&#x2013;2):1&#x2013;39. doi: 10.1007/s10462-009-9124-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10462-009-9124-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumera G, Roli F. Performance analysis and comparison of linear combiners for classifier fusion. In&#xa0;Joint IAPR International Workshops on Statistical Techniques in Pattern Recognition (SPR) and Structural and Syntactic Pattern Recognition (SSPR) Springer, Berlin, Heidelberg.&#xa0;2002:424&#x2013;432.</Citation></Reference><Reference><Citation>Wolpert DH. Stacked generalization. Neural Netw. 1992;5(2):241&#x2013;259. doi: 10.1016/S0893-6080(05)80023-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0893-6080(05)80023-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoudnia S, Ebrahimpour R. Mixture of experts: a literature survey. Artif Intell Rev. 2014;42(2):275&#x2013;293. doi: 10.1007/s10462-012-9338-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10462-012-9338-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Breiman L. Random forests. Mach Learn. 2001;45:5&#x2013;32. doi: 10.1023/A:1010933404324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1010933404324</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund Y, Schapire RE. Experiments with a new boosting algorithm. Machine learning: proceedings of the thirteenth international conference 1996:325&#x2013;332</Citation></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;223:553&#x2013;564. doi: 10.1093/jamia/ocu023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, et al. Massive parallelization of serial inference algorithms for complex generalized linear models. ACM Transact Model Comput Simul. 2013;231:10&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Calster B, Nieboer D, Vergouwe Y, et al. A calibration hierarchy for risk models was defined: from utopia to empirical data. J Clin Epidemiol. 2016;74:167&#x2013;176. doi: 10.1016/j.jclinepi.2015.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.12.005</ArticleId><ArticleId IdType="pubmed">26772608</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Ryan PB, Rijnbeek PR, et al. Design matters in patient-level prediction: evaluation of a cohort vs. case&#x2013;control design when developing predictive models in observational healthcare datasets. J Big Data. 2021;8:108. doi: 10.1186/s40537-021-00501-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40537-021-00501-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35631157</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Opportunities of Digital Infrastructures for Disease Management-Exemplified on COVID-19-Related Change in Diagnosis Counts for Diabetes-Related Eye Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2016</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu14102016</ELocationID><Abstract><AbstractText><b>Background:</b> Retrospective research on real-world data provides the ability to gain evidence on specific topics especially when running across different sites in research networks. Those research networks have become increasingly relevant in recent years; not least due to the special situation caused by the COVID-19 pandemic. An important requirement for those networks is the data harmonization by ensuring the semantic interoperability. <b>Aims:</b> In this paper we demonstrate (1) how to facilitate digital infrastructures to run a retrospective study in a research network spread across university and non-university hospital sites; and (2) to answer a medical question on COVID-19 related change in diagnostic counts for diabetes-related eye diseases. <b>Materials and methods:</b> The study is retrospective and non-interventional and runs on medical case data documented in routine care at the participating sites. The technical infrastructure consists of the OMOP CDM and other OHDSI tools that is provided in a transferable format. An ETL process to transfer and harmonize the data to the OMOP CDM has been utilized. Cohort definitions for each year in observation have been created centrally and applied locally against medical case data of all participating sites and analyzed with descriptive statistics. <b>Results:</b> The analyses showed an expectable drop of the total number of diagnoses and the diagnoses for diabetes in general; whereas the number of diagnoses for diabetes-related eye diseases surprisingly decreased stronger compared to non-eye diseases. Differences in relative changes of diagnoses counts between sites show an urgent need to process multi-centric studies rather than single-site studies to reduce bias in the data. <b>Conclusions:</b> This study has demonstrated the ability to utilize an existing portable and standardized infrastructure and ETL process from a university hospital setting and transfer it to non-university sites. From a medical perspective further activity is needed to evaluate data quality of the utilized real-world data documented in routine care and to investigate its eligibility of this data for research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bathelt</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-4139-5489</Identifier><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinecke</LastName><ForeName>Ines</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-0154-2867</Identifier><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weidner</LastName><ForeName>Jens</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4373-8147</Identifier><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartos</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Klinikum Chemnitz gGmbH, Flemmingstr. 2, 09116 Chemnitz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;tt</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Core Unit Datenintegrationszentrum, Universit&#xe4;tsmedizin Greifswald, Walther-Rathenau-Str. 48, 17475 Greifswald, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waltemath</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Core Unit Datenintegrationszentrum, Universit&#xe4;tsmedizin Greifswald, Walther-Rathenau-Str. 48, 17475 Greifswald, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelmann</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Klinikum Chemnitz gGmbH, Flemmingstr. 2, 09116 Chemnitz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Peter Eh</ForeName><Initials>PE</Initials><Identifier Source="ORCID">0000-0001-6317-7880</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Dresden, Carl Gustav Carus, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>01ZZ2101A</GrantID><Agency>Federal Ministry of Education and Research</Agency><Country/></Grant><Grant><GrantID>01ZZ2101E</GrantID><Agency>Federal Ministry of Education and Research</Agency><Country/></Grant><Grant><GrantID>01ZZ1801L</GrantID><Agency>Federal Ministry of Education and Research</Agency><Country/></Grant><Grant><GrantID>01ZZ1801M</GrantID><Agency>Federal Ministry of Education and Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005128" MajorTopicYN="Y">Eye Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">eye-disease</Keyword></KeywordList><CoiStatement>Professor Schwarz receives funding within the project MiHUBx. For this study he provided medical expertise, discussed the cohort definitions and supported the interpretations. None of the other authors have any conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>1</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35631157</ArticleId><ArticleId IdType="pmc">PMC9147678</ArticleId><ArticleId IdType="doi">10.3390/nu14102016</ArticleId><ArticleId IdType="pii">nu14102016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schneeweiss S., Patorno E. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments. Endocr. Rev. 2021;42:658&#x2013;690. doi: 10.1210/endrev/bnab007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endrev/bnab007</ArticleId><ArticleId IdType="pmc">PMC8476933</ArticleId><ArticleId IdType="pubmed">33710268</ArticleId></ArticleIdList></Reference><Reference><Citation>EHDEN  European Health Data &amp; Evidence Network.  [(accessed on 1 April 2022)].  Available online:  https://www.ehden.eu/</Citation></Reference><Reference><Citation>European Medical Agency  Data Analysis and Real World Interrogation Network (DARWIN EU)  [(accessed on 1 April 2022)].  Available online:  https://www.ema.europa.eu/en/about-us/how-we-work/big-data/data-analysis-real-world-interrogation-network-darwin-eu.</Citation></Reference><Reference><Citation>Reinecke I., Zoch M., Reich C., Sedlmayr M., Bathelt F. The Usage of OHDSI OMOP&#x2014;A Scoping Review. In: R&#xf6;hrig R., Bei&#xdf;barth T., K&#xf6;nig J., Ose C., Rauch G., Sax U., Schreiweis B., Sedlmayr M., editors. Studies in Health Technology and Informatics. IOS Press; Amsterdam, The Nethderlands: 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34545824</ArticleId></ArticleIdList></Reference><Reference><Citation>Semler S., Wissing F., Heyder R. German Medical Informatics Initiative: A National Approach to Integrating Health Data from Patient Care and Medical Research. Methods Inf. Med. 2018;57:e50&#x2013;e56. doi: 10.3414/ME18-03-0003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME18-03-0003</ArticleId><ArticleId IdType="pmc">PMC6178199</ArticleId><ArticleId IdType="pubmed">30016818</ArticleId></ArticleIdList></Reference><Reference><Citation>HL7.org, Health Level Seven International Fast Healthcare Interoperability Resources (HL7 FHIR)  [(accessed on 1 April 2022)].  Available online:  https://www.hl7.org/fhir/</Citation></Reference><Reference><Citation>Henke E., Peng Y., Reinecke I., Zoch M., Sedlmayr M. Development of an ETL Process for Bulk and Incremental Load of German Patient Data into OMOP CDM Using FHIR.  [(accessed on 19 April 2022)].  Available online:  https://www.ohdsi.org/2021-global-symposium-showcase-44/</Citation></Reference><Reference><Citation>Prokosch H.-U., Acker T., Bernarding J., Binder H., Boeker M., Boerries M., Daumke P., Ganslandt T., Hesser J., H&#xf6;ning G., et al. MIRACUM: Medical Informatics in Research and Care in University Medicine: A Large Data Sharing Network to Enhance Translational Research and Medical Care. Methods Inf. Med. 2018;57:e82&#x2013;e91. doi: 10.3414/ME17-02-0025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME17-02-0025</ArticleId><ArticleId IdType="pmc">PMC6178200</ArticleId><ArticleId IdType="pubmed">30016814</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo Z.L., Tham Y.-C., Yu M., Chee M.L., Rim T.H., Cheung N., Bikbov M.M., Wang Y.X., Tang Y., Lu Y., et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045. Ophthalmology. 2021;128:1580&#x2013;1591. doi: 10.1016/j.ophtha.2021.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2021.04.027</ArticleId><ArticleId IdType="pubmed">33940045</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhafiz A.H., Emmerton D., Sinclair A.J. Diabetes in COVID-19 pandemic-prevalence, patient characteristics and adverse outcomes. Int. J. Clin. Pract. 2021;75:e14112. doi: 10.1111/ijcp.14112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14112</ArticleId><ArticleId IdType="pmc">PMC7995213</ArticleId><ArticleId IdType="pubmed">33630378</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindeke-Myers A., Zhao P.Y.C., Meyer B.I., Liu E.A., Levine D.A., Bennett O.M., Ji S., Newman-Casey P.A., Rao R.C., Jain N. Patient Perceptions of SARS-CoV-2 Exposure Risk and Association With Continuity of Ophthalmic Care. JAMA Ophthalmol. 2021;139:508. doi: 10.1001/jamaophthalmol.2021.0114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2021.0114</ArticleId><ArticleId IdType="pmc">PMC7953331</ArticleId><ArticleId IdType="pubmed">33704358</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Dwairi R.A., Rwashdeh H., Otoom M. The Influence of COVID-19 Lockdown in Jordan on Patients with Diabetic Retinopathy: A Case&#x2013;Control Study. Ther. Clin. Risk Manag. 2021;17:1011&#x2013;1022. doi: 10.2147/TCRM.S316265.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S316265</ArticleId><ArticleId IdType="pmc">PMC8462094</ArticleId><ArticleId IdType="pubmed">34584415</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatziralli I., Dimitriou E., Kazantzis D., Machairoudia G., Theodossiadis G., Theodossiadis P. Effect of COVID-19-Associated Lockdown on Patients With Diabetic Retinopathy. Cureus. 2021;13:e14831. doi: 10.7759/cureus.14831.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.14831</ArticleId><ArticleId IdType="pmc">PMC8173491</ArticleId><ArticleId IdType="pubmed">34094782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruhl M., Reinecke I., Sedlmayr M. Specification and Distribution of Vocabularies Among Consortial Partners. Stud. Health Technol. Inform. 2020;270:1393&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">32570675</ArticleId></ArticleIdList></Reference><Reference><Citation>The Book of OHDSI. 2021.  [(accessed on 19 April 2022)]. Observational Health Data Sciences and Informatics. independently published. Available online:  https://ohdsi.github.io/TheBookOfOhdsi/</Citation></Reference><Reference><Citation>InEK&#x2014;Institut f&#xfc;r das Entgeltsystem im Krankenhaus GmbH Data Set Description (&#xa7;21 KHEntG)  [(accessed on 20 April 2022)].  Available online:  https://www.g-drg.de/Datenlieferung_gem._21_KHEntgG/Datenlieferung_gem._21_Abs.1_KHEntgG/Dokumente_zur_Datenlieferung/Datensatzbeschreibung.</Citation></Reference><Reference><Citation>Lang L. Mapping eines deutschen, klinischen Datensatzes nach OMOP Common Data Model. 2020.  [(accessed on 19 April 2022)].  Available online:  https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/14831.</Citation></Reference><Reference><Citation>Goffrier B., Mandy S., B&#xe4;tzing-Feigenbaum J. Administrative Pr&#xe4;valenzen und Inzidenzen des Diabetes mellitus von 2009 bis 2015. 2017.  [(accessed on 19 April 2022)].  Available online:  https://www.versorgungsatlas.de/fileadmin/ziva_docs/79/VA-79-Bericht_Final.pdf.</Citation></Reference><Reference><Citation>Manuwald U., Schoffer O., Kugler J., Riemenschneider H., Kapellen T.M., Kiess W., Rothe U. Trends in incidence and prevalence of type 1 diabetes between 1999 and 2019 based on the Childhood Diabetes Registry of Saxony, Germany. PLOS ONE. 2021;16:e0262171. doi: 10.1371/journal.pone.0262171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262171</ArticleId><ArticleId IdType="pmc">PMC8719733</ArticleId><ArticleId IdType="pubmed">34972197</ArticleId></ArticleIdList></Reference><Reference><Citation>Altun F.B., Folz M., Reinert D., Pinnau M., Walther D., Mate S., Reinecke I., Vengadeswaran A., Schaaf J., Kadioglu D., et al.  IT support for cross-site data sharing of research inquiries. 2021.  [(accessed on 19 April 2022)].  Available online:  https://www.egms.de/static/en/meetings/gmds2021/21gmds070.shtml.</Citation></Reference><Reference><Citation>Sun J.K., Jampol L.M. The Diabetic Retinopathy Clinical Research Network (DRCR.net) and Its Contributions to the Treatment of Diabetic Retinopathy. Ophthalmic Res. 2019;62:225&#x2013;230. doi: 10.1159/000502779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000502779</ArticleId><ArticleId IdType="pubmed">31554001</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C., Lang L., Storf H., Vormstein P., Bieber R., Bernarding J., Herrmann T., Haverkamp C., Horki P., Laufer J., et al. Towards Implementation of OMOP in a German University Hospital Consortium. Appl. Clin. Inform. 2018;9:54&#x2013;61. doi: 10.1055/s-0037-1617452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1617452</ArticleId><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts P.K., Vogl W.-D., Gerendas B.S., Glassman A.R., Bogunovic H., Jampol L.M., Schmidt-Erfurth U.M. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020;138:945&#x2013;953. doi: 10.1001/jamaophthalmol.2020.2457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2020.2457</ArticleId><ArticleId IdType="pmc">PMC7378869</ArticleId><ArticleId IdType="pubmed">32722799</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.-H., Liu T.Y.A., Hsu W.-T., Ho J.H.-C., Lee C.-C. Performance and Limitation of Machine Learning Algorithms for Diabetic Retinopathy Screening: Meta-analysis. J. Med. Internet Res. 2021;23:e23863. doi: 10.2196/23863.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/23863</ArticleId><ArticleId IdType="pmc">PMC8406115</ArticleId><ArticleId IdType="pubmed">34407500</ArticleId></ArticleIdList></Reference><Reference><Citation>Voets M., M&#xf8;llersen K., Bongo L.A. Reproduction study using public data of: Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. PLoS ONE. 2019;14:e0217541. doi: 10.1371/journal.pone.0217541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0217541</ArticleId><ArticleId IdType="pmc">PMC6553744</ArticleId><ArticleId IdType="pubmed">31170223</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Curated"><PMID Version="2">35653017</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study.</ArticleTitle><Pagination><StartPage>685</StartPage><EndPage>698</EndPage><MedlinePgn>685-698</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-022-01187-y</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Vaccine-induced thrombotic thrombocytopenia (VITT) has been identified as a rare but serious adverse event associated with coronavirus disease 2019 (COVID-19) vaccines.</AbstractText><AbstractText Label="OBJECTIVES">In this study, we explored the pre-pandemic co-occurrence of thrombosis with thrombocytopenia (TWT) using 17 observational health data sources across the world. We applied multiple TWT definitions, estimated the background rate of TWT, characterized TWT patients, and explored the makeup of thrombosis types among TWT patients.</AbstractText><AbstractText Label="METHODS">We conducted an international network retrospective cohort study using electronic health records and insurance claims data, estimating background rates of TWT amongst persons observed from 2017 to 2019. Following the principles of existing VITT clinical definitions, TWT was defined as patients with a diagnosis of embolic or thrombotic arterial or venous events and a diagnosis or measurement of thrombocytopenia within 7 days. Six TWT phenotypes were considered, which varied in the approach taken in defining thrombosis and thrombocytopenia in real world data.</AbstractText><AbstractText Label="RESULTS">Overall TWT incidence rates ranged from 1.62 to 150.65 per 100,000 person-years. Substantial heterogeneity exists across data sources and by age, sex, and alternative TWT phenotypes. TWT patients were likely to be men of older age with various comorbidities. Among the thrombosis types, arterial thrombotic events were the most common.</AbstractText><AbstractText Label="CONCLUSION">Our findings suggest that identifying VITT in observational data presents a substantial challenge, as implementing VITT case definitions based on the co-occurrence of TWT results in large and heterogeneous incidence rate and in a cohort of patints with baseline characteristics that are inconsistent with the VITT cases reported to date.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6976-2594</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA. ashoaibi@its.jnj.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA. ashoaibi@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Miguel Angel</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-Anguita</LastName><ForeName>Juan Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maljkovi&#x107;</LastName><ForeName>Filip</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Heliant Ltd, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carevi&#x107;</LastName><ForeName>Biljana</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Hospital Epidemiology, University Clinical Center of Serbia, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horban</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Health Informatics Centre (HIC), University of Dundee, Dundee, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Health Informatics Centre (HIC), University of Dundee, Dundee, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraboulet</LastName><ForeName>Clement</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Assistance Publique - H&#xf4;pitaux de Marseille, Marseille, Provence-Alpes-Cote d'Azur, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Carrour</LastName><ForeName>Tanguy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Easter-eggs, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denaxas</LastName><ForeName>Spiros</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University College London, Institute of Health Informatics, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papez</LastName><ForeName>Vaclav</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>University College London, Institute of Health Informatics, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Luis H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijneek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departmnet of Biomedical Data Sciences, Stanford University, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collage of pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makadia</LastName><ForeName>Rupa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Biomathematics and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_20051</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_20059</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K006584/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013921" MajorTopicYN="Y">Thrombocytopenia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>AS, GR, EAV, RM, AGS, CB, FD, and PBR are employees of Janssen Biotech Inc., a Janssen Pharmaceutical Company of Johnson &amp; Johnson and shareholder of Johnson &amp; Johnson, the product manufacturer of Janssen COVID-19 Vaccine. PRR is an employee of an institution that receives/received research grants from Janssen Research and Development LLC. DPA&#x2019;s research group has received research grants from the European Medicines Agency, from the Innovative Medicines Initiative, and from Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, and UCB Biopharma. AO has received funding from the US National Institutes of Health and the US Food and Drug Administration. MAS receives grants and contracts from the US Food and Drug Administration and the US Department of Veterans Affairs within the scope of this research, and grants and contracts from the US National Institutes of Health, IQVIA, and Private Health Management outside the scope of this research. MAM, JMRA, FM, BC, SH, DRM, TDS, CF, TC, SD, VP, LHJ, EM, and TMA have no conflicts of interest to declare that are directly relevant to the contents of this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>2</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35653017</ArticleId><ArticleId IdType="pmc">PMC9160850</ArticleId><ArticleId IdType="doi">10.1007/s40264-022-01187-y</ArticleId><ArticleId IdType="pii">10.1007/s40264-022-01187-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shimabukuro TT. Update: thrombosis with thrombocytopenia syndrome (tTS) following COVID-19 vaccination. 2021.</Citation></Reference><Reference><Citation>Bhuyan P, et al. Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis. Lancet. 2021;398(10300):577&#x2013;578. doi: 10.1016/S0140-6736(21)01693-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01693-7</ArticleId><ArticleId IdType="pmc">PMC9753120</ArticleId><ArticleId IdType="pubmed">34329583</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B, Bridwell R, Gottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. Am J Emerg Med. 2021;49:58&#x2013;61. doi: 10.1016/j.ajem.2021.05.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2021.05.054</ArticleId><ArticleId IdType="pmc">PMC8143907</ArticleId><ArticleId IdType="pubmed">34062319</ArticleId></ArticleIdList></Reference><Reference><Citation>Shay DK. Safety Monitoring of the Janssen (Johnson &amp; Johnson) COVID-19 Vaccine&#x2014;United States, March&#x2013;April 2021. MMWR. Morbidity and Mortality Weekly Report, 2021;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9368748</ArticleId><ArticleId IdType="pubmed">33956784</ArticleId></ArticleIdList></Reference><Reference><Citation>See I, et al. Case series of thrombosis with thrombocytopenia syndrome following COVID-19 vaccination&#x2014;United States, December 2020&#x2013;August 2021. medRxiv. 2021;384:2124.</Citation></Reference><Reference><Citation>Chen RT, Black S. Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS). 2021. https://brightoncollaboration.us/wp-content/uploads/2021/04/TTS-Case-Finding-and-Definition-Process.v1.0-1-1.pdf. Accessed 11 Apr 2022.</Citation></Reference><Reference><Citation>Chen RT, Black S. Updated Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS).</Citation></Reference><Reference><Citation>Overhage JM, et al. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI CDM Documentation. GitHub IO. https://github.com/OHDSI/CommonDataModel. Accessed 11 Apr 2022.</Citation></Reference><Reference><Citation>Vlug A, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med. 1999;38(04/05):339&#x2013;344. doi: 10.1055/s-0038-1634402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1634402</ArticleId><ArticleId IdType="pubmed">10805025</ArticleId></ArticleIdList></Reference><Reference><Citation>Biobank data. https://www.ukbiobank.ac.uk/. Accessed 11 Apr 2022.</Citation></Reference><Reference><Citation>JMCD data. https://www.jmdc.co.jp/en/jmdc&#x2010;claims&#x2010;database. Accessed 11 Apr 2022.</Citation></Reference><Reference><Citation>Burn E, et al. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 20.6 million people in six European countries. medRxiv. 2021;384:403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088543</ArticleId><ArticleId IdType="pubmed">35191114</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao G. CohortDiagnostics. 2020; https://ohdsi.github.io/CohortDiagnostics/. Accessed 11 Apr 2022.</Citation></Reference><Reference><Citation>Li X, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373:n1435. doi: 10.1136/bmj.n1435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro TT. Thrombosis with thrombocytopenia syndrome (TTS) following Janssen COVID-19 vaccine. 2021.</Citation></Reference><Reference><Citation>MacIntyre CR, et al. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination&#x2013;A risk&#x2013;benefit analysis for people&lt; 60 years in Australia. Vaccine. 2021;39(34):4784&#x2013;4787. doi: 10.1016/j.vaccine.2021.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.07.013</ArticleId><ArticleId IdType="pmc">PMC8270740</ArticleId><ArticleId IdType="pubmed">34272095</ArticleId></ArticleIdList></Reference><Reference><Citation>Potteg&#xe5;rd A, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114. doi: 10.1136/bmj.n1114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1114</ArticleId><ArticleId IdType="pmc">PMC8097496</ArticleId><ArticleId IdType="pubmed">33952445</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews NJ, et al. Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: a national cohort study in England. Lancet Regional Health-Europe. 2022;13:100260. doi: 10.1016/j.lanepe.2021.100260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100260</ArticleId><ArticleId IdType="pmc">PMC8668159</ArticleId><ArticleId IdType="pubmed">34927118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemminki K, et al. Surveillance bias in cancer risk after unrelated medical conditions: example urolithiasis. Sci Rep. 2017;7(1):1&#x2013;4. doi: 10.1038/s41598-017-08839-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-08839-5</ArticleId><ArticleId IdType="pmc">PMC5556042</ArticleId><ArticleId IdType="pubmed">28808281</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35672970</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>290</Volume><PubDate><Year>2022</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>A Multi-Omics Common Data Model for Primary Immunodeficiencies.</ArticleTitle><Pagination><StartPage>56</StartPage><EndPage>60</EndPage><MedlinePgn>56-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI220031</ELocationID><Abstract><AbstractText>Primary Immunodeficiencies (PIDs) are associated with more than 400 rare monogenic diseases affecting various biological functions (e.g., development, regulation of the immune response) with a heterogeneous clinical expression (from no symptom to severe manifestations). To better understand PIDs, the ATRACTion project aims to perform a multi-omics analysis of PIDs cases versus a control group patients, including single-cell transcriptomics, epigenetics, proteomics, metabolomics, metagenomics and lipidomics. In this study, our goal is to develop a common data model integrating clinical and omics data, which can be used to obtain standardized information necessary for characterization of PIDs patients and for further systematic analysis. For that purpose, we extend the OMOP Common Data Model (CDM) and propose a multi-omics ATRACTion OMOP-CDM to integrate multi-omics data. This model, available for the community, is customizable for other types of rare diseases (https://framagit.org/imagine-plateforme-bdd/pub-rhu4-atraction).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buy</LastName><ForeName>M&#xe9;lanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, Imagine Institute, Data Science Platform, INSERM UMR 1163, F-75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Digan</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, Imagine Institute, Data Science Platform, INSERM UMR 1163, F-75015, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de Recherche des Cordeliers, INSERM, Universit&#xe9; de Paris, Sorbonne Universit&#xe9;, F-75006, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaoyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Centre de Recherche des Cordeliers, INSERM, Universit&#xe9; de Paris, Sorbonne Universit&#xe9;, F-75006, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Husson</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, Imagine Institute, Data Science Platform, INSERM UMR 1163, F-75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe9;nager</LastName><ForeName>Mickael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, F-75015 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rieux-Laucat</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, Imagine Institute, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM UMR U1163, F-75015 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcelon</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, Imagine Institute, Data Science Platform, INSERM UMR 1163, F-75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ATRACTion Members</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="Y">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035583" MajorTopicYN="N">Rare Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cohort Studies</Keyword><Keyword MajorTopicYN="N">Databases</Keyword><Keyword MajorTopicYN="N">rare diseases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>8</Day><Hour>1</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35672970</ArticleId><ArticleId IdType="doi">10.3233/SHTI220031</ArticleId><ArticleId IdType="pii">SHTI220031</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35672974</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>290</Volume><PubDate><Year>2022</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Translating the Observational Medical Outcomes Partnership - Common Data Model (OMOP-CDM) Electronic Health Records to an OWL Ontology.</ArticleTitle><Pagination><StartPage>76</StartPage><EndPage>80</EndPage><MedlinePgn>76-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI220035</ELocationID><Abstract><AbstractText>The heterogeneity of electronic health records model is a major problem: it is necessary to gather data from various models for clinical research, but also for clinical decision support. The Observational Medical Outcomes Partnership - Common Data Model (OMOP-CDM) has emerged as a standard model for structuring health records populated from various other sources. This model is proposed as a relational database schema. However, in the field of decision support, formal ontologies are commonly used. In this paper, we propose a translation of OMOP-CDM into an ontology, and we explore the utility of the semantic web for structuring EHR in a clinical decision support perspective, and the use of the SPARQL language for querying health records. The resulting ontology is available online.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jean-Baptiste</LastName><ForeName>Lamy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Sorbonne Paris Nord, LIMICS, Sorbonne Universit&#xe9;, INSERM, UMR 1142, F-93000, Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouazer</LastName><ForeName>Abdelmalek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Sorbonne Paris Nord, LIMICS, Sorbonne Universit&#xe9;, INSERM, UMR 1142, F-93000, Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedki</LastName><ForeName>Karima</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Sorbonne Paris Nord, LIMICS, Sorbonne Universit&#xe9;, INSERM, UMR 1142, F-93000, Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsopra</LastName><ForeName>Rosy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>INSERM, Universit&#xe9; de Paris, Sorbonne Universit&#xe9;, Centre de Recherche des Cordeliers, Information Sciences to support Personalized Medicine, F-75006 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, H&#xf4;pital Europ&#xe9;en Georges-Pompidou, AP-HP, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INRIA Paris, 75012 Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biological Ontologies</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">Medical Records</Keyword><Keyword MajorTopicYN="N">SPARQL</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>8</Day><Hour>1</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35672974</ArticleId><ArticleId IdType="doi">10.3233/SHTI220035</ArticleId><ArticleId IdType="pii">SHTI220035</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35673206</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>290</Volume><PubDate><Year>2022</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>A Natural Language Processing Tool Offering Data Extraction for COVID-19 Related Information (DECOVRI).</ArticleTitle><Pagination><StartPage>1062</StartPage><EndPage>1063</EndPage><MedlinePgn>1062-1063</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI220268</ELocationID><Abstract><AbstractText>A new natural language processing (NLP) application for COVID-19 related information extraction from clinical text notes is being developed as part of our pandemic response efforts. This NLP application called DECOVRI (Data Extraction for COVID-19 Related Information) will be released as a free and open source tool to convert unstructured notes into structured data within an OMOP CDM-based ecosystem. The DECOVRI prototype is being continuously improved and will be released early (beta) and in a full version.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heider</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pipaliya</LastName><ForeName>Ronak M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>College of Medicine, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meystre</LastName><ForeName>St&#xe9;phane M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017753" MajorTopicYN="N">Ecosystem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="N">Information Storage and Retrieval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Machine Learning</Keyword><Keyword MajorTopicYN="N">Natural Language Processing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>8</Day><Hour>1</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35673206</ArticleId><ArticleId IdType="doi">10.3233/SHTI220268</ArticleId><ArticleId IdType="pii">SHTI220268</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35680274</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies.</ArticleTitle><Pagination><StartPage>e057977</StartPage><MedlinePgn>e057977</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e057977</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2021-057977</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Therapeutic options for type 2 diabetes mellitus (T2DM) have expanded over the last decade with the emergence of cardioprotective novel agents, but without such data for older drugs, leaving a critical gap in our understanding of the relative effects of T2DM agents on cardiovascular risk.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">The large-scale evidence generations across a network of databases for T2DM (LEGEND-T2DM) initiative is a series of systematic, large-scale, multinational, real-world comparative cardiovascular effectiveness and safety studies of all four major second-line anti-hyperglycaemic agents, including sodium-glucose co-transporter-2 inhibitor, glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas. LEGEND-T2DM will leverage the Observational Health Data Sciences and Informatics (OHDSI) community that provides access to a global network of administrative claims and electronic health record data sources, representing 190&#x2009;million patients in the USA and about 50&#x2009;million internationally. LEGEND-T2DM will identify all adult, patients with T2DM who newly initiate a traditionally second-line T2DM agent. Using an active comparator, new-user cohort design, LEGEND-T2DM will execute all pairwise class-versus-class and drug-versus-drug comparisons in each data source, producing extensive study diagnostics that assess reliability and generalisability through cohort balance and equipoise to examine the relative risk of cardiovascular and safety outcomes. The primary cardiovascular outcomes include a composite of major adverse cardiovascular events and a series of safety outcomes. The study will pursue data-driven, large-scale propensity adjustment for measured confounding, a large set of negative control outcome experiments to address unmeasured and systematic bias.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">The study ensures data safety through a federated analytic approach and follows research best practices, including prespecification and full disclosure of results. LEGEND-T2DM is dedicated to open science and transparency and will publicly share all analytic code from reproducible cohort definitions through turn-key software, enabling other research groups to leverage our methods, data and results to verify and extend our findings.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khera</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9467-6199</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0817-5361</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5264-2169</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0847-6682</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>RuiJun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Translational Data Science and Informatics, Geisinger, Danville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0003-2046-127X</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9818-479X</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, Los Angeles, California, USA msuchard@ucla.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomathematics, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Salt Lake City, Utan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 HL153775</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG006139</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013453">Sulfonylurea Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="Y">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013453" MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiology</Keyword><Keyword MajorTopicYN="N">DIABETES &amp; ENDOCRINOLOGY</Keyword><Keyword MajorTopicYN="N">Health informatics</Keyword></KeywordList><CoiStatement>Competing interests: This protocol is undertaken within Observational Health Data Sciences and Informatics (OHDSI), an open collaboration. RK is a founder of Evidence2Health, and receives grant funding from the US National Institutes of Health. MJS and PBR are employees of Janssen Research and Development and shareholders in John &amp; Johnson. GH receives grant funding from the US National Institutes of Health and the US Food &amp; Drug Administration and contracts from Janssen Research and Development. HMK receives grants from the US Food &amp; Drug Administration, Medtronics and Janssen Research and Development, is co-founder of HugoHealth and chairs the Cardiac Scientific Advisory Board for UnitedHealth. MAS receives grant funding from the US National Institutes of Health, the US Department of Veterans Affairs and the US Food &amp; Drug Administration and contracts from Janssen Research and Development and IQVIA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>21</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35680274</ArticleId><ArticleId IdType="pmc">PMC9185490</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2021-057977</ArticleId><ArticleId IdType="pii">bmjopen-2021-057977</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lo C, Toyama T, Wang Y. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane database of systematic reviews 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6513625</ArticleId><ArticleId IdType="pubmed">30246878</ArticleId></ArticleIdList></Reference><Reference><Citation>North EJ, Newman JD. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Curr Opin Cardiol 2019;34:687&#x2013;92. 10.1097/HCO.0000000000000673</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HCO.0000000000000673</ArticleId><ArticleId IdType="pmc">PMC6876849</ArticleId><ArticleId IdType="pubmed">31436559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B, Wanner C, Lachin JM, et al. . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117&#x2013;28. 10.1056/NEJMoa1504720</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504720</ArticleId><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Neal B, Perkovic V, Mahaffey KW, et al. . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644&#x2013;57. 10.1056/NEJMoa1611925</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1611925</ArticleId><ArticleId IdType="pubmed">28605608</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso SP, Daniels GH, Brown-Frandsen K, et al. . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311&#x2013;22. 10.1056/NEJMoa1603827</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1603827</ArticleId><ArticleId IdType="pmc">PMC4985288</ArticleId><ArticleId IdType="pubmed">27295427</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso SP, Bain SC, Consoli A, et al. . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834&#x2013;44. 10.1056/NEJMoa1607141</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1607141</ArticleId><ArticleId IdType="pubmed">27633186</ArticleId></ArticleIdList></Reference><Reference><Citation>Scirica BM, Bhatt DL, Braunwald E, et al. . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317&#x2013;26. 10.1056/NEJMoa1307684</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1307684</ArticleId><ArticleId IdType="pubmed">23992601</ArticleId></ArticleIdList></Reference><Reference><Citation>White WB, Cannon CP, Heller SR, et al. . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327&#x2013;35. 10.1056/NEJMoa1305889</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1305889</ArticleId><ArticleId IdType="pubmed">23992602</ArticleId></ArticleIdList></Reference><Reference><Citation>Green JB, Bethel MA, Armstrong PW, et al. . Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232&#x2013;42. 10.1056/NEJMoa1501352</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1501352</ArticleId><ArticleId IdType="pubmed">26052984</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Kahn SE, Johansen OE, et al. . Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the Carolina randomized clinical trial. JAMA 2019;322:1155&#x2013;66. 10.1001/jama.2019.13772</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.13772</ArticleId><ArticleId IdType="pmc">PMC6763993</ArticleId><ArticleId IdType="pubmed">31536101</ArticleId></ArticleIdList></Reference><Reference><Citation>Cefalu WT, Kaul S, Gerstein HC, et al. . Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2018;41:14&#x2013;31. 10.2337/dci17-0057</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dci17-0057</ArticleId><ArticleId IdType="pmc">PMC5741160</ArticleId><ArticleId IdType="pubmed">29263194</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer SC, Tendal B, Mustafa RA, et al. . Sodium-Glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573. 10.1136/bmj.m4573</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4573</ArticleId><ArticleId IdType="pmc">PMC7804890</ArticleId><ArticleId IdType="pubmed">33441402</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu M, Ding L-L, Wei X-B, et al. . Comparative efficacy of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis. J Cardiovasc Pharmacol 2021;77:34&#x2013;7. 10.1097/FJC.0000000000000916</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000000916</ArticleId><ArticleId IdType="pubmed">33136765</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T, Wakabayashi M, Bhalla A, et al. . Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol 2021;20:14. 10.1186/s12933-020-01197-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-01197-z</ArticleId><ArticleId IdType="pmc">PMC7792332</ArticleId><ArticleId IdType="pubmed">33413348</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhan MA, Sch&#xfc;nemann HJ, Murad MH, et al. . A grade Working group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. 10.1136/bmj.g5630</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g5630</ArticleId><ArticleId IdType="pubmed">25252733</ArticleId></ArticleIdList></Reference><Reference><Citation>Brignardello-Petersen R, Izcovich A, Rochwerg B, et al. . Grade approach to drawing conclusions from a network meta-analysis using a partially contextualised framework. BMJ 2020;371:m3907. 10.1136/bmj.m3907</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3907</ArticleId><ArticleId IdType="pubmed">33172877</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy RG, Dykhoff HJ, Sangaralingham L, et al. . Adoption of new glucose-lowering medications in the U.S.-The case of SGLT2 inhibitors: nationwide cohort study. Diabetes Technol Ther 2019;21:702&#x2013;12. 10.1089/dia.2019.0213</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dia.2019.0213</ArticleId><ArticleId IdType="pmc">PMC7207017</ArticleId><ArticleId IdType="pubmed">31418588</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis HJ, Dennis JM, Shields BM, et al. . Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab 2018;20:2159&#x2013;68. 10.1111/dom.13346</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13346</ArticleId><ArticleId IdType="pmc">PMC6099452</ArticleId><ArticleId IdType="pubmed">29732725</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SV, Inzucchi SE, Tang F, et al. . Real-World use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR&#xae; research to practice project. Eur J Prev Cardiol 2017;24:1637&#x2013;45. 10.1177/2047487317729252</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487317729252</ArticleId><ArticleId IdType="pubmed">28870145</ArticleId></ArticleIdList></Reference><Reference><Citation>Dave CV, Schneeweiss S, Wexler DJ, et al. . Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018. Diabetes Care 2020;43:921&#x2013;4. 10.2337/dc19-1943</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc19-1943</ArticleId><ArticleId IdType="pmc">PMC7519473</ArticleId><ArticleId IdType="pubmed">32041899</ArticleId></ArticleIdList></Reference><Reference><Citation>Le P, Chaitoff A, Misra-Hebert AD. Use of antihyperglycemic medications in US. Adults: An analysis of the national health and nutrition examination survey.. Diabetes care 2020;43:1227&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">32234720</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. . Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:1816&#x2013;26. 10.1016/S0140-6736(19)32317-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 2015;11:437&#x2013;41. 10.1038/nrrheum.2015.30</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.30</ArticleId><ArticleId IdType="pmc">PMC4486631</ArticleId><ArticleId IdType="pubmed">25800216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, et al. . Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf 2013;36 Suppl 1:S59&#x2013;72. 10.1007/s40264-013-0099-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0099-6</ArticleId><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Cepeda MS, Suchard MA, et al. . How Confident are we about observational findings in healthcare: a benchmark study. Harv Data Sci Rev 2020;2. 10.1162/99608f92.147cc28e. [Epub ahead of print: 31 01 2020].</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/99608f92.147cc28e</ArticleId><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010;19:858&#x2013;68. 10.1002/pds.1926</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1926</ArticleId><ArticleId IdType="pmc">PMC2917262</ArticleId><ArticleId IdType="pubmed">20681003</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne JJ, Fireman B, Ryan PB, et al. . Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:32&#x2013;40. 10.1002/pds.2316</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2316</ArticleId><ArticleId IdType="pubmed">22262591</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ES, Bartman BA, Briesacher BA, et al. . The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 2013;22:1&#x2013;6. 10.1002/pds.3334</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3334</ArticleId><ArticleId IdType="pubmed">23023988</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Patrick AR, St&#xfc;rmer T, et al. . Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007;45:S131&#x2013;42. 10.1097/MLR.0b013e318070c08e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e318070c08e</ArticleId><ArticleId IdType="pmc">PMC2905666</ArticleId><ArticleId IdType="pubmed">17909372</ArticleId></ArticleIdList></Reference><Reference><Citation>Suissa S, Moodie EEM, Dell'Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf 2017;26:459&#x2013;68. 10.1002/pds.4107</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4107</ArticleId><ArticleId IdType="pubmed">27610604</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol 2018;47:2005&#x2013;14. 10.1093/ije/dyy120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, et al. . Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med 2014;33:209&#x2013;18. 10.1002/sim.5925</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, et al. . Robust empirical calibration of p-values using observational data. Stat Med 2016;35:3883&#x2013;8. 10.1002/sim.6977</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6977</ArticleId><ArticleId IdType="pmc">PMC5108459</ArticleId><ArticleId IdType="pubmed">27592566</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, et al. . Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci U S A 2018;115:2571&#x2013;7. 10.1073/pnas.1708282114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, et al. . Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci 2018;376. 10.1098/rsta.2017.0356. [Epub ahead of print: 13 Sep 2018].</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. . Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411&#x2013;8. 10.1001/jama.2010.920</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.920</ArticleId><ArticleId IdType="pubmed">20584880</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner RM, Kwok CS, Chen-Turner C, et al. . Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2014;78:258&#x2013;73. 10.1111/bcp.12306</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12306</ArticleId><ArticleId IdType="pmc">PMC4137819</ArticleId><ArticleId IdType="pubmed">24325197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 2016;183:758&#x2013;64. 10.1093/aje/kwv254</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwv254</ArticleId><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n M. Antihyperglycemic therapy and cardiovascular risk: design and emulation of a target trial using healthcare databases. Patient-Centered Outcomes Research Institute, 2019.</Citation></Reference><Reference><Citation>American Diabetes Association . 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018;41:S73&#x2013;85. 10.2337/dc18-S008</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc18-S008</ArticleId><ArticleId IdType="pubmed">29222379</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan DM, Buse JB, Kahn SE, et al. . Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (grade). Diabetes Care 2013;36:2254&#x2013;61. 10.2337/dc13-0356</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-0356</ArticleId><ArticleId IdType="pmc">PMC3714493</ArticleId><ArticleId IdType="pubmed">23690531</ArticleId></ArticleIdList></Reference><Reference><Citation>. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43:S98&#x2013;110. 10.2337/dc20-S009</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-S009</ArticleId><ArticleId IdType="pubmed">31862752</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N. Large-Scale evidence generation and evaluation across a network of databases (legend): assessing validity using hypertension as a case study. J Am Med Inform Assoc : JAMIA:ocaa124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481033</ArticleId><ArticleId IdType="pubmed">32827027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Buse JB, Schuemie MJ, et al. . Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 2018;20:2585&#x2013;97. 10.1111/dom.13424</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13424</ArticleId><ArticleId IdType="pmc">PMC6220807</ArticleId><ArticleId IdType="pubmed">29938883</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, Rho Y, Bikdeli B. Association of ticagrelor versus clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention in clinical practice. J Am Med Assoc. In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592033</ArticleId><ArticleId IdType="pubmed">33107944</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Desai M, Ryan PB. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. Diabetes Res Clin Pract 2017;128:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">28448895</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein RB, Ryan PB, Berlin JA, et al. . Channeling bias in the analysis of risk of myocardial infarction, stroke, gastrointestinal bleeding, and acute renal failure with the use of paracetamol compared with ibuprofen. Drug Saf 2020;43:927&#x2013;42. 10.1007/s40264-020-00950-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-00950-3</ArticleId><ArticleId IdType="pmc">PMC7434801</ArticleId><ArticleId IdType="pubmed">32500272</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z, DeFalco FJ, Ryan PB, et al. . Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study. Diabetes Obes Metab 2018;20:582&#x2013;9. 10.1111/dom.13115</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13115</ArticleId><ArticleId IdType="pmc">PMC5836890</ArticleId><ArticleId IdType="pubmed">28898514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammann EM, Schweizer ML, Robinson JG. Chart validation of inpatient ICD-9-CM administrative diagnosis codes for acute myocardial infarction (AMI) among intravenous immune globulin (IGIV) users in the sentinel distributed database. Pharmacoepidemiol Drug Saf 2018;27:398&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410350</ArticleId><ArticleId IdType="pubmed">29446185</ArticleId></ArticleIdList></Reference><Reference><Citation>Floyd JS, Blondon M, Moore KP. Validation of methods for assessing cardiovascular disease using electronic health data in a cohort of veterans with diabetes. Pharmacoepidemiol Drug Saf 2016;25:467&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826840</ArticleId><ArticleId IdType="pubmed">26555025</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubbo B, Fitzpatrick NK, Denaxas S. Use of electronic health records to ascertain, validate and phenotype acute myocardial infarction: a systematic review and recommendations. Int J Cardiol 2015;187:705&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">25966015</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Fouayzi H, Anzuoni K. Diagnostic algorithms for cardiovascular death in administrative claims databases: a systematic review. Drug Saf 2018;23:018&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">30471046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl PM, Rodgers K, Schneeweiss S, et al. . Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 2010;19:596&#x2013;603. 10.1002/pds.1924</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1924</ArticleId><ArticleId IdType="pubmed">20140892</ArticleId></ArticleIdList></Reference><Reference><Citation>Normand SL, Morris CN, Fung KS, et al. . Development and validation of a claims based index for adjusting for risk of mortality: the case of acute myocardial infarction. J Clin Epidemiol 1995;48:229&#x2013;43. 10.1016/0895-4356(94)00126-b</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(94)00126-b</ArticleId><ArticleId IdType="pubmed">7869069</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade SE, Harrold LR, Tjia J, et al. . A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:100&#x2013;28. 10.1002/pds.2312</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2312</ArticleId><ArticleId IdType="pmc">PMC3412674</ArticleId><ArticleId IdType="pubmed">22262598</ArticleId></ArticleIdList></Reference><Reference><Citation>Park TH, Choi JC. Validation of stroke and thrombolytic therapy in Korean National health insurance claim data. J Clin Neurol 2016;12:42&#x2013;8. 10.3988/jcn.2016.12.1.42</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2016.12.1.42</ArticleId><ArticleId IdType="pmc">PMC4712285</ArticleId><ArticleId IdType="pubmed">26365022</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon Y, Kabata D, Yamamoto K, et al. . Validation of an algorithm that determines stroke diagnostic code accuracy in a Japanese hospital-based cancer registry using electronic medical records. BMC Med Inform Decis Mak 2017;17:157. 10.1186/s12911-017-0554-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-017-0554-x</ArticleId><ArticleId IdType="pmc">PMC5715513</ArticleId><ArticleId IdType="pubmed">29202795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung S-F, Hsieh C-Y, Lin H-J, et al. . Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. Int J Cardiol 2016;215:277&#x2013;82. 10.1016/j.ijcard.2016.04.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2016.04.069</ArticleId><ArticleId IdType="pubmed">27128546</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu K, Wang M, Young J, et al. . Validity of administrative data for identifying patients who have had a stroke or transient ischemic attack using EMRALD as a reference standard. Can J Cardiol 2013;29:1388&#x2013;94. 10.1016/j.cjca.2013.07.676</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2013.07.676</ArticleId><ArticleId IdType="pubmed">24075778</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z, Voss EA, DeFalco FJ, et al. . Risk prediction for ischemic stroke and transient ischemic attack in patients without atrial fibrillation: a retrospective cohort study. J Stroke Cerebrovasc Dis 2017;26:1721&#x2013;31. 10.1016/j.jstrokecerebrovasdis.2017.03.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2017.03.036</ArticleId><ArticleId IdType="pubmed">28392100</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy S, Leonard CE, Freeman CP, et al. . Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf 2010;19:555&#x2013;62. 10.1002/pds.1869</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1869</ArticleId><ArticleId IdType="pmc">PMC2924585</ArticleId><ArticleId IdType="pubmed">19844945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar M, Fette G, G&#xfc;der G, et al. . Underestimated prevalence of heart failure in hospital inpatients: a comparison of ICD codes and discharge letter information. Clin Res Cardiol 2018;107:778&#x2013;87. Epub 2018 Apr 17. 10.1007/s00392-018-1245-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-018-1245-z</ArticleId><ArticleId IdType="pmc">PMC6105250</ArticleId><ArticleId IdType="pubmed">29667017</ArticleId></ArticleIdList></Reference><Reference><Citation>Feder SL, Redeker NS, Jeon S, et al. . Validation of the ICD-9 diagnostic code for palliative care in patients hospitalized with heart failure within the Veterans health administration. Am J Hosp Palliat Care 2018;35:959&#x2013;65. 10.1177/1049909117747519</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1049909117747519</ArticleId><ArticleId IdType="pmc">PMC7491538</ArticleId><ArticleId IdType="pubmed">29254358</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenman M, He J, Martin J, et al. . Database queries for hospitalizations for acute congestive heart failure: flexible methods and validation based on set theory. J Am Med Inform Assoc 2014;21:345&#x2013;52. Epub 2013 Oct 10. 10.1136/amiajnl-2013-001942</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-001942</ArticleId><ArticleId IdType="pmc">PMC3932461</ArticleId><ArticleId IdType="pubmed">24113802</ArticleId></ArticleIdList></Reference><Reference><Citation>Voors AA, Ouwerkerk W, Zannad F, et al. . Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail 2017;19:627&#x2013;34. 10.1002/ejhf.785</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.785</ArticleId><ArticleId IdType="pubmed">28247565</ArticleId></ArticleIdList></Reference><Reference><Citation>Floyd JS, Wellman R, Fuller S, et al. . Use of electronic health data to estimate heart failure events in a population-based cohort with CKD. Clin J Am Soc Nephrol 2016;11:1954&#x2013;61. 10.2215/CJN.03900416</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.03900416</ArticleId><ArticleId IdType="pmc">PMC5108195</ArticleId><ArticleId IdType="pubmed">27507770</ArticleId></ArticleIdList></Reference><Reference><Citation>Gini R, Schuemie MJ, Mazzaglia G. Automatic identification of type 2 diabetes, hypertension, ischaemic heart disease, heart failure and their levels of severity from italian general practitioners&#x2019; electronic medical records: A validation study. BMJ Open 2016;6:e012413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5168667</ArticleId><ArticleId IdType="pubmed">27940627</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal Z, Schuemie MJ, van Blijderveen JC, van BJC, et al. . Improving sensitivity of machine learning methods for automated case identification from free-text electronic medical records. BMC Med Inform Decis Mak 2013;13:30. 10.1186/1472-6947-13-30</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-13-30</ArticleId><ArticleId IdType="pmc">PMC3602667</ArticleId><ArticleId IdType="pubmed">23452306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenihan CR, Montez-Rath ME, Mora Mangano CT, et al. . Trends in acute kidney injury, associated use of dialysis, and mortality after cardiac surgery, 1999 to 2008. Ann Thorac Surg 2013;95:20&#x2013;8. 10.1016/j.athoracsur.2012.05.131</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2012.05.131</ArticleId><ArticleId IdType="pmc">PMC4115367</ArticleId><ArticleId IdType="pubmed">23272825</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelmayer WC, Schneeweiss S, Mogun H, et al. . Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis 2005;46:225&#x2013;32. 10.1053/j.ajkd.2005.04.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2005.04.029</ArticleId><ArticleId IdType="pubmed">16112040</ArticleId></ArticleIdList></Reference><Reference><Citation>Grams ME, Waikar SS, MacMahon B, et al. . Performance and limitations of administrative data in the identification of AKI. Clin J Am Soc Nephrol 2014;9:682&#x2013;9. 10.2215/CJN.07650713</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.07650713</ArticleId><ArticleId IdType="pmc">PMC3974361</ArticleId><ArticleId IdType="pubmed">24458075</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold J, Ng KP, Sims D, et al. . Incidence and impact on outcomes of acute kidney injury after a stroke: a systematic review and meta-analysis. BMC Nephrol 2018;19:283. 10.1186/s12882&#x2013;018&#x2013;1085&#x2013;0. 10.1186/s12882-018-1085-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-018-1085-0</ArticleId><ArticleId IdType="pmc">PMC6196566</ArticleId><ArticleId IdType="pubmed">30348107</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland SM, Byrnes JJ, Kothari M, et al. . Aki in hospitalized children: comparing the pRIFLE, akin, and KDIGO definitions. Clin J Am Soc Nephrol 2015;10:554&#x2013;61. 10.2215/CJN.01900214</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.01900214</ArticleId><ArticleId IdType="pmc">PMC4386245</ArticleId><ArticleId IdType="pubmed">25649155</ArticleId></ArticleIdList></Reference><Reference><Citation>Waikar SS, Wald R, Chertow GM, et al. . Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol 2006;17:1688&#x2013;94. 10.1681/ASN.2006010073</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2006010073</ArticleId><ArticleId IdType="pubmed">16641149</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee C, Murphy MV, Li L, et al. . Improving documentation and coding for acute organ dysfunction biases estimates of changing sepsis severity and burden: a retrospective study. Crit Care 2015;19:338. 10.1186/s13054-015-1048-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-1048-9</ArticleId><ArticleId IdType="pmc">PMC4570698</ArticleId><ArticleId IdType="pubmed">26369326</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, et al. . Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the observational health data sciences and informatics initiative. JAMA Netw Open 2018;1:e181755&#x2013;5. 10.1001/jamanetworkopen.2018.1755</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2018.1755</ArticleId><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Broder MS, Chang E, Cherepanov D, et al. . Identification of potential markers for Cushing disease. Endocr Pract 2016;22:567&#x2013;74. 10.4158/EP15914.OR</Citation><ArticleIdList><ArticleId IdType="doi">10.4158/EP15914.OR</ArticleId><ArticleId IdType="pubmed">26789346</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams BA. The clinical epidemiology of fatigue in newly diagnosed heart failure BMC Cardiovasc Disord 2017;1710.1186/s12872-017-0555-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-017-0555-9</ArticleId><ArticleId IdType="pmc">PMC5426047</ArticleId><ArticleId IdType="pubmed">28490326</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabe D, Kuwata H, Kaneko M, et al. . Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes Obes Metab 2015;17:430&#x2013;4. 10.1111/dom.12381</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12381</ArticleId><ArticleId IdType="pmc">PMC4409841</ArticleId><ArticleId IdType="pubmed">25146418</ArticleId></ArticleIdList></Reference><Reference><Citation>Dore DD, Hussein M, Hoffman C, et al. . A pooled analysis of exenatide use and risk of acute pancreatitis. Curr Med Res Opin 2013;29:1577&#x2013;86. 10.1185/03007995.2013.838550</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/03007995.2013.838550</ArticleId><ArticleId IdType="pubmed">23981106</ArticleId></ArticleIdList></Reference><Reference><Citation>Dore DD, Chaudhry S, Hoffman C, et al. . Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus. Pharmacoepidemiol Drug Saf 2011;20:209&#x2013;13. 10.1002/pds.2077</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2077</ArticleId><ArticleId IdType="pubmed">21254293</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H-J, Wang J-J, Tsay W-I, et al. . Epidemiology and outcome of acute pancreatitis in end-stage renal disease dialysis patients: a 10-year national cohort study. Nephrol Dial Transplant 2017;32:1731&#x2013;6. 10.1093/ndt/gfw400</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfw400</ArticleId><ArticleId IdType="pubmed">28088773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooba N, Setoguchi S, Ando T. Claims-based definition of death in Japanese claims database: validity and implications. PLoS One 2013;8:e66116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3669209</ArticleId><ArticleId IdType="pubmed">23741526</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson TE, Elley CR, Kenealy T, et al. . Development and validation of a predictive risk model for all-cause mortality in type 2 diabetes. Diabetes Res Clin Pract 2015;108:482&#x2013;8. 10.1016/j.diabres.2015.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2015.02.015</ArticleId><ArticleId IdType="pubmed">25869581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Voss EA, Weaver J, et al. . Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: an observational study of four us administrative claims databases. Pharmacoepidemiol Drug Saf 2019;28:1620&#x2013;8. 10.1002/pds.4887</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4887</ArticleId><ArticleId IdType="pmc">PMC6916409</ArticleId><ArticleId IdType="pubmed">31456304</ArticleId></ArticleIdList></Reference><Reference><Citation>Buono JL, Mathur K, Averitt AJ, et al. . Economic burden of irritable bowel syndrome with diarrhea: retrospective analysis of a U.S. commercially insured population. J Manag Care Spec Pharm 2017;23:453&#x2013;60. 10.18553/jmcp.2016.16138</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2016.16138</ArticleId><ArticleId IdType="pubmed">28345443</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnarajah G, Duh MS, Korves C, et al. . Public health impact of complete and incomplete rotavirus vaccination among commercially and Medicaid insured children in the United States. PLoS One 2016;11:e0145977. eCollection 2016. 10.1371/journal.pone.0145977</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0145977</ArticleId><ArticleId IdType="pmc">PMC4709043</ArticleId><ArticleId IdType="pubmed">26751375</ArticleId></ArticleIdList></Reference><Reference><Citation>Panozzo CA, Becker-Dreps S, Pate V, et al. . Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007-2010. Am J Epidemiol 2014;179:895&#x2013;909. 10.1093/aje/kwu001</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwu001</ArticleId><ArticleId IdType="pmc">PMC3969536</ArticleId><ArticleId IdType="pubmed">24578359</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols GA, Brodovicz KG, Kimes TM, et al. . Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. J Diabetes Complications 2017;31:1587&#x2013;91. 10.1016/j.jdiacomp.2017.07.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2017.07.018</ArticleId><ArticleId IdType="pubmed">28888425</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas S, Ihle P, Harder S, et al. . Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort. Pharmacoepidemiol Drug Saf 2015;24:406&#x2013;13. 10.1002/pds.3748</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3748</ArticleId><ArticleId IdType="pubmed">25683504</ArticleId></ArticleIdList></Reference><Reference><Citation>Betts KA, Woolley JM, Mu F, et al. . The prevalence of hyperkalemia in the United States. Curr Med Res Opin 2018;34:971&#x2013;8. 10.1080/03007995.2018.1433141</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2018.1433141</ArticleId><ArticleId IdType="pubmed">29368958</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitch K, Woolley JM, Engel T, et al. . The clinical and economic burden of hyperkalemia on Medicare and commercial payers. Am Health Drug Benefits 2017;10:202&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536196</ArticleId><ArticleId IdType="pubmed">28794824</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard CE, Han X, Brensinger CM, et al. . Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2018;27:9&#x2013;18. 10.1002/pds.4337</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4337</ArticleId><ArticleId IdType="pmc">PMC5770147</ArticleId><ArticleId IdType="pubmed">29108130</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrischilles E, Rubenstein L, Chao J, et al. . Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. Clin Ther 2001;23:727&#x2013;43. 10.1016/s0149-2918(01)80022-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0149-2918(01)80022-9</ArticleId><ArticleId IdType="pubmed">11394731</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein JL, Zhao SZ, Burke TA. Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States. Am J Gastroenterol;2003:2627&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687808</ArticleId></ArticleIdList></Reference><Reference><Citation>Donga PZ, Bilir SP, Little G, et al. . Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura. J Med Econ 2017;20:1200&#x2013;6. 10.1080/13696998.2017.1370425</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2017.1370425</ArticleId><ArticleId IdType="pubmed">28882075</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrett E, Kwong WJ, Frech F, et al. . Health care utilization and costs associated with nausea and vomiting in patients receiving oral immediate-release opioids for outpatient acute pain management. Pain Ther 2016;5:215&#x2013;26. Epub 2016 Oct 4. 10.1007/s40122-016-0057-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40122-016-0057-y</ArticleId><ArticleId IdType="pmc">PMC5130907</ArticleId><ArticleId IdType="pubmed">27704485</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:154&#x2013;62. 10.1002/pds.2341</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2341</ArticleId><ArticleId IdType="pubmed">22262602</ArticleId></ArticleIdList></Reference><Reference><Citation>Burwen DR, Wu C, Cirillo D, et al. . Venous thromboembolism incidence, recurrence, and mortality based on women's health Initiative data and Medicare claims. Thromb Res 2017;150:78&#x2013;85. 10.1016/j.thromres.2016.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2016.11.015</ArticleId><ArticleId IdType="pubmed">28063368</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman CI, Peacock WF, Fermann GJ, et al. . External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications. BMC Health Serv Res 2016;16:610. 10.1186/s12913-016-1855-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-016-1855-y</ArticleId><ArticleId IdType="pmc">PMC5075157</ArticleId><ArticleId IdType="pubmed">27770814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammann EM, Cuker A, Carnahan RM, et al. . Chart validation of inpatient International classification of diseases, ninth revision, clinical modification (ICD-9-CM) administrative diagnosis codes for venous thromboembolism (VTe) among intravenous immune globulin (IGIV) users in the sentinel distributed database. Medicine 2018;97:e9960. 10.1097/MD.0000000000009960</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000009960</ArticleId><ArticleId IdType="pmc">PMC5841980</ArticleId><ArticleId IdType="pubmed">29465588</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41&#x2013;55. 10.1093/biomet/70.1.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/70.1.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Rassen JA, Glynn RJ, et al. . High-Dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512&#x2013;22. 10.1097/EDE.0b013e3181a663cc</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181a663cc</ArticleId><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Hern&#xe1;ndez-D&#xed;az S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 2012;9:48&#x2013;55. 10.1177/1740774511420743</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774511420743</ArticleId><ArticleId IdType="pmc">PMC3731071</ArticleId><ArticleId IdType="pubmed">21948059</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray EJ, Caniglia EC, Swanson SA, et al. . Patients and Investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials. J Clin Epidemiol 2018;103:10&#x2013;21. 10.1016/j.jclinepi.2018.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2018.06.009</ArticleId><ArticleId IdType="pmc">PMC6175611</ArticleId><ArticleId IdType="pubmed">29966732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Per-Protocol analyses of pragmatic trials. N Engl J Med 2017;377:1391&#x2013;8. 10.1056/NEJMsm1605385</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsm1605385</ArticleId><ArticleId IdType="pubmed">28976864</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986;7:177&#x2013;88. 10.1016/0197-2456(86)90046-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronsbell J, Hong C, Nie L, et al. . Exact inference for the random-effect model for meta-analyses with rare events. Stat Med 2020;39:252&#x2013;64. 10.1002/sim.8396</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8396</ArticleId><ArticleId IdType="pmc">PMC7704100</ArticleId><ArticleId IdType="pubmed">31820458</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 2009;172:137&#x2013;59. 10.1111/j.1467-985X.2008.00552.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-985X.2008.00552.x</ArticleId><ArticleId IdType="pmc">PMC2667312</ArticleId><ArticleId IdType="pubmed">19381330</ArticleId></ArticleIdList></Reference><Reference><Citation>et alSchuemie MJ, Chen Y, Madigan D. Combining COX regressions across a heterogeneous distributed research network facing small and zero counts, 2021. Available: http://arxiv.org/abs/2101.01551</Citation><ArticleIdList><ArticleId IdType="pubmed">34841975</ArticleId></ArticleIdList></Reference><Reference><Citation>Varin C, Reid N, Firth D. An overview of composite likelihood methods. Stat Sin 2011.</Citation></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, et al. . Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform 2017;66:72&#x2013;81. 10.1016/j.jbi.2016.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.12.005</ArticleId><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukes O, Martinussen T, Tchetgen Tchetgen EJ, et al. . On doubly robust estimation of the hazard difference. Biometrics 2019;75:100&#x2013;9. 10.1111/biom.12943</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/biom.12943</ArticleId><ArticleId IdType="pmc">PMC7735191</ArticleId><ArticleId IdType="pubmed">30133696</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk MJ, Westreich D, Wiesen C, et al. . Doubly robust estimation of causal effects. Am J Epidemiol 2011;173:761&#x2013;7. 10.1093/aje/kwq439</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwq439</ArticleId><ArticleId IdType="pmc">PMC3070495</ArticleId><ArticleId IdType="pubmed">21385832</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinussen T, Vansteelandt S, Gerster M, et al. . Estimation of direct effects for survival data by using the Aalen additive hazards model. J R Stat Soc Series B Stat Methodol 2011;73:773&#x2013;88. 10.1111/j.1467-9868.2011.00782.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-9868.2011.00782.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalen OO. A linear regression model for the analysis of life times. Stat Med 1989;8:907&#x2013;25. 10.1002/sim.4780080803</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4780080803</ArticleId><ArticleId IdType="pubmed">2678347</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Lee M, Liu P, et al. . Doubly robust additive hazards models to estimate effects of a continuous exposure on survival. Epidemiology 2017;28:771&#x2013;9. 10.1097/EDE.0000000000000742</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000742</ArticleId><ArticleId IdType="pmc">PMC5737934</ArticleId><ArticleId IdType="pubmed">28832358</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083&#x2013;107. 10.1002/sim.3697</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3697</ArticleId><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N. Large-Scale evidence generation and evaluation across a network of databases (legend): principles and methods. J Am Med Inform Assoc:ocaa103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 2010;21:383&#x2013;8. 10.1097/EDE.0b013e3181d61eeb</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181d61eeb</ArticleId><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Suchard MA, Shea S, et al. . Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020;180:542. 10.1001/jamainternmed.2019.7454</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.7454</ArticleId><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="pubmed">32065600</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Man KKC, et al. . A plea to stop using the case-control design in retrospective database studies. Stat Med 2019;38:4199&#x2013;208. 10.1002/sim.8215</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8215</ArticleId><ArticleId IdType="pmc">PMC6771795</ArticleId><ArticleId IdType="pubmed">31436848</ArticleId></ArticleIdList></Reference><Reference><Citation>Woelfle M, Olliaro P, Todd MH. Open science is a research accelerator. Nat Chem 2011;3:745&#x2013;8. 10.1038/nchem.1149</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchem.1149</ArticleId><ArticleId IdType="pubmed">21941234</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35685531</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1742-1241</ISSN><JournalIssue CitedMedium="Internet"><Volume>2022</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>International journal of clinical practice</Title><ISOAbbreviation>Int J Clin Pract</ISOAbbreviation></Journal><ArticleTitle>Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States.</ArticleTitle><Pagination><StartPage>6707985</StartPage><MedlinePgn>6707985</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6707985</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/6707985</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Data directly comparing trends in the use of different oral anticoagulants (OACs) among patients with atrial fibrillation (AF) from different countries are limited. We addressed this using a large-scale network cohort study in the United States (US), Belgium, France, Germany, and the United Kingdom (UK).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We used nine databases (claims or electronic health records) that had been converted into the Observational Medical Outcomes Partnership Common Data Model with analysis performed using open-source analytical tools. We identified adults with AF and a first OAC prescription, either vitamin K antagonist (VKA) or direct oral anticoagulant (DOAC), from 2010 to 2017. We described time trends in use, continuation, and switching.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In 2010, 87.5%-99.8% of patients started on a VKA. By 2017, the majority started on a DOAC: 87.0% (US), 88.3% (Belgium), 93.1% (France), 88.4% (Germany), and 86.1%-86.7% (UK). In the UK, DOACs became the most common starting OAC in 2015, 2-3 years later than elsewhere. Apixaban was the most common starting OAC by 2017, 50.2%-57.8% (US), 31.4% (Belgium), 45.9% (France), 39.5% (Germany), and 49.8%-50.5% (UK), followed by rivaroxaban, 24.8%-32.5% (US), 25.7% (Belgium), 38.4% (France), 24.9% (Germany), and 30.2%-31.2% (UK). Long-term treatment was less common in the US than in Europe, especially the UK. A minority of patients switched from their index OAC in the short and long term.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">From 2010 to 2017, VKA use had significantly declined and DOAC use had significantly increased in the US and Europe. Apixaban was the most prescribed OAC in 2017, followed by rivaroxaban.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Pareen Vora et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vora</LastName><ForeName>Pareen</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5822-2453</Identifier><AffiliationInfo><Affiliation>Epidemiology, Bayer AG, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan Stewart</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>IQVIA, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Beth</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5640-8425</Identifier><AffiliationInfo><Affiliation>Epidemiology, Bayer AG, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asiimwe</LastName><ForeName>Alex</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7633-0220</Identifier><AffiliationInfo><Affiliation>Epidemiology, Bayer AG, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brobert</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-7446-9851</Identifier><AffiliationInfo><Affiliation>Epidemiology, Bayer AB, Solna, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Int J Clin Pract</MedlineTA><NlmUniqueID>9712381</NlmUniqueID><ISSNLinking>1368-5031</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NDF7JZ4M3</RegistryNumber><NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance></Chemical><Chemical><RegistryNumber>I0VM4M70GC</RegistryNumber><NameOfSubstance UI="D000069604">Dabigatran</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069604" MajorTopicYN="N">Dabigatran</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>PV and AA are employees of Bayer AG (Germany). GB was an employee of Bayer AB (Sweden) at the time the study was carried out and is currently a paid consultant for Bayer AB (Sweden). HMS was an employee of IQVIA at the time the study was carried out, who received funding from Bayer to perform the data analysis. BR received consultancy fees for her work as an Intern at Bayer at the time the study was carried out. The authors declare that they have no other conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>2</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35685531</ArticleId><ArticleId IdType="pmc">PMC9159118</ArticleId><ArticleId IdType="doi">10.1155/2022/6707985</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Connolly S. J., Ezekowitz M. D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine . 2009;361(12):1139&#x2013;1151. doi: 10.1056/nejmoa0905561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa0905561</ArticleId><ArticleId IdType="pubmed">19717844</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger C. B., Alexander J. H., McMurray J. J. V., et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine . 2011;365(11):981&#x2013;992. doi: 10.1056/nejmoa1107039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1107039</ArticleId><ArticleId IdType="pubmed">21870978</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M. R., Mahaffey K. W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine . 2011;365(10):883&#x2013;891. doi: 10.1056/nejmoa1009638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1009638</ArticleId><ArticleId IdType="pubmed">21830957</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano R. P., Ruff C. T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine . 2013;369(22):2093&#x2013;2104. doi: 10.1056/nejmoa1310907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1310907</ArticleId><ArticleId IdType="pubmed">24251359</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo S. Y., Dell&#x2019;Aniello S., Huiart L., Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. British Journal of Clinical Pharmacology . 2017;83(9):2096&#x2013;2106. doi: 10.1111/bcp.13299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13299</ArticleId><ArticleId IdType="pmc">PMC5555878</ArticleId><ArticleId IdType="pubmed">28390065</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinogradova Y., Coupland C., Hill T., Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ . 2018;362 doi: 10.1136/bmj.k2505.k2505</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k2505</ArticleId><ArticleId IdType="pmc">PMC6031213</ArticleId><ArticleId IdType="pubmed">29973392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjerpeseth L. J., Ellekj&#xe6;r H., Selmer R., Ariansen I., Furu K., Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. European Journal of Clinical Pharmacology . 2017;73(11):1417&#x2013;1425. doi: 10.1007/s00228-017-2296-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-017-2296-1</ArticleId><ArticleId IdType="pubmed">28735494</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Alexander G. C., Nazarian S., Segal J. B., Wu A. W. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010&#x2013;2017. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy . 2018;38(9):907&#x2013;920. doi: 10.1002/phar.2158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.2158</ArticleId><ArticleId IdType="pmc">PMC6448138</ArticleId><ArticleId IdType="pubmed">29920705</ArticleId></ArticleIdList></Reference><Reference><Citation>Alalwan A. A., Voils S. A., Hartzema A. G. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. American Journal of Health-System Pharmacy . 2017;74(16):1237&#x2013;1244. doi: 10.2146/ajhp160756.</Citation><ArticleIdList><ArticleId IdType="doi">10.2146/ajhp160756</ArticleId><ArticleId IdType="pubmed">28652320</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadsb&#xf8;ll K., Staerk L., Fosb&#xf8;l E. L., et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. European Heart Journal . 2017;38(12):899&#x2013;906. doi: 10.1093/eurheartj/ehw658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw658</ArticleId><ArticleId IdType="pubmed">28110293</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu A. Y. X., Malo S., Svenson L. W., Wilton S. B., Hill M. D. Temporal trends in the use and comparative effectiveness of direct oral anticoagulant agents versus warfarin for nonvalvular atrial fibrillation: a Canadian population-based study. Journal of American Heart Association . 2017;6(11) doi: 10.1161/JAHA.117.007129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.117.007129</ArticleId><ArticleId IdType="pmc">PMC5721787</ArticleId><ArticleId IdType="pubmed">29080863</ArticleId></ArticleIdList></Reference><Reference><Citation>Maura G., Billionnet C., Drouin J., Weill A., Neumann A., Pariente A. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011&#x2013;2016. BMJ Open . 2019;9(4) doi: 10.1136/bmjopen-2018-026645.e026645</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-026645</ArticleId><ArticleId IdType="pmc">PMC6500377</ArticleId><ArticleId IdType="pubmed">31005934</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a Rodr&#xed;guez L. A., Cea Soriano L., Munk Hald S., et al. Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke. Heart . 2020;107(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7958105</ArticleId><ArticleId IdType="pubmed">33310887</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez C., Katholing A., Wallenhorst C., Freedman S. B. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thrombosis &amp; Haemostasis . 2016;115(1):31&#x2013;39. doi: 10.1160/TH15-04-0350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH15-04-0350</ArticleId><ArticleId IdType="pubmed">26246112</ArticleId></ArticleIdList></Reference><Reference><Citation>Deitelzweig S. B., Buysman E., Pinsky B., et al. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clinical Therapeutics . 2013;35(8):1201&#x2013;1210. doi: 10.1016/j.clinthera.2013.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2013.06.005</ArticleId><ArticleId IdType="pubmed">23867114</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Caravaca J. M., Roldan V., Esteve-Pastor M. A., et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thrombosis &amp; Haemostasis . 2017;117(7):1448&#x2013;1454. doi: 10.1160/th16-12-0961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/th16-12-0961</ArticleId><ArticleId IdType="pubmed">28331926</ArticleId></ArticleIdList></Reference><Reference><Citation>Spivey C. A., Liu X., Qiao Y., et al. Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. Current Medical Research and Opinion . 2015;31(11):2021&#x2013;2029. doi: 10.1185/03007995.2015.1082995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/03007995.2015.1082995</ArticleId><ArticleId IdType="pubmed">26390258</ArticleId></ArticleIdList></Reference><Reference><Citation>2021.  
 https://ohdsi.github.io/TheBookOfOhdsi/CommonDataModel.html#fn20 Blacketer. Chapter 4. The common data model. In The Book of OHDSI Observational Health Data Sciences and Informatics.</Citation></Reference><Reference><Citation>Hripcsak G., Duke J. D., Shah N. H., et al. Observational health data Sciences and Informatics (OHDSI): opportunities for observational researchers. Studies in Health Technology and Informatics . 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Heuvel J. M., H&#xf6;vels A. M., B&#xfc;ller H. R., Mantel-Teeuwisse A. K., De Boer A., Maitland-Van Der Zee A. H. NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands. Thrombosis Journal . 2018;16(1):p. 7. doi: 10.1186/s12959-017-0156-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-017-0156-y</ArticleId><ArticleId IdType="pmc">PMC5905161</ArticleId><ArticleId IdType="pubmed">29692686</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen J. B., Sorensen R., Hansen M. L., et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011&#x2013;2013. Europace . 2015;17(2):187&#x2013;193. doi: 10.1093/europace/euu225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euu225</ArticleId><ArticleId IdType="pubmed">25236181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ib&#xe1;&#xf1;ez L., Sabat&#xe9; M., Vidal X., et al. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008&#x2013;2015): a cross&#x2010;national drug utilization study. British Journal of Clinical Pharmacology . 2019;85(11):2524&#x2013;2539. doi: 10.1111/bcp.14071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14071</ArticleId><ArticleId IdType="pmc">PMC6848911</ArticleId><ArticleId IdType="pubmed">31318059</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcusky M., McManus D. D., Hume A. L., Fisher M., Tjia J., Lapane K. L. Changes in anticoagulant utilization among United States nursing home residents with atrial fibrillation from 2011 to 2016. Journal of American Heart Association . 2019;8(9) doi: 10.1161/JAHA.119.012023.e012023</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.012023</ArticleId><ArticleId IdType="pmc">PMC6512099</ArticleId><ArticleId IdType="pubmed">31046504</ArticleId></ArticleIdList></Reference><Reference><Citation>Camm A. J., Lip G. Y., De Caterina R., et al. Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace . 2012;14(10):1385&#x2013;1413.</Citation><ArticleIdList><ArticleId IdType="pubmed">22923145</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. 
Dabigatran Etexilate for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation. Technology Appraisal Guidance
. London, UK: NICE; 2012.  Published: 15 March 2012.  https://www.nice.org.uk/guidance/ta249.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. 
Rivaroxaban for the Prevention of Stroke and Systemic Embolism in People with Atrial Fibrillation. Technology Appraisal Guidance
. London, UK: NICE; 2012.  Published: 23 May 2012.  https://www.nice.org.uk/guidance/ta256.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. 
Apixaban for Preventing Stroke and Systemic Embolism in People with Non-Valvular Atrial Fibrillation. Technology Appraisal Guidance
. London, UK: NICE; 2013.  Published: 27 February 2013.  https://www.nice.org.uk/guidance/ta275.</Citation></Reference><Reference><Citation>January C. T., Wann L. S., Calkins H., et al. AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation . 2019;140:e125&#x2013;e151. doi: 10.1161/cir.0000000000000665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/cir.0000000000000665</ArticleId><ArticleId IdType="pubmed">30686041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhof P., Benussi S., Kotecha D., et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal . 2016;37(38):2893&#x2013;2962.</Citation><ArticleIdList><ArticleId IdType="pubmed">27567408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lip G. Y. H., Pan X., Kamble S., et al. Discontinuation risk comparison among &#x2018;real-world&#x2019; newly anticoagulated atrial fibrillation patients: apixaban, warfarin, dabigatran, or rivaroxaban. PLoS One . 2018;13(4) doi: 10.1371/journal.pone.0195950.e0195950</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0195950</ArticleId><ArticleId IdType="pmc">PMC5927458</ArticleId><ArticleId IdType="pubmed">29709012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruig&#xf3;mez A., Vora P., Balabanova Y., et al. Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from the Health Improvement Network in the UK. BMJ Open . 2019;9(10) doi: 10.1136/bmjopen-2019-031342.e031342</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-031342</ArticleId><ArticleId IdType="pmc">PMC6803078</ArticleId><ArticleId IdType="pubmed">31630107</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson M. E., Lef&#xe8;vre C., Collings S.-L., et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open . 2016;6(9) doi: 10.1136/bmjopen-2016-011471.e011471</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-011471</ArticleId><ArticleId IdType="pmc">PMC5051466</ArticleId><ArticleId IdType="pubmed">27678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J. D., Shewale A. R., Talbert J. C. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention for newly diagnosed and treatment-naive atrial fibrillation patients: an update using 2013-2014 data. Journal of Managed Care &amp; Specialty Pharmacy . 2017;23(9):958&#x2013;967. doi: 10.18553/jmcp.2017.23.9.958.</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2017.23.9.958</ArticleId><ArticleId IdType="pmc">PMC5747360</ArticleId><ArticleId IdType="pubmed">28854077</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food &amp; Drug Administration. 
FDA Drug Safety Communication: Safety review of Post-Market Reports of Serious Bleeding Events with the Anticoagulant Pradaxa (Dabigatran Etexilate Mesylate)
 Silver Spring, Maryland: U.S. Food &amp; Drug Administration; 2011.  
 https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-post-market-reports-serious-bleeding-events
.</Citation></Reference><Reference><Citation>Sipahi I., Celik S., Tozun N. A comparison of results of the US food and drug administration&#x2019;s mini-sentinel program with randomized clinical trials. JAMA Internal Medicine . 2014;174(1):150&#x2013;151. doi: 10.1001/jamainternmed.2013.12217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.12217</ArticleId><ArticleId IdType="pubmed">24247291</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore T. J., Cohen M. R., Mattison D. R. Dabigatran, bleeding, and the regulators. BMJ . 2014;349 doi: 10.1136/bmj.g4517.g4517</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g4517</ArticleId><ArticleId IdType="pubmed">25056265</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora P., Stewart H. M., Russell B., Asiimwe A., Brobert G. Time trends and treatment pathways in the prescribing of individual oral anticoagulants in patients with non-valvular atrial fibrillation: an observational study of more than three million patients from Europe and the United States. Authorea. April . 2021;25 doi: 10.22541/au.161932997.71916310/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.22541/au.161932997.71916310/v1</ArticleId><ArticleId IdType="pmc">PMC9159118</ArticleId><ArticleId IdType="pubmed">35685531</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35701668</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2398-6352</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>NPJ digital medicine</Title><ISOAbbreviation>NPJ Digit Med</ISOAbbreviation></Journal><ArticleTitle>Distributed learning for heterogeneous clinical data with application to integrating COVID-19 data across 230 sites.</ArticleTitle><Pagination><StartPage>76</StartPage><MedlinePgn>76</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">76</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41746-022-00615-8</ELocationID><Abstract><AbstractText>Integrating real-world data (RWD) from several clinical sites offers great opportunities to improve estimation with a more general population compared to analyses based on a single clinical site. However, sharing patient-level data across sites is practically challenging due to concerns about maintaining patient privacy. We develop a distributed algorithm to integrate heterogeneous RWD from multiple clinical sites without sharing patient-level data. The proposed distributed conditional logistic regression (dCLR) algorithm can effectively account for between-site heterogeneity and requires only one round of communication. Our simulation study and data application with the data of 14,215 COVID-19 patients from 230 clinical sites in the UnitedHealth Group Clinical Research Database demonstrate that the proposed distributed algorithm provides an estimator that is robust to heterogeneity in event rates when efficiently integrating data from multiple clinical sites. Our algorithm is therefore a practical alternative to both meta-analysis and existing distributed algorithms for modeling heterogeneous multi-site binary outcomes.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Chongliang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Islam</LastName><ForeName>Md Nazmul</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Optum Labs, UnitedHealth Group, Minnetonka, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheils</LastName><ForeName>Natalie E</ForeName><Initials>NE</Initials><Identifier Source="ORCID">0000-0002-0631-5834</Identifier><AffiliationInfo><Affiliation>Optum Labs, UnitedHealth Group, Minnetonka, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buresh</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Optum Labs, UnitedHealth Group, Minnetonka, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edmondson</LastName><ForeName>Mackenzie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merkel</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lautenbach</LastName><ForeName>Ebbing</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0835-0788</Identifier><AffiliationInfo><Affiliation>Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01AI130460</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country/></Grant><Grant><GrantID>1R56AG069880</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>ME-2019C3-18315</GrantID><Agency>Patient-Centered Outcomes Research Institute (PCORI)</Agency><Country/></Grant><Grant><GrantID>ME-2018C3-14899</GrantID><Agency>Patient-Centered Outcomes Research Institute (PCORI)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Digit Med</MedlineTA><NlmUniqueID>101731738</NlmUniqueID><ISSNLinking>2398-6352</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>14</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35701668</ArticleId><ArticleId IdType="pmc">PMC9198031</ArticleId><ArticleId IdType="doi">10.1038/s41746-022-00615-8</ArticleId><ArticleId IdType="pii">10.1038/s41746-022-00615-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sherman RE, et al. Real-world evidence&#x2014;what is it and what can it tell us. N. Engl. J. Med. 2016;375:2293&#x2013;2297. doi: 10.1056/NEJMsb1609216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb1609216</ArticleId><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>Fda, U. S., Food, Administration, D. &amp; Others. Framework for FDA&#x2019;s Real-World Evidence Program. (2018).</Citation></Reference><Reference><Citation>Bowens FM, Frye PA, Jones WA. Health information technology: integration of clinical workflow into meaningful use of electronic health records. Perspect. Heal. Inf. Manag. 2010;7:1d.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966355</ArticleId><ArticleId IdType="pubmed">21063545</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman CP, Wong AK, Blumenthal D. Achieving a nationwide learning health system. Sci. Transl. Med. 2010;2:57cm29. doi: 10.1126/scitranslmed.3001456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001456</ArticleId><ArticleId IdType="pubmed">21068440</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, et al. Using EHRs to integrate research with patient care: promises and challenges. J. Am. Med. Inform. Assoc. 2012;19:684&#x2013;687. doi: 10.1136/amiajnl-2012-000878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000878</ArticleId><ArticleId IdType="pmc">PMC3422845</ArticleId><ArticleId IdType="pubmed">22542813</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene SM, Reid RJ, Larson EB. Implementing the learning health system: from concept to action. Ann. Intern. Med. 2012;157:207&#x2013;210. doi: 10.7326/0003-4819-157-3-201208070-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-157-3-201208070-00012</ArticleId><ArticleId IdType="pubmed">22868839</ArticleId></ArticleIdList></Reference><Reference><Citation>Smoyer WE, Embi PJ, Moffatt-Bruce S. Creating local learning health systems: think globally, act locally. JAMA. 2016;316:2481&#x2013;2482. doi: 10.1001/jama.2016.16459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.16459</ArticleId><ArticleId IdType="pubmed">27997662</ArticleId></ArticleIdList></Reference><Reference><Citation>Maro JC, et al. Design of a national distributed health data network. Ann. Intern. Med. 2009;151:341&#x2013;344. doi: 10.7326/0003-4819-151-5-200909010-00139.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-151-5-200909010-00139</ArticleId><ArticleId IdType="pubmed">19638403</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, et al. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med. Care. 2010;48:S45&#x2013;S51. doi: 10.1097/MLR.0b013e3181d9919f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e3181d9919f</ArticleId><ArticleId IdType="pubmed">20473204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud. Heal. Technol. Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J. Am. Med. Inform. Assoc. 2012;19:54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest CB, et al. PEDSnet: a National Pediatric Learning Health System. J. Am. Med. Inform. Assoc. 2014;21:602&#x2013;606. doi: 10.1136/amiajnl-2014-002743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002743</ArticleId><ArticleId IdType="pmc">PMC4078288</ArticleId><ArticleId IdType="pubmed">24821737</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence RL, et al. Launching PCORnet, a national patient-centered clinical research network. J. Am. Med. Inform. Assoc. 2014;21:578&#x2013;582. doi: 10.1136/amiajnl-2014-002747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002747</ArticleId><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R, et al. The US Food and Drug Administration&#x2019;s Mini-Sentinel program: status and direction. Pharmacoepidemiol. Drug Saf. 2012;21:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262586</ArticleId></ArticleIdList></Reference><Reference><Citation>Brat GA, et al. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. Npj Digit. Med. 2020;3:1&#x2013;9. doi: 10.1038/s41746-020-00308-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00308-0</ArticleId><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, H.-D. I. Effect of Ignoring Heterogeneity in Hazards Regression. in Parametric and Semiparametric Models with Applications to Reliability, Survival Analysis, and Quality of Life (eds. Balakrishnan, N., Nikulin, M. S., Mesbah, M. &amp; Limnios, N.) 239&#x2013;250 (Birkh&#xe4;user Boston, 2004). 10.1007/978-0-8176-8206-4_16.</Citation></Reference><Reference><Citation>Arellano AM, Dai W, Wang S, Jiang X, Ohno-Machado L. Privacy policy and technology in biomedical data science. Annu Rev. Biomed. Data Sci. 2018;1:115&#x2013;129. doi: 10.1146/annurev-biodatasci-080917-013416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biodatasci-080917-013416</ArticleId><ArticleId IdType="pmc">PMC6497413</ArticleId><ArticleId IdType="pubmed">31058261</ArticleId></ArticleIdList></Reference><Reference><Citation>Loukides G, Denny JC, Malin B. The disclosure of diagnosis codes can breach research participants&#x2019; privacy. J. Am. Med. Inform. Assoc. 2010;17:322&#x2013;327. doi: 10.1136/jamia.2009.002725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.002725</ArticleId><ArticleId IdType="pmc">PMC2995712</ArticleId><ArticleId IdType="pubmed">20442151</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason, H. et al. Ideas for how informaticians can get involved with COVID-19 research. Bio. Data Mining. 13, 10.1186/s13040-020-00213-y (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7216865</ArticleId><ArticleId IdType="pubmed">32419848</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez K, Malin B. Evaluating re-identification risks with respect to the HIPAA privacy rule. J. Am. Med. Inform. Assoc. 2010;17:169&#x2013;177. doi: 10.1136/jamia.2009.000026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.000026</ArticleId><ArticleId IdType="pmc">PMC3000773</ArticleId><ArticleId IdType="pubmed">20190059</ArticleId></ArticleIdList></Reference><Reference><Citation>McGraw D. Building public trust in uses of health insurance portability and accountability act de-identified data. J. Am. Med. Inform. Assoc. 2013;20:29&#x2013;34. doi: 10.1136/amiajnl-2012-000936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000936</ArticleId><ArticleId IdType="pmc">PMC3555317</ArticleId><ArticleId IdType="pubmed">22735615</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, et al. Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin. JAMA Netw. Open. 2018;1:e181755. doi: 10.1001/jamanetworkopen.2018.1755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2018.1755</ArticleId><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, et al. Uncovering exposures responsible for birth season&#x2013;disease effects: a global study. J. Am. Med. Inform. Assoc. 2018;25:275&#x2013;288. doi: 10.1093/jamia/ocx105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocx105</ArticleId><ArticleId IdType="pmc">PMC7282503</ArticleId><ArticleId IdType="pubmed">29036387</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc. Natl Acad. Sci. USA. 2016;113:7329&#x2013;7336. doi: 10.1073/pnas.1510502113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R, et al. Learning from local to global-an efficient distributed algorithm for modeling time-to-event data. J. Am. Med. Inform. Assoc. 2020;27:1028&#x2013;1036. doi: 10.1093/jamia/ocaa044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa044</ArticleId><ArticleId IdType="pmc">PMC7647322</ArticleId><ArticleId IdType="pubmed">32626900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Jiang X, Kim J, Ohno-Machado L. Grid Binary LOgistic REgression (GLORE): building shared models without sharing data. J. Am. Med. Inform. Assoc. 2012;19:758&#x2013;764. doi: 10.1136/amiajnl-2012-000862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000862</ArticleId><ArticleId IdType="pmc">PMC3422844</ArticleId><ArticleId IdType="pubmed">22511014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-L, et al. WebDISCO: a web service for distributed cox model learning without patient-level data sharing. J. Am. Med. Inform. Assoc. 2015;22:1212&#x2013;1219. doi: 10.1093/jamia/ocv083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv083</ArticleId><ArticleId IdType="pmc">PMC5009917</ArticleId><ArticleId IdType="pubmed">26159465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno-Machado L, et al. pSCANNER: patient-centered Scalable National Network for Effectiveness Research. J. Am. Med. Inform. Assoc. 2014;21:621&#x2013;626. doi: 10.1136/amiajnl-2014-002751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002751</ArticleId><ArticleId IdType="pmc">PMC4078293</ArticleId><ArticleId IdType="pubmed">24780722</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R, Boland MR, Moore JH, Chen Y. ODAL: A one-shot distributed algorithm to perform logistic regressions on electronic health records data from multiple clinical sites. Pac. Symp. Biocomput. 2019;24:30&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417819</ArticleId><ArticleId IdType="pubmed">30864308</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R, et al. Learning from electronic health records across multiple sites: A communication-efficient and privacy-preserving distributed algorithm. J. Am. Med. Inform. Assoc. 2020;27:376&#x2013;385. doi: 10.1093/jamia/ocz199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocz199</ArticleId><ArticleId IdType="pmc">PMC7025371</ArticleId><ArticleId IdType="pubmed">31816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang KY. Extended Mantel-Haenszel estimating procedure for multivariate logistic regression models. Biometrics. 1987;43:289&#x2013;299. doi: 10.2307/2531813.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531813</ArticleId><ArticleId IdType="pubmed">3607201</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong, J. et al. Robust-ODAL: Learning from heterogeneous health systems without sharing patient-level data. In Pacific Symposium on Biocomputing vol. 25 695&#x2013;706 (World Scientific Publishing Co. Pte Ltd, 2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6905508</ArticleId><ArticleId IdType="pubmed">31797639</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan, R., Ning, Y. &amp; Chen, Y. Heterogeneity-aware and communication-efficient distributed statistical inference. Biometrika. 10.1093/biomet/asab007 (2021).</Citation></Reference><Reference><Citation>CRAN - Package usmap. https://cran.r-project.org/web/packages/usmap/index.html.</Citation></Reference><Reference><Citation>Breslow, N. E. &amp; Day, N. E. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci. Publ. 5&#x2013;338 10.2307/2981542 (1980).</Citation><ArticleIdList><ArticleId IdType="pubmed">7216345</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan MI, Lee JD, Yang Y. Communication-efficient distributed statistical inference. J. Am. Stat. Assoc. 2019;114:668&#x2013;681. doi: 10.1080/01621459.2018.1429274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.2018.1429274</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J., Kolar, M., Srebro, N. &amp; Zhang, T. Efficient distributed learning with sparsity. in International Conference on Machine Learning 3636&#x2013;3645 (PMLR, 2017).</Citation></Reference><Reference><Citation>Luo X, Tsai WY. A proportional likelihood ratio model. Biometrika. 2012;99:211&#x2013;222. doi: 10.1093/biomet/asr060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/asr060</ArticleId><ArticleId IdType="pmc">PMC3888642</ArticleId><ArticleId IdType="pubmed">24421412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning Y, Zhao T, Liu H. A likelihood ratio framework for high-dimensional semiparametric regression. Ann. Stat. 2017;45:2299&#x2013;2327.</Citation></Reference><Reference><Citation>Chongliang, L. R. et al. ODACH: a one-shot distributed algorithm for Cox model with heterogeneous multi-center data. Sci. Rep.12, 10.1038/s41598-022-09069-0 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9033863</ArticleId><ArticleId IdType="pubmed">35459767</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie J. et al. Distributed Quasi-Poisson Regression Algorithm for Modeling Multi-Site Count Outcomes in Distributed Data Networks. J. Biomed. Inform. 104097 10.1016/j.jbi.2022.104097 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35643272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie J. et al. An efficient and accurate distributed learning algorithm for modeling multi-site zero-inflated count outcomes. Sci. Rep.11, 10.1038/s41598-021-99078-2 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8490431</ArticleId><ArticleId IdType="pubmed">34608222</ArticleId></ArticleIdList></Reference><Reference><Citation>Chongliang, C. T. et al. DLMM as a lossless one-shot algorithm for collaborative multi-site distributed linear mixed models. Nat. Commun.13, 10.1038/s41467-022-29160-4 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8967932</ArticleId><ArticleId IdType="pubmed">35354802</ArticleId></ArticleIdList></Reference><Reference><Citation>Chongliang, L. Md. N. et al. dPQL: a lossless distributed algorithm for generalized linear mixed model with application to privacy-preserving hospital profiling. J. Am. Med. Inform. Assoc.10.1093/jamia/ocac067 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35579348</ArticleId></ArticleIdList></Reference><Reference><Citation>David A. et al. Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic. JAMA Intern. Med.181, 47110.1001/jamainternmed.2020.8193 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7756246</ArticleId><ArticleId IdType="pubmed">33351068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Ning J, Cai C. Regression analysis of longitudinal data with irregular and informative observation times. Biostatistics. 2015;16:727&#x2013;739. doi: 10.1093/biostatistics/kxv008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/kxv008</ArticleId><ArticleId IdType="pubmed">25813646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KCG. Nuisance parameter elimination for proportional likelihood ratio models with nonignorable missingness and random truncation. Biometrika. 2013;100:269&#x2013;276. doi: 10.1093/biomet/ass056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/ass056</ArticleId><ArticleId IdType="pmc">PMC3809024</ArticleId><ArticleId IdType="pubmed">24179236</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C, Deng Y, Jiang X, Long Q. Multiple imputation for analysis of incomplete data in distributed health data networks. Nat. Commun. 2020;11:1&#x2013;11. doi: 10.1038/s41467-019-13993-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13993-7</ArticleId><ArticleId IdType="pmc">PMC7596726</ArticleId><ArticleId IdType="pubmed">33122624</ArticleId></ArticleIdList></Reference><Reference><Citation>Epic. https://www.epic.com (2020).</Citation></Reference><Reference><Citation>Cerner. https://www.cerner.com (2020).</Citation></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987;40:373&#x2013;383. doi: 10.1016/0021-9681(87)90171-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35705182</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>Transforming Thyroid Cancer Diagnosis and Staging Information from Unstructured Reports to the Observational Medical Outcome Partnership Common Data Model.</ArticleTitle><Pagination><StartPage>521</StartPage><EndPage>531</EndPage><MedlinePgn>521-531</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0042-1748144</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cancer staging information is an essential component of cancer research. However, the information is primarily stored as either a full or semistructured free-text clinical document which is limiting the data use. By transforming the cancer-specific data to the Observational Medical Outcome Partnership Common Data Model (OMOP CDM), the information can contribute to establish multicenter observational cancer studies. To the best of our knowledge, there have been no studies on OMOP CDM transformation and natural language processing (NLP) for thyroid cancer to date.</AbstractText><AbstractText Label="OBJECTIVE">We aimed to demonstrate the applicability of the OMOP CDM oncology extension module for thyroid cancer diagnosis and cancer stage information by processing free-text medical reports.</AbstractText><AbstractText Label="METHODS">Thyroid cancer diagnosis and stage-related modifiers were extracted with rule-based NLP from 63,795 thyroid cancer pathology reports and 56,239 Iodine whole-body scan reports from three medical institutions in the Observational Health Data Sciences and Informatics data network. The data were converted into the OMOP CDM v6.0 according to the OMOP CDM oncology extension module. The cancer staging group was derived and populated using the transformed CDM data.</AbstractText><AbstractText Label="RESULTS">The extracted thyroid cancer data were completely converted into the OMOP CDM. The distributions of histopathological types of thyroid cancer were approximately 95.3 to 98.8% of papillary carcinoma, 0.9 to 3.7% of follicular carcinoma, 0.04 to 0.54% of adenocarcinoma, 0.17 to 0.81% of medullary carcinoma, and 0 to 0.3% of anaplastic carcinoma. Regarding cancer staging, stage-I thyroid cancer accounted for 55 to 64% of the cases, while stage III accounted for 24 to 26% of the cases. Stage-II and -IV thyroid cancers were detected at a low rate of 2 to 6%.</AbstractText><AbstractText Label="CONCLUSION">As a first study on OMOP CDM transformation and NLP for thyroid cancer, this study will help other institutions to standardize thyroid cancer-specific data for retrospective observational research and participate in multicenter studies.</AbstractText><CopyrightInformation>The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Healthcare Innovation Park, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Eunsil</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Healthcare Innovation Park, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boo</LastName><ForeName>Dachung</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Healthcare Innovation Park, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Borham</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Healthcare Innovation Park, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Healthcare Innovation Park, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paeng</LastName><ForeName>Jin Chul</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Seoul National University, College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Ie Ryung</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>In Young</ForeName><Initials>IY</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, The Catholic University of Korea, College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedicine and Health Sciences, The Catholic University of Korea, College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kwangsoo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Transdisciplinary Department of Medicine and Advanced Technology, Seoul National University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryoo</LastName><ForeName>Hyun Gee</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Seoul National University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sun Jung</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, The Catholic University of Korea, College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedicine and Health Sciences, The Catholic University of Korea, College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Eunhye</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Data Science Research, Innovative Medical Technology Research Institute, Seoul National University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joo</LastName><ForeName>Young-Hwan</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Junmo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ho-Young</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Healthcare Innovation Park, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Seoul National University, College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018278" MajorTopicYN="Y">Carcinoma, Neuroendocrine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>19</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35705182</ArticleId><ArticleId IdType="pmc">PMC9200482</ArticleId><ArticleId IdType="doi">10.1055/s-0042-1748144</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khozin S, Blumenthal G M, Pazdur R. Real-world data for clinical evidence generation in oncology. J Natl Cancer Inst. 2017;109(11):1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">29059439</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang L, Rastegar-Mojarad M. Clinical information extraction applications: a literature review. J Biomed Inform. 2018;77(77):34&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5771858</ArticleId><ArticleId IdType="pubmed">29162496</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Luo L, Wang Y, Wampfler J, Yang P, Liu H. Natural language processing for populating lung cancer clinical research data. BMC Med Inform Decis Mak. 2019;19 05:239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6894100</ArticleId><ArticleId IdType="pubmed">31801515</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmukh P R, Phalnikar R. Anatomic stage extraction from medical reports of breast Cancer patients using natural language processing. Health Technol (Berl) 2020;10(06):1555&#x2013;1570.</Citation></Reference><Reference><Citation>Johanna Johnsi Rani G, Gladis D, Manipadam M T, Ishitha G.Breast cancer staging using Natural Language Processing 2015. Presented in International Conference on Advances in Computing, Communications and Informatics, ICACCI, August 10&#x2013;13:2015. Kochi, India</Citation></Reference><Reference><Citation>Wieneke A E, Bowles E J, Cronkite D. Validation of natural language processing to extract breast cancer pathology procedures and results. J Pathol Inform. 2015;6(01):38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4485196</ArticleId><ArticleId IdType="pubmed">26167382</ArticleId></ArticleIdList></Reference><Reference><Citation>Yala A, Barzilay R, Salama L. Using machine learning to parse breast pathology reports. Breast Cancer Res Treat. 2017;161(02):203&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">27826755</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobel J M, Puts S, Bakers F CH, Robben S GF, Dekker A LAJ. Natural language processing in dutch free text radiology reports: challenges in a small language area staging pulmonary oncology. J Digit Imaging. 2020;33(04):1002&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7522136</ArticleId><ArticleId IdType="pubmed">32076924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu B, Yoon E, Kim S. Transformation of pathology reports into the common data model with oncology module: use case for colon cancer. J Med Internet Res. 2020;22(12):e18526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7758167</ArticleId><ArticleId IdType="pubmed">33295294</ArticleId></ArticleIdList></Reference><Reference><Citation>Spasi&#x107; I, Livsey J, Keane J A, Nenadi&#x107; G. Text mining of cancer-related information: review of current status and future directions. Int J Med Inform. 2014;83(09):605&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">25008281</ArticleId></ArticleIdList></Reference><Reference><Citation>Idarraga A J, Luong G, Hsiao V, Schneider D F. False negative rates in benign thyroid nodule diagnosis: machine learning for detecting malignancy. J Surg Res. 2021;268(268):562&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">34464894</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Zhang S, Li J.Improved diagnosis of thyroid cancer aided with deep learning applied to sonographic text reports: a retrospective, multi-cohort, diagnostic studyCancer Biol Med 2021;18j.issn.2095-3941.2020.0509</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9196053</ArticleId><ArticleId IdType="pubmed">34491007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke J D, Shah N H. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage J M, Ryan P B, Reich C G, Hartzema A G, Stang P E. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(01):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Seong Y, You S C, Ostropolets A. Incorporation of korean electronic data interchange vocabulary into observational medical outcomes partnership vocabulary. Healthc Inform Res. 2021;27(01):29&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7921574</ArticleId><ArticleId IdType="pubmed">33611874</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenkaya R, Gurley M, Dymshyts D. Standardized observational cancer research using the OMOP CDM oncology module. Stud Health Technol Inform. 2019;264:1831&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438365</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge S B, Byrd D R, Compton C C, Fritz A G, Greene F Trotti A. 7th ed. New York, NY: Springer; 2010. AJCC Cancer Staging Manual.</Citation></Reference><Reference><Citation>Ortiz S, Rodr&#xed;guez J M, Soria T. Extrathyroid spread in papillary carcinoma of the thyroid: clinicopathological and prognostic study. Otolaryngol Head Neck Surg. 2001;124(03):261&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">11240987</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P E, Kinsella J, Loree T R, Shaha A R, Shah J P. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg. 1995;170(05):467&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">7485734</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn H Y, Park Y J. Incidence and clinical characteristics of thyroid cancer in Korea. Korean J Med. 2009;77(05):537&#x2013;542.</Citation></Reference><Reference><Citation>Belenkaya R, Gurley M J, Golozar A. Extending the OMOP common data model and standardized vocabularies to support observational cancer research. JCO Clin Cancer Inform. 2021;5:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8140810</ArticleId><ArticleId IdType="pubmed">33411620</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35715561</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology.</ArticleTitle><Pagination><StartPage>10162</StartPage><MedlinePgn>10162</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10162</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-14386-5</ELocationID><Abstract><AbstractText>Despite many studies, optimal treatment sequences or intervals are still questionable in retinal vein occlusion (RVO) macular edema. The aim of this study was to examine the real-world treatment patterns of RVO macular edema. A retrospective analysis of the Observational Medical Outcomes Partnership Common Data Model, a distributed research network, of four large tertiary referral centers (n&#x2009;=&#x2009;9,202,032) identified 3286 eligible. We visualized treatment pathways (prescription volume and treatment sequence) with sunburst and Sankey diagrams. We calculated the average number of intravitreal injections per patient in the first and second years to evaluate the treatment intensities. Bevacizumab was the most popular first-line drug (80.9%), followed by triamcinolone (15.1%)&#xa0;and&#xa0;dexamethasone (2.28%). Triamcinolone was the most popular drug (8.88%), followed by dexamethasone (6.08%) in patients who began treatment with anti-vascular endothelial growth factor (VEGF) agents. The average number of all intravitreal injections per person decreased in the second year compared with the first year. The average number of injections per person in the first year increased throughout the study. Bevacizumab was the most popular first-line drug and steroids were considered the most common as second-line drugs in patients first treated with anti-VEGF agents. Intensive treatment patterns may cause an increase in intravitreal injections.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mun</LastName><ForeName>Yongseok</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Park</LastName><ForeName>ChulHyoung</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Da Yun</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tong Min</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Ki Won</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healthcare ICT Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Yoo-Ri</ForeName><Initials>YR</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kihwang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Ji Hun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Young-Jung</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul, 07345, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jee</LastName><ForeName>Donghyun</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Jin-Woo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Se Joon</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Kyu Hyung</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healthcare ICT Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Dong-Jin</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul, 07345, South Korea. hpalways@songeui.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sang Jun</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea. sangjunpark@snu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>1ZK20VI6TY</RegistryNumber><NameOfSubstance UI="D014221">Triamcinolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S9ZZM9Q9V</RegistryNumber><NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008269" MajorTopicYN="Y">Macular Edema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009885" MajorTopicYN="Y">Ophthalmology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012170" MajorTopicYN="Y">Retinal Vein Occlusion</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014221" MajorTopicYN="N">Triamcinolone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>17</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35715561</ArticleId><ArticleId IdType="pmc">PMC9205933</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-14386-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-14386-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rogers S, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313&#x2013;9.e1. doi: 10.1016/j.ophtha.2009.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2009.07.017</ArticleId><ArticleId IdType="pmc">PMC2945292</ArticleId><ArticleId IdType="pubmed">20022117</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SJ, Choi NK, Park KH, Woo SJ. Nationwide incidence of clinically diagnosed retinal vein occlusion in Korea, 2008 through 2011: Preponderance of women and the impact of aging. Ophthalmology. 2014;121:1274&#x2013;1280. doi: 10.1016/j.ophtha.2013.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2013.12.024</ArticleId><ArticleId IdType="pubmed">24491641</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JY, Park SJ, Byun SJ, Woo SJ, Park KH. Twelve-year incidence of retinal vein occlusion and its trend in Korea. Graefes Arch. Clin. Exp. Ophthalmol. 2020;258:2095&#x2013;2104. doi: 10.1007/s00417-020-04811-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-020-04811-8</ArticleId><ArticleId IdType="pubmed">32591976</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller JA, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453&#x2013;2460. doi: 10.1016/j.ophtha.2011.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2011.05.014</ArticleId><ArticleId IdType="pubmed">21764136</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Erfurth U, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA) Ophthalmol. J. Int. d'ophtalmol. Int. J. Ophthalmol. Zeitschrift fur Augenheilkunde. 2019;242:123&#x2013;162. doi: 10.1159/000502041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000502041</ArticleId><ArticleId IdType="pubmed">31412332</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura Y, et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-Month results of the phase 3 GALILEO study. Am. J. Ophthalmol. 2014;158:1032&#x2013;1038. doi: 10.1016/j.ajo.2014.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2014.07.027</ArticleId><ArticleId IdType="pubmed">25068637</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott IU, et al. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: The SCORE2 randomized clinical trial. JAMA. 2017;317:2072&#x2013;2087. doi: 10.1001/jama.2017.4568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.4568</ArticleId><ArticleId IdType="pmc">PMC5710547</ArticleId><ArticleId IdType="pubmed">28492910</ArticleId></ArticleIdList></Reference><Reference><Citation>Campochiaro PA, et al. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102&#x2013;12.e1. doi: 10.1016/j.ophtha.2010.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2010.02.021</ArticleId><ArticleId IdType="pubmed">20398941</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DM, et al. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124&#x2013;33.e1. doi: 10.1016/j.ophtha.2010.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2010.02.022</ArticleId><ArticleId IdType="pubmed">20381871</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark WL, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-Week results of the VIBRANT study. Ophthalmology. 2016;123:330&#x2013;336. doi: 10.1016/j.ophtha.2015.09.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2015.09.035</ArticleId><ArticleId IdType="pubmed">26522708</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaxel CJ, et al. Age-related macular degeneration preferred practice pattern(R) Ophthalmology. 2020;127:P1&#x2013;P65. doi: 10.1016/j.ophtha.2019.09.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.09.024</ArticleId><ArticleId IdType="pubmed">31757502</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier JS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: Two-year results from the COPERNICUS study. Ophthalmology. 2014;121:1414&#x2013;20.e1. doi: 10.1016/j.ophtha.2014.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2014.01.027</ArticleId><ArticleId IdType="pubmed">24679444</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller JA, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134&#x2013;46.e3. doi: 10.1016/j.ophtha.2010.03.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2010.03.032</ArticleId><ArticleId IdType="pubmed">20417567</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott IU, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch. Ophthalmol. (Chicago, Ill: 1960) 2009;127:1115&#x2013;1128. doi: 10.1001/archophthalmol.2009.233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archophthalmol.2009.233</ArticleId><ArticleId IdType="pmc">PMC2806600</ArticleId><ArticleId IdType="pubmed">19752420</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh S, et al. Therapies for macular edema associated with central retinal vein occlusion: A report by the American Academy of Ophthalmology. Ophthalmology. 2015;122:769&#x2013;778. doi: 10.1016/j.ophtha.2014.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2014.10.013</ArticleId><ArticleId IdType="pubmed">25576994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers JP, et al. Therapies for macular edema associated with branch retinal vein occlusion: A report by the American Academy of Ophthalmology. Ophthalmology. 2017;124:1412&#x2013;1423. doi: 10.1016/j.ophtha.2017.03.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.03.060</ArticleId><ArticleId IdType="pubmed">28551163</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazha B, Yang JC, Owonikoko TK. Benefits and limitations of real-world evidence: Lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2021;17:965&#x2013;977. doi: 10.2217/fon-2020-0951.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2020-0951</ArticleId><ArticleId IdType="pubmed">33242257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for observational researchers. Stud. Health Technol. Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, et al. Characterization of anti-seizure medication treatment pathways in pediatric epilepsy using the electronic health record-based common data model. Front. Neurol. 2020;11:409. doi: 10.3389/fneur.2020.00409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00409</ArticleId><ArticleId IdType="pmc">PMC7235379</ArticleId><ArticleId IdType="pubmed">32477256</ArticleId></ArticleIdList></Reference><Reference><Citation>Mun Y, et al. Real-world incidence of endophthalmitis after intravitreal anti-VEGF injection: Common Data Model in ophthalmology. Epidemiol. Health. 2021 doi: 10.4178/epih.e2021097.</Citation><ArticleIdList><ArticleId IdType="doi">10.4178/epih.e2021097</ArticleId><ArticleId IdType="pmc">PMC8864106</ArticleId><ArticleId IdType="pubmed">34773936</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: A systematic, multinational, large-scale analysis. Lancet. 2019;394:1816&#x2013;1826. doi: 10.1016/S0140-6736(19)32317-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, et al. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern. Med. 2020;180:542&#x2013;551. doi: 10.1001/jamainternmed.2019.7454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.7454</ArticleId><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="pubmed">32065600</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. The Book of OHDSI. https://ohdsi.github.io/TheBookOfOhdsi (2019).</Citation></Reference><Reference><Citation>SNOMED International. Systematized Nomenclature of Medicine Clinical Terms. https://www.snomed.org/snomed-ct/get-snomed.</Citation></Reference><Reference><Citation>Hripcsak G, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc. Natl. Acad. Sci. USA. 2016;113:7329&#x2013;7336. doi: 10.1073/pnas.1510502113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. Treatment Pathways Study Protocol. https://www.ohdsi.org/web/wiki/doku.php?id=research:treatment_pathways_in_chronic_disease_12_mos (2014).</Citation></Reference><Reference><Citation>Hoerauf H, et al. Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): A European label study. Am. J. Ophthalmol. 2016;169:258&#x2013;267. doi: 10.1016/j.ajo.2016.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2016.04.020</ArticleId><ArticleId IdType="pubmed">27163237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattenbach LO, et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B) Acta Ophthalmol. 2018;96:e10&#x2013;e18. doi: 10.1111/aos.13381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.13381</ArticleId><ArticleId IdType="pubmed">28251811</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalchi Z, Mahroo O, Bunce C, Mitry D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst. Rev. 2020;7:Cd009510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388176</ArticleId><ArticleId IdType="pubmed">32633861</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld PJ. Intravitreal avastin: The low cost alternative to lucentis? Am. J. Ophthalmol. 2006;142:141&#x2013;143. doi: 10.1016/j.ajo.2006.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2006.03.036</ArticleId><ArticleId IdType="pubmed">16815262</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan R, et al. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br. J. Ophthalmol. 2015;99:954&#x2013;959. doi: 10.1136/bjophthalmol-2014-306543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2014-306543</ArticleId><ArticleId IdType="pubmed">25631483</ArticleId></ArticleIdList></Reference><Reference><Citation>Vader MJC, et al. Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion: The bevacizumab to ranibizumab in retinal vein occlusions (BRVO) study, a randomized trial. Ophthalmol. Retina. 2020;4:576&#x2013;587. doi: 10.1016/j.oret.2019.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2019.12.019</ArticleId><ArticleId IdType="pubmed">32107188</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotfy A, Solaiman KAM, Abdelrahman A, Samir A. Efficacy and frequency of intravitreal aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina (Philadelphia, Pa) 2018;38:1795&#x2013;1800. doi: 10.1097/IAE.0000000000001782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000001782</ArticleId><ArticleId IdType="pubmed">28767552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip MS, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch. Ophthalmol. 2009;127:1101&#x2013;1114. doi: 10.1001/archophthalmol.2009.234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archophthalmol.2009.234</ArticleId><ArticleId IdType="pmc">PMC2872173</ArticleId><ArticleId IdType="pubmed">19752419</ArticleId></ArticleIdList></Reference><Reference><Citation>Wecker T, et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br. J. Ophthalmol. 2017;101:353&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5339568</ArticleId><ArticleId IdType="pubmed">27215744</ArticleId></ArticleIdList></Reference><Reference><Citation>Campochiaro PA, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: The RETAIN study. Ophthalmology. 2014;121:209&#x2013;219. doi: 10.1016/j.ophtha.2013.08.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2013.08.038</ArticleId><ArticleId IdType="pubmed">24112944</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale R, et al. Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser. Br. J. Ophthalmol. 2021;105:549&#x2013;554. doi: 10.1136/bjophthalmol-2020-315836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2020-315836</ArticleId><ArticleId IdType="pmc">PMC8005793</ArticleId><ArticleId IdType="pubmed">32532760</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciulla T, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: A real-world analysis of 15 613 patient eyes. Br. J. Ophthalmol. 2021;105:1696&#x2013;1704. doi: 10.1136/bjophthalmol-2020-317337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2020-317337</ArticleId><ArticleId IdType="pmc">PMC8639936</ArticleId><ArticleId IdType="pubmed">33055088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung AE, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol. 2007;143:566&#x2013;583. doi: 10.1016/j.ajo.2007.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2007.01.028</ArticleId><ArticleId IdType="pubmed">17386270</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer DS, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1731&#x2013;1739. doi: 10.1016/j.ophtha.2009.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2009.05.024</ArticleId><ArticleId IdType="pubmed">19643495</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper JM, Dugel PU, Chen S, Blinder KJ, Walt JG. Anti-VEGF treatment of macular edema associated with retinal vein occlusion: Patterns of use and effectiveness in clinical practice (ECHO study report 2) Clin. Ophthalmol. (Auckland, NZ) 2018;12:621&#x2013;629. doi: 10.2147/OPTH.S163859.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S163859</ArticleId><ArticleId IdType="pmc">PMC5892950</ArticleId><ArticleId IdType="pubmed">29662298</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao P, et al. Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS Registry. Ophthalmology. 2018;125:522&#x2013;528. doi: 10.1016/j.ophtha.2017.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.10.010</ArticleId><ArticleId IdType="pubmed">29146306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mun Y, et al. An innovative strategy for standardized, structured, and interoperable results in ophthalmic examinations. BMC Med. Inform. Decis. Mak. 2021;21:9. doi: 10.1186/s12911-020-01370-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-020-01370-0</ArticleId><ArticleId IdType="pmc">PMC7789748</ArticleId><ArticleId IdType="pubmed">33407448</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35727911</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>373</Volume><PubDate><Year>2021</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.</ArticleTitle><Pagination><StartPage>n1435</StartPage><MedlinePgn>n1435</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">n1435</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.n1435</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To quantify the background incidence rates of 15 prespecified adverse events of special interest (AESIs) associated with covid-19 vaccines.</AbstractText><AbstractText Label="DESIGN">Multinational network cohort study.</AbstractText><AbstractText Label="SETTING">Electronic health records and health claims data from eight countries: Australia, France, Germany, Japan, the Netherlands, Spain, the United Kingdom, and the United States, mapped to a common data model.</AbstractText><AbstractText Label="PARTICIPANTS">126&#x2009;661&#x2009;070 people observed for at least 365 days before 1 January 2017, 2018, or 2019 from 13 databases.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Events of interests were 15 prespecified AESIs (non-haemorrhagic and haemorrhagic stroke, acute myocardial infarction, deep vein thrombosis, pulmonary embolism, anaphylaxis, Bell's palsy, myocarditis or pericarditis, narcolepsy, appendicitis, immune thrombocytopenia, disseminated intravascular coagulation, encephalomyelitis (including acute disseminated encephalomyelitis), Guillain-Barr&#xe9; syndrome, and transverse myelitis). Incidence rates of AESIs were stratified by age, sex, and database. Rates were pooled across databases using random effects meta-analyses and classified according to the frequency categories of the Council for International Organizations of Medical Sciences.</AbstractText><AbstractText Label="RESULTS">Background rates varied greatly between databases. Deep vein thrombosis ranged from 387 (95% confidence interval 370 to 404) per 100&#x2009;000 person years in UK CPRD GOLD data to 1443 (1416 to 1470) per 100&#x2009;000 person years in US IBM MarketScan Multi-State Medicaid data among women aged 65 to 74 years. Some AESIs increased with age. For example, myocardial infarction rates in men increased from 28 (27 to 29) per 100&#x2009;000 person years among those aged 18-34 years to 1400 (1374 to 1427) per 100&#x2009;000 person years in those older than 85 years in US Optum electronic health record data. Other AESIs were more common in young people. For example, rates of anaphylaxis among boys and men were 78 (75 to 80) per 100&#x2009;000 person years in those aged 6-17 years and 8 (6 to 10) per 100&#x2009;000 person years in those older than 85 years in Optum electronic health record data. Meta-analytic estimates of AESI rates were classified according to age and sex.</AbstractText><AbstractText Label="CONCLUSION">This study found large variations in the observed rates of AESIs by age group and sex, showing the need for stratification or standardisation before using background rates for safety surveillance. Considerable population level heterogeneity in AESI rates was found between databases.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xintong</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-6872-5804</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makadia</LastName><ForeName>Rupa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0001-8630-5347</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Hernandez</LastName><ForeName>Eugenia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8317-7068</Identifier><AffiliationInfo><Affiliation>Neurology Department, Hospital Clinic de Barcelona and University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhamme</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bio-Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg, Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000707" MajorTopicYN="Y">Anaphylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: All authors have completed the ICMJE disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare the following interests: DPA receives funding from the UK National Institute for Health Research (NIHR) in the form of a senior research fellowship and the Oxford NIHR Biomedical Research Centre. XL receives the Clarendon Fund and Brasenose College Scholarship (University of Oxford) to support her DPhil study. DPA&#x2019;s research group has received research grants from the European Medicines Agency; the Innovative Medicines Initiative; Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, and UCB Biopharma. GH and AO receive funding from the US National Institutes of Health (NIH) and the US Food and Drug Administration. KV and PR work for a research group that receives/received unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, Novartis, GSK, Amgen, and Chiesi, none of which relates to the content of this paper. PBR, RM, AS, GR, and AGS are employees of Janssen Research and Development and shareholders in Johnson and Johnson. MAS receives grants and contracts from the FDA and the US Department of Veterans Affairs within the scope of this research, and grants and contracts from NIH, IQVIA, and Private Health Management outside the scope of this research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>14</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35727911</ArticleId><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
WHO COVID-19 Dashboard. Geneva: World Health Organization 
2020; Available at https://covid19.who.int/ (accessed 11 Mar 2021).</Citation></Reference><Reference><Citation>Black S, Eskola J, Siegrist C-A, et al. . Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009;374:2115-22. 10.1016/S0140-6736(09)61877-8&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId><ArticleId IdType="pmc">PMC2861912</ArticleId><ArticleId IdType="pubmed">19880172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijnans L, Lecomte C, de Vries C, et al. . The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013;31:1246-54. 10.1016/j.vaccine.2012.12.015&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.12.015</ArticleId><ArticleId IdType="pubmed">23246544</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology. CBER Surveillance Program Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Protocol. https://www.bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-FINAL-2020.pdf (accessed 11 Mar 2021).</Citation></Reference><Reference><Citation>ACCESS. Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines. 2020. http://www.encepp.eu/encepp/viewResource.htm?id=37274 (accessed 11 Mar 2021).</Citation></Reference><Reference><Citation>Report of CIOMS Working Group on Vaccine Safety. CIOMS Guide to Active Vaccine Safety Surveillance. https://cioms.ch/wp-content/uploads/2020/04/240WEB-CIOMS-Guide-AVSS-20170202-protected.pdf (accessed 11 Mar 2021).</Citation></Reference><Reference><Citation>Vlug AE, van der Lei J, Mosseveld BM, et al. . Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38:339-44. 10.1055/s-0038-1634402&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1634402</ArticleId><ArticleId IdType="pubmed">10805025</ArticleId></ArticleIdList></Reference><Reference><Citation>Jouaville SL, Miotti H, Coffin G, et al. . Validity and limitations of the longitudinal patient database France for use in pharmacoepidemiological and pharmacoeconomics studies. Value Health 2015;18:A18 10.1016/j.jval.2015.03.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2015.03.115</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Gil MdelM, Hermosilla E, Prieto-Alhambra D, et al. . Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care 2011;19:135-45.</Citation><ArticleIdList><ArticleId IdType="pubmed">22688222</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K, et al. . Data resource profile: Clinical practice research datalink (CPRD). Int J Epidemiol 2015;44:827-36. 10.1093/ije/dyv098&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv098</ArticleId><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood) 2014;33:1187-94. 10.1377/hlthaff.2014.0038&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2014.0038</ArticleId><ArticleId IdType="pubmed">25006145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T. Data resource profile: JMDC claims databases sourced from Medical Institutions. J Gen Fam Med 2020;21:211-8. 10.1002/jgf2.367&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgf2.367</ArticleId><ArticleId IdType="pmc">PMC7689231</ArticleId><ArticleId IdType="pubmed">33304714</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen L. The Truven health MarketScan databases for life sciences researchers. 2017. https://www.ibm.com/uk-en/products/marketscan-research-databases</Citation></Reference><Reference><Citation>Hripcsak G, Schuemie MJ, Madigan D, Ryan PB, Suchard MA. Drawing reproducible conclusions from observational clinical data with OHDSI. Yearb Med Inform 2021. 10.1055/s-0041-1726481.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1726481</ArticleId><ArticleId IdType="pmc">PMC8416226</ArticleId><ArticleId IdType="pubmed">33882595</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. . Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015;22:553-64. 10.1093/jamia/ocu023&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. . Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform 2015;216:574-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>bc-coordinator. Priority list of adverse events of special interest: COVID-19. 2020. https://brightoncollaboration.us/priority-list-aesi-covid/ (accessed 11 Mar 2021).</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. 10.1016/0197-2456(86)90046-2&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Balduzzi S, R&#xfc;cker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019;22:153-60. 10.1136/ebmental-2019-300117&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ebmental-2019-300117</ArticleId><ArticleId IdType="pubmed">31563865</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549. 10.1136/bmj.d549&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d549</ArticleId><ArticleId IdType="pubmed">21310794</ArticleId></ArticleIdList></Reference><Reference><Citation>The Council for International Organizations of Medical Sciences (CIOMS). Guidelines for Preparing Core Clinical-Safety Information on Drugs Second Edition &#x2013; Report of CIOMS Working Groups III and V. Geneva: 1999.</Citation></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2021. https://www.R-project.org/.</Citation></Reference><Reference><Citation>Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 2021;372:n699. 10.1136/bmj.n699&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n699</ArticleId><ArticleId IdType="pubmed">33707182</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus vaccine - weekly summary of Yellow Card reporting. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting (accessed 22 Mar 2021).</Citation></Reference><Reference><Citation>CoViD Vaccines and thrombotic events: Possibility of mRNA translation and spike protein synthesis by platelets? Published Online First: 15 March 2021. https://www.bmj.com/content/372/bmj.n699/rr-6 (accessed 22 Mar 2021).</Citation></Reference><Reference><Citation>COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. 2021. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots (accessed 22 Mar 2021).</Citation></Reference><Reference><Citation>Black S, Eskola J, Siegrist C-A, et al. . Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009;374:2115-22. 10.1016/S0140-6736(09)61877-8&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId><ArticleId IdType="pmc">PMC2861912</ArticleId><ArticleId IdType="pubmed">19880172</ArticleId></ArticleIdList></Reference><Reference><Citation>Yih WK, Kulldorff M, Fireman BH, et al. . Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics 2011;127(Suppl 1):S54-64. 10.1542/peds.2010-1722I&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-1722I</ArticleId><ArticleId IdType="pubmed">21502252</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein NP, Ray P, Carpenter D, et al. . Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 2010;28:1062-8. 10.1016/j.vaccine.2009.10.115&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.10.115</ArticleId><ArticleId IdType="pubmed">19896453</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker MA, Nguyen M, Cole DV, Lee GM, Lieu TA. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization. Vaccine 2013;31(Suppl 10):K98-112. 10.1016/j.vaccine.2013.04.088&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.04.088</ArticleId><ArticleId IdType="pubmed">24331080</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen TA, J&#xf8;rgensen MRS, Bjerrum S, et al. . Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. BMJ 2012;345:e5823. 10.1136/bmj.e5823&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e5823</ArticleId><ArticleId IdType="pmc">PMC3444137</ArticleId><ArticleId IdType="pubmed">22988304</ArticleId></ArticleIdList></Reference><Reference><Citation>Willame C, Dodd C, van der Aa L, et al. . Incidence rates of autoimmune diseases in European healthcare databases: A contribution of the ADVANCE project. Drug Saf 2021;44:383-95. 10.1007/s40264-020-01031-1&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-01031-1</ArticleId><ArticleId IdType="pmc">PMC7892524</ArticleId><ArticleId IdType="pubmed">33462778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hense S, Schink T, Kreisel SH, et al. . Estimation of background incidence rates of Guillain-Barr&#xe9; syndrome in Germany - a retrospective cohort study with electronic healthcare data. Neuroepidemiology 2014;43:244-52. 10.1159/000369344&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000369344</ArticleId><ArticleId IdType="pubmed">25531827</ArticleId></ArticleIdList></Reference><Reference><Citation>Granieri E, Andreasi NG, De Martin P, et al. . Incidence study of Guillain-Barr&#xe9; syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up. Neurol Sci 2019;40:603-9. 10.1007/s10072-018-3688-4&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3688-4</ArticleId><ArticleId IdType="pubmed">30617450</ArticleId></ArticleIdList></Reference><Reference><Citation>Black SB, Law B, Chen RT, et al. . The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety. Vaccine 2021;39:2712-8. 10.1016/j.vaccine.2021.03.016&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.03.016</ArticleId><ArticleId IdType="pmc">PMC7936550</ArticleId><ArticleId IdType="pubmed">33846042</ArticleId></ArticleIdList></Reference><Reference><Citation>Levison LS, Thomsen RW, Christensen DH, Mellemkj&#xe6;r T, Sindrup SH, Andersen H. Guillain-Barr&#xe9; syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period. Clin Epidemiol 2019;11:275-83. 10.2147/CLEP.S199839&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S199839</ArticleId><ArticleId IdType="pmc">PMC6497480</ArticleId><ArticleId IdType="pubmed">31114387</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Maas NAT, Kramer MA, Jacobs BC, et al. . Guillain-Barr&#xe9; syndrome: background incidence rates in The Netherlands. J Peripher Nerv Syst 2011;16:243-9. 10.1111/j.1529-8027.2011.00356.x&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1529-8027.2011.00356.x</ArticleId><ArticleId IdType="pubmed">22003939</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012;19:54-60. 10.1136/amiajnl-2011-000376&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, et al. . Principles of Large-scale Evidence Generation and Evaluation across a network of databases (LEGEND). J Am Med Inform Assoc 2020;27:1331-7. 10.1093/jamia/ocaa103&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa103</ArticleId><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. . Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:1816-26. 10.1016/S0140-6736(19)32317-7&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Suchard MA, Shea S, et al. . Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020;180:542-51. 10.1001/jamainternmed.2019.7454&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.7454</ArticleId><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="pubmed">32065600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane JCE, Weaver J, Kostka K, et al. OHDSI-COVID-19 consortium . Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol 2020;2:e698-711. 10.1016/S2665-9913(20)30276-9&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30276-9</ArticleId><ArticleId IdType="pmc">PMC7442425</ArticleId><ArticleId IdType="pubmed">32864627</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales DR, Conover MM, You SC, et al. . Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. Lancet Digit Health 2021;3:e98-114. 10.1016/S2589-7500(20)30289-2&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(20)30289-2</ArticleId><ArticleId IdType="pmc">PMC7834915</ArticleId><ArticleId IdType="pubmed">33342753</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35728447</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-866X</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Seminars in arthritis and rheumatism</Title><ISOAbbreviation>Semin Arthritis Rheum</ISOAbbreviation></Journal><ArticleTitle>Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis.</ArticleTitle><Pagination><StartPage>152050</StartPage><MedlinePgn>152050</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semarthrit.2022.152050</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-0172(22)00101-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Identification of rheumatoid arthritis (RA) patients at high risk of adverse health outcomes remains a major challenge. We aimed to develop and validate prediction models for a variety of adverse health outcomes in RA patients initiating first-line methotrexate (MTX) monotherapy.</AbstractText><AbstractText Label="METHODS">Data from 15 claims and electronic health record databases across 9 countries were used. Models were developed and internally validated on Optum&#xae; De-identified Clinformatics&#xae; Data Mart Database using L1-regularized logistic regression to estimate the risk of adverse health outcomes within 3 months (leukopenia, pancytopenia, infection), 2 years (myocardial infarction (MI) and stroke), and 5 years (cancers [colorectal, breast, uterine] after treatment initiation. Candidate predictors included demographic variables and past medical history. Models were externally validated on all other databases. Performance was assessed using the area under the receiver operator characteristic curve (AUC) and calibration plots.</AbstractText><AbstractText Label="FINDINGS">Models were developed and internally validated on 21,547 RA patients and externally validated on 131,928 RA patients. Models for serious infection (AUC: internal 0.74, external ranging from 0.62 to 0.83), MI (AUC: internal 0.76, external ranging from 0.56 to 0.82), and stroke (AUC: internal 0.77, external ranging from 0.63 to 0.95), showed good discrimination and adequate calibration. Models for the other outcomes showed modest internal discrimination (AUC &lt; 0.65) and were not externally validated.</AbstractText><AbstractText Label="INTERPRETATION">We developed and validated prediction models for a variety of adverse health outcomes in RA patients initiating first-line MTX monotherapy. Final models for serious infection, MI, and stroke demonstrated good performance across multiple databases and can be studied for clinical use.</AbstractText><AbstractText Label="FUNDING">This activity under the European Health Data &amp; Evidence Network (EHDEN) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: c.yang@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Jo&#xe3;o Rafael</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>DETI/IEETA, University of Aveiro, Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brouwer</LastName><ForeName>Emily S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmona</LastName><ForeName>Loreto</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Instituto de Salud Musculoesquel&#xe9;tica, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatzidionysiou</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Solna, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fakhouri</LastName><ForeName>Walid</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Windlesham, Surrey, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hottgenroth</LastName><ForeName>Antje</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lilly Deutschland GmbH, Bad Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jani</LastName><ForeName>Meghna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolde</LastName><ForeName>Raivo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kors</LastName><ForeName>Jan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kullamaa</LastName><ForeName>Lembe</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia; Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia; European Patients' Forum, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinier</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Servier, Suresnes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michel</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epidemiology, Bayer Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Henry Morgan</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Brighton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Sulev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia; STACC, Tartu, Estonia; Quretec, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands; Janssen Research and Development, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre</LastName><ForeName>Carmen O</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Brighton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhamme</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizcaya</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bayer Pharmaceuticals, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, United States; Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, United States; Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21605</GrantID><Acronym>VAC_</Acronym><Agency>Versus Arthritis</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Arthritis Rheum</MedlineTA><NlmUniqueID>1306053</NlmUniqueID><ISSNLinking>0049-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">Infections</Keyword><Keyword MajorTopicYN="N">Methotrexate</Keyword><Keyword MajorTopicYN="N">Prediction models</Keyword><Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest CY, RDW, JRA, EB, TDS, MJ, RK, JAK, LK, APU, SR, HMS, and COT report no competing interests related to this work. JNS, AGS, JW, and PR are employees of Janssen Research &amp; Development, a pharmaceutical company of Johnson &amp; Johnson, and shareholders of Johnson &amp; Johnson. At the time the study was conducted, ESB was an employee of Janssen Research &amp; Development, a pharmaceutical company of Johnson &amp; Johnson, shareholder of Johnson &amp; Johnson, and shareholder of Takeda Pharmaceuticals. LC reports her institute has been hired for methodological consultancy by AbbVie Spain, S.L.U., Astellas Pharma, SA, Bristol-Myers Squibb, S.A.U. (BMS), Daiichi-Sankyo Espa&#xf1;a, S.A., Dentsply Sirona Iberia, S.A.U., Eisai Farmac&#xe9;utica, SA, Fresenius Kabi Espa&#xf1;a, S. A. U., Laboratorios Gebro Pharma, SA, Lilly, S.A., Merck Sharp &amp; Dohme Espa&#xf1;a, S.A., Novartis Farmaceutica, SA, Pfizer, S.L.U., Roche Farma, S.A, Sanofi Aventis, UCB Pharma, S.A., outside the submitted work. KC reports consultancy fees from Eli Lilly, AbbVie, and Pfizer, outside the submitted work. WF is an employee and shareholder of Eli Lilly. AHO is an employee of Lilly Deutschland GmbH. JL reports grants from Versus Arthritis, grants from Medical Research Council, outside the submitted work. AM is an employee of Bayer AG. At the time the study was conducted, KM was an employee of Servier. KV works for a research institute which receives/received unconditional research grants from Yamanouchi, Pfizer/Boehringer Ingelheim, Novartis, GSK, UCB, Amgen, Chiesi, none of these are related to the content of this paper. DV reports personal fees from Bayer, during the conduct of the study and outside the submitted work. DPA reports grants and other (DPA's department has received fees for speaker services and advisory board membership) from AMGEN, grants, non-financial support and other (DPA's department has received fees for consultancy services) from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA's department and open for external participants. PRR works for a research institute who receives/received unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, GSK, Amgen, UCB, Novartis, AstraZeneca, Chiesi, Janssen Research and Development, none of which relate to the content of this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35728447</ArticleId><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152050</ArticleId><ArticleId IdType="pii">S0049-0172(22)00101-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35752163</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-6340</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Med (New York, N.Y.)</Title><ISOAbbreviation>Med</ISOAbbreviation></Journal><ArticleTitle>A database of pediatric drug effects to evaluate ontogenic mechanisms from child growth and development.</ArticleTitle><Pagination><StartPage>579</StartPage><EndPage>595.e7</EndPage><MedlinePgn>579-595.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medj.2022.06.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-6340(22)00232-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Adverse drug effects (ADEs) in children are common and may result in disability and death, necessitating post-marketing monitoring of their use. Evaluating drug safety is especially challenging in children due to the processes of growth and maturation, which can alter how children respond to treatment. Current drug safety-signal-detection methods do not account for these dynamics.</AbstractText><AbstractText Label="METHODS">We recently developed a method called disproportionality generalized additive models (dGAMs) to better identify safety signals for drugs across child-development stages.</AbstractText><AbstractText Label="FINDINGS">We used dGAMs on a database of 264,453 pediatric adverse-event reports and found 19,438 ADEs signals associated with development and validated these signals against a small reference set of pediatric ADEs. Using our approach, we can hypothesize on the ontogenic dynamics of ADE signals, such as that montelukast-induced psychiatric disorders appear most significant in the second year of life. Additionally, we integrated pediatric enzyme expression data and found that pharmacogenes with dynamic childhood expression, such as CYP2C18 and CYP27B1, are associated with pediatric ADEs.</AbstractText><AbstractText Label="CONCLUSIONS">We curated KidSIDES, a database of pediatric drug safety signals, for the research community and developed the Pediatric Drug Safety portal (PDSportal) to facilitate evaluation of drug safety signals across childhood growth and development.</AbstractText><AbstractText Label="FUNDING">This study was supported by grants from the National Institutes of Health (NIH).</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giangreco</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Departments of Systems Biology and Biomedical Informatics, Columbia University, 622 W. 168(th) Street, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Departments of Systems Biology and Biomedical Informatics, Columbia University, 622 W. 168(th) Street, New York, NY 10032, USA. Electronic address: nick.tatonetti@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM107145</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA209997</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med</MedlineTA><NlmUniqueID>101769215</NlmUniqueID><ISSNLinking>2666-6340</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048788" MajorTopicYN="N">Growth and Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Translation to population health</Keyword><Keyword MajorTopicYN="N">adverse drug events</Keyword><Keyword MajorTopicYN="N">child development</Keyword><Keyword MajorTopicYN="N">data mining</Keyword><Keyword MajorTopicYN="N">pharmacology</Keyword><Keyword MajorTopicYN="N">precision medicine</Keyword></KeywordList><CoiStatement>Declarations of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35752163</ArticleId><ArticleId IdType="mid">NIHMS1819585</ArticleId><ArticleId IdType="pmc">PMC9378670</ArticleId><ArticleId IdType="doi">10.1016/j.medj.2022.06.001</ArticleId><ArticleId IdType="pii">S2666-6340(22)00232-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Smyth RMD et al. Adverse drug reactions in children--a systematic review. PLoS One 7, e24061 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3293884</ArticleId><ArticleId IdType="pubmed">22403604</ArticleId></ArticleIdList></Reference><Reference><Citation>Impicciatore P et al. Incidence of adverse drug reactions in paediatric in/out-patients: A systematic review and meta-analysis of prospective studies. Br. J. Clin. Pharmacol 52, 77&#x2013;83 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2014499</ArticleId><ArticleId IdType="pubmed">11453893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceci A et al. Clinical Trials in Paediatrics &#x2014; Regulatory and Methodological Aspects. in Drug Discovery and Development - From Molecules to Medicine (2015). doi:10.5772/60611</Citation><ArticleIdList><ArticleId IdType="doi">10.5772/60611</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang TJ, Orenstein L, Kesselheim AS &amp; Bourgeois FT Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies under the US Pediatric Research Equity Act. JAMA Pediatr. 173, 68&#x2013;74 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583440</ArticleId><ArticleId IdType="pubmed">30452498</ArticleId></ArticleIdList></Reference><Reference><Citation>Momper JD, Mulugeta Y &amp; Burckart GJ Failed Pediatric Drug Development Trials. Clin. Pharmacol. Ther 98, 245&#x2013;251 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25963725</ArticleId></ArticleIdList></Reference><Reference><Citation>Wharton GT et al. Impact of Pediatric Exclusivity on Drug Labeling and Demonstrations of Efficacy. Pediatrics 134, e512&#x2013;e518 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25022732</ArticleId></ArticleIdList></Reference><Reference><Citation>Balan S, Hassali MAA &amp; Mak VSL Two decades of off-label prescribing in children: a literature review. World J. Pediatr 14, 528&#x2013;540 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30218415</ArticleId></ArticleIdList></Reference><Reference><Citation>Giangreco NP, Elias JE &amp; Tatonetti NP No population left behind: Improving paediatric drug safety using informatics and systems biology. Br. J. Clin. Pharmacol bcp.14705 (2020). doi:10.1111/bcp.14705</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14705</ArticleId><ArticleId IdType="pmc">PMC8209126</ArticleId><ArticleId IdType="pubmed">33332641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hines RN Ontogeny of human hepatic cytochromes P450. J. Biochem. Mol. Toxicol 21, 169&#x2013;175 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17936930</ArticleId></ArticleIdList></Reference><Reference><Citation>Saghir SA, Khan SA &amp; McCoy AT Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies. Crit. Rev. Toxicol 42, 323&#x2013;357 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22512665</ArticleId></ArticleIdList></Reference><Reference><Citation>Redmond GP, Bell JJ &amp; Perel JM Effect of human growth hormone on amobarbital metabolism in children. Clin. Pharmacol. Ther 24, 213&#x2013;8 (1978).</Citation><ArticleIdList><ArticleId IdType="pubmed">679599</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens A et al. Human growth is associated with distinct patterns of gene expression in evolutionarily conserved networks. BMC Genomics 14, 547 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3765282</ArticleId><ArticleId IdType="pubmed">23941278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy MJ Hormonal Regulation of Hepatic Drug-Metabolizing Enzyme Activity During Adolescence. Clin. Pharmacol. Ther 84, 662&#x2013;673 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684751</ArticleId><ArticleId IdType="pubmed">18971926</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Anker JN How to Improve the Safe and Effective Use of Doxorubicin in Children with Cancer. Clin. Pharmacokinet 54, 1091&#x2013;1093 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26123706</ArticleId></ArticleIdList></Reference><Reference><Citation>Solleveld MM, Schrantee A, Puts NAJ, Reneman L &amp; Lucassen PJ Age-dependent, lasting effects of methylphenidate on the GABAergic system of ADHD patients. NeuroImage Clin. 15, 812&#x2013;818 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5506880</ArticleId><ArticleId IdType="pubmed">28725548</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldrick P Juvenile animal testing in drug development - Is it useful? Regul. Toxicol. Pharmacol 57, 291&#x2013;299 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20350578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z &amp; Zajicek A Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience? Semin. Perinatol 39, 530&#x2013;531 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4634862</ArticleId><ArticleId IdType="pubmed">26455383</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin DK et al. Safety and Transparency of Pediatric Drug Trials. Arch. Pediatr. Adolesc. Med 163, 1080&#x2013;1086 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2792563</ArticleId><ArticleId IdType="pubmed">19996043</ArticleId></ArticleIdList></Reference><Reference><Citation>Osokogu OU et al. Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification. Drug Saf. 39, 873&#x2013;881 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4982893</ArticleId><ArticleId IdType="pubmed">27255487</ArticleId></ArticleIdList></Reference><Reference><Citation>Star K, Nor&#xe9;n GN, Nordin K &amp; Edwards IR Suspected adverse drug reactions reported for children worldwide: An exploratory study using vigibase. Drug Saf. 34, 415&#x2013;428 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21513364</ArticleId></ArticleIdList></Reference><Reference><Citation>Star K Detecting unexpected adverse drug reactions in children. Pediatr. Drugs 13, 71&#x2013;73 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21351806</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaeda T, Tamon A, Kadoyama K &amp; Okuno Y Data mining of the public version of the FDA adverse event reporting system. International Journal of Medical Sciences 10, 796&#x2013;803 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3689877</ArticleId><ArticleId IdType="pubmed">23794943</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti NPP, Ye PPP, Daneshjou R &amp; Altman RBB Data-driven prediction of drug effects and interactions. Sci. Transl. Med 4, 125ra31&#x2013;125ra31 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3382018</ArticleId><ArticleId IdType="pubmed">22422992</ArticleId></ArticleIdList></Reference><Reference><Citation>Almenoff JS et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin. Pharmacol. Ther 82, 157&#x2013;166 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17538548</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate A &amp; Evans SJW Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol. Drug Saf 18, 427&#x2013;436 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19358225</ArticleId></ArticleIdList></Reference><Reference><Citation>CIOMS. Practical Aspects of Signal Detection in Pharmacovigilance Report of CIOMS Working Group VIII. (2010).</Citation></Reference><Reference><Citation>Reinblatt SP, dosReis S, Walkup JT &amp; Riddle MA Activation Adverse Events Induced by the Selective Serotonin Reuptake Inhibitor Fluvoxamine in Children and Adolescents. J. Child Adolesc. Psychopharmacol 19, 119&#x2013;126 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856972</ArticleId><ArticleId IdType="pubmed">19364290</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaja AS et al. Electronic health record (EHR) based postmarketing surveillance of adverse events associated with pediatric off-label medication use: A case study of short-acting beta-2 agonists and arrhythmias. Pharmacoepidemiol. Drug Saf 27, 815&#x2013;822 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29806185</ArticleId></ArticleIdList></Reference><Reference><Citation>Giangreco NP &amp; Tatonetti NP Evaluating risk detection methods to uncover ontogenic-mediated adverse drug effect mechanisms in children. BioData Min. 2021 141 14, 1&#x2013;17 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8296590</ArticleId><ArticleId IdType="pubmed">34294093</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood SN, Li Z, Shaddick G &amp; Augustin NH Generalized Additive Models for Gigadata: Modeling the U.K. Black Smoke Network Daily Data. J. Am. Stat. Assoc 112, 1199&#x2013;1210 (2017).</Citation></Reference><Reference><Citation>McLaren JD et al. Artificial light at night confounds broad-scale habitat use by migrating birds. Ecol. Lett 21, 356&#x2013;364 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29316091</ArticleId></ArticleIdList></Reference><Reference><Citation>Osokogu OU et al. Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems. Drug Saf. 38, 207&#x2013;17 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4328124</ArticleId><ArticleId IdType="pubmed">25663078</ArticleId></ArticleIdList></Reference><Reference><Citation>Giangreco N GRiP_pediatric_ADE-reference_set. GitHub (2020). doi:10.5281/zenodo.4453379</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.4453379</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallerstedt SM, Brunl&#xf6;f G, Sundstr&#xf6;m A &amp; Eriksson AL Montelukast and psychiatric disorders in children. Pharmacoepidemiol. Drug Saf 18, 858&#x2013;64 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19551697</ArticleId></ArticleIdList></Reference><Reference><Citation>Bygdell M, Brunl&#xf6;f G, Wallerstedt SM &amp; Kindblom JM Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population. Pharmacoepidemiol. Drug Saf 21, 79&#x2013;86 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22076661</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldea Perona A, Garc&#xed;a-S&#xe1;iz M &amp; Sanz &#xc1;lvarez E Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase&#xae;. Drug Saf. 39, 69&#x2013;78 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26620206</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanger UM &amp; Schwab M Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther 138, 103&#x2013;41 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23333322</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson T The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 192, 37&#x2013;48 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14511902</ArticleId></ArticleIdList></Reference><Reference><Citation>Upreti VV &amp; Wahlstrom JL Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J. Clin. Pharmacol 56, 266&#x2013;83 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26139104</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanstone MB, Oberfield SE, Shader L, Ardeshirpour L &amp; Carpenter TO Hypercalcemia in children receiving pharmacologic doses of vitamin D. Pediatrics 129, (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194455</ArticleId><ArticleId IdType="pubmed">22412034</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MB Insights into the Structural Determinants of Substrate Binding to Human Cytochromes P450 2C9 and 2C18. FASEB J. 32, 564.3&#x2013;564.3 (2018).</Citation></Reference><Reference><Citation>Nicolao P &amp; Giometto B Neurological Toxicity of Ifosfamide. Oncology 65, 11&#x2013;16 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14586141</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilic S et al. Protection from cyclophosphamide-induced ovarian damage with bone marrow-derived mesenchymal stem cells during puberty. Gynecol. Endocrinol 30, 135&#x2013;140 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24308768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman J, Messazos B, Sharples-blissland N &amp; Cameron F Extreme physiological gynaecomastia in the neonate&#x202f;: Observation not intervention. 51, 1030&#x2013;1032 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25940908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass-Hout TA et al. OpenFDA: An innovative platform providing access to a wealth of FDA&#x2019;s publicly available data. J. Am. Med. Informatics Assoc 23, 596&#x2013;600 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4901374</ArticleId><ArticleId IdType="pubmed">26644398</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K et al. Standard 6: Age groups for pediatric trials. Pediatrics 129, S153&#x2013;S160 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22661762</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. Athena.</Citation></Reference><Reference><Citation>Wishart DS et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, 668&#x2013;672 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347430</ArticleId><ArticleId IdType="pubmed">16381955</ArticleId></ArticleIdList></Reference><Reference><Citation>Buja BYA, Hastie T &amp; Tibshirani R Linear Smoothers and Additive Models. Ann. Stat 17, 453&#x2013;510 (1989).</Citation></Reference><Reference><Citation>Hastie T &amp; Tibshirani R Generalized additive models for medical research. Stat. Methods Med. Res 4, 187&#x2013;196 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8548102</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood SN Generalized additive models: An introduction with R, second edition. Generalized Additive Models: An Introduction with R, Second Edition; (2017). doi:10.1201/9781315370279</Citation><ArticleIdList><ArticleId IdType="doi">10.1201/9781315370279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sard&#xe1;-Espinosa A Comparing time-series clustering algorithms in R using the dtwclust package. R J. 11, 1&#x2013;45 (2019).</Citation></Reference><Reference><Citation>Sard&#xe1;-Espinosa A Time-Series Clustering in R Using the dtwclust Package. R J. 11, 22 (2019).</Citation></Reference><Reference><Citation>Paparrizos J &amp; Gravano L K-shape: Efficient and accurate clustering of time series. Proc. ACM SIGMOD Int. Conf. Manag. Data 2015-May, 1855&#x2013;1870 (2015).</Citation></Reference><Reference><Citation>Cuturi M Fast global alignment kernels. Proc. 28th Int. Conf. Mach. Learn. ICML 2011 929&#x2013;936 (2011).</Citation></Reference><Reference><Citation>Crespi B The evolutionary biology of child health. Proc. R. Soc. B Biol. Sci 278, 1441&#x2013;1449 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081756</ArticleId><ArticleId IdType="pubmed">21288946</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunewardena SS et al. Deciphering the Developmental Dynamics of the Mouse Liver Transcriptome. PLoS One 10, e0141220 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4619800</ArticleId><ArticleId IdType="pubmed">26496202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn M, Letunic I, Jensen LJ &amp; Bork P The SIDER database of drugs and side effects. 44, 1075&#x2013;1079 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702794</ArticleId><ArticleId IdType="pubmed">26481350</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35773820</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>295</Volume><PubDate><Year>2022</Year><Month>Jun</Month><Day>29</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Beyond the Brain: MIDS Extends BIDS to Multiple Modalities and Anatomical Regions.</ArticleTitle><Pagination><StartPage>116</StartPage><EndPage>117</EndPage><MedlinePgn>116-117</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI220674</ELocationID><Abstract><AbstractText>Brain Imaging Data Structure (BIDS) provides a valuable tool to organise brain imaging data into a clear and easy standard directory structure. Moreover, BIDS is widely supported by the scientific community and has been established as a powerful standard for medical imaging management. Nonetheless, the original BIDS is restricted to magnetic resonance imaging (MRI) of the brain, limiting its implantation to other techniques and anatomical regions. We developed Medical Imaging Data Structure (MIDS), conceived to extend BIDS methodology to other anatomical regions and multiple imaging systems in these areas. The MIDS standard was developed to store and manage medical images as an extension of BIDS. It allows the user to handily save studies of multiple anatomical regions and imaging techniques. Besides, MIDS improves the classification of multiple images within the structure, allowing the possibility to unify them in a single study to apply on them preprocessing or artificial intelligence algorithms. Finally, the results generated are saved in the derivatives folder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saborit-Torres</LastName><ForeName>Jose Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadal-Almela</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montell-Serrano</LastName><ForeName>Joaquim Angel</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliver-Garcia</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carceller</LastName><ForeName>Hector</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERSAM, ISC III. Av. Blasco Ib&#xe1;&#xf1;ez 15, 46010 - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Biotechnology and Biomedicine (BIOTECMED), Universitat de Valencia, Burjassot, 46100, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-&#xc1;drian</LastName><ForeName>Jon Ander</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Computer Systems and Computation, Universitat Polit&#xe8;cnica de Val&#xe8;ncia - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caparr&#xf3;s-Redondo</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Garc&#xed;a</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioinformatics &amp; Biostatistics Unit, Principe Felipe Research Center - Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domenech-Fern&#xe1;ndez</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Arnau de Vilanova - Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De La Iglesia-Vay&#xe1;</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad Mixta de Imagen Biom&#xe9;dica FISABIO-CIPF. Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERSAM, ISC III. Av. Blasco Ib&#xe1;&#xf1;ez 15, 46010 - Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Directorate of Research, Innovation, Technology and Quality. Subdirectorate General of Information Systems for Health - Valencia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="Y">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BIDS</Keyword><Keyword MajorTopicYN="N">Database</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Standardization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>1</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35773820</ArticleId><ArticleId IdType="doi">10.3233/SHTI220674</ArticleId><ArticleId IdType="pii">SHTI220674</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35773924</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>295</Volume><PubDate><Year>2022</Year><Month>Jun</Month><Day>29</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>An OHDSI ATLAS Extension to Support Feasibility Requests in a Research Network.</ArticleTitle><Pagination><StartPage>515</StartPage><EndPage>516</EndPage><MedlinePgn>515-516</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI220778</ELocationID><Abstract><AbstractText>Checking the feasibility of real-world data to answer a certain research question is crucial especially in a multi-site research network. In this work we present an extension of the ATLAS user interface for the OMOP common data model that integrates into an existing national feasibility network and thus foster capabilities for future participation in international research studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reinecke</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruhl</LastName><ForeName>Mirko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinnau</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Medical Informatics, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altun</LastName><ForeName>Fatma Bet&#xfc;l</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Institute of Medical Informatics, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Folz</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Medical Informatics, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoch</LastName><ForeName>Mich&#xe9;le</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bathelt</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="Y">Feasibility Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">feasibility requests</Keyword><Keyword MajorTopicYN="N">interoperability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>1</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35773924</ArticleId><ArticleId IdType="doi">10.3233/SHTI220778</ArticleId><ArticleId IdType="pii">SHTI220778</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35780114</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>BMC medical research methodology</Title><ISOAbbreviation>BMC Med Res Methodol</ISOAbbreviation></Journal><ArticleTitle>Empirical assessment of alternative methods for identifying seasonality in observational healthcare data.</ArticleTitle><Pagination><StartPage>182</StartPage><MedlinePgn>182</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">182</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12874-022-01652-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Seasonality classification is a well-known and important part of time series analysis. Understanding the seasonality of a biological event can contribute to an improved understanding of its causes and help guide appropriate responses. Observational data, however, are not comprised of biological events, but timestamped diagnosis codes the combination of which (along with additional requirements) are used as proxies for biological events. As there exist different methods for determining the seasonality of a time series, it is necessary to know if these methods exhibit concordance. In this study we seek to determine the concordance of these methods by applying them to time series derived from diagnosis codes in observational data residing in databases that vary in size, type, and provenance.</AbstractText><AbstractText Label="METHODS">We compared 8 methods for determining the seasonality of a time series at three levels of significance (0.01, 0.05, and 0.1), against 10 observational health databases. We evaluated 61,467 time series at each level of significance, totaling 184,401 evaluations.</AbstractText><AbstractText Label="RESULTS">Across all databases and levels of significance, concordance ranged from 20.2 to 40.2%. Across all databases and levels of significance, the proportion of time series classified seasonal ranged from 4.9 to 88.3%. For each database and level of significance, we computed the difference between the maximum and minimum proportion of time series classified seasonal by all methods. The median within-database difference was 54.8, 34.7, and 39.8%, for p&#x2009;&lt;&#x2009;0.01, 0.05, and 0.1, respectively.</AbstractText><AbstractText Label="CONCLUSION">Methods of binary seasonality classification when applied to time series derived from diagnosis codes in observational health data produce inconsistent results. The methods exhibit considerable discord within all databases, implying that the discord is a result of the difference between the methods themselves and not due to the choice of database. The results indicate that researchers relying on automated methods to assess the seasonality of time series derived from diagnosis codes in observational data should be aware that the methods are not interchangeable and thus the choice of method can affect the generalizability of their work. Seasonality determination is highly dependent on the method chosen.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Molinaro</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, 1125 Trenton Harbourton Rd, Titusville, NJ, 08560, USA. amolin19@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, 1125 Trenton Harbourton Rd, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Res Methodol</MedlineTA><NlmUniqueID>100968545</NlmUniqueID><ISSNLinking>1471-2288</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="Y">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACHILLES</Keyword><Keyword MajorTopicYN="N">ARIMA</Keyword><Keyword MajorTopicYN="N">CASTOR</Keyword><Keyword MajorTopicYN="N">Classification</Keyword><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Cyclical</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Observational data</Keyword><Keyword MajorTopicYN="N">R</Keyword><Keyword MajorTopicYN="N">Seasonality</Keyword><Keyword MajorTopicYN="N">Time series</Keyword></KeywordList><CoiStatement>Both authors are full time employees of Janssen Research and Development, a unit of Johnson and Johnson. The work on this study was part of their employment. They also hold pension rights from the company and own stock and stock options.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>2</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35780114</ArticleId><ArticleId IdType="pmc">PMC9250712</ArticleId><ArticleId IdType="doi">10.1186/s12874-022-01652-3</ArticleId><ArticleId IdType="pii">10.1186/s12874-022-01652-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Martinez ME. The calendar of epidemics: Seasonal cycles of infectious diseases. PLoS Pathog. 2018;14(11):e1007327. doi: 10.1371/journal.ppat.1007327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007327</ArticleId><ArticleId IdType="pmc">PMC6224126</ArticleId><ArticleId IdType="pubmed">30408114</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon JY, Cha JM, Kim HI, Kwak MS. Seasonal variation of peptic ulcer disease, peptic ulcer bleeding, and acute pancreatitis: A nationwide population-based study using a common data model. Medicine (Baltimore) 2021;100(21):e25820. doi: 10.1097/MD.0000000000025820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000025820</ArticleId><ArticleId IdType="pmc">PMC8154390</ArticleId><ArticleId IdType="pubmed">34032695</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisman DN. Seasonality of infectious diseases. Annu Rev Public Health. 2007;28:127&#x2013;143. doi: 10.1146/annurev.publhealth.28.021406.144128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.publhealth.28.021406.144128</ArticleId><ArticleId IdType="pubmed">17222079</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisman D. Seasonality of viral infections: mechanisms and unknowns. Clin Microbiol Infect. 2012;18(10):946&#x2013;954. doi: 10.1111/j.1469-0691.2012.03968.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03968.x</ArticleId><ArticleId IdType="pubmed">22817528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan K, Thenmozhi M, George S, Anandan S, Veeraraghavan B, Naumova EN, Jeyaseelan L. Assessing Seasonality Variation with Harmonic Regression: Accommodations for Sharp Peaks. Int J Environ Res Public Health. 2020;17(4):1318. doi: 10.3390/ijerph17041318.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17041318</ArticleId><ArticleId IdType="pmc">PMC7068504</ArticleId><ArticleId IdType="pubmed">32085630</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP Common Data Model (https://ohdsi.github.io/CommonDataModel/) Accessed 20 Oct 2021.</Citation></Reference><Reference><Citation>Achilles (https://github.com/OHDSI/Achilles) Accessed 27 June 2019.</Citation></Reference><Reference><Citation>Castor (https://github.com/OHDSI/Castor) Accessed 2 Oct 2020.</Citation></Reference><Reference><Citation>Forecast (https://cran.r-project.org/web/packages/forecast/index.html): Forecasting Functions for Time Series and Linear Models. Methods and tools for displaying and analysing univariate time series forecasts including exponential smoothing via state space models and automatic ARIMA modelling. Accessed 8 Feb 2020</Citation></Reference><Reference><Citation>Webel K, Ollech D. Proceedings of the 5th International Conference on Time Series and Forecasting. 2018. An overall seasonality test based on recursive feature elimination in conditional random forests; pp. 20&#x2013;31.</Citation></Reference><Reference><Citation>Seastests (https://cran.r-project.org/web/packages/seastests/index.html): Seasonality Tests - An overall test for seasonality of a given time series in addition to a set of single seasonality tests as used in Ollech and Webel (forthcoming): An overall seasonality test. Bundesbank Discussion Paper. Accessed 17 June&#xa0;2020.</Citation></Reference><Reference><Citation>Edwards JH. The recognition and estimation of cyclic trends. Ann Hum Genet. 1961;25:83&#x2013;87. doi: 10.1111/j.1469-1809.1961.tb01501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-1809.1961.tb01501.x</ArticleId><ArticleId IdType="pubmed">13725808</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookhart MA, Rothman KJ. Simple estimators of the intensity of seasonal occurrence. BMC Med Res Methodol. 2008;8:67. doi: 10.1186/1471-2288-8-67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-8-67</ArticleId><ArticleId IdType="pmc">PMC2596789</ArticleId><ArticleId IdType="pubmed">18945366</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein RB, Schuemie MJ, Ryan PB, Stang PE. Seasonality in acute liver injury? Findings in two health care claims databases. Drug Healthc Patient Saf. 2016;8:39&#x2013;48. doi: 10.2147/DHPS.S95399.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DHPS.S95399</ArticleId><ArticleId IdType="pmc">PMC4824282</ArticleId><ArticleId IdType="pubmed">27099532</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman M. The Use of Ranks to Avoid the Assumption of Normality Implicit in the Analysis of Variance. J Am Stat Assoc. 1937;32(200):675&#x2013;701. doi: 10.1080/01621459.1937.10503522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1937.10503522</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyndman R. Detecting Seasonality. https://robjhyndman.com/hyndsight/detecting-seasonality/ (2014). Accessed 27 June 2019.</Citation></Reference><Reference><Citation>Hyndman R, Athanasopoulos G. Forecasting: Principles and Practice. Online Edition. https://otexts.com/fpp2/, https://otexts.com/fpp2/seasonal-arima.html, https://otexts.com/fpp2/arima-ets.html, https://otexts.com/fpp2/arima-r.html, https://otexts.com/fpp2/ets.html, https://otexts.com/fpp2/estimation-and-model-selection.html (2018). Accessed 27 June 2019.</Citation></Reference><Reference><Citation>Hyndman R. Period detection of a generic time series. https://stats.stackexchange.com/questions/1207/period-detection-of-a-generic-time-series/1214#1214 (2010). Accessed 27 June 2019.</Citation></Reference><Reference><Citation>Hyndman R. Measuring time series characteristics. https://robjhyndman.com/hyndsight/tscharacteristics (2012). Accessed 27 June 2019.</Citation></Reference><Reference><Citation>Hyndman RJ, Khandakar Y. Automatic time series forecasting: The forecast package for R. J Stat Softw. 2008;27(1):1&#x2013;22. doi: 10.18637/jss.v027.i03.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v027.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez V, Maravall A. Programs TRAMO and SEATS: instructions for the user. Mimeo, Banco de Espa&#xf1;a (1997).</Citation></Reference><Reference><Citation>Kruskal W, Wallis W. Use of Ranks in One-Criterion Variance Analysis. J Am Stat Assoc. 1952;47(260):583&#x2013;621. doi: 10.2307/2280779.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2280779</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch B. On the Comparison of Several Mean Values: An Alternative Approach. Biometrika. 1951;38(3/4):330&#x2013;336. doi: 10.2307/2332579.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2332579</ArticleId></ArticleIdList></Reference><Reference><Citation>Beveridge WH. Wheat Prices and Rainfall in Western Europe. J R Stat Soc. 1922;85(3):412&#x2013;475. doi: 10.2307/2341183.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2341183</ArticleId></ArticleIdList></Reference><Reference><Citation>Yule GU. Why do we sometimes get nonsense-correlations between time series? A study in sampling and the nature of time series. J R Stat Soc. 1926;89(1):1&#x2013;63. doi: 10.2307/2341482.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2341482</ArticleId></ArticleIdList></Reference><Reference><Citation>Shumway R, Stoffer DS. Time Series Analysis and Its Applications With R Examples. 3. Springer; 2011.</Citation></Reference><Reference><Citation>Wilks SS. The Large-Sample Distribution of the Likelihood Ratio for Testing Composite Hypotheses. Ann Math Statist. 1938;9(1):60&#x2013;62. doi: 10.1214/aoms/1177732360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/aoms/1177732360</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35786634</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2561-326X</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>JMIR formative research</Title><ISOAbbreviation>JMIR Form Res</ISOAbbreviation></Journal><ArticleTitle>Methodological Issues in Using a Common Data Model of COVID-19 Vaccine Uptake and Important Adverse Events of Interest: Feasibility Study of Data and Connectivity COVID-19 Vaccines Pharmacovigilance in the United Kingdom.</ArticleTitle><Pagination><StartPage>e37821</StartPage><MedlinePgn>e37821</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e37821</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/37821</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Data and Connectivity COVID-19 Vaccines Pharmacovigilance (DaC-VaP) UK-wide collaboration was created to monitor vaccine uptake and effectiveness and provide pharmacovigilance using routine clinical and administrative data. To monitor these, pooled analyses may be needed. However, variation in terminologies present a barrier as England uses the Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT), while the rest of the United Kingdom uses the Read v2 terminology in primary care. The availability of data sources is not uniform across the United Kingdom.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to use the concept mappings in the Observational Medical Outcomes Partnership (OMOP) common data model (CDM) to identify common concepts recorded and to report these in a repeated cross-sectional study. We planned to do this for vaccine coverage and 2 adverse events of interest (AEIs), cerebral venous sinus thrombosis (CVST) and anaphylaxis. We identified concept mappings to SNOMED CT, Read v2, the World Health Organization's International Classification of Disease Tenth Revision (ICD-10) terminology, and the UK Dictionary of Medicines and Devices (dm+d).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Exposures and outcomes of interest to DaC-VaP for pharmacovigilance studies were selected. Mappings of these variables to different terminologies used across the United Kingdom's devolved nations' health services were identified from the Observational Health Data Sciences and Informatics (OHDSI) Automated Terminology Harmonization, Extraction, and Normalization for Analytics (ATHENA) online browser. Lead analysts from each nation then confirmed or added to the mappings identified. These mappings were then used to report AEIs in a common format. We reported rates for windows of 0-2 and 3-28 days postvaccine every 28 days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We listed the mappings between Read v2, SNOMED CT, ICD-10, and dm+d. For vaccine exposure, we found clear mapping from OMOP to our clinical terminologies, though dm+d had codes not listed by OMOP at the time of searching. We found a list of CVST and anaphylaxis codes. For CVST, we had to use a broader cerebral venous thrombosis conceptual approach to include Read v2. We identified 56 SNOMED CT codes, of which we selected 47 (84%), and 15 Read v2 codes. For anaphylaxis, our refined search identified 60 SNOMED CT codes and 9 Read v2 codes, of which we selected 10 (17%) and 4 (44%), respectively, to include in our repeated cross-sectional studies.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This approach enables the use of mappings to different terminologies within the OMOP CDM without the need to catalogue an entire database. However, Read v2 has less granular concepts than some terminologies, such as SNOMED CT. Additionally, the OMOP CDM cannot compensate for limitations in the clinical coding system. Neither Read v2 nor ICD-10 is sufficiently granular to enable CVST to be specifically flagged. Hence, any pooled analysis will have to be at the less specific level of cerebrovascular venous thrombosis. Overall, the mappings within this CDM are useful, and our method could be used for rapid collaborations where there are only a limited number of concepts to pool.</AbstractText><CopyrightInformation>&#xa9;Gayathri Delanerolle, Robert Williams, Ana Stipancic, Rachel Byford, Anna Forbes, Ruby S M Tsang, Sneha N Anand, Declan Bradley, Siobh&#xe1;n Murphy, Ashley Akbari, Stuart Bedston, Ronan A Lyons, Rhiannon Owen, Fatemeh Torabi, Jillian Beggs, Antony Chuter, Dominique Balharry, Mark Joy, Aziz Sheikh, F D Richard Hobbs, Simon de Lusignan. Originally published in JMIR Formative Research (https://formative.jmir.org), 22.08.2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delanerolle</LastName><ForeName>Gayathri</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9628-9245</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1370-8898</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stipancic</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6503-8278</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal College of General Practitioners, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byford</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4792-8995</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forbes</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7860-3782</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsang</LastName><ForeName>Ruby S M</ForeName><Initials>RSM</Initials><Identifier Source="ORCID">0000-0002-2520-526X</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Sneha N</ForeName><Initials>SN</Initials><Identifier Source="ORCID">0000-0002-0538-3974</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Declan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1468-1823</Identifier><AffiliationInfo><Affiliation>Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Agency, Belfast, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Siobh&#xe1;n</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9765-3873</Identifier><AffiliationInfo><Affiliation>Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbari</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0814-0801</Identifier><AffiliationInfo><Affiliation>Population Data Science, Swansea University, Swansea, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedston</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5635-5957</Identifier><AffiliationInfo><Affiliation>Population Data Science, Swansea University, Swansea, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Ronan A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0001-5225-000X</Identifier><AffiliationInfo><Affiliation>Population Data Science, Swansea University, Swansea, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Rhiannon</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5977-376X</Identifier><AffiliationInfo><Affiliation>Population Data Science, Swansea University, Swansea, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torabi</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5853-4625</Identifier><AffiliationInfo><Affiliation>Population Data Science, Swansea University, Swansea, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beggs</LastName><ForeName>Jillian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7591-3256</Identifier><AffiliationInfo><Affiliation>Usher Institute, University of Edinburgh, Edingburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuter</LastName><ForeName>Antony</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0646-5939</Identifier><AffiliationInfo><Affiliation>Usher Institute, University of Edinburgh, Edingburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balharry</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7439-2105</Identifier><AffiliationInfo><Affiliation>Usher Institute, University of Edinburgh, Edingburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joy</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4974-3724</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Aziz</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7022-3056</Identifier><AffiliationInfo><Affiliation>Usher Institute, University of Edinburgh, Edingburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hobbs</LastName><ForeName>F D Richard</ForeName><Initials>FDR</Initials><Identifier Source="ORCID">0000-0001-7976-7172</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lusignan</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8553-2641</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal College of General Practitioners, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/V028367/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Form Res</MedlineTA><NlmUniqueID>101726394</NlmUniqueID><ISSNLinking>2561-326X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">Systematized Nomenclature of Medicine</Keyword><Keyword MajorTopicYN="N">anaphylaxis</Keyword><Keyword MajorTopicYN="N">clinical coding system</Keyword><Keyword MajorTopicYN="N">clinical outcome</Keyword><Keyword MajorTopicYN="N">data model</Keyword><Keyword MajorTopicYN="N">health database</Keyword><Keyword MajorTopicYN="N">health information</Keyword><Keyword MajorTopicYN="N">medical outcome</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">sinus thrombosis</Keyword><Keyword MajorTopicYN="N">vaccine effect</Keyword><Keyword MajorTopicYN="N">vaccine uptake</Keyword></KeywordList><CoiStatement>Conflicts of Interest: SdeL reports that through his university, he has had grants from AstraZeneca, GSK, Sanofi, Seqirus, and Takeda for vaccine-related research and membership of advisory boards for AstraZeneca, Sanofi, and Seqirus. FDRH acknowledges part support as director of the National Institute for Health and Care Research (NIHR) Applied Research Collaboration (ARC) Oxford Thames Valley, and theme lead of the NIHR Oxford University Hospitals (OUH) Biomedical Research Centre (BRC). FDRH also received occasional fees or expenses for speaking or consultancy from AstraZeneca, Boehringer Ingelheim (BI), Bayer, Bristol Myers Squibb (BMS)/Pfizer, and Novartis. A Sheikh serves as an adviser to the UK and the Scottish Governments. He is also a member of Astra-Zeneca's Thrombotic Thrombocytopenic TaskForce. All these roles are unremunerated. RO is a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee, member of the NICE Decision Support Unit (DSU), and associate member of the NICE Technical Support Unit (TSU). She has served as a paid consultant to the pharmaceutical industry, providing unrelated methodological advice. She reports teaching fees from the Association of British Pharmaceutical Industry (ABPI) and the University of Bristol. RAL is an unrenumerated member of the Welsh Government COVID-19 Technical Advisory Group. All other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>5</Day><Hour>14</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35786634</ArticleId><ArticleId IdType="pmc">PMC9400842</ArticleId><ArticleId IdType="doi">10.2196/37821</ArticleId><ArticleId IdType="pii">v6i8e37821</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO Coronavirus (COVID-19) Dashboard.  [2022-07-21].  
 https://tinyurl.com/mpzcu3b7
.</Citation></Reference><Reference><Citation>Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270&#x2013;273. doi: 10.14293/s2199-1006.1.sor-uncat.atfigj.v1.rpnimv.</Citation><ArticleIdList><ArticleId IdType="doi">10.14293/s2199-1006.1.sor-uncat.atfigj.v1.rpnimv</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa,the UK. Lancet. 2021;397(10269):99&#x2013;111. doi: 10.3410/f.739172196.793581032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3410/f.739172196.793581032</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi P, T&#xfc;reci &#xd6;, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, &#x15e;ahin U, Gruber WC. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020 Dec 17;383(25):2439&#x2013;2450. doi: 10.1056/nejmoa2027906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O'Doherty M, Brown K, Cameron C, Stockton D, McMenamin J, Ramsay M. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021 May 13;373:n1088. doi: 10.1136/bmj.n1088. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1088</ArticleId><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter A, de Lusignan S, Docherty AB, Ford D, Hobbs FR, Joy M, Katikireddi SV, Marple J, McCowan C, McGagh D, McMenamin J, Moore E, Murray JL, Pan J, Ritchie L, Shah SA, Stock S, Torabi F, Tsang RS, Wood R, Woolhouse M, Robertson C, Sheikh A. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021 May;397(10285):1646&#x2013;1657. doi: 10.1016/s0140-6736(21)00677-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00677-2</ArticleId><ArticleId IdType="pmc">PMC8064669</ArticleId><ArticleId IdType="pubmed">33901420</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021 Jun 03;384(22):2092&#x2013;2101. doi: 10.1056/nejmoa2104840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2104840</ArticleId><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, McCowan C, Agrawal U, Shah SA, Ritchie LD, Murray J, Pan J, Bradley DT, Stock SJ, Wood R, Chuter A, Beggs J, Stagg HR, Joy M, Tsang RSM, de Lusignan S, Hobbs R, Lyons RA, Torabi F, Bedston S, O'Leary M, Akbari A, McMenamin J, Robertson C, Sheikh A. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med. 2021 Jul 09;27(7):1290&#x2013;1297. doi: 10.1038/s41591-021-01408-4. 
 
10.1038/s41591-021-01408-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01408-4</ArticleId><ArticleId IdType="pmc">PMC8282499</ArticleId><ArticleId IdType="pubmed">34108714</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan S. Codes, classifications, terminologies and nomenclatures: definition, development and application in practice. Inform Prim Care. 2005 Mar 01;13(1):65&#x2013;70. doi: 10.14236/jhi.v13i1.580. 
 
580</Citation><ArticleIdList><ArticleId IdType="doi">10.14236/jhi.v13i1.580</ArticleId><ArticleId IdType="pubmed">15949178</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifir&#xf2; G, Coloma PM, Rijnbeek PR, Romio S, Mosseveld B, Weibel D, Bonhoeffer J, Schuemie M, van der Lei J, Sturkenboom M. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014 Jun 27;275(6):551&#x2013;561. doi: 10.1111/joim.12159. doi: 10.1111/joim.12159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12159</ArticleId><ArticleId IdType="doi">10.1111/joim.12159</ArticleId><ArticleId IdType="pubmed">24635221</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Ostropolets A, Makadia R, Shaoibi A, Rao G, Sena A, Martinez-Hernandez E, Delmestri A, Verhamme K, Rijnbeek PR, Duarte-Salles T, Suchard M, Ryan P, Hripcsak G, Prieto-Alhambra D. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. medRxiv. doi: 10.1101/2021.03.25.21254315. doi: 10.1101/2021.03.25.21254315. Preprint posted online April 17, 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.25.21254315</ArticleId><ArticleId IdType="doi">10.1101/2021.03.25.21254315</ArticleId><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="pubmed">35727911</ArticleId></ArticleIdList></Reference><Reference><Citation>Liyanage H, Liaw S, Jonnagaddala J, Hinton W, de LS. Common data models (CDMs) to enhance international big data analytics: a diabetes use case to compare three CDMs. Stud Health Technol Inform. 2018;255:60&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30306907</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, DeFalco FJ, Londhe A, Zhu V, Ryan PB. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015 May;22(3):553&#x2013;564. doi: 10.1093/jamia/ocu023. 
 
ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf. 2014 Nov 4;37(11):945&#x2013;959. doi: 10.1007/s40264-014-0214-3. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0214-3</ArticleId><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Bennett TD, Eichmann DA, Guinney J, Kibbe WA, Payne PRO, Pfaff ER, Robinson PN, Saltz JH, Spratt H, Suver C, Wilbanks J, Wilcox AB, Williams AE, Wu C, Blacketer C, Bradford RL, Cimino JJ, Clark M, Colmenares EW, Francis PA, Gabriel D, Graves A, Hemadri R, Hong SS, Hripscak G, Jiao D, Klann JG, Kostka K, Lee AM, Lehmann HP, Lingrey L, Miller RT, Morris M, Murphy SN, Natarajan K, Palchuk MB, Sheikh U, Solbrig H, Visweswaran S, Walden A, Walters KM, Weber GM, Zhang XT, Zhu RL, Amor B, Girvin AT, Manna A, Qureshi N, Kurilla MG, Michael SG, Portilla LM, Rutter JL, Austin CP, Gersing KR, N3C Consortium  The National COVID Cohort Collaborative (N3C): eationale, design, infrastructure, and deployment. J Am Med Inform Assoc. 2021 Mar 01;28(3):427&#x2013;443. doi: 10.1093/jamia/ocaa196. 
 
5893482</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa196</ArticleId><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;ggeberg JU, Gold MS, Bayas J, Blum MD, Bonhoeffer J, Friedlander S, de Souza Brito G, Heininger U, Imoukhuede B, Khamesipour A, Erlewyn-Lajeunesse M, Martin S, M&#xe4;kel&#xe4; M, Nell P, Pool V, Simpson N, Brighton Collaboration Anaphylaxis Working Group Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007 Aug 01;25(31):5675&#x2013;5684. doi: 10.1016/j.vaccine.2007.02.064.S0264-410X(07)00264-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.02.064</ArticleId><ArticleId IdType="pubmed">17448577</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan S, Lopez Bernal J, Byford R, Amirthalingam G, Ferreira F, Akinyemi O, Andrews N, Campbell H, Dabrera G, Deeks A, Elliot AJ, Krajenbrink E, Liyanage H, McGagh D, Okusi C, Parimalanathan V, Ramsay M, Smith G, Tripathy M, Williams J, Victor W, Zambon M, Howsam G, Nicholson BD, Tzortziou Brown V, Butler CC, Joy M, Hobbs FR. Influenza and respiratory virus surveillance, vaccine uptake, and effectiveness at a time of cocirculating COVID-19: protocol for the English primary care Sentinel System for 2020-2021. JMIR Public Health Surveill. 2021 Feb 19;7(2):e24341. doi: 10.2196/24341. 
 
v7i2e24341</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/24341</ArticleId><ArticleId IdType="pmc">PMC7899204</ArticleId><ArticleId IdType="pubmed">33605892</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler CC, Dorward J, Yu L, Gbinigie O, Hayward G, Saville BR, Van Hecke O, Berry N, Detry M, Saunders C, Fitzgerald M, Harris V, Patel MG, de Lusignan S, Ogburn E, Evans PH, Thomas NP, Hobbs FR. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021 Mar;397(10279):1063&#x2013;1074. doi: 10.1016/s0140-6736(21)00461-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00461-x</ArticleId><ArticleId IdType="pmc">PMC7972318</ArticleId><ArticleId IdType="pubmed">33676597</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan S, Correa A, Smith GE, Yonova I, Pebody R, Ferreira F, Elliot AJ, Fleming D. RCGP Research and Surveillance Centre: 50 years&#x2019; surveillance of influenza, infections, and respiratory conditions. Br J Gen Pract. 2017 Sep 29;67(663):440&#x2013;441. doi: 10.3399/bjgp17x692645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp17x692645</ArticleId><ArticleId IdType="pmc">PMC5604796</ArticleId><ArticleId IdType="pubmed">28963401</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan S, Jones N, Dorward J, Byford R, Liyanage H, Briggs J, Ferreira F, Akinyemi O, Amirthalingam G, Bates C, Lopez Bernal J, Dabrera G, Eavis A, Elliot AJ, Feher M, Krajenbrink E, Hoang U, Howsam G, Leach J, Okusi C, Nicholson B, Nieri P, Sherlock J, Smith G, Thomas M, Thomas N, Tripathy M, Victor W, Williams J, Wood I, Zambon M, Parry J, O'Hanlon S, Joy M, Butler C, Marshall M, Hobbs FR. The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: protocol to develop extended COVID-19 surveillance and trial platforms. JMIR Public Health Surveill. 2020 Jul 02;6(3):e19773. doi: 10.2196/19773. 
 
v6i3e19773</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/19773</ArticleId><ArticleId IdType="pmc">PMC7333793</ArticleId><ArticleId IdType="pubmed">32484782</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS Digital  Data Security and Information Governance.  [2022-07-21].  
 https://digital.nhs.uk/data-and-information/looking-after-information/data-security-and-information-governance
.</Citation></Reference><Reference><Citation>Information Security  Patient Data Application under a DSP Toolkit.  [2022-07-21].  
 https://www.infosec.ox.ac.uk/apply-to-be-made-part-of-university-of-oxford-dspt#/
</Citation></Reference><Reference><Citation>Duarte-Salles T, Prieto-Alhambra D. Heterologous vaccine regimens against COVID-19. Lancet. 2021 Jul;398(10295):94&#x2013;95. doi: 10.1016/s0140-6736(21)01442-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)01442-2</ArticleId><ArticleId IdType="pmc">PMC8233006</ArticleId><ArticleId IdType="pubmed">34181881</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35790207</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1598-6357</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>26</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>04</Day></PubDate></JournalIssue><Title>Journal of Korean medical science</Title><ISOAbbreviation>J Korean Med Sci</ISOAbbreviation></Journal><ArticleTitle>Perceived Risk of Re-Identification in OMOP-CDM Database: A Cross-Sectional Survey.</ArticleTitle><Pagination><StartPage>e205</StartPage><MedlinePgn>e205</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e205</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3346/jkms.2022.37.e205</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The advancement of information technology has immensely increased the quality and volume of health data. This has led to an increase in observational study, as well as to the threat of privacy invasion. Recently, a distributed research network based on the common data model (CDM) has emerged, enabling collaborative international medical research without sharing patient-level data. Although the CDM database for each institution is built inside a firewall, the risk of re-identification requires management. Hence, this study aims to elucidate the perceptions CDM users have towards CDM and risk management for re-identification.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The survey, targeted to answer specific in-depth questions on CDM, was conducted from October to November 2020. We targeted well-experienced researchers who actively use CDM. Basic statistics (total number and percent) were computed for all covariates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 33 valid respondents. Of these, 43.8% suggested additional anonymization was unnecessary beyond, "minimum cell count" policy, which obscures a cell with a value lower than certain number (usually 5) in shared results to minimize the liability of re-identification due to rare conditions. During extract-transform-load processes, 81.8% of respondents assumed structured data is under control from the risk of re-identification. However, respondents noted that date of birth and death were highly re-identifiable information. The majority of respondents (n = 22, 66.7%) conceded the possibility of identifier-contained unstructured data in the <i>NOTE</i> table.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overall, CDM users generally attributed high reliability for privacy protection to the intrinsic nature of CDM. There was little demand for additional de-identification methods. However, unstructured data in the CDM were suspected to have risks. The necessity for a coordinating consortium to define and manage the re-identification risk of CDM was urged.</AbstractText><CopyrightInformation>&#xa9; 2022 The Korean Academy of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Tak</LastName><ForeName>Yae Won</ForeName><Initials>YW</Initials><Identifier Source="ORCID">0000-0002-6639-9013</Identifier><AffiliationInfo><Affiliation>Department of Information Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5052-6399</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Jeong Hyun</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-2336-3595</Identifier><AffiliationInfo><Affiliation>Department of Information Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Soon-Seok</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-8458-7077</Identifier><AffiliationInfo><Affiliation>Department of Big Data Science, Halla University, Wonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Gi-Tae</ForeName><Initials>GT</Initials><Identifier Source="ORCID">0000-0002-1635-5653</Identifier><AffiliationInfo><Affiliation>UPS Data Corporation, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yura</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2048-3727</Identifier><AffiliationInfo><Affiliation>Department of Information Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. haepary@naver.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20005021</GrantID><Agency>Ministry of Trade, Industry and Energy</Agency><Country>Korea</Country></Grant><Grant><GrantID>22213MFDS486</GrantID><Agency>Ministry of Food and Drug Safety</Agency><Country>Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Korean Med Sci</MedlineTA><NlmUniqueID>8703518</NlmUniqueID><ISSNLinking>1011-8934</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">De-identification</Keyword><Keyword MajorTopicYN="N">Privacy</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>5</Day><Hour>20</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35790207</ArticleId><ArticleId IdType="pmc">PMC9259248</ArticleId><ArticleId IdType="doi">10.3346/jkms.2022.37.e205</ArticleId><ArticleId IdType="pii">37.e205</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878&#x2013;1886.</Citation><ArticleIdList><ArticleId IdType="pubmed">10861324</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshta I, Odeh A. Security and privacy of electronic health records: concerns and challenges. Egypt Inform J. 2021;22(2):177&#x2013;183.</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, et al. Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA. 2020;324(16):1640&#x2013;1650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592033</ArticleId><ArticleId IdType="pubmed">33107944</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenfant JM, Hochstadt J, Nolan B, Barrett K, Corriveau D, Dee D, et al. Cross-Network Directory Service: Infrastructure to enable collaborations across distributed research networks. Learn Health Syst. 2019;3(2):e10187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508802</ArticleId><ArticleId IdType="pubmed">31245605</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon S, Seo J, Kim S, Lee J, Kim JH, Sohn JW, et al. Proposal and assessment of a de-identification strategy to enhance anonymity of the observational medical outcomes partnership common data model (OMOP-CDM) in a public cloud-computing environment: anonymization of medical data using privacy models. J Med Internet Res. 2020;22(11):e19597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7728527</ArticleId><ArticleId IdType="pubmed">33177037</ArticleId></ArticleIdList></Reference><Reference><Citation>International Organization for Standardization. Privacy Enhancing Data De-identification Terminology and Classification of Techniques. Geneva, Switzerland: International Organization for Standardization; 2018.</Citation></Reference><Reference><Citation>International Organization for Standardization. Health Informatics &#x2014; Pseudonymization. Geneva, Switzerland: International Organization for Standardization; 2017.</Citation></Reference><Reference><Citation>O&#x2019;Keefe CM, Rubin DB. Individual privacy versus public good: protecting confidentiality in health research. Stat Med. 2015;34(23):3081&#x2013;3103.</Citation><ArticleIdList><ArticleId IdType="pubmed">26045214</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. ATLAS &#x2013; a unified interface for the OHDSI tools.  [Accessed May 2, 2022].  
 https://www.ohdsi.org/atlas-a-unified-interface-for-the-ohdsi-tools/
</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare R, Utidjian LH, Razzaghi H, Soucek V, Burrows E, Eckrich D, et al. Design and refinement of a data quality assessment workflow for a large pediatric research network. EGEMS (Wash DC) 2019;7(1):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6676917</ArticleId><ArticleId IdType="pubmed">31531382</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff ER, Haendel MA, Kostka K, Lee A, Niehaus E, Palchuk MB, et al. Ensuring a safe(r) harbor: excising personally identifiable information from structured electronic health record data. J Clin Transl Sci. 2021;6(1):e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8826001</ArticleId><ArticleId IdType="pubmed">35211336</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Brown JS, Bate A, Trifir&#xf2; G, Bartels DB. Choosing among common data models for real-world data analyses fit for making decisions about the effectiveness of medical products. Clin Pharmacol Ther. 2020;107(4):827&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">31330042</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35810265</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Hip Fracture Risk After Treatment with Tramadol or Codeine: An Observational Study.</ArticleTitle><Pagination><StartPage>791</StartPage><EndPage>807</EndPage><MedlinePgn>791-807</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-022-01198-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Hip fractures among older people are a major public health issue, which can impact quality of life and increase mortality within the year after they occur. A recent observational study found an increased risk of hip fracture in subjects who were new users of tramadol compared with codeine. These drugs have somewhat different indications. Tramadol is indicated for moderate to severe pain and can be used for an extended period; codeine is indicated for mild to moderate pain and cough suppression.</AbstractText><AbstractText Label="OBJECTIVE">In this observational study, we compared the risk of hip fracture in new users of tramadol or codeine, using multiple databases and analytical methods.</AbstractText><AbstractText Label="METHODS">Using data from the Clinical Practice Research Datalink and three US claims databases, we compared the risk of hip fracture after exposure to tramadol or codeine in subjects aged 50-89 years. To ensure comparability, large-scale propensity scores were used to adjust for confounding.</AbstractText><AbstractText Label="RESULTS">We observed a calibrated hazard ratio of 1.10 (95% calibrated confidence interval 0.99-1.21) in the Clinical Practice Research Datalink database, and a pooled estimate across the US databases yielded a calibrated hazard ratio of 1.06 (95% calibrated confidence interval 0.97-1.16).</AbstractText><AbstractText Label="CONCLUSIONS">Our results did not demonstrate a statistically significant difference between subjects treated for pain with tramadol compared with codeine for the outcome of hip fracture risk.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0002-0651-0613</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, 920 Route 202, Raritan, NJ, 08869, USA. evoss3@its.jnj.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA. evoss3@its.jnj.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands. evoss3@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Saberi Rana</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, 920 Route 202, Raritan, NJ, 08869, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Arun</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9567-6139</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, 920 Route 202, Raritan, NJ, 08869, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0817-5361</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, 920 Route 202, Raritan, NJ, 08869, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fife</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, 920 Route 202, Raritan, NJ, 08869, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance></Chemical><Chemical><RegistryNumber>39J1LGJ30J</RegistryNumber><NameOfSubstance UI="D014147">Tramadol</NameOfSubstance></Chemical><Chemical><RegistryNumber>UX6OWY2V7J</RegistryNumber><NameOfSubstance UI="D003061">Codeine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003061" MajorTopicYN="N">Codeine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014147" MajorTopicYN="Y">Tramadol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Erica A. Voss, Saberi Rana Ali, Arum Singh, and Martijn J. Schuemie are employees of Janssen Research and Development LLC and shareholders of Johnson &amp; Johnson (J&amp;J) stock. Daniel Fife, at the time of this research, was also an employee Janssen Research and Development LLC and shareholder of J&amp;J stock; however, he has since retired. Peter R. Rijnbeek is an employee of an institution that receives/received research grants from Janssen Research and Development LLC. J&amp;J subsidiary companies market both tramadol-containing and codeine-containing products.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35810265</ArticleId><ArticleId IdType="pmc">PMC9296392</ArticleId><ArticleId IdType="doi">10.1007/s40264-022-01198-9</ArticleId><ArticleId IdType="pii">10.1007/s40264-022-01198-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ray WA, Griffin MR, Fought RL, et al. Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992;45(7):703&#x2013;714. doi: 10.1016/0895-4356(92)90047-q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(92)90047-q</ArticleId><ArticleId IdType="pubmed">1619449</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari M, Swiontkowski M. Management of acute hip fracture. N Engl J Med. 2017;377(21):2053&#x2013;2062. doi: 10.1056/NEJMcp1611090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp1611090</ArticleId><ArticleId IdType="pubmed">29166235</ArticleId></ArticleIdList></Reference><Reference><Citation>Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc. 2003;51(3):364&#x2013;370. doi: 10.1046/j.1532-5415.2003.51110.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2003.51110.x</ArticleId><ArticleId IdType="pubmed">12588580</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper C, Campion G, Melton LJ., 3rd Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2(6):285&#x2013;289. doi: 10.1007/bf01623184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf01623184</ArticleId><ArticleId IdType="pubmed">1421796</ArticleId></ArticleIdList></Reference><Reference><Citation>Veronese N, Maggi S. Epidemiology and social costs of hip fracture. Injury. 2018;49(8):1458&#x2013;1460. doi: 10.1016/j.injury.2018.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2018.04.015</ArticleId><ArticleId IdType="pubmed">29699731</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, Lane NE, Bolster MB, et al. Association of tramadol use with risk of hip fracture. J Bone Miner Res. 2020;35(4):631&#x2013;640. doi: 10.1002/jbmr.3935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.3935</ArticleId><ArticleId IdType="pmc">PMC8282603</ArticleId><ArticleId IdType="pubmed">32020683</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ULTRAM: tramadol hydrochloride tablet, coated. 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45f59e6f-1794-40a4-8f8b-3a9415924468. Accessed 16 Dec 2020.</Citation></Reference><Reference><Citation>Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl.):S133&#x2013;S153. doi: 10.36076/ppj.2008/11/S133.</Citation><ArticleIdList><ArticleId IdType="doi">10.36076/ppj.2008/11/S133</ArticleId><ArticleId IdType="pubmed">18443637</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillson A-M. Pulmonary medicine. In: Hui D, Leung AA, Padwal R, editors. Approach to internal medicine: a resource book for clinical practice. Cham: Springer International Publishing; 2016. pp. 1&#x2013;26.</Citation></Reference><Reference><Citation>Hassamal S, Miotto K, Dale W, et al. Tramadol: understanding the risk of serotonin syndrome and seizures. Am J Med. 2018;131(11):1382.e1&#x2013;6. doi: 10.1016/j.amjmed.2018.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2018.04.025</ArticleId><ArticleId IdType="pubmed">29752906</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricke JR, Jr, Hewitt DJ, Jordan DM, et al. A double-blind placebo-controlled comparison of tramadol/acetaminophen and tramadol in patients with postoperative dental pain. Pain. 2004;109(3):250&#x2013;257. doi: 10.1016/j.pain.2004.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2004.01.004</ArticleId><ArticleId IdType="pubmed">15157685</ArticleId></ArticleIdList></Reference><Reference><Citation>Altis K, Schmidtko A, Angioni C, et al. Analgesic efficacy of tramadol, pregabalin and ibuprofen in menthol-evoked cold hyperalgesia. Pain. 2009;147(1&#x2013;3):116&#x2013;121. doi: 10.1016/j.pain.2009.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2009.08.018</ArticleId><ArticleId IdType="pubmed">19762153</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouquet A, Cudennec T, Benoist S, et al. Impaired mobility, ASA status and administration of tramadol are risk factors for postoperative delirium in patients aged 75 years or more after major abdominal surgery. Ann Surg. 2010;251(4):759&#x2013;765. doi: 10.1097/SLA.0b013e3181c1cfc9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181c1cfc9</ArticleId><ArticleId IdType="pubmed">20224380</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Drugs@FDA: FDA-approved drugs: New Drug Application (NDA): 020281 - ULTRAM. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=020281. [Accessed 3 Apr 2022].</Citation></Reference><Reference><Citation>US Food and Drug Administration. Drugs@FDA: FDA-approved drugs: Abbreviated New Drug Application (ANDA): 085055-TYLENOL W/CODEINE. 2022. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=085055. Accessed 3 Apr 2022.</Citation></Reference><Reference><Citation>Weinstein RB, Ryan P, Berlin JA, et al. Channeling in the use of nonprescription paracetamol and ibuprofen in an electronic medical records database: evidence and implications. Drug Saf. 2017;40(12):1279&#x2013;1292. doi: 10.1007/s40264-017-0581-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-017-0581-7</ArticleId><ArticleId IdType="pmc">PMC5688206</ArticleId><ArticleId IdType="pubmed">28780741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, et al. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl. 1):S59&#x2013;72. doi: 10.1007/s40264-013-0099-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0099-6</ArticleId><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub. Comparing the estimated risk of hip fracture among subjects exposed to tramadol as compared to subjects exposed to codeine. 2021. https://github.com/ohdsi-studies/TramadolVsCodeineForHipFracture. Accessed 2 Mar 2021.</Citation></Reference><Reference><Citation>EUPAS36038: comparing the estimated risk of hip fracture among subjects exposed to tramadol as compared to subjects exposed to codeine. 2020. http://www.encepp.eu/encepp/viewResource.htm?id=36039. Accessed 29 Jul 2020.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(3):553&#x2013;564. doi: 10.1093/jamia/ocu023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub IO. Janssen CDM documentation. 2021. https://ohdsi.github.io/ETL-LambdaBuilder/. Accessed 24 Jun 2021.</Citation></Reference><Reference><Citation>Berry SD, Zhu Y, Choi H, et al. Diuretic initiation and the acute risk of hip fracture. Osteoporos Int. 2013;24(2):689&#x2013;695. doi: 10.1007/s00198-012-2053-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-012-2053-3</ArticleId><ArticleId IdType="pmc">PMC3594771</ArticleId><ArticleId IdType="pubmed">22790610</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair SS, Lenihan CR, Montez-Rath ME, et al. Temporal trends in the incidence, treatment and outcomes of hip fracture after first kidney transplantation in the United States. Am J Transplant. 2014;14(4):943&#x2013;951. doi: 10.1111/ajt.12652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.12652</ArticleId><ArticleId IdType="pmc">PMC4117735</ArticleId><ArticleId IdType="pubmed">24712332</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, et al. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33(2):209&#x2013;218. doi: 10.1002/sim.5925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, et al. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform. 2017;66:72&#x2013;81. doi: 10.1016/j.jbi.2016.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.12.005</ArticleId><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce RD, Ryan PB, Nor&#xe9;n GN, et al. Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf. 2014;37(8):557&#x2013;567. doi: 10.1007/s40264-014-0189-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0189-0</ArticleId><ArticleId IdType="pmc">PMC4134480</ArticleId><ArticleId IdType="pubmed">24985530</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, et al. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci U S A. 2018;115(11):2571&#x2013;2577. doi: 10.1073/pnas.1708282114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xa0;OHDSI. The book of Observational Health Data Sciences and Informatics (OHDSI). Observational Health Data Sciences and Informatics (OHDSI).&#xa0;2019.https://ohdsi.github.io/TheBookOfOhdsi/2022.06.22.</Citation></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, et al. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23:1. doi: 10.1145/2414416.2414791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47(6):2005&#x2013;2014. doi: 10.1093/ije/dyy120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150&#x2013;161. doi: 10.1002/pst.433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pst.433</ArticleId><ArticleId IdType="pmc">PMC3120982</ArticleId><ArticleId IdType="pubmed">20925139</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A, Patrick A, Lauer M, et al. A tool for assessing the feasibility of comparative effectiveness research. Comp Effect Res. 2013;3:11&#x2013;12. doi: 10.2147/CER.S40357.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CER.S40357</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083&#x2013;3107. doi: 10.1002/sim.3697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3697</ArticleId><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services (CMS). Opioid oral morphine milligram equivalent (MME) conversion factors. 2020. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Oral-MME-CFs-vFeb-2018.pdf. Accessed 25 Sep 2020.</Citation></Reference><Reference><Citation>GitHub. Janssen CDM documentation: CDM table name: stem_table: reading from CPRD. Therapy. 2020. https://ohdsi.github.io/ETL-LambdaBuilder/CPRD/CPRD_Therapy_STEM.html. Accessed 11 Oct 2020.</Citation></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, et al. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf. 2014;37(11):945&#x2013;959. doi: 10.1007/s40264-014-0214-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0214-3</ArticleId><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Collaborating Centre for Drug Statistics Methodology. ATC: structure and principles. 2018. https://www.whocc.no/atc/structure_and_principles/. Accessed 17 Jan 2021.</Citation></Reference><Reference><Citation>Wolinsky FD, Fitzgerald JF, Stump TE. The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am J Public Health. 1997;87(3):398&#x2013;403. doi: 10.2105/ajph.87.3.398.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.87.3.398</ArticleId><ArticleId IdType="pmc">PMC1381011</ArticleId><ArticleId IdType="pubmed">9096540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentler SE, Liu L, Obrizan M, et al. The aftermath of hip fracture: discharge placement, functional status change, and mortality. Am J Epidemiol. 2009;170(10):1290&#x2013;1299. doi: 10.1093/aje/kwp266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwp266</ArticleId><ArticleId IdType="pmc">PMC2781759</ArticleId><ArticleId IdType="pubmed">19808632</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepner S, Claxton R. Anti-epileptic drugs for pain #271. J Palliat Med. 2013;16(7):799&#x2013;800. doi: 10.1089/jpm.2013.9497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jpm.2013.9497</ArticleId><ArticleId IdType="pubmed">23672271</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen R&amp;D, LLC. ULTRAM&#xae; (tramadol hydrochloride) tablets, for oral use, C-IV. 2021. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/ULTRAM-pi.pdf. Accessed 21 Feb 2022.</Citation></Reference><Reference><Citation>Electronic Medicines Compendium (emc). Zydol 50 mg capsules. 2021. https://www.medicines.org.uk/emc/product/81/smpc. Accessed 21 Feb 2022.</Citation></Reference><Reference><Citation>US Food and Drug Administration. Butalbital, acetaminophen, caffeine, and codeine phosphate capsules for oral use, CIII. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020232s044lbl.pdf. Accessed 21 Feb 2022.</Citation></Reference><Reference><Citation>Electronic Medicines Compendium (emc). Codeine phosphate 15mg tablets. 2020. https://www.medicines.org.uk/emc/product/11268/smpc. Accessed 21 Feb 2022.</Citation></Reference><Reference><Citation>Ho PT, Li CF, Ng YK, et al. Prevalence of and factors associated with psychiatric morbidity in chronic pain patients. J Psychosom Res. 2011;70(6):541&#x2013;547. doi: 10.1016/j.jpsychores.2010.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2010.10.006</ArticleId><ArticleId IdType="pubmed">21624577</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor SL, Estroff TW, Empting LD, et al. Prevalence of substance use and psychiatric disorders in a highly select chronic pain population. J Addict Med. 2013;7(1):17&#x2013;24. doi: 10.1097/ADM.0b013e3182738655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ADM.0b013e3182738655</ArticleId><ArticleId IdType="pubmed">23131838</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole H, White S, Blake C, et al. Depression in chronic pain patients: prevalence and measurement. Pain Pract. 2009;9(3):173&#x2013;180. doi: 10.1111/j.1533-2500.2009.00274.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1533-2500.2009.00274.x</ArticleId><ArticleId IdType="pubmed">19298363</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagheer MA, Khan MF, Sharif S. Association between chronic low back pain, anxiety and depression in patients at a tertiary care centre. J Pak Med Assoc. 2013;63(6):688&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">23901665</ArticleId></ArticleIdList></Reference><Reference><Citation>McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain. 2003;106(1&#x2013;2):127&#x2013;133. doi: 10.1016/s0304-3959(03)00301-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0304-3959(03)00301-4</ArticleId><ArticleId IdType="pubmed">14581119</ArticleId></ArticleIdList></Reference><Reference><Citation>McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. 2004;111(1&#x2013;2):77&#x2013;83. doi: 10.1016/j.pain.2004.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2004.06.002</ArticleId><ArticleId IdType="pubmed">15327811</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep. 2007;30(2):213&#x2013;218. doi: 10.1093/sleep/30.2.213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/30.2.213</ArticleId><ArticleId IdType="pubmed">17326547</ArticleId></ArticleIdList></Reference><Reference><Citation>Husak AJ, Bair MJ. Chronic pain and sleep disturbances: a pragmatic review of their relationships, comorbidities, and treatments. Pain Med. 2020;21(6):1142&#x2013;1152. doi: 10.1093/pm/pnz343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnz343</ArticleId><ArticleId IdType="pubmed">31909797</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok K, Tejani A. Assessing the need for proton pump inhibitors for patients using long-term nonsteroidal anti-inflammatory drugs without a history of ulcers. Can J Hosp Pharm. 2020;73(3):216&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308151</ArticleId><ArticleId IdType="pubmed">32616948</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwee KA, Goh V, Lima G, et al. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. J Pain Res. 2018;11:361&#x2013;374. doi: 10.2147/JPR.S156938.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JPR.S156938</ArticleId><ArticleId IdType="pmc">PMC5817415</ArticleId><ArticleId IdType="pubmed">29491719</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hobok) 2012;64(4):465&#x2013;474. doi: 10.1002/acr.21596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21596</ArticleId><ArticleId IdType="pubmed">22563589</ArticleId></ArticleIdList></Reference><Reference><Citation>Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline. J Am Acad Orthop Surg. 2013;21(9):571&#x2013;576. doi: 10.5435/jaaos-21-09-571.</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/jaaos-21-09-571</ArticleId><ArticleId IdType="pubmed">23996988</ArticleId></ArticleIdList></Reference><Reference><Citation>Prescribers' Digital Reference. Morphine sulfate: drug summary. 2020. https://www.pdr.net/drug-summary/Morphine-Sulfate-Oral-Solution-morphine-sulfate-1228.8394. Accessed 9 Dec 2020.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35849195</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1262</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of colorectal disease</Title><ISOAbbreviation>Int J Colorectal Dis</ISOAbbreviation></Journal><ArticleTitle>Developing prediction models for short-term mortality after surgery for colorectal cancer using a Danish national quality assurance database.</ArticleTitle><Pagination><StartPage>1835</StartPage><EndPage>1843</EndPage><MedlinePgn>1835-1843</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00384-022-04207-6</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The majority of colorectal cancer surgeries are performed electively, and treatment is often decided at the multidisciplinary team conference. Although the average 30-day mortality rate is low, there is substantial population heterogeneity from young, healthy patients to frail, elderly patients. The individual risk of surgery can vary widely, and tailoring treatment for colorectal cancer may lead to better outcomes. This requires prediction of risk that is accurate and available prior to surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from the Danish Colorectal Cancer Group database was transformed into the Observational Medical Outcomes Partnership Common Data Model. Models were developed to predict the risk of mortality within 30, 90, and 180&#xa0;days after colorectal cancer surgery using only covariates decided at the multidisciplinary team conference. Several machine-learning models were trained, but due to superior performance, a Least Absolute Shrinkage and Selection Operator logistic regression was used for the final model. Performance was assessed with discrimination (area under the receiver operating characteristic and precision recall curve) and calibration measures (calibration in large, intercept, slope, and Brier score).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The cohort contained 65,612 patients operated for colorectal cancer in the period from 2001 to 2019 in Denmark. The Least Absolute Shrinkage and Selection Operator model showed an area under the receiver operating characteristic for 30-, 90-, and 180-day mortality after colorectal cancer surgery of 0.871 (95% CI: 0.86-0.882), 0.874 (95% CI: 0.864-0.882), and 0.876 (95% CI: 0.867-0.883) and calibration in large of 1.01, 0.98, and 1.01, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The postoperative short-term mortality prediction model showed excellent discrimination and calibration using only preoperatively known predictors.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Br&#xe4;uner</LastName><ForeName>Karoline B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark. karob@regionsjaelland.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Andreas W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsouchnika</LastName><ForeName>Adamantia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walbech</LastName><ForeName>Julie S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;genur</LastName><ForeName>Mikail</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Viviane A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clausen</LastName><ForeName>Johan S R</ForeName><Initials>JSR</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;genur</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Faculty of Health Science, University of Copenhagen, Blegdamsvej 6, 2200, Copenhagen N, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Int J Colorectal Dis</MedlineTA><NlmUniqueID>8607899</NlmUniqueID><ISSNLinking>0179-1958</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colorectal cancer</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Postoperative</Keyword><Keyword MajorTopicYN="N">Prediction model</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>18</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35849195</ArticleId><ArticleId IdType="doi">10.1007/s00384-022-04207-6</ArticleId><ArticleId IdType="pii">10.1007/s00384-022-04207-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Center MM, Jemal A, Smith RA, Ward E (2010) Worldwide variations in colorectal cancer. Dis Colon Rectum 53:1099. https://doi.org/10.1007/DCR.0b013e3181d60a51</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/DCR.0b013e3181d60a51</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojesen RD, Degett TH, Dalton SO, G&#xf6;genur I (2021) High World Heath Organization performance status is associated with short and long-term outcomes after colorectal cancer surgery. Dis Colon Rectum 58&#x2013;66. https://doi.org/10.1097/DCR.0000000000001982</Citation></Reference><Reference><Citation>Bojesen RD, J&#xf8;rgensen LB, Grube C, Skou ST, Johansen C, Dalton SO et al (2022) Fit for surgery &#x2014; feasibility of short-course multimodal individualized prehabilitation in high-risk frail colon cancer patients prior to surgery. Pilot Feasibility Stud 1&#x2013;13. https://doi.org/10.1186/s40814-022-00967-8</Citation></Reference><Reference><Citation>Palmer G, Martling A, Cedermark B, Holm T (2011) Preoperative tumour staging with multidisciplinary team assessment improves the outcome in locally advanced primary rectal cancer. Colorectal Dis 1361&#x2013;9. https://doi.org/10.1111/j.1463-1318.2010.02460.x</Citation></Reference><Reference><Citation>Rosander E, Holm T, Sj&#xf6;vall A, Hjern F, Weibull CE, Nordenvall C (2021) Preoperative multidisciplinary team assessment is associated with improved survival in patients with locally advanced colon cancer; a nationwide cohort study in 3157 patients. Eur J Surg Oncol 47:2398&#x2013;2404. https://doi.org/10.1016/j.ejso.2021.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejso.2021.05.008</ArticleId><ArticleId IdType="pubmed">34112562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingeholm P, G&#xf6;genur I, Iversen LH (2016) Danish colorectal cancer group database. Clin Epidemiol 8:465&#x2013;468. https://doi.org/10.2147/CLEP.S99481</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S99481</ArticleId><ArticleId IdType="pubmed">27822086</ArticleId><ArticleId IdType="pmc">5094575</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein MF, G&#xf6;genur I, Ingeholm P, Njor SH, Iversen LH, Emmertsen KJ (2020) Validation of the Danish Colorectal Cancer Group (DCCG.dk) database - on behalf of the Danish Colorectal Cancer Group. Color Dis Off J Assoc Coloproctology Gt Britain Irel 22:2057&#x2013;67. https://doi.org/10.1111/codi.15352</Citation></Reference><Reference><Citation>Vogelsang RP, Bojesen RD, Hoelmich ER, Orhan A, Buzquurz F, Cai L et al (2021) Prediction of 90-day mortality after surgery for colorectal cancer using standardized nationwide quality-assurance data. BJS Open 5. https://doi.org/10.1093/bjsopen/zrab023</Citation></Reference><Reference><Citation>Observational health data sciences and informatics (2019) The Book of OHDSI 1&#x2013;470.</Citation></Reference><Reference><Citation>Danish Colorectal Cancer Group (DCCG) (2022) No title. Var List 2022. https://www.rkkp-dokumentation.dk/Public/Download.aspx (Accessed 16 June 2022).</Citation></Reference><Reference><Citation>Mandrekar JN (2010) Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 5:1315&#x2013;1316. https://doi.org/10.1097/JTO.0b013e3181ec173d</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JTO.0b013e3181ec173d</ArticleId><ArticleId IdType="pubmed">20736804</ArticleId></ArticleIdList></Reference><Reference><Citation>Rufibach K (2010) Use of Brier score to assess binary predictions. J Clin Epidemiol 63:938&#x2013;939. https://doi.org/10.1016/j.jclinepi.2009.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2009.11.009</ArticleId><ArticleId IdType="pubmed">20189763</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KGM (2015) Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 162:55&#x2013;63. https://doi.org/10.7326/M14-0697</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-0697</ArticleId><ArticleId IdType="pubmed">25560714</ArticleId></ArticleIdList></Reference><Reference><Citation>Iversen LH, Ingeholm P, G&#xf6;genur I, Laurberg S (2014) Major reduction in 30-day mortality after elective colorectal cancer surgery: a nationwide population-based study in Denmark 2001&#x2013;2011. Ann Surg Oncol 21:2267&#x2013;2273. https://doi.org/10.1245/s10434-014-3596-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-014-3596-7</ArticleId><ArticleId IdType="pubmed">24585408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingeholm P (2017) Landsd&#xe6;kkende database for kr&#xe6;ft i tyk- og endetarm (dccg.dk) Klinisk rapport. Danish Color Cancer Gr</Citation></Reference><Reference><Citation>Panis Y, Maggiori L, Caranhac G, Bretagnol F, Vicaut E (2011) Mortality after colorectal cancer surgery: a French survey of more than 84,000 patients. Ann Surg 254:738&#x2013;743. https://doi.org/10.1097/SLA.0b013e31823604ac</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31823604ac</ArticleId><ArticleId IdType="pubmed">21997816</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris EJA, Taylor EF, Thomas JD, Quirke P, Finan PJ, Coleman MP et al (2011) Thirty-day postoperative mortality after colorectal cancer surgery in England. Gut 60:806&#x2013;813. https://doi.org/10.1136/gut.2010.232181</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2010.232181</ArticleId><ArticleId IdType="pubmed">21486939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ketelaers SHJ, Orsini RG, Burger JWA, Nieuwenhuijzen GAP, Rutten HJT (2019) Significant improvement in postoperative and 1-year mortality after colorectal cancer surgery in recent years. Eur J Surg Oncol 45:2052&#x2013;2058. https://doi.org/10.1016/j.ejso.2019.06.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejso.2019.06.017</ArticleId><ArticleId IdType="pubmed">31255442</ArticleId></ArticleIdList></Reference><Reference><Citation>Gietelink L, Wouters MWJM, Bemelman WA, Dekker JW, Tollenaar RAEM, Tanis PJ (2016) Reduced 30-day mortality after laparoscopic colorectal cancer surgery. Ann Surg 264:135&#x2013;140. https://doi.org/10.1097/SLA.0000000000001412</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001412</ArticleId><ArticleId IdType="pubmed">27272958</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallaro P, Bordeianou L (2019) Implementation of an ERAS pathway in colorectal surgery. Clin Colon Rectal Surg 32:102&#x2013;108. https://doi.org/10.1055/s-0038-1676474</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1676474</ArticleId><ArticleId IdType="pubmed">30833858</ArticleId><ArticleId IdType="pmc">6395097</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmiecik TE, Ko CY et al (2013) Surgical risk calculator: a decision aide and informed consent tool for patients and surgeons. J Am Coll Surg 217(5):833-842.e3. https://doi.org/10.1016/j.jamcollsurg.2013.07.385.Development</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2013.07.385.Development</ArticleId><ArticleId IdType="pubmed">24055383</ArticleId><ArticleId IdType="pmc">3805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazio VW, Tekkis PP, Remzi F, Lavery IC (2004) Assessment of operative risk in colorectal cancer surgery: the cleveland clinic foundation colorectal cancer model. Dis Colon Rectum 47:2015&#x2013;2024. https://doi.org/10.1007/s10350-004-0704-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10350-004-0704-y</ArticleId><ArticleId IdType="pubmed">15657649</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sluis FJ, Espin E, Vallribera F, de Bock GH, Hoekstra HJ, van Leeuwen BL et al (2014) Predicting postoperative mortality after colorectal surgery: a novel clinical model. Color Dis 16:631&#x2013;639. https://doi.org/10.1111/codi.12580</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/codi.12580</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch T, Warps ALK, De Ner&#xe9;e Tot Babberich MPM, Stamm C, Geerts BF, Vermeulen L et al (2021) Predictors of 30-day mortality among Dutch patients undergoing colorectal cancer surgery, 2011&#x2013;2016. JAMA Netw Open 4:2011&#x2013;6. https://doi.org/10.1001/jamanetworkopen.2021.7737</Citation></Reference><Reference><Citation>Assel M, Sjoberg DD, Vickers AJ (2017) The Brier score does not evaluate the clinical utility of diagnostic tests or prediction models. Diagnostic Progn Res 1:19. https://doi.org/10.1186/s41512-017-0020-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41512-017-0020-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N et al (2010) Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21:128&#x2013;138. https://doi.org/10.1097/EDE.0b013e3181c30fb2</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181c30fb2</ArticleId><ArticleId IdType="pubmed">20010215</ArticleId><ArticleId IdType="pmc">3575184</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott I, Carter S, Coiera E (2021) Clinician checklist for assessing suitability of machine learning applications in healthcare. BMJ Heal Care Informatics 28. https://doi.org/10.1136/bmjhci-2020-100251</Citation></Reference><Reference><Citation>Kim JH (2019) Introduction multicollinearity and misleading statistical results KJA. Korean J Anesth 558&#x2013;69. https://doi.org/10.4097/kja.19087</Citation></Reference><Reference><Citation>Cepeda MS, Reps J, Ryan P (2018) Finding factors that predict treatment-resistant depression: results of a cohort study. Depress Anxiety 35:668&#x2013;673. https://doi.org/10.1002/da.22774</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/da.22774</ArticleId><ArticleId IdType="pubmed">29786922</ArticleId><ArticleId IdType="pmc">6055726</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35852842</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Fast Healthcare Interoperability Resources (FHIR) for Interoperability in Health Research: Systematic Review.</ArticleTitle><Pagination><StartPage>e35724</StartPage><MedlinePgn>e35724</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e35724</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/35724</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The standard Fast Healthcare Interoperability Resources (FHIR) is widely used in health information technology. However, its use as a standard for health research is still less prevalent. To use existing data sources more efficiently for health research, data interoperability becomes increasingly important. FHIR provides solutions by offering resource domains such as "Public Health &amp; Research" and "Evidence-Based Medicine" while using already established web technologies. Therefore, FHIR could help standardize data across different data sources and improve interoperability in health research.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of our study was to provide a systematic review of existing literature and determine the current state of FHIR implementations in health research and possible future directions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched the PubMed/MEDLINE, Embase, Web of Science, IEEE Xplore, and Cochrane Library databases for studies published from 2011 to 2022. Studies investigating the use of FHIR in health research were included. Articles published before 2011, abstracts, reviews, editorials, and expert opinions were excluded. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and registered this study with PROSPERO (CRD42021235393). Data synthesis was done in tables and figures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified a total of 998 studies, of which 49 studies were eligible for inclusion. Of the 49 studies, most (73%, n=36) covered the domain of clinical research, whereas the remaining studies focused on public health or epidemiology (6%, n=3) or did not specify their research domain (20%, n=10). Studies used FHIR for data capture (29%, n=14), standardization of data (41%, n=20), analysis (12%, n=6), recruitment (14%, n=7), and consent management (4%, n=2). Most (55%, 27/49) of the studies had a generic approach, and 55% (12/22) of the studies focusing on specific medical specialties (infectious disease, genomics, oncology, environmental health, imaging, and pulmonary hypertension) reported their solutions to be conferrable to other use cases. Most (63%, 31/49) of the studies reported using additional data models or terminologies: Systematized Nomenclature of Medicine Clinical Terms (29%, n=14), Logical Observation Identifiers Names and Codes (37%, n=18), International Classification of Diseases 10th Revision (18%, n=9), Observational Medical Outcomes Partnership common data model (12%, n=6), and others (43%, n=21). Only 4 (8%) studies used a FHIR resource from the domain "Public Health &amp; Research." Limitations using FHIR included the possible change in the content of FHIR resources, safety, legal matters, and the need for a FHIR server.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our review found that FHIR can be implemented in health research, and the areas of application are broad and generalizable in most use cases. The implementation of international terminologies was common, and other standards such as the Observational Medical Outcomes Partnership common data model could be used as a complement to FHIR. Limitations such as the change of FHIR content, lack of FHIR implementation, safety, and legal matters need to be addressed in future releases to expand the use of FHIR and, therefore, interoperability in health research.</AbstractText><CopyrightInformation>&#xa9;Carina Nina Vorisek, Moritz Lehne, Sophie Anne Ines Klopfenstein, Paula Josephine Mayer, Alexander Bartschke, Thomas Haese, Sylvia Thun. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 19.07.2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vorisek</LastName><ForeName>Carina Nina</ForeName><Initials>CN</Initials><Identifier Source="ORCID">0000-0001-7499-8115</Identifier><AffiliationInfo><Affiliation>Core Facility Digital Medicine and Interoperability, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehne</LastName><ForeName>Moritz</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8435-1374</Identifier><AffiliationInfo><Affiliation>Core Facility Digital Medicine and Interoperability, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klopfenstein</LastName><ForeName>Sophie Anne Ines</ForeName><Initials>SAI</Initials><Identifier Source="ORCID">0000-0002-8470-2258</Identifier><AffiliationInfo><Affiliation>Core Facility Digital Medicine and Interoperability, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Medical Informatics, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Paula Josephine</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-6441-5913</Identifier><AffiliationInfo><Affiliation>Core Facility Digital Medicine and Interoperability, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartschke</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5849-482X</Identifier><AffiliationInfo><Affiliation>Core Facility Digital Medicine and Interoperability, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haese</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1997-0333</Identifier><AffiliationInfo><Affiliation>Core Facility Digital Medicine and Interoperability, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thun</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3346-6806</Identifier><AffiliationInfo><Affiliation>Core Facility Digital Medicine and Interoperability, Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">Fast Healthcare Interoperability Resources</Keyword><Keyword MajorTopicYN="N">clinical research</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">health care</Keyword><Keyword MajorTopicYN="N">health information technology</Keyword><Keyword MajorTopicYN="N">health research</Keyword><Keyword MajorTopicYN="N">interoperability</Keyword><Keyword MajorTopicYN="N">public health</Keyword><Keyword MajorTopicYN="N">research</Keyword></KeywordList><CoiStatement>Conflicts of Interest: ST is the vice chair of Health Level Seven Deutschland. The remaining authors declare no other conflicts of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>19</Day><Hour>11</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35852842</ArticleId><ArticleId IdType="pmc">PMC9346559</ArticleId><ArticleId IdType="doi">10.2196/35724</ArticleId><ArticleId IdType="pii">v10i7e35724</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bauer DC, Metke-Jimenez Alejandro, Maurer-Stroh Sebastian, Tiruvayipati S, Wilson LOW, Jain Y, Perrin A, Ebrill K, Hansen DP, Vasan SS. Interoperable medical data: The missing link for understanding COVID-19. Transbound Emerg Dis. 2021 Jul;68(4):1753&#x2013;1760. doi: 10.1111/tbed.13892. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tbed.13892</ArticleId><ArticleId IdType="pmc">PMC8359419</ArticleId><ArticleId IdType="pubmed">33095970</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten J, da Silva Santos LB, Bourne PE, Bouwman J, Brookes AJ, Clark T, Crosas M, Dillo I, Dumon O, Edmunds S, Evelo CT, Finkers R, Gonzalez-Beltran A, Gray AJ, Groth P, Goble C, Grethe JS, Heringa J, 't Hoen Peter A C, Hooft R, Kuhn T, Kok R, Kok J, Lusher SJ, Martone ME, Mons A, Packer AL, Persson B, Rocca-Serra P, Roos M, van Schaik R, Sansone S, Schultes E, Sengstag T, Slater T, Strawn G, Swertz MA, Thompson M, van der Lei J, van Mulligen E, Velterop J, Waagmeester A, Wittenburg P, Wolstencroft K, Zhao J, Mons B. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016 Mar 15;3:160018. doi: 10.1038/sdata.2016.18. doi: 10.1038/sdata.2016.18.sdata201618</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.18</ArticleId><ArticleId IdType="doi">10.1038/sdata.2016.18</ArticleId><ArticleId IdType="pmc">PMC4792175</ArticleId><ArticleId IdType="pubmed">26978244</ArticleId></ArticleIdList></Reference><Reference><Citation>ODM-XML. Clinical Data Interchange Standards Consortium.  [2021-06-17].  
 https://www.cdisc.org/standards/data-exchange/odm
.</Citation></Reference><Reference><Citation>Resourcelist - FHIR v4.3.0. Health Level Seven International.  [2021-12-20].  
 https://www.hl7.org/fhir/resourcelist.html
.</Citation></Reference><Reference><Citation>Index - FHIR v4.3.0. Health Level Seven International.  [2021-09-03].  
 https://hl7.org/FHIR/index.html
.</Citation></Reference><Reference><Citation>Neues B&#xfc;ndnis f&#xfc;r mehr Interoperabilit&#xe4;t im Gesundheitswesen. &#xc4;rzte Zeitung. 2020. Aug 26,  [2021-08-30].  
 https://www.aerztezei tung.de/Wirtschaft/Neues-Buendnis-fuer-mehr-Interoperabilitaet-im-Gesundheitswesen-412313.html
.</Citation></Reference><Reference><Citation>Policies and technology for interoperability and burden reduction. Centers for Medicare &amp; Medicaid Services.  [2021-08-30].  
 https://www.cms.gov/Regulations-and-Guidance/Guidance/Interoperability/index
.</Citation></Reference><Reference><Citation>Craven J. FDA drafts data standards guidance for RWD. Regulatory Focus. 2021. Oct 22,  [2022-04-22].  
 https://www.raps.org/news- and-articles/news-articles/2021/10/fda-drafts-data-standards-guidance-for-rwd
.</Citation></Reference><Reference><Citation>Vulcan. Health Level Seven International.  [2022-04-22].  
 https://www.hl7.org/vulcan/
</Citation></Reference><Reference><Citation>MedMorph Research Data Exchange Content IG. Health Level Seven International.  [2022-04-22].  
 http://build.fhir.org/ig/HL7/fhir -medmorph-research-dex-ig/index.html
.</Citation></Reference><Reference><Citation>HL7 International and OHDSI announce collaboration to provide single common data model for sharing information in clinical care and observational research. Observational Health Data Science and Informatics.  [2022-04-22].  
 https://www.ohdsi.org/ohdsi-hl7-collaboration/
</Citation></Reference><Reference><Citation>Khvastova M, Witt M, Essenwanger A, Sass J, Thun S, Krefting D. Towards interoperability in clinical research - enabling FHIR on the open-source research platform XNAT. J Med Syst. 2020 Jul 09;44(8):137. doi: 10.1007/s10916-020-01600-y. 
 
10.1007/s10916-020-01600-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10916-020-01600-y</ArticleId><ArticleId IdType="pmc">PMC7343726</ArticleId><ArticleId IdType="pubmed">32642856</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus DS, Olsen TR, Ramaratnam M, Buckner RL. The Extensible Neuroimaging Archive Toolkit: an informatics platform for managing, exploring, and sharing neuroimaging data. Neuroinformatics. 2007;5(1):11&#x2013;34. doi: 10.1385/ni:5:1:11.NI:5:1:11</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/ni:5:1:11</ArticleId><ArticleId IdType="pubmed">17426351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehne Moritz, Luijten Sandra, Vom Felde Genannt Imbusch Paulina, Thun Sylvia. The use of FHIR in digital health - a review of the scientific literature. Stud Health Technol Inform. 2019 Sep 03;267:52&#x2013;58. doi: 10.3233/SHTI190805.SHTI190805</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI190805</ArticleId><ArticleId IdType="pubmed">31483254</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayaz Muhammad, Pasha Muhammad F, Alzahrani Mohammed Y, Budiarto Rahmat, Stiawan Deris. Correction: The Fast Health Interoperability Resources (FHIR) standard: systematic literature review of implementations, applications, challenges and opportunities. JMIR Med Inform. 2021 Aug 17;9(8):e32869. doi: 10.2196/32869. 
 
v9i8e32869</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/32869</ArticleId><ArticleId IdType="pmc">PMC8408751</ArticleId><ArticleId IdType="pubmed">34403353</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097. doi: 10.1371/journal.pmed.1000097. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorisek C, Klopfenstein S, Lehne M, Haese T, Bartschke A, Thun S. Use of Fast Healthcare Interoperability Resources (FHIR) in health care research data &#x2013; a systematic review. National Institute for Health Research. 2021. Mar 13,  [2021-03-15].  
 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=235393
.</Citation></Reference><Reference><Citation>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016 Dec 05;5(1):210. doi: 10.1186/s13643-016-0384-4. 
 
10.1186/s13643-016-0384-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-016-0384-4</ArticleId><ArticleId IdType="doi">10.1186/s13643-016-0384-4</ArticleId><ArticleId IdType="pmc">PMC5139140</ArticleId><ArticleId IdType="pubmed">27919275</ArticleId></ArticleIdList></Reference><Reference><Citation>The R Project for Statistical Computing. R Foundation for Statistical Computing.  [2021-06-17].  
 https://www.r-project.org./
</Citation></Reference><Reference><Citation>Wickham H, Averick M, Bryan J, Chang W, McGowan L, Fran&#xe7;ois R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Pedersen T, Miller E, Bache S, M&#xfc;ller K, Ooms J, Robinson D, Seidel D, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H. Welcome to the Tidyverse. JOSS. 2019 Nov;4(43):1686. doi: 10.21105/joss.01686.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.01686</ArticleId></ArticleIdList></Reference><Reference><Citation>FHIR-Research-Review. GitHub.  [2021-12-20].  
 https://github.com/BIH-CEI/FHIR-Research-Review
.</Citation></Reference><Reference><Citation>Pfiffner PB, Pinyol I, Natter MD, Mandl KD. C3-PRO: Connecting ResearchKit to the Health System Using i2b2 and FHIR. PLoS One. 2016;11(3):e0152722. doi: 10.1371/journal.pone.0152722. 
 
PONE-D-16-04786</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0152722</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0152722</ArticleId><ArticleId IdType="pmc">PMC4816293</ArticleId><ArticleId IdType="pubmed">27031856</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Kung H, Lee Y, Chao JC, Udayasankaran JG, Fan H, Ng K, Chang Y, Kijsanayotin B, Marcelo AB, Hsu C. Global infectious disease surveillance and case tracking system for COVID-19: development study. JMIR Med Inform. 2020 Dec 22;8(12):e20567. doi: 10.2196/20567. 
 
v8i12e20567</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/20567</ArticleId><ArticleId IdType="pmc">PMC7758088</ArticleId><ArticleId IdType="pubmed">33320826</ArticleId></ArticleIdList></Reference><Reference><Citation>Eapen Bell Raj, Costa Andrew, Archer Norm, Sartipi Kamran. FHIRForm: an open-source framework for the management of electronic forms in healthcare. Stud Health Technol Inform. 2019;257:80&#x2013;85. doi: 10.3233/978-1-61499-951-5-80.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-951-5-80</ArticleId><ArticleId IdType="pubmed">30741177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Na, Prodduturi Naresh, Wang Chen, Jiang Guoqian. Shiny FHIR: an integrated framework leveraging Shiny R and HL7 FHIR to empower standards-based clinical data applications. Stud Health Technol Inform. 2017;245:868&#x2013;872. doi: 10.3233/978-1-61499-830-3-868. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-830-3-868</ArticleId><ArticleId IdType="pmc">PMC5939961</ArticleId><ArticleId IdType="pubmed">29295223</ArticleId></ArticleIdList></Reference><Reference><Citation>Sass J, Bartschke A, Lehne M, Essenwanger A, Rinaldi E, Rudolph S, Heitmann KU, Vehreschild JJ, von Kalle C, Thun S. The German Corona Consensus Dataset (GECCO): a standardized dataset for COVID-19 research in university medicine and beyond. BMC Med Inform Decis Mak. 2020 Dec 21;20(1):341. doi: 10.1186/s12911-020-01374-w. 
 
10.1186/s12911-020-01374-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-020-01374-w</ArticleId><ArticleId IdType="doi">10.1186/s12911-020-01374-w</ArticleId><ArticleId IdType="pmc">PMC7751265</ArticleId><ArticleId IdType="pubmed">33349259</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Katsuya, Yamamoto Ryuichi. Implementation of a secured cross-institutional data collection infrastructure by applying HL7 FHIR on an existing distributed EMR storages. Stud Health Technol Inform. 2020 Jun 26;272:155&#x2013;158. doi: 10.3233/SHTI200517.SHTI200517</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI200517</ArticleId><ArticleId IdType="pubmed">32604624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bild R, Bialke M, Buckow K, Ganslandt T, Ihrig K, Jahns R, Merzweiler A, Roschka S, Schreiweis B, St&#xe4;ubert Sebastian, Zenker S, Prasser F. Towards a comprehensive and interoperable representation of consent-based data usage permissions in the German medical informatics initiative. BMC Med Inform Decis Mak. 2020 Jun 05;20(1):103. doi: 10.1186/s12911-020-01138-6. 
 
10.1186/s12911-020-01138-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-020-01138-6</ArticleId><ArticleId IdType="doi">10.1186/s12911-020-01138-6</ArticleId><ArticleId IdType="pmc">PMC7275462</ArticleId><ArticleId IdType="pubmed">32503529</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinecke Ines, Gulden Christian, K&#xfc;mmel Mich&#xe9;le, Nassirian Azadeh, Blasini Romina, Sedlmayr Martin. Design for a modular clinical trial recruitment support system based on FHIR and OMOP. Stud Health Technol Inform. 2020 Jun 16;270:158&#x2013;162. doi: 10.3233/SHTI200142.SHTI200142</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI200142</ArticleId><ArticleId IdType="pubmed">32570366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulden C, Blasini R, Nassirian A, Stein A, Altun FB, Kirchner M, Prokosch H, Boeker M. Prototypical clinical trial registry based on Fast Healthcare Interoperability Resources (FHIR): design and implementation study. JMIR Med Inform. 2021 Jan 12;9(1):e20470. doi: 10.2196/20470. 
 
v9i1e20470</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/20470</ArticleId><ArticleId IdType="pmc">PMC7837997</ArticleId><ArticleId IdType="pubmed">33433393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulden Christian, Mate Sebastian, Prokosch Hans-Ulrich, Kraus Stefan. Investigating the capabilities of FHIR search for clinical trial phenotyping. Stud Health Technol Inform. 2018;253:3&#x2013;7. doi: 10.3233/978-1-61499-896-9-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-896-9-3</ArticleId><ArticleId IdType="pubmed">30147028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackerbauer Anna M, Krauss Oliver, Helm Emmanuel. Automated verification of structured questionnaires using HL7. Stud Health Technol Inform. 2019;258:11&#x2013;15. doi: 10.3233/978-1-61499-959-1-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-959-1-11</ArticleId><ArticleId IdType="pubmed">30942704</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins KJ, Gauvreau K, Newburger JW, Spray TL, Moller JH, Iezzoni LI. Consensus-based method for risk adjustment for surgery for congenital heart disease. J Thorac Cardiovasc Surg. 2002 Jan;123(1):110&#x2013;8. doi: 10.1067/mtc.2002.119064.S0022522302909451</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mtc.2002.119064</ArticleId><ArticleId IdType="pubmed">11782764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich Hannes, Kock Ann-Kristin, Duhm-Harbeck Petra, Habermann Jens K, Ingenerf Josef. Metadata repository for improved data sharing and reuse based on HL7 FHIR. Stud Health Technol Inform. 2016;228:162&#x2013;6. doi: 10.3233/978-1-61499-678-1-162.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-678-1-162</ArticleId><ArticleId IdType="pubmed">27577363</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer Patrick, St&#xf6;hr Mark R, Gall Henning, Michel-Backofen Achim, Majeed Raphael W. Data integration into OMOP CDM for heterogeneous clinical data collections via HL7 FHIR bundles and XSLT. Stud Health Technol Inform. 2020 Jun 16;270:138&#x2013;142. doi: 10.3233/SHTI200138.SHTI200138</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI200138</ArticleId><ArticleId IdType="pubmed">32570362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagholikar KB, Jain R, Oliveira E, Mandel J, Klann J, Colas R, Patil P, Yadav K, Mandl KD, Carton T, Murphy SN. Evolving research data sharing networks to clinical app sharing networks. AMIA Jt Summits Transl Sci Proc. 2017;2017:302&#x2013;307. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5543356</ArticleId><ArticleId IdType="pubmed">28815145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Honghan, Toti Giulia, Morley Katherine I, Ibrahim Zina M, Folarin Amos, Jackson Richard, Kartoglu Ismail, Agrawal Asha, Stringer Clive, Gale Darren, Gorrell Genevieve, Roberts Angus, Broadbent Matthew, Stewart Robert, Dobson Richard J B. SemEHR: a general-purpose semantic search system to surface semantic data from clinical notes for tailored care, trial recruitment, and clinical research. J Am Med Inform Assoc. 2018 May 01;25(5):530&#x2013;537. doi: 10.1093/jamia/ocx160. 
 
4817428</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocx160</ArticleId><ArticleId IdType="pmc">PMC6019046</ArticleId><ArticleId IdType="pubmed">29361077</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalique F, Khan SA. An FHIR-based framework for consolidation of augmented EHR from hospitals for public health analysis. 2017 IEEE 11th International Conference on Application of Information and Communication Technologies (AICT); September 20-22, 2017; Moscow, Russia. 2017. pp. 1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/icaict.2017.8687289</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber Manuela, Griessbach Alexandra, Grossmann Regina, Blaser J&#xfc;rg. A FHIr-based eConsent app for the digital hospital. Stud Health Technol Inform. 2020 Jun 16;270:3&#x2013;7. doi: 10.3233/SHTI200111.SHTI200111</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI200111</ArticleId><ArticleId IdType="pubmed">32570335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialke M, Bahls T, Geidel L, Rau H, Blumentritt A, Pasewald S, Wolff R, Steinmann J, Bronsch T, Bergh B, Tremper G, Lablans M, &#xdc;ckert Frank, Lang S, Idris T, Hoffmann W. MAGIC: once upon a time in consent management-a FHIR tale. J Transl Med. 2018 Sep 14;16(1):256. doi: 10.1186/s12967-018-1631-3. 
 
10.1186/s12967-018-1631-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1631-3</ArticleId><ArticleId IdType="doi">10.1186/s12967-018-1631-3</ArticleId><ArticleId IdType="pmc">PMC6137912</ArticleId><ArticleId IdType="pubmed">30217236</ArticleId></ArticleIdList></Reference><Reference><Citation>Klopfenstein Sophie Anne Ines, Vorisek Carina Nina, Shutsko Aliaksandra, Lehne Moritz, Sass Julian, L&#xf6;be Matthias, Schmidt Carsten Oliver, Thun Sylvia. Fast Healthcare Interoperability Resources (FHIR) in a FAIR metadata registry for COVID-19 research. Stud Health Technol Inform. 2021 Nov 18;287:73&#x2013;77. doi: 10.3233/SHTI210817.SHTI210817</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210817</ArticleId><ArticleId IdType="pubmed">34795084</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruendner J, Gulden C, Kampf M, Mate S, Prokosch H, Zierk J. A framework for criteria-based selection and processing of Fast Healthcare Interoperability Resources (FHIR) data for statistical analysis: design and implementation study. JMIR Med Inform. 2021 Apr 01;9(4):e25645. doi: 10.2196/25645. 
 
v9i4e25645</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/25645</ArticleId><ArticleId IdType="pmc">PMC8050750</ArticleId><ArticleId IdType="pubmed">33792554</ArticleId></ArticleIdList></Reference><Reference><Citation>Metke-Jimenez A, Hansen D. FHIRCap: Transforming REDCap forms into FHIR resources. AMIA Jt Summits Transl Sci Proc. 2019;2019:54&#x2013;63. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568121</ArticleId><ArticleId IdType="pubmed">31258956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A C, Duda S N, Taylor R, Delacqua F, Lewis A A, Bosler T, Johnson K B, Harris P A. REDCap on FHIR: clinical data interoperability services. J Biomed Inform. 2021 Sep;121:103871. doi: 10.1016/j.jbi.2021.103871. doi: 10.1016/j.jbi.2021.103871.S1532-0464(21)00200-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2021.103871</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2021.103871</ArticleId><ArticleId IdType="pmc">PMC9217161</ArticleId><ArticleId IdType="pubmed">34298155</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi Eugenia, Saas Julian, Thun Sylvia. Use of LOINC and SNOMED CT with FHIR for microbiology data. Stud Health Technol Inform. 2021 May 24;278:156&#x2013;162. doi: 10.3233/SHTI210064.SHTI210064</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210064</ArticleId><ArticleId IdType="pubmed">34042889</ArticleId></ArticleIdList></Reference><Reference><Citation>Sass Julian, Zabka Susanne, Essenwanger Andrea, Schepers Josef, Boeker Martin, Thun Sylvia. Fast Healthcare Interoperability Resources (FHIR&#xae;) representation of medication data derived from German Procedure Classification Codes (OPS) using Identification of Medicinal Products (IDMP) compliant terminology. Stud Health Technol Inform. 2021 May 24;278:231&#x2013;236. doi: 10.3233/SHTI210074.SHTI210074</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210074</ArticleId><ArticleId IdType="pubmed">34042899</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi E, Thun S. From OpenEHR to FHIR and OMOP data model for microbiology findings. Stud Health Technol Inform. 2021 May 27;281:402&#x2013;406. doi: 10.3233/SHTI210189.SHTI210189</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210189</ArticleId><ArticleId IdType="pubmed">34042774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Xingtong, Lehmann Harold, Botsis Taxiarchis. Can FHIR support standardization in post-market safety surveillance? Stud Health Technol Inform. 2021 May 27;281:33&#x2013;37. doi: 10.3233/SHTI210115.SHTI210115</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210115</ArticleId><ArticleId IdType="pubmed">34042700</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt Pascal S, Pacheco Jennifer A, Rasmussen Luke V. Development of a repository of computable phenotype definitions using the clinical quality language. JAMIA Open. 2021 Oct;4(4):ooab094. doi: 10.1093/jamiaopen/ooab094. 
 
ooab094</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooab094</ArticleId><ArticleId IdType="pmc">PMC8672934</ArticleId><ArticleId IdType="pubmed">34926996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenert Leslie A, Ilatovskiy Andrey V, Agnew James, Rudisill Patricia, Jacobs Jeff, Weatherston Duncan, Deans Kenneth R. Automated production of research data marts from a canonical fast healthcare interoperability resource data repository: applications to COVID-19 research. J Am Med Inform Assoc. 2021 Jul 30;28(8):1605&#x2013;1611. doi: 10.1093/jamia/ocab108. 
 
6276433</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocab108</ArticleId><ArticleId IdType="pmc">PMC8243354</ArticleId><ArticleId IdType="pubmed">33993254</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu&#xe9;rin Julien, Laizet Y, Le Texier V, Chanas L, Rance B, Koeppel F, Lion F, Gourgou S, Martin A, Tejeda M, Toulmonde M, Cox S, Hess E, Rousseau-Tsangaris M, Jouhet V, Saintigny P. OSIRIS: a minimum data set for data sharing and interoperability in oncology. JCO Clin Cancer Inform. 2021 Mar;5:256&#x2013;265. doi: 10.1200/CCI.20.00094. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.20.00094?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed</ArticleId><ArticleId IdType="doi">10.1200/CCI.20.00094</ArticleId><ArticleId IdType="pmc">PMC8140800</ArticleId><ArticleId IdType="pubmed">33720747</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Yuan, Nassirian Azadeh, Ahmadi Najia, Sedlmayr Martin, Bathelt Franziska. Towards the representation of genomic data in HL7 FHIR and OMOP CDM. Stud Health Technol Inform. 2021 Sep 21;283:86&#x2013;94. doi: 10.3233/SHTI210545.SHTI210545</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210545</ArticleId><ArticleId IdType="pubmed">34545823</ArticleId></ArticleIdList></Reference><Reference><Citation>Hund Hauke, Wettstein Reto, Heidt Christian M, Fegeler Christian. Executing distributed healthcare and research processes - the HiGHmed data sharing framework. Stud Health Technol Inform. 2021 May 24;278:126&#x2013;133. doi: 10.3233/SHTI210060.SHTI210060</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210060</ArticleId><ArticleId IdType="pubmed">34042885</ArticleId></ArticleIdList></Reference><Reference><Citation>Greiner MV, Beal SJ, Dexheimer J, Krummen K. Evaluating IDENTITY, an automated data sharing platform to improve health outcomes for youth in protective custody. Pediatr. 2020 Jul 01;146(1_MeetingAbstract):507&#x2013;508. doi: 10.1542/peds.146.1MA6.507. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.146.1MA6.507</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Castro Lorena, Cal-Gonz&#xe1;lez Victoria M, Del Fiol G, L&#xf3;pez-Nores Mart&#xed;n. CASIDE: A data model for interoperable cancer survivorship information based on FHIR. J Biomed Inform. 2021 Dec;124:103953. doi: 10.1016/j.jbi.2021.103953. 
 
S1532-0464(21)00282-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2021.103953</ArticleId><ArticleId IdType="pubmed">34781009</ArticleId></ArticleIdList></Reference><Reference><Citation>Banach Alexandra, Ulrich Hannes, Kroll Bj&#xf6;rn, Kiel Alexander, Ingenerf Josef, Kock-Schoppenhauer Ann-Kristin. APERITIF - Automatic Patient Recruiting for Clinical Trials Based on HL7 FHIR. Stud Health Technol Inform. 2021 May 27;281:58&#x2013;62. doi: 10.3233/SHTI210120.SHTI210120</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210120</ArticleId><ArticleId IdType="pubmed">34042705</ArticleId></ArticleIdList></Reference><Reference><Citation>Deppenwiese Noemi, Delpy Pierre, Lambarki Mohamed, Lablans Martin. ADT2FHIR - a tool for converting ADT/GEKID oncology data to HL7 FHIR resources. Stud Health Technol Inform. 2021 Sep 21;283:104&#x2013;110. doi: 10.3233/SHTI210547.SHTI210547</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210547</ArticleId><ArticleId IdType="pubmed">34545825</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambarki Mohamed, Kern Jori, Croft David, Engels C&#xe4;cilia, Deppenwiese Noemi, Kerscher Alexander, Kiel Alexander, Palm Stefan, Lablans Martin. Oncology on FHIR: A Data Model for Distributed Cancer Research. Stud Health Technol Inform. 2021 May 24;278:203&#x2013;210. doi: 10.3233/SHTI210070.SHTI210070</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210070</ArticleId><ArticleId IdType="pubmed">34042895</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilintzis V, Beredimas N, Kaimakamis E, Stefanopoulos L, Chatzis E, Jahaj E, Bitzani M, Kotanidou A, Katsaggelos AK, Maglaveras N. CoCross: An ICT Platform Enabling Monitoring Recording and Fusion of Clinical Information Chest Sounds and Imaging of COVID-19 ICU Patients. Healthcare (Basel) 2022 Jan 30;10(2):276. doi: 10.3390/healthcare10020276. 
 
healthcare10020276</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare10020276</ArticleId><ArticleId IdType="pmc">PMC8871733</ArticleId><ArticleId IdType="pubmed">35206889</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed Raphael W, St&#xf6;hr Mark R, G&#xfc;nther Andreas. HIStream-Import: A Generic ETL Framework for Processing Arbitrary Patient Data Collections or Hospital Information Systems into HL7 FHIR Bundles. Stud Health Technol Inform. 2021 May 24;278:75&#x2013;79. doi: 10.3233/SHTI210053.SHTI210053</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210053</ArticleId><ArticleId IdType="pubmed">34042878</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza Maryam Y, Rutherford Michael, Myneni Sahiti, Fenton Susan, Walden Anita, Topaloglu Umit, Eisenstein Eric, Kumar Karan R, Zimmerman Kanecia O, Rocca Mitra, Gordon Gideon Scott, Hume Sam, Wang Zhan, Zozus Meredith. Evaluating the coverage of the HL7 FHIR standard to support eSource data exchange implementations for use in multi-site clinical research studies. AMIA Annu Symp Proc. 2020;2020:472&#x2013;481. 
 
080_3416716</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075534</ArticleId><ArticleId IdType="pubmed">33936420</ArticleId></ArticleIdList></Reference><Reference><Citation>Wettstein Reto, Hund Hauke, Kobylinski Insa, Fegeler Christian, Heinze Oliver. Feasibility Queries in Distributed Architectures - Concept and Implementation in HiGHmed. Stud Health Technol Inform. 2021 May 24;278:134&#x2013;141. doi: 10.3233/SHTI210061.SHTI210061</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210061</ArticleId><ArticleId IdType="pubmed">34042886</ArticleId></ArticleIdList></Reference><Reference><Citation>Wettstein Reto, Hund Hauke, Fegeler Christian, Heinze Oliver. Data Sharing in Distributed Architectures - Concept and Implementation in HiGHmed. Stud Health Technol Inform. 2021 Sep 21;283:111&#x2013;118. doi: 10.3233/SHTI210548.SHTI210548</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210548</ArticleId><ArticleId IdType="pubmed">34545826</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Cox S, Stillwell L, Pfaff E, Champion J, Ahalt SC, Fecho K. FHIR PIT: an open software application for spatiotemporal integration of clinical data and environmental exposures data. BMC Med Inform Decis Mak. 2020 Mar 11;20(1):53. doi: 10.1186/s12911-020-1056-9. 
 
10.1186/s12911-020-1056-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-020-1056-9</ArticleId><ArticleId IdType="doi">10.1186/s12911-020-1056-9</ArticleId><ArticleId IdType="pmc">PMC7066811</ArticleId><ArticleId IdType="pubmed">32160884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong N, Wen A, Stone DJ, Sharma DK, Wang C, Yu Y, Liu H, Shi Q, Jiang G. Developing an FHIR-Based Computational Pipeline for Automatic Population of Case Report Forms for Colorectal Cancer Clinical Trials Using Electronic Health Records. JCO Clin Cancer Inform. 2020 Mar;4:201&#x2013;209. doi: 10.1200/CCI.19.00116. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.19.00116?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed</ArticleId><ArticleId IdType="doi">10.1200/CCI.19.00116</ArticleId><ArticleId IdType="pmc">PMC7113084</ArticleId><ArticleId IdType="pubmed">32134686</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong N, Stone DJ, Sharma DK, Wen A, Wang C, Yu Y, Huang M, Liu S, Liu H, Shi Q, Jiang G. Modeling cancer clinical trials using HL7 FHIR to support downstream applications: a case study with colorectal cancer data. Int J Med Inform. 2021 Jan;145:104308. doi: 10.1016/j.ijmedinf.2020.104308. 
 
S1386-5056(20)30999-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2020.104308</ArticleId><ArticleId IdType="pmc">PMC7736510</ArticleId><ArticleId IdType="pubmed">33160272</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroux H, Metke-Jimenez A, Lawley MJ. Towards achieving semantic interoperability of clinical study data with FHIR. J Biomed Semantics. 2017 Sep 19;8(1):41. doi: 10.1186/s13326-017-0148-7. 
 
10.1186/s13326-017-0148-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13326-017-0148-7</ArticleId><ArticleId IdType="doi">10.1186/s13326-017-0148-7</ArticleId><ArticleId IdType="pmc">PMC5606031</ArticleId><ArticleId IdType="pubmed">28927443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong N, Sharma DK, Yu Y, Egan JB, Davila JI, Wang C, Jiang G. Developing a FHIR-based framework for phenome wide association studies: a case study with a pan-cancer cohort. AMIA Jt Summits Transl Sci Proc. 2020;2020:750&#x2013;759. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233075</ArticleId><ArticleId IdType="pubmed">32477698</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruendner J, Wolf N, T&#xf6;gel Lars, Haller F, Prokosch H, Christoph J. Integrating genomics and clinical data for statistical analysis by using GEnome MINIng (GEMINI) and Fast Healthcare Interoperability Resources (FHIR): system design and implementation. J Med Internet Res. 2020 Oct 07;22(10):e19879. doi: 10.2196/19879. 
 
v22i10e19879</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/19879</ArticleId><ArticleId IdType="pmc">PMC7578821</ArticleId><ArticleId IdType="pubmed">33026356</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Guoqian, Kiefer Richard C, Sharma Deepak K, Prud'hommeaux Eric, Solbrig Harold R. A consensus-based approach for harmonizing the OHDSI common data model with HL7 FHIR. Stud Health Technol Inform. 2017;245:887&#x2013;891. doi: 10.3233/978-1-61499-830-3-887. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-830-3-887</ArticleId><ArticleId IdType="pmc">PMC5939955</ArticleId><ArticleId IdType="pubmed">29295227</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt Pascal S, Pacheco Jennifer A, Rasmussen Luke V. Development of a repository of computable phenotype definitions using the clinical quality language. JAMIA Open. 2021 Oct;4(4):ooab094. doi: 10.1093/jamiaopen/ooab094. 
 
ooab094</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooab094</ArticleId><ArticleId IdType="pmc">PMC8672934</ArticleId><ArticleId IdType="pubmed">34926996</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;pcke Felix, Prokosch H. Employing computers for the recruitment into clinical trials: a comprehensive systematic review. J Med Internet Res. 2014 Jul 01;16(7):e161. doi: 10.2196/jmir.3446. 
 
v16i7e161</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.3446</ArticleId><ArticleId IdType="pmc">PMC4128959</ArticleId><ArticleId IdType="pubmed">24985568</ArticleId></ArticleIdList></Reference><Reference><Citation>Resourcelist - FHIR v4.2.0. Health Level Seven International.  [2021-12-21].  
 http://hl7.org/fhir/2020Feb/resourcelist.html
.</Citation></Reference><Reference><Citation>Kubrick W. CR 3.0 &#x2013; a manifesto for the next generation of clinical research data standards. Reimagine Research. 2016. Aug 30,  [2021-06-17].  
 https://waynekubick.com/2016/08/30/cr-3-0-a-manifesto-for-the-next-generation-of-clinical-research-data-standards/
</Citation></Reference><Reference><Citation>Aerts Jozef. Towards a single data exchange standard for use in healthcare and in clinical research. Stud Health Technol Inform. 2018;248:55&#x2013;63. doi: 10.3233/978-1-61499-858-7-55.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-858-7-55</ArticleId><ArticleId IdType="pubmed">29726419</ArticleId></ArticleIdList></Reference><Reference><Citation>FHIR to CDISC joint mapping implementation guide v1.0. Clinical Data Interchange Standards Consortium. 2021. Sep 01,  [2022-04-22].  
 https://www.cdisc.org/standards/real-world-data/fhir-cdisc-joint-mapping-implementation-guide-v1-0
.</Citation></Reference><Reference><Citation>FHIR to CDISC joint mapping implementation guide 1.0.0 - STU 1. Health Level Seven International.  [2022-04-22].  
 http://hl7.org/fhir/uv/cdisc-mapping/STU1/
</Citation></Reference><Reference><Citation>Olson CM, Rennie Drummond, Cook Deborah, Dickersin Kay, Flanagin Annette, Hogan Joseph W, Zhu Qi, Reiling Jennifer, Pace Brian. Publication bias in editorial decision making. JAMA. 2002 Jun 05;287(21):2825&#x2013;8. doi: 10.1001/jama.287.21.2825.joc10235</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.287.21.2825</ArticleId><ArticleId IdType="pubmed">12038924</ArticleId></ArticleIdList></Reference><Reference><Citation>National Research Data Infrastructure for Personal Health Data. NFDI4Health Consortium.  [2022-06-21].  
 https://www.nfdi4health.de/
</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35854720</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2153-4063</ISSN><JournalIssue CitedMedium="Internet"><Volume>2022</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science</Title><ISOAbbreviation>AMIA Jt Summits Transl Sci Proc</ISOAbbreviation></Journal><ArticleTitle>Advancing Interoperability of Patient-level Social Determinants of Health Data to Support COVID-19 Research.</ArticleTitle><Pagination><StartPage>396</StartPage><EndPage>405</EndPage><MedlinePgn>396-405</MedlinePgn></Pagination><Abstract><AbstractText>Including social determinants of health (SDoH) data in health outcomes research is essential for studying the sources of healthcare disparities and developing strategies to mitigate stressors. In this report, we describe a pragmatic design and approach to explore the encoding needs for transmitting SDoH screening tool responses from a large safety-net hospital into the National Covid Cohort Collaborative (N3C) OMOP dataset. We provide a stepwise account of designing data mapping and ingestion for patient-level SDoH and summarize the results of screening. Our approach demonstrates that sharing of these important data - typically stored as non-standard, EHR vendor specific codes - is feasible. As SDoH screening gains broader use nationally, the approach described in this paper could be used for other screening instruments and improve the interoperability of these important data.</AbstractText><CopyrightInformation>&#xa9;2022 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phuong</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Biomedical and Health Informatics, UW Medicine, Seattle, Washington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Washington Medicine Research IT, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Biomedical Informatics and Data Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palchuk</LastName><ForeName>Matvey B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>TriNetX, LLC, Cambridge, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinoza</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeker</LastName><ForeName>Daniella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorr</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics &amp; Clinical Epidemiology, Oregon Health &amp; Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lozinski</LastName><ForeName>Galina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Boston Medical Center/Boston University School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madlock-Brown</LastName><ForeName>Charisse</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Tennessee Clinical and Translational Science Institute, University of Tennessee Health Science Center, Memphis, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>William G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Boston Medical Center/Boston University School of Medicine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001430</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Jt Summits Transl Sci Proc</MedlineTA><NlmUniqueID>101539486</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>2</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35854720</ArticleId><ArticleId IdType="pmc">PMC9285174</ArticleId><ArticleId IdType="pii">2345</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braveman P, Gottlieb L. The Social Determinants of Health: It&#x2019;s Time to Consider the Causes of the Causes. Public Health Rep. 2014;129:19&#x2013;31. [Internet]. Available from: [cited 2021 Aug 26]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3863696</ArticleId><ArticleId IdType="pubmed">24385661</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuels-Kalow ME, Ciccolo GE, Lin MP, Schoenfeld EM, Camargo CA. The terminology of social emergency medicine: Measuring social determinants of health, social risk, and social need. J Am Coll Emerg Physicians Open. 2020;1:852&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7593464</ArticleId><ArticleId IdType="pubmed">33145531</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramm JM, Nieboer AP. Relationships between frailty, neighborhood security, social cohesion and sense of belonging among community-dwelling older people. Geriatr Gerontol Int. 2013;13:759&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">23190426</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GL, Kahana E, Gallo WT, Stansbury KL, Thielke S. The price of mental well-being in later life: the role of financial hardship and debt. Aging Ment Health. 2021;25:1338&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">32426995</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker-Seeley RD, Li Y, Subramanian SV, Sorensen G. Financial hardship and mortality among older adults using the 1996-2004 Health and Retirement Study. Ann Epidemiol. 2009;19:850&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2835519</ArticleId><ArticleId IdType="pubmed">19944348</ArticleId></ArticleIdList></Reference><Reference><Citation>Despard M, Grinstein-Weiss M, Guo S, Taylor S, Russell B. Financial Shocks, Liquid Assets, and Material Hardship in Low- and Moderate-Income Households: Differences by Race. J Econ Race Policy. 2018;1:205&#x2013;16. [Internet]. Available from: [cited 2021 Aug 26]</Citation></Reference><Reference><Citation>Marshall GL, Tucker-Seeley R. The association between hardship and self-rated health: does the choice of indicator matter? Ann Epidemiol. 2018;28:462&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986601</ArticleId><ArticleId IdType="pubmed">29656847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottrell EK, Dambrun K, Cowburn S, Mossman N, Bunce AE, Marino M, et al. Variation in Electronic Health Record Documentation of Social Determinants of Health Across a National Network of Community Health Centers. Am J Prev Med. 2019;57:S65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">31753281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatef E, Rouhizadeh M, Tia I, Lasser E, Hill-Briggs F, Marsteller J, et al.  Assessing the Availability of Data on Social and Behavioral
Determinants in Structured and Unstructured Electronic Health Records: A
Retrospective Analysis of a Multilevel Health Care System. JMIR Med Inform. 2019;7:e13802.  [cited 2021 Jun 21]Available from: http://medinform.jmir.org/2019/3/e13802/  [Internet]. </Citation><ArticleIdList><ArticleId IdType="pmc">PMC6696855</ArticleId><ArticleId IdType="pubmed">31376277</ArticleId></ArticleIdList></Reference><Reference><Citation>Lybarger K, Ostendorf M, Yetisgen M. Annotating social determinants of health using active learning, and characterizing determinants using neural event extraction. J Biomed Inform. 2021;113:103631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7856628</ArticleId><ArticleId IdType="pubmed">33290878</ArticleId></ArticleIdList></Reference><Reference><Citation>PRAPARE. 2021. [Internet]. NACHC. [cited Aug 26]. Available from: https://www.nachc.org/research-and-data/prapare/ </Citation></Reference><Reference><Citation>Page-Reeves J, Kaufman W, Bleecker M, Norris J, McCalmont K, Ianakieva V, et al.  Addressing Social Determinants of Health in a Clinic Setting: The
WellRx Pilot in Albuquerque, New Mexico. The Journal of the American Board of Family Medicine. 2016;29:414&#x2013;8.  [cited 2021 Jul 6]Available from: http://www.jabfm.org/cgi/doi/10.3122/jabfm.2016.03.150272. 
[Internet]. </Citation><ArticleIdList><ArticleId IdType="pubmed">27170801</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Toy S, Tripodis Y, Silverstein M, Freeman E. Addressing Social Determinants of Health at Well Child Care
Visits: A Cluster RCT. PEDIATRICS. 2015;135:e296&#x2013;304.  [cited 2021 Jul 6]Available from: http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2014-2888. 
[Internet]. </Citation><ArticleIdList><ArticleId IdType="pmc">PMC4306802</ArticleId><ArticleId IdType="pubmed">25560448</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Boynton-Jarrett R, Dworkin PH. Avoiding the Unintended Consequences of Screening for Social
Determinants of Health. JAMA. 2016;316:813.  [cited 2021 Jul 6]Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.9282. 
[Internet]. </Citation><ArticleIdList><ArticleId IdType="pubmed">27367226</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Butz AM, Dworkin PH, Lewis RA, Serwint JR. Screening for basic social needs at a medical home for low-income children. Clin Pediatr. 2009;48:32&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18566347</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Butz AM, Dworkin PH, Lewis RA, Thompson RE, Serwint JR. Improving the management of family psychosocial problems at low-income children&#x2019;s well-child care visits: the WE CARE Project. Pediatrics. 2007;120:547&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">17766528</ArticleId></ArticleIdList></Reference><Reference><Citation>Buitron de la Vega P, Losi S, Sprague Martinez L, Bovell-Ammon A, Garg A, James T, et al. Implementing an EHR-based Screening and Referral System to Address Social Determinants of Health in Primary Care. Med Care. 2019;2:S133&#x2013;9. ;57 Suppl 6 Suppl.</Citation><ArticleIdList><ArticleId IdType="pubmed">31095052</ArticleId></ArticleIdList></Reference><Reference><Citation>Byhoff E, Cohen AJ, Hamati MC, Tatko J, Davis MM, Tipirneni R. Screening for Social Determinants of Health in Michigan Health Centers. J Am Board Fam Med. 2017;30:418&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">28720624</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong HP, Luke AA, Hammond G, Wadhera RK, Reidhead M, Joynt Maddox KE. Utilization of Social Determinants of Health ICD-10 Z-Codes Among Hospitalized Patients in the United States, 2016-2017. Med Care. 2020;58:1037&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7666017</ArticleId><ArticleId IdType="pubmed">32925453</ArticleId></ArticleIdList></Reference><Reference><Citation>The Gravity Project.   [Internet]. [cited 2021 Aug 26]. Available from: https://confluence.hl7.org/display/GRAV/The+Gravity+Project. 
(Phila). </Citation></Reference><Reference><Citation>Qui&#xf1;ones-Rivera A, Wing HE, Barr-Walker J, Yee M, Harrison JM, Gottlieb LM. Provider Impacts of Socioeconomic Risk Screening and Referral Programs: A Scoping Review. J Am Board Fam Med. 2021;34:820&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312275</ArticleId></ArticleIdList></Reference><Reference><Citation>Phuong J, Zampino E, Dobbins N, Espinoza J, Meeker D, Spratt H, et al. AMIA Annual Symposium. 2021. Extracting Patient-level Social Determinants of Health into the OMOP Common Data Model.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861735</ArticleId><ArticleId IdType="pubmed">35308947</ArticleId></ArticleIdList></Reference><Reference><Citation>Winden TJ, Chen ES, Monsen KA, Melton GB. AMIA Summits on Translational Science Proceedings. 2018. Evaluation of Flowsheet Documentation in the Electronic Health Record for Residence, Living Situation, and Living Conditions; pp. 236&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961798</ArticleId><ArticleId IdType="pubmed">29888079</ArticleId></ArticleIdList></Reference><Reference><Citation>Topaloglu U, Palchuk MB. Using a Federated Network of Real-World Data to Optimize Clinical Trials Operations. JCO Clin Cancer Inform. 2018;2:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816049</ArticleId><ArticleId IdType="pubmed">30652541</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda JM. Fully connecting the Observational Health Data Science and Informatics (OHDSI) initiative with the world of linked open data. Genomics Inform. 2019;17:e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6808628</ArticleId><ArticleId IdType="pubmed">31307128</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Bennett TD, Eichmann DA, Guinney J, Kibbe WA, et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. J Am Med Inform Assoc. 2021;28:427&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Mendis M, Hackett K, Kuttan R, Pan W, Phillips LC, et al. AMIA Annu Symp Proc. 2007. Architecture of the open-source clinical research chart from Informatics for Integrating Biology and the Bedside; pp. 548&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655844</ArticleId><ArticleId IdType="pubmed">18693896</ArticleId></ArticleIdList></Reference><Reference><Citation>UCSF Social Interventions Research &amp; Evaluation Network (SIREN)
[Internet] 2020. Social Needs Screening Tool Comparison Table.  [Internet]. [cited 2021 Mar 10]. Available from: https://sirenetwork.ucsf.edu/SocialNeedsScreeningToolComparisonTable .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35873596</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Vaccine Safety Surveillance Using Routinely Collected Healthcare Data-An Empirical Evaluation of Epidemiological Designs.</ArticleTitle><Pagination><StartPage>893484</StartPage><MedlinePgn>893484</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">893484</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2022.893484</ELocationID><Abstract><AbstractText><b>Background:</b> Routinely collected healthcare data such as administrative claims and electronic health records (EHR) can complement clinical trials and spontaneous reports to detect previously unknown risks of vaccines, but uncertainty remains about the behavior of alternative epidemiologic designs to detect and declare a true risk early. <b>Methods:</b> Using three claims and one EHR database, we evaluate several variants of the case-control, comparative cohort, historical comparator, and self-controlled designs against historical vaccinations using real negative control outcomes (outcomes with no evidence to suggest that they could be caused by the vaccines) and simulated positive control outcomes. <b>Results:</b> Most methods show large type 1 error, often identifying false positive signals. The cohort method appears either positively or negatively biased, depending on the choice of comparator index date. Empirical calibration using effect-size estimates for negative control outcomes can bring type 1 error closer to nominal, often at the cost of increasing type 2 error. After calibration, the self-controlled case series (SCCS) design most rapidly detects small true effect sizes, while the historical comparator performs well for strong effects. <b>Conclusion:</b> When applying any method for vaccine safety surveillance we recommend considering the potential for systematic error, especially due to confounding, which for many designs appears to be substantial. Adjusting for age and sex alone is likely not sufficient to address differences between vaccinated and unvaccinated, and for the cohort method the choice of index date is important for the comparability of the groups. Analysis of negative control outcomes allows both quantification of the systematic error and, if desired, subsequent empirical calibration to restore type 1 error to its nominal value. In order to detect weaker signals, one may have to accept a higher type 1 error.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Schuemie, Arshad, Pratt, Nyberg, Alshammari, Hripcsak, Ryan, Prieto-Alhambra, Lai, Li, Fortin, Minty and Suchard.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen R&amp;D, Titusville, NJ, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arshad</LastName><ForeName>Faaizah</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Prince Sattam Bin Abdulaziz University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen R&amp;D, Titusville, NJ, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Lana Y H</ForeName><Initials>LYH</Initials><AffiliationInfo><Affiliation>O'Brien Institute for Public Health, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xintong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Medical Sciences, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen R&amp;D, Titusville, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>O'Brien Institute for Public Health, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Front Pharmacol. 2022 Nov 24;13:1088973</RefSource><PMID Version="1">36506524</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse event</Keyword><Keyword MajorTopicYN="N">methods</Keyword><Keyword MajorTopicYN="N">routinely collected data</Keyword><Keyword MajorTopicYN="N">surveillance</Keyword><Keyword MajorTopicYN="N">vaccine safety</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>25</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35873596</ArticleId><ArticleId IdType="pmc">PMC9299244</ArticleId><ArticleId IdType="doi">10.3389/fphar.2022.893484</ArticleId><ArticleId IdType="pii">893484</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Black S., Eskola J., Siegrist C. A., Halsey N., Macdonald N., Law B., et al. (2009). Importance of Background Rates of Disease in Assessment of Vaccine Safety during Mass Immunisation with Pandemic H1N1 Influenza Vaccines. Lancet 374, 2115&#x2013;2122. 10.1016/S0140-6736(09)61877-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId><ArticleId IdType="pmc">PMC2861912</ArticleId><ArticleId IdType="pubmed">19880172</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacketer C., Defalco F. J., Ryan P. B., Rijnbeek P. R. (2021). Increasing Trust in Real-World Evidence through Evaluation of Observational Data Quality. J. Am. Med. Inf. Assoc. 28, 2251&#x2013;2257. 10.1093/jamia/ocab132</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocab132</ArticleId><ArticleId IdType="pmc">PMC8449628</ArticleId><ArticleId IdType="pubmed">34313749</ArticleId></ArticleIdList></Reference><Reference><Citation>Glanz J. M., Mcclure D. L., Xu S., Hambidge S. J., Lee M., Kolczak M. S., et al. (2006). Four Different Study Designs to Evaluate Vaccine Safety Were Equally Validated with Contrasting Limitations. J. Clin. Epidemiol. 59, 808&#x2013;818. 10.1016/j.jclinepi.2005.11.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2005.11.012</ArticleId><ArticleId IdType="pubmed">16828674</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G., Duke J. D., Shah N. H., Reich C. G., Huser V., Schuemie M. J., et al. (2015). Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud. Health Technol. Inf. 216, 574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulaylat A. S., Schaefer E. W., Messaris E., Hollenbeak C. S. (2019). Truven Health Analytics MarketScan Databases for Clinical Research in Colon and Rectal Surgery. Clin. Colon Rectal Surg. 32, 54&#x2013;60. 10.1055/s-0038-1673354</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1673354</ArticleId><ArticleId IdType="pmc">PMC6327721</ArticleId><ArticleId IdType="pubmed">30647546</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulldorff M., Davis R. L., Kolczak&#x2020; M., Lewis E., Lieu T., Platt R. (2011). A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance. Seq. Anal. 30, 58&#x2013;78. 10.1080/07474946.2011.539924</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07474946.2011.539924</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai L., Arshad F., Alshammari T. M., Areia C., Alghoul H., Casajust P., et al. (2022). Current Approaches to Vaccine Safety: A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Event under Surveillance -for Vaccines) Study Design. JFrontiers Pharmacology-Pharmacoepidemiology. In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8980923</ArticleId><ArticleId IdType="pubmed">35392566</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite A., Andrews N. J., Thomas S. L. (2016). Near Real-Time Vaccine Safety Surveillance Using Electronic Health Records-A Systematic Review of the Application of Statistical Methods. Pharmacoepidemiol Drug Saf. 25, 225&#x2013;237. 10.1002/pds.3966</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3966</ArticleId><ArticleId IdType="pmc">PMC5021108</ArticleId><ArticleId IdType="pubmed">26817940</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Lai L. Y., Ostropolets A., Arshad F., Tan E. H., Casajust P., et al. (2021). Bias, Precision and Timeliness of Historical (Background) Rate Comparison Methods for Vaccine Safety Monitoring: An Empirical Multi-Database Analysis. Front. Pharmacol. 12, 773875. 10.3389/fphar.2021.773875</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.773875</ArticleId><ArticleId IdType="pmc">PMC8652333</ArticleId><ArticleId IdType="pubmed">34899334</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcclure D. L., Glanz J. M., Xu S., Hambidge S. J., Mullooly J. P., Baggs J. (2008). Comparison of Epidemiologic Methods for Active Surveillance of Vaccine Safety. Vaccine 26, 3341&#x2013;3345. 10.1016/j.vaccine.2008.03.074</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.03.074</ArticleId><ArticleId IdType="pubmed">18462849</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesfin Y. M., Cheng A., Lawrie J., Buttery J. (2019). Use of Routinely Collected Electronic Healthcare Data for Postlicensure Vaccine Safety Signal Detection: a Systematic Review. BMJ Glob. Health 4, e001065. 10.1136/bmjgh-2018-001065</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2018-001065</ArticleId><ArticleId IdType="pmc">PMC6615875</ArticleId><ArticleId IdType="pubmed">31354969</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal S., Chen R. (1995). The Reporting Sensitivities of Two Passive Surveillance Systems for Vaccine Adverse Events. Am. J. Public Health 85, 1706&#x2013;1709. 10.2105/ajph.85.12.1706</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.85.12.1706</ArticleId><ArticleId IdType="pmc">PMC1615747</ArticleId><ArticleId IdType="pubmed">7503351</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Hripcsak G., Ryan P. B., Madigan D., Suchard M. A. (2018a). Empirical Confidence Interval Calibration for Population-Level Effect Estimation Studies in Observational Healthcare Data. Proc. Natl. Acad. Sci. U. S. A. 115, 2571&#x2013;2577. 10.1073/pnas.1708282114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Ryan P. B., Dumouchel W., Suchard M. A., Madigan D. (2014). Interpreting Observational Studies: Why Empirical Calibration Is Needed to Correct P-Values. Stat. Med. 33, 209&#x2013;218. 10.1002/sim.5925</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Ryan P. B., Hripcsak G., Madigan D., Suchard M. A. (2018b). Improving Reproducibility by Using High-Throughput Observational Studies with Empirical Calibration. Philos. Trans. A Math. Phys. Eng. Sci. 376. 10.1098/rsta.2017.0356</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva I. R., Kulldorff M. (2021). The &#x2018;Sequential&#x2019; R Package. 1 ed, 3.</Citation></Reference><Reference><Citation>Tian Y., Schuemie M. J., Suchard M. A. (2018). Evaluating Large-Scale Propensity Score Performance through Real-World and Synthetic Data Experiments. Int. J. Epidemiol. 47, 2005&#x2013;2014. 10.1093/ije/dyy120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker H. J., Farrington C. P., Spiessens B., Musonda P. (2006). Tutorial in Biostatistics: the Self-Controlled Case Series Method. Stat. Med. 25, 1768&#x2013;1797. 10.1002/sim.2302</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2302</ArticleId><ArticleId IdType="pubmed">16220518</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35911666</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2574-2531</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JAMIA open</Title><ISOAbbreviation>JAMIA Open</ISOAbbreviation></Journal><ArticleTitle>An ordinal severity scale for COVID-19 retrospective studies using Electronic Health Record data.</ArticleTitle><Pagination><StartPage>ooac066</StartPage><MedlinePgn>ooac066</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamiaopen/ooac066</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Although the World Health Organization (WHO) Clinical Progression Scale for COVID-19 is useful in prospective clinical trials, it cannot be effectively used with retrospective Electronic Health Record (EHR) datasets. Modifying the existing WHO Clinical Progression Scale, we developed an ordinal severity scale (OS) and assessed its usefulness in the analyses of COVID-19 patient outcomes using retrospective EHR data.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">An OS was developed to assign COVID-19 disease severity using the Observational Medical Outcomes Partnership common data model within the National COVID Cohort Collaborative (N3C) data enclave. We then evaluated usefulness of the developed OS using heterogenous EHR data from January 2020 to October 2021 submitted to N3C by 63 healthcare organizations across the United States. Principal component analysis (PCA) was employed to characterize changes in disease severity among patients during the 28-day period following COVID-19 diagnosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The data set used in this analysis consists of 2&#xa0;880&#xa0;456 patients. PCA of the day-to-day variation in OS levels over the totality of the 28-day period revealed contrasting patterns of variation in disease severity within the first and second 14 days and illustrated the importance of evaluation over the full 28-day period.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">An OS with well-defined, robust features, based on discrete EHR data elements, is useful for assessments of COVID-19 patient outcomes, providing insights on the progression of COVID-19 disease severity over time.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The OS provides a framework that can facilitate better understanding of the course of acute COVID-19, informing clinical decision-making and resource allocation.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khodaverdi</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7559-1656</Identifier><AffiliationInfo><Affiliation>West Virginia Clinical and Translational Sciences Institute, Morgantown, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Bradley S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>West Virginia Clinical and Translational Sciences Institute, Morgantown, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porterfield</LastName><ForeName>J Zachary</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Kentucky, Lexington, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bunnell</LastName><ForeName>H Timothy</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Biomedical Research Informatics Center, Nemours Children's Health, Wilmington, Delaware, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vest</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Section of Pulmonary and Critical Care Medicine, Christiana Care Health System, Newark, Delaware, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anzalone</LastName><ForeName>Alfred Jerrod</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harper</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1244-8948</Identifier><AffiliationInfo><Affiliation>Owl Health Works LLC, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimble</LastName><ForeName>Wes D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>West Virginia Clinical and Translational Sciences Institute, Morgantown, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moradi</LastName><ForeName>Hamidreza</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Data Science, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendricks</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, West Virginia University, Morgantown, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santangelo</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Center for Psychiatric Research, Maine Medical Center Research Institute, and Maine Medical Center, Portland, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodder</LastName><ForeName>Sally L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>West Virginia Clinical and Translational Sciences Institute, Morgantown, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>N3C Consortium Collaborators </CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>Dryad</DataBankName><AccessionNumberList><AccessionNumber>10.5061/dryad.dncjsxm2q</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM104942</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115458</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMIA Open</MedlineTA><NlmUniqueID>101730643</NlmUniqueID><ISSNLinking>2574-2531</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 ordinal scale</Keyword><Keyword MajorTopicYN="N">Electronic Health Record</Keyword><Keyword MajorTopicYN="N">N3C</Keyword><Keyword MajorTopicYN="N">National COVID Cohort Collaborative</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>1</Day><Hour>3</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35911666</ArticleId><ArticleId IdType="pmc">PMC9278199</ArticleId><ArticleId IdType="doi">10.1093/jamiaopen/ooac066</ArticleId><ArticleId IdType="pii">ooac066</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>JAMA Netw Open. 2021 Jul 1;4(7):e2116901</Citation><ArticleIdList><ArticleId IdType="pubmed">34255046</ArticleId></ArticleIdList></Reference><Reference><Citation>EGEMS (Wash DC). 2016 Sep 11;4(1):1244</Citation><ArticleIdList><ArticleId IdType="pubmed">27713905</ArticleId></ArticleIdList></Reference><Reference><Citation>NPJ Digit Med. 2020 Aug 19;3:109</Citation><ArticleIdList><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Aug;20(8):e192-e197</Citation><ArticleIdList><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2021 Aug 2;73(3):531-534</Citation><ArticleIdList><ArticleId IdType="pubmed">32770240</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Aug 4;324(5):460-470</Citation><ArticleIdList><ArticleId IdType="pubmed">32492084</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Jun 9;323(22):2262-2263</Citation><ArticleIdList><ArticleId IdType="pubmed">32364561</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2021 Mar 1;28(3):427-443</Citation><ArticleIdList><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation><ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2021 Jul 14;28(7):1411-1420</Citation><ArticleIdList><ArticleId IdType="pubmed">33566082</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2022 Mar 15;29(4):609-618</Citation><ArticleIdList><ArticleId IdType="pubmed">34590684</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2022 Jun 14;29(7):1172-1182</Citation><ArticleIdList><ArticleId IdType="pubmed">35435957</ArticleId></ArticleIdList></Reference><Reference><Citation>Stud Health Technol Inform. 2015;216:574-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMIA Open. 2021 Feb 04;4(3):ooab001</Citation><ArticleIdList><ArticleId IdType="pubmed">34514354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 16;395(10236):1525-1527</Citation><ArticleIdList><ArticleId IdType="pubmed">32423580</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35933465</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2614</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of clinical monitoring and computing</Title><ISOAbbreviation>J Clin Monit Comput</ISOAbbreviation></Journal><ArticleTitle>Development and usage of an anesthesia data warehouse: lessons learnt from a 10-year project.</ArticleTitle><Pagination><StartPage>461</StartPage><EndPage>472</EndPage><MedlinePgn>461-472</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10877-022-00898-y</ELocationID><Abstract><AbstractText>This paper describes the development and implementation of an anesthesia data warehouse in the Lille University Hospital. We share the lessons learned from a ten-year project and provide guidance for the implementation of such a project. Our clinical data warehouse is mainly fed with data collected by the anesthesia information management system and hospital discharge reports. The data warehouse stores historical and accurate data with an accuracy level of the day for administrative data, and of the second for monitoring data. Datamarts complete the architecture and provide secondary computed data and indicators, in order to execute queries faster and easily. Between 2010 and 2021, 636 784 anesthesia records were integrated for 353 152 patients. We reported the main concerns and barriers during the development of this project and we provided 8 tips to handle them. We have implemented our data warehouse into the OMOP common data model as a complementary downstream data model. The next step of the project will be to disseminate the use of the OMOP data model for anesthesia and critical care, and drive the trend towards federated learning to enhance collaborations and multicenter studies.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lamer</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9546-1808</Identifier><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, Lille, France. antoine.lamer@univ-lille.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>InterHop, Rennes, France. antoine.lamer@univ-lille.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moussa</LastName><ForeName>Mouhamed Djahoum</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, Cardiovascular Anesthesia and Intensive Care, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcilly</LastName><ForeName>Romaric</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, CIC-IT 1403 - Investigation Center, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logier</LastName><ForeName>R&#xe9;gis</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CHU Lille, CIC-IT 1403 - Investigation Center, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallet</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavernier</LastName><ForeName>Beno&#xee;t</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, P&#xf4;le d'Anesth&#xe9;sie-R&#xe9;animation, 59000, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Monit Comput</MedlineTA><NlmUniqueID>9806357</NlmUniqueID><ISSNLinking>1387-1307</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073458" MajorTopicYN="Y">Data Warehousing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000758" MajorTopicYN="Y">Anesthesia</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anesthesia information management system</Keyword><Keyword MajorTopicYN="N">Data reuse</Keyword><Keyword MajorTopicYN="N">Data warehouse</Keyword><Keyword MajorTopicYN="N">Database</Keyword><Keyword MajorTopicYN="N">Retrospective studies</Keyword></KeywordList><CoiStatement>The authors have no relevant financial or non-financial interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>6</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35933465</ArticleId><ArticleId IdType="pmc">PMC10068662</ArticleId><ArticleId IdType="doi">10.1007/s10877-022-00898-y</ArticleId><ArticleId IdType="pii">10.1007/s10877-022-00898-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Douglas JR, Ritter MJ. Implementation of an anesthesia information management system (AIMS) Ochsner J. 2011;11:102&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119212</ArticleId><ArticleId IdType="pubmed">21734847</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger Halbeis CB, Epstein RH, Macario A, Pearl RG, Grunwald Z. Adoption of anesthesia information management systems by academic departments in the United States. Anesth Analg. 2008;107:1323&#x2013;1329. doi: 10.1213/ane.0b013e31818322d2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0b013e31818322d2</ArticleId><ArticleId IdType="pubmed">18806048</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson M, Junger A, Michel A, Sciuk G, Quinzio L, Marquardt K, et al. Comparison of manual and automated documentation of adverse events with an Anesthesia Information Management System (AIMS) Stud Health Technol Inform. 2000;77:925&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">11187690</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesser JB, Sanborn KV, Valskys R, Kuroda M. Severe bradycardia during spinal and epidural anesthesia recorded by an anesthesia information management system. Anesthesiology. 2003;99:859&#x2013;866. doi: 10.1097/00000542-200310000-00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200310000-00018</ArticleId><ArticleId IdType="pubmed">14508318</ArticleId></ArticleIdList></Reference><Reference><Citation>Balust J, Macario A. Can anesthesia information management systems improve quality in the surgical suite? Curr Opin Anaesthesiol. 2009;22:215&#x2013;222. doi: 10.1097/ACO.0b013e328324b9e6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACO.0b013e328324b9e6</ArticleId><ArticleId IdType="pubmed">19390248</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozental O, White RS. Anesthesia information management systems: evolution of the paper anesthetic record to a multisystem electronic medical record network that streamlines perioperative care. J Anesth Hist. 2019;5:93&#x2013;98. doi: 10.1016/j.janh.2019.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.janh.2019.04.001</ArticleId><ArticleId IdType="pubmed">31570203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Jeanne M, Marcilly R, Kipnis E, Schiro J, Logier R, et al. Methodology to automatically detect abnormal values of vital parameters in anesthesia time-series: proposal for an adaptable algorithm. Comput Methods Programs Biomed. 2016;129:160&#x2013;171. doi: 10.1016/j.cmpb.2016.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2016.01.004</ArticleId><ArticleId IdType="pubmed">26817405</ArticleId></ArticleIdList></Reference><Reference><Citation>Sessler DI, Sigl JC, Kelley SD, Chamoun NG, Manberg PJ, Saager L, et al. Hospital stay and mortality are increased in patients having a &#x201c;triple low&#x201d; of low blood pressure, low bispectral index, and low minimum alveolar concentration of volatile anesthesia. Anesthesiology. 2012;116:1195&#x2013;1203. doi: 10.1097/ALN.0b013e31825683dc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e31825683dc</ArticleId><ArticleId IdType="pubmed">22546967</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, et al. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013;119:507&#x2013;515. doi: 10.1097/ALN.0b013e3182a10e26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e3182a10e26</ArticleId><ArticleId IdType="pubmed">23835589</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu R, You J, Mascha EJ, Sessler DI, Kasuya Y, Turan A. Anesthetic induction with etomidate, rather than propofol, is associated with increased 30-day mortality and cardiovascular morbidity after noncardiac surgery. Anesth Analg. 2013;117:1329&#x2013;1337. doi: 10.1213/ANE.0b013e318299a516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0b013e318299a516</ArticleId><ArticleId IdType="pubmed">24257383</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin MA, McCormick PJ, Lin HM, Hosseinian L, Fischer GW. Low intraoperative tidal volume ventilation with minimal PEEP is associated with increased mortality. Br J Anaesth. 2014;113:97&#x2013;108. doi: 10.1093/bja/aeu054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aeu054</ArticleId><ArticleId IdType="pmc">PMC9585620</ArticleId><ArticleId IdType="pubmed">24623057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimball R. The data warehouse lifecycle toolkit: expert methods for designing, developing, and deploying data warehouses. New York: Wiley; 1998.</Citation></Reference><Reference><Citation>Wisniewski MF, Kieszkowski P, Zagorski BM, Trick WE, Sommers M, Weinstein RA. Development of a clinical data warehouse for hospital infection control. J Am Med Inform Assoc. 2003;10:454&#x2013;462. doi: 10.1197/jamia.M1299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M1299</ArticleId><ArticleId IdType="pmc">PMC212782</ArticleId><ArticleId IdType="pubmed">12807807</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Weber G, Mendis M, Gainer V, Chueh HC, Churchill S, et al. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) J Am Med Inform Assoc. 2010;17:124&#x2013;130. doi: 10.1136/jamia.2009.000893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.000893</ArticleId><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>de Mul M, Alons P, van der Velde P, Konings I, Bakker J, Hazelzet J. Development of a clinical data warehouse from an intensive care clinical information system. Comput Methods Programs Biomed. 2012;105:22&#x2013;30. doi: 10.1016/j.cmpb.2010.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2010.07.002</ArticleId><ArticleId IdType="pubmed">20728956</ArticleId></ArticleIdList></Reference><Reference><Citation>Jannot A-S, Zapletal E, Avillach P, Mamzer M-F, Burgun A, Degoulet P. The Georges Pompidou University Hospital Clinical Data Warehouse: a 8-years follow-up experience. Int J Med Inform. 2017;102:21&#x2013;28. doi: 10.1016/j.ijmedinf.2017.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2017.02.006</ArticleId><ArticleId IdType="pubmed">28495345</ArticleId></ArticleIdList></Reference><Reference><Citation>Inmon WH. Building the data warehouse. New York: Wiley; 1992.</Citation></Reference><Reference><Citation>DIANE Anesthesia - Medical software [Internet]. BOW Medical. [cited 2021 Dec 26]. Available from https://bowmedical.com/en/diane-anesthesia-medical-software/</Citation></Reference><Reference><Citation>Post AR, Ai M, Kalsanka Pai A, Overcash M, Stephens DS. Architecting the data loading process for an i2b2 research data warehouse: full reload versus incremental updating. AMIA Annu Symp Proc. 2018;2017:1411&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977612</ArticleId><ArticleId IdType="pubmed">29854210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Jeanne M, Ficheur G, Marcilly R. Automated data aggregation for time-series analysis: study case on anaesthesia data warehouse. Stud Health Technol Inform. 2016;221:102&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">27071886</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Hripcsak G, Swaminathan S, Weng C. Defining and measuring completeness of electronic health records for secondary use. J Biomed Inform. 2013;46:830&#x2013;836. doi: 10.1016/j.jbi.2013.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2013.06.010</ArticleId><ArticleId IdType="pmc">PMC3810243</ArticleId><ArticleId IdType="pubmed">23820016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, De Jonckheere J, Marcilly R, Tavernier B, Vallet B, Jeanne M, et al. A substitution method to improve completeness of events documentation in anesthesia records. J Clin Monit Comput. 2015;29(6):741&#x2013;747. doi: 10.1007/s10877-015-9661-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10877-015-9661-3</ArticleId><ArticleId IdType="pubmed">25634428</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Ficheur G, Rousselet L, van Berleere M, Chazard E, Caron A. From data extraction to analysis: proposal of a methodology to optimize hospital data reuse process. Stud Health Technol Inform. 2018;247:41&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">29677919</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent G, Moussa MD, Cirenei C, Tavernier B, Marcilly R, Lamer A. Development, implementation and preliminary evaluation of clinical dashboards in a department of anesthesia. J Clin Monit Comput. 2021;35(3):617&#x2013;26. doi: 10.1007/s10877-020-00522-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10877-020-00522-x</ArticleId><ArticleId IdType="pmc">PMC7229430</ArticleId><ArticleId IdType="pubmed">32418147</ArticleId></ArticleIdList></Reference><Reference><Citation>Degoul S, Chazard E, Lamer A, Lebuffe G, Duhamel A, Tavernier B. lntraoperative administration of 6% hydroxyethyl starch 130/0.4 is not associated with acute kidney injury in elective non-cardiac surgery: a sequential and propensity-matched analysis. Anaesth Crit Care Pain Med. 2020;39(2):199&#x2013;206. doi: 10.1016/j.accpm.2019.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.accpm.2019.08.002</ArticleId><ArticleId IdType="pubmed">32068135</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussa MD, Lamer A, Labreuche J, Brandt C, Mass G, Louvel P, Lecailtel S, Mesnard T, Deblauwe D, Gantois G, Nodea M. Mid-term survival and risk factors associated with myocardial injury after fenestrated and/or branched endovascular aortic aneurysm repair. Eur J Vasc Endovasc Surg. 2021;62(4):550&#x2013;8. doi: 10.1016/j.ejvs.2021.02.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejvs.2021.02.043</ArticleId><ArticleId IdType="pubmed">33846076</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlich C, Lamer A, Moussa MD, Martin J, Rogeau S, Tavernier B. End-tidal carbon dioxide for diagnosing anaphylaxis in patients with severe postinduction hypotension. Anesthesiology. 2022;136(3):472&#x2013;481. doi: 10.1097/ALN.0000000000004123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000004123</ArticleId><ArticleId IdType="pubmed">35041738</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI&#x2014;Observational Health Data Sciences and Informatics [Internet]. [cited 2019 May 3]. Available from https://www.ohdsi.org/</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudis F, Clement G, Bruandet A, Lamer A. Automated generation of individual and population clinical pathways with the OMOP common data model. Stud Health Technol Inform. 2021;281:218&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">34042737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Abou-Arab O, Bourgeois A, Parrot A, Popoff B, Beuscart J-B, et al. Transforming anesthesia data into the observational medical outcomes partnership common data model: development and usability study. J Med Internet Res. 2021;23:e29259. doi: 10.2196/29259.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/29259</ArticleId><ArticleId IdType="pmc">PMC8590192</ArticleId><ArticleId IdType="pubmed">34714250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogowicz M, Jochems A, Deist TM, Tanadini-Lang S, Huang SH, Chan B, et al. Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. Sci Rep. 2020;10:4542. doi: 10.1038/s41598-020-61297-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-61297-4</ArticleId><ArticleId IdType="pmc">PMC7066122</ArticleId><ArticleId IdType="pubmed">32161279</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangold P, Filiot A, Moussa M, Sobanski V, Ficheur G, Andrey P, et al. A decentralized framework for biostatistics and privacy concerns. Stud Health Technol Inform. 2020;275:137&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">33227756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Filiot A, Bouillard Y, Mangold P, Andrey P, Schiro J. Specifications for the routine implementation of federated learning in hospitals networks. Stud Health Technol Inform. 2021;281:128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">34042719</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AEW, Pollard TJ, Shen L, Lehman LH, Feng M, Ghassemi M, et al. MIMIC-III, a freely accessible critical care database. Sci Data. 2016;3:1&#x2013;9. doi: 10.1038/sdata.2016.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.35</ArticleId><ArticleId IdType="pmc">PMC4878278</ArticleId><ArticleId IdType="pubmed">27219127</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">35962355</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6947</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>BMC medical informatics and decision making</Title><ISOAbbreviation>BMC Med Inform Decis Mak</ISOAbbreviation></Journal><ArticleTitle>Leveraging artificial intelligence and data science techniques in harmonizing, sharing, accessing and analyzing SARS-COV-2/COVID-19 data in Rwanda (LAISDAR Project): study design and rationale.</ArticleTitle><Pagination><StartPage>214</StartPage><MedlinePgn>214</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">214</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12911-022-01965-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Since the outbreak of COVID-19 pandemic in Rwanda, a vast amount of SARS-COV-2/COVID-19-related data have been collected including COVID-19 testing and hospital routine care data. Unfortunately, those data are fragmented in silos with different data structures or formats and cannot be used to improve understanding of the disease, monitor its progress, and generate evidence to guide prevention measures. The objective of this project is to leverage the artificial intelligence (AI) and data science techniques in harmonizing datasets to support Rwandan government needs in monitoring and predicting the COVID-19 burden, including the hospital admissions and overall infection rates.</AbstractText><AbstractText Label="METHODS">The project will gather the existing data including hospital electronic health records (EHRs), the COVID-19 testing data and will link with longitudinal data from community surveys. The open-source tools from Observational Health Data Sciences and Informatics (OHDSI) will be used to harmonize hospital EHRs through the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The project will also leverage other OHDSI tools for data analytics and network integration, as well as R Studio and Python. The network will include up to 15 health facilities in Rwanda, whose EHR data will be harmonized to OMOP CDM.</AbstractText><AbstractText Label="EXPECTED RESULTS">This study will yield a technical infrastructure where the 15 participating hospitals and health centres will have EHR data in OMOP CDM format on a local Mac Mini ("data node"), together with a set of OHDSI open-source tools. A central server, or portal, will contain a data catalogue of participating sites, as well as the OHDSI tools that are used to define and manage distributed studies. The central server will also integrate the information from the national Covid-19 registry, as well as the results of the community surveys. The ultimate project outcome is the dynamic prediction modelling for COVID-19 pandemic in Rwanda.</AbstractText><AbstractText Label="DISCUSSION">The project is the first on the African continent leveraging AI and implementation of an OMOP CDM based federated data network for data harmonization. Such infrastructure is scalable for other pandemics monitoring, outcomes predictions, and tailored response planning.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nishimwe</LastName><ForeName>Aurore</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda. auroreshimwa@yahoo.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruranga</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>African Center of Excellence in Data Science, University of Rwanda, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musanabaganwa</LastName><ForeName>Clarisse</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rwanda Biomedical Center, Ministry of Health, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mugeni</LastName><ForeName>Regine</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rwamagana Provincial Hospital, East province, Rwamagana, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semakula</LastName><ForeName>Muhammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rwanda Biomedical Center, Ministry of Health, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nzabanita</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Science and Technology, University of Rwanda, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabano</LastName><ForeName>Ignace</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>African Center of Excellence in Data Science, University of Rwanda, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uwimana</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>African Center of Excellence in Data Science, University of Rwanda, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utumatwishima</LastName><ForeName>Jean N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Rwamagana Provincial Hospital, East province, Rwamagana, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabakambira</LastName><ForeName>Jean Damascene</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>The University Teaching Hospital of Kigali (CHUK), Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uwineza</LastName><ForeName>Annette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The University Teaching Hospital of Kigali (CHUK), Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halvorsen</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>edenceHealth NV, Kontich, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Descamps</LastName><ForeName>Freija</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>edenceHealth NV, Kontich, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houghtaling</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>edenceHealth NV, Kontich, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>edenceHealth NV, Kontich, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahati</LastName><ForeName>Odile</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Regional Alliance of Sustainable Development, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bizimana</LastName><ForeName>Clement</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Regional Alliance of Sustainable Development, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Twizere</LastName><ForeName>Celestin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center of Excellence in Biomedical Engineering and eHealth, University of Rwanda, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nkurikiyeyezu</LastName><ForeName>Kizito</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center of Excellence in Biomedical Engineering and eHealth, University of Rwanda, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birungi</LastName><ForeName>Francine</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nsanzimana</LastName><ForeName>Sabin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rwanda Biomedical Center, Ministry of Health, Kigali, Rwanda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Twagirumukiza</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Inform Decis Mak</MedlineTA><NlmUniqueID>101088682</NlmUniqueID><ISSNLinking>1472-6947</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="N">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="N">Data Science</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012432" MajorTopicYN="N" Type="Geographic">Rwanda</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Artificial intelligence</Keyword><Keyword MajorTopicYN="N">Data science</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Rwanda</Keyword><Keyword MajorTopicYN="N">SARS-COV-2/COVID-19</Keyword></KeywordList><CoiStatement>The authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35962355</ArticleId><ArticleId IdType="pmc">PMC9372951</ArticleId><ArticleId IdType="doi">10.1186/s12911-022-01965-9</ArticleId><ArticleId IdType="pii">10.1186/s12911-022-01965-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med. 2020;9(1):1&#x2013;7. doi: 10.1186/s40169-020-00271-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40169-020-00271-z</ArticleId><ArticleId IdType="pmc">PMC7033263</ArticleId><ArticleId IdType="pubmed">32078069</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020;80(6):656&#x2013;665. doi: 10.1016/j.jinf.2020.03.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.041</ArticleId><ArticleId IdType="pmc">PMC7151416</ArticleId><ArticleId IdType="pubmed">32283155</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270&#x2013;273. doi: 10.1038/s41586-020-2012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G, Chen S, Chen Z, Back to the spring of, facts and hope of COVID-19 outbreak. Vol. 14, Frontiers of Medicine. Springer. 2020;2020:113&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7089213</ArticleId><ArticleId IdType="pubmed">32172487</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. Addendum: a pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;588(7836):E6&#x2013;E6. doi: 10.1038/s41586-020-2951-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2951-z</ArticleId><ArticleId IdType="pubmed">33199918</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. BioRxiv. 2020. Available from: 10.1101/2020.01.22.914952v2.</Citation></Reference><Reference><Citation>A&#xe7;ikg&#xf6;z &#xd6;, G&#xfc;nay A. The early impact of the Covid-19 pandemic on the global and Turkish economy. Turkish J Med Sci. 2020;50(SI-1):520&#x2013;526. doi: 10.3906/sag-2004-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.3906/sag-2004-6</ArticleId><ArticleId IdType="pmc">PMC7195973</ArticleId><ArticleId IdType="pubmed">32283904</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt MA, Holmes RM, Jr, Arregle J-L. The (COVID-19) pandemic and the new world (dis) order. J World Bus. 2021;56(4):101210. doi: 10.1016/j.jwb.2021.101210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jwb.2021.101210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Singh R, Kaur J, Pandey S, Sharma V, Thakur L, et al. Wuhan to world: the COVID-19 pandemic. Front Cell Infect Microbiol. 2021;11:242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8042280</ArticleId><ArticleId IdType="pubmed">33859951</ArticleId></ArticleIdList></Reference><Reference><Citation>Lone SA, Ahmad A. COVID-19 pandemic&#x2013;an African perspective. Emerg Microbes Infect. 2020;9(1):1300&#x2013;1308. doi: 10.1080/22221751.2020.1775132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1775132</ArticleId><ArticleId IdType="pmc">PMC7473237</ArticleId><ArticleId IdType="pubmed">32458760</ArticleId></ArticleIdList></Reference><Reference><Citation>Hager E, Odetokun IA, Bolarinwa O, Zainab A, Okechukwu O, Al-Mustapha AI. Knowledge, attitude, and perceptions towards the 2019 Coronavirus Pandemic: a bi-national survey in Africa. PLoS ONE. 2020;15(7):e0236918. doi: 10.1371/journal.pone.0236918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0236918</ArticleId><ArticleId IdType="pmc">PMC7390376</ArticleId><ArticleId IdType="pubmed">32726340</ArticleId></ArticleIdList></Reference><Reference><Citation>Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency. Sci Total Environ. 2020;730:138996. doi: 10.1016/j.scitotenv.2020.138996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2020.138996</ArticleId><ArticleId IdType="pmc">PMC7190497</ArticleId><ArticleId IdType="pubmed">32371230</ArticleId></ArticleIdList></Reference><Reference><Citation>Rwanda_Biomed_Center. Rwanda COVID Response 2021 [Internet]. 2021. Available from: https://www.rbc.gov.rw/index.php?id=707</Citation></Reference><Reference><Citation>Karim N, Jing L, Lee JA, Kharel R, Lubetkin D, Clancy CM, et al. Lessons learned from Rwanda: innovative strategies for prevention and containment of COVID-19. Ann Glob Heal. 2021;87(1):23. doi: 10.5334/aogh.3172.</Citation><ArticleIdList><ArticleId IdType="doi">10.5334/aogh.3172</ArticleId><ArticleId IdType="pmc">PMC7908927</ArticleId><ArticleId IdType="pubmed">33665145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngamije J, Yadufashije C. COVID-19 pandemic in Rwanda: An overview of prevention strategies. Asian Pac J Trop Med. 2020;13(8):333. doi: 10.4103/1995-7645.289437.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1995-7645.289437</ArticleId></ArticleIdList></Reference><Reference><Citation>Condo J, Uwizihiwe JP, Nsanzimana S. Learn from Rwanda&#x2019;s success in tackling COVID-19. Nature. 2020;581(7809):384&#x2013;385. doi: 10.1038/d41586-020-01563-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-01563-7</ArticleId><ArticleId IdType="pubmed">32457526</ArticleId></ArticleIdList></Reference><Reference><Citation>Nkeshimana M, Igiraneza D, Turatsinze D, Niyonsenga O, Abimana D, Iradukunda C, et al. Experience of Rwanda on COVID-19 case management: from uncertainties to the era of neutralizing monoclonal antibodies. Int J Environ Res Public Health. 2022;19(3):1023. doi: 10.3390/ijerph19031023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19031023</ArticleId><ArticleId IdType="pmc">PMC8834306</ArticleId><ArticleId IdType="pubmed">35162047</ArticleId></ArticleIdList></Reference><Reference><Citation>Loemb&#xe9; MM, Nkengasong JN. COVID-19 vaccine access in Africa: global distribution, vaccine platforms, and challenges ahead. Immunity. 2021;54(7):1353&#x2013;1362. doi: 10.1016/j.immuni.2021.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.06.017</ArticleId><ArticleId IdType="pmc">PMC8276532</ArticleId><ArticleId IdType="pubmed">34260880</ArticleId></ArticleIdList></Reference><Reference><Citation>Musanabaganwa C, Cubaka V, Mpabuka E, Semakula M, Nahayo E, Hedt-Gauthier BL, et al. One hundred thirty-three observed COVID-19 deaths in 10 months: unpacking lower than predicted mortality in Rwanda. BMJ Glob Heal. 2021;6(2):e004547. doi: 10.1136/bmjgh-2020-004547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2020-004547</ArticleId><ArticleId IdType="pmc">PMC7907833</ArticleId><ArticleId IdType="pubmed">33627363</ArticleId></ArticleIdList></Reference><Reference><Citation>Dairi A, Harrou F, Zeroual A, Hittawe MM, Sun Y. Comparative study of machine learning methods for COVID-19 transmission forecasting. J Biomed Inform. 2021;118:103791. doi: 10.1016/j.jbi.2021.103791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2021.103791</ArticleId><ArticleId IdType="pmc">PMC8074522</ArticleId><ArticleId IdType="pubmed">33915272</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Hong S, Song M, Li H, Wang Z. Predicting COVID-19 disease progression and patient outcomes based on temporal deep learning. BMC Med Inform Decis Mak. 2021;21(1):1&#x2013;16. doi: 10.1186/s12911-020-01362-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-020-01362-0</ArticleId><ArticleId IdType="pmc">PMC7869774</ArticleId><ArticleId IdType="pubmed">33557818</ArticleId></ArticleIdList></Reference><Reference><Citation>Li WT, Ma J, Shende N, Castaneda G, Chakladar J, Tsai JC, et al. Using machine learning of clinical data to diagnose COVID-19: a systematic review and meta-analysis. BMC Med Inform Decis Mak. 2020;20(1):1&#x2013;13. doi: 10.1186/s12911-019-1002-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-019-1002-x</ArticleId><ArticleId IdType="pmc">PMC7522928</ArticleId><ArticleId IdType="pubmed">32993652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudat SEK, Robinson SC, Mudiganti S, Mani A, Pressman AR. Mind the clinical-analytic gap: electronic health records and COVID-19 pandemic response. J Biomed Inform. 2021;116:103715. doi: 10.1016/j.jbi.2021.103715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2021.103715</ArticleId><ArticleId IdType="pmc">PMC7892315</ArticleId><ArticleId IdType="pubmed">33610878</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Shilo S, Rossman H, Kalkstein N, Marcus K, Barer Y, et al. Longitudinal symptom dynamics of COVID-19 infection. Nat Commun. 2020;11(1):1&#x2013;10. doi: 10.1038/s41467-020-20053-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20053-y</ArticleId><ArticleId IdType="pmc">PMC7718370</ArticleId><ArticleId IdType="pubmed">33277494</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborative O, Network. OpenMRS: open-source platform to build customized EMR system. 2016; Available from: https://openmrs.org/</Citation></Reference><Reference><Citation>Verbeke F. OpenClinic GA: open-source integrated hospital information management system [Internet]. 2016. Available from: https://sourceforge.net/projects/open-clinic/</Citation></Reference><Reference><Citation>[Rwanda] NIoSo RN, [Rwanda] MoHM II. RwandaDemographic and Health Survey 2019&#x2013;20 Key Indicators Report. [Internet]. 2020. Available from: https://dhsprogram.com/pubs/pdf/PR124/PR124.pdf</Citation></Reference><Reference><Citation>Laisdar Project Investigators. Laisdar website. 2020; Available from: https://laisdar.rbc.gov.rw/</Citation></Reference><Reference><Citation>OHDSI: Observational Health Data Sciences and Informatics. ArachneNodeAPI. 2020; Available from: https://github.com/OHDSI/ArachneNodeAPI</Citation></Reference><Reference><Citation>Gupta PK, Siddiqui MK, Huang X, Morales-Menendez R, Pawar H, Terashima-Marin H, et al. COVID-WideNet&#x2014;A capsule network for COVID-19 detection. Appl Soft Comput. 2022;122:108780. doi: 10.1016/j.asoc.2022.108780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.asoc.2022.108780</ArticleId><ArticleId IdType="pmc">PMC8962064</ArticleId><ArticleId IdType="pubmed">35369122</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman TW, Vergeynst J, De Visscher L, Rollier M, Torfs E, Nopens I, et al. Assessing the effects of non-pharmaceutical interventions on SARS-CoV-2 transmission in Belgium by means of an extended SEIQRD model and public mobility data. Epidemics. 2021;37:100505. doi: 10.1016/j.epidem.2021.100505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.epidem.2021.100505</ArticleId><ArticleId IdType="pmc">PMC8487325</ArticleId><ArticleId IdType="pubmed">34649183</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman T, Torfs E, Nopens I. Covid-19: from model prediction to model predictive control. Unpubl Pre-print, https//biomathugentbe/sites/default/files/2020-04/Alleman_etal_v2 pdf [Google Sch. 2020].</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35966642</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-5723</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>6</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Gastro hep advances</Title><ISOAbbreviation>Gastro Hep Adv</ISOAbbreviation></Journal><ArticleTitle>Associations Between Gastrointestinal Symptoms and COVID-19 Severity Outcomes Based on a Propensity Score-Weighted Analysis of a Nationwide Cohort.</ArticleTitle><Pagination><StartPage>977</StartPage><EndPage>984</EndPage><MedlinePgn>977-984</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gastha.2022.06.015</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="UNASSIGNED">Gastrointestinal (GI) symptoms are well-recognized manifestations of coronavirus disease 2019 (COVID-19). Our primary objective was to evaluate the association between GI symptoms and COVID-19 severity.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this nationwide cohort of US veterans, we evaluated GI symptoms (nausea/vomiting/diarrhea) reported 30 days before and including the date of positive SARS-CoV-2 testing (March 1, 2020, to February 20, 2021). All patients had &#x2265;1 year of prior baseline data and &#x2265;60 days follow-up relative to the test date. We used propensity score (PS)-weighting to balance covariates in patients with vs without GI symptoms. The primary composite outcome was severe COVID-19, defined as hospital admission, intensive care unit admission, mechanical ventilation, or death within 60 days of positive testing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of 218,045 SARS-CoV-2 positive patients, 29,257 (13.4%) had GI symptoms. After PS weighting, all covariates were balanced. In the PS-weighted cohort, patients with vs without GI symptoms had severe COVID-19 more often (29.0% vs 17.1%; <i>P</i> &lt; .001). When restricted to hospitalized patients (14.9%; n=32,430), patients with GI symptoms had similar frequencies of intensive care unit admission and mechanical ventilation compared with patients without symptoms. There was a significant age interaction; among hospitalized patients aged &#x2265;70 years, lower COVID-19-associated mortality was observed in patients with vs without GI symptoms, even after accounting for COVID-19-specific medical treatments.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In the largest integrated US health care system, SARS-CoV-2-positive patients with GI symptoms experienced severe COVID-19 outcomes more often than those without symptoms. Additional research on COVID-19-associated GI symptoms may inform preventive efforts and interventions to reduce severe COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2022 Published by Elsevier Inc. on behalf of the AGA Institute.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Shailja C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Gastroenterology Section, VA San Diego, San Diego, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, University of California, San Diego, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canakis</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halvorson</LastName><ForeName>Alese E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorn</LastName><ForeName>Chad</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Otis</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denton</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauger</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California San Diego, La Jolla, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Stress and Mental Health, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterology Section, Durham VA Health Care System, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterology Section, Durham VA Health Care System, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Tennessee Valley Healthcare System, Health Services Research and Development, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siew</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VA Tennessee Valley Healthcare System, Health Services Research and Development, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VA Tennessee Valley Healthcare System, Health Services Research and Development, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greevy</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Tennessee Valley Healthcare System, Clinical Services Research and Development, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roumie</LastName><ForeName>Christianne L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Tennessee Valley Healthcare System, Clinical Services Research and Development, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Geriatrics Research Education and Clinical Center (GRECC), VA Tennessee Valley Health System, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 CX001727</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 CX001897</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>IK2 CX002027</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Gastro Hep Adv</MedlineTA><NlmUniqueID>9918350485906676</NlmUniqueID><ISSNLinking>2772-5723</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BMI, body mass index</Keyword><Keyword MajorTopicYN="N">CDW, Corporate Data Warehouse</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19, coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">GI, gastrointestinal</Keyword><Keyword MajorTopicYN="N">ICD, International Classification of Diseases</Keyword><Keyword MajorTopicYN="N">ICU, intensive care unit</Keyword><Keyword MajorTopicYN="N">Infectious diseases</Keyword><Keyword MajorTopicYN="N">OMOP, Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">OR, odds ratios</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword><Keyword MajorTopicYN="N">PCR, polymerase chain reaction</Keyword><Keyword MajorTopicYN="N">PS, propensity score</Keyword><Keyword MajorTopicYN="N">RAASi, renin-angiotensin-aldosterone system inhibitors</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2, severe acute respiratory syndrome coronavirus 2</Keyword><Keyword MajorTopicYN="N">SD, standard deviation</Keyword><Keyword MajorTopicYN="N">SDR, Shared Data Resource</Keyword><Keyword MajorTopicYN="N">SMD, standardized mean differences</Keyword><Keyword MajorTopicYN="N">VHA, Veterans Health Administration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>15</Day><Hour>3</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35966642</ArticleId><ArticleId IdType="pmc">PMC9357443</ArticleId><ArticleId IdType="doi">10.1016/j.gastha.2022.06.015</ArticleId><ArticleId IdType="pii">S2772-5723(22)00113-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int</Citation></Reference><Reference><Citation>Woolf S.H., Chapman D.A., Lee J.H. COVID-19 as the leading cause of death in the United States. JAMA. 2021;325(2):123&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553021</ArticleId><ArticleId IdType="pubmed">33331845</ArticleId></ArticleIdList></Reference><Reference><Citation>Han C., Duan C., Zhang S., et al. Digestive symptoms in COVID-19 patients with mild disease severity: clinical Presentation, Stool viral RNA testing, and outcomes. Am J Gastroenterol. 2020;115(6):916&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172493</ArticleId><ArticleId IdType="pubmed">32301761</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmunzer B.J., Spitzer R.L., Foster L.D., et al. Digestive manifestations in patients hospitalized with coronavirus disease 2019. Clin Gastroenterol Hepatol. 2021;19(7):1355&#x2013;1365.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7527302</ArticleId><ArticleId IdType="pubmed">33010411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou G.N., Locke E., Green P., et al. Risk factors for hospitalization, mechanical ventilation, or death among 10 131 US veterans with SARS-CoV-2 infection. JAMA Netw Open. 2020;3(9):e2022310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7512055</ArticleId><ArticleId IdType="pubmed">32965502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M.K., Yue H.Y., Cai J., et al. COVID-19 and the digestive system: a comprehensive review. World J Clin Cases. 2021;9(16):3796&#x2013;3813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8180220</ArticleId><ArticleId IdType="pubmed">34141737</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao F., Tang M., Zheng X., et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831&#x2013;1833.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130181</ArticleId><ArticleId IdType="pubmed">32142773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L., Jiang X., Zhang Z., et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020;69(6):997&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">32241899</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo S., Zhang X., Xu H. Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19) Clin Gastroenterol Hepatol. 2020;18(7):1636&#x2013;1637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7154217</ArticleId><ArticleId IdType="pubmed">32205220</ArticleId></ArticleIdList></Reference><Reference><Citation>Concas G., Barone M., Francavilla R., et al. Twelve months with COVID-19: what gastroenterologists need to know. Dig Dis Sci. 2021;67(7):2771&#x2013;2791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8325547</ArticleId><ArticleId IdType="pubmed">34333726</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Q., Fan L., Liu W., et al. Direct evidence of active SARS-CoV-2 replication in the intestine. Clin Infect Dis. 2021;73(3):361&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454471</ArticleId><ArticleId IdType="pubmed">32638022</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.Y., Li L., Zhang Y., et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9(1):45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186534</ArticleId><ArticleId IdType="pubmed">32345362</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh Y.K., Zuo T., Lui G.C.Y., et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Donowitz M., Tse C.M., Dokladny K., et al. SARS-COV-2 induced Diarrhea is inflammatory, Ca 2+ Dependent and involves activation of calcium activated Cl channels. Biorxiv. 2021 doi: 10.1101/2021.04.27.441695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.27.441695</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;nkem&#xfc;ller K., Fry L., Rickes S. COVID-19, coronavirus, SARS-CoV-2 and the small bowel. Rev Esp Enferm Dig. 2020;112(5):383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">32343593</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S., Halvorson A., McBay B., et al. Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort. Gut. 2021;71(7):1447&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013721</ArticleId><ArticleId IdType="pubmed">34663578</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkelo B.C., Parr S.K., Perkins A.M., et al. Comparison of COVID-19 versus influenza on the incidence, features, and recovery from acute kidney injury in hospitalized United States Veterans. Kidney Int. 2021;100(4):894&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183091</ArticleId><ArticleId IdType="pubmed">34111501</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.A., Park R., Yang J.H., et al. Increased risk of acute kidney injury in coronavirus disease patients with renin&#x2013;angiotensin&#x2013;aldosterone-system blockade use: a systematic review and meta-analysis. Sci Rep. 2021;11(1):13588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245570</ArticleId><ArticleId IdType="pubmed">34193877</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan H., Sundararajan V., Halfon P., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">16224307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley T. Analysis of complex survey samples. J&#xa0;Stat Softw. 2004;9:1&#x2013;19.</Citation></Reference><Reference><Citation>Sultan S., Altayar O., Siddique S.M., et al. AGA Institute rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020;159(1):320&#x2013;334.e27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7212965</ArticleId><ArticleId IdType="pubmed">32407808</ArticleId></ArticleIdList></Reference><Reference><Citation>Laszkowska M., Faye A.S., Kim J., et al. Disease course and outcomes of COVID-19 among hospitalized patients with gastrointestinal manifestations. Clin Gastroenterol Hepatol. 2021;19(7):1402&#x2013;1409.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7525451</ArticleId><ArticleId IdType="pubmed">33007514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajifathalian K., Krisko T., Mehta A., et al. Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients from New York: clinical implications. Gastroenterology. 2020;159(3):1137&#x2013;1140.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205652</ArticleId><ArticleId IdType="pubmed">32389667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran P., Onukogu I., Ghanta S., et al. Gastrointestinal symptoms and outcomes in hospitalized coronavirus disease 2019 patients. Dig Dis. 2020;38(5):373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445385</ArticleId><ArticleId IdType="pubmed">32599601</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq R., Saha S., Furqan F., et al. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(8):1632&#x2013;1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7284248</ArticleId><ArticleId IdType="pubmed">32753138</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao R., Qiu Y., He J.S., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217643</ArticleId><ArticleId IdType="pubmed">32405603</ArticleId></ArticleIdList></Reference><Reference><Citation>Blecker S., Jones S.A., Petrilli C.M., et al. Hospitalizations for chronic disease and acute conditions in the time of COVID-19. JAMA Intern Med. 2021;181(2):269&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7589070</ArticleId><ArticleId IdType="pubmed">33104158</ArticleId></ArticleIdList></Reference><Reference><Citation>Findling M.G., Blendon R.J., Benson J.M. Delayed care with harmful health consequences&#x2014;reported experiences from national surveys during coronavirus disease 2019. JAMA Health Forum. 2020;1(12):e201463.</Citation><ArticleIdList><ArticleId IdType="pubmed">36218479</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhambhvani H.P., Rodrigues A.J., Yu J.S., et al. Hospital volumes of 5 medical emergencies in the COVID-19 pandemic in 2 US medical centers. JAMA Intern Med. 2021;181(2):272&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7589046</ArticleId><ArticleId IdType="pubmed">33104161</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJong C., Katz M.H., Covinsky K. Deferral of care for serious non-COVID-19 conditions: a hidden harm of COVID-19. JAMA Intern Med. 2021;181(2):274.</Citation><ArticleIdList><ArticleId IdType="pubmed">33104166</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu T., Mack J.A., Salvatore M., et al. Characteristics associated with racial/ethnic disparities in COVID-19 outcomes in an academic health care system. JAMA Netw Open. 2020;3(10):e2025197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578774</ArticleId><ArticleId IdType="pubmed">33084902</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35995107</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>135</Volume><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>PheValuator 2.0: Methodological improvements for the PheValuator approach to semi-automated phenotype algorithm evaluation.</ArticleTitle><Pagination><StartPage>104177</StartPage><MedlinePgn>104177</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2022.104177</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(22)00188-5</ELocationID><Abstract><AbstractText Label="PURPOSE">Phenotype algorithms are central to performing analyses using observational data. These algorithms translate the clinical idea of a health condition into an executable set of rules allowing for queries of data elements from a database. PheValuator, a software package in the Observational Health Data Sciences and Informatics (OHDSI) tool stack, provides a method to assess the performance characteristics of these algorithms, namely, sensitivity, specificity, and positive and negative predictive value. It uses machine learning to develop predictive models for determining a probabilistic gold standard of subjects for assessment of cases and non-cases of health conditions. PheValuator was developed to complement or even replace the traditional approach of algorithm validation, i.e., by expert assessment of subject records through chart review. Results in our first PheValuator paper suggest a systematic underestimation of the PPV compared to previous results using chart review. In this paper we evaluate modifications made to the method designed to improve its performance.</AbstractText><AbstractText Label="METHODS">The major changes to PheValuator included allowing all diagnostic conditions, clinical observations, drug prescriptions, and laboratory measurements to be included as predictors within the modeling process whereas in the prior version there were significant restrictions on the included predictors. We also have allowed for the inclusion of the temporal relationships of the predictors in the model. To evaluate the performance of the new method, we compared the results from the new and original methods against results found from the literature using traditional validation of algorithms for 19 phenotypes. We performed these tests using data from five commercial databases.</AbstractText><AbstractText Label="RESULTS">In the assessment aggregating all phenotype algorithms, the median difference between the PheValuator estimate and the gold standard estimate for PPV was reduced from -21 (IQR -34, -3) in Version 1.0 to 4 (IQR -3, 15) using Version 2.0. We found a median difference in specificity of 3 (IQR 1, 4.25) for Version 1.0 and 3 (IQR 1, 4) for Version 2.0. The median difference between the two versions of PheValuator and the gold standard for estimates of sensitivity was reduced from -39 (-51, -20) to -16 (-34, -6).</AbstractText><AbstractText Label="CONCLUSION">PheValuator 2.0 produces estimates for the performance characteristics for phenotype algorithms that are significantly closer to estimates from traditional validation through chart review compared to version 1.0. With this tool in researcher's toolkits, methods, such as quantitative bias analysis, may now be used to improve the reliability and reproducibility of research studies using observational data.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA; Observational Health Data Sciences and Informatics (OHDSI), New York, NY. Electronic address: jswerdel@its.jns.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA; Observational Health Data Sciences and Informatics (OHDSI), New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Gayle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA; Columbia University, New York, NY, USA; Observational Health Data Sciences and Informatics (OHDSI), New York, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Phenotype algorithms</Keyword><Keyword MajorTopicYN="N">Positive predictive value</Keyword><Keyword MajorTopicYN="N">Sensitivity</Keyword><Keyword MajorTopicYN="N">Specificity</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35995107</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2022.104177</ArticleId><ArticleId IdType="pii">S1532-0464(22)00188-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36029954</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Towards quality improvement of vaccine concept mappings in the OMOP vocabulary with a semi-automated method.</ArticleTitle><Pagination><StartPage>104162</StartPage><MedlinePgn>104162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2022.104162</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(22)00174-5</ELocationID><Abstract><AbstractText>The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) provides a unified model to integrate disparate real-world data (RWD) sources. An integral part of the OMOP CDM is the Standardized Vocabularies (henceforth referred to as the OMOP vocabulary), which enables organization and standardization of medical concepts across various clinical domains of the OMOP CDM. For concepts with the same meaning from different source vocabularies, one is designated as the standard concept, while the others are specified as non-standard or source concepts and mapped to the standard one. However, due to the heterogeneity of source vocabularies, there may exist mapping issues such as erroneous mappings and missing mappings in the OMOP vocabulary, which could affect the results of downstream analyses with RWD. In this paper, we focus on quality assurance of vaccine concept mappings in the OMOP vocabulary, which is necessary to accurately harness the power of RWD on vaccines. We introduce a semi-automated lexical approach to audit vaccine mappings in the OMOP vocabulary. We generated two types of vaccine-pairs: mapped and unmapped, where mapped vaccine-pairs are pairs of vaccine concepts with a "Maps to" relationship, while unmapped vaccine-pairs are those without a "Maps to" relationship. We represented each vaccine concept name as a set of words, and derived term-difference pairs (i.e., name differences) for mapped and unmapped vaccine-pairs. If the same term-difference pair can be obtained by both mapped and unmapped vaccine-pairs, then this is considered as a potential mapping inconsistency. Applying this approach to the vaccine mappings in OMOP, a total of 2087 potentially mapping inconsistencies were obtained. A randomly selected 200 samples were evaluated by domain experts to identify, validate, and categorize the inconsistencies. Experts identified 95 cases revealing valid mapping issues. The remaining 105 cases were found to be invalid due to the external and/or contextual information used in the mappings that were not reflected in the concept names of vaccines. This indicates that our semi-automated approach shows promise in identifying mapping inconsistencies among vaccine concepts in the OMOP vocabulary.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abeysinghe</LastName><ForeName>Rashmie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaduk</LastName><ForeName>Denys</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yupeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Merck &amp;amp; Co., Inc., Rahway, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IQVIA, Cambridge, MA, USA; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davydov</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Lixia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Merck &amp;amp; Co., Inc., Rahway, NJ, USA. Electronic address: lixia.yao@merck.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Licong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address: licong.cui@uth.tmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM013335</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS116287</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014825" MajorTopicYN="Y">Vocabulary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="N">Vocabulary, Controlled</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Concept mappings</Keyword><Keyword MajorTopicYN="N">Mapping quality assurance</Keyword><Keyword MajorTopicYN="N">OMOP standardized vocabularies</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Lixia Yao and Yupeng Li are employees and stockholders of Merck &amp;amp; Co., Inc., Rahway, NJ.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36029954</ArticleId><ArticleId IdType="mid">NIHMS1870816</ArticleId><ArticleId IdType="pmc">PMC9940475</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2022.104162</ArticleId><ArticleId IdType="pii">S1532-0464(22)00174-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, Feikin DR, Groome MJ, Hajjeh RA, Johnson HL, et al., Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls, Vaccine 35 (25) (2017) 3295&#x2013;3302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7007298</ArticleId><ArticleId IdType="pubmed">28442231</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggs J, Gee J, Lewis E, Fowler G, Benson P, Lieu T, Naleway A, Klein NP, Baxter R, Belongia E, et al., The vaccine safety datalink: a model for monitoring immunization safety, Pediatrics 127 (Supplement_1) (2011) S45&#x2013;S53.</Citation><ArticleIdList><ArticleId IdType="pubmed">21502240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray P, Black S, Shinefield H, Dillon A, Carpenter D, Lewis E, Ross P, Chen RT, Klein NP, Baxter R, et al., Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15&#x2013;59 years of age, Vaccine 29 (38) (2011) 6592&#x2013;6597.</Citation><ArticleIdList><ArticleId IdType="pubmed">21763385</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrow R, Taha M-K, Giuliani MM, Pizza M, Banzhoff A, Bekkat-Berkani R, Methods to evaluate serogroup B meningococcal vaccines: from predictions to real-world evidence, J Infect. 81 (6) (2020) 862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">32745637</ArticleId></ArticleIdList></Reference><Reference><Citation>Isitt C, Cosgrove CA, Ramsay ME, Ladhani SN, Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience, Arch. Dis. Child 105 (8) (2020) 784&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">32029437</ArticleId></ArticleIdList></Reference><Reference><Citation>The United States Food and Drug Administration, National drug code directory, 2021, (accessed 13 December 2021) https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory.</Citation></Reference><Reference><Citation>The Centers for Medicare and Medicaid Services (CMS), HCPCS - general information, 2021, (accessed 13 December 2021) https://www.cms.gov/medicare/coding/medhcpcsgeninfo.</Citation></Reference><Reference><Citation>Dotson P, CPT&#xae; codes: What are they, why are they necessary, and how are they developed? Adv. Wound Care (New Rochelle) 2 (10) (2013) 583&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3865623</ArticleId><ArticleId IdType="pubmed">24761332</ArticleId></ArticleIdList></Reference><Reference><Citation>The Centers for Medicare and Medicaid Services (CMS), 2021 ICD-10-PCS, 2021, (accessed 13 December 2021) https://www.cms.gov/medicare/icd-10/2021-icd-10-pcs.</Citation></Reference><Reference><Citation>Hirsch J, Nicola G, McGinty G, Liu R, Barr R, Chittle M, Manchikanti L, ICD-10: history and context, AJNR Am. J. Neuroradiol 37 (4) (2016) 596&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7960170</ArticleId><ArticleId IdType="pubmed">26822730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipscomb CE, Medical subject headings (MeSH), Bull. Med. Libr. Assoc 88 (3) (2000) 265&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC35238</ArticleId><ArticleId IdType="pubmed">10928714</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Disease Control and Prevention, International classification of diseases, ninth revision, clinical modification (ICD-9-CM), 2022, (accessed 13 July 2022) https://www.cdc.gov/nchs/icd/icd9cm.htm#:~:text=ICD%2D9%2DCM%20is%20the,10%20for%20mortality%20coding%20started.</Citation></Reference><Reference><Citation>Donnelly K, et al., SNOMED-CT: The advanced terminology and coding system for ehealth, Stud. Health Technol. Inf 121 (2006) 279&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">17095826</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Ma W, Moore R, Ganesan V, Nelson S, RxNorm: prescription for electronic drug information exchange, IT Prof. 7 (5) (2005) 17&#x2013;23.</Citation></Reference><Reference><Citation>McDonald CJ, Huff SM; Suico JG, Hill G, Leavelle D, Aller R, Forrey A, Mercer K, DeMoor G, Hook J, et al., LOINC, a universal standard for identifying laboratory observations: a 5-year update, Clin. Chem 49 (4) (2003) 624&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">12651816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch JA, Leslie-Mazwi TM, Nicola GN, Barr RM, Bello JA, Donovan WD, Tu R, Alson MD, Manchikanti L, Current procedural terminology; a primer, J. Neurointerv. Surg 7 (4) (2015) 309&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">24589819</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI), OMOP common data model version 5.0, 2021, (accessed 13 December 2021) https://www.ohdsi.org/data-standardization/the-common-data-model/.</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI), Mapping of concepts, 2022, (accessed 8 April 2022) https://www.ohdsi.org/web/wiki/doku.php?id=documentation:vocabulary:mapping.</Citation></Reference><Reference><Citation>Stratton KR, Howe CJ, Johnston RB, et al., Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality, Natl Academy Pr, 1994.</Citation><ArticleIdList><ArticleId IdType="pubmed">25144097</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi N, Song I-Y, Han H, A survey on ontology mapping, ACM Sigmod. Record 35 (3) (2006) 34&#x2013;41.</Citation></Reference><Reference><Citation>Falconer SM, Noy NF, Storey M-AD, Ontology mapping-A user survey, in: Proceedings of the Workshop on Ontology Matching (OM2007) At ISWC/ASWC2007, Busan, South Korea, 2007, pp. 113&#x2013;125.</Citation></Reference><Reference><Citation>Hooi YK, Hassan MF, Shariff AM, A survey on ontology mapping techniques, Adv. Comput. Sci. Appl 279 (2014) 829&#x2013;836.</Citation></Reference><Reference><Citation>Ochieng P, Kyanda S, Large-scale ontology matching: State-of-the-art analysis, ACM Comput. Surv 51 (4) (2019) 1&#x2013;35.</Citation></Reference><Reference><Citation>Oliveira D, Pesquita C, Improving the interoperability of biomedical ontologies with compound alignments, J. Biomed. Semant 9 (1) (2018) 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5761129</ArticleId><ArticleId IdType="pubmed">29316968</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Black A, Baltus GA, Cho C, Chandrasekaran V, Dasbach E, Yao L, Quality assessment of vaccine concepts in OMOP common data model, 2021, (accessed 11 May 2022) https://www.ohdsi.org/2020-global-symposium-showcase-26/.</Citation></Reference><Reference><Citation>Kaduk D, Black A, Li Y, Yao L, Evaluation of vaccine concept mappings in OMOP vocabulary: a real-world database study, 2022, (accessed 11 May 2022) https://www.ohdsi.org/2021-global-symposium-showcase-11/.</Citation></Reference><Reference><Citation>Reich C, Ostropolets A, Chapter 5 standardized vocabularies, 2022, (accessed 8 April 2022) https://ohdsi.github.io/TheBookOfOhdsi/StandardizedVocabularies.html.</Citation></Reference><Reference><Citation>National Library of Medicine, Rxnorm technical documentation, 2022, (accessed 15 February 2022) https://www.nlm.nih.gov/research/umls/rxnorm/docs/index.html.</Citation></Reference><Reference><Citation>Bodenreider O, The unified medical language system (UMLS): integrating biomedical terminology, Nucl. Acids Res 32 (Supplement_1) (2004) D267&#x2013;D270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308795</ArticleId><ArticleId IdType="pubmed">14681409</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeysinghe R, Zheng F, Hinderer EW, Moseley HN, Cui L, A lexical approach to identifying subtype inconsistencies in biomedical terminologies, in: Proceedings of the 2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM), 2018, pp. 1982&#x2013;1989.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36073478</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>298</Volume><PubDate><Year>2022</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Preserving Privacy when Querying OMOP CDM Databases.</ArticleTitle><Pagination><StartPage>163</StartPage><EndPage>164</EndPage><MedlinePgn>163-164</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI220930</ELocationID><Abstract><AbstractText>Anonymisation is currently one of the biggest challenges when sharing sensitive personal information. Its importance depends largely on the application domain, but when dealing with health information, this becomes a more serious issue. A simpler approach to avoid inadequate disclosure is to ensure that all data that can be associated directly with an individual is removed from the original dataset. However, some studies have shown that simple anonymisation procedures can sometimes be reverted using specific patients' characteristics. In this work, we propose a secure architecture to share information from distributed databases without compromising the subjects' privacy. The anonymiser system was validated using the OMOP CDM data schema, which is widely adopted in observational research studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Joao Rafael</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>DETI/IEETA, University of Aveiro, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computation, University of A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barraca</LastName><ForeName>Joao Paulo</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>IT, DETI, University of Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Jos&#xe9; Lu&#xed;s</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>DETI/IEETA, University of Aveiro, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068241" MajorTopicYN="Y">Personally Identifiable Information</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018907" MajorTopicYN="Y">Privacy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data anonymisation</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Privacy preserving</Keyword><Keyword MajorTopicYN="N">k-Anonymity</Keyword><Keyword MajorTopicYN="N">l-Diversity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>5</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36073478</ArticleId><ArticleId IdType="doi">10.3233/SHTI220930</ArticleId><ArticleId IdType="pii">SHTI220930</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36085809</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2694-0604</ISSN><JournalIssue CitedMedium="Internet"><Volume>2022</Volume><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference</Title><ISOAbbreviation>Annu Int Conf IEEE Eng Med Biol Soc</ISOAbbreviation></Journal><ArticleTitle>Accelerating Multi-site Health Informatics with Streamlined Data Infrastructure using OMOP-on-FHIR.</ArticleTitle><Pagination><StartPage>4687</StartPage><EndPage>4690</EndPage><MedlinePgn>4687-4690</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1109/EMBC48229.2022.9871865</ELocationID><Abstract><AbstractText>Shriners Children's (SHC) is a hospital system whose mission is to advance the treatment and research of pediatric diseases. SHC success has generated a wealth of clinical data. Unfortunately, barriers to healthcare data access often limit data-driven clinical research. We decreased this burden by allowing access to clinical data via the standardized data access standard called FHIR (Fast Healthcare Interoperability Resources). Specifically, we converted existing data in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) standard into FHIR data elements using a technology called OMOP-on-FHIR. In addition, we developed two applications leveraging the FHIR data elements to facilitate patient cohort curation to advance research into pediatric musculoskeletal diseases. Our work enables clinicians and clinical researchers to use hundreds of currently available open-sourced FHIR applications. Our successful implementation of OMOP-on-FHIR within a large hospital system will accelerate advancements in pediatric disease treatment and research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marteau</LastName><ForeName>Benoit L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuanda</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Giuste</LastName><ForeName>Felipe</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Wenqi</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Carpenter</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hilton</LastName><ForeName>Coleman</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>May D</ForeName><Initials>MD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Annu Int Conf IEEE Eng Med Biol Soc</MedlineTA><NlmUniqueID>101763872</NlmUniqueID><ISSNLinking>2375-7477</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006268" MajorTopicYN="N">Health Facilities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009140" MajorTopicYN="Y">Musculoskeletal Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013672" MajorTopicYN="N">Technology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>10</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36085809</ArticleId><ArticleId IdType="doi">10.1109/EMBC48229.2022.9871865</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36089199</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>FHIR-Ontop-OMOP: Building clinical knowledge graphs in FHIR RDF with the OMOP Common data Model.</ArticleTitle><Pagination><StartPage>104201</StartPage><MedlinePgn>104201</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2022.104201</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(22)00206-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Knowledge graphs (KGs) play a key role to enable explainable artificial intelligence (AI) applications in healthcare. Constructing clinical knowledge graphs (CKGs) against heterogeneous electronic health records (EHRs) has been desired by the research and healthcare AI communities. From the standardization perspective, community-based standards such as the Fast Healthcare Interoperability Resources (FHIR) and the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) are increasingly used to represent and standardize EHR data for clinical data analytics, however, the potential of such a standard on building CKG has not been well investigated.</AbstractText><AbstractText Label="OBJECTIVE">To develop and evaluate methods and tools that expose the OMOP CDM-based clinical data repositories into virtual clinical KGs that are compliant with FHIR Resource Description Framework (RDF) specification.</AbstractText><AbstractText Label="METHODS">We developed a system called FHIR-Ontop-OMOP to generate virtual clinical KGs from the OMOP relational databases. We leveraged an OMOP CDM-based Medical Information Mart for Intensive Care (MIMIC-III) data repository to evaluate the FHIR-Ontop-OMOP system in terms of the faithfulness of data transformation and the conformance of the generated CKGs to the FHIR RDF specification.</AbstractText><AbstractText Label="RESULTS">A beta version of the system has been released. A total of more than 100 data element mappings from 11 OMOP CDM clinical data, health system and vocabulary tables were implemented in the system, covering 11 FHIR resources. The generated virtual CKG from MIMIC-III contains 46,520 instances of FHIR Patient, 716,595 instances of Condition, 1,063,525 instances of Procedure, 24,934,751 instances of MedicationStatement, 365,181,104 instances of Observations, and 4,779,672 instances of CodeableConcept. Patient counts identified by five pairs of SQL (over the MIMIC database) and SPARQL (over the virtual CKG) queries were identical, ensuring the faithfulness of the data transformation. Generated CKG in RDF triples for 100 patients were fully conformant with the FHIR RDF specification.</AbstractText><AbstractText Label="CONCLUSION">The FHIR-Ontop-OMOP system can expose OMOP database as a FHIR-compliant RDF graph. It provides a meaningful use case demonstrating the potentials that can be enabled by the interoperability between FHIR and OMOP CDM. Generated clinical KGs in FHIR RDF provide a semantic foundation to enable explainable AI applications in healthcare.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Guohui</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Bergen, Norway; University of Oslo, Norway; Ontopic S.r.l., Italy. Electronic address: guohui.xiao@uib.no.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prud'hommeaux</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Janeiro Digital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Booth</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Yosemite Project, Somerville, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Deepak K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zong</LastName><ForeName>Nansu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruddy</LastName><ForeName>Kathryn J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Guoqian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA. Electronic address: jiang.guoqian@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EB030529</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="Y">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073458" MajorTopicYN="N">Data Warehousing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010363" MajorTopicYN="Y">Pattern Recognition, Automated</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical Knowledge Graphs</Keyword><Keyword MajorTopicYN="N">Data Standards</Keyword><Keyword MajorTopicYN="N">Fast Healthcare Interoperability Resources (FHIR)</Keyword><Keyword MajorTopicYN="N">Semantic Web</Keyword><Keyword MajorTopicYN="N">Shape Expressions (ShEx)</Keyword><Keyword MajorTopicYN="N">Virtual Knowledge Graphs</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>11</Day><Hour>19</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36089199</ArticleId><ArticleId IdType="mid">NIHMS1839711</ArticleId><ArticleId IdType="pmc">PMC9561043</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2022.104201</ArticleId><ArticleId IdType="pii">S1532-0464(22)00206-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Paton C, Kobayashi S, An open science approach to artificial intelligence in healthcare: a contribution from the international medical informatics association open source working group, Yearb Med. Inform 28 (01) (2019) 047&#x2013;051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697543</ArticleId><ArticleId IdType="pubmed">31022753</ArticleId></ArticleIdList></Reference><Reference><Citation>Berners-Lee T, Hendler J, Lassila O, The Semantic Web - A new form of Web content that is meaningful to computers will unleash a revolution of new possibilities, Sci. Am 284 (5) (2001) 34, 10.1038/scientificamerican0501-34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/scientificamerican0501-34</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Provenance Ontology. 2022.  [February 18, 2022]. Available from: https://www.w3.org/TR/prov-o/.</Citation></Reference><Reference><Citation>OWL2 Profiles. 2022. 
[February 18, 2022]. Available from: https://www.w3.org/TR/owl2-profiles.</Citation></Reference><Reference><Citation>Draicchio F, Gangemi A, Presutti V, Nuzzolese AG (Eds.). FRED: From Natural Language Text to RDF and OWL in One Click. ESWC 2013; 2013: LNCS.</Citation></Reference><Reference><Citation>Tiddi I, Lecue F, Hitzler P, Knowledge graphs for eXplainable artificial intelligence: foundations, Applications Challenges (2020).</Citation></Reference><Reference><Citation>Yoon B-H, Kim S-K, Kim S-Y, Use of graph database for the integration of heterogeneous biological data, Genomics Inform. 15 (1) (2017) 19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389944</ArticleId><ArticleId IdType="pubmed">28416946</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabregat A, Korninger F, Viteri G, Sidiropoulos K, Marin-Garcia P, Ping P, Wu G, Stein L, D&#x2019;Eustachio P, Hermjakob H, Reactome graph database: Efficient access to complex pathway data, PLoS Comput. Biol 14 (1) (2018) e1005968, 10.1371/journal.pcbi.1005968. Epub 2018/01/30</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1005968</ArticleId><ArticleId IdType="pmc">PMC5805351</ArticleId><ArticleId IdType="pubmed">29377902</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotmensch M, Halpern Y, Tlimat A, Horng S, Sontag D, Learning a health knowledge graph from electronic medical records, Sci. Rep 7 (1) (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519723</ArticleId><ArticleId IdType="pubmed">28729710</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Knowledge Graph Integrates Proteomics Data into Clinical Decision-Making 2020. [February 18, 2022]. Available from: 10.1101/2020.05.09.084897vl.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.09.084897vl</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Ma C, Wu Y (Eds.). Clinical Knowledge Graph Embeddings with Hierarchical Structure for Thyroid Treatment Recommendation, 2019 IEEE Intl Conf on Dependable, Autonomic and Secure Computing, Intl Conf on Pervasive Intelligence and Computing, Intl Conf on Cloud and Big Data Computing, Intl Conf on Cyber Science and Technology Congress (DASC/PiCom/CBDCom/CyberSciTech); 2019.</Citation></Reference><Reference><Citation>SMR: Medical Knowledge Graph Embedding for Safe Medicine Recommendation 2020. [February 18, 2022]. Available from: .</Citation></Reference><Reference><Citation>HL7 Fast Healthcare Interoperability Resources (FHIR)
2022.  [February 18, 2022]. Available from: https://www.hl7.org/fhir/.</Citation></Reference><Reference><Citation>The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM)
2022.  [February 18, 2022]. Available from: https://oh.dsi.github.io/CommonDataModel/.</Citation></Reference><Reference><Citation>Solbrig HR, Prud&#x2019;hommeaux E, Grieve G, McKenzie L, Mandel JC, Sharma DK, Jiang G, Modeling and validating HL7 FHIR profiles using semantic web Shape Expressions (ShEx), J. Biomed. Inform 67 (2017) 90&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502481</ArticleId><ArticleId IdType="pubmed">28213144</ArticleId></ArticleIdList></Reference><Reference><Citation>Solbrig HR, Solbrig HR, Prud&#x2019;hommeaux E, Booth D, Endle CM, Stone DJ, Jiang G, Exploring JSON-LD as an executable definition of FHIR RDF to enable, in: AMIA Annu Symp Proc. 2020;2020:1140&#x2013;9. Epub 2021/05/04.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075421</ArticleId><ArticleId IdType="pubmed">33936490</ArticleId></ArticleIdList></Reference><Reference><Citation>Prud&#x2019;hommeaux E, Collins J, Booth D, Peterson KJ, Solbrig HR, Jiang G, Development of a FHIR RDF data transformation and validation framework and its evaluation, J. Biomed. Inform 117 (2021) 103755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8131260</ArticleId><ArticleId IdType="pubmed">33781919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong N, Wen A, Shen F, Sohn S, Wang C, Liu H, Jiang G, Developing a scalable FHIR-based clinical data normalization pipeline for standardizing and integrating unstructured and structured electronic health record data, JAMIA Open 2 (4) (2019) 570&#x2013;579, 10.1093/jamiaopen/ooz056. Epub 2020/02/07</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooz056</ArticleId><ArticleId IdType="pmc">PMC6993992</ArticleId><ArticleId IdType="pubmed">32025655</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong N.a., Wen A, Stone DJ, Tsuji S, Kingsbury PR, Rasmussen LV, Pacheco JA, Adekkanattu P, Wang F, Luo Y, Pathak J, Liu H, Jiang G, Developing a FHIR-based EHR phenotyping framework: a case study for identification of patients with obesity and multiple comorbidities from discharge summaries, J. Biomed. Inform 99 (2019) 103310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990976</ArticleId><ArticleId IdType="pubmed">31622801</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong N, Ngo V, Stone DJ, Wen A, Zhao Y, Yu Y, Liu S, Huang M, Wang C, Jiang G, Leveraging genetic reports and electronic health records for the prediction of primary cancers: algorithm development and validation study, JMIR Med. Inform 9 (5) (2021) e23586, 10.2196/23586. Epub 2021/05/26.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/23586</ArticleId><ArticleId IdType="pmc">PMC8188315</ArticleId><ArticleId IdType="pubmed">34032581</ArticleId></ArticleIdList></Reference><Reference><Citation>FHIR Model Ontology
2022.  [February 22, 2022]. Available from: http://build.fhir.org/fhir.ttl.</Citation></Reference><Reference><Citation>FHIR StructureDefinition
2022. 
[February 18, 2022]. Available from: http://www.hl7.org/fhir/structuredefinition.html.</Citation></Reference><Reference><Citation>Xiao GH, Ding LF, Cogrel B, Calvanese D, Virtual knowledge graphs: an overview of systems and use cases, Data Intelligence. 1 (3) (2019) 201&#x2013;223, 10.1162/dint_a_00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/dint_a_00011</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao GH, Calvanese D, Kontchakov R, Lembo D, Poggi A, Rosati R, Zakharyaschev M, Ontology-based data access: a suervy. IJCAI-182018. p. 5511&#x2013;9.</Citation></Reference><Reference><Citation>Calvanese D, Cogrel B, Komla-Ebri S, Kontchakov R, Lanti D, Rezk M, Rodriguez-Muro M, Xiao G, Corcho &#xd3;, Ontop: Answering SPARQL queries over relational databases, Semant Web 8 (3) (2016) 471&#x2013;487.</Citation></Reference><Reference><Citation>Calvanese D, Lanti D, De Farias TM, Mosca A, Xiao GH, Accessing scientific data through knowledge graphs with Ontop, Patterns 2 (10) (2021), 100346, 10.1016/j.patter.2021.100346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.patter.2021.100346</ArticleId><ArticleId IdType="pmc">PMC8515008</ArticleId><ArticleId IdType="pubmed">34693372</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao GH, Lanti D, Kontchakov R, Komla-Ebri S, Guzel-Kalayci E, Ding L, Corman J, Cogrel B, Calvanese D, Botoeva E (Eds). The Virtual Knowledge Graph System Ontop. International Semantic Web Conference 2020; 2020.</Citation></Reference><Reference><Citation>Ontop
2022.  [February 18, 2022]. Available from: https://ontop-vkg.org/.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9561043</ArticleId><ArticleId IdType="pubmed">36089199</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AEW, Pollard TJ, Shen L.u., Lehman L-W, Feng M, Ghassemi M, Moody B, Szolovits P, Anthony Celi L, Mark RG, MIMIC-III, a freely accessible critical care database, Sci Data 3 (1) (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878278</ArticleId><ArticleId IdType="pubmed">27219127</ArticleId></ArticleIdList></Reference><Reference><Citation>MIMIC2OMOP ETL Tool
2022.  [February 18, 2022]. Available from: https://github.com/MIT-LCP/mimic-omop.</Citation></Reference><Reference><Citation>R2RML: RDB to RDF Mapping Language
2022.  [April 19, 2022]. Available from: https://www.w3.org/TR/r2rml/.</Citation></Reference><Reference><Citation>OHDSI FHIR Workgroup
2022.  [February 18, 2022]. Available from: https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:fhir-wg.</Citation></Reference><Reference><Citation>The Common Data Models Harmonization (CDMH) FHIR Implementation Guide (IG)
2022.  [February 18, 2022]. Available from: https://build.fhir.org/ig/HL7/cdmh/.</Citation></Reference><Reference><Citation>OMOP on FHIR
2022.  [February 18, 2022]. Available from: https://omoponfhir.org/.</Citation></Reference><Reference><Citation>FHIR DAF Research Implementation Guide
2022.  [February 18, 2022]. Available from: http://hl7.org/fhir/us/daf-research/STU2/.</Citation></Reference><Reference><Citation>The shexjs library. 2022.  [February 18, 2022]. Available from: https://npm.io/package/@shexjs/cli.</Citation></Reference><Reference><Citation>OHDSI HL7 Collaboration
2022. 
[February 22, 2022]. Available from: https://www.ohdsi.org/ohdsi-hl7-collaboration/.</Citation></Reference><Reference><Citation>Time Functions Extensions of GraphDB. 2022.  [March 8, 2022]. Available from: https://graphdb.ontotext.com/free/devhub/time-functions.html.</Citation></Reference><Reference><Citation>Linked Data API
2022.  [February 18, 2022]. Available from: https://github.com/UKGovLD/linked-data-api/blob/wiki/Specification.md.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36106377</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-1167</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Epilepsia</Title><ISOAbbreviation>Epilepsia</ISOAbbreviation></Journal><ArticleTitle>Identification of patients with drug-resistant epilepsy in electronic medical record data using the Observational Medical Outcomes Partnership Common Data Model.</ArticleTitle><Pagination><StartPage>2981</StartPage><EndPage>2993</EndPage><MedlinePgn>2981-2993</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/epi.17409</ELocationID><Abstract><AbstractText Label="OBJECTIVE">More than one third of appropriately treated patients with epilepsy have continued seizures despite two or more medication trials, meeting criteria for drug-resistant epilepsy (DRE). Accurate and reliable identification of patients with DRE in observational data would enable large-scale, real-world comparative effectiveness research and improve access to specialized epilepsy care. In the present study, we aim to develop and compare the performance of computable phenotypes for DRE using the Observational Medical Outcomes Partnership (OMOP) Common Data Model.</AbstractText><AbstractText Label="METHODS">We randomly sampled 600 patients from our academic medical center's electronic health record (EHR)-derived OMOP database meeting previously validated criteria for epilepsy (January 2015-August 2021). Two reviewers manually classified patients as having DRE, drug-responsive epilepsy, undefined drug responsiveness, or no epilepsy as of the last EHR encounter in the study period based on consensus definitions. Demographic characteristics and codes for diagnoses, antiseizure medications (ASMs), and procedures were tested for association with DRE. Algorithms combining permutations of these factors were applied to calculate sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for DRE. The F1 score was used to compare overall performance.</AbstractText><AbstractText Label="RESULTS">Among 412 patients with source record-confirmed epilepsy, 62 (15.0%) had DRE, 163 (39.6%) had drug-responsive epilepsy, 124 (30.0%) had undefined drug responsiveness, and 63 (15.3%) had insufficient records. The best performing phenotype for DRE in terms of the F1 score was the presence of &#x2265;1 intractable epilepsy code and&#x2009;&#x2265;2 unique non-gabapentinoid ASM exposures each with &#x2265;90-day drug era (sensitivity = .661, specificity = .937, PPV = .594, NPV = .952, F1 score = .626). Several phenotypes achieved higher sensitivity at the expense of specificity and vice versa.</AbstractText><AbstractText Label="SIGNIFICANCE">OMOP algorithms can identify DRE in EHR-derived data with varying tradeoffs between sensitivity and specificity. These computable phenotypes can be applied across the largest international network of standardized clinical databases for further validation, reproducible observational research, and improving access to appropriate care.</AbstractText><CopyrightInformation>&#xa9; 2022 International League Against Epilepsy.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castano</LastName><ForeName>Victor G</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2869-0237</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldman</LastName><ForeName>Genna J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joiner</LastName><ForeName>Evan F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Hyunmi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-0826-2350</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0847-6682</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKhann</LastName><ForeName>Guy M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0002-9695-3564</Identifier><AffiliationInfo><Affiliation>Department of Neurological Surgery, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ottman</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7074-242X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Translational Epidemiology and Mental Health Equity, New York State Psychiatric Institute, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neugut</LastName><ForeName>Alfred I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2664-7614</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youngerman</LastName><ForeName>Brett E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0002-4792-3190</Identifier><AffiliationInfo><Affiliation>Department of Neurological Surgery, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS104076</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epilepsia</MedlineTA><NlmUniqueID>2983306R</NlmUniqueID><ISSNLinking>0013-9580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069279" MajorTopicYN="Y">Drug Resistant Epilepsy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="Y">Epilepsy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Observational Health Data Science and Informatics</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">computable phenotype</Keyword><Keyword MajorTopicYN="N">drug-resistant epilepsy</Keyword><Keyword MajorTopicYN="N">electronic health record</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>15</Day><Hour>3</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36106377</ArticleId><ArticleId IdType="doi">10.1111/epi.17409</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-9.</Citation></Reference><Reference><Citation>Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069-77.</Citation></Reference><Reference><Citation>Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78(20):1548-54.</Citation></Reference><Reference><Citation>Sperling MR, Barshow S, Nei M, Asadi-Pooya AA. A reappraisal of mortality after epilepsy surgery. Neurology. 2016;86(21):1938-44.</Citation></Reference><Reference><Citation>Jokeit H, Ebner A. Long term effects of refractory temporal lobe epilepsy on cognitive abilities: a cross sectional study. J Neurol Neurosurg Psychiatry. 1999;67(1):44-50.</Citation></Reference><Reference><Citation>Spencer SS, Berg AT, Vickrey BG, Sperling MR, Bazil CW, Haut S, et al. Health-related quality of life over time since resective epilepsy surgery. Ann Neurol. 2007;62(4):327-34.</Citation></Reference><Reference><Citation>Begley C, Wagner RG, Abraham A, Beghi E, Newton C, Kwon CS, et al. The global cost of epilepsy: a systematic review and extrapolation. Epilepsia. 2022;63(4):892-903.</Citation></Reference><Reference><Citation>Willems LM, Hochbaum M, Frey K, Schulz J, Menzler K, Langenbruch L, et al. Multicenter, cross-sectional study of the costs of illness and cost-driving factors in adult patients with epilepsy. Epilepsia. 2022;63(4):904-18.</Citation></Reference><Reference><Citation>Spotnitz M, Ostropolets A, Castano VG, Natarajan K, Waldman GJ, Argenziano M, et al. Patient characteristics and antiseizure medication pathways in newly diagnosed epilepsy: feasibility and pilot results using the common data model in a single-center electronic medical record database. Epilepsy Behav 2022;129:108630.</Citation></Reference><Reference><Citation>Terman SW, Youngerman BE, Choi H, Burke JF. Antiseizure medication treatment pathways for US Medicare beneficiaries with newly treated epilepsy. Epilepsia. 2022;63(6):1571-9.</Citation></Reference><Reference><Citation>Chen Z, Rollo B, Antonic-Baker A, Anderson A, Ma Y, O'Brien TJ, et al. New era of personalised epilepsy management. BMJ. 2020;371:m3658.</Citation></Reference><Reference><Citation>Devinsky O, Dilley C, Ozery-Flato M, Aharonov R, Goldschmidt Y, Rosen-Zvi M, et al. Changing the approach to treatment choice in epilepsy using big data. Epilepsy Behav. 2016;56:32-7.</Citation></Reference><Reference><Citation>K&#xf6;hler S, Gargano M, Matentzoglu N, Carmody LC, Lewis-Smith D, Vasilevsky NA, et al. The human phenotype ontology in 2021. Nucleic Acids Res. 2021;49:D1207-17.</Citation></Reference><Reference><Citation>Koko M, Motelow JE, Stanley KE, Bobbili DR, Dhindsa RS, May P, et al. Association of ultra-rare coding variants with genetic generalized epilepsy: a case-control whole exome sequencing study. Epilepsia. 2022;63(3):723-35.</Citation></Reference><Reference><Citation>Engel J, Wiebe S, French J, Sperling M, Williamson P, Spencer D, et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology. 2003;60(4):538-47.</Citation></Reference><Reference><Citation>Patel AD, Baca C, Franklin G, Herman ST, Hughes I, Meunier L, et al. Quality improvement in neurology: epilepsy quality measurement set 2017 update. Neurology. 2018;91(18):829-36.</Citation></Reference><Reference><Citation>Engel J. What can we do for people with drug-resistant epilepsy? The 2016 Wartenberg lecture. Neurology. 2016;87(23):2483-9.</Citation></Reference><Reference><Citation>Choi H, Carlino R, Heiman G, Hauser WA, Gilliam FG. Evaluation of duration of epilepsy prior to temporal lobe epilepsy surgery during the past two decades. Epilepsy Res. 2009;86(2-3):224-7.</Citation></Reference><Reference><Citation>Jett&#xe9; N, Reid AY, Quan H, Hill MD, Wiebe S. How accurate is ICD coding for epilepsy? Epilepsia. 2010;51(1):62-9.</Citation></Reference><Reference><Citation>Tu K, Wang M, Jaakkimainen RL, Butt D, Ivers NM, Young J, et al. Assessing the validity of using administrative data to identify patients with epilepsy. Epilepsia. 2014;55(2):335-43.</Citation></Reference><Reference><Citation>Holden EW, Grossman E, Nguyen HT, Gunter MJ, Grebosky B, Von Worley A, et al. Developing a computer algorithm to identify epilepsy cases in managed care organizations. Dis Manag. 2005;8(1):1-14.</Citation></Reference><Reference><Citation>Moura LMVR, Price M, Cole AJ, Hoch DB, Hsu J. Accuracy of claims-based algorithms for epilepsy research: revealing the unseen performance of claims-based studies. Epilepsia. 2017;58(4):683-91.</Citation></Reference><Reference><Citation>Freedman DA, Grinspan Z, Glynn P, Mittlesteadt J, Dawes A, Patel AD. Validating coding for the identification of pediatric treatment resistant epilepsy patients. Child Neurol Open. 2021;8:2329048X211037806.</Citation></Reference><Reference><Citation>Pan S, Wu A, Weiner M, Grinspan MZ. Development and evaluation of computable phenotypes in pediatric epilepsy: 3 cases. J Child Neurol. 2021;36(11):990-7.</Citation></Reference><Reference><Citation>Hill CE, Lin CC, Terman SW, Rath S, Parent JM, Skolarus LE, et al. Definitions of drug-resistant epilepsy for administrative claims data research. Neurology. 2021;97(13):e1343-50.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574-8.</Citation></Reference><Reference><Citation>Hill CE, Lin CC, Burke JF, Kerber KA, Skolarus LE, Esper GJ, et al. Claims data analyses unable to properly characterize the value of neurologists in epilepsy care. Neurology. 2019;92(9):e973-87.</Citation></Reference><Reference><Citation>Bakaki PM, Koroukian SM, Jackson LW, Albert JM, Kaiboriboon K. Defining incident cases of epilepsy in administrative data. Epilepsy Res. 2013;106(1):273-9.</Citation></Reference><Reference><Citation>Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-82.</Citation></Reference><Reference><Citation>R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022. Available from:. https://www.R-project.org/. Accessed 1 Jul 2022.</Citation></Reference><Reference><Citation>Cornet R, de Keizer N. Forty years of SNOMED: a literature review. BMC Med Inform Decis Mak. 2008;8:S2.</Citation></Reference><Reference><Citation>Sultana B, Panzini MA, Carpentier AV, Comtois J, Rioux B, Gore G, et al. Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis. Neurology. 2021;96(17):805-17.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36108816</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Adjusting for indirectly measured confounding using large-scale propensity score.</ArticleTitle><Pagination><StartPage>104204</StartPage><MedlinePgn>104204</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2022.104204</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(22)00209-X</ELocationID><Abstract><AbstractText>Confounding remains one of the major challenges to causal inference with observational data. This problem is paramount in medicine, where we would like to answer causal questions from large observational datasets like electronic health records (EHRs) and administrative claims. Modern medical data typically contain tens of thousands of covariates. Such a large set carries hope that many of the confounders are directly measured, and further hope that others are indirectly measured through their correlation with measured covariates. How can we exploit these large sets of covariates for causal inference? To help answer this question, this paper examines the performance of the large-scale propensity score (LSPS) approach on causal analysis of medical data. We demonstrate that LSPS may adjust for indirectly measured confounders by including tens of thousands of covariates that may be correlated with them. We present conditions under which LSPS removes bias due to indirectly measured confounders, and we show that LSPS may avoid bias when inadvertently adjusting for variables (like colliders) that otherwise can induce bias. We demonstrate the performance of LSPS with both simulated medical data and real medical data.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Linying</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, 622&#xa0;W. 168th Street, PH20, New York, 10032, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yixin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Statistics, University of Michigan, 1085 S University Ave, Ann Arbor, 48109, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, 1125 Trenton-Harbourton Road, Titusville, 08560, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blei</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, 1255 Amsterdam Ave, New York, 10027, NY, USA; Department of Computer Science, Columbia University, 500 West 120 Street, Room 450 MC0401, New York, 10027, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, 622&#xa0;W. 168th Street, PH20, New York, 10032, NY, USA; Medical Informatics Services, New York-Presbyterian Hospital, 622&#xa0;W. 168th Street, PH20, New York, 10032, NY, USA. Electronic address: hripcsak@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015986" MajorTopicYN="Y">Confounding Factors, Epidemiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Causal inference</Keyword><Keyword MajorTopicYN="N">Electronic health record</Keyword><Keyword MajorTopicYN="N">Observational study</Keyword><Keyword MajorTopicYN="N">Propensity score</Keyword><Keyword MajorTopicYN="N">Unmeasured confounder</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Martijn Schuemie reports a relationship with Janssen Research and Development LLC that includes: employment.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>15</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36108816</ArticleId><ArticleId IdType="mid">NIHMS1849792</ArticleId><ArticleId IdType="pmc">PMC9692203</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2022.104204</ArticleId><ArticleId IdType="pii">S1532-0464(22)00209-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosenbaum PR, Rubin DB, The central role of the propensity score in observational studies for causal effects, Biometrika 70 (1) (1983) 41&#x2013;55.</Citation></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA, Evaluating large-scale propensity score performance through real-world and synthetic data experiments, International Journal of Epidemiology 47 (6) (2018) 2005&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB, Matching to Remove Bias in Observational Studies, Biometrics. Journal of the International Biometric Society 29 (1) (1973) 159.</Citation></Reference><Reference><Citation>Rubin DB, The Use of Matched Sampling and Regression Adjustment to Remove Bias in Observational Studies, Biometrics. Journal of the International Biometric Society 29 (1) (1973) 185.</Citation></Reference><Reference><Citation>Stuart EA, Matching Methods for Causal Inference: A Review and a Look Forward, Statistical Science 25 (1) (2010) 1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943670</ArticleId><ArticleId IdType="pubmed">20871802</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB, Reducing Bias in Observational Studies Using Subclassification on the Propensity Score, Journal of the American Statistical Association 79 (387) (1984) 516.</Citation></Reference><Reference><Citation>Rubin DB, The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials, Statistics in Medicine 26 (1) (2007) 20&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">17072897</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrier I, Re: The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials, Statistics in Medicine 27 (14) (2008) 2740&#x2013;2741.</Citation><ArticleIdList><ArticleId IdType="pubmed">18069729</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB, Author&#x2019;s reply re: The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials, Statistics in Medicine 27 (14) (2008) 2741&#x2013;2742.</Citation><ArticleIdList><ArticleId IdType="pubmed">18069729</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrier I, Propensity scores, Statistics in Medicine 28 (8) (2009) 1317&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">19288531</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;lander A, Propensity scores and M-structures, Statistics in Medicine 28 (9) (2009) 1416&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pubmed">19340845</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearl J, Remarks on the method of propensity score, Statistics in Medicine 28 (9) (2009) 1415&#x2013;1416.</Citation><ArticleIdList><ArticleId IdType="pubmed">19340847</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB, Should observational studies be designed to allow lack of balance in covariate distributions across treatment groups?, Statistics in Medicine 28 (9) (2009) 1420&#x2013;1423.</Citation></Reference><Reference><Citation>Rubin DB, Estimating causal effects from large data sets using propensity scores, Annals of Internal Medicine 127 (8 Pt 2) (1997) 757&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">9382394</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers JA, Rassen JA, Gagne JJ, Huybrechts KF, Schneeweiss S, Rothman KJ, Joffe MM, Glynn RJ, Effects of Adjusting for Instrumental Variables on Bias and Precision of Effect Estimates, American Journal of Epidemiology 174 (11) (2011) 1213&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254160</ArticleId><ArticleId IdType="pubmed">22025356</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, St&#xfc;rmer T, Variable selection for propensity score models, American Journal of Epidemiology 163 (12) (2006) 1149&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513192</ArticleId><ArticleId IdType="pubmed">16624967</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC, Grootendorst P, Anderson GM, A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study, Statistics in Medicine 26 (4) (2007) 734&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">16708349</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearl J, On a Class of Bias-Amplifying Variables that Endanger Effect Estimates, in: Proceedings of the Twenty-Sixth Conference on Uncertainty in Artificial Intelligence, 2010, pp. 417&#x2013;424.</Citation></Reference><Reference><Citation>Pearl J, Invited Commentary: Understanding Bias Amplification, American Journal of Epidemiology 174 (11) (2011) 1223&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3224255</ArticleId><ArticleId IdType="pubmed">22034488</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearl J, Linear Models: A Useful &#x201c;Microscope&#x201d; for Causal Analysis, Journal of Causal Inference 1 (1) (2013) 155&#x2013;170.</Citation></Reference><Reference><Citation>Wooldridge JM, Should instrumental variables be used as matching variables?, Research in Economics 70 (2) (2016) 232&#x2013;237.</Citation></Reference><Reference><Citation>Steiner PM, Kim Y, The Mechanics of Omitted Variable Bias: Bias Amplification and Cancellation of Offsetting Biases, Journal of Causal Inference 4 (2) (2016) 20160009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6095678</ArticleId><ArticleId IdType="pubmed">30123732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding P, Vanderweele TJ, Robins JM, Instrumental variables as bias amplifiers with general outcome and confounding, Biometrika 104 (2) (2017) 291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5636691</ArticleId><ArticleId IdType="pubmed">29033459</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D, Empirical Performance of a New User Cohort Method: Lessons for Developing a Risk Identification and Analysis System, Drug Safety 36 (Suppl 1) (2013) 59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein RB, Ryan P, Berlin JA, Matcho A, Schuemie M, Swerdel J, Patel K, Fife D, Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications, Drug Safety 40 (12) (2017) 1279&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688206</ArticleId><ArticleId IdType="pubmed">28780741</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein RB, Ryan PB, Berlin JA, Schuemie MJ, Swerdel J, Fife D, Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen, Drug Safety 43 (9) (2020) 927&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434801</ArticleId><ArticleId IdType="pubmed">32500272</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, Biedermann P, Banda JM, Burn E, Casajust P, Conover MM, Culhane AC, Davydov A, DuVall SL, Dymshyts D, Fernandez-Bertolin S, Fi&#x161;ter K, Hardin J, Hester L, Hripcsak G, Kaas-Hansen BS, Kent S, Khosla S, Kolovos S, Lambert CG, Lei J. v. d.,Lynch KE, Makadia R, Margulis AV, Matheny ME, Mehta P, Morales DR, Morgan-Stewart H, Mosseveld M, Newby D, Nyberg F, Ostropolets A, Park RW, Prats-Uribe A, Rao GA, Reich C, Reps J, Rijnbeek P, Sathappan SMK, Schuemie M, Seager S, Sena AG, Shoaibi A, Spotnitz M, Suchard MA, Torre CO, Vizcaya D, Wen H, Wilde M. d., Xie J, You SC, Zhang L, Zhuk O, Ryan P, Prieto-Alhambra D, O.-C.-. consortium, Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study, The Lancet Rheumatology 2 (11) (2020) e698&#x2013;e711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442425</ArticleId><ArticleId IdType="pubmed">32864627</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JD, Ryan PB, Suchard MA, Hripcsak G, Jin P, Reich C, Schwalm M, Khoma Y, Wu Y, Xu H, Shah NH, Banda JM, Schuemie MJ, Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network, Epilepsia 58 (8) (2017) e101&#x2013;e106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632067</ArticleId><ArticleId IdType="pubmed">28681416</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales DR, Conover MM, You SC, Pratt N, Kostka K, Duarte-Salles T, Fern&#xe1;ndez-Bertol&#xed;n S, Arag&#xf3;n M, DuVall SL, Lynch K, Falconer T, Bochove K. v., Sung C, Matheny ME, Lambert CG, Nyberg F, Alshammari TM, Williams AE, Park RW, Weaver J, Sena AG, Schuemie MJ, Rijnbeek PR, Williams RD, Lane JCE, Prats-Uribe A, Zhang L, Areia C, Krumholz HM, Prieto-Alhambra D, Ryan PB, Hripcsak G, Suchard MA, Renin&#x2013;angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis, The Lancet Digital Health 3 (2) (2021) e98&#x2013;e114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834915</ArticleId><ArticleId IdType="pubmed">33342753</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, Weaver J, Morales D, Prats-Uribe A, Delmestri A, Strauss VY, He Y, Robinson DE, Pinedo-Villanueva R, Kolovos S, Duarte-Salles T, Sproviero W, Yu D, Speybroeck MV, Williams R, John LH, Hughes N, Sena AG, Costello R, Birlie B, Culliford D, O&#x2019;Leary C, Morgan H, Burkard T, Prieto-Alhambra D, Ryan P, Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study, The Lancet Rheumatology 1 (4) (2019) e229&#x2013;e236.</Citation></Reference><Reference><Citation>Wilcox MA, Villasis-Keever A, Sena AG, Knoll C, Fife D, Evaluation of disability in patients exposed to fluoroquinolones, BMC Pharmacology and Toxicology 21 (1) (2020) 40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7268406</ArticleId><ArticleId IdType="pubmed">32493505</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB, Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis, The Lancet 394 (10211) (2019) 1816&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, Jung S, Swerdel JN, Ryan PB, Schuemie MJ, Suchard MA, Lee S, Cho J, Hripcsak G, Park RW, Park S, Comparison of First-Line Dual Combination Treatments in Hypertension: Real-World Evidence from Multinational Heterogeneous Cohorts, Korean Circulation Journal 50 (1) (2019) 52&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6923236</ArticleId><ArticleId IdType="pubmed">31642211</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Suchard MA, Shea S, Chen R, You SC, Pratt N, Madigan D, Krumholz HM, Ryan PB, Schuemie MJ, Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension, JAMA Internal Medicine 180 (4) (2020) 542&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="pubmed">32065600</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Tian Y, Yang J, Huser V, Jin P, Lambert CG, Park H, You SC, Park RW, Rijnbeek PR, Zandt MV, Reich C, Vashisht R, Wu Y, Duke J, Hripcsak G, Madigan D, Shah NH, Ryan PB, Schuemie MJ, Suchard MA, Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis, Scientific Reports 10 (1) (2020) 11115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7338498</ArticleId><ArticleId IdType="pubmed">32632237</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, Londhe A, Cho J, Park J, Schuemie M, Suchard MA, Madigan D, Hripcsak G, Gupta A, Reich CG, Ryan PB, Park RW, Krumholz HM, Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention, JAMA : the Journal of the American Medical Association 324 (16) (2020) 1640&#x2013;1650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592033</ArticleId><ArticleId IdType="pubmed">33107944</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, Banda JM, Park RW, Jin S, Li L, Dudley JT, Johnson KW, Shervey MM, Xu H, Wu Y,Natrajan K, Hripcsak G, Jin P, Zandt MV, Reckard A, Reich CG, Weaver J, Schuemie MJ, Ryan PB, Callahan A, Shah NH, Association of Hemoglobin A 1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative, JAMA Network Open 1 (4) (2018) e181755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Weinstein R, Ryan PB, Berlin JA, Quantifying bias in epidemiologic studies evaluating the association between acetaminophen use and cancer, Regulatory Toxicology and Pharmacology 120 (2021) 104866.</Citation><ArticleIdList><ArticleId IdType="pubmed">33454352</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Cepede MS, Suchard MA, Yang J, Schuler YTA, Ryan PB, Madigan D, Hripcsak G, How Confident Are We About Observational Findings in Health Care: A Benchmark Study, Harvard Data Science Review 2 (1) (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, Chen R, You SC, Krumholz HM, Madigan D, Hripcsak G, Suchard MA, Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study, Journal of the American Medical Informatics Association 27 (8) (2020) 1268&#x2013;1277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481033</ArticleId><ArticleId IdType="pubmed">32827027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA, Improving reproducibility by using high-throughput observational studies with empirical calibration, Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences 376 (2128) (2018) 20170356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA, Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data, Proceedings of the National Academy of Sciences 115 (11) (2018) 2571&#x2013;2577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, Chen R, You SC, Krumholz HM, Madigan D, Hripcsak G, Suchard MA, Principles of Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND), Journal of the American Medical Informatics Association 27 (8) (2020) 1331&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Schuemie M, Suchard M, Ostropolets A, Zhang L, Hripcsak G, Evaluation of large-scale propensity score modeling and covariate balance on potential unmeasured confounding in observational research (abstract), in: Proceedings of the AMIA Symposium, 2020.</Citation></Reference><Reference><Citation>Wang Y, Blei DM, The Blessings of Multiple Causes, Journal of the American Statistical Association 114 (528) (2019) 1574&#x2013;1596.</Citation></Reference><Reference><Citation>Wang Y, Blei DM, Towards Clarifying the Theory of the Deconfounder, ArXiv (2020).</Citation></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM, Instruments for Causal Inference, Epidemiology (Cambridge, Mass.) 17 (4) (2006) 360&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">16755261</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie T, Tibshirani R, Friedman J, The elements of statistical learning: data mining, inference and prediction, 2nd Edition, Springer, 2009.</Citation></Reference><Reference><Citation>Walker A, Patrick, Lauer, Hornbrook, Marin, Platt, Roger V, Stang, Schneeweiss, A tool for assessing the feasibility of comparative effectiveness research, Comparative Effectiveness Research Volume 3 (2013) 11&#x2013;20.</Citation></Reference><Reference><Citation>Austin PC, Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research, Communications in Statistics - Simulation and Computation 38 (6) (2009) 1228&#x2013;1234.</Citation></Reference><Reference><Citation>Cox DR, Regression Models and Life-Tables, JSTOR 34 (2) (1972) 187&#x2013;220.</Citation></Reference><Reference><Citation>Rubin DB, Estimating causal effects of treatments in randomized and nonrandomized studies, Journal of Educational Psychology 66 (5) (1974) 688.</Citation></Reference><Reference><Citation>Ogburn EL, Vanderweele TJ, Bias attenuation results for nondifferentially mismeasured ordinal and coarsened confounders, Biometrika 100 (1) (2013) 241&#x2013;248. doi:10.1093/biomet/ass054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/ass054</ArticleId><ArticleId IdType="pmc">PMC3761876</ArticleId><ArticleId IdType="pubmed">24014285</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya J, Vogt WB, Do Instrumental Variables Belong in Propensity Scores?, Working Paper, National Bureau of Economic Research; (2007).</Citation></Reference><Reference><Citation>Middleton JA, Scott MA, Diakow R, Hill JL, Bias Amplification and Bias Unmasking, Political Analysis 24 (3) (2016) 307&#x2013;323.</Citation></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM, Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available, American Journal of Epidemiology 183 (8) (2016) 758&#x2013;764. doi:10.1093/aje/kwv254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwv254</ArticleId><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien S-C, Ou S-M, Shih C-J, Chao P-W, Li S-Y, Lee Y-J, Kuo S-C, Wang S-J, Chen T-J, Tarng D-C, Chu H, Chen Y-T, Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients, Medicine 94 (43) (2015) e1751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4985382</ArticleId><ArticleId IdType="pubmed">26512568</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L, Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study, BMJ (Clinical Research Ed.) 363 (2018) k4209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199558</ArticleId><ArticleId IdType="pubmed">30355745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku E, McCulloch CE, Vittinghoff E, Lin F, Johansen KL, Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers, Journal of the American Heart Association 7 (19) (2018) e009992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6404880</ArticleId><ArticleId IdType="pubmed">30371331</ArticleId></ArticleIdList></Reference><Reference><Citation>Magid DJ, Shetterly SM, Margolis KL, Tavel HM, O&#x2019;Connor PJ, Selby JV, Ho PM, Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors Versus Beta-Blockers as Second-Line Therapy for Hypertension, Circulation: Cardiovascular Quality and Outcomes 3 (5) (2010) 453&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3517880</ArticleId><ArticleId IdType="pubmed">20716714</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasvold LP, Bodeg&#xe5;rd J, Thuresson M, St&#xe5;lhammar J, Hammar N, Sundstr&#xf6;m J, Russell D, Kjeldsen SE, Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients, Journal of Human Hypertension 28 (11) (2014) 663&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4191159</ArticleId><ArticleId IdType="pubmed">25211055</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroki M, Pearl J, Measurement bias and effect restoration in causal inference, Biometrika 101 (2) (2014) 423&#x2013;437.</Citation></Reference><Reference><Citation>Miao W, Geng Z, Tchetgen Tchetgen EJ, Identifying causal effects with proxy variables of an unmeasured confounder, Biometrika 105 (4) (2018) 987&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746017</ArticleId><ArticleId IdType="pubmed">33343006</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchetgen Tchetgen EJ, Ying A, Cui Y, Shi X, Miao W, An Introduction to Proximal Causal Learning, ArXiv (2020).</Citation></Reference><Reference><Citation>Albogami Y, Winterstein AG, Plasmode simulation of multiple imputation performance using internal validation data to adjust for unmeasured confounders, in: Pharmacoepidemiology and Drug Safety, Vol. 29, 2020, pp. 414&#x2013;414.</Citation></Reference><Reference><Citation>Albogami Y, Cusi K, Daniels MJ, Wei Y-JJ, Winterstein AG, Glucagon-like peptide 1 receptor agonists and chronic lower respiratory disease exacerbations among patients with type 2 diabetes, Diabetes Care (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8247488</ArticleId><ArticleId IdType="pubmed">33875487</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA, High-dimensional propensity score adjustment in studies of treatment effects using health care claims data, Epidemiology 20 (4) (2009) 512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Wang Y, Ostropolets A, Mulgrave JJ, Blei DM, Hripcsak G, The Medical Deconfounder: Assessing Treatment Effects with Electronic Health Records, in: Proceedings of the 4th Machine Learning for Healthcare Conference, PMLR, 2019, pp. 490&#x2013;512.</Citation></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D, Massive parallelization of serial inference algorithms for complex generalized linear models, ACM Transactions on Modeling and Computer Simulation 23 (2013) 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36123617</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1463-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Diabetes, obesity &amp; metabolism</Title><ISOAbbreviation>Diabetes Obes Metab</ISOAbbreviation></Journal><ArticleTitle>iGlarLixi versus basal plus Rapid-Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real-World study.</ArticleTitle><Pagination><StartPage>68</StartPage><EndPage>77</EndPage><MedlinePgn>68-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/dom.14844</ELocationID><Abstract><AbstractText Label="AIM">For people with suboptimally controlled type 2 diabetes (T2D) on basal insulin (BI), guidelines recommend several treatment advancement options. This study compared the clinical effectiveness of once-daily iGlarLixi versus a multiple-injection BI&#x2009;+&#x2009;rapid acting insulin (RAI) regimen in adults with T2D advancing from BI therapy in real-world clinical practice.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Electronic medical records from the Observational Medical Outcomes Partnership (OMOP) database were analysed retrospectively using propensity score matching to compare therapy advancement with iGlarLixi or BI&#x2009;+&#x2009;RAI in US adults &#x2265;18&#x2009;years with T2D on BI who had &#x2265;1 valid glycated haemoglobin (HbA1c) value at baseline and at the 6-month follow-up. The primary objective was non-inferiority of iGlarLixi to BI&#x2009;+&#x2009;RAI in HbA1c change from baseline to 6&#xa0;months (margin 0.3%).</AbstractText><AbstractText Label="RESULTS">Propensity score matching generated cohorts with balanced baseline characteristics (N&#xa0;=&#xa0;814 in each group). HbA1c reduction from baseline to 6&#xa0;months with iGlarLixi was non-inferior to BI&#x2009;+&#x2009;RAI [mean difference (95% confidence interval): 0.1 (-0.1, 0.2)%; one-sided p&#xa0;=&#xa0;.0032]. At 6&#xa0;months, weight gain was significantly lower with iGlarLixi than with BI&#x2009;+&#x2009;RAI [-0.8 (-1.3, -0.2) kg; two-sided p&#xa0;=&#xa0;.0069]. Achievement of HbA1c &lt;7% without hypoglycaemia and weight gain were similar between groups [odds ratio (95% confidence interval): 1.15 (0.81, 1.63); p&#xa0;=&#xa0;.4280]. Hypoglycaemia was low in both groups, probably because of underreporting.</AbstractText><AbstractText Label="CONCLUSIONS">In real-world clinical practice, glycaemic outcomes 6&#xa0;months after treatment advancement from BI are similar for people with T2D using iGlarLixi versus BI&#x2009;+&#x2009;RAI, with iGlarLixi leading to less weight gain.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McCrimmon</LastName><ForeName>Rory J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-3957-1981</Identifier><AffiliationInfo><Affiliation>Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Alice Y Y</ForeName><Initials>AYY</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galstyan</LastName><ForeName>Gagik</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Diabetic Foot Department, Endocrinology Research Center, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djaballah</LastName><ForeName>Khier</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sanofi, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Sanofi, Bridgewater, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coudert</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sanofi, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frias</LastName><ForeName>Juan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Velocity Clinical Research, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diabetes Obes Metab</MedlineTA><NlmUniqueID>100883645</NlmUniqueID><ISSNLinking>1462-8902</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061266">Insulin, Short-Acting</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061266" MajorTopicYN="Y">Insulin, Short-Acting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015430" MajorTopicYN="N">Weight Gain</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">basal insulin</Keyword><Keyword MajorTopicYN="N">database research</Keyword><Keyword MajorTopicYN="N">glucagon-like peptide-1 analogue</Keyword><Keyword MajorTopicYN="N">glycaemic control</Keyword><Keyword MajorTopicYN="N">iGlarLixi</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36123617</ArticleId><ArticleId IdType="pmc">PMC10087837</ArticleId><ArticleId IdType="doi">10.1111/dom.14844</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Diabetes Control and Complications Trial Research Group , Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long&#x2010;term complications in insulin&#x2010;dependent diabetes mellitus. N Engl J Med. 1993;329(14):977&#x2010;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">8366922</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association . 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes&#x2014;2022. Diabetes Care. 2022;45(Supplement 1):S125&#x2010;S143.</Citation><ArticleIdList><ArticleId IdType="pubmed">34964831</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellana M, Cignarelli A, Brescia F, Laviola L, Giorgino F. GLP&#x2010;1 receptor agonist added to insulin versus basal&#x2010;plus or basal&#x2010;bolus insulin therapy in type 2 diabetes: a systematic review and meta&#x2010;analysis. Diabetes Metab Res Rev. 2019;35(1):e3082.</Citation><ArticleIdList><ArticleId IdType="pubmed">30270567</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716&#x2010;1730.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890232</ArticleId></ArticleIdList></Reference><Reference><Citation>Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed&#x2010;ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan&#x2010;L randomized trial. Diabetes Care. 2016;39(11):1972&#x2010;1980.</Citation><ArticleIdList><ArticleId IdType="pubmed">27650977</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Emral R, Sauque&#x2010;Reyna L, et al. Advancing therapy in suboptimally controlled basal insulin&#x2010;treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. Diabetes Care. 2021;44:2361&#x2010;2370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8740944</ArticleId><ArticleId IdType="pubmed">34183429</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal&#x2010;bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin; DUAL VII randomized clinical trial. Diabetes Care. 2018;41:1009&#x2010;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">29483185</ArticleId></ArticleIdList></Reference><Reference><Citation>Home P, Blonde L, Kalra S, et al. Insulin glargine/lixisenatide fixed&#x2010;ratio combination (iGlarLixi) compared with premix or addition of meal&#x2010;time insulin to basal insulin in people with type 2 diabetes: a systematic review and Bayesian network meta&#x2010;analysis. Diabetes Obes Metab. 2020;22(11):2179&#x2010;2188.</Citation><ArticleIdList><ArticleId IdType="pubmed">32700442</ArticleId></ArticleIdList></Reference><Reference><Citation>Tab&#xe1;k &#xc1;G, Anderson J, Aschner P, et al. Efficacy and safety of iGlarLixi, fixed&#x2010;ratio combination of insulin glargine and lixisenatide, compared with basal&#x2010;bolus regimen in patients with type 2 diabetes: propensity score matched analysis. Diabetes Ther. 2020;11(1):305&#x2010;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6965545</ArticleId><ArticleId IdType="pubmed">31848983</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu&#x2010;Jones BK, Finlayson SG, Yuan W, et al. Examining the use of real&#x2010;world evidence in the regulatory process. Clin Pharmacol Ther. 2020;107(4):843&#x2010;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7093234</ArticleId><ArticleId IdType="pubmed">31562770</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman RE, Anderson SA, Dal Pan GJ, et al. Real&#x2010;world evidence&#x2014;what is it and what can it tell us? N Engl J Med. 2016;375(23):2293&#x2010;2297.</Citation><ArticleIdList><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal&#x2010;plus or basal&#x2010;bolus in type 2 diabetes: the GetGoal Duo&#x2010;2 trial. Diabetes Care. 2016;39:1318&#x2010;1328.</Citation><ArticleIdList><ArticleId IdType="pubmed">27222510</ArticleId></ArticleIdList></Reference><Reference><Citation>Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299&#x2010;1307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4966497</ArticleId><ArticleId IdType="pubmed">27524885</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijan S, Hayward RA, Ronis DL, Hofer TP. Brief report: the burden of diabetes therapy: implications for the design of effective patient&#x2010;centered treatment regimens. J Gen Intern Med. 2005;20(5):479&#x2010;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1490106</ArticleId><ArticleId IdType="pubmed">15963177</ArticleId></ArticleIdList></Reference><Reference><Citation>Lajara R, Heller C, Pantalone KM, et al. iGlarLixi vs. premixed insulin initiation in adults with type 2 diabetes (T2D) advancing from basal insulin (BI) therapy: SoliComplex real&#x2010;world study. Diabetes. 2022;71(Supplement_1):739&#x2010;P.</Citation><ArticleIdList><ArticleId IdType="pubmed">36633506</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantalone KM, Heller C, Lajara R, et al. Initiation of iGlarLixi vs. basal&#x2010;bolus insulin (BB) in adults with type 2 diabetes (T2D) advancing from basal insulin (BI) therapy: the SoliComplex real&#x2010;world study. Diabetes. 2022;71(Supplement_1):733&#x2010;P.</Citation><ArticleIdList><ArticleId IdType="pubmed">36633506</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DSU, Lee H. Adherence and persistence rates of major antidiabetic medications: a review. Diabetol Metab Syndr. 2022;14(1):12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761325</ArticleId><ArticleId IdType="pubmed">35033161</ArticleId></ArticleIdList></Reference><Reference><Citation>Raccah D, Huet D, Dib A, et al. Review of basal&#x2010;plus insulin regimen options for simpler insulin intensification in people with type 2 diabetes mellitus. Diabet Med. 2017;34(9):1193&#x2010;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599968</ArticleId><ArticleId IdType="pubmed">28574177</ArticleId></ArticleIdList></Reference><Reference><Citation>Carls GS, Tuttle E, Tan RD, et al. Understanding the gap between efficacy in randomized controlled trials and effectiveness in real&#x2010;world use of GLP&#x2010;1 RA and DPP&#x2010;4 therapies in patients with type 2 diabetes. Diabetes Care. 2017;40(11):1469&#x2010;1478.</Citation><ArticleIdList><ArticleId IdType="pubmed">28801475</ArticleId></ArticleIdList></Reference><Reference><Citation>Freemantle N, Mauricio D, Giaccari A, et al. Real&#x2010;world outcomes of treatment with insulin glargine 300&#x2009;U/mL versus standard&#x2010;of&#x2010;care in people with uncontrolled type 2 diabetes mellitus. Curr Med Res Opin. 2020;36(4):571&#x2010;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">31865758</ArticleId></ArticleIdList></Reference><Reference><Citation>Egede LE, Bogdanov A, Fischer L, Da Rocha Fernandes JD, Kallenbach L. Glycemic control among patients newly prescribed IDegLira across prior therapy group in US real&#x2010;world practice. Diabetes Ther. 2020;11(7):1579&#x2010;1589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324461</ArticleId><ArticleId IdType="pubmed">32506223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenari L, Da Porto A, De Moliner L, et al. Real&#x2010;world evaluation of glycemic outcomes and extra&#x2010;glycemic parameters in diabetic patients treated with the combined formulation degludec&#x2010;liraglutide (IDegLira). Diabetes Ther. 2021;12(1):197&#x2010;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7843811</ArticleId><ArticleId IdType="pubmed">33104959</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2020.</Citation></Reference><Reference><Citation>Kis JT, Nagy G, Kovacs G. Effectiveness of iGlarLixi, a fixed&#x2010;ratio combination of insulin glargine 100 U/mL and lixisenatide, in people with type 2 diabetes. Diabetes Ther. 2021;12(9):2517&#x2010;2529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385086</ArticleId><ArticleId IdType="pubmed">34357560</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautsch D, Boggs R, Wang T, et al. Individualized HbA1c goals, and patient awareness and attainment of goals in type 2 diabetes mellitus: a real&#x2010;world multinational survey. Adv Ther. 2022;39(2):1016&#x2010;1032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8706771</ArticleId><ArticleId IdType="pubmed">34951678</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauricio D, Meneghini L, Seufert J, et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017;19(8):1155&#x2010;1164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573947</ArticleId><ArticleId IdType="pubmed">28251792</ArticleId></ArticleIdList></Reference><Reference><Citation>Blonde L, Bailey T, Sullivan SD, Freemantle N. Insulin glargine 300&#x2009;units/mL for the treatment of individuals with type 2 diabetes in the real world: a review of the DELIVER programme. Diabetes Obes Metab. 2021;23(8):1713&#x2010;1721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362061</ArticleId><ArticleId IdType="pubmed">33881797</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell&#x2010;Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20(3):488&#x2010;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5836933</ArticleId><ArticleId IdType="pubmed">29053215</ArticleId></ArticleIdList></Reference><Reference><Citation>Frier BM, Ratzki&#x2010;Leewing A, Harris SB. Reporting of hypoglycaemia in clinical trials of basal insulins: a need for consensus. Diabetes Obes Metab. 2019;21(7):1529&#x2010;1542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6767397</ArticleId><ArticleId IdType="pubmed">30924567</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;stenson CG, Geelhoed&#x2010;Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen&#x2010;Bjergaard U. Self&#x2010;reported non&#x2010;severe hypoglycaemic events in Europe. Diabet Med. 2014;31(1):92&#x2010;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232857</ArticleId><ArticleId IdType="pubmed">23796113</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes AP, Yang J, Radican L, et al. Assessing occurrence of hypoglycemia and its severity from electronic health records of patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016;121:192&#x2010;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">27744128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratzki&#x2010;Leewing A, Harris SB, Mequanint S, et al. Real&#x2010;world crude incidence of hypoglycemia in adults with diabetes: results of the InHypo&#x2010;DM study, Canada. BMJ Open Diabetes Res Care. 2018;6(1):e000503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5922478</ArticleId><ArticleId IdType="pubmed">29713480</ArticleId></ArticleIdList></Reference><Reference><Citation>Klonoff DC, Gutierrez A, Fleming A, Kerr D. Real&#x2010;world evidence should be used in regulatory decisions about new pharmaceutical and medical device products for diabetes. J Diabetes Sci Technol. 2019;13(6):995&#x2010;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6835188</ArticleId><ArticleId IdType="pubmed">30943790</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650&#x2010;2664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507610</ArticleId><ArticleId IdType="pubmed">23100048</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhafiz AH, Rodr&#xed;guez&#x2010;Ma&#xf1;as L, Morley JE, Sinclair AJ. Hypoglycemia in older people &#x2010; a less well recognized risk factor for frailty. Aging Dis. 2015;6(2):156&#x2010;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4365959</ArticleId><ArticleId IdType="pubmed">25821643</ArticleId></ArticleIdList></Reference><Reference><Citation>Guja C, Giorgino F, Blonde L, et al. Concomitant iGlarLixi and sodium&#x2010;glucose co&#x2010;transporter&#x2010;2 inhibitor therapy in adults with type 2 diabetes: LixiLan&#x2010;G trial and real&#x2010;world evidence results. Diabetes Ther. 2022;13(1):205&#x2010;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8776928</ArticleId><ArticleId IdType="pubmed">34894329</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>